

“পুঁজিবাজারে বিনিয়োগ ঝুঁকিপূর্ণ। জেনে ও বুঝে বিনিয়োগ করুন”

“Investment in capital market involves certain degree of risks. The investors are required to read the prospectus and risk factors carefully, assess their own financial conditions and risk-taking ability before making their investment decisions.”

“পুঁজিবাজারে বিনিয়োগ ঝুঁকিপূর্ণ। বিনিয়োগকারীগণ প্রোসপেক্টাস পড়ে এবং ঝুঁকির বিষয়গুলি সতর্কতার সাথে অনুধাবন করে নিজ আর্থিক অবস্থা ও ঝুঁকিগ্রহণ করার সক্ষমতা বিবেচনা করে বিনিয়োগ সিদ্ধান্ত গ্রহণ করবেন।”

Initial Public Offer (IPO) of 36,199,095 ordinary shares, from which 7,692,307 ordinary shares are reserved for Eligible Investors (EIs) at their own bid price and quantity on highest to lowest bid basis in a descending order of individual bid price till exhaustion of the quota for EIs category at on or above the cut-off price of Tk. 34.00 and 5,429,865 ordinary shares at 20% premium over fair value i.e., Tk. 34.00 per share for Employees and Others and remaining 23,076,923 ordinary shares at a 30% discounted price from the cut-off price i.e., Tk. 24.00 per share for General Public including NRBs totaling Tk. 1,000,000,000.00.

Issue date of prospectus: May 08, 2024

Date of Subscription

Opening date of subscription: June 09, 2024

Closing date of subscription: June 13, 2024

PROSPECTUS

Of



Techno Drugs Ltd.

Where innovation never stops...

Issue Managers



EBL Investments Ltd.

A full-fledged merchant bank and subsidiary of Eastern Bank PLC

EBL Investments Limited



IMPERIAL
CAPITAL LIMITED

Imperial Capital Limited

Credit Rating Status

| Credit Rating by | Emerging Credit Ratings Ltd. | |
|------------------|------------------------------|--------------|
| Rating | Entity Rating | |
| | Long-Term | Short Term |
| | A | ST-2 |
| Outlook | Stable | Stable |
| Validity | May 20, 2024 | May 20, 2024 |

Preliminary Information and Declarations:

- (i) **Name(s), address(s), telephone number(s), web address(s), e-mail(s), fax number(s) and contact persons of the issuer, issue manager(s), underwriter(s), auditors, credit rating company and valuer, where applicable;**

| Issuer | | |
|---|---|--|
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| Techno Drugs Ltd. (TDL) J K Tower, 31 Segunbagicha, Dhaka-1000 | Tel: +88-02-58316038 Fax: +88-02-58315821 Email: contact@technodrugsLtd.com Web: www.technodrugsLtd.com | Debasish Das Gupta Company Secretary |
| Issue Managers | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| EBL Investments Limited BSC Tower (4th Floor), 2-3 Rajuk Avenue, Motijheel C/A, Dhaka-1000 | Tel: +88-02-47111096, +88-02-47111867 Fax: +88-02-47111218 E-mail: info@eblinvestments.com Web: www.eblinvestments.com | Ahmed Arefin FCA Managing Director |
| Imperial Capital Limited Saiham Sky View Tower (3rd Floor), 45 Bijoy Nagar, Dhaka-1000. | Tel: +88-02-9361870 Fax: +88-02-9361870 (Ext.-102) E-mail: imperialcapLtd@gmail.com Web: www.imperialcapital.org | Md. Abul Bashar Parvez Chief Executive Officer |
| Underwriters | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| EBL Investments Limited BSC Tower (4th Floor), 2-3 Rajuk Avenue, Motijheel C/A, Dhaka-1000 | Tel: +88-02-47111096, +88-02-47111867 Fax: +88-02-47111218 E-mail: info@eblinvestments.com Web: www.eblinvestments.com | Ahmed Arefin FCA Managing Director |
| BMSL Investment Limited Shareef Mansion (4th Floor) 56-57 Motijheel C/A Dhaka-1000. | Tel: +88-02-9577651, +88-02-9570624, +88-02-9565183 Fax: +88-02-47117218 E-mail: info@bmslinvestment.com Web: www.bmslinvestment.com | Md. Riyad Matin Managing Director |

| Auditor | | |
|--|--|--|
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| ISLAM QUAZI SHAFIQUE & CO. Chartered Accountants Moghbazar Office: Al-HajShamsuddin Mansion (4th Floor), 17, New Eskaton Road, Moghbazar, Dhaka-1000 Uttara Office: ABC SkyRise Tower (6th Floor) 6B Unit, Shahjalal Avenue Road, Sector # 4 Uttara, Dhaka | Tel: +88-02-48312349 Fax: no Fax Number E-mail: info@qsibd.com biplabhossainfca@gmail.com web: www.qsibd.com | Biplab Hossain FCA Partner |
| CREDIT RATING COMPANY | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| Emerging Credit Rating Ltd. Shams Rangs, House-104, Park Road, Level A1, A2, & A5, Baridhara, Dhaka-1212 | Tel: +88-02-9860911, +88-02-9860897 Fax: +88-02-9860828 E-mail: eclinfo@emergingrating.com web: www.ncrbd.com | Arifur Rahman, FCCA, FCA, CSAA Chief Executive Officer |
| VALUER | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| G. KIBRIA & CO. Sadharan Bima Sadan (5th Floor), 24-25, Dilkusha C/A, Dhaka-1000 | Tel: +88-02-223355324 Fax: +88-02-9553630 E-mail: gkibria@gkibriaandco.com www.gkibriaandco.com | Mohammad Showket Akber, FCA Engagement Partner |

(ii) Declaration: "A person interested to get a prospectus may obtain from the issuer and the issue manager"

(iii) Statement: "If you have any query about this document, you may consult the issuer, issue managers and underwriters"

(iv) "CONSENT OF THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION HAS BEEN OBTAINED TO THE ISSUE OR OFFER OF THESE SECURITIES UNDER THE SECURITIES AND EXCHANGE ORDINANCE, 1969, AND THE BANGLADESH SECURITIES AND EXCHANGE COMMISSION (PUBLIC ISSUE) RULES, 2015. IT MUST BE DISTINCTLY UNDERSTOOD THAT IN GIVING THIS CONSENT THE COMMISSION DOES NOT TAKE ANY RESPONSIBILITY FOR THE FINANCIAL SOUNDNESS OF THE ISSUER COMPANY, ANY OF ITS PROJECTS OR THE ISSUE PRICE OF ITS SECURITIES OR FOR THE CORRECTNESS OF ANY OF THE STATEMENTS MADE OR OPINION EXPRESSED WITH REGARD TO THEM. SUCH RESPONSIBILITY LIES WITH THE ISSUER, ITS DIRECTORS, CHIEF EXECUTIVE OFFICER, MANAGING DIRECTOR, CHIEF FINANCIAL OFFICER, COMPANY SECRETARY, ISSUE MANAGER, ISSUE MANAGER'S CHIEF EXECUTIVE OFFICER, UNDERWRITERS, AUDITOR(S), VALUER AND/OR CREDIT RATING COMPANY (IF ANY)."

(v) *'Risks in relation to the First Issue'*

"This being the first issue of the issuer, there has been no formal market for the securities of the issuer. The face value of the securities is Tk. 10.00 (ten) and the issue price Tk. 24.00, i.e. 2.4 times of the face value. The issue price has been determined and justified by the issuer and the issue manager as stated under the paragraph on "Justification of Issue Price" should not be taken to be indicative of the market price of the securities after listing. No assurance can be given regarding an active or sustained trading of the securities or the price after listing."

(vi) *'General Risk'*

"Investment in securities involves a degree of risk and investors should not invest any funds in this offer unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offer. For taking an investment decision, investors must rely on their own examination of the issuer and the offer including the risks involved. The securities have not been recommended by the Bangladesh Securities and Exchange Commission (BSEC) nor does BSEC guarantee the accuracy or adequacy of this document. Specific attention of investors is invited to the statement of 'risk factors' given on page number(s) 245 to 253"

(vii) *Techno Drugs Ltd.'s Absolute Responsibility'*

(vii)"The issuer, having made all reasonable inquiries, accepts responsibility for and confirms that this red-herring prospectus contains all material information with regard to the issuer and the issue, that the information contained in the red-herring prospectus are true, fair and correct in all material aspects and are not misleading in any respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which make this document as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect."

Availability of Prospectus

- (i) **Names, addresses, telephone numbers, fax numbers, website addresses and e-mail addresses and names of contact persons of the institutions where the prospectus and abridged version of prospectus are available in hard and soft forms;**

The Prospectus and abridged version prospectus in hard and soft forms of the Company shall be obtained from the following addresses:

| Issuer | | |
|---|---|--|
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| Techno Drugs Ltd. (TDL) J K Tower, 31 Segunbagicha, Dhaka-1000 | Tel: +88-02-58316038 Fax: +88-02-58315821 Email: contact@technodrugsLtd.com Web: www.technodrugsLtd.com | Debasish Das Gupta Company Secretary |
| Issue Managers | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| EBL Investments Limited BSC Tower (4th Floor), 2-3 Rajuk Avenue, Motijheel C/A, Dhaka-1000 | Tel: +88-02-47111096, +88-02-47111867 Fax: +88-02-47111218 E-mail: info@eblinvestments.com Web: www.eblinvestments.com | Ahmed Arefin FCA Managing Director |
| Imperial Capital Limited Saiham Sky View Tower (3rd Floor), 45 Bijoy Nagar, Dhaka-1000. | Tel: +88-02-9361870 Fax: +88-02-9361870 (Ext.-102) E-mail: imperialcapLtd@gmail.com Web: www.imperialcapital.org | Md. Abul Bashar Parvez Chief Executive Officer |
| REGISTRAR TO THE ISSUE | | |
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| BMSL Investment Limited Shareef Mansion (4th Floor) 56-57 Motijheel C/A Dhaka-1000. | Tel: +88-02-9577651, +88-02-9570624, +88-02-9565183 Fax: +88-02-47117218 E-mail: info@bmslinvestment.com Web: www.bmslinvestment.com | Md. Riyad Matin Managing Director |

| Stock Exchanges | | |
|--|---|---|
| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
| Dhaka Stock Exchange PLC DSE Library, DSE Tower, Plot # 46, Road # 21, Nikunja-2, Dhaka-1229 | Tel: +88-02-41040189-200 Fax: +88-02-41040096 E-mail: imdsp@dse.com.bd Web: www.dse.com.bd | Mohammed Mahfuzur Rahman Assistant General Manager & Head of Index Management, Data Services and Publication Department |
| Chittagong Stock Exchange PLC CSE Library, CSE Building, 1080, Sheikh Mujib Road Agrabad, Chittagong- 4100 | Tel: 031-714632-3 Fax: 031-714101 E-mail: habib.ullah@cse.com.bd Web: www.cse.com.bd | Mohammad Habib Ullah Deputy Manager |

Prospectus would also be available on the web sites of **Techno Drugs Ltd.** (www.technodrugs.com), **EBL Investments Limited** (www.eblinvestments.com), **Imperial Capital Limited** (www.imperialcapital.org), **Bangladesh Securities and Exchange Commission (BSEC)** (www.sec.gov.bd), **Dhaka Stock Exchange PLC (DSE)** (www.dse.com.bd), **Chittagong Stock Exchange PLC (CSE)** (www.csebd.com) and at the Public Reference Room of the **Bangladesh Securities and Exchange Commission (BSEC)** for the reading and studying.

(ii) **Names and dates of the newspapers where abridged version of prospectus was published.**

Names and dates of the newspapers where abridged version of prospectus will be published:

| Sl. | Name of the Newspaper | Date of Publication |
|---------------------------|------------------------------|----------------------------|
| Bengali Newspapers | | |
| 1 | The Financial Express | May 09, 2024 |
| 2 | New Age | |
| English Newspapers | | |
| 1 | The Daily Samakal | May 09, 2024 |
| 2 | Daily Bonik Barta | |

(iii) Definitions and Acronyms or Elaborations

Acronyms or Elaborations:

A

| | |
|--|--|
| AGM | Annual General Meeting |
| Allotment | Letter of Allotment of shares |
| “Articles” or “Articles of Association” or “AoA” | The Articles of Association of Techno Drugs Ltd. |

B

| | |
|--|--|
| “Board” or “Board of Directors” or “our Board” | The Board of Directors of Techno Drugs Ltd., as duly constituted from time to time including any committees thereof |
| BAS | Bangladesh Accounting Standards |
| Bidders | The Eligible Institutional Investors who have participated in the bidding |
| BDT | Bangladeshi Taka |
| BFRS | Bangladesh Financial Reporting Standards |
| BIDA | Bangladesh Investment Development Authority |
| Book-Building Method | The process by which an issuer attempts to determine the price to offer its security based on demand from Eligible Institutional Investors (EIs) |
| BO A/C | Beneficiary Owner's Account |
| BSEC | Bangladesh Securities and Exchange Commission |

C

| | |
|---------------|---|
| CDBL | Central Depository Bangladesh Limited |
| CFO | Chief Financial Officer |
| CIB | Credit Information Bureau |
| Commission | Bangladesh Securities and Exchange Commission |
| CS | Company Secretary |
| CSE | Chittagong Stock Exchange PLC |
| Cut-off Price | The lowest price offered by the bidders at which the total issue could be exhausted |

D

| | |
|------|--|
| DGDA | Directorate General of Drug Administration & Licensing Authority (Drugs) |
| DSE | Dhaka Stock Exchange PLC |

E

| | |
|-----------|-------------------------|
| EBLIL | EBL Investments Limited |
| EI | Eligible Investor |
| E-Mail | Electronic Mail |
| EPS | Earnings Per Share |
| Exchanges | Stock Exchanges |

F

| | |
|--------|--------------------------|
| FC A/C | Foreign Currency Account |
| FDR | Fixed Deposit Receipt |
| FY | Fiscal Year |

G

| | |
|----|----------------|
| GP | General Public |
|----|----------------|

| | |
|--|---|
| I | |
| ICL | Imperial Capital Limited |
| IPO | Initial Public Offering |
| ISO | International Standardization Organization |
| Issue | Public Issue of shares |
| Issue Managers | EBL Investments Limited & Imperial Capital Limited |
| Issuer | Techno Drugs Ltd. |
| L | |
| L/C | Letter of Credit |
| M | |
| “Memorandum” or “Memorandum of Association” or “MoA” | The Memorandum of Association of Techno Drugs Ltd. |
| MS-Word | Microsoft word |
| N | |
| NAV | Net Asset Value |
| NBR | National Board of Revenue |
| NRB | Non-Resident Bangladeshi |
| NOCFPS | Net Operating Cash Flow Per Share |
| O | |
| “Our Company” | Techno Drugs Ltd. (TDL) a Public Limited Company under the Companies Act |
| Offer Price | Price of the Share of The Techno Drugs Limited being offered |
| P | |
| Price Discovery | A method of determining the price for a specific security through demand and supply factors related to the market |
| PE | Price to Earnings |
| Q | |
| QA | Quality Assurance |
| QC | Quality Control |
| R | |
| RJSC | Registrar of Joint Stock Companies and Firms |
| R & D | Research & Development |
| Road Show | Presentation by an issuer of security to potential investors about its issuance of security |
| Registered Office | Head Office of the Company |
| S | |
| Securities | Share of Techno Drugs Ltd. |
| Securities Market | The Share Market of Bangladesh |
| Sponsors | The sponsor shareholders of Techno Drugs Ltd. |
| Subscription | Application Money |
| T | |
| The Company/Issuer | Techno Drugs Ltd. (TDL), a Public Limited Company under the Companies Act |
| U | |
| UK Pound | United Kingdom Pound |
| USD | United States Dollar |
| V | |
| VAT | Value Added Tax |
| W | |
| WHO | World Health Organization |

Table of Contents

| | |
|--|-----|
| CHAPTER (I) | 1 |
| EXECUTIVE SUMMARY | 1 |
| (a) About the industry: | 2 |
| (b) About the Issuer: | 4 |
| (c) Financial Information: | 6 |
| (d) Features of the issue and its objects: | 6 |
| (e) Legal and other Information: | 7 |
| (f) Promoters' background: | 8 |
| (g) Capital structure and history of capital raising:..... | 10 |
| (h) Summary of Valuation Report of securities: | 10 |
| (i) Others:..... | 11 |
| CHAPTER (II) | 12 |
| CONDITIONS IMPOSED BY THE COMMISSION IN THE CONSENT LETTER | 12 |
| CHAPTER (III) | 22 |
| DECLARATION AND DUE DILIGENCE CERTIFICATES | 22 |
| DECLARATION ABOUT THE RESPONSIBILITY OF THE DIRECTORS, INCLUDING THE CEO OF THE ISSUER IN RESPECT OF THE RED-HERRING PROSPECTUS..... | 23 |
| DUE DILIGENCE CERTIFICATE BY ISSUE MANAGER IN THE RED- HERRING PROSPECTUS | 24 |
| DUE DILIGENCE CERTIFICATE BY ISSUE MANAGER IN THE RED- HERRING PROSPECTUS | 26 |
| DUE DILIGENCE CERTIFICATE BY THE UNDERWRITER | 28 |
| DUE DILIGENCE CERTIFICATE BY THE UNDERWRITER | 29 |
| CHAPTER (IV) | 30 |
| ABOUT THE ISSUER | 30 |
| Particulars of the Company:..... | 31 |
| Name of the Sponsors and Directors: | 31 |
| Particulars of Auditor and Registrar to the Issue: | 32 |
| Name of the Stock Exchanges where the Securities to be listed:..... | 32 |
| CHAPTER (V) | 33 |
| CORPORATE DIRECTORY OF THE ISSUER | 33 |
| CHAPTER (VI) | 35 |
| DESCRIPTION OF THE ISSUER | 35 |
| (a) Summary:..... | 36 |
| (b) General Information:..... | 38 |
| (c) Capital Structure:..... | 51 |
| (d) Description of Business: | 58 |
| (e) Description of Property: | 86 |
| (f) Plan of Operation and discussion of Financial Condition: | 143 |
| (a) Internal and external sources of cash;..... | 144 |
| (b) Any material commitments for capital expenditure and expected sources of funds for such expenditure; | 145 |
| (c) Causes for any material changes from period to period in revenues, cost of goods sold, other operating expenses and net income; | 145 |
| (d) Any seasonal aspects of the issuer's business; | 146 |
| (e) Any known trends, events or uncertainties that may have material effect on the issuer's future business; | 146 |
| (f) Any assets of the company used to pay off any liabilities; | 146 |
| (g) Any loan taken from or given to any related party or connected person of the issuer with details of the same;..... | 146 |
| (h) Any future contractual liabilities the issuer may enter into within next one year, and the impact, if any, on the financial fundamentals of the issuer; | 146 |
| (i) The estimated amount, where applicable, of future capital expenditure; | 146 |
| (j) Any VAT, income tax, customs duty or other tax liability which is yet to be paid, including any contingent liabilities stating why the same was not paid prior to | |

| | | |
|-----|---|-----|
| | the issuance of the prospectus. Updated income tax status for the last 5 years or from commercial operation, which is shorter; | 147 |
| (k) | Any financial commitment, including lease commitment, the company had entered into during the past five years or from commercial operation, which is shorter, giving details as to how the liquidation was or is to be affected; | 148 |
| (l) | Details of all personnel related schemes for which the company has to make provision for in future years; | 151 |
| (m) | Break down of all expenses related to the public issue;..... | 152 |
| (n) | If the issuer has revalued any of its assets, the name, qualification and experiences of the valuer and the reason for the revaluation, showing the value of the assets prior to the revaluation separately for each asset revalued in a manner which shall facilitate comparison between the historical value and the amount after revaluation and giving a summary of the valuation report along with basis of pricing and certificates required under the revaluation guideline of the Commission; | 154 |
| (o) | Where the issuer is a holding or subsidiary company, full disclosure about the transactions, including its nature and amount, between the issuer and its subsidiary or holding company, including transactions which had taken place within the last five years of the issuance of the prospectus or since the date of incorporation of the issuer, whichever is later, clearly indicating whether the issuer is a debtor or a creditor; | 155 |
| (p) | Financial Information of Group Companies and Companies under common ownership by more than 50%: following information for the last three years based on the audited financial statements, in respect of all the group companies of the issuer, wherever applicable, along with significant notes of auditors: | 155 |
| (q) | Where the issuer is a banking company, insurance company, non-banking financial institution or any other company which is regulated and licensed by another primary regulator, a declaration by the board of directors shall be included in the prospectus stating that all requirements of the relevant laws and regulatory requirements of its primary regulator have been adhered to by the issuer; | 155 |
| (r) | A report from the auditors regarding any allotment of shares to any person for any consideration otherwise than cash along with relationship of that person with the issuer and rationale of issue price of the shares;..... | 155 |
| (s) | Any material information, which is likely to have an impact on the offering or change the terms and conditions under which the offer has been made to the public; | 156 |
| (t) | Business strategies and future plans - projected financial statements shall be required only for companies not started commercial operation yet and authenticated by Chairman, two Directors, Managing Director, CFO, and Company Secretary;..... | 156 |
| (u) | Discussion on the results of operations shall inter-alia contain the following: . | 157 |
| (v) | Comparison of recent financial year with the previous financial years on the major heads of the profit and loss statement, including an analysis of reasons for the changes in significant items of income and expenditure, inter-alia, containing the following:..... | 158 |
| (w) | Defaults or rescheduling of borrowings with financial institutions or banks, conversion of loans into equity along with reasons thereof, lock out, strikes and reasons for the same etc. during the history of operation of the company; .. | 160 |
| (x) | Details regarding the changes in the activities of the issuer during the last five years which may had a material effect on the profits or loss, including discontinuance of lines of business, loss of agencies or markets and similar factors; | 161 |
| (y) | Injunction or restraining order, if any, with possible implications; | 161 |
| (z) | Technology, market, managerial competence and capacity built-up; | 161 |

| | | |
|---|--|------------|
| (aa) | Changes in accounting policies in the last three years;..... | 162 |
| (bb) | Significant developments subsequent to the last financial year: A statement by the directors whether in their opinion there have arisen any circumstances since the date of the last financial statements as disclosed in the prospectus and which materially and adversely affect or is likely to affect the trading or profitability of the issuer, or the value of its assets, or its ability to pay its liabilities within the next twelve months; | 163 |
| (cc) | If any quarter of the financial year of the issuer ends after the period ended in the audited financial statements as disclosed in the prospectus, unaudited financial statements for each of the said quarters duly authenticated by the CEO and CFO of the issuer;..... | 164 |
| (dd) | Factors that may affect the results of operations..... | 167 |
| CHAPTER (VII) | | 168 |
| MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION | | 168 |
| (a) | Overview of business and strategies:..... | 169 |
| (b) | SWOT ANALYSIS:..... | 170 |
| (c) | Analysis of the financial statements of last five years with reason(s) of fluctuating revenue or sales, other income, total income, cost of material, finance cost, depreciation and amortization expense, other expense; changes of inventories, net profit before & after tax, EPS etc. | 171 |
| (d) | Known trends demands, commitments, events or uncertainties that are likely to have an effect on the company's business: | 172 |
| (e) | Trends or expected fluctuations in liquidity:..... | 172 |
| (f) | Off-balance sheet arrangements those have or likely to have a current or future effect on financial condition: | 172 |
| CHAPTER (VIII) | | 173 |
| DIRECTORS AND OFFICERS | | 173 |
| (a) | Name, Father's name, age, residential address, educational qualification, experience and position of each of the directors of the company and any person nominated or represented to be a director, showing the period for which, the nomination has been made and the name of the organization which has nominated him:..... | 174 |
| (b) | The date on which he first became a director and the date on which his current term of office shall expire: | 176 |
| (c) | If any director has any type of interest in other businesses, names and types of business of such organizations. If any director is also a director of another company or owner or partner of any other concern, the names of such organizations: | 176 |
| (d) | Statement of if any of the directors of the issuer are associated with the securities market in any manner. If any director of the Issuer Company is also a director of any issuer of other listed securities during last three years, then dividend payment history and market performance of that issuer: | 176 |
| (e) | Any family relationship (father, mother, spouse, brother, sister, son, daughter, spouse's father, spouse's mother, spouse's brother, spouse's sister) among the directors and top five officers: | 177 |
| (f) | A very brief description of other businesses of the directors:..... | 178 |
| (g) | Short bio-data of each director: | 180 |
| (h) | Loan status of the issuer, its directors and shareholders who hold 10% or more shares in the paid-up capital of the issuer in terms of the CIB Report of Bangladesh Bank: | 182 |
| (i) | Name with position, educational qualification, age, date of joining in the company, overall experience (in year), previous employment, salary paid for the financial year of the Chief Executive Officer, Managing Director, Chief Financial Officer, Company Secretary, Advisers, Consultants and all Departmental Heads. If the Chairman, any director or any shareholder received any monthly salary than this information should also be included:..... | 183 |

| | | |
|---|---|------------|
| (j) | Changes in the key management persons during the last three years. Any change otherwise than by way of retirement in the normal course in the senior key management personnel particularly in charge of production, planning, finance and marketing during the last three years prior to the date of filing the information memorandum. If the turnover of key management personnel is high compared to the industry, reasons should be discussed:..... | 184 |
| (k) | A profile of the sponsors including their names, father's names, age, personal addresses, educational qualifications, and experiences in the business, positions or posts held in the past, directorship held, other ventures of each sponsor and present position:..... | 185 |
| (l) | If the present directors are not the sponsors and control of the issuer was acquired within five years immediately preceding the date of filing prospectus details regarding the acquisition of control, date of acquisition, terms of acquisition, consideration paid for such acquisition etc. | 187 |
| (m) | If the sponsors or directors do not have experience in the proposed line of business, the fact explaining how the proposed activities would be carried out or managed: | 187 |
| (n) | Interest of the key management persons: | 187 |
| (o) | All interests and facilities enjoyed by a director, whether pecuniary or non-pecuniary: | 187 |
| (p) | Number of shares held and percentage of shareholding (pre issue): | 187 |
| (q) | Change in board of directors during last three years:..... | 187 |
| (r) | Director's engagement with similar business: | 187 |
| CHAPTER (IX)..... | | 188 |
| CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS | | 188 |
| CHAPTER (X)..... | | 192 |
| EXECUTIVE COMPENSATION..... | | 192 |
| (a) | The total amount of remuneration or salary or perquisites paid to the top five salaried officers of the issuer in the last accounting year and the name and designation of each such officer: | 193 |
| (b) | Aggregate amount of remuneration paid to all directors and officers as a group during the last accounting year: | 193 |
| (c) | If any shareholder director received any monthly salary or perquisite or benefit it must be mentioned along with date of approval in AGM or EGM, terms thereof and payments made during the last accounting year:..... | 193 |
| (d) | The board meeting attendance fees received by the director including the managing director along with date of approval in AGM or EGM: | 193 |
| (e) | Any contract with any director or officer providing for the payment of future compensation:..... | 193 |
| (f) | If the issuer intends to substantially increase the remuneration paid to its directors and officers in the current year, appropriate information regarding thereto: | 193 |
| (g) | Any other benefit or facility provided to the above persons during the last accounting year: | 193 |
| CHAPTER (XI)..... | | 194 |
| OPTIONS GRANTED TO DIRECTORS, OFFICERS AND EMPLOYEES | | 194 |
| CHAPTER (XII)..... | | 195 |
| TRANSACTION WITH THE DIRECTORS AND SUBSCRIBERS TO THE MEMORANDUM | | 195 |
| CHAPTER (XIII)..... | | 198 |
| OWNERSHIP OF THE COMPANY'S SECURITIES | | 198 |
| a) | The names, addresses, BO ID Number of all shareholders of the company before IPO, indicating the amount of securities owned and the percentage of the securities represented by such ownership, in tabular form:..... | 199 |
| b) | There shall also be a table showing the name and address, age, experience, BO ID Number, TIN number, numbers of shares held including Percentage, position held in other companies of all the directors before the public issue: | 200 |

| | | |
|---|---|------------|
| c) | The average cost of acquisition of equity shares by the directors certified by the auditors: | 203 |
| d) | A detail description of capital built up in respect of shareholding (name-wise) of the issuer's sponsors or directors. In this connection, a statement to be included: - | 204 |
| e) | Detail of shares issued by the company at a price lower than the issue price: | 207 |
| f) | History of significant (5% or more) changes in ownership of securities from inception: | 207 |
| CHAPTER (XIV) | | 208 |
| CORPORATE GOVERNANCE | | 208 |
| CHAPTER (XV) | | 228 |
| VALUATION REPORT OF SECURITIES PREPARED BY THE ISSUE MANAGER | | 228 |
| CHAPTER (XVI) | | 234 |
| DEBT SECURITIES | | 234 |
| CHAPTER (XVII) | | 235 |
| PARTIES INVOLVED AND THEIR RESPONSIBILITIES | | 235 |
| CHAPTER (XVIII) | | 237 |
| MATERIAL CONTRACTS | | 237 |
| CHAPTER (XIX) | | 243 |
| OUTSTANDING LITIGATIONS, FINE OR PENALTY | | 243 |
| CHAPTER (XX) | | 245 |
| RISK FACTORS AND MANAGEMENT'S PERCEPTIONS ABOUT THE RISKS | | 245 |
| (i) | Internal risk factors may include, among others: | 246 |
| (ii) | External risk factors may include among others: | 251 |
| CHAPTER (XXI) | | 254 |
| DESCRIPTION OF THE ISSUE | | 254 |
| (a) | Issue Size: Taka 1,000,000,000.00 | 255 |
| (b) | Number of securities to be issued:..... | 255 |
| (c) | Authorized capital and paid-up capital; | 255 |
| (d) | Face value, premium and offer price per unit of securities; | 255 |
| (e) | Number of securities to be entitled for each category of applicants;..... | 255 |
| (f) | Holding structure of different classes of securities before and after the issue; | 255 |
| (g) | Objective of the issue including financing requirements and feasibility in respect of enhanced paid-up capital. | 256 |
| CHAPTER (XXII) | | 262 |
| USE OF PROCEED | | 262 |
| (a) | Use of net proceeds of the offer indicating the amount to be used for each purpose with head-wise break-up;..... | 263 |
| (b) | Utilization of the total amount of paid-up capital and share premium, if any, including the sponsors' contribution and capital raised of the issuer at the time of submission of prospectus, in details with indication of use of such funds in the financial statements; | 267 |
| (c) | If one of the objects is an investment in a joint venture, a subsidiary, an associate or any acquisition, details of the form of investment, nature of benefit expected to accrue to the issuer as a result of the investment, brief description of business and financials of such venture;..... | 267 |
| (d) | If IPO proceeds are not sufficient to complete the project, then source of additional fund must be mentioned. In this connection, copies of contract to meet the additional funds are required to be submitted to the Commission. The means and source of financing, including details of bridge loan or other financial arrangement, which may be repaid from the proceeds of the issue along with utilization of such funds;..... | 267 |
| (e) | A schedule mentioning the stages of implementation and utilization of funds received through public offer in a tabular form, progress made so far, giving details of land acquisition, civil works, installation of plant and machinery, the approximate date of completion of the project and the projected date of full commercial operation etc. The schedule shall be signed by the Chief Executive Officer or | |

| | |
|---|-----|
| Managing Director, Chief Financial Officer and Chairman on behalf of Board of Directors of the issuer; | 268 |
| (f) If there are contracts covering any of the activities of the issuer for which the proceeds of sale of securities are to be used, such as contracts for the purchase of land or contracts for the construction of buildings, the issuer shall disclose the terms of such contracts, and copies of the contracts shall be enclosed as annexure to the prospectus;..... | 268 |
| (g) If one of the objects of the issue is utilization of the issue proceeds for working capital, basis of estimation of working capital requirement along with the relevant assumptions, reasons for raising additional working capital substantiating the same with relevant facts and figures and also the reasons for financing short with long term investments and an item-wise break-up of last three years working capital and next two years projection; | 268 |
| (h) Where the issuer proposes to undertake one or more activities like diversification, modernization, expansion, etc., the total project cost activity-wise or project-wise, as the case may be; | 268 |
| (i) Where the issuer is implementing the project in a phased manner, the cost of each phase, including the phases, if any, which have already been implemented; | 269 |
| (j) The details of all existing or anticipated material transactions in relation to utilization of the issue proceeds or project cost with sponsors, directors, key management personnel, associates and group companies; | 269 |
| (k) Summary of the project appraisal or feasibility report by the relevant professionals not connected with the issuer, issue manager and registrar to the issue with cost of the project and means of finance, weaknesses and threats, if any, as given in the appraisal or feasibility report. | 269 |
| CHAPTER (XXIII) | 270 |
| LOCK-IN | 270 |
| CHAPTER (XXIV) | 273 |
| MARKETS FOR THE SECURITIES BEING OFFERED | 273 |
| CHAPTER (XXV) | 275 |
| DESCRIPTION OF SECURITIES OUTSTANDING OR BEING OFFERED | 275 |
| CHAPTER (XXVI) | 277 |
| FINANCIAL STATEMENTS | 277 |
| (a) The latest financial statements prepared and audited by the Commission's panel auditors in adherence to the provisions of the Securities and Exchange Rules, 1987, the কোম্পানি আইন, ১৯৯৪, International financial Reporting and Auditing Standards as adopted in Bangladesh from time to time and any other law as applicable; | 278 |
| (b) Information as is required under section 186 of the কোম্পানি আইন, ১৯৯৪ relating to holding company;..... | 319 |
| (c) Selected ratios as specified in Annexure-D;..... | 319 |
| (d) Auditors report under Section 135(1), Paragraph 24(1) of Part II of Schedule III of the কোম্পানি আইন, ১৯৯৪. The report shall include comparative income statements and balance sheet and aforementioned ratios for immediate preceding five accounting years of the issuer. If the issuer has been in commercial operation for less than five years, the above mentioned inclusion and submission will have to be made for the period since commercial operation; | 323 |
| (e) Financial spread sheet analysis for the latest audited financial statements; | 326 |
| (f) Earnings Per Share (EPS) on fully diluted basis (with the total existing number of shares) in addition to the weighted average number of shares basis. Future projected Net Income should not be considered while calculating the weighted average EPS; .. | 328 |
| (g) All extra-ordinary income or non-recurring income coming from other than core operations should be shown separately while showing the Net Profit as well as the Earnings Per Share; | 329 |
| (h) Quarterly or half-yearly EPS should not be annualized while calculating the EPS; .. | 329 |

| | | |
|---|--|-----|
| (i) | Net asset value (with and without considering revaluation surplus or reserve) per unit of the securities being offered at the date of the latest audited statement of financial position..... | 329 |
| (j) | The Commission may require the issuer to re-audit the audited financial statements, if any deficiency or anomaly is found in the financial statements. In such a case, cost of audit should be borne by the concerned issuer..... | 329 |
| (k) | Following statements for the last five years or any shorter period of commercial operation certified by the auditors:- | 330 |
| (i) | Statement of long term and short term borrowings including borrowing from related party or connected persons with rate of interest and interest paid or accrued; | 330 |
| (ii) | Statement of principal terms of secured loans and assets on which charge have been created against those loans with names of lenders, purpose, sanctioned amount, rate of interest, primary security, collateral or other security, repayment schedule and status; | 332 |
| (iii) | Statement of unsecured loans with terms and conditions; | 335 |
| (iv) | Statement of inventories showing amount of raw material, packing material, stock-in-process and finished goods, consumable items, store and spares parts, inventory of trading goods etc.; | 335 |
| (v) | Statement of trade receivables showing receivable from related party and connected persons; | 336 |
| (vi) | Statement of any loan given by the issuer including loans to related party or connected persons with rate of interest and interest realized or accrued; ... | 336 |
| (vii) | Statement of other income showing interest income, dividend income, discount received, other non operating income; | 337 |
| (ix) | Statement of related party transaction; | 338 |
| (x) | Reconciliation of business income shown in tax return with net income shown in audited financial statements; | 339 |
| (xi) | Confirmation that all receipts and payments of the issuer above Tk.5,00,000/- (five lac) were made through banking channel; | 339 |
| (xii) | Confirmation that Bank Statements of the issuer are in conformity with its books of accounts; | 339 |
| (xiii) | Statement of payment status of TAX, VAT and other taxes or duties; | 340 |
| CHAPTER (XXVII) | | 341 |
| CREDIT RATING REPORT | | 341 |
| CHAPTER (XXVIII) | | 360 |
| PUBLIC ISSUE APPLICATION PROCEDURE | | 360 |
| CHAPTER (XXIX) | | 364 |
| OTHERS | | 364 |


CHAPTER (I)

EXECUTIVE SUMMARY

(a) About the industry:

Pharmaceutical industry of Bangladesh has earned a considerable reputation for producing quality medicine by maintaining international standards. Today, Bangladesh has become one of the top pharmaceutical exporting countries of the world where 98% of the country's total demand for medicines is being produced locally. We are exporting our medicines to about 150+ countries of the world and our medicines have high demand for value and quality in European, American, Middle Eastern, and Central Asian markets.

However, just 35 years ago, this scenario wasn't the same. More than 90% of the medicines in the country had to be imported from abroad. Since the formulation of the National Drug Policy in 1982, we have seen a significant growth in the pharmaceutical industry of the Bangladesh. In 2020, the whole world came to a standstill and almost all services and businesses were stopped due to the pandemic. Even at that time our pharma sector workers continued providing services. Employees at all levels of the pharma sector served people without stopping to work even for even a single day during that horrific time.



During that time, the turnover decreased slightly but the production, marketing and operating costs also dropped by a lot. Furthermore, the government provided various benefits to the industry, including the relaxation of loan repayment rules. As a result, the pharmaceutical companies of the country did not suffer any major losses.

In 2021, pharmaceutical exports of the country achieved an 11.7% growth. In 2022, the whole world faced a difficult situation with raw material shortages, transport cost hikes and a dollar crisis. As a result, the industry plunged into a crisis. During this period, we became dependent on diesel due to gas shortages. As a result, the primary energy costs increased up to 100%. The import cost has also increased by 25%. However, we have only increased drug prices by an average of 4%. The reason for not increasing the medicine prices, despite a rise in the production cost, is that we have considered the purchasing power of the people of our country.

One of our major possibilities are in the export of medicines and the pharmaceutical industry of Bangladesh is preparing for this for a long time. Approximately 20 to 22 companies in this sector are spending a lot of money on research and development to boost exports. The local companies are trying hard to manufacture necessary raw materials and Active Pharmaceutical Ingredients (API) at a competitive price. Many companies have already been successful in producing APIs for some products.

In today's competitive world, the price of medicines is an important factor besides quality. People of Bangladesh now get medicines at a much lower price than in any other countries around the world. We are trying to produce raw materials at a lower price than the other companies in different parts of the world. Once we start preparing and marketing APIs in large quantity, the country's pharmaceutical industry will reach a different level. We will probably be able to export drugs abroad with our own APIs from 2024. It will also reduce our dependency on import of raw materials.

Currently, we need raw materials worth \$700 million in a year, which will come down to \$200 million after 2024. On the other hand, our export income will be more than \$1 billion and it will make the pharmaceutical industry a dollar-surplus industry. Currently, India is the top supplier of raw materials for the pharmaceutical industry. But the country is raising prices slowly. It will create an opportunity for us. We want to enter the international market as a low-cost manufacturer, with uncompromised quality.

We are now meeting 98% of local demand for medicines. After 2024, we will continue to advance in the same way and cover 100% of the local demands and dominate the international market. After five years, our pharmaceutical industry will enter a new era. We will have to set up factories and sales centers outside the country to conquer the global market. For this expansion, our government will need to be a little more liberal in terms of providing policy support to the industry.

There are strict regulations and restrictions in importing various raw materials, including formalin and acid. Chemicals which are classified as narcotics are subject to more stringent import restrictions. We demand a separate import policy for the pharmaceutical industry. Laws should be made to remove the complexities in importing any kind of raw materials for the purpose of making medicines.

While everyone is excited about the prospects of our pharmaceutical industry, some are also concerned about the challenges in the post-TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) era. In this case, the hope is that the patents of most of the products we are exporting right now have already expired. As a result, there is nothing to worry about their patents in the post-TRIPS era. However, our concern is about the affordability of medicines in the country.

Source:<https://www.tbsnews.net/supplement/pharmaceuticals-will-be-dollar-surplus-industry-next-year-574330>

(b) About the Issuer:

| | | | |
|---|--|-------------------|--|
| Incorporation | Incorporated as Private Limited Company on September 30, 2009 & vide reg. no. C-79890/09 | | |
| Converted to Public Limited Company | August 18, 2019 | | |
| Commencement of Commercial Operation | July 01, 2010 | | |
| Registered & Corporate Office | J K Tower, 31 Segunbagicha, Dhaka-1000 | | |
| Factory | Satirpara, Narsingdi-1600 | | |
| | B.K. Bari Mirzapur, Gazipur-1703 | | |
| Nature of Business | Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human and Veterinary medicines and selling them in local and international market. We are also the pioneer of Oncology medicines in Bangladesh. | | |
| Back ground of the Company | Techno Drugs Ltd. was incorporated in 2009 as a Private Limited Company of Bangladesh with the issuance of Certificate of incorporation bearing no. Reg. No. C-79890/09 dated on 30-Sep-2009 by the Registrar of Joint Stock Companies & Firms, Dhaka, Bangladesh. The Company Converted into public Limited Company and split of Share value from Tk. 1,000.00 to Tk. 10.00 dated on 18-Aug-2019. | | |
| Sales Depot | Sl. | Depot Name | Depot Address |
| | 1 | Barishal | House Name- Niloy, Holding No-872, Ward No-14, Barishal City Corporation, Barishal Sadar, C&B Road, Barishal |
| | 2 | Sylhet | Holding No-16/A, Shoroshpur Charanir, Lama Bazar, Sylhet-3100, Sylhet Sadar, Sylhet |
| | 3 | Rajshahi | House: 0233, Housing Estate, Sector-2, Post office: Rajshahi Shenanibash-6202, Boalia, Rajshahi. |
| | 4 | Bogura | House-399/431, Opposite of Tajma Ceramic, Thonthonia, Bogura |
| | 5 | Faridpur | Aloknondan- Holding No.-10/32/01, Alauddin Khan Road, South Alipur, Faridpur Sadar. |
| | 6 | Rangpur | House No.-78/4, road no.-01, PTI road, Katkipara, kotoali Rangpur |
| | 7 | Mymensingh | House No-6/1, Natokghor Lane, Kotoali, Mymensingh |
| | 8 | Bhairab | Holding No-920, Kolompur, Bhairab, Kishorgonj |
| | 9 | Jeshore | Holding No-1/B, Najnin Gopi Central Road, Jeshore Town, Police Station-Kotoali, Jeshore |
| | 10 | Chattogram | 523, Shahid Nagar, Hathazari Road, (Near Oxygen) P.O Amin Jute Mills Ltd. Chattogram-4211 |
| | 11 | Cumilla | Holding No-355/420, Munshi Bari, Rail Station Road, Adorssho Sadar, Cumilla |
| | 12 | Khulna | Afroja Kanon, Holding No.-294, Road No.-17, Nirala Housing Area, Post |

| | | |
|----|----------|--|
| | | Office: Khulna City-9100, Khulna Sadar, District: Khulna |
| 13 | Dinajpur | Shishuniketon Road, ShipahiPara, Block no.-10, Ward No.-09, Dinajpur |
| 14 | Kushtia | Road No.-48/1, Bicharpoti Mahbub Morshed Road, Kotapara (Peyaratala), Kushtia Sadar, Kushtia |
| 15 | Noakhali | House No.-08, Road No.-36, Housing Estate, Majidi Court, Noakhali |
| 16 | Tangail | Plot No.-1030/1, Shabalia, Suroj Road, Tangail |
| 17 | Dhaka | J K Tower, 31 Segunbagicha, Dhaka- 1000 |

(c) Financial Information:

Major financial information of Techno Drugs Ltd. is as follows:

Figures in BDT

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|---------------------------------|------------------|------------------|------------------|------------------|------------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Gross Profit | 1,159,834,813 | 1,815,159,593 | 1,461,264,210 | 830,772,839 | 889,124,664 |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Net Profit After Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |
| Total Assets | 6,041,255,752 | 5,364,011,238 | 4,383,677,859 | 3,783,496,160 | 2,976,374,229 |
| Share Capital | 941,574,000 | 941,574,000 | 818,760,000 | 687,600,000 | 99,600,000 |
| Retained Earnings | 1,183,337,389 | 987,831,030 | 630,866,603 | 269,923,774 | 681,598,589 |
| Total Liabilities | 2,718,106,868 | 2,356,235,516 | 2,412,600,806 | 2,484,389,812 | 1,978,461,844 |
| Net Asset Value (NAV) per share | 27.74 | 25.83 | 17.71 | 14.83 | 78.43 |
| Earnings Per Share (Diluted) | 2.08 | 5.10 | 3.83 | 1.74 | 2.40 |

* The Company split its share as on August 18, 2019 to Tk. 10.00 from Tk. 1,000.00 each.

(d) Features of the issue and its objects:

| | |
|---------------------------------------|--|
| Cut Off Price | Tk. 34.00 |
| Public Offering Price | Tk. 24.00 |
| Number of Shares to be offered | 36,199,095 |
| Total Issue Size | Tk. 1,000,000,000 |
| Issue Manager (s) | EBL Investments Limited and Imperial Capital Limited |
| Underwriter (s) | EBL Investments Limited and BMSL Investment Limited |
| Purpose of IPO Fund | Please see details in the Chapter (XXII) as titled of "Use of proceeds" of this prospectus |
| Date of Implementation | Within 24 months from receiving IPO fund |

(e) Legal and other Information:

| Sl. | Description of Certificate/License/Registration | License Issuer/Issuing Authority | Certificate/Licenses No. | Validity |
|-----|--|---|-------------------------------|------------------------------------|
| 1 | Certificate of Incorporation | Registrar of Joint Stock Companies & Firms (RJSC) | C-79890/09 September 30, 2009 | N/A |
| 2 | Commencement of Business | N/A | N/A | N/A |
| 3 | Trade License (Head office) | Dhaka South City Corporation | TRAD/DSCC/096078/2019 | 30-Jun-24 |
| | Trade License (Factory-Narsingdi) | Narsingdi Pourashava | 07704 | 30-Jun-24 |
| | Trade License (Factory-Gazipur) | Mirzapur Union Parishad | 162432000088 | 30-Jun-24 |
| 4 | Certificate of Good Manufacturing Practice (GMP) For Pharmaceutical Products | Ministry of Health & Family Welfare | DA/6-60/2001/8357 | 08-Apr-25 |
| | | | DGDA/6-176/2012/07 | 01-Jan-24 (Applied for renewal) |
| 5 | TIN Certificate | National Board of Revenue, Dhaka | 353088771582 | N/A |
| 6 | VAT Certificate | Customs, Excise and VAT Commissionerate, Dhaka (East), Narsingdi Division | 000180068-0306 | N/A |
| 7 | Drugs Manufacturing License | Directorate General of Drug Administration (DGDA) | Drug License no 446 and 211 | 22-Apr-24 (Applied for renewal) |
| | | | Drug License no 482 and 274 | 06-Sep-23 (Applied for renewal) |
| 8 | Drugs License | Directorate General of Drug Administration (DGDA) | ১৬৩৭ পাইকারী | 24-Apr-24 (Applied for renewal) |
| 9 | Environmental Clearance | Department of Environment, Narsingdi | 24-114888-08 | 30-Nov-24 |
| | | Department of Environment, Gazipur | 23-99143 | 17-Jun-23 (Applied for renewal) |
| 10 | Fire License | Fire Service & civil defense | AD/DHAKA/40233/18 | 30-Jun-24 |
| | | | AD/DHAKA/36697/17 | 30-Jun-24 |
| | | | AD/DHAKA/52544/22 | 30-Jun-24 |
| 11 | Factory License | Factory and Organization Inspection Authority, Narsingdi | 11731/Narsingdi | 11-Jun-24 |
| | | Factory and Organization Inspection Authority, Gazipur | 19050/Gazipur | 30-Jun-24 |
| 12 | Boiler License | Department of Explosive, Narsingdi | বা: ব: ২৪৯৯ | 16-Apr-24 (Applied for renewal) |
| | | Department of Explosive, Gazipur | বা: ব: ৯৮৪০ | 13-Dec-23 (Applied for renewal) |
| 13 | Import Registration Certificate (IRC) | Chief Controller of Import & Export | 260326120307020 | 30-Jun-24 |
| 14 | Export Registration Certificate (ERC) | | 260326210447420 | 30-Jun-24 |
| 15 | ISO: 9001:2015 | International Certification Authority | ICAN200306 | 15-Nov-26 |

(f) Promoters' background:

At the time of incorporation following persons were the subscribers to the memorandum:

| Sl. | Name of Promoter | Present Status |
|------------|-------------------------|-----------------------------|
| 1 | Shah Jalal Uddin Ahmed | Sponsor & Managing Director |
| 2 | Khaleda Akhter Khan | Sponsor & Chairman |
| 3 | Mehreen Ahmed | Sponsor & Director |
| 4 | Arefeen Raafi Ahmed | Sponsor & Director |

Their background is stated below:

Shah Jalal Uddin Ahmed

Managing Director

Shah Jalal Uddin Ahmed was born in Brahmanbaria, Bangladesh in the year 1953. He has completed his B.Sc. (Hon's) Bachelors in Pharmacy and M.Sc. Masters in Pharmacy from The University of Dhaka. He is a renowned pharmacist of the country and beyond. He started his career back in the late 70's in a leading pharmaceutical industry of Bangladesh, where he earned enormous fame for his excellence in manufacturing innovative products. After working 19 years in the same industry, he thought it's time for a change and with the experiences he has gained over the years in pharmaceutical formulation, inspired him to establish a new pharmaceutical industry on his own. And that this how Techno Drugs Ltd emerged. Since its inception, Techno Drugs Ltd has always been giving priority to the availability of locally manufactured medicines and a high quality of product that ultimately leads to maintaining a steady growth in the market. Mr. Shah Jalal Uddin Ahmed is a registered pharmacist of the Bangladesh Pharmacy Council. He also has an Executive Membership of Bangladesh Association of Pharmaceutical Industries. He is a senior member of Bangladesh Pharmaceutical Society, and one of the top pharmacists of the country. He is a member of Dhaka Chamber of Commerce and Industry and Narsingdi Chamber of Commerce and Industry. He is the innovator of many new pharmaceutical products in Bangladesh. He has a portfolio of introducing over 77 generics formulations for the first time in the country.

Khaleda Akhter Khan

Chairman

Mrs. Khaleda Akhter Khan is the Chairman and one of the sponsor directors of Techno Drugs Ltd. She was born in Gazipur, Bangladesh in the year 1954. She has completed her B.Sc. in Zoology (Hon's) and finished her M.Sc. in Fisheries, from The University of Dhaka. She started her carrier as a banker at Agrani Bank Ltd in the year 1983. With over 25 years of banking experience, she started at Techno Drugs Ltd as the Finance Director of the company since the company's incorporation in 2009. She single handedly monitored the accounts department until she was assigned to be the Chairman of the company by the board. Now she oversees the overall business of the company as Chairman. Her interpersonal skills, leadership behavior, high analytical ability in business and very hard working nature made her worth being the Chairman of Techno Drugs Ltd.

Mehreen Ahmed

Director

Dr. Mehreen Ahmed is the only daughter and the elder of two children of Khaleda Akhter Khan and Shah Jalal Uddin Ahmed. She was born in Barishal, Bangladesh in the year 1987. She is an Executive Director and one of the sponsor directors of the company. She has completed her B.Sc. Bachelors in Pharmacy from The University of Asia Pacific and obtained the registration of Bangladesh Pharmacy Council before moving to The United Kingdom for her Master's degree. She has completed her M.Sc. Pharmacology Masters in Pharmacy from The University of Hertfordshire, UK. She has also achieved her PhD in Pre-Clinical Oncology from The University of Nottingham, UK. She then moved to Sweden to pursue her postdoctoral fellowship at The Lund University, Sweden. Her leadership skills, knowledge about the industry gathered from the top institutions of the world, highly analytical and research oriented abilities in pharmaceutical formulation, and her hard working nature made her worthy of being a director of Techno Drugs Ltd.

Arefeen Raafi Ahmed

Director

Arefeen Raafi Ahmed is the only son and the younger of two children of Khaleda Akhter Khan and Shah Jalal Uddin Ahmed. He was born in Barishal, Bangladesh in the year 1991. He is an Executive Director and one of the sponsor directors of the company. He has graduated in B.Sc. ICT, Information and Communication Technology, from The University of Western Sydney, Australia. He has more than 11 years of experience in managing and leading teams across multiple sectors. He is also The Managing Director of Pulse Tech Ltd., a leading healthcare technology company of Bangladesh, and Managing Director of Greentech Holidays Ltd., a travel and tourism based industry. Mr. Arefeen Raafi Ahmed is the Executive Director of Greentech Resort and Convention Center, a leading resort of the country situated at Gazipur. He is also the Director of G.C. Box Ltd., a corrugated carton manufacturing industry, Medbox Solution Ltd., a medicine supply chain solution by Pulse Tech Ltd. Besides this, he is the 2023 National Vice President of JCI Bangladesh and a Senator of Junior Chamber International. He is also an active member of Bangladesh Association of Pharmaceuticals Industries, and Dhaka Chamber of Commerce and Industry. He is also the Director of the 2023-2025 executive committee of Bangladesh China Chamber of Commerce and industry. Being a member of Dubai Chamber of Commerce and Industry is just one of the many associations he is associated with. He is performing his duty at Techno Drugs Ltd., by looking after the entire sales and marketing team nationwide and internationally. His regular works, CSR activities, international presence and creative and innovative ideas to the board adds value to the overall company.

(g) Capital structure and history of capital raising:

| Particulars | No. of Shares | Face Value (Tk.) | Issue Price (Tk.) | Amount in Taka |
|-----------------------------------|--------------------|------------------|-------------------|----------------------|
| Authorized Capital | 200,000,000 | 10 | 10 | 2,000,000,000 |
| Before IPO: | | | | |
| Paid up capital | 94,157,400 | 10 | 10 | 941,574,000 |
| After IPO: | | | | |
| Issued through IPO | 36,199,095 | 10 | - | 361,990,950 |
| Paid up capital (Post IPO) | 130,356,495 | 10 | - | 1,303,564,950 |

History of capital raising:

| Particulars of Allotment | Date of Allotment | Form of Consideration (No. of Shares) | | | Face Value of Share (Tk.) | Paid-up Capital |
|---|-------------------|---------------------------------------|--------------------|------------|---------------------------|--------------------|
| | | In cash | Other than in cash | Bonus | | |
| 1 st (subscriber to the Memorandum & Articles of Association) | 30-Sep-09 | 400 | - | - | 1,000.00 | 400,000 |
| 2 nd | 8-Sep-12 | - | 80,000 | - | 1,000.00 | 80,000,000 |
| 3 rd | 16-Oct-17 | 19,200 | - | - | 1,000.00 | 19,200,000 |
| 4 th | 11-Jul-19 | 15,000 | - | - | 1,000.00 | 15,000,000 |
| 5 th | 7-Jan-20 | - | - | 57,300,000 | 10.00 | 573,000,000 |
| 6 th | 25-Oct-20 | 6,240,000 | - | - | 10.00 | 62,400,000 |
| 7 th | 11-Apr-21 | 6,876,000 | - | - | 10.00 | 68,760,000 |
| 8 th | 30-Dec-21 | - | - | 12,281,400 | 10.00 | 122,814,000 |
| Total | | | | | 10.00 | 941,574,000 |

* The Company split its share as on August 18, 2019 to Tk. 10.00 from Tk. 1,000.00 each.

(h) Summary of Valuation Report of securities:

| Particulars | | Amount (in Tk.) |
|------------------|--|-----------------|
| Method 1: | a) Share price on Net Asset Value (NAV)/Equity based valuation with revaluation reserve | 27.74 |
| | b) Share price on Net Asset Value (NAV)/Equity based valuation without revaluation reserve | 22.57 |
| Method 2: | a) Earnings based Value per share based on Overall Market P/E | 46.61 |
| | b) Earnings based Value per share based on Pharmaceuticals Sector P/E | 57.16 |
| Method 3: | Average market price of similar stock based valuation | 384.92 |
| Method 4: | P/BV multiple of similar stock based valuation | 67.31 |
| Method 5: | P/E multiple of similar stock based valuation | 58.31 |

(i) Others:

- a) Declaration by the issuer as required by Rule 3 (2) of the Bangladesh Securities & Exchange Commission (Public Issue) Rules, 2015:

DECLARATION OF MATERIAL CHANGES

We, the Issuer, declare that we did not make any material changes including raising of paid-up capital after the date of audited financial statements as included in the prospectus.

Sd/-

Shah Jalal Uddin Ahmed
Managing Director
Techno Drugs Ltd.

- b) Declaration by the issue manager as required by Rule 3 (2) of the Bangladesh Securities & Exchange Commission (Public Issue) Rules, 2015:

ISSUE MANAGER DECLARATION IN CONNECTION WITH ISSUER

We, the Issue Managers, declare that we do not have any connection with the Issuer, nor any connected persons of us are connected with the Issuer. Moreover, we do not have any connection with the connected persons of the Issuer nor hold any securities thereof.

Sd/-

Ahmed Arefin FCA
Managing Director
EBL Investments Limited

Sd/-

Md. Salauddin Sikder FCMA
CEO & Managing Director
Imperial Capital Limited

c) ISSUER DECLARATION IN CONNECTION WITH ISSUE MANAGERS

We, the Issuer, declare that we do not have any connection with the Issue Managers, nor any connected persons of Issue Managers. Moreover, the Issue Managers do not hold any securities of us.

Sd/-

Shah Jalal Uddin Ahmed
Managing Director
Techno Drugs Ltd.

CHAPTER (II)

CONDITIONS IMPOSED BY THE COMMISSION IN THE CONSENT LETTER

Disclosure in respect of issuance of security in Dematerialized Form

As per provision of the Depository Act, 1999 and regulation made there under, shares will be issued in dematerialized condition. All transfer/transmission/splitting will take place in the Central Depository Bangladesh Limited (CDBL) system and any further issuance of shares (rights/bonus) will be issued in dematerialized form only.

Conditions under 2CC of the Securities and Exchange Ordinance, 1969

PART-A

(Commence electronic bidding by the eligible investors to determine the cut-off price)

The Commission hereby imposes further conditions under 2CC of the Securities and Exchange Ordinance, 1969, to determine the cut-off price of ordinary shares of Navana Pharmaceuticals Limited in adherence to Rules 4(2)(c) of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015:

1. Each Eligible Investor (EI) who intends to submit application through the Electronic Subscription System (ESS) of the exchange(s) shall maintain a minimum investment of **Tk. 1,50,00,000.00 (Taka one crore fifty lac only)** for approved pension funds, recognized provident funds and approved gratuity funds and **other EIs of Tk. 3,00,00,000.00 (Taka three crore only)** in the listed securities (matured securities) at market price (the close price of both Exchanges whichever is higher) as on the end of a working day which is immediately preceded by 5 (five) working days from the first day of starting the bidding as per clause (e) of sub-rule (1) of rule 2 of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015. The minimum bid value for bidding shall be Tk. 20,00,000.00 (Taka Twenty Lac only). Exchanges shall send the list of BO Accounts who have applied in the IPO to the Central Depository Bangladesh Limited (CDBL). CDBL shall send a report to the Exchanges on the basis of the list of BO Accounts provided by the Exchanges regarding holding of EIs in listed securities and the Exchange shall ensure the compliance in this regard.
2. Within 5 (five) working days of completion of the bidding process, the Issuer and Issue Manager shall **jointly** submit the following papers/documents to the Commission:
 - a) 10 (ten) copies of draft prospectus duly signed by the issuer and issue manager containing among others, the cut-off price and offer price for general public as discovered through the bidding process, number of shares to be allotted to each category of investors and a statement of shares to be allotted to each of the eligible institutional investors;
 - b) Statement of the designated bank account evidencing deposit of full bid amount by the eligible investors; and
 - c) Hard copy and soft copy of the bidding results.
3. The Company along with the Issue Manager and Registrar to the Issue shall ensure compliance of the above and the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 and subsequent amendments made there under;
4. Within 5 (five) working days of completion of the bidding period, the concerned Exchange(s) shall report to the Commission whether the bidding has been successfully completed or not and also furnish a summary report thereof;
5. The concerned Exchange(s) shall extend cooperation to the Issuer and Issue Manager for compliance of condition No. 3 of this letter and Rule 4(2)(c)(xii) of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015;

6. The Commission's Directive No. BSEC/CMRRCD/2021-389/04 dated 01 February 2021 shall be complied with;
7. Electronic bidding shall be started **within 15 (fifteen) working days** from the date of issuance of this letter;
8. The fund collected through electronic bidding by the eligible investors shall not be utilized prior to listing with the Exchange(s) and that utilization of the said fund shall be effected through banking channel, i.e. through account payee cheque, pay order or bank drafts etc.; and
9. Upon completion of bidding process, the Issuer shall submit the prospectus for vetting and publication along with consent fee in advance @ 0.40% on the public offer amount by way of pay order/demand draft in favor of the 'Bangladesh Securities and Exchange Commission' **within 5 (five) working days of completion of such bidding.**

PART-B

(Raising of capital through Initial Public Offer (IPO) for General Public including NRB)

1. According to the compliance with the conditions of Part-A of this letter, the Company shall go for Initial Public Offering (IPO) for raising of Tk.1000,000,000.00 (taka one hundred crore) from which 25% of securities are reserved for Eligible Investors (EIs) including Mutual Funds and CISs (EIs) at their own bid price and quantity on highest to lowest bid basis in a descending order of individual bid price till exhaustion of the quota for EI category and the remaining 75% of securities will be offered for General Public including NRB at an issue price which is **30% discounted (at nearest integer) from the cut-off price**, totaling Tk.1000,000,000.00 (taka one hundred crore) approximately following the Securities and Exchange Ordinance, 1969, the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, the Depository Act 1999 and rules made there under.
2. The abridged version of the prospectus, as approved and vetted by the Commission, shall be published by the issuer in 4 (Four) national daily newspapers (two in Bangla and two in English), **within 5 (Five) working days** of submission of compliance report of bidding to the Commission according to the conditions of Part-A of this letter. The issuer shall post the full prospectus in the issuer's website and shall also put on the websites of the Commission, stock exchanges, and the issue manager, **within 2 (two) working days** of publication of abridged version of prospectus in the newspaper and shall remain posted till the closure of the subscription list. The issuer shall submit to the Commission, the stock exchanges and the issue manager a diskette containing the text of the vetted prospectus in "MS- Word" format.
3. The Company shall submit **40 (Forty)** copies of the printed prospectus to the Commission for official record within **5 (Five) working days** from the date of publication of the abridged version of the prospectus in the newspaper.
4. The issuer company and the issue manager shall ensure the transmission of the prospectus and its abridged version for NRBs through email to the Bangladesh Embassies and Missions abroad within **5 (Five) working days** from the date of publication of the abridged version of the prospectus in the newspaper. A compliance report shall be submitted in this respect to the Commission jointly by the Issuer and the Issue Manager within **2 (Two) working days** from the date of said transmission of the prospectus.

5. The following declaration shall be made by the Company in the prospectus, namely: -

“DECLARATION ABOUT LISTING OF SHARES WITH THE STOCK EXCHANGE(S):

None of the stock exchange(s), if for any reason, grants listing within **20 (twenty) working days** from the closure of subscription, any allotment in terms of this prospectus shall be void and the company shall refund the subscription money within **15 (Fifteen) days** from the date of refusal for listing by the stock exchanges, or from the date of expiry of the said **20 (twenty) working days**, as the case may be.

In case of non-refund of the subscription money within the aforesaid **15 (Fifteen) days**, the Directors of the company, in addition to the issuer company, shall be collectively and severally liable for refund of the subscription money, with interest at the rate of 2% (two percent) above the bank rate, to the subscribers concerned.

The issue manager, in addition to the issuer company, shall ensure due compliance of the above-mentioned conditions and shall submit compliance report thereon to the Commission within **7 (Seven) days** of expiry of the aforesaid **15 (Fifteen) days'** time period allowed for refund of the subscription money."

The stock exchanges shall complete the listing procedure and start of trading of securities within 20 (Twenty) working days from the closure of subscription.

6. Each General Public applicants (without NRB) and Non-resident Bangladeshi (NRB) applicants who intends to submit application through the Electronic Subscription System (ESS) of the exchange(s) shall maintain a minimum investment of Tk. 50,000/- (Taka Fifty thousand only) and Tk. 1,00,000/- (Taka One lakh only) respectively in the listed securities (matured securities) at market price (the close price of both Exchanges whichever is higher) as on the end of a working day which is immediately preceded by 5 (five) working days from the first day of starting the subscription. **The application amount shall be Tk. 10,000/- (Taka ten thousand) only or its multiple but not exceeding Tk.1,000,000/- (Taka Ten Lac) Only.** Exchanges shall send the list of BO Accounts who have applied in the IPO to the Central Depository Bangladesh Limited (CDBL). CDBL shall verify the list of BO Accounts provided by the Exchanges regarding investment of general applicants in listed securities.
7. The IPO shall stand cancelled in case of under- subscription in GP category above 35%. In such an event, the issuer and issue manager shall inform the Commission **within 2 (two) working days** and release the subscription money **within 7 (Seven) working days** after receiving verification report from CDBL and the information from exchanges regarding subscription.
8. In case of under-subscription under any of sub-categories of General Public category, the unsubscribed portion shall be added to other sub-category of the General Public category. In case of over subscription in the general public category, the securities shall be allotted on pro-rata basis, any fraction shall be considered to the nearest integer and accumulated fractional securities shall be allotted on random basis.
9. An applicant cannot submit more than two applications, one in his/her own name and the other jointly with another person. In case, an applicant submits more than two applications, all applications will be treated as invalid and will not be considered for allotment purpose. In addition, 15% (fifteen) of the application money will be forfeited and deposited to the Commission by the exchanges and the balance amount will be refunded to the applicant.
10. The applicants who have applied for more than two applications using the same bank account, their application will not be considered for allotment purpose. In addition, 15% of their subscription money shall be forfeited and deposited to the Commission by the exchange and the balance amount will be refunded to the applicant.

11. Making of any false statement or giving any incorrect information or suppressing any relevant information in the application shall make the application liable to rejection and subject to forfeiture of 25% of the application money and/or forfeiture of share (unit) before or after issuance of the same by the issuer. The said forfeited application money or sell proceed of forfeited shares (units) will be deposited in the account of the Bangladesh Securities and Exchange Commission (BSEC) by the exchange. This is in addition to any other penalties as may be provided for by the law.
12. The company shall furnish the list of allottees simultaneously to the Commission and the stock exchange(s) in which the shares will be listed, **within 24 (Twenty-Four) hours** of allotment.
13. Shares which are not allotted at the time of according this consent, but allotted after listing, in favor of sponsors, directors or shareholders having 10% or more shares, other than alternative investment funds, through stock dividends, shall be subject to a lock-in period of 2 (two) years **from the first trading day at the exchange**.
14. If any share of Sponsors/Directors/Promoters is in paper format, it shall be handed over to securities custodian registered with the Commission and shall remain held till completion of lock-in period and the name of the securities custodian shall be furnished to the Commission jointly by the issuer and issue manager, along with a confirmation thereof from the custodian, within one week of listing of the shares with the stock exchange(s).

Otherwise, those shares (shares of Sponsors/ Directors/ Promoters) can be dematerialized and shall remain in lock-in under CDBL system and the issuer shall submit a dematerialization confirmation report generated by CDBL system and attested by Managing Director of the company along with the lock-in confirmation to the Commission within one week of listing of the shares with the stock exchange(s). In respect of shares other than Sponsors/Directors/Promoters, the issuer will ensure their lock-in of those shares and submit a statement to this effect to the Commission.
15. **The company shall not declare any dividend/bonus shares before listing with any Exchange from the date of this letter.**
16. **The company shall issue shares to the General Investors (GI) at 30% discount of Cut-off price;**
17. **The company shall not provide/sanction any Inter-company loan from the date of this letter until further order of the Commission;**
18. The company shall not engage itself into any merger/amalgamation or acquisition activities without taking "No Objection" from the Commission, on the scheme of the said merger/amalgamation or acquisition, as recommended by the Board of Directors, before approval by the shareholders in the General Meeting, and
19. **The Issuer shall not increase its paid-up capital within 4 (four) years from the first trading day at the exchanges through issuance of bonus shares;**

PART-C
Application Process

Step-1 (Applicant)

1. An applicant for public issue of securities shall submit an application/buy instruction to the Stockbroker/ Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date), which shall be **commenced after 20 (twenty) working days and remain open up to 25th (twenty fifth) working days** from the date of publication of an abridged version of the prospectus.
2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Total Amount and Category of the Applicant. At the same time:
 - a) Non-Resident Bangladeshi (NRB) applicants shall:
 - Apply to Stockbroker/ Merchant Banker through BDT/NITA and provide bank certificate evidencing remit of foreign currency in the ESS;
 - Provide relevant documents in ESS in supporting of NRB.
 - b) Eligible investors shall submit an application through the electronic subscription system of the exchange(s) and deposit the full amount intended to subscribe by the method as determined by exchange(s).
 - c) The General Public and Non-resident Bangladeshi (NRB) applicants shall submit the application in the electronic subscription system of the exchange(s) through the Stockbrokers/Merchant Bankers where the applicant maintains customer account.

Step-2 (Intermediary)

3. The registered Stock broker/Merchant Banker in the ESS shall:
 - a) Post the amount separately in the customer account equivalent to the application money;
 - b) Accumulate all the applications/buy instructions received up to the cut-off date and transfer the amount to their respective Consolidated Customer Account;
4. The registered Stockbroker/Merchant Banker in the ESS shall prepare category wise lists of the applicants containing Customer ID, Name, BO Account Number and within **3 (three) working days** from the cut-off date, upload to the ESS, the lists of applicants in electronic (text format with tilde '~' separator) format, deposit the full amount received from the General Public and Non-Resident Bangladeshi (NRB) applicants by the method as determined by exchange(s).
5. The application/buy instructions shall be preserved by the Stock broker/Merchant Bankers up to **6 (six) months** from listing of the securities with the exchange.
6. The Exchanges shall prepare a consolidated list of the applications and send the applicants' BOIDs in electronic (text) format in a CDROM to CDBL for verification **on the next working day**. Simultaneously, the Issuer shall post the consolidated list of applicants on its website and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not, verify more than two applications by an individual, verify more than two applications using same bank account and investment criteria.
7. **On the next working day**, CDBL shall provide the Exchanges with an updated database of the applicants containing BO Account Number, Name, Addresses, Parent s' Name and Joint Account information along with the verification report.

8. After receiving verification report and information from CDBL, the Exchanges shall scrutinize the applications, prepare category wise consolidated lists of valid and invalid applications **within 5 (five) working days**.
9. **On the next working day**, the Exchanges shall provide the Commission, Issuer and Issue Manager with the soft copy of subscription result.

Step-3 (Issuer)

10. The Issuer and issue manager shall post the final status of subscription on their **websites within 6 (six) hours** and on the websites of the Commission and Exchanges **within 12 (twelve) hours** of receiving information by the Commission and the Exchanges.
11. **Within 3 (three) working days** of receipt of the subscription result, the Issuer and Exchanges shall:
 - a) Process pro-rata allotment of securities to the General Public and Non-Resident Bangladeshi (NRB) applicants;
 - b) Prepare category wise lists of invalid applicants who are subject to penal provisions as per conditions of the consent letter issued by the Commission in electronic (text format with tilde '~' separator) format mentioning the penalty amount against each applicant;
 - c) Issuer shall issue allotment letters in the names of allottees in electronic format, and
 - d) Issuer shall credit the allotted shares to the respective BO accounts on the basis of allotment data (BOID and number of securities) via their CDBL VeDAS Terminal.
12. **15% Private Offer to employees or others of the Issuer:**

According to the compliance with the provisions of the Commission's Notification No. BSEC/CMRRCD/2009-193/27/Admin/127 dated 19 July 2021, application process of the 'employees & others' category of the issuer in the initial public offering (IPO) through ESS of the Exchanges shall be conducted as follows:

- a. Employees or others will get 15% of total IPO size subject to payment of 20% premium over fair value for each share. Unsubscribed portion of employees or others will be entitled for General Public (GP) excluding NRB.
- b. The issuer shall upload the list of the existing employees or others in the electronic subscription system of the exchange(s) in electronic (text format with tilde separator) format containing Customer ID, Name (as per BO ID), BO ID, Total Quantity, Total Amount, Category of the Applicant, NID, Employee ID, Service Start Date and Designation.
- c. The existing employees of the issuer or others shall submit application in the electronic subscription system of the exchange(s) through the Stockbrokers/Merchant Bankers where the applicant maintains customer account.
- d. The registered Stockbroker/Merchant Banker in the ESS shall upload the lists of existing employees of the issuer in electronic (text format with tilde '~' separator) format.
- e. The Exchanges shall verify (name, BO ID, amount, duplicate, etc.) the applications of existing employees and send the valid BOIDs in electronic (text) format to CDBL for verification. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not.
- f. CDBL shall provide the Exchanges with an updated database of the applicants containing BO Account Number, Name, Addresses, Parent s' Name and Joint Account information along with the verification report.

The Existing employees of the issuer whose applications are valid and active will be allotted securities as per their applied quantities, **subject to a lock-in period of 2 (two) years from the first trading day at the exchanges**

Step-4 (Intermediary)

13. **On the next working day**, Exchanges shall:
 - a) remit the number of allotted applicants to the Issuer's respective Escrow Account opened for subscription purpose.
 - b) send the penalty amount who are subject to penal provisions to the Issuer's respective Escrow Accounts along with a list.
 - c) distribute the information and allotment letters to the stock broker/Merchant Bankers concerned in electronic format with a request to refund the balance application money.
14. **On the next working day** of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall refund the excess application money in the customer accounts and inform the applicants about allotment of securities.

Miscellaneous:

15. The Issuer, Issue Manager(s), Stockbrokers and Merchant Bankers shall ensure compliance of the above.
16. The Issuer shall pay the costs related to process the Eligible Investors allotment if claimed by the Exchange concerned up to an amount of Tk. 2,00,000/- (Taka Two Lac) only and Tk. 8,00,000/- (Taka Eight Lac) only for processing the applications of General Public and Non-Resident Bangladeshi (NRB) applicants.
17. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk. 5/- (Taka five) only per application irrespective of the amount or category for the service provided till withdrawal of the money. The service charge shall be paid by the applicant at the time of submitting an application.
18. The Exchanges shall provide the Issuer with a statement of the remittance.
19. The exchange shall send the penalty amount to the Commission through a bank draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.
20. The concerned Exchange is authorized to settle any complaints and take necessary actions against any Stockbroker/ Merchant Banker in case of violation of any provision of the public issue application process with intimation to the Commission.

PART-D

1. The issue manager(s) shall carefully examine and compare the published prospectus and its abridged version on the date of publication with the copies vetted by the Commission. If any discrepancy is found, both the issuer and the issue manager shall jointly publish a corrigendum immediately in the same newspapers concerned, simultaneously endorsing copies thereof to the Commission and the stock exchanges concerned. In this regard, the issue manager shall submit a compliance report to the Commission within **5 (five) working days** from the date of such publications.
2. The fund collected through Public Offering shall not be utilized prior to listing with Exchange(s) and that utilization of the said fund shall be affected through banking channel, i.e. through account payee cheque, pay order or bank drafts etc.

3. The company shall furnish a status report on the utilization of Public Offering proceeds audited by foreign-affiliated auditors and authenticated by the Board of Directors of the Company to the Commission and the Exchanges within 15 (Fifteen) days of the closing of each quarter until such fund is fully utilized, as mentioned in the schedule contained in the prospectus. The issuer shall simultaneously post the status report on its website and Exchanges shall also post the same in company information contained in websites of the Exchanges. In the event of any irregularity or inconsistency, the Commission may employ or engage any person to examine whether the issuer has utilized the proceeds for the purpose disclosed in the prospectus.
4. While auditing the utilization of IPO proceeds, the auditors will perform their jobs under the following terms of reference (TOR) and confirm the same in their report/certificate:
 - (a) Whether IPO proceeds have been utilized for the purposes/heads as specified in the prospectus;
 - (b) Whether IPO proceeds have been utilized in line with the condition (if any) of the Commission's consent letter;
 - (c) Whether the utilization of IPO proceeds have been completed within the time schedule/implementation schedule as specified in the published prospectus;
 - (d) Whether utilization of IPO proceeds is accurate and for the purpose of the company as mentioned/specified in the published prospectus; and
 - (e) The auditors should also confirm that: (i) assets have been procured/imported/constructed maintaining proper/required procedure as well as at a reasonable price; and (ii) auditors' report has been made on verification of all necessary documents/papers/vouchers in support of IPO proceeds making reconciliation with Bank Statement.
5. All transactions, excluding petty cash expenses, shall be affected by crossed cheques or bank transfers.
6. Proceeds of the public offering shall not be transferred to any other bank account before listing with the Exchange(s). The proceeds shall not be used for any purpose other than those specified in the prospectus without any valid ground. **Any material deviation in this respect must have prior approval of at least 51% of the public shareholders, other than sponsors and directors, in a general meeting through a board-approved agenda and due notification to the shareholders. Before the said general meeting, such deviation as recommended by the Board of Directors shall be published as price-sensitive information with detailed description and reasons for such deviation. If approved by the shareholders, the meeting resolution shall be submitted to the Commission along with reasonable explanations and the decision shall be published as price-sensitive information.**
7. If any quarter of the financial year-end after publication of the abridged version of prospectus and before listing of its securities with any exchange, the company shall disseminate/transmit/submit the said quarterly financial statements in accordance with the Commission's Notification BSEC/CMRRCD/2006-158/208/Admin/81 dated 20 June 2018 and Rules 15 of the Securities and Exchange Rules, 2020.
8. In the event of rising issues concerning Price Sensitive Information as defined under the সিকিউরিটিজ ও এক্সচেঞ্জ কমিশন (সুবিধাভোগী ব্যবসা নিষিদ্ধকরণ) বিধিমালা ১৯৯৫ after publication of the abridged version of prospectus and before listing of its securities with any exchange, the company shall disseminate/ transmit/ submit the information as price-sensitive in accordance with the Commission's Notification No. SEC/SRMI/200-953/1950 dated October 24, 2000.

PART-E

1. As per provision of the Depositories Act, 1999 & Regulations made thereunder, shares will only be issued in dematerialized condition. All transfer/ transmission/ splitting will take place in the depository system of Central Depository Bangladesh Ltd. (CDBL) and any further issuance of shares (including rights/bonus) will be made in dematerialized form only.
2. The issuer and the issue manager shall ensure due compliance of all the above conditions, the 'Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015' and subsequent amendments along with the listing regulations of the Exchanges:

Provided that the Board of Directors of the issuer along with the Issue Manager(s) shall conduct a quarterly meeting with the Capital Issue Department of the Commission regarding compliance status of its business plan as mentioned in the Prospectus.

3. The Commission may impose further conditions/ restrictions etc. from time to time as and when considered necessary which shall also be binding upon the issuer company.

CHAPTER (III)

DECLARATION AND DUE DILIGENCE CERTIFICATES

DECLARATION ABOUT THE RESPONSIBILITY OF THE DIRECTORS, INCLUDING THE CEO OF THE ISSUER IN RESPECT OF THE RED-HERRING PROSPECTUS

[Rule 4 (1) (d)]

This red-herring prospectus has been prepared, seen and approved by us, and we, individually and collectively, accept full responsibility for the authenticity, accuracy and adequacy of the statements made, information given in the prospectus, documents, financial statements, exhibits, annexes, papers submitted to the Commission in support thereof, and confirm, after making all reasonable inquiries that all conditions concerning this public issue and prospectus have been met and that there are no other information or documents, the omission of which make any information or statements therein misleading for which the Commission may take any civil, criminal or administrative actions against any or all of us as it may deem fit.

We also confirm that full and fair disclosures have been made in this red-herring prospectus to enable the investors to make a well-informed decision for investment.

Sd/-

Shah Jalal Uddin Ahmed

Managing Director

Sd/-

Khaleda Akhter Khan

Chairman

Sd/-

Mehreen Ahmed

Director

Sd/-

Arefeen Raafi Ahmed

Director

Sd/-

Md. Mamunur Rashid

Director

Sd/-

SK. Motiur Rahman

Independent Director

Sd/-

Uttam Kumar Saha, FCA

Independent Director

Date: January 18, 2024

DUE DILIGENCE CERTIFICATE BY ISSUE MANAGER IN THE RED- HERRING PROSPECTUS
(EBL INVESTMENTS LIMITED)

[Rule 4 (1) (d)]

To

The Bangladesh Securities and Exchange Commission

Sub: Public Issue of 36,199,095 Ordinary Shares of Tk. 1,000,000,000.00 by Techno Drugs Ltd.

Dear Sir,

We, the issue manager to the above-mentioned forthcoming issue, state and confirm as follows:

- (1) We have examined all the documents submitted with the application for the above-mentioned public issue, visited the premises of the issuer and interviewed the Chairperson, Directors and key management personnel of the issuer in connection with the finalization of the prospectus pertaining to the said issue;
- (2) On the basis of such examination and the discussions with the directors, officers and auditors of the issuer, other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer.

WE CONFIRM THAT:

- (a) The red-herring prospectus filed with the Commission is in conformity with the documents, materials and papers relevant to the issue;
- (b) All the legal requirements relating to the issue as also in the rules, notification, guidelines, instructions, etc. framed/issued by the Commission, other competent authorities in this behalf and the Government have been duly complied with;
- (c) The disclosures made in prospectus are true, fair and adequate to enable the investors to make a well-informed decision for investment in the proposed issue and such disclosures are in accordance with the requirements of the Companies Act, 1994, the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 and other applicable laws;
- (d) Besides ourselves, all the intermediaries named in the prospectus are registered with the Commission and that till date such registrations are valid;
- (e) We have satisfied ourselves about the capability of the underwriters to fulfill their underwriting commitments;
- (f) The proposed activities of the issuer for which the funds are being raised in the present issue fall within the 'main objects' listed in the object clause of the Memorandum of Association or other charter of the issuer and that the activities which have been carried out till now are valid in terms of the object clause of its Memorandum of Association;

- (g) Necessary arrangements have been made to ensure that the moneys to be received pursuant to the issue shall be kept in a separate insurance account and shall be used for the purposes disclosed in the use of proceeds section of the red-herring prospectus;
- (h) All the applicable disclosures mandated in the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 have been made in addition to other disclosures which, in our view, are fair and adequate to enable the investor to make a well-informed decision;
- (i) We enclose a note explaining how the process of due diligence has been exercised by us in view of the nature of current business background or the issuer, situation at which the proposed business stands, the risk factors, sponsors experiences etc. We also confirm that the due diligence related process, documents and approval memos shall be kept in record by us for the next 5 (five) years after the IPO for any further inspection by the Commission;
- (j) We enclose a checklist confirming rule-wise compliance with the applicable provisions of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 containing details such as the rule number, its text, the status of compliance, page numbers of the prospectus where the rules has been complied with and our comments, if any;
- (k) We also declare that we have managed the public issue of following issuers in the last 05 (five) years:

| <u>Sl. No.</u> | <u>Name of the Issue</u> | <u>Month/ Year</u> | <u>Issue Price (BDT)</u> | <u>Dividend Payment History</u> |
|----------------|-----------------------------|--------------------|--------------------------|--|
| 1 | Navana Pharmaceuticals Ltd. | 19 Jun, 2022 | 24 | 2023: C-13% 2022: C-11% |
| 2 | Index Agro Industries Ltd. | Jan 20, 2021 | 50 | 2023: C-20% 2022: C-10% 2021: C-25% |
| 3 | Silco Pharmaceuticals Ltd. | 07 Feb, 2019 | 10 | 2023: C-3% 2022: C-5% 2021: C-10% 2020: C-10% 2019: C-2% & B-10% |

For the Issue Manager

Place: Dhaka;
Date: April 30, 2024

Sd/-
Ahmed Arefin FCA
Managing Director
EBL Investments Limited

DUE DILIGENCE CERTIFICATE BY ISSUE MANAGER IN THE RED- HERRING PROSPECTUS
(IMPERIAL CAPITAL LIMITED)

[Rule 4 (1) (d)]

To

The Bangladesh Securities and Exchange Commission

Sub: Public Issue of 36,199,095 Ordinary Shares of Tk. 1,000,000,000.00 by Techno Drugs Ltd.

Dear Sir,

We, the issue manager to the above-mentioned forthcoming issue, state and confirm as follows:

- (1) We have examined all the documents submitted with the application for the above-mentioned public issue, visited the premises of the issuer and interviewed the Chairperson, Directors and key management personnel of the issuer in connection with the finalization of the prospectus pertaining to the said issue;
- (2) On the basis of such examination and the discussions with the directors, officers and auditors of the issuer, other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer.

WE CONFIRM THAT:

- (a) The red-herring prospectus filed with the Commission is in conformity with the documents, materials and papers relevant to the issue;
- (b) All the legal requirements relating to the issue as also in the rules, notification, guidelines, instructions, etc. framed/issued by the Commission, other competent authorities in this behalf and the Government have been duly complied with;
- (c) The disclosures made in prospectus are true, fair and adequate to enable the investors to make a well-informed decision for investment in the proposed issue and such disclosures are in accordance with the requirements of the Companies Act, 1994, the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 and other applicable laws;
- (d) Besides ourselves, all the intermediaries named in the prospectus are registered with the Commission and that till date such registrations are valid;
- (e) We have satisfied ourselves about the capability of the underwriters to fulfill their underwriting commitments;
- (f) The proposed activities of the issuer for which the funds are being raised in the present issue fall within the 'main objects' listed in the object clause of the Memorandum of Association or other charter of the issuer and that the activities which have been carried out till now are valid in terms of the object clause of its Memorandum of Association;

- (g) Necessary arrangements have been made to ensure that the moneys to be received pursuant to the issue shall be kept in a separate insurance account and shall be used for the purposes disclosed in the use of proceeds section of the red-herring prospectus;
- (h) All the applicable disclosures mandated in the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 have been made in addition to other disclosures which, in our view, are fair and adequate to enable the investor to make a well-informed decision;
- (i) We enclose a note explaining how the process of due diligence has been exercised by us in view of the nature of current business background or the issuer, situation at which the proposed business stands, the risk factors, sponsors experiences etc. We also confirm that the due diligence related process, documents and approval memos shall be kept in record by us for the next 5 (five) years after the IPO for any further inspection by the Commission;
- (j) We enclose a checklist confirming rule-wise compliance with the applicable provisions of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 containing details such as the rule number, its text, the status of compliance, page numbers of the prospectus where the rules has been complied with and our comments, if any;
- (k) We also declare that we have managed the public issue of following issuers in the last 05 (five) years:

| <u>Serial No</u> | <u>Issue Month/Year</u> | <u>Issue Price</u> | <u>Dividend Payment History</u> |
|------------------|-------------------------|--------------------|---------------------------------|
| - | - | - | - |

For the Issue Manager

Place: Dhaka;
Date: April 30, 2024

Sd/-
Md. Abul Bashar Parvez
Chief Executive Officer
Imperial Capital Limited

DUE DILIGENCE CERTIFICATE BY THE UNDERWRITER
(EBL Investments Limited)
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Issue of 36,199,095 of Ordinary Shares of Tk 1,000,000,000 of Techno Drugs Ltd.

Dear Sir,

We, the under-noted Underwriter to the above-mentioned forthcoming issue, state individually and collectively as follows:

- (1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and
- (2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

- (a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 680,000,000 (Sixty-Eight Crore) and we have the capacity to underwrite a total amount of Tk. 3,400,000,000 (Three Hundred and Forty Crore) as per relevant legal requirements. We have committed to underwrite for up to Tk. 86,877,828.00 (Taka Eight Crore Sixty-Eight Lac Seventy-Seven Thousand Eight Hundred Twenty-Eight) for the upcoming issue.
- (b) At present, the following underwriting obligations are pending for us.

| Sl. | Name of the company | Amount Underwritten (in Taka) |
|--------------|---------------------------------------|-------------------------------|
| 1 | Bangla Trac Rental Services PLC (QIO) | 11,250,000 |
| Total | | 11,250,000 |

- (c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;
- (d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and
- (e) The underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-
Ahmed Arefin FCA
 Managing Director
EBL Investments Limited

Place: Dhaka,
 Date: April 30, 2024

DUE DILIGENCE CERTIFICATE BY THE UNDERWRITER
BMSL INVESTMENT LIMITED
[Rule 4 (1) (d)]

To
The Bangladesh Securities and Exchange Commission

Sub: Public Issue of 36,199,095 of Ordinary Shares of Tk 1,000,000,000.00 of Techno Drugs Ltd.

Dear Sir,

We, the under-noted Underwriter to the above-mentioned forthcoming issue, state individually and collectively as follows:

- (1) We, while underwriting the above mentioned issue on a firm commitment basis, have examined the draft prospectus, other documents and materials as relevant to our underwriting decision; and
- (2) On the basis of such examination and the discussions with the issuer company, its directors and officers, and other agencies, independent verification of the statements concerning objects of the issue and the contents of the documents and other materials furnished by the issuer company.

WE CONFIRM THAT:

- (a) We are registered with the Bangladesh Securities and Exchange Commission as a merchant banker and eligible to carry out the underwriting activities. Our present paid-up capital stands at Tk. 420,000,000.00 (Forty-Two Core only) and we have the capacity to underwrite a total amount of Tk. 2,100,000,000.00 (Two Hundred Ten Core only) as per relevant legal requirements. We have committed to underwrite for up to Tk. 106,968,325.00 (Taka Ten Crore Sixty-Nine Lac Sixty-Eight Thousand Three Hundred Twenty-Five) only for the upcoming issue.
- (b) At present, the following underwriting obligations are pending for us.

| Sl. No. | Name of the company | Amount Underwritten (In Tk.) |
|--------------|---------------------|------------------------------|
| - | - | - |
| Total | | - |

- (c) All information as are relevant to our underwriting decision have been received by us and the draft prospectus forwarded to the Commission has been approved by us;
- (d) We shall subscribe and take up the un-subscribed securities against the above-mentioned public issue within 15 (fifteen) days of calling up thereof by the issuer; and
- (e) The underwriting commitment is unequivocal and irrevocable.

For the Underwriter:

Sd/-

Md. Riyad Matin
 Managing Director
BMSL Investment Limited


Place: Dhaka,
 Date: April 30, 2024

CHAPTER (IV)

ABOUT THE ISSUER

- (a) **Name of the issuer, dates of incorporation and commencement of its commercial operations, its logo, addresses of its registered office, other offices and plants, telephone number, fax number, contact person, website address and e-mail address;**

Particulars of the Company:

| Particulars | Description |
|---|--|
| Name of the Issuer | : Techno Drugs Ltd. (TDL) |
| Dates of Incorporation | : September 30, 2009 |
| Commencement of its Commercial Operations | : July 01, 2010 |
| Logo | :  |
| Registered & Corporate office | : J K Tower, 31 Segunbagicha, Dhaka-1000 Tel: +88-02-58316038 Fax: +88-02-58315821 |
| Factory | : Satirpara, Narsingdi-1600 Tel: +88-02-9462842 : B.K. Bari Mirzapur, Gazipur-1703 Cell: +8801313011740 |
| Contact Person | : Pijush Kumar Chakroborty FCA : Chief Financial Officer |
| Website Address | : www.technodrugsLtd.com |
| E-mail Address | : contact@technodrugsLtd.com |

- (b) **The names of the sponsors and directors of the issuer:**

Name of the Sponsors and Directors:

Sponsors:

| Sl. | Sponsors |
|------------|------------------------|
| 1 | Shah Jalal Uddin Ahmed |
| 2 | Khaleda Akhter Khan |
| 3 | Mehreen Ahmed |
| 4 | Arefeen Raafi Ahmed |


Directors:

| Sl. | Name | Position |
|------------|------------------------|----------------------|
| 1 | Shah Jalal Uddin Ahmed | Managing Director |
| 2 | Khaleda Akhter Khan | Chairman |
| 3 | Mehreen Ahmed | Director |
| 4 | Arefeen Raafi Ahmed | Director |
| 5 | Md. Mamunur Rashid | Director |
| 6 | SK. Motiur Rahman | Independent Director |
| 7 | Uttam Kumar Saha, FCA | Independent Director |

- (c) The name, logo and address of the auditors and registrar to the issue, along with their telephone numbers, fax numbers, contact persons, website and e-mail addresses:

Particulars of Auditor and Registrar to the Issue:

Auditor:



| Particulars | Description |
|------------------|---|
| Name | : ISLAM QUAZI SHAFIQUE & CO. Chartered Accountants |
| Logo | :  |
| Address | : Moghbazar Office: Al-HajShamsuddin Mansion (4th Floor), 17, New Eskaton Road, Moghbazar, Dhaka-1000 Uttara Office: ABC Sky Rise Tower (6th Floor) 6B Unit, Shahjalal Avenue Road, Sector # 4 Uttara, Dhaka |
| Telephone Number | : Tel: +88-02-48312349 |
| Fax Number | : Fax: no Fax Number |
| Contact Person | : Biplab Hossain FCA Partner |
| Website Address | : www.qsibd.com |
| E-mail Address | : info@qsibd.com, biplabhossainfca@gmail.com |

Registrar to the Issue:

| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
|--|--|---|
| BMSL Investment Limited Shareef Mansion (4th Floor) 56-57 Motijheel C/A Dhaka-1000. | Tel: +88-02-9577651, +88-02-9570624, +88-02-9565183 Fax: +88-02-47117218 E-mail: info@bmslinvestment.com Web: www.bmslinvestment.com | Md. Riyad Matin Managing Director |


- (d) The name(s) of the stock exchanges where the specified securities are proposed to be listed.

Name of the Stock Exchanges where the Securities to be listed:

| | | | |
|------------------------|---|--|--|
| Stock Exchanges | Dhaka Stock Exchange PLC DSE Tower, Plot # 46, Road # 21, Nikunja-2, Dhaka-1229 |  | Tel: +88-02-41040189-200 Fax: +88-02-41040096 |
| | Chittagong Stock Exchange PLC CSE Building, 1080, Sheikh Mujib Road Chittagong 4100 |  | Tel: +880-2-9513911-15 Fax: +880-2-9513906 |

CHAPTER (V)

CORPORATE DIRECTORY OF THE ISSUER

| | | |
|---|---|--|
| Name of the Company | : | Techno Drugs Ltd. (TDL) |
| Logo | : |  |
| Nature of Business | : | Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human and Veterinary medicines and selling them in local and international market. We are also the pioneer of Oncology medicines in Bangladesh. |
| Date of Incorporation | : | September 30, 2009 |
| Commencement of its Commercial Operations | : | July 01, 2010 |
| Authorized Capital | : | Tk. 2,000,000,000 divided into 200,000,000 Ordinary Share of Tk. 10.00 each |
| Paid up Capital | : | Tk. 941,574,000 divided into 94,157,400 Ordinary Share of Tk. 10.00 each |
| Registered & Head Office | : | J K Tower, 31 Segunbagicha, Dhaka-1000 Tel: +88-02-58316038 Fax: +88-02-58315821 Email: contact@technodrugsLtd.com Web: www.technodrugsLtd.com |
| Factory | : | Satirpara, Narsingdi-1600 Tel: +88-02-9462842 B.K. Bari Mirzapur, Gazipur-1703 Cell: +8801313011740 |
| Board of Directors | : | 7 Directors including 2 Independent Directors. |
| Auditors | : | ISLAM QUAZI SHAFIQUE & CO. Chartered Accountants Moghbazar Office: Al-HajShamsuddin Mansion (4th Floor), 17, New Eskaton Road, Moghbazar, Dhaka-1000 Uttara Office: ABC SkyRise Tower (6th Floor) 6B Unit, Shahjalal Avenue Road, Sector # 4 Uttara, Dhaka Tel: +88-02-48312349 Fax: no Fax Number E-mail: info@qsibd.com, biplabhossainfca@gmail.com web: www.qsibd.com |
| Tax Consultant | : | Adv. Mohammad Nazmul Consultant and Attorney Chamber Pa-67/2, Middle Badda, Badda, Dhaka-1212 Tel: +8801713205419 E-mail: mnaazmul@gmail.com |
| Legal Advisor | : | Haque, Hasan, Ahmed & Associates Sultan Building (2nd Floor, East), 147 Motijheel C/A, Dhaka-1000 Tel: +88-02-9564216 E-mail: kmmahmed@gmail.com |
| Banker for IPO | : | One Bank Limited |
| Banker of the Company | : | AB Bank Ltd., One Bank Ltd., Community Bank Ltd., Agrani Bank Ltd., Dhaka Bank Ltd., Dutch Bangla Bank Ltd., Trust Bank Ltd., Sonali Bank Ltd., Simanto Bank Ltd. and IFIC Bank Ltd. |
| Compliance Officer | : | Debasish Das Gupta |

CHAPTER (VI)

DESCRIPTION OF THE ISSUER


(a) Summary:

- (i) **The summary of the industry and business environment of the issuer. The summary shall not be one-sided or biased to highlight the issuer or the issue;**

Summary of the industry:

Pharmaceutical industry of Bangladesh has earned a considerable reputation for producing quality medicine by maintaining international standards. Today, Bangladesh has become one of the top pharmaceutical exporting countries of the world where 98% of the country's total demand for medicines is being produced locally. We are exporting our medicines to about 150+ countries of the world and our medicines have high demand for value and quality in European, American, Middle Eastern, and Central Asian markets.

However, just 35 years ago, this scenario wasn't the same. More than 90% of the medicines in the country had to be imported from abroad. Since the formulation of the National Drug Policy in 1982, we have seen a significant growth in the pharmaceutical industry of the Bangladesh. In 2020, the whole world came to a standstill and almost all services and businesses were stopped due to the pandemic. Even at that time our pharma sector workers continued providing services. Employees at all levels of the pharma sector served people without stopping to work even for even a single day during that horrific time.



During that time, the turnover decreased slightly but the production, marketing and operating costs also dropped by a lot. Furthermore, the government provided various benefits to the industry, including the relaxation of loan repayment rules. As a result, the pharmaceutical companies of the country did not suffer any major losses.

In 2021, pharmaceutical exports of the country achieved an 11.7% growth. In 2022, the whole world faced a difficult situation with raw material shortages, transport cost hikes and a dollar crisis. As a result, the industry plunged into a crisis. During this period, we became dependent on diesel due to gas shortages. As a result, the primary energy costs increased up to 100%. The import cost has also increased by 25%. However, we have only increased drug prices by an average of 4%. The reason for not increasing the medicine prices, despite a rise in the production cost, is that we have considered the purchasing power of the people of our country.

One of our major possibilities are in the export of medicines and the pharmaceutical industry of Bangladesh is preparing for this for a long time. Approximately 20 to 22 companies in this sector are spending a lot of money on research and development to boost exports. The local companies are trying hard to manufacture necessary raw materials and Active Pharmaceutical Ingredients (API) at a competitive price. Many companies have already been successful in producing APIs for some products.

In today's competitive world, the price of medicines is an important factor besides quality. People of Bangladesh now get medicines at a much lower price than in any other countries around the world. We are trying to produce raw materials at a lower price than the other companies in different parts of the world. Once we start preparing and marketing APIs in large quantity, the country's pharmaceutical industry will reach a different level. We will probably be able to export drugs abroad with our own APIs from 2024. It will also reduce our dependency on import of raw materials.

Currently, we need raw materials worth \$700 million in a year, which will come down to \$200 million after 2024. On the other hand, our export income will be more than \$1 billion and it will make the pharmaceutical industry a dollar-surplus industry. Currently, India is the top supplier of raw materials for the pharmaceutical industry. But the country is raising prices slowly. It will create an opportunity for us. We want to enter the international market as a low-cost manufacturer, with uncompromised quality.

We are now meeting 98% of local demand for medicines. After 2024, we will continue to advance in the same way and cover 100% of the local demands and dominate the international market. After five years, our pharmaceutical industry will enter a new era. We will have to set up factories and sales centers outside the country to conquer the global market. For this expansion, our government will need to be a little more liberal in terms of providing policy support to the industry.

There are strict regulations and restrictions in importing various raw materials, including formalin and acid. Chemicals which are classified as narcotics are subject to more stringent import restrictions. We demand a separate import policy for the pharmaceutical industry. Laws should be made to remove the complexities in importing any kind of raw materials for the purpose of making medicines.

While everyone is excited about the prospects of our pharmaceutical industry, some are also concerned about the challenges in the post-TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) era. In this case, the hope is that the patents of most of the products we are exporting right now have already expired. As a result, there is nothing to worry about their patents in the post-TRIPS era. However, our concern is about the affordability of medicines in the country.

Source: <https://www.tbsnews.net/supplement/pharmaceuticals-will-be-dollar-surplus-industry-next-year-574330>

Business environment of the issuer:

TDL's business environment is conducive to the business as it has good supply of raw materials. TDL has skilled labors as well. The wage of labor is reasonable also. Government policy is favorable to the sector. Overall, it is a business-friendly situation.

(ii) Summary of consolidated financial, operating and other information.

Techno Drugs Ltd. has no subsidiary, associate or holding company. So, consolidation is not applicable for the company.

(b) General Information:**(i) Name and address, telephone and fax numbers of the registered office, corporate head office, other offices, factory, business premises and outlets of the issuer;**

| Particulars | Description |
|-------------------------------|--|
| Name | : Techno Drugs Ltd. (TDL) |
| Registered & Corporate office | : J K Tower, 31 Segunbagicha, Dhaka-1000 Tel: +88-02-58316038 Fax: +88-02-58315821 |
| Factory | : Satirpara, Narsingdi-1600 Tel: +88-02-9462842 : B.K. Bari Mirzapur, Gazipur-1703 Cell: +8801313011740 |
| Sales Depots: | |
| Barishal | : House Name- Niloy, Holding No-872, Ward No-14, Barishal City Corporation, Barishal Sadar, C&B Road, Barishal |
| Sylhet | : Holding No-16/A, Shoroshpur Charanir, Lama Bazar, Sylhet-3100, Sylhet Sadar, Sylhet |
| Rajshahi | : House: 0233, Housing Estate, Sector-2, Post office: Rajshahi Shenanibash-6202, Boalia, Rajshahi. |
| Bogura | : House-399/431, Opposite of Tajma Ceramic, Thonthonia, Bogura |
| Faridpur | : Aloknondan- Holding No.-10/32/01, Alauddin Khan Road, South Alipur, Faridpur Sadar. |
| Rangpur | : House No.-78/4, road no.-01, PTI road, Katkipara, kotoali Rangpur |
| Mymensingh | : House No-6/1, Natokghor Lane, Kotoali, Mymensingh |
| Bhairab | : Holding No-920, Kolompur, Bhairab, Kishorgonj |
| Jeshore | : Holding No-1/B, Najnin Gopi Central Road, Jeshore Town, Police Station-Kotoali, Jeshore |
| Chattogram | : 523, Shahid Nagar, Hathazari Road, (Near Oxygen) P.O Amin Jute Mills Ltd. Chattogram-4211 |
| Cumilla | : Holding No-355/420, Munshi Bari, Rail Station Road, Adorsho Sadar, Cumilla |
| Khulna | : Afroja Kanon, Holding No.-294, Road No.-17, Nirala Housing Area, Post Office: Khulna City-9100, Khulna Sadar, District: Khulna |
| Dinajpur | : Shishuniketon Road, ShipahiPara, Block no.-10, Ward No.-09, Dinajpur |
| Kushtia | : Road No.-48/1, Bicharpoti Mahbub Morshed Road, Kotapara (Peyaratala), Kushtia Sadar, Kushtia |
| Noakhali | : House No.-08, Road No.-36, Housing Estate, Maijdi Court, Noakhali |
| Tangail | : Plot No.-1030/1, Shabalia, Suroj Road, Tangail |
| Dhaka | : J K Tower, 31 Segunbagicha, Dhaka-1000 |

(ii) **The board of directors of the issuer;**

| Sl. | Name | Designation |
|-----|------------------------|----------------------|
| 1 | Shah Jalal Uddin Ahmed | Managing Director |
| 2 | Khaleda Akhter Khan | Chairman |
| 3 | Mehreen Ahmed | Director |
| 4 | Arefeen Raafi Ahmed | Director |
| 5 | Md. Mamunur Rashid | Director |
| 6 | SK. Motiur Rahman | Independent Director |
| 7 | Uttam Kumar Saha, FCA | Independent Director |

(iii) **Names, addresses, telephone numbers, fax numbers and e-mail addresses of the chairman, managing director, whole time directors, etc. of the issuer;**

| Sl. | Name & Address | Telephone and Fax No. & E-mail Address |
|-----|---|---|
| 1 | Name: Shah Jalal Uddin Ahmed Position: Managing Director Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: md@technodrugsLtd.com |
| 2 | Name: Khaleda Akhter Khan Position: Chairman Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: chairman@technodrugsLtd.com |
| 3 | Name: Mehreen Ahmed Position: Director Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: director@technodrugsLtd.com |
| 4 | Name: Arefeen Raafi Ahmed Position: Director Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: a.a.raafi@gmail.com |
| 5 | Name: Md. Mamunur Rashid Position: Director Address: Vill: Barikhola, PO: Laur Fatehpur, PS: Nabinagar, Dist: B. Baria | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: xtrenza.mamun@gmail.com |
| 6 | Name: SK. Motiur Rahman Position: Independent Director Address: 10/B Concord, 5 Segunbagicha, Ramna, Dhaka | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: barrister.motiur@gmail.com |
| 7 | Name: Uttam Kumar Saha, FCA Position: Independent Director Address: Level-5, Green Zone Tower, 1 No Hatkhola Road, Wari Dhaka-1203 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: uksmpl@gmail.com |

* Shah Jalal Uddin Ahmed, Managing Director; Mehreen Ahmed, Director and Arefeen Raafi Ahmed, Director are the whole time Directors who receive remuneration from the Company.

- (iv) **Names, addresses, telephone numbers, fax numbers and e-mail addresses of the CFO, company secretary, legal advisor, auditors and compliance officer;**

| Sl. | Name & Address | Telephone and Fax No. & E-mail Address |
|-----|--|--|
| 1 | Pijush Kumar Chakroborty FCA Chief Financial Officer J K Tower, 31 Segunbagicha, Dhaka-1000 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: cfo@technodrugsLtd.com |
| 2 | Debasish Das Gupta Company Secretary & Compliance Officer J K Tower, 31 Segunbagicha, Dhaka-1000 | Tel: +88-02-58316038 Fax: +88-02-58315821 E-mail: cs@technodrugsLtd.com |
| 3 | Haque, Hasan, Ahmed & Associates Legal Advisor Sultan Building (2nd Floor, East), 147 Motijheel C/A, Dhaka-1000 | Tel: +88-02-9564216 Fax: No Fax Number E-mail: kmmahmed@gmail.com |
| 4 | ISLAM QUAZI SHAFIQUE & CO. Chartered Accountants Moghbazar Office: Al-HajShamsuddin Mansion (4th Floor), 17, New Eskaton Road, Moghbazar, Dhaka-1000 Uttara Office: ABC SkyRise Tower (6th Floor) 6B Unit, Shahjalal Avenue Road, Sector # 4 Uttara, Dhaka | Tel: +88-02-48312349 Fax: no Fax Number E-mail: info@qsibd.com biplabhossainfca@gmail.com |

- v) **Names, addresses, telephone numbers, fax numbers, contact person, website addresses and e-mail addresses of the issue manager(s), registrar to the issue etc.;**

Issue Managers:

| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
|---|---|--|
| EBL Investments Limited BSC Tower (4th Floor), 2-3 Rajuk Avenue, Motijheel C/A, Dhaka-1000 | Tel: +88-02-47111096, +88-02-47111867 Fax: +88-02-47111218 E-mail: info@eblinvestments.com Web: www.eblinvestments.com | Ahmed Arefin FCA Managing Director |
| Imperial Capital Limited Saiham Sky View Tower (3rd Floor), 45 Bijoy Nagar, Dhaka-1000. | Tel: +88-02-9361870 Fax: +88-02-9361870 (Ext.-102) E-mail: imperialcapltd@gmail.com Web: www.imperialcapital.org | Md. Abul Bashar Parvez Chief Executive Officer |

Registrar to the Issue:

| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person |
|--|---|---|
| BMSL Investment Limited Shareef Mansion (4th Floor) 56-57 Motijheel C/A Dhaka-1000. | Tel: +88-02-9577651, +88-02-9570624, +88-02-9565183 Fax: +88-02-47117218 E-mail: info@bmslinvestment.com Web: www.bmslinvestment.com | Md. Riyad Matin Managing Director |

(vi) **The following details of credit rating, where applicable:**

- a) **The names of all the credit rating agencies from which credit rating has been obtained;**

| Name of The Credit Rating Agencies | Rating Date |
|---|--------------------|
| Emerging Credit Ratings Ltd. | April 07, 2023 |

- b) **The details of all the credit ratings obtained for the issue and the issuer;**

| Credit Rating by | Emerging Credit Ratings Ltd. | |
|-------------------------|-------------------------------------|--------------|
| Rating | Entity Rating | |
| | Long-Term | Short Term |
| | A | ST-2 |
| Outlook | Stable | Stable |
| Validity | May 20, 2024 | May 20, 2024 |

- c) **The rationale or description of the ratings (s) so obtained, as furnished by the credit rating agency(s);**

Emerging Credit Rating Limited (hereafter referred to as 'ECRL') has affirmed **A** long term credit rating (Pronounced as Single A) and **ST-2** short term credit rating to Techno Drugs Ltd. (hereinafter referred to as 'TDL'). The outlook of the rating is **Stable**. The company is manufacturing variety of human and animal drug. The ratings are consistent with ECRL's methodology for this type of company. The rating is based on the audited financial of FY 2019-2022, bank information and other relevant information till the date of rating.

Techno Drug Limited was incorporated as a private limited pharmaceuticals company on September 09, 2009. Subsequently, the company converted into Public Limited Company vides EGM dated 18th August, 2019. Initially, the company was engaged in manufacturing of Animal Drugs. Presently, the company is manufacturing varieties of human and animal drug. Moreover, TDL has taken a master plan to set up additional unit under BMRE program at BK Bari, Gazipur over 1,300 decimal lands. The rest of the facilities are on construction and will go on to commercial production on stages. The final stage will be completed by December 2024, and commercial production will start by January 2025 as per the project schedule.

TDL's revenue climbed by 30.90% in FY2022, reaching BDT 5,028.54 million, owing to utilization of the increased production capacity facilitated by the partial completion of the expansion project. As per management correspondence, the new expansion unit has enabled the company to increase its production capacity by approximately 30.00%, which is reflected in the rising revenue trend. The cost of items sold followed this trend, growing as a result of increased expenses associated with raw materials and production. Operating costs increased by 43.69%, primarily due to increased employee-related expenses. Despite rising finance costs, the company achieved a significant net profit of BDT 479.78 million, a 32.92% rise year on year, largely compensating higher expenses.

Liquidity remained moderate over four years, with a current ratio of 1.08 times suggesting reasonable coverage of current liabilities. Total current assets climbed by 6.39% as inventories, receivables, and cash balance increased while current liabilities increased by 0.94 percent. On the other hand, the quick asset ratio fell slightly from 0.75 to 0.70. Moreover, In FY2022, the company's cash position improved significantly with a surplus cash flow of BDT 593.05 million.

In addition, the company's sustained performance increased cumulative retained earnings, boosting equity. Long-term debt gradually declined, resulting in a debt-to-equity ratio of 0.95 times in FY2022, down from 1.63 times in FY2021. Furthermore, OPBIT interest coverage ratio exhibited a comfortable coverage of the interest obligations by generated operating profit in 2022.

Techno Drugs Ltd. has been banking with multiple banks and financial institutions. As per sanction letters the company's total bank facility limit stood at BDT 4,634.06 million. The short-term loan facilities consisted by LC, BG, OD and time loan for the purpose of import raw materials and machineries, meet working capital requirements and the term loan for expansion of existing business. The company also received stimulus packages from both bank due to the pandemic. TDL's total loan outstanding liabilities were BDT 2,786.79 million as on the above mentioned dates. There is an overdue of BDT 7.95 million against the loan from IDLC Finance Limited. Against the availed facilities, the company has kept registered mortgage, personal guarantee of the directors, lien of FDR, registered irrevocable power of attorney etc. as securities.

The concern's **Stable** outlook represents current business set up, additional new facilities, distribution and management's experience. The future direction of the rating will depend on the ability to generate incremental revenue and profit margin, on time completion of expansion plans and proper utilization of new facilities.

d) **Observations and risk factors as stated in the credit rating report.**

The Company operates under the Drugs Ordinance, Companies Act, 1994, Directorate of Drug Administration (DDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act, 1969, Value Added Tax (VAT) Act 1991 and Value Added Tax (VAT) Rules 1991. Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the Company. The company operates in a highly regulated market with registration of products, operational reviews and inspections required by Directorate of Drug Administration (DDA) periodically. The company received Certificate of Good Manufacturing Practice (GMP) for Pharmaceutical Products from the Directorate General of Drug Administration Ministry of Health & Family Welfare dated April 21, 2021.

Pharmaceutical industry is a competitive industry in Bangladesh. The industry faces a number of aggressive competitors within the country and abroad as well. There are over 257 other manufacturers of pharmaceutical products in Bangladesh which the company has to compete with. The industry rivalry of this kind of business is moderate to high. The exit barrier is moderate to high with backward & forward linkages for many of the industry participants in Bangladesh. But the Bangladeshi industries have certain advantage in this industry over other countries of the world, one of them are competitive labor price and availability. Due to low bargaining power the industry has to depend on international policy. Influence of medical practitioner, wholesalers and retail outlet also dominate the product of certain companies.

Bangladesh's pharmaceutical sector largely relies on imports for raw, and almost 90% of the raw materials are import-dependent which leads to higher costs, risk due to change in international policy, import regulation, exchange rate risks etc. However, an API Industrial Park is being set up by the Government at Munshiganj, 37 Km from the capital city Dhaka. The project is being implemented on 200 acres of land. There will be 42 plots in which Pharmaceutical Ingredient Manufacturing

Industrial units will be set up. Producing the API locally will decrease the cost of locally manufactured drugs and it will add to the cost advantage for exports.

Technology always plays a vital role for each and every type of business. Better technology can increase productivity and reduce costs of production. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the company which may cause operational inefficiency. TDL has adopted latest technology according to its needs committed in maintaining quality and brand image. In connection with this, TDL has imported machinery from European countries such as Spain, Korea, China and also Asian countries such as Indonesia, Malaysia etc. to maintain manufacturing quality and standard. For quality maintaining, the entity follows the GMP guideline. The inventory is handled by QA and QC where temperature, quality, IPQC is checked before producing the medicines.

The major requirements for smooth operations of pharmaceuticals industry are continuous power support; smooth functioning of the machineries and efficient & quality performance of the workers. The profitability of the company can be adversely affected from unavailability or increase in price of raw materials of pharmaceutical products, natural calamities like flood, cyclone, and earthquake. These events are likely to hamper the normal business operation of the entity and can adversely impact the profitability of TDL. TDL has arranged back up power support for its plants. The company has installed high-tech and latest machineries at its plants. In order to ensure efficient and quality performance of tasks, it has a good number of SOPs and well-trained staff.

Bangladesh and other LDCs are exempted from patent protection by WTO for an extended period until 2033 (from original 2016). Bangladesh is allowed to produce any patented medicines without taking prior permission from innovator. However, since Bangladesh is looking forward to graduating from LDC by 2026, Bangladesh is likely to lose the patent exemption facility 7 years before the expiration date. Which may stop the development of the pharmaceutical industry in Bangladesh because if Bangladesh loses the benefits of the TRIPS agreement, pharmaceutical companies will have to enact new patent laws. As a result, manufacturing of many types of generic medicine is likely to cease. If domestic manufacturers want to maintain production of these medicines, they may have to pay royalties on patents. As a result, the overall price of medicine in Bangladesh may increase. Otherwise companies will face patent violations and exports will be severely hampered.

In addition, the pharmaceuticals industry in Bangladesh is highly regulated as compared to other industries due to its impact on the citizens. As Per the Drugs (Control) Ordinance, 1982, The Government may, by notification in the official Gazette, fix the maximum price at which any medicine may be sold, and can also fix the maximum price at which any pharmaceutical raw material may be imported or sold. This could limit the profitability of the pharmaceutical manufactures since they cannot increase the price if costs increase.

As TDL uses credit facilities from various financial institutions, it is exposed to interest rate risks. The Bangladesh Bank (BB) has removed the previously imposed interest rate cap of 6%-9% and introduced a reference rate driven by market forces, which will be regulated based on the average treasury bills rate effective from July 1, 2023. This could have an adverse impact on the finance cost of the company in the coming years.

Since TDL procures some of its raw materials from international market, and also exports in the international markets, it does have exposure in exchange rates such as the USD/Euro/Pound. Recent appreciation of USD against BDT has had an adverse impact on the raw material costs of the company. Although, the export proceeds would have been positively impacted by this, the company did not generate any export revenue during the year.

The rating process was based on qualitative aspects which are based on the company's policies in relation with the operating strategies, financial leverage and ultimate financial goals of the companies. For this purpose of the overall financial risk assessment of the company, ECRL divided the financial portion into five different criteria which are Profitability Analysis, Liquidity Analysis, Cash flow Analysis, Asset Management, Capital Structure, and overall Financial Flexibility.

The revenue of TDL has been experiencing a remarkable growth trajectory for the last two years consecutively. In FY2022, the revenue of company surged by 30.90% and stood at BDT 5,028.54 million from BDT 3,841.38 million in the previous year. Such a significant growth was achieved due to utilization of the increased production capacity facilitated by the partial completion of the expansion project. As per management correspondence, the new expansion unit has enabled the company to increase its production capacity by approximately 30.00%. However, although the company is involved in exporting its products, 100% of the revenue was generated from local sales during the period. The cost of goods sold has followed a similar trajectory to the revenue figures. As a manufacturing company, expenses related to raw materials, factory overhead, and other costs have increased significantly in tandem with the revenue growth. Due to the nature of the industry, majority of the raw materials of the company are imported. Hence, global inflation and appreciation of BDT against USD has adversely affected the raw material cost of the company. As a consequence, the growth of the cost of goods sold outpaced the revenue growth, leading to a slightly lower gross profit margin compared to the previous year.

Over the past four years, the company's liquidity position has remained at a moderate level, with a current ratio of 1.08 times, in comparison to its current liabilities at the end of FY2022. The current assets demonstrate a moderate coverage of the current liabilities, indicating a stringent working capital condition. With the increase of closing stock of inventories, receivables and cash balance, and the decrease of investment in FDR and advance, deposit and prepayments, total current assets of the company showed an overall increase of 6.39% in FY2022. On the other hand, with the increase in current maturity of lease liabilities and long term loan, accounts and other payable and, decrease of short term loan, provisions and WPPF liabilities, the current liabilities displayed a marginal incline of 0.94% in FY2022. As a consequence, there was a marginal improvement in the current ratio in FY2022. In the meantime, the due to the increase in closing stock of inventories, the quick asset ratio declined marginally from 0.75 in FY2021 to 0.70 times in FY2022. The cash conversion cycle of the company slightly increased from 100 days in FY2021 to 106 days in FY2022 mainly influenced by the increase in inventory and receivables at the year end.

(vii) **Following details of underwriting:**

a) **The names, addresses, telephone numbers, fax numbers, contact persons and e-mail addresses of the underwriters and the amount underwritten by them;**

| Name & Address | Telephone & Fax Number, E-mail, Web Address | Contact Person | Amount Underwritten |
|--|---|--|----------------------------|
| EBL Investments Limited BSC Tower (4th Floor), 2-3 Rajuk Avenue, Motijheel C/A, Dhaka-1000 | Tel: +88-02-47111096, +88-02-47111867 Fax: +88-02-47111218 E-mail: info@eblinvestments.com Web: www.eblinvestments.com | Ahmed Arefin FCA Managing Director | 86,877,828 |
| BMSL Investment Limited Shareef Mansion (4th Floor) 56-57 Motijheel C/A Dhaka-1000. | Tel: +88-02-9577651, +88-02-9570624, +88-02-9565183 Fax: +88-02-47117218 E-mail: info@bmslinvestment.com Web: www.bmslinvestment.com | Md. Riyad Matin Managing Director | 106,968,325 |

- b) **Declaration by the underwriters that they have sufficient resources as per the regulatory requirements to discharge their respective obligations;**

DECLARATION BY EBL INVESTMENTS LIMITED

We are one of the underwriters to the Initial Public Offering (IPO) of Techno Drugs Ltd. We will underwrite totaling to Tk. 86,877,828.00 (Taka Eight Crore Sixty-Eight Lac Seventy-Seven Thousand Eight Hundred Twenty-Eight) only out of total underwriting Tk. 193,846,153.00 (Taka Nineteen Crore Thirty-Eight Lac Forty-Six Thousand One Hundred Fifty-Three) on a firm commitment basis. In this connection, we hereby declare that:

We have sufficient resources as per regulatory requirements to discharge our respective obligations.

For Underwriter:

Sd/-

Ahmed Arefin FCA
Managing Director
EBL Investments Limited

Place: Dhaka,
Date: April 30, 2024

DECLARATION BY BMSL INVESTMENT LIMITED

We are one of the underwriters to the Initial Public Offering (IPO) of Techno Drugs Ltd. We will underwrite totaling to Tk. 106,968,325.00 (Taka Ten Crore Sixty-Nine Lac Sixty-Eight Thousand Three Hundred Twenty-Five) only out of total underwriting Tk. 193,846,153.00 (Taka Nineteen Crore Thirty-Eight Lac Forty-Six Thousand One Hundred Fifty-Three) on a firm commitment basis. In this connection, we hereby declare that:

We have sufficient resources as per regulatory requirements to discharge our respective obligations.

For Underwriter:

Sd/-

Md. Riyad Matin
Managing Director
BMSL Investment Limited

Place: Dhaka,
Date: April 30, 2024

c) **Major terms and conditions of the underwriting agreements.**

**Article – I
Underwriting**

As per guideline of Bangladesh Securities and Exchanges Commission, 35% of the quota allocate for General Public Category shall have to be underwritten securities shall have to be underwritten on a firm commitment basis by the underwriter(s), subject to the major terms stated below:

- (i) The IPO shall stand cancelled if at least 65% (General Public Category) of the IPO is not subscribed.
- (ii) In case of under subscription in collectively (i.e., General Public Category) by up to 35% of the IPO the under-subscribed securities shall be taken up by the underwriters.
- (iii) Notwithstanding anything contained in the agreement in case of inconsistency between the provision of the agreement and the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, the Public Issue Rules shall prevail.
- (iv) Prior to publication of the prospectus, the Company shall have obtained consent from the Bangladesh Securities and Exchange Commission permitting the issue as described in Article 2.01 and providing for payment of underwriting commission 0.50% (zero-point five zero percent) on the amount underwritten.
- (v) The Issuer shall **within 10 (Ten) days** of the closure of subscription call upon the underwriter in writing with a copy of said writing to the Bangladesh Securities and Exchange Commission, to subscribe for the shares not subscribed by the closing date and to pay for in cash in full for such unsubscribed shares **within 15 (Fifteen) days** of the date of said notice and the said amount shall have to be credited into shares subscription account within the said period.
- (vi) In any case **within 7 (seven) days** after the expiry of the aforesaid **15 (fifteen) days**, the Company shall send proof of subscription and payment by the Underwriters to the Commission.

In the case of failure by the underwriter to pay for the shares within the stipulated time, the Company/Issuer will be under no obligation to pay any underwriting commission under this Agreement.

**Article – II
The Public Offer**

- The Company shall raise **BDT 1,000,000,000.00** through Eligible Investors and General Public subscription through publishing a prospectus in accordance with the consent of the Bangladesh Securities and Exchange Commission (BSEC) and the provision of this agreement.
- The Public Offer shall be final after completion of the bidding period, where the cut-off price will be determined.
- Prior to the publication of the Prospectus, the Company shall obtain a consent from the Bangladesh Securities and Exchange Commission permitting the issue as described in Article 2.01 and provide for the payment of initial underwriting commission not exceeding **0.50%** on the amount underwritten.

- The Company shall make media campaign and publicity of the offer for a subscription to the extent as may be reasonably requested by the Issue Manager prior to the opening of subscription period with publicity material as approved by the BSEC.
- The Company shall comply with any other formalities required under law of the land, for raising fund publicly.
- If and to the extent that the shares offered to the public by a prospectus authorized hereunder shall not have been subscribed and paid for in cash in full by the Closing Date of subscription, the Company shall within **10 (Ten) days** of the closure of subscription call upon the underwriter in writing with a copy of the said writing to the Bangladesh Securities and Exchange Commission, to subscribe the shares not subscribed by the closing date and to pay for in cash in full, inclusive of any premium if applicable, for such unsubscribed shares within **15 (Fifteen) days** after being called upon to do so. If payment is made by Cheques-Bank Draft by the underwriter it will be deemed that the underwriter has not fulfilled his obligation towards his underwriting commitment under this Agreement, until such time as the Cheques-Bank Draft has been encased and the Company's account credited. In any case within **7 (seven) days** after the expiry of the aforesaid 15 (fifteen) days, the Company shall send proof of subscription and payment by the underwriter to the Commission. In the case of failure by the underwriter to pay for the shares under the terms mentioned above, the said underwriter will not be eligible to underwrite any issue, until such time as he fulfills his underwriting commitment under this Agreement and also other penalties as may be determined by the Commission may be imposed. In the case of failure by the underwriter to pay for the shares within the stipulated time, the Company-issuer will be under no obligation to pay any underwriting commission under this Agreement. In the case of failure by the Company to call upon the underwriter for the aforementioned purpose within the stipulated time, the Company and its Directors shall individually and collectively be held responsible for the consequences and-or penalties as determined by the Bangladesh Securities and Exchange Commission under the law.
- That the signatories to this Agreement have duly been authorized by the Board of Directors of both the Company and the underwriter to execute and give effect to this Agreement from the date written herein above.
- The liability of the underwriter under this clause shall be in proportion to but not exceeding the shares agreed to be underwritten by it; provided that the aforementioned request of the Company shall be supported by official certificates and other documents of subscription obtained from the Bankers to the Issue and a declaration of the Company as to the final result of the Public subscription.
- The Company shall pay to the underwriter an underwriting commission at the rate of **0.50%** of the amount underwritten hereby agreed to be underwritten by it.

**Article – III
Disclosure**

- (a) The Company shall furnish to the underwriter such data as the Underwriter may reasonably request.
- (b) The Company shall:
 - a. Not change its financial plan or take steps to increase or decrease its paid-up capital to the disadvantage of the Underwriter.
 - b. Promptly advise the Underwriter of all amendments and changes required to be made in the Prospectus by the Bangladesh Securities and Exchange Commission and-or the Stock Exchange(s) and furnish amended Copies of Prospectus to the Underwriter and continue to inform him of all material facts relating to Public offering.

**Article – IV
Miscellaneous**

- (c) Any notice or request required or permitted to be given or made under this Agreement to the Underwriter or to the Company shall be in writing. Such notice or request shall be deemed to have been duly given or made when it shall be delivered by hand or sent by registered post in a prepaid letter to the party to which it is required or permitted to be given or made at such party's registered address or at such other address as such notice or making such request is to be made. Such notice shall be deemed to have been delivered in the ordinary course of post.
- (d) This Agreement shall bind and insure to the benefit of, the respective successors of the parties hereto.
- (e) This Agreement shall be valid until the completion of subscription of shares in accordance with section 2.06.
- (f) All questions or differences whatsoever which may at any time hereinafter arise between the parties hereto or their respective representatives touching these presents or the subject matter hereof or arising out of or in connection thereto respectively and whether as to construction or otherwise shall be referred to a single arbitrator in case the parties agree upon one Arbitrator, otherwise to two umpires in accordance with and subject to the provisions of the Arbitration Act, 2001 or any statutory modification thereof.
- (g) The rights and responsibilities of either party shall terminate in the event of full subscription of the public offering of shares.
- (h) Notwithstanding anything contained in this Agreement, in case of any inconsistency between the provision of this Agreement and the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, shall prevail.
- (i) The underwriter warrants and represents that it has a certificate of registration from the Bangladesh Securities and Exchange Commission to fully underwrite or place primary securities on a firm commitment basis.

(c) Capital Structure:

- (i) **Authorized, issued, subscribed and paid-up capital (number and class of securities, allotment dates, nominal price, issue price and form of consideration);**

| Particulars | No. of Securities | Class of Securities | Allotment | | Nominal & Issue Price (Tk.) | Form of Consideration | Amount in Taka |
|--|--------------------|-----------------------|-----------|-------------|-----------------------------|-----------------------|----------------------|
| | | | Dates | Amount | | | |
| Authorized Capital | 200,000,000 | Ordinary Share | - | - | 10.00 | - | 2,000,000,000 |
| Before IPO: | | | | | | | |
| Issued, Subscribed and paid up capital | 94,157,400 | Ordinary Share | 30-Sep-09 | 400,000 | 1,000.00 | Cash | 941,574,000 |
| | | | 8-Sep-12 | 80,000,000 | 1,000.00 | Other than Cash | |
| | | | 16-Oct-17 | 19,200,000 | 1,000.00 | Cash | |
| | | | 11-Jul-19 | 15,000,000 | 1,000.00 | Cash | |
| | | | 7-Jan-20 | 573,000,000 | 10.00 | Bonus | |
| | | | 25-Oct-20 | 62,400,000 | 10.00 | Cash | |
| | | | 11-Apr-21 | 68,760,000 | 10.00 | Cash | |
| 30-Dec-21 | 122,814,000 | 10.00 | Bonus | | | | |
| After IPO: | | | | | | | |
| Issued through IPO | 36,199,095 | Ordinary Share | - | - | - | Cash | 361,990,950 |
| Paid up capital (Post IPO) | 130,356,495 | Ordinary Share | - | - | - | Cash | 1,303,564,950 |

* The Company split its share as on August 18, 2019 to Tk. 10.00 from Tk. 1,000.00 each.

(ii) **Size of the present issue, with break-up (number of securities, description, nominal value and issue amount);**

The total size of the present issue will be Tk. 1,000,000,000.00. A detail break-down of the distribution mechanism is as follows:

| Particulars | | No. of Shares | Nominal Value | Issue Price | Issue Amount | Description | % of Shares |
|--------------------------------|------------------|-------------------|---------------|-------------|----------------------|-----------------|----------------|
| Offer to EI and GP | | | | | | | |
| For Eis | | 7,692,307 | 10 | 34 | 261,538,438 | Ordinary Shares | 25.00% |
| For General Public | NRB | 1,538,461 | 10 | 24 | 36,923,064 | | 5.00% |
| | GP excluding NRB | 21,538,462 | 10 | 24 | 516,923,088 | | 70.00% |
| Total Public Offer (A) | | 30,769,230 | | | 815,384,590 | | 100.00% |
| Private Offer | | | | | | | |
| Employees and Others | | 5,429,865 | 10 | 34 | 184,615,410 | | 15.00% |
| Total Private Offer (B) | | 5,429,865 | | | 184,615,410 | | 100.00% |
| Grand Total (A+B) | | 36,199,095 | 10 | - | 1,000,000,000 | | |

(iii) **Paid up capital before and after the present issue, after conversion of convertible instruments (if any) and share premium account (before and after the issue);**

The Company has no convertible instruments and share premium account.

| Particulars | Before the Present Issue (BDT) | After the Present Issue (BDT) |
|------------------------|--------------------------------|-------------------------------|
| Paid up capital | 941,574,000 | 1,303,564,950 |
| Convertible Instrument | N/A | N/A |
| Share Premium Account | Nil | 638,009,050 |

- The Company has no outstanding convertible Instruments.

(iv) **Category wise shareholding structure with percentage before and after the present issue and after conversion of convertible instruments (if any);**

The paid-up capital of the Company is Tk. 941,574,000.00. The Company intends to issue 36,199,095 ordinary shares through Initial public offering (IPO) totaling Tk. 1,000,000,000.00 under book building method. The Company has no convertible instrument.

Category wise shareholding structure with percentage before and after the present issue is as follows:

| Sl. | Category of Shareholders | No. of Ordinary Shares Hold | | Percentage of Holding | |
|--------------|----------------------------------|-----------------------------|--------------------|-----------------------|----------------|
| | | Pre-IPO | Post-IPO | Pre-IPO | Post-IPO |
| 1 | Director & Sponsor | 82,776,200 | 82,776,200 | 87.91% | 63.50% |
| 2 | Institutional | - | 4,492,307 | 0.00% | 3.45% |
| 3 | Mutual Funds and CIS | - | 3,200,000 | 0.00% | 2.45% |
| 4 | Individual | 11,381,200 | 38,349,527 | 12.09% | 29.42% |
| 5 | Non Resident Bangladeshis (NRBs) | - | 1,538,461 | 0.00% | 1.18% |
| Total | | 94,157,400 | 130,356,495 | 100.00% | 100.00% |

(v) **Where shares have been issued for consideration in other than cash at any point of time, details in a separate table, indicating the date of issue, persons to whom those are issued, relationship with the issuer, issue price, consideration and valuation thereof, reasons for the issue and whether any benefits have been accrued to the issuer out of the issue;**

The Company issued the following ordinary shares for consideration in other than cash:

Net Assets:

| Date of issue | Person to whom those are issued | No. of shares allotted | Relationship with the issuer | Issue price | Consideration & Valuation | Reasons for the issue | Benefit from the issue |
|---------------|---------------------------------|------------------------|------------------------------|-------------|---------------------------|-----------------------|--|
| 8-Sep-12 | Shahjalal Uddin Ahmed | 8,000,000 | Managing Director | Tk. 10.00 | Other than Cash | To acquire net assets | Acquisition of net assets as well as operational and products licenses |

The Company has changed the face value of its ordinary share from Tk. 1000.00 to Tk. 10.00 by passing a special resolution in its extraordinary general meeting held on August 18, 2019 and necessary amendments in capital clause of the Memorandum and Articles of Association were made accordingly.

Bonus:

| Date of issue | Persons to whom those are issued | No. of shares allotted | Relationship with the issuer | Issue price | Consideration & Valuation | Reasons for the issue | Benefit from the issue |
|---------------|----------------------------------|------------------------|------------------------------|-------------|---------------------------|------------------------------------|--|
| 7-Jan-20 | All existing shareholders | 57,300,000 | Shareholder | Tk. 10.00 | Bonus | Distribution of accumulated profit | Business expansion & Enhancements of working capital |
| 30-Dec-21 | | 12,281,400 | | | | | |

- (vi) **Where shares have been allotted in terms of any merger, amalgamation or acquisition scheme, details of such scheme and shares allotted;**

The Company has not allotted any shares in terms of any merger, amalgamation or acquisition scheme.

- (vii) **Where the issuer has issued equity shares under one or more employee stock option schemes, date-wise details of equity shares issued under the schemes, including the price at which such equity shares were issued;**

The Company did not issue any equity shares under stock option to its employees. A private offer to be made to employees and others as part of the IPO, subject to consent of the Bangladesh Securities and Exchange commission (BSEC).

- (viii) **If the issuer has made any issue of specified securities at a price lower than the issue price during the preceding two years, specific details of the names of the persons to whom such specified securities have been issued, relation with the issuer, reasons for such issue and the price thereof;**

The issuer has not made any issue of specified securities at a price lower than the issue price during the preceding two years.

- (ix) **The decision or intention, negotiation and consideration of the issuer to alter the capital structure by way of issue of specified securities in any manner within a period of one year from the date of listing of the present issue;**

The Company has no decision or intention, negotiation and consideration to alter the capital structure by way of issue of specified securities in any manner within a period of one year from the date of listing of the present issue.

(x) The total shareholding of the sponsors and directors in a tabular form, clearly stating the names, nature of issue, date of allotment, number of shares, face value, issue price, consideration, date when the shares were made fully paid up, percentage of the total pre and post issue capital, the lock in period and the number and percentage of pledged shares, if any, held by each of them;

| Name & Position | Nature of Issue | Date of Allotment and Acquisition & date of shares fully paid-up | No. of shares | Face Value & Issue Price | Consideration | Pre IPO % | Post IPO % | Lock in Period* | Number & % of pledge of shares |
|---|-----------------|--|-------------------|--------------------------|-----------------|-----------|------------|-----------------|--------------------------------|
| Name: Shah Jalal Uddin Ahmed Position: Managing Director | Ordinary | 30-Sep-09 | 10,000 | 10.00 | Cash | 63.14% | 45.61% | 3 Yrs. | No Pledge |
| | | 8-Sep-12 | 8,000,000 | | Other than cash | | | | |
| | | 16-Oct-17 | 1,920,000 | | Cash | | | | |
| | | 29-Jun-19 | (1,485,000) | | Cash | | | | |
| | | 7-Jan-20 | 42,225,000 | | Bonus | | | | |
| | | 25-Oct-20 | 1,030,000 | | Cash | | | | |
| | | 30-Dec-21 | 7,755,000 | | Bonus | | | | |
| | | Total | 59,455,000 | | | | | | |
| Name: Khaleda Akhter Khan Position: Chairman | Ordinary | 30-Sep-09 | 10,000 | 10.00 | Cash | 7.94% | 5.73% | 3 Yrs. | No Pledge |
| | | 29-Jun-19 | 495,000 | | Cash | | | | |
| | | 7-Jan-20 | 2,525,000 | | Bonus | | | | |
| | | 25-Oct-20 | 3,470,000 | | Cash | | | | |
| | | 30-Dec-21 | 975,000 | | Bonus | | | | |
| | | Total | 7,475,000 | | | | | | |
| Name: Mehreen Ahmed Position: Director | Ordinary | 30-Sep-09 | 10,000 | 10.00 | Cash | 4.76% | 3.44% | 3 Yrs. | No Pledge |
| | | 29-Jun-19 | 495,000 | | Cash | | | | |
| | | 7-Jan-20 | 2,525,000 | | Bonus | | | | |
| | | 25-Oct-20 | 870,000 | | Cash | | | | |
| | | 30-Dec-21 | 585,000 | | Bonus | | | | |
| | | Total | 4,485,000 | | | | | | |

| | | | | | | | | | |
|---|----------|------------------|-------------|-------|------------------|-------|-------|--------|-----------|
| Name: Arefeen Raafi Ahmed Position: Director | Ordinary | 30-Sep-09 | 10,000 | 10.00 | Cash | 4.76% | 3.44% | 3 Yrs. | No Pledge |
| | | 29-Jun-19 | 495,000 | | Cash | | | | |
| | | 7-Jan-20 | 2,525,000 | | Bonus | | | | |
| | | 25-Oct-20 | 870,000 | | Cash | | | | |
| | | 30-Dec-21 | 585,000 | | Bonus | | | | |
| Total | | 4,485,000 | | | | | | | |
| Name: Md. Mamunur Rashid Position: Director | Ordinary | 11-Apr-21 | 6,876,000 | 10.00 | Cash | 7.30% | 5.27% | 3 Yrs. | No Pledge |
| | | 30-Dec-21 | 1,031,400 | | Bonus | | | | |
| | | 16-May-22 | (1,031,200) | | Cash | | | | |
| | | Total | | | 6,876,200 | | | | |
| Name: SK. Motiur Rahman Position: Independent Director | Ordinary | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Name: Uttam Kumar Saha, FCA Position: Independent Director | Ordinary | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

The Company has changed the face value of its ordinary share from Tk. 1000.00 to Tk. 10.00 by passing a special resolution in its extraordinary general meeting held on August 18, 2019 and necessary amendments in capital clause of the Memorandum and Articles of Association were made accordingly.

*[*From the first trading day of the securities]*

- (xi) **The details of the aggregate shareholding of the sponsors and directors, the aggregate number of specified securities purchased or sold or otherwise transferred by the sponsor and/or by the directors of the issuer and their related parties within six months immediately preceding the date of filing the prospectus;**

Aggregate shareholding of the Sponsors and Directors:

| Sl. | Name of Sponsor & Director | Number of Ordinary Shares Held | Face Value & Issue Price | Date of acquisition | Percentage | |
|--------------|----------------------------|--------------------------------|--------------------------|---------------------|---------------|---------------|
| | | | | | Pre-IPO | Post-IPO |
| 1 | Shah Jalal Uddin Ahmed | 59,455,000 | 10.00 | 30-Sep-09 | 63.14% | 45.61% |
| 2 | Khaleda Akhter Khan | 7,475,000 | 10.00 | 30-Sep-09 | 7.94% | 5.73% |
| 3 | Mehreen Ahmed | 4,485,000 | 10.00 | 30-Sep-09 | 4.76% | 3.44% |
| 4 | Arefeen Raafi Ahmed | 4,485,000 | 10.00 | 30-Sep-09 | 4.76% | 3.44% |
| 5 | Md. Mamunur Rashid | 6,876,200 | 10.00 | 11-Apr-21 | 7.30% | 5.27% |
| 6 | SK. Motiur Rahman | - | 10.00 | N/A | 0.00% | 0.00% |
| 7 | Uttam Kumar Saha, FCA | - | 10.00 | N/A | 0.00% | 0.00% |
| Total | | 82,776,200 | | | 87.91% | 63.50% |

Transfer of specified securities by the sponsor or by the directors of the issuer:

No Shares have been transferred within six months immediately preceding the date of filling the prospectus by the sponsors and/or by the directors of the issuer and their related parties.

- (xii) **The name and address of any person who owns, beneficially or of record, 5% or more of the securities of the issuer, indicating the amount of securities owned, whether they are owned beneficially or of record, and the percentage of the securities represented by such ownership including number of equity shares which they would be entitled to upon exercise of warrant, option or right to convert any convertible instrument;**

| Sl. | Name of the Shareholders | Relationship | Number of Shares Held | Pre IPO % |
|-----|--------------------------|-------------------|-----------------------|-----------|
| 1 | Shah Jalal Uddin Ahmed | Managing Director | 59,455,000 | 63.14% |
| 2 | Khaleda Akhter Khan | Chairman | 7,475,000 | 7.94% |
| 3 | Md. Mamunur Rashid | Director | 6,876,200 | 7.30% |

There is no event or intent of exercising warrant, option or right to convert any convertible instrument.

- (xiii) **The number of securities of the issuer owned by each of the top ten salaried officers, and all other officers or employees as group, indicating the percentage of outstanding shares represented by the securities owned.**

The following employees hold shares of the Company:

| Sl. | Name of Director | Position | Number of Shares Held | Pre- IPO% |
|-----|------------------------|----------------------------------|-----------------------|-----------|
| 1 | Shah Jalal Uddin Ahmed | Managing Director | 59,455,000 | 63.14% |
| 2 | Arefeen Raafi Ahmed | Director (Admin, Marketing & IT) | 4,485,000 | 4.76% |
| 3 | Mehreen Ahmed | Director (Factory Operation) | 4,485,000 | 4.76% |

(d) Description of Business:

- (i) The date on which the issuer company was incorporated and the date on which it commenced operations and the nature of the business which the company and its subsidiaries are engaged in or propose to engage in;**

Date of Incorporation and commencement of commercial operation

Techno Drugs Ltd. was incorporated in 2009 as a Private Limited Company of Bangladesh with the issuance of Certificate of incorporation bearing no. Reg. No. C-79890/09 dated on 30-Sep-2009 by the Registrar of Joint Stock Companies & Firms, Dhaka, Bangladesh. The Company Converted into public Limited Company and split of Share value from Tk. 1,000.00 to Tk. 10.00 dated on 18-Aug-2019.

Nature of the Business

Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human and Veterinary medicines and selling them in local and international market. We are also the pioneer of Oncology medicines in Bangladesh.

The products of the company are sold in domestic and international markets.

Associates, Subsidiary-related holding Company and their Core areas of business

Techno Drugs Ltd. has neither any subsidiary nor it is operated under a holding company.

- (ii) Location of the Project;**

The location of the factory is at Satirpara, Narsingdi-1600 and B.K. Bari Mirzapur, Gazipur-1703.

Location of the Depots:

The list of depots of Techno Drugs Ltd. along with their addresses is given below:

| SL. | Depot Name | Depot Address |
|------------|-------------------|--|
| 1 | Barishal | House Name- Niloy, Holding No-872, Ward No-14, Barishal City Corporation, Barishal Sadar, C&B Road, Barishal |
| 2 | Sylhet | Holding No-16/A, Shoroshpur Charanir, Lama Bazar, Sylhet-3100, Sylhet Sadar, Sylhet |
| 3 | Rajshahi | House: 0233, Housing Estate, Sector-2, Post office: Rajshahi Shenanibash-6202, Boalia, Rajshahi. |
| 4 | Bogura | House-399/431, Opposite of Tajma Ceramic, Thonthonia, Bogura |
| 5 | Faridpur | Aloknandan- Holding No.-10/32/01, Alauddin Khan Road, South Alipur, Faridpur Sadar. |
| 6 | Rangpur | House No.-78/4, road no.-01, PTI road, Katkipara, kotoali Rangpur |
| 7 | Mymensingh | House No-6/1, Natokghor Lane, Kotoali, Mymensingh |
| 8 | Bhairab | Holding No-920, Kolompur, Bhairab, Kishorgonj |
| 9 | Jeshore | Holding No-1/B, Najnin Gopi Central Road, Jeshore Town, Police Station-Kotoali, Jeshore |
| 10 | Chattogram | 523, Shahid Nagar, Hathazari Road, (Near Oxygen) P.O Amin Jute Mills Ltd. Chattogram-4211 |

| | | |
|----|----------|--|
| 11 | Cumilla | Holding No-355/420, Munshi Bari, Rail Station Road, Adorssho Sadar, Cumilla |
| 12 | Khulna | Afroja Kanon, Holding No.-294, Road No.-17, Nirala Housing Area, Post Office: Khulna City-9100, Khulna Sadar, District: Khulna |
| 13 | Dinajpur | Shishuniketon Road, ShipahiPara, Block no.-10, Ward No.-09, Dinajpur |
| 14 | Kushtia | Road No.-48/1, Bicharpoti Mahbub Morshed Road, Kotapara (Peyaratala), Kushtia Sadar, Kushtia |
| 15 | Noakhali | House No.-08, Road No.-36, Housing Estate, Maijdi Court, Noakhali |
| 16 | Tangail | Plot No.-1030/1, Shabalia, Suroj Road, Tangail |
| 17 | Dhaka | J K Tower, 31 Segunbagicha, Dhaka-1000 |

(iii) Plant, machinery, technology, process, etc.

Techno Drugs Ltd. is vertically integrated generic pharmaceuticals formulation products manufacturer, marketer, promoter and distributor.


Its manufacturing process is heavily technology driven, dynamic in nature and using highly sophisticated state-of-the-art cutting edge technology.

The plant adheres to GMP standard, hygiene and safety. The facilities are unique for World-class Structural Design, Dust-free Environment, well-designed HVAC System, Zero Cross- contamination, Vacuum Transfer Close System, Different Storage Conditions, High-tech Chemical & Microbiological Laboratories, Modern R&D facility. Most up-to-date Water Treatment Plant (WTP), Fire Management System and Eco-friendly Effluent Treatment Plant (ETP).


TDL maintains total Quality System, which includes Strict Monitoring, End-to-end Regulation. State-of-the-art Equipment, True Measurements, Equipment Calibration, Trained professionals.

Process:

Product Manufacturing Process – Solid



Product Manufacturing Process – Liquid



(iv) Details of the major events in the history of the issuer, including details of capacity or facility creation, launching of plant, products, marketing, change in ownership and/or key management personnel etc.;

| | |
|--|--|
| History of the issuer | Techno Drugs Ltd. (TDL) was incorporated as Private Limited Company on September 30, 2009 & vide reg. no. C-79890/09. Converted into a Public Limited Company on August 18, 2019. |
| Commencement of Commercial Operation | July 01, 2010 |
| Capital raise (Last) | Tk. 122,814,000 (bonus) on 30 December, 2021. |
| Nature of business | Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human and Veterinary medicines and selling them in local and international market. We are also the pioneer of Oncology medicines in Bangladesh. |
| Market for the product | The products of the company are sold in domestic and international markets. |
| Change in ownership/key management personnel | The following ownership/key management personnel has been appointed; <ol style="list-style-type: none"> 1. On 31-Aug-23: Md. Mamunur Rashid was appointed as Director; SK. Motiur Rahman and Uttam Kumar Saha, FCA were appointed as Independent Directors; 2. On 15-Oct-22: Md. Shafiqul Islam appointed as Plant In Charge; 3. On 17-Mar-22: Md. Liakat Ali Khan appointed as General Manager in Marketing Department. |

(v) Principal products or services of the issuer and markets for such products or services. Past trends and future prospects regarding exports (if applicable) and local market, demand and supply forecasts for the sector in which the product is included with source of data;

Principal products:

Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human pharmaceuticals' drugs and animal health care drugs.

The products of the company are sold in domestic and international markets.

List of Non-Biological Products:

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

| Sl. | Products Name | Generic Name & Composition | DAR No. | Expiry Date |
|-----|-------------------------|---|----------------|-------------|
| 1 | MOTILEX 10 TABLET | Domperidone Maleate BP 12.73 mg (eq.to 10 mg Domperidone) | 353-102-118 | 22.05.2026 |
| 2 | MOTILEX (suspension) | Domperidone BP 100.0 mg | 353-103-018 | 22.05.2026 |
| 3 | Romilac 10 tablet | Ketorolac tromethamine USP10.0 mg | 353-104-064 | 22.05.2026 |
| 4 | LOTEM 10 TABLET | Montelukast Sodium USP 10.04 mg (eq. to 10.00 mg Montelukast) | 353-105-044 | 22.05.2026 |
| 5 | LOTEM ODT TABLET | Montelukast Sodium USP 4.15 mg (eq. to 4.00 mg Montelukast) | 353-106-044 | 22.05.2026 |
| 6 | LOTEM 5 ODT TABLET | Montelukast Sodium USP 5.188 mg (eq. to 5.00 mg Montelukast) | 353-107-044 | 22.05.2026 |
| 7 | PROLAN 30 CAPSULE | Dexlansoprazole Pellets 20% (as enteric coated) INN 150 mg (eq. to Dexlansoprazole 30 mg) | 353-108-067 | 22.05.2026 |
| 8 | PROLAN 60 CAPSULE | Dexlansoprazole Pellets 20% (as enteric coated) INN 300 mg (eq. to Dexlansoprazole 60 mg) | 353-109-067 | 22.05.2026 |
| 9 | Exonid 60 Tablet | Fexofenadine Hydrochloride USP 60.00 mg | 353-110-021 | 22.05.2026 |
| 10 | Exonid 120 Tablet | Fexofenadine Hydrochloride USP 120.00 mg | 353-111-021 | 22.05.2026 |
| 11 | Exonid 180 Tablet | Fexofenadine Hydrochloride USP 180.00 mg | 353-112-021 | 22.05.2026 |
| 12 | Exonid suspension | Fexofenadine Hydrochloride USP 0.600 gm | 353-113-021 | 22.05.2026 |
| 13 | Neo zinc B syrup | Zinc Sulfate USP 549gm (eqv. to 200 mg Elemental Zinc) + Thiamin HCl BP 100 mg+ Riboflavin 5-phosphate Sodium USP 50.8 mg (eqv. to Riboflavin 40mg)+ Pyridoxine HCl BP 40mg+ Nicotinamide BP 400 mg/100 ml | 353-114-078 | 07.07.2026 |
| 14 | Neo Zinc syrup | Zinc Sulfate Monohydrate USP 549 mg (epv. to 200 mg elemental Zinc)/100 ml | 353-115-062 | 07.07.2026 |
| 15 | Neo Zinc 20 Tab. | Zinc Sulphate Monohydrate USP 54.89 mg (eqv. to 20 mg elemental Zinc)/Tablet | 353-124-062 | 07.07.2026 |
| 16 | Algicar Plus Suspension | Sodium Alginate BP 5 gm, Sodium Bicarbonate BP 2.67 gm, Calcium Carbonate BP 1.6 gm/ 100 ml Suspension | 353-125-007 | 07.07.2026 |
| 17 | Neo Zinc B Tab. | Thiamine Mononitrate USP 5 mg, Riboflavin BP 2 mg, Pyridoxine Hydrochloride BP 2 mg, Nicotinamide BP 20 mg, Zinc Sulfate Monohydrate USP 27.45 mg (eqv. to 10 mg elemental Zinc)/Tablet | 353-126-078 | 07.07.2026 |
| 18 | Pyrovet bolus (vet) | Paracetamol BP 2 gm/Bolus | 353-131(v)-077 | 07.07.2026 |

| | | | | |
|----|------------------------|--|----------------|------------|
| 19 | Metrovet bolus (vet) | Metronidazole BP 2 gm/Bolus | 353-132(v)-077 | 07.07.2026 |
| 20 | Coraltec-D | Calcium Carbonate USP 1250 mg (eqv. to 500 mg Elemental Calcium) Cholecalciferol (Vitamin D3) USP 2.30 mg (eqv. to 200 IU)/Tablet | 353-151-062 | 31.10.2026 |
| 21 | Coraltec-DX | Calcium Carbonate USP 1500 mg (eqv. to 600 mg Elemental Calcium) and Cholecalciferol (Vitamin D3) USP 4 mg (eqv. to 400 IU Vitamin D3)/Tablet | 353-152-062 | 31.10.2026 |
| 22 | Neovitan | Thiamine mononitrate (Vitamin B1) USP 100 mg, Pyridoxine Hydrochloride (Vitamin B6) BP 200 mg, Cyanocobalamin (Vitamin B12) 0.1% Premix 200 mg (eqv. to 200 mcg Cyanocobalamin)/Tablet | 353-153-078 | 31.10.2026 |
| 23 | Odiver 3 | Ivermectin BP 3 mg/Tablet | 353-162-008 | 31.10.2026 |
| 24 | Odiver 6 | Ivermectin BP 6 mg/Tablet | 353-163-008 | 31.10.2026 |
| 25 | Odiver 12 | Ivermectin BP 12 mg/Tablet | 353-164-008 | 31.10.2026 |
| 26 | Cozil .5 | Clonazepam USP 0.5 mg/Tablet | 353-167-046 | 31.10.2026 |
| 27 | Cozil 1 | Clonazepam USP 1 mg/Tablet | 353-168-046 | 31.10.2026 |
| 28 | Tesco GL | Guaifenesin BP 2 gm, Levomenthol BP 22 mg, Diphenhydramine Hydrochloride BP 280 mg/100 ml Syrup | 353-169-031 | 31.10.2026 |
| 29 | Esmosec 20 Tablet | Esomeprazole Magnesium Trihydrate USP 22.21 mg (eqv. to Esomeprazole 20 mg)/Tablet | 353-171-067 | 05.01.2027 |
| 30 | Esmosec 40 Tablet | Esomeprazole Magnesium Trihydrate USP 44.42 mg (eqv. to Esomeprazole 40 mg)/Tablet | 353-172-067 | 05.01.2027 |
| 31 | Omsec 20 Capsule | Omeprazole Enteric Coated BP 285.71 mg (eqv. to Omeprazole 20 mg)/Capsule | 353-174-067 | 05.01.2027 |
| 32 | Tesco DL Oral Solution | Dextromethorphan Hydrobromide BP 130 mg, Levomenthol BP 40 mg, Diphenhydramine Hydrochloride BP 280 mg/ 100ml Oral Solution | 353-177-067 | 05.01.2027 |
| 33 | Omsec 40 Capsule | Omeprazole Enteric Coated BP 571.43 mg (eqv. to Omeprazole 40 mg)/Capsule | 353-178-067 | 15.03.2027 |
| 34 | Omten 5/20 Tablet | Amlodipine Besilate BP 6.935 mg (eqv. to 5 mg Amlodipine)/ Olmesartan Medoxomil USP 20 mg/ Tablet | 353-179-022 | 15.03.2027 |
| 35 | Omten 5/40 Tablet | Amlodipine Besilate BP 6.935 mg (eqv. to 5 mg Amlodipine)/ Olmesartan Medoxomil USP 40 mg/ Tablet | 353-180-022 | 15.03.2027 |
| 36 | Kilpro 400 Tablet | Metronidazole BP 400 mg/Tablet | 353-181-027 | 15.03.2027 |
| 37 | Ketodil Syrup | Ketotifen Fumarate BP 27.6 mg (eqv. to Ketotifen 20 mg)100 ml Syrup | 353-186-021 | 13.08.2027 |
| 38 | Apegestrol Suspension | Megestrol Acetate (Micronized) USP 4 gm/100ml Suspension | 353-187-010 | 13.08.2027 |
| 39 | Arodex Tablet | Anastrozole USP 1mg | 304-320-71 | 20.07.2025 |
| 40 | Captabine Tablet | Capecitabine USP 150mg | 304-321-71 | 20.07.2025 |

| | | | | |
|----|----------------------|---|-------------|------------|
| 41 | Captabine Tablet | Capecitabine USP 500mg | 304-325-71 | 26.12.2025 |
| 42 | Zolomide 100 Capsule | Temozolomide Hydrochloride INN 100.00 mg | 304-343-71 | 30.01.2027 |
| 43 | Zolomide 250 Capsule | Temozolomide Hydrochloride INN 250.00 mg | 304-344-71 | 30.01.2027 |
| 44 | Tarcentib 100 Tablet | Erlotinib Hydrochloride INN 100.00 mg | 304-345-71 | 30.01.2027 |
| 45 | Tarcentib 150 Tablet | Erlotinib Hydrochloride INN 150.00 mg | 304-346-71 | 30.01.2027 |
| 46 | Imatin 400 Tablet | Imatinib Mesilate INN 477.874mg (eqv. To 400mg of Imatinib) | 304-386-010 | 17.02.2024 |
| 47 | Eposide 50 Capsule | Etoposide BP 50.0mg | 304-402-10 | 10.09.2024 |
| 48 | Apegestrol Tablet | Megestrol Acetate USP 160.0mg | 304-404-10 | 10.09.2024 |
| 49 | Imatin 100 Tablet | Imatinib Mesilate INN 119.50mg (eqv. To 100 mg of Imatinib) | 304-406-10 | 07.06.2025 |
| 50 | Reparib Cap. | Olaparib INN 100 mg/Capsule | 304-425-010 | 22.06.2027 |
| 51 | Fibronil Tab. | Ruxolitinib Phosphate INN 6.6 mg (eqv. to 5 mg)/Tablet | 304-426-011 | 22.06.2027 |
| 52 | Vinytek Tab. | Venetoclax INN 100 mg/Tablet | 304-428-012 | 22.06.2027 |

List of Biological Products:

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

| Sl. | Products Name | Generic Name & Composition | DAR No. | Inclusion Date | Expiry Date |
|-----|--|--|------------|----------------|-------------|
| 1 | PREMICON TABLET | Conjugated Oestrogens USP 0.625mg/ Tablet | 353-09-56 | 07.09.2009 | 06.09.2024 |
| 2 | PROVERA INJECTION | Medroxyprogesterone Acetate USP 150.00mg/ml | 353-10-039 | 07.09.2009 | 06.09.2024 |
| 3 | CYNOCORT INJECTION | Triamcinolone Acetonide BP 40 mg/ml | 353-11-050 | 07.09.2009 | 06.09.2024 |
| 4 | NORGEST TABLET | Levonorgestrel BP 0.15mg + Ethinyloestradiol BP 0.03mg/Tablet | 353-12-039 | 07.09.2009 | 06.09.2024 |
| 5 | TD Syringe 2ml Disposable & Reuse Prevention Feature PP Syringe | Polypropylene Ph. Gr. 2.2980gm + Polyethylene Ph. Gr. 1.0975gm | 353-17-41 | 18.02.2016 | 17.02.2026 |
| 6 | TD Syringe 5ml Disposable & Reuse Prevention Feature PP Syringe | Polypropylene Ph. Gr. 2.2980gm + Polyethylene Ph. Gr. 1.0975gm | 353-18-41 | 18.02.2016 | 17.02.2026 |
| 7 | MARVELOUS TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.02 mg/Tablet | 353-19-039 | 18.02.2019 | 17.02.2024 |

| | | | | | |
|----|---------------------------------|---|------------|------------|------------|
| 8 | MARVELOUS PLUS TABLET | Desogestrel BP (Micronized) 0.15 mg + Ethinylestradiol (Micronized) BP 0.03 mg /Tablet | 353-20-039 | 18.02.2019 | 17.02.2024 |
| 9 | ETHIDROS TABLET | Drospirenone BP (Micronized) 3 mg + Ethinylestradiol (Micronized) BP 0.02 mg/Tablet | 353-21-039 | 18.02.2019 | 17.02.2024 |
| 10 | ETHIDROS PLUS TABLET | Drospirenone BP (Micronized) 3 mg + Ethinylestradiol (Micronized) BP 0.03 mg/Tablet | 353-22-039 | 18.02.2019 | 17.02.2024 |
| 11 | ETHILA TABLET | Lynestrenol (Micronized) BP 0.75 mg + Ethinylestradiol (Micronized) BP 0.0375 mg /Tablet | 353-23-039 | 18.02.2019 | 17.02.2024 |
| 12 | ETHILA PLUS TABLET | Lynestrenol BP (Micronized) 2.5 mg + Ethinylestradiol (Micronized) BP 0.05 mg /Tablet | 353-24-039 | 18.02.2019 | 17.02.2024 |
| 13 | MISOCLEAN TABLET | Misoprostol (Misoprostol 1% Dispersion with Hypromellose) 20 mg /Tablet | 353-25-049 | 18.02.2019 | 17.02.2024 |
| 14 | MARVELOUS- FE TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.02 mg Ferrous Fumarate BP 75 mg /Tablet | 353-26-039 | 02.04.2019 | 01.04.2024 |
| 15 | MARVELOUS PLUS- FE TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.03 mg Ferrous Fumarate BP 75 mg /Tablet | 353-27-039 | 02.04.2019 | 01.04.2024 |
| 16 | ETHIDROS- FE TABLET | Drospirenone (Micronized) BP 3 mg + Ethinylestradiol (Micronized) BP 0.02 mg Ferrous Fumarate BP 75 mg /Tablet | 353-28-039 | 02.04.2019 | 01.04.2024 |
| 17 | ETHIDROS PLUS- FE TABLET | Drospirenone (Micronized) BP 3 mg + Ethinylestradiol (Micronized) BP 0.03 mg Ferrous Fumarate BP 75 mg /Tablet | 353-29-039 | 02.04.2019 | 01.04.2024 |
| 18 | ETHILA- FE TABLET | Lynestrenol (Micronized) BP 0.75 mg + Ethinylestradiol (Micronized) BP 0.0375 mg Ferrous Fumarate BP 75 mg /Tablet | 353-30-039 | 02.04.2019 | 01.04.2024 |
| 19 | ETHILA PLUS- FE TABLET | Lynestrenol (Micronized) BP 2.5 mg + Ethinylestradiol (Micronized) BP 0.05 mg Ferrous Fumarate BP 75 mg /Tablet | 353-31-039 | 02.04.2019 | 01.04.2024 |
| 20 | PENMOX PFS | Amoxicillin Trihydrate (Micronized) BP 2.875gm (eqv. to Amoxicillin 2.5 gm)/100ml | 353-32-023 | 03.10.2019 | 02.10.2024 |
| 21 | PENMOX 500 Powder for Injection | Amoxicillin Sodium (Sterile Powder) BP 530.000mg eqv. to Amoxicillin 500mg / Vial Powder for Injection | 353-33-023 | 03.10.2019 | 02.10.2024 |
| 22 | PENMOX 250 Powder for Injection | Amoxicillin Sodium (Sterile Powder) BP 265.000mg eqv. to Amoxicillin 250mg / Vial Powder for Injection | 353-34-023 | 03.10.2019 | 02.10.2024 |
| 23 | AMOCCLAV PFS | Amoxicillin Trihydrate (Micronized) BP 2.875gm eqv. to Amoxicillin 2.5gm + Diluted Potassium Clavulanate [Diluted with Silica 1:1] BP 1.489gm (Contains Potassium Clavulanate 0.745 gm eqv. to Clavulanic Acid 0.625gm) / 100ml Powder for Suspension | 353-35-023 | 03.10.2019 | 02.10.2024 |
| 24 | AMOCCLAV FORTE PFS | Amoxicillin Trihydrate (Micronized) BP 9.200gm (eqv. to Amoxicillin 8.0 gm) + Diluted Potassium Clavulanate [Diluted with Silica 1:1] BP | 353-36-023 | 03.10.2019 | 02.10.2024 |

| | | | | | |
|----|----------------------------------|---|------------|------------|------------|
| | | 2.740gm (eqv. to Clavulanic Acid 1.15 gm) / 100ml Powder for Suspension | | | |
| 25 | AMOCLAV 0.6 Powder for Injection | Amoxicillin Sodium BP 530.000mg eqv. to Amoxicillin 500.000mg + Potassium Clavulanate BP 119.120mg eqv. to Clavulanic Acid 100.000mg/Vial Powder for Injection | 353-37-023 | 03.10.2019 | 02.10.2024 |
| 26 | AMOCLAV 1.2 Powder for Injection | Amoxicillin Sodium BP 1060.000mg eqv. to Amoxicillin 1000.000mg + Potassium Clavulanate BP 238.240mg eqv. to Clavulanic Acid 200.000mg/Vial Powder for Injection | 353-38-023 | 03.10.2019 | 02.10.2024 |
| 27 | Femi plant (Sub-dermal Implant) | Levonorgestrel BP/USP 75.00mg/rod | 353-39-039 | 31.12.2019 | 30.12.2024 |
| 28 | Pronacillin Injection (Vet) | Procaine Benzylpenicillin (Penicillin G Procaine) (1000 Units/mg) BP 3.000 gm [equivalent to procaine Benzylpenicillin (Penicillin G Procaine) 30,00,000 Units] + Benzylpenicillin Sodium (Penicillin G Sodium) (1666.67 Units/mg) BP 0.600 gm [equivalent to Benzylpenicillin Sodium (Penicillin G Sodium) 10,00,000 Units]/vial | 353-40-077 | 18.02.2020 | 17.02.2025 |
| 29 | Amoxyvet-30 Powder (Vet) | Amoxicillin Trihydrate (Micronized) BP 34.500 gm (equivalent to Amoxicillin 30 gm)/100gm | 353-41-077 | 18.02.2020 | 17.02.2025 |
| 30 | Amoxyvet Injection (Vet) | Amoxicillin Sodium (Sterile Powder) BP 1.060 gm (equivalent to 1 gm)/Vial | 353-42-077 | 18.02.2020 | 17.02.2025 |
| 31 | Dolopen-500 Injection | Flucloxacillin Sodium (Sterile Powder) BP 544.060 mg (Equivalent to Flucloxacillin 500 mg)/Vial | 353-43-023 | 18.02.2020 | 17.02.2025 |
| 32 | Dolopen-250 Injection | Flucloxacillin Sodium (Sterile Powder) BP 272.030 mg (Equivalent to Flucloxacillin 250 mg)/Vial | 353-44-023 | 18.02.2020 | 17.02.2025 |
| 33 | Dolopen DS PFS | Flucloxacillin Sodium (Micronized) BP 2.7203 gm (Equivalent to Flucloxacillin 2.5 gm)/100ml | 353-45-023 | 18.02.2020 | 17.02.2025 |
| 34 | Dolopen-250 Capsule | Flucloxacillin Sodium (Compacted) BP 272.030 mg (Equivalent to Flucloxacillin 250 mg)/ Capsule | 353-46-023 | 18.02.2020 | 17.02.2025 |
| 35 | Dolopen-500 Capsule | Flucloxacillin Sodium (Compacted) BP 544.060 mg (Equivalent to Flucloxacillin 500 mg)/ Capsule | 353-47-023 | 18.02.2020 | 17.02.2025 |
| 36 | Penmox-500 Capsule | Amoxicillin Trihydrate (Compacted) BP 575.000 mg (Equivalent to Amoxicillin 500 mg) / Capsule | 353-48-023 | 18.02.2020 | 17.02.2025 |
| 37 | Amoclav 1gm Tablet | Amoxicillin Trihydrate (Compacted) BP 1006.250 mg (Equivalent to Amoxicillin 875 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-49-023 | 18.02.2020 | 17.02.2025 |

| | | | | | |
|----|---------------------------------|---|---------------|------------|------------|
| 38 | Amoclav 375 Tablet | Amoxicillin Trihydrate (Compacted) BP 287.500 mg (equivalent to Amoxicillin 250 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-50-023 | 18.02.2020 | 17.02.2025 |
| 39 | Amoclav 625 Tablet | Amoxicillin Trihydrate (Compacted) BP 575.000 mg (Equivalent to Amoxicillin 500 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-51-023 | 18.02.2020 | 17.02.2025 |
| 40 | EC-Pill | Levonorgestrel (Micronized) BP 1.500 mg/ Tablet | 353-52-039 | 18.02.2020 | 17.02.2025 |
| 41 | TECHNOSOL Hand Rub | Chlorhexidine Gluconate Solution BP 2.5 ml | 353-53-071 | 06.04.2020 | 05.04.2025 |
| 42 | CITRUS-C Chewable Tablet | Ascorbic Acid BP 112.5 mg Sodium Ascorbate BP 158.00 mg | 353-54-078 | 30.04.2020 | 29.04.2025 |
| 43 | PARASOL Antiseptic Disinfectant | Chlorhexidine Gluconate 20% Solution BP 1.500 gm (eq. to Chlorhexidine Gluconate 0.3gm), Cetrimide 40% Solution BP 7.500 gm (eq. to Cetrimide 3.0 gm) | 353-55-071 | 30.04.2020 | 29.04.2025 |
| 44 | QUENIL Tablet | Hydroxychloroquine Sulphate USP 200.00 mg | 353-56-024 | 30.04.2020 | 29.04.2025 |
| 45 | TD-QUINE Tablet | Chloroquine Phosphate BP 250.00 mg | 353-57-024 | 30.04.2020 | 29.04.2025 |
| 46 | TD-QUINE Syrup | Chloroquine Phosphate BP 0.960 gm | 353-58-024 | 30.04.2020 | 29.04.2025 |
| 47 | FAVILAVIR Tablet | Favipiravir INN 200.00 mg | 353-59-024 | 30.04.2020 | 29.04.2025 |
| 48 | PROSTENOL INJECTION (VET) | Cloprostenol Sodium BP 263 mcg (eqv. to Cloprostenol 250 mcg) /mL | 353-60(v)-077 | 13.08.2020 | 12.08.2025 |
| 49 | FERTILON INJECTION (VET) | Gonadorelin Acetate BP 0.105 mg eqv. to Gonadorelin 0.1 mg/mL | 353-61(v)-077 | 13.08.2020 | 12.08.2025 |
| 50 | Oxcin 10 INJECTION (VET) | Oxytocin BP 16.66 mcg (eqv. to 10 IU) /mL | 353-62(v)-077 | 13.08.2020 | 12.08.2025 |
| 51 | Dexavet INJECTION (VET) | Dexamethasone Sodium Phosphate BP 2.0 mg/mL | 353-63(v)-077 | 13.08.2020 | 12.08.2025 |
| 52 | Medrol 40 injection | Methylprednisolone Acetate BP 40.00 mg/mL | 353-64-072 | 01.09.2020 | 31.08.2025 |
| 53 | Medrol 80 injection | Methylprednisolone Acetate BP 80.00 mg/2mL | 353-65-072 | 01.09.2020 | 31.08.2025 |
| 54 | Decafos injection | Dexamethasone Sodium Phosphate BP 5 mg/mL | 353-66-072 | 01.09.2020 | 31.08.2025 |
| 55 | Syntocin injection | Oxytocin BP 8.33 mcg (eqv. to 5 IU) /mL | 353-67-049 | 01.09.2020 | 31.08.2025 |

| | | | | | |
|----|---------------------------|---|----------------|------------|------------|
| 56 | Tibone tablet | Tibolone BP 2.5 mg/Tablet | 353-68-056 | 01.09.2020 | 31.08.2025 |
| 57 | Anabolin injection | Nandrolone Phenylpropionate BP 25 mg/mL | 353-69-048 | 01.09.2020 | 31.08.2025 |
| 58 | Decabolon injection | Nandrolone Decanoate BP 50 mg/mL | 353-70-048 | 01.09.2020 | 31.08.2025 |
| 59 | Sustogen injection | Testosterone Propionate BP 30 mg+ Testosterone Phenyl propionate BP 60 mg+ Testosterone Isocaproate BP 60 mg+ Testosterone Decanoate BP 100 mg/mL | 353-071-056 | 01.09.2020 | 31.08.2025 |
| 60 | Amoclav BoLUS (VET) | Amoxicillin Trihydrate (Compacted) BP 460.000 mg (eqv. to Amoxicillin 400mg) /Bolus | 353-072(v)-023 | 30.11.2020 | 29.11.2025 |
| 61 | Amoclav BoLUS DS (VET) | Amoxicillin Trihydrate (Compacted) BP 920.000 mg (eqv. to Amoxicillin 800mg) + Diluted Potassium Clavulanate [Diluted with Microcrystalline Cellulose (1:1)] BP 476.480 mg (eqv. to Clavulanic Acid 200 mg)/Bolus | 353-073(v)-023 | 30.11.2020 | 29.11.2025 |
| 62 | Amoclav ORAL POWDER (VET) | Amoxicillin Trihydrate (Miconized) BP 10.00gm + Diluted Potassium Clavulanate [Diluted with Silica (1:1)] BP 5.00 gm (eqv. to Potassium Clavulanate 2.5 gm)/ 100 gm | 353-074(v)-023 | 30.11.2020 | 29.11.2025 |
| 63 | TDCef 200 Tablet | Cefixime Trihydrate (Compacted) BP 224.00 mg (eqv. to Cefixime 200mg) /Tablet | 353-075-023 | 02.02.2021 | 01.02.2026 |
| 64 | TDCef 400 Tablet | Cefixime Trihydrate (Compacted) BP 448.00 mg (eqv. to Cefixime 400mg) /Tablet | 353-076-023 | 02.02.2021 | 01.02.2026 |
| 65 | TDCef | Cefixime Trihydrate (Micronized) BP 2.240gm (eqv. to Cefixime 2gm) /100ml | 353-077-023 | 02.02.2021 | 01.02.2026 |
| 66 | TDCef DS | Cefixime Trihydrate (Micronized) BP 4.480gm (eqv. to Cefixime 4gm) /100ml | 353-078-023 | 02.02.2021 | 01.02.2026 |
| 67 | Cefixon 500 IM | Ceftriaxone Sodium (Sterile Powder) USP 595.000 mg (eqv. to Ceftriaxone 500 mg) /Vial | 353-079-023 | 02.02.2021 | 01.02.2026 |
| 68 | Cefixon 500 IV | Ceftriaxone Sodium (Sterile Powder) USP 595.000 mg (eqv. to Ceftriaxone 500 mg) /Vial | 353-080-023 | 02.02.2021 | 01.02.2026 |
| 69 | Cefixon 1 gm IV | Ceftriaxone Sodium (Sterile Powder) USP1.190 gm (eqv. to Ceftriaxone 1 gm) /Vial | 353-81-023 | 02.02.2021 | 01.02.2026 |
| 70 | Cefixon 2 gm IV | Ceftriaxone Sodium (Sterile Powder) USP 2.380gm (eqv. to Ceftriaxone 2 gm) /Vial | 353-82-023 | 02.02.2021 | 01.02.2026 |
| 71 | Rapiclav 250 Tablet | Cefuroxime Axetil (DC Granules) BP 300.7 mg (eqv. to Cefuroxime 250mg) + Diluted Potassium Clavulanate [Diluted with MCC (1:1)] BP 178.9 mg (eqv. to clavulanic Acid 62.5 mg)/Tablet | 353-83-023 | 02.02.2021 | 01.02.2026 |

| | | | | | |
|----|---------------------------------|---|---------------|------------|------------|
| 72 | Rapiclav 500 Tablet | Cefuroxime Axetil (DC Granules) BP 601.400 mg (eqv. to Cefuroxime 500mg) + Diluted Potassium Clavulanate [Diluted with MCC (1:1)] BP 297.800 mg (eqv. to clavulanic Acid 125 mg)/Tablet | 353-84-023 | 02.02.2021 | 01.02.2026 |
| 73 | Rapiclav | Cefuroxime Axetil (Amorphous) BP 3.007 gm (eqv. to Cefuroxime 2.5 gm) + Diluted Potassium Clavulanate [Diluted with Silica (1:1)] BP 1.489 gm (eqv. to clavulanic Acid 0.625 gm)/Bottle | 353-85-023 | 02.02.2021 | 01.02.2026 |
| 74 | Dexavet injection (vet) | Dexamethasone Sodium Phosphate BP 2.0 mg/ml | 353-86(v)-077 | 07.03.2021 | 06.03.2026 |
| 75 | Cefixon 500 iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 595 mg (eqv. to Ceftriaxone 500 mg) | 353-87(v)-077 | 11.04.2021 | 10.04.2026 |
| 76 | Cefixon 1 gm iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 1.190 gm (eqv. to Ceftriaxone 1 gm) | 353-88(v)-077 | 11.04.2021 | 10.04.2026 |
| 77 | Cefixon 2 gm iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 2.380 gm (eqv. to Ceftriaxone 2 gm) | 353-89(v)-077 | 11.04.2021 | 10.04.2026 |
| 78 | Cefixon 500 IM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 595 mg (eqv. to Ceftriaxone 500 mg) | 353-90(v)-077 | 11.04.2021 | 10.04.2026 |
| 79 | Cefixon 1 gm iM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 1.190 gm (eqv. to Ceftriaxone 1 gm) | 353-91(v)-077 | 11.04.2021 | 10.04.2026 |
| 80 | Cefixon 2 gm iM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 2.380 gm (eqv. to Ceftriaxone 2 gm) | 353-92(v)-077 | 11.04.2021 | 10.04.2026 |
| 81 | Merom 1gm IV Injection | Sterile mixture of Meropenem Trihydrate and Sodium Carbonate Anhydrous USP 1.417 g (eqv. to 1.0 gm Meropenem)/Vial | 353-93-023 | 15.04.2021 | 14.04.2026 |
| 82 | Merom 500 IV Injection | Sterile mixture of Meropenem Trihydrate and Sodium Carbonate Anhydrous USP 708.70 mg (eqv. to 500.0 mg Meropenem) /Vial | 353-94-023 | 15.04.2021 | 14.04.2026 |
| 83 | Imipen 500 IV Injection | Imipenem Monohydrate USP 568.18 mg (eqv. to 500.0 mg Imipenem) Cilastatin Sodium USP 530.0 mg (eqv. to 500.0 mg Cilastatin) /Vial | 353-95-023 | 15.04.2021 | 14.04.2026 |
| 84 | Anacort | Hydrocortisone Sodium Succinate Sterile USP 134.00 mg (eqv. To 100.00 mg Hydrocortisone) /Vial | 353-96-071 | 15.04.2021 | 14.04.2026 |
| 85 | TDcef 200 | Cefixime Trihydrate (Compacted) BP 224.000 mg (eqv. to Cefixime 200 mg) | 353-97-023 | 15.04.2021 | 14.04.2026 |
| 86 | TDcef 400 | Cefixime Trihydrate (Compacted) BP 448.000 mg (eqv. to Cefixime 400 mg) | 353-98-023 | 15.04.2021 | 14.04.2026 |
| 87 | Water for Injection | Sterile Water for Injection BP 2ml/Ampoule | 353-99-079 | 15.04.2021 | 14.04.2026 |
| 88 | AVALON 500 TABLET | Azithromycin Dihydrate(compacted) USP 524.059 mg (eq. to 500.0 mg Azithromycin) | 353-100-023 | 23.05.2021 | 22.05.2026 |

| | | | | | |
|-----|--------------------------------|---|----------------|------------|------------|
| 89 | AVALON (POWDER FOR SUSPENSION) | Azithromycin Dihydrate (Micronized) | 353-101-023 | 23.05.2021 | 22.05.2026 |
| 90 | SEVORAN INHALATION GAS | Sevoflurane USP 250 ml/ 250 ml Bottle | 353-116-004 | 08.07.2021 | 07.07.2026 |
| 91 | FLURANE INHALATION GAS | Isoflurane USP 100 ml/ 100 Bottle | 353-117-004 | 08.07.2021 | 07.07.2026 |
| 92 | Peron 5 | Prednisolone BP 5 mg/Tablet | 353-118-072 | 08.07.2021 | 07.07.2026 |
| 93 | Peron 10 | Prednisolone BP 10 mg/Tablet | 353-119-072 | 08.07.2021 | 07.07.2026 |
| 94 | Peron 20 | Prednisolone BP 20 mg/Tablet | 353-120-072 | 08.07.2021 | 07.07.2026 |
| 95 | Lidocaine 1% Inj | Lidocaine Hydrochloride BP 10 mg/ml Injection | 353-121-005 | 03.08.2021 | 02.08.2026 |
| 96 | Lidocaine 2% Inj | Lidocaine Hydrochloride BP 20 mg/ml Injection | 353-122-005 | 03.08.2021 | 02.08.2026 |
| 97 | Water for Injection | Sterile Water for Injection BP 1 ml/1ml ampoule | 353-123-079 | 08.07.2021 | 07.07.2026 |
| 98 | Amoclav injection (vet) | Amoxicillin Sodium (Sterile Powder) BP 1.060 gm (eqv. to Amoxicillin 1gm) / Vial Powder for | 353-127(v)-023 | 08.07.2021 | 07.07.2026 |
| 99 | Xfur injection (vet) | Ceftiofur Sodium Sterile USP 1.042 gm (eqv. to Ceftiofur 1.0 gm/vial | 353-128(v)-077 | 08.07.2021 | 07.07.2026 |
| 100 | Xfur injection (vet) | Ceftiofur Sodium Sterile USP 0.521 gm (eqv. to Ceftiofur 0.500 gm/vial | 353-129(v)-077 | 08.07.2021 | 07.07.2026 |
| 101 | Cefavet powder (vet) | Cefalexin Monohydrate (Micronized) BP 7.889 gm (eqv. to Cefalexin 7.5 gm)/100 gm Powder | 353-130(v)-077 | 08.07.2021 | 07.07.2026 |
| 102 | Thioton 500 | Thiopental Sodium, Sterile BP 500 mg/Vial Injection | 353-133-004 | 03.08.2021 | 02.08.2026 |
| 103 | Thioton 1 gm | Thiopental Sodium, Sterile BP 1 gm/Vial Injection | 353-134-004 | 03.08.2021 | 02.08.2026 |
| 104 | Diapamiro-370 | Iopamidol USP 75.5 gm/100ml Injection | 353-135-041 | 03.08.2021 | 02.08.2026 |
| 105 | Diapac-350 | Iohexol USP 755 mg (eqv. to 350 mg Iodine)/ml Injection | 353-136-041 | 03.08.2021 | 02.08.2026 |
| 106 | Dixanol-320 | Iodixanol USP 651.5 mg (eqv. to 320 mg of organically bound iodine) /ml Injection | 353-137-041 | 03.08.2021 | 02.08.2026 |
| 107 | Relaxton | Atracurium Besylate USP 25 mg/2.5 ml Injection | 353-138-063 | 03.08.2021 | 02.08.2026 |
| 108 | Suxonium | Suxamethonium Chloride BP 100 mg/2 ml Injection | 353-139-063 | 03.08.2021 | 02.08.2026 |
| 109 | Propofol | Propofol USP 10 mg/ml Injection | 353-140-004 | 03.08.2021 | 02.08.2026 |
| 110 | Vencuron-10 | Vecuronium Bromide BP 10 mg/Vial Injection | 353-141-063 | 03.08.2021 | 02.08.2026 |
| 111 | Avalon IV | Azithromycin Dihydrate (Micronized) USP 524.059 mg (eqv. to Azithromycin 500 mg)/Vial Injection | 353-142-023 | 03.08.2021 | 02.08.2026 |
| 112 | Omsec IV | Omeprazole Sodium BP 44.63 mg (eqv. to Omeprazole 40 mg)/Vial Injection | 353-143-067 | 03.08.2021 | 02.08.2026 |
| 113 | Romilac 30 | Ketorolac Tromethamine USP Injection 30 mg/1ml Injection | 353-144-064 | 03.08.2021 | 02.08.2026 |
| 114 | Romilac 60 | Ketorolac Tromethamine USP Injection 30 mg/1ml Injection | 353-145-064 | 03.08.2021 | 02.08.2026 |

| | | | | | |
|-----|-----------------------|---|-------------|------------|------------|
| 115 | Urilev IV | Levofloxacin Hemihydrate USP 512.5mg (eqv. to Levofloxacin 500mg)/100 ml IV Infusion | 353-146-023 | 03.08.2021 | 02.08.2026 |
| 116 | Panalon | Pancuronium Bromide BP 4mg/2ml Injection | 353-147-063 | 03.08.2021 | 02.08.2026 |
| 117 | Stigmin | Neostigmine Methylsulfate USP 0.5 mg/ml Injection | 353-148-037 | 03.08.2021 | 02.08.2026 |
| 118 | Duracain | Bupivacaine Hydrochloride Monohydrate USP 21.1 mg (eqv. to Anhydrous Bupivacaine Hydrochloride 20 mg)/4ml Injection | 353-149-005 | 03.08.2021 | 02.08.2026 |
| 119 | Maclar IV | Clarithromycin USP 500 mg/Vial Infusion | 353-150-023 | 03.08.2021 | 02.08.2026 |
| 120 | Neovitan IM Inj. | Thiamine hydrochloride (Vitamin B1) BP 100 mg, Pyridoxine Hydrochloride (Vitamin B6) BP 100 mg, Cyanocobalamin (Vitamin B12) BP 1/3ml Inj | 353-154-078 | 01.11.2021 | 31.10.2026 |
| 121 | Maclar | Clarithromycin taste masked granules USP 9.259 gm (eqv. to 2.5 gm Clarithromycin)/100 ml Powder for Suspension | 353-155-023 | 01.11.2021 | 31.10.2026 |
| 122 | Medrol 120 | Methylprednisolone Acetate BP 120 mg/3ml Injection | 353-156-072 | 01.11.2021 | 31.10.2026 |
| 123 | Pro-Medrol 125 | Methylprednisolone Sodium Succinate Sterile USP 165.8 mg (eqv. to 125 mg Methylprednisolone)/Vial Injection | 353-157-072 | 01.11.2021 | 31.10.2026 |
| 124 | Pro-Medrol 500 | Methylprednisolone Sodium Succinate Sterile USP 663 mg (eqv. to 500 mg Methylprednisolone)/Vial Injection | 353-158-072 | 01.11.2021 | 31.10.2026 |
| 125 | Pro-Medrol 1 g | Methylprednisolone Sodium Succinate Sterile USP 1326 mg (eqv. to 1000 mg Methylprednisolone)/Vial Injection | 353-159-072 | 01.11.2021 | 31.10.2026 |
| 126 | Syntocin 10 | Oxytocin BP 16.66 mcg (eqv. to 10 IU)/1ml Injecton | 353-160-049 | 01.11.2021 | 31.10.2026 |
| 127 | Lidocaine Plus | Lidocaine hydrochloride BP 20 mg Epinephrine Bitrtrate BP 36 mcg (eqv. to 20 mcg Epinephrine)/ml Injection | 353-161-005 | 01.11.2021 | 31.10.2026 |
| 128 | Doxym 50 | Doxycycline Hyclate BP 57.70 mg (eqv. to 50mg Doxycycline)/Capsule | 353-165-023 | 01.11.2021 | 31.10.2026 |
| 129 | Doxym 100 | Doxycycline Hyclate BP 115.40 mg (eqv. to 100mg Doxycycline)/Capsule | 353-166-023 | 01.11.2021 | 31.10.2026 |
| 130 | Ciplon IV | Ciprofloxacin Lactate BP 254.32 mg (eqv. to Ciprofloxacin 200 mg)100ml IV Infusion | 353-170-023 | 01.11.2021 | 31.10.2026 |
| 131 | Esmosec 40 IV Inj. | Esomeprazole Sodium BP 42.55 mg (eqv. to Esomeprazole 40 mg)/Vial IV Injection | 353-173-067 | 06.01.2022 | 05.01.2027 |
| 132 | Pantosec IV Injection | Pantoprazole Sodium Sesquihydrate BP 45.12 mg (eqv. to Pantoprazole 40 mg) Vial IV Injection | 353-175-067 | 06.01.2022 | 05.01.2027 |
| 133 | Diascan Injection | Gadodiamide USP 287 mg (eqv. to 0.5 mg mmol) ml Injection | 353-176-041 | 06.01.2022 | 05.01.2027 |
| 134 | Kilpro IV Infusion | Metronidazole BP 500 mg/100ml Iv Infusion | 353-182-027 | 16.03.2022 | 15.03.2027 |
| 135 | Viscer Injection | Tiemonium methysulfate INN 5 mg/2ml Injection | 353-183-011 | 23.06.2022 | 22.06.2027 |

| | | | | | |
|-----|-----------------------------|--|-------------|------------|-------------|
| 136 | Mifisol Tablet | Mifepristone USP 200 mg/ Tablet | 353-184-049 | 23.06.2022 | 22.06.2027 |
| 137 | Caproxex Injection | Aminocaproic Acid USP 2gm/10 ml Injection | 353-185-033 | 14.08.2022 | 13.08.2027 |
| 138 | SC-Drops (Sterile Solution) | Sodium Chloride BP 0.9 gm/100ml | 353-188-050 | 14.08.2022 | 13.08.2027 |
| 139 | Paclitex Injection | Paclitaxel USP 30 mg | 304-292-71 | 14.12.2009 | 13.12.2024 |
| 140 | Doxorub Injection 50 mg | Doxorubicin Hydrochloride USP 50 mg | 304-293-71 | 14.12.2009 | 13.12.2024 |
| 141 | Cesalin Injection 50 mg | Cisplatin BP 50 mg | 304-294-71 | 14.12.2009 | 13.12.2024 |
| 142 | 5-Fluril Injection | 5- Fluorouracil BP 500 mg | 304-295-71 | 14.12.2009 | 13.12.2024 |
| 143 | Cyclomide Injection 200 mg | Cuclophosphamide Monohydrate BP 214 mg (eq to Cuclophosphamide Anhydrous 200 mg) | 304-296-71 | 14.12.2009 | 13.12.2024 |
| 144 | Oxalotin Injection 50 mg | Oxaliplatin BP 50 mg | 304-297-71 | 14.12.2009 | 13.12.2024 |
| 145 | Carbotin Injection 450 mg | Carboplatin BP 450 mg | 304-298-71 | 14.12.2009 | 13.12.2024 |
| 146 | Gemcetin Injection 1 g | Gemcitabine Hydrochloride USP 1.1385 gm (eq to Anhydrous Gemcitabine 1 g) | 304-299-71 | 14.12.2009 | 13.12.2024 |
| 147 | Gemcetin Injection 200 m g | Gemcitabine Hydrochloride USP 228 mg (eq to Anhydrous Gemcitabine 200 mg) | 304-300-71 | 14.12.2009 | 13.12.2024 |
| 148 | Eposide Injection | Etoposide BP 100 mg | 304-301-71 | 14.12.2009 | 13.12.2024 |
| 149 | Cyclomide – 1g Injection | Cyclophosphamide Monohydrate BP 1070mg (eq. to Cyclophosphamide Anhydrous 1g) | 304-308-71 | 25.02.2010 | 24.02.2025 |
| 150 | Doxorub-10 Injection | Doxorubicin Hydrochloride USP 10mg | 304-309-71 | 25.02.2010 | 24.02.2025 |
| 151 | Carbotin 150 Injection | Carboplatin BP 150mg | 304-310-71 | 25.02.2010 | 24.02.2025 |
| 152 | Cesalin-10 Injection | Cisplatin BP 10mg | 304-311-71 | 25.02.2010 | 24.02.2025 |
| 153 | Vincrist Injection | Vincristine Sulphate USP 1mg | 304-317-71 | 20.04.2010 | 19.04. 2025 |
| 154 | Mtrex Injection | Methotrexate BP 50mg (as Methotrexate Sodium) | 304-318-71 | 20.04.2010 | 19.04.2025 |
| 155 | Docetax 80 Injection | Docetaxel INN 80 mg | 304-319-71 | 03.06.2010 | 02.06.2025 |
| 156 | Oxalotin 100 Injection | Oxaliplatin BP 100 mg | 304-331-71 | 20.10.2011 | 19.10.2026 |
| 157 | Mesna Injection | Mesna Disulfide USP 400mg | 304-335-71 | 22.11.2011 | 21.11.2026 |
| 158 | Ifamide 1 gm Injection | Ifosfamide USP 1.0 gm | 304-338-71 | 12.01.2012 | 11.01.2027 |
| 159 | Ifamide 2 gm Injection | Ifosfamide USP 2.0 gm | 304-339-71 | 12.01.2012 | 11.01.2027 |
| 160 | Paclitaxel 300 Injection | Paclitaxel USP 300.00 mg | 304-340-71 | 12.01.2012 | 11.01.2027 |
| 161 | Docetax 20 Injection | Docetaxel INN 20.00 mg | 304-342-71 | 31.01.2012 | 30.01.2027 |

| | | | | | |
|-----|-----------------------|--|-------------|------------|------------|
| 162 | Ostometa Injection | Zoledronic Acid Monohydrate INN 4.264mg (eqv. To 4 mg of Zoledronic Acid Anhydrous) | 304-387-010 | 18.02.2014 | 17.02.2024 |
| 163 | Irotin 100 Injection | Irinotecan Hydrochloride Trihydrate USP 108.67mg (eqv. To 100.00mg Irinotecan Hydrochloride) | 304-393-10 | 29.05.2014 | 28.05.2024 |
| 164 | Irotin 40 Injection | Irinotecan Hydrochloride Trihydrate USP 43.47mg (eqv. To 40.00mg Irinotecan Hydrochloride) | 304-394-10 | 29.05.2014 | 28.05.2024 |
| 165 | Folicid 100 Injection | Folinic Acid (as Calcium folinate) BP 100.00mg | 304-395-10 | 29.05.2014 | 28.05.2024 |
| 166 | Folicid 50 Injection | Folinic Acid (as Calcium folinate) BP 50.00mg | 304-396-10 | 29.05.2014 | 28.05.2024 |
| 167 | Epicin 10 Injection | Epicubicin Hydrochloride BP 10.00mg | 304-397-10 | 29.05.2014 | 28.05.2024 |
| 168 | Epicin 50 Injection | Epicubicin Hydrochloride BP 50.00mg | 304-398-10 | 29.05.2014 | 28.05.2024 |
| 169 | Tagribo 80 Tablet | Osimertinib Mesylate INN 95.43 mg eqv. to Osimertinib 80 mg | 304-409-010 | 8/1/2020 | 7.01.2025 |
| 170 | Tagribo 40 Tablet | Osimertinib Mesylate INN 47.72 mg eqv. to Osimertinib 40 mg | 304-410-010 | 8/1/2020 | 7.01.2025 |

List of Products: Animal Health Division

| Sl. | Products Name | Generic Name & Composition | DAR No. | Expiry Date |
|-----|----------------------------------|---|----------------|-------------|
| 1 | Flumil 10 (Vet) | Flumequine INN 10.00 gm | 304-3(V)-83 | 23.04.2026 |
| 2 | Peraclear Bolus (Vet) | Fenbendazole INN 0.250 gm | 304-5(V)-83 | 08.07.2026 |
| 3 | Tetranid Bolus (Vet) | TetramisoleHCl BP 2.00 gm | 304-8(V)-83 | 23.04.2026 |
| 4 | Aldazole Bolus (Vet) | Albendazole BP 600 mg | 304-10(V)-83 | 19.08.2026 |
| 5 | Sulfatrim Powder (Vet) | Sulfadiazine BP 4000 gm | 304-11(V)-83 | 19.08.2026 |
| 6 | Cositrim Powder (Vet) | Sulphachloropyridazine Sodium BP 10.00 gm | 304-12(V)-83 | 19.08.2026 |
| 7 | Technomysol Bolus (Vet) | LevamisoleHCl BP 600 mg | 304-15(V)-83 | 19.08.2026 |
| 8 | Flumil 20 (Vet) Oral Solution | Flumequine INN 20 gm | 304-16(V)-83 | 06.01.2027 |
| 9 | Sulphatrim Bolus (Vet) | Sulphadiazine BP 1.0 gm | 304-44(V)-77 | 10.11.2024 |
| 10 | Levex Bolus (Vet) | LevamisoleHCl BP 600 mg | 304-45(V)-77 | 10.11.2024 |
| 11 | Nemasole 46 Powder (Vet) | LevamisoleHCl BP 46.00 gm | 304-48(V)-83 | 21.11.2024 |
| 12 | Pirazin 100 (Vet) | Piperazine Citrate USP 100 gm | 304-55(V)-83 | 13.11.2026 |
| 13 | Nilamide Powder (Vet) | Sulphanilamide BP 100 gm | 304-56(V)-83 | 13.11.2026 |
| 14 | Tylosin Powder (Vet) | Tylosin Tartrate BP 100 gm | 304-64(V)-83 | 31.12.2026 |
| 15 | CypmetSollution (Vet) | Cypermethrin USP 20 gm | 304-235(V)-83 | 05.12.2026 |
| 16 | Furadon Powder (Vet) | Furaltadone Hydrochloride USP 556.28 mg (eqv. 500 mg) | 304-237(V)-83 | 05.12.2026 |
| 17 | Amprolin Powder (Vet) | Amprolium Hydrochloride USP 678.57 mg (Eqv. 600 mg) | 304-238(V)-83 | 05.12.2026 |
| 18 | Amprolin Plus Powder (Vet) | Amprolium USP 17.0 gm | 304-239(V)-83 | 05.12.2026 |
| 19 | Melovet Injection | Meloxicam BP 0.500 gm | 304-341(v)-83 | 11.01.2027 |
| 20 | TD Cough Oral Solution (vet) | Bromhexine Hydrochloride BP 10.00gm + Phenylbutazone BP 50.00gm | 304-384(v)-077 | 17.02.2024 |
| 21 | Gentacin Inj. 5% (Vet) | Gentamycin Sulphate BP 8.500 gm (eqv 5 gm) | 304-6(V)-83 | 23.04.2026 |
| 22 | Technomycin Bolus (Vet) | Oxytetracycline Hydrochloride BP 0.540 gm (eqv 5 gm) | 304-9(V)-83 | 08.07.2026 |
| 23 | Bional Forte Inj. (Vet) | Thiamine Hydrochloride BP 50 mg | 304-42(V)-77 | 10.11.2024 |
| 24 | Oxynil Inj. (Vet) | Nitroxynil BP 250 mg | 304-46(V)-77 | 10.11.2024 |
| 25 | Ciprosol 10 (Vet) Oral Solution | Ciprofloxacin Hydrochloride USP 200 mg | 304-49(V)-83 | 17.12.2025 |
| 26 | Vermic (Vet) Injectable Solution | Ivermectin BP 1.0 gm | 304-50(V)-83 | 17.12.2025 |
| 27 | Enrox 10 (Vet) Oral Solution | Enrofloxacin INN 10 gm | 304-51(V)-83 | 24.01.2026 |
| 28 | Technomycin-DS Bolus (Vet) | OxytetracyclineDihydrate BP 1.00 gm | 304-53(V)-83 | 24.01.2026 |
| 29 | Dimidin Inj. (Vet) | Sulphadimidin Sodium BP 33.33 gm | 304-54(V)-83 | 24.01.2026 |
| 30 | Adesol Forte Inj. (Vet) | Vitamin A BP 300,000 IU | 304-57(V)-83 | 13.11.2026 |

| | | | | |
|----|---|--|----------------|------------|
| 31 | Neovet 70 (Vet) | Neomycin Sulphate BP 700 mg (eqv. 476 mg) | 304-58(V)-77 | 13.11.2026 |
| 32 | Caldifos Inj. (Vet) | Calcium Gluconate BP 20 gm | 304-61(V)-83 | 13.11.2026 |
| 33 | Pyramin Oral Solution (Vet) | Pyrimethamine BP 15 gm | 304-241(V)-83 | 05.12.2026 |
| 34 | Ciprosol Inj. (Vet) | Ciprofloxacin Hydrochloride USP 5.822 gm (eqv. 5 gm) | 304-244(V)-83 | 05.12.2026 |
| 35 | Anthiomat Inj. | Lithium Antimony Thiomalate IP 60 mg (eqv. 12 mg) | 304-245(V)-83 | 05.12.2026 |
| 36 | XtravetInj (Vet). | Vitamin A BP 100000 IU | 304-248(V)-83 | 05.12.2026 |
| 37 | Oxylin Spray (Vet) | Oxytetracycline Hydrochloride USP 2.5 gm | 304-252(V)-83 | 05.12.2026 |
| 38 | Gentamax Powder (vet) | Gentamycin Sulfate BP 200.00mg | 304-381(v)-077 | 17.02.2024 |
| 39 | Roxyvet DS Bolus (vet) | Cobalt Sulfate BP 100.00mg + Dried Ferrous Sulfate BP 200.00mg + Thiamine Mononitrate BP 50.00mg + Vitamin B ₁₂ BP 40.00mcg + Choline Bitartrate BP 18.20mg | 304-385(v)-077 | 17.02.2024 |
| 40 | LEVOSOL 10% ORAL SOLUTION (VET) | Levofloxacin (as Levofloxacin Hemihydrate) USP 10.249 gm | 304-413-077 | 10.04.2026 |
| 41 | MELOVET Bolus (Vet) | Meloxicam BP 100 mg | 304-414v-077 | 10.04.2026 |
| 42 | MELOVET 2% Injection (Vet) (10 ml clear glass vial) | Meloxicam BP 20.0 mg | 304-415(V)-077 | 10.04.2026 |
| 43 | Marbosol Bolus (Vet) | Marbofloxacin BP 50 mg | 304-416(v)-077 | 7.07.2026 |
| 44 | Marbosol Injection (Vet) | Marbofloxacin BP 100 mg | 304-417(v)-077 | 7.07.2026 |
| 45 | Melovet 2% Injection (vet) (30 ml Amber Tubular Glass Vial) | Meloxicam BP 20 mg | 304-418(v)-077 | 7.07.2026 |
| 46 | Vermic Plus Injection (vet) | Ivermectin BP 10 mg | 304-419(v)-077 | 7.07.2026 |
| 47 | Vermic Pour-On Solution (vet) | Ivermectin BP 5.0 mg | 304-420(v)-077 | 10.31.2026 |
| 48 | Vermic 1% Oral Solution (vet) | Ivermectin BP 10.0 mg | 304-421(v)-077 | 10.31.2026 |
| 49 | ColistinSulphate Oral Solution (vet) | ColistinSulphate BP 120 mg | 304-422(v)-077 | 10.31.2026 |
| 50 | Ticor (vet) Oral Solution | Tilmicosin Phosphate USP 278.18 eq. to 250 mg | 304-423(v)-077 | 12.08.2026 |
| 51 | FM (vet) Inj. | FlunixinMeglumine USP 83 mg (eqv. to 50 mg of Flunixin)/ ml Injection (Vet) | 304-424(v)-077 | 1.10.2027 |

Market

All of the products' markets are throughout the Bangladesh and approximately 25 products are exporting outside the country.

Past trends and future prospects regarding local market:

Last 5 years' net revenue of Techno Drugs Ltd.:

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|-------------|---------------|---------------|---------------|---------------|---------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |

Local market, demand and supply forecasts for the sector:

The pharmaceutical market of Bangladesh is expected to surpass \$6 billion by 2025 with an absolute growth of 114% from its 2019 levels, according to a report from a Dublin-based market insight and analysis firm, Research and Markets.

"The pharmaceutical market has been witnessing excellent growth in recent years, and it is expected to have a compound annual growth rate of more than 12 per cent during the 2019-2025 period," said the report titled "Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025".

Demand:

A majority of the growth will be contributed by local companies with a market share of more than 90 percent as similar to past trends attained over the last two decades, the report said.

The notable change that attracted the world towards Bangladesh is a consequence of innovation in the science and research and development sector, the Research and Markets said in its report.

Rise in life expectancy, growing per capita income, changing disease profile, population growth, lifestyle changes and increasing patient population are some of the key drivers that are boosting consumption in the local market, it said.

In the upcoming years, the government of Bangladesh will play a significant role in the rapid growth of the pharmaceutical market by providing favorable policies for easy drug approval, production and marketing of new products, the Irish firm expects.

The government is focusing on reducing the country's dependence on the import of raw materials. The establishment of an API Park will act as a turning point for this purpose.

Supply Forecast:

In recent times, local pharmaceutical companies have emerged as a game-changer by contributing more than 90% of the overall available medicines in the market.

The top 50 companies are setting up their facilities at the Active Pharmaceuticals Ingredient Industrial Park in Munshiganj that will help in the production of patented and already opened active pharmaceuticals ingredients.

It is expected that the development of the API Park will be complete by the next two years, which will reduce the expenditure related to the import of raw materials.

The report said the share of generic drugs is expected to surpass 85% by 2025, which will further strengthen the dominance of local pharmaceutical companies in the market.

- (vi) **If the issuer has more than one product or service, the relative contribution to sales and income of each product or service that accounts for more than 10% of the company's total revenues;**

There is no product that account for more than 10% of the Company's total revenue.


- (vii) **Description of associates, subsidiary and holding company of the issuer and core areas of business thereof;**

At present, there are no associates, subsidiary and holding company of The Techno Drugs Ltd.

- (viii) **How the products or services are distributed with details of the distribution channel. Export possibilities and export obligations, if any;**

TDL has its own distribution network to distribute its products throughout the country. All products produced in the factory, are brought to the central depot at Dhaka, before a fleet of 24 delivery vehicles of the company distribute the products to 17 other sales centers/depots located across the country.

Company's product distribution systems are depicted below:



Export possibilities and export obligations:

The company currently exports approximately 25 pharmaceutical formulations to Philippines, Myanmar, Cambodia, Sri Lanka, Yemen and Afghanistan.

The company has further market exploration plan to United Arab Emirates, Venezuela, Ethiopia, Kenya, Uganda, Runda, South Africa, Turkey, China, Oman and Mauritius.

(ix) Competitive conditions in business with names, percentage and volume of market shares of major competitors;

In 1981, there were only 166 licensed pharmaceutical manufacturers in the country. The local market and production, however, was largely dominated by eight multinational companies, which used to cover almost 75% of the local demand. Medium size local companies used to meet about 15% of the demand and the remaining 10% was met by small companies. The Drug Regulatory Committee enforced some new regulations on multinationals to constrain their domination and also to encourage the local companies.

Following the 1982 ordinance, the value of locally produced medicine rose from Tk. 1.1 million in 1981 to Tk 19.23 billion in 2000. Nearly 95% of total domestic demand for medicines was met by local production.

At present, there are 284 licensed pharmaceutical companies in Bangladesh, with about 150 of them functional. Bangladeshi medicines are now being exported to 150 countries.

The market share data in terms of value and percentage for the leaders is given below:

| Competitors | Market Share% | Position |
|------------------------------|----------------------|-----------------|
| Square Pharmaceuticals Ltd. | 17.73% | 1 |
| Incepta Pharmaceutical Ltd. | 10.21% | 2 |
| Beximco Pharmaceuticals Ltd. | 8.39% | 3 |
| Opsonin Pharma Ltd. | 5.54% | 4 |
| Renata Ltd. | 4.97% | 5 |

Source: <https://businessinspection.com.bd/top-pharmaceutical-companies-in-bd/>

Apart from this, as per audited reports of the major listed companies and audited financial statements of The Techno Drugs Ltd. the sales amounts are presented below:

| Company Name | Amount (Tk. mn) | Period |
|------------------------------|------------------------|---------------------|
| ACI Ltd. | 96,571.64 | Jul 2021 - Jun 2022 |
| Beximco Pharmaceuticals Ltd. | 34,669.17 | |
| Orion Pharma Ltd. | 9,661.61 | |
| Renata Ltd. | 31,070.55 | |
| Square Pharmaceuticals Ltd. | 57,597.94 | |
| Techno Drugs Ltd. | 2,733.48 | Jul 2022 - Jun 2023 |

(x) Sources and availability of raw materials, names and addresses of the principal suppliers and contingency plan in case of any disruption;

Most of the raw materials and some primary packing materials of the Company are procured from abroad. The names of main suppliers are mentioned below:

| Sl. | Supplier name | Country of origin | Supplier Address, Contract No., e-mail, Web address | Material |
|-----|--|-------------------|---|--|
| 1 | Sicor DE mexico,S.A.DE C.V.AV. | China | SAN Rafael No.35 Parque Ind. Lerma, CP 52000 Lerma Estado DE Mexico. Tel: +31 (0)20-2193222 | Other Organic Compound, Nes Docetaxel Anhydrous, Cisplatin BP Oxaliplatin BP Carboplatin BP Cisplatin, Carboplatn, Docetaxel Anhydrous |
| 2 | North China Pharmaceutical group Semisyntech co. Limited | China | 20 Yangzi Road, shijiazhuange and T development Zone Hebei China. Tel: +86 (311) 89699650 | Denzylpenicillin Procaine., Denzylpenicillin Soudium, Penicilins and derivatives with A penicilianic acid structure salts for tified procaine penicilline sterile BP |
| 3 | Shandong New Time Pharmaceutical Co. Ltd. | China | No: 1, North Outer Ring Road. Feixian, Shandong, China. Tel: +865393116123 Fax: +865398331269 | Other acyclic ethers and their halogenated derivatives nes soflurane USP, sevoflurane USP |
| 4 | Lasa Supergenerics Limited. | India | Reg Office: c-105, M.I.D.C, Mahad, Dist: Raigad State Maharashtra, India. | Compounds with quinoline or isoquinoline ring-System not further fused Fenaen Dazole EP |
| 5 | Teva API B.V. | Netherlands | Piet Hein Building, Piet Heinkade 107, 1019 GM Amsterdam, Netherlands. Tel: 202193169 E-mail: cx@teva-api.com Web: www.tevapharm.com | Antibiotics Nes Doxorubicin Hydrochloride, Azithromycin Epirubicin Hydrochloride |
| 6 | SBI Corporation | South Korea | 1220 Poonglim Building ,127, Mapo-Daero,Mapo-GU, Seoul 04144, South korea | Propylene Glycol USP |
| 7 | Zhejiang Guobang Pharmaceutical CO, LTD | China | No 6 Welwu road hangzhou gulf shangyu Industrial Zone zhejiang China. Tel: +86-571-81396108, Fax: +86-571-81396111 | Azithromycin Azithromycin Dihydrate Compacted |
| 8 | AXXO Im- und Export GmbH | Australia | Rödingsmarkt 20, 20459 Hamburg, Germany. Tel: +49 – 40 – 389 19 40 Fax: +49 – 40 – 386 19 409 E-mail: pharma@axxo.de Web: axxo.de/en | Raw mat:filgrastim |

| | | | | |
|----|--|------------|---|--|
| 9 | Fipharm CO., Limited | China | 22 nd Floor, Tianying Square, 22 Guoxing Avenue Haikou City, Hainan Province, China | Antibiotics Tilmicosine Phosphate |
| 10 | Beijing Tian Nuo Rui Lang Trading Co., Ltd. | China | No. 62, Yunjing, South Street, Tongzhou District, Beijing, China Tel: +86-10-65767020 E-mail: cathy@cloudybuy.com Web: www.tnrl-chem.com | Other Organic Compounds Nes Etonogestret, Halogenated derivatives of adrenal cortical hormones Triamcinol one acetone BP/USP |
| 11 | Fermion Oy | Finland | Koivu-Mankkaan tie 6 A, FI-02200 Espoo, Finland. Tel: +358 10 4261 E-mail: fermionsales@fermion.fi. Web: www.fermion.fi | raw mat:irinotecan hydrochloride |
| 12 | United Pharma and Ch emicalCo., Ltd. | China | Room 514, No.939 Jinqiao Road Pudong new district, Shanghai, China. Tel: 0086-21-61630457 Web: unitedpharma@163.com | VITAMIN E and its Derivatives Unimixed Vitamin E acetat, Tetracyclines and their derivatives salts thereof Oxytetracycline hydrochl oride BP/USP, Cortisone, hydrocortisone And Predisolone Prednisolone BP |
| 13 | Agrani Traders | Bangladesh | 67/9, Eastern Mansion, E-mail: agranitraders001@gmail.com Suite # 12-03 Kakrail, Dhaka-1000. Cell: +8801718-193422 E-mail: agranitraders001@gmail.com | Coral Calcium Carbonate, Citric Acid Monohudrate BP, Quienoive laka colour |
| 14 | Venus Scientific Store | Bangladesh | 32/1, Hatkhola Road, Suvechcha Plaza, Shop No. 7, Dhaka-1203. Tel: 47113256 E-mail: venus.prodip@gmail.com | N-Hexane, NEOMYCIN SULPHATE, Acetonitile HPLC Scherlow Spain |
| 15 | Zaman Trade International | Bangladesh | 18/3/A, A.N.A Tower, Armanian Street Armanitola, Dhaka-1100. Cell: +8801711-111201 E-mail: zamantradeintl@gmail.com | Domperdone Plain, Nutricnt Agar – Himidis, Cetrimidl Agar - Himidis |
| 16 | M/s Siyam Enterprise | Bangladesh | 88/1, Distilary Road, Gandaria, Dhaka-1204. Cell: +8801673-910464 E-mail: inceppion1612@gmail.com | Sodium Bi Carbonate, Manitol Salt Agar, Tylosin-20 powder 10 gm Sechet Foil |

Contingency plan in case of Disruption of supplier:

TDL is a vertically integrated finished formulation pharmaceuticals product manufacturer, promoter, distributor and seller. Its business is product wise brand driven in nature. But a key part of its business model is managing a complex supply chain management. To ensure each brand growth, it is indispensable to make available of all ingredients with right quality, right quantity, from right sources. Being a member of highly regulated industry, we have to keep familiarity with at least three processes firstly is it coming from validated sources, secondly is it processed in a right way and finally how it is reaching to the final consumers.

To meet the Good Manufacturing Practice (cGMP), the Company always conducts vendors audit and selects several validated vendors, which helps to tackle disruption of supply and minimize the risk of short supply.

(xi) Sources of, and requirement for, power, gas and water; or any other utilities and contingency plan in case of any disruption;

Factory Location: Satirpara, Narsingdi-1600.

| Utilities | Requirements | Sources |
|-----------------------|-----------------|---|
| Electricity | 1250KVA | The Company has Palli Bidyut Connection of 1250KVA |
| Electricity (Back up) | 300 KVA | In house generator (Diesel Generator) |
| Electricity (Back up) | 250 KVA | In house generator (Gas generator) |
| Gas | 800 Cubic meter | The gas required for both official and manufacturing Purpose is supplied from Titas Gas Transmission and Distribution Company Limited. |
| Water | 1000 liter/hr. | Water is Drawn by own Deep Tube well/ Submersible Pump Stored in Center Storage Tank (1000 Liter Capacity) for Water Treatment Plant (WTP) and Other regular Usage. |

Factory Location: B.K. Bari Mirzapur, Gazipur-1703.

| Utilities | Requirements | Sources |
|-----------------------|-------------------------|---|
| Electricity | 5000KVA | The Company has REB Connection of 5000KVA (33KV/11KV/0.4KV) substation. |
| Electricity (Captive) | 930KVA, 650KVA & 150KVA | In house generator (Diesel Generator) |
| Electricity (Captive) | 750KVA, 750KVA | In house generator (Gas generator) |
| Gas | 23530 Cubic meter | The gas required for both official and manufacturing Purpose is supplied from Titas Gas Transmission and Distribution Company Limited. |
| Water | 40,000 liter/hr. | Water is drawn by own deep tube well and stored in central storage tank (60000 Liter Capacity) for Water Treatment Plant (WTP) and Other regular Usage. |

Contingency Plan in case of any disruption:

To manage the disruption of utilities, the Company has installed generators as mentioned in above. The company has 7 generators to avoid any disruption.

(xii) Names, address(s), telephone number, web address, e-mail and fax number of the customers who account for 10% or more of the company's products or services with amount and percentage thereof;

The Company has no customers who contribute 10% or more of the total revenue.

(xiii) Names, address(s), telephone number, web address, e-mail and fax number of the suppliers from whom the issuer purchases 10% or more of its raw material or finished goods with amount and percentage thereof;

The Company has no suppliers from whom the company purchases 10% or more of its raw material/finished goods.

(xiv) Description of any contract which the issuer has with its principal suppliers or customers showing the total amount and quantity of transaction for which the contract is made and the duration of the contract. If there is not any of such contract, a declaration is to be disclosed duly signed by CEO or MD, CFO and Chairman on behalf of Board of Directors;

| Sl. | Name of Party | Relationship with the issuer | Transaction Amount | Quantity of transaction (No. of Invoice) | Duration of the contract (Years) | Number of Product |
|-----|---|------------------------------|--------------------|--|----------------------------------|-------------------|
| 1 | Advanced Chemical Industries (ACI) Ltd. | Customers | - | - | 5 | 12 |
| 2 | Al-Madina Pharmaceuticals Ltd. | Customers | - | - | 5 | 32 |
| 3 | Director of Drug Administration | Customers | - | - | 2 | 156 |
| 4 | Jenphar Bangladesh Ltd. | Customers | - | - | 5 | 83 |
| 5 | Biogen Pharmaceuticals Ltd. | Customers | - | - | 4 | 67 |
| 6 | General Pharmaceuticals Ltd. | Customers | - | - | 3 | 67 |
| 7 | Aristopharma Ltd. | Customers | - | - | 5 | 39 |

(xv) Description of licenses, registrations, NOC and permissions obtained by the issuer with issue, renewal and expiry dates;

Techno Drugs Ltd. has several regulatory licenses and certificates in order to continue its operations. The table shows list of licenses:

| Sl. | Description of Certificate/License/Registration | License Issuer/Issuing Authority | Certificate/Licenses No. | Validity |
|-----|--|---|-------------------------------|------------------------------------|
| 1 | Certificate of Incorporation | Registrar of Joint Stock Companies & Firms (RJSC) | C-79890/09 September 30, 2009 | N/A |
| 2 | Commencement of Business | N/A | N/A | N/A |
| 3 | Trade License (Head office) | Dhaka South City Corporation | TRAD/DSCC/096078/2019 | 30-Jun-24 |
| | Trade License (Factory-Narsingdi) | Narsingdi Pourashava | 07704 | 30-Jun-24 |
| | Trade License (Factory-Gazipur) | Mirzapur Union Parishad | 162432000088 | 30-Jun-24 |
| 4 | Certificate of Good Manufacturing Practice (GMP) For Pharmaceutical Products | Ministry of Health & Family Welfare | DA/6-60/2001/8357 | 08-Apr-25 |
| | | | DGDA/6-176/2012/07 | 01-Jan-24 (Applied for renewal) |
| 5 | TIN Certificate | National Board of Revenue, Dhaka | 353088771582 | N/A |
| 6 | VAT Certificate | Customs, Excise and VAT Commissionerate, Dhaka (East), Narsingdi Division | 000180068-0306 | N/A |
| 7 | Drugs Manufacturing License | Directorate General of Drug Administration (DGDA) | Drug License no 446 and 211 | 22-Apr-24 (Applied for renewal) |
| | | | Drug License no 482 and 274 | 06-Sep-23 (Applied for renewal) |
| 8 | Drugs License | Directorate General of Drug Administration (DGDA) | ১৬৩৭ পাইকারী | 24-Apr-24 (Applied for renewal) |
| 9 | Environmental Clearance | Department of Environment, Narsingdi | 23-94005-033 | 30-Nov-24 |
| | | Department of Environment, Gazipur | 23-99143 | 17-Jun-23 (Applied for renewal) |
| 10 | Fire License | Fire Service & civil defense | AD/DHAKA/40233/18 | 30-Jun-24 |
| | | | AD/DHAKA/36697/17 | 30-Jun-24 |
| | | | AD/DHAKA/52544/22 | 30-Jun-24 |
| 11 | Factory License | Factory and Organization Inspection Authority, Narsingdi | 11731/Narsingdi | 11-Jun-24 |
| | | Factory and Organization Inspection Authority, Gazipur | 19050/Gazipur | 30-Jun-24 |
| 12 | Boiler License | Department of Explosive, Narsingdi | বা: ব: ২৪৯৯ | 16-Apr-24 (Applied for renewal) |
| | | Department of Explosive, Gazipur | বা: ব: ৯৮৪০ | 13-Dec-23 (Applied for renewal) |
| 13 | Import Registration Certificate (IRC) | Chief Controller of Import & Export | 260326120307020 | 30-Jun-24 |
| 14 | Export Registration Certificate (ERC) | | 260326210447420 | 30-Jun-24 |
| 15 | ISO: 9001:2015 | International Certification Authority | ICAN200306 | 15-Nov-26 |

(xvi) Description of any material patents, trademarks, licenses or royalty agreements;

The Company has not entered into any agreements other than operation licenses or certificates.

(xvii) Number of total employees and number of full-time employees;

As per Audit Report

| Particulars | 30th June, 2023 |
|---|------------------------|
| Salary/Wages per month, Below Tk. 8,000 | Nil |
| Salary/Wages per month, Above 8,000 | 1,518 |
| Total No. of Employees | 1,518 |

(xviii) A brief description of business strategy;

Business Strategies

Business strategy refers to a framework wherein a company develops action and tactical plans depending on the company's goals and objectives. Business strategies help in decision making processes which in turn support different departmental needs all working together to achieve the overall objectives of a company.

Techno Drugs Ltd. considers the following as its business strategies:

Improvement of Local Market Share

Techno Drugs Ltd. since its inception has been giving importance to ensuring the availability of locally manufactured and quality pharmaceutical products in Bangladesh. As a result, Techno Drugs always focuses on improving the local market share of its pharmaceutical products.

Expand in the International Market Scene

Techno Drugs Ltd. emphasizes on manufacturing quality and innovative pharmaceutical products and increase exports to expand into the international market.

Innovate and Develop Quality Pharmaceutical Products

Techno Drugs Ltd. since inception has been inclined towards developing and manufacturing innovative and high-quality pharmaceutical products. Techno Drugs started production of Anti-Cancer medicines for the first time in the country when the country depended on imported Oncology medicines at that time.

Revolutionize and Leverage Hormonal Medicine

Techno Drugs Ltd. is a major manufacturer of Hormonal medicine. In addition to that the company is the fifth Contraceptive Implant manufacturer in the world and the first of its kind in Bangladesh. Techno Drugs Ltd. is also the largest injectable hormonal medicine manufacturer and supplier to the Government of Bangladesh. Techno Drugs Ltd. has a separate hormonal division and modern production process which it intends to leverage to cater the orders of the Government of Bangladesh.

Future Plans

Techno Drugs Ltd. will utilize the IPO proceeds for acquisition and installation of machineries & equipment, BMRE at Satirpara, Narsingdi-1600, building and other construction at B.K. Bari Mirzapur, Gazipur-1703, Partial loan repayment and IPO expenses.

(xix) A table containing the existing installed capacities for each product or service, capacity utilization for these products or services in the previous years, projected capacities for existing as well as proposed products or services and the assumptions for future capacity utilization for the next three years in respect of existing as well as proposed products or services. If the projected capacity utilization is higher than the actual average capacity utilization, rationale to achieve the projected levels.

Existing Capacity Utilization:

| Particulars | Unit | Installed Capacity (Million Unit) | | | Production Output (Million Unit) | | | Utilization (%) | | |
|----------------|-------------------|-----------------------------------|---------------|---------------|----------------------------------|---------------|---------------|-----------------|------|------|
| | | 2023 | 2022 | 2021 | 2023 | 2022 | 2021 | 2023 | 2022 | 2021 |
| Tablet | Pcs | 350.51 | 324.80 | 299.37 | 140.20 | 228.38 | 196.94 | 40% | 70% | 66% |
| Capsule | Pcs | 93.63 | 79.62 | 63.27 | 35.18 | 60.10 | 37.32 | 38% | 75% | 59% |
| Injection | Pcs | 34.55 | 29.40 | 22.46 | 16.53 | 25.89 | 18.32 | 48% | 88% | 82% |
| Powder | Sachet/ Bottle | 3.54 | 3.09 | 2.36 | 1.49 | 1.94 | 1.29 | 42% | 63% | 55% |
| Liquid & Syrup | Bottle | 6.99 | 6.56 | 5.01 | 3.71 | 5.71 | 3.94 | 53% | 87% | 79% |
| Total | | 489.22 | 443.48 | 392.48 | 197.12 | 322.01 | 257.81 | | | |

Capacity is calculated considering 300 days per year 1 shift per day. If needed, to meet the market demand the company may run two/ three shifts operation per day. That is why in some areas actual utilization of capacity shows more than 100%.

Projected Capacity Utilization:

| Particulars | Unit | Installed Capacity (Million Unit) | | | Production Output (Million Unit) | | | Utilization (%) | | |
|----------------|-------------------|-----------------------------------|---------------|---------------|----------------------------------|---------------|---------------|-----------------|------|------|
| | | 2024 | 2025 | 2026 | 2024 | 2025 | 2026 | 2024 | 2025 | 2026 |
| Tablet | Pcs | 402.74 | 472.41 | 517.11 | 289.97 | 349.58 | 398.18 | 72% | 74% | 77% |
| Capsule | Pcs | 106.72 | 126.04 | 134.89 | 79.93 | 98.31 | 109.26 | 75% | 78% | 81% |
| Injection | Pcs | 39.76 | 46.88 | 51.85 | 34.56 | 40.32 | 45.63 | 87% | 86% | 88% |
| Powder | Sachet/ Bottle | 4.03 | 4.76 | 5.25 | 2.60 | 3.43 | 3.89 | 65% | 72% | 74% |
| Liquid & Syrup | Bottle | 8.09 | 9.46 | 10.63 | 6.70 | 8.04 | 9.14 | 83% | 85% | 86% |
| Total | | 561.34 | 659.55 | 719.74 | 413.75 | 499.68 | 566.10 | | | |

Projected capacity utilization will be higher than the actual average capacity utilization due to expansion and upgradation as well as increase in the market demand for medicine. The company will utilize its remaining capacity to meet the additional market demand for existing products as well as new products.

(e) Description of Property:

The written down value of Property, Plant & Equipments owned by the company as per audited accounts as on 30 June 2023 are stated below:

| Sl. No. | Particulars | Written Down Value |
|----------------|-------------------------|---------------------------|
| 1 | Land & Land Development | 770,524,759 |
| 2 | Building | 1,678,364,388 |
| 3 | Plant & Machinery | 1,040,829,998 |
| 4 | Furniture & Fixture | 22,026,432 |
| 5 | Office Equipment | 3,664,922 |
| 6 | Laboratory Equipment | 5,367,390 |
| 7 | Motor vehicle | 1,859,828 |
| 8 | Electric Equipments | 63,498,350 |
| Total | | 3,586,136,067 |

(i) Location and area of the land, building, principal plants and other property of the company and the condition thereof;

The entire above mentioned assets are located at rented registered & head office: J K Tower, 31 Segunbagicha, Dhaka-1000 and factory: Satirpara, Narsingdi-1600 & B.K. Bari Mirzapur, Gazipur-1703. All of the above-mentioned Property, Plant & Equipments are in working condition.

(ii) Whether the property is owned by the company or taken on lease;

All the above-mentioned assets of the Company are in its own name except motor vehicle, rented registered & corporate office at J K Tower, 31 Segunbagicha, Dhaka-1000 and the depots.

(iii) Dates of purchase, last payment date of current rent (খাজনা) and mutation date of lands, deed value and other costs including details of land development cost, if any and current use thereof;

Land:

| Deed No. | Date of purchase | R.S. Dag No. | Deed Value In Tk. | Registration & Other Cost in Tk. | Area of Land (Decimal) | Current use |
|--------------|------------------|--|-------------------|----------------------------------|------------------------|---|
| 6721 | 07-May-14 | 581//541/520/521/588/584/525/524/1084/1090/591/593/592 | 32,800,000 | 2,952,000 | 596.57 | Solid & Powder Production, Liquid Production, Change Room, FP Quarantine, IPQC, AHU ROOM, Cold Room, Office Room, R & D Department, Prayer Room, Washing Room, Injection Production Processing, Blister Room, Secondary Packing Hall, Batch Printing Area, Intermediate Storage, Finished Product Quarantine, QA & QC, Documentation Storage Room, Laundry Room, Distilled Water Plant Room, Retention Sample Room, Encapsulation Room, FG Quarantine Room, Bulk Room, RM Dispensing ROOM, Change Parts Room, Injection Filling Sealing Room, Secondary PM Room, Injectable Production, Water System, Production, Technical, Canteen, Admin & Accounts Office, Office & Security Room, Substation, Control panel & Office, Air Compressor, Chemicals Dosing System & Office, Workshop & Engineering store, Central Quality Control, Central Quality Assurance, Molding Section, Warehouse, Assembly & Printing, Packing & Micro Biology, Technical & Quality Control Laboratory, Raw Materials Warehouse & Packaging, Finished Goods & Packaging Materials store, Fire Pump Operation, Transformer Operation, Incinerator Operation, Boiler & HVAC Store, Label Printing, Different Solvent Dispensing, Residents |
| 10148 | 28-Jun-14 | 587/586/582/591/583 | 5,000,000 | 450,000 | 273.93 | |
| 10719 | 09-Jul-14 | 584 | 500,000 | 45,000 | 27.00 | |
| 11218 | 20-Jun-14 | 593/591/588 | 4,500,000 | 405,000 | 35.00 | |
| 8257 | 20-Jun-17 | 589 | 1,050,000 | 94,500 | 35.00 | |
| 7271 | 10-Sep-18 | 590 | 5,880,000 | 705,840 | 70.00 | |
| 10680 | 11-Jun-12 | 8438/8445 | 4,200,000 | 378,000 | 120.00 | |
| 9927 | 19-Jun-13 | 2671/2750/2566/2565 | 4,000,000 | 360,000 | 98.00 | |
| 11430 | 18-Jul-13 | 1243 | 810,000 | 72,900 | 35.00 | |
| 9507 | 26-Jun-22 | 48 | 40,000,000 | 3,400,240 | 27.00 | |
| Total | | | 98,740,000 | 8,863,480 | 1,317.50 | |

- (iv) The names of the persons from whom the lands has been acquired or proposed to be acquired along with the cost of acquisition and relation, if any, of such persons to the issuer or any sponsor or director thereof;

| Deed No. | Name of the persons from whom the land has been acquired | Cost of acquisition | Relations |
|----------|--|---------------------|-----------------|
| 6721 | Hasan Mahmud | 32,800,000 | No relationship |
| 10148 | Hasan Mahmud, Mrs Juyena Mahmud | 5,000,000 | |
| 10719 | Tomiron Nessa, Musa Mia, Sokhina Bibi, Emon Sarker | 500,000 | |
| 11218 | Sirajul Islam | 4,500,000 | |
| 8257 | Hasan Mahmud, Mrs Juyena Mahmud | 1,050,000 | |
| 7271 | Foziron Nessa | 5,880,000 | |
| 10680 | Md. Golam Kibria, Shree Robindro Chandra Coch, Babul Hossain | 4,200,000 | |
| 9927 | Jamal Uddin Shikder, Shafinaz Shikder | 4,000,000 | |
| 11430 | Abdul Rashid | 810,000 | |
| 9507 | M/S. Techno Drugs | 40,000,000 | |

- (v) Details of whether the issuer has received all the approvals pertaining to use of the land, if required;

The company has received all the approvals pertaining to use of the land from Narsingdi Pourashava and Mirzapur Union Parishad.

- (vi) If the property is owned by the issuer, whether there is a mortgage or other type of charge on the property, with name of the mortgagee;

967.50 decimal land, factory building and machinery are mortgaged to One Bank Ltd.; 27.00 decimal land are mortgaged to AB Bank Ltd. and 133.00 decimal land are mortgaged to Community Bank Ltd.

- (vii) If the property is taken on lease, the expiration dates of the lease with name of the lessor, principal terms and conditions of the lease agreements and details of payment;

All the assets of the company are owned by the company except for motor vehicles. The company has two operating lease agreements regarding the leasing of motor vehicles. Details of the lease agreements are as follows:

Operating lease-1:

| Particulars | Lease Agreement for Motor Vehicles |
|--|------------------------------------|
| Lessor | IPDC Finance Limited |
| Lessee | Techno Drugs Limited |
| Effective Date of the Lease Agreement | 05 September, 2021 |
| Period of Lease | 60 Months |
| Date of Lease Expiration | 04 September, 2026 |
| Description of Leased Asset | SUV, Sedan and Commercial Vehicles |

| | |
|---------------------------------------|--|
| Principal Terms and Conditions | <ul style="list-style-type: none"> • Lease limit of BDT 30 million. • Vehicle model will be not older than 6 years from the date of manufacturing. • Vehicles to be procured will be used for official uses. • Approx. 80% but not exceeding the lease limit of total purchase price of the vehicles will be provided by IPDC and approx. 20% of total purchase price of the vehicles will be provided by Techno Drugs Ltd. • Ownership of the leased vehicles will be in favor of IPDC Finance Ltd. • All expenses including cost of registration, documentation, insurance and any other cost in connection with the facility will be borne by Techno Drugs Ltd. |
| Details of Payment | Lease payment of BDT 622,752.00 per month. |

Operating lease-2:

| Particulars | Lease Agreement for Motor Vehicles |
|--|--|
| Lessor | IPDC Finance Limited |
| Lessee | Techno Drugs Limited |
| Effective Date of the Lease Agreement | 18 February, 2021 |
| Period of Lease | 60 Months |
| Date of Lease Expiration | 17 February, 2026 |
| Description of Leased Asset | SUV, Sedan and Commercial Vehicles |
| Principal Terms and Conditions | <ul style="list-style-type: none"> • Lease limit of BDT 20 million. • Vehicle model will be not older than 6 years from the date of manufacturing. • Vehicles to be procured will be used for official uses. • Approx. 75% but not exceeding the lease limit of total purchase price of the vehicles will be provided by IPDC and approx. 25% of total purchase price of the vehicles will be provided by Techno Drugs Ltd. • Ownership of the leased vehicles will be in favor of IPDC Finance Ltd. • All expenses including cost of registration, documentation, insurance and any other cost in connection with the facility will be borne by Techno Drugs Ltd. |
| Details of Payment | Lease payment of BDT 432,360.00 per month. |

(viii) Dates of purchase of plant and machineries along with sellers name, address, years of sale, condition when purchased, country of origin, useful economic life at purchase and remaining economic life, purchase price and written down value;

| Sl. | Year of Acquisition | Name of Machinery | Name of the Suppliers | Address of the Suppliers | Year of Disposal | Condition when purchased | Country of Origin | Useful economic life | Remaining economic life | Purchase price | Written Down Value as on 30th June, 2023 |
|-----|---------------------|---|----------------------------------|--|------------------|--------------------------|-------------------|----------------------|-------------------------|----------------|--|
| 1 | 2010 | Dihumidifier | Shameem Refrigeration Works Ltd. | Lake Circus, Kalabagan, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 174,000 | 1 |
| 2 | 2010 | Rapid pack blister packing machine | Bio-Xin (Pvt.) Limited | DOHS, Section-12, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 5 | - | 9,744,275 | 1 |
| 3 | 2010 | Horizontal Sachet Packing Machine | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 2,556,729 | 1 |
| 4 | 2010 | Sandwich Panel System | Bio-Xin (Pvt.) Limited | DOHS, Section-12, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 5 | - | 2,224,606 | 1 |
| 5 | 2010 | B/N. Ph. Ind. Quality Control Equipment | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 994,758 | 1 |
| 6 | 2010 | Isolator | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 222,000 | 1 |
| 7 | 2010 | HPLCC Spare Parts | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 120,000 | 1 |
| 8 | 2010 | Moisture Analyzer | Venus Scientific Store | Hatkhola Road, Dhaka-1203. | Not Sold | Brand New | Bangladesh | 5 | - | 105,000 | 1 |
| 9 | 2010 | Autoclave | Poweredge Engineering | 92/1, Motijheel, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 5 | - | 1,498,199 | 1 |
| 10 | 2010 | Refrigerator | New Jes Machinery Corporation | 209, Nawabpur Road, Dhaka-1100. | Not Sold | Brand New | Bangladesh | 5 | - | 910,000 | 1 |
| 11 | | Air Compressor | | | Not Sold | Brand New | | | | | |
| 12 | | Line Filter | | | Not Sold | Brand New | | | | | |
| 13 | 2010 | Electronic Balance | Poweredge Engineering | 92/1, Motijheel, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 5 | - | 330,000 | 1 |
| 14 | 2010 | High Pressure Homogenizer HPH Spare Parts | Bio-Xin (Pvt.) Limited | DOHS, Section-12, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 5 | - | 448,074 | 1 |

| | | | | | | | | | | | |
|----|------|---|--|---|----------|-----------|------------|---|---|------------|---|
| 15 | 2010 | Die Punch | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | | 5 | - | 162,000 | 1 |
| 16 | 2010 | HVAC-Spare Parts | Active Environmental Technology | Kallyanpur, Mirpur, Dhaka-1207. | Not Sold | Brand New | Bangladesh | 5 | - | 385,738 | 1 |
| 17 | 2010 | Mean Droplet Size Analyzer | Bio-Xin (Pvt.) Limited | DOHS, Section-12, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 5 | - | 3,022,250 | 1 |
| 18 | 2010 | IKA Inline Homogenizer With Accessories | Bio-Xin (Pvt.) Limited | DOHS, Section-12, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 7 | - | 2,090,555 | 1 |
| 19 | 2010 | Electronic Balance | Venus Scientific Store | Hatkhola Road, Dhaka-1203. | Not Sold | Brand New | Bangladesh | 5 | - | 200,000 | 1 |
| 20 | 2010 | Magnetic Stirrer | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 70,000 | 1 |
| 21 | 2010 | Pharmaceuticals Machinery | M/S. Techno Drugs (By Vendor Agreements) | J. K. Tower 31, Segunbagicha, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 5 | - | 39,664,825 | 1 |
| 22 | 2011 | High Speed Rotary | Shanghai Tianhe Pharmaceutical Machinery Co., Ltd. | Chenjia Town, Chongming Country, Shanghai 202162, China | Not Sold | Brand New | China | 5 | - | 2,814,699 | 1 |
| | | Tablet Press Machine | | | Not Sold | Brand New | | | | | |
| 23 | 2011 | Die Punch | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 162,000 | 1 |
| 24 | 2011 | HVAC-Spare Parts | Active Environmental Technology | 24/A, Shahid Minar Road, Kallyanpur, Mirpur, Dhaka-1207. | Not Sold | Brand New | Bangladesh | 5 | - | 204,652 | 1 |
| 25 | 2011 | Desktop Liquid Filling Line | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 5 | - | 895,614 | 1 |
| 26 | 2011 | Air Shower | Suzhou Industrial Park Hjc Clean Tech Co., Ltd. | No. 1288 Ruyuan Road Xiang Cheng, District Suzhou, Chana. | Not Sold | Brand New | China | 5 | - | 510,390 | 1 |
| 27 | 2011 | Vortex Mixer | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 1,797,894 | 1 |
| 28 | 2011 | Isolator | Bectochem Consultants and Engineers Pvt. Ltd. | Building 5c/204, Mittal Estate, Andheri-Kula Road, Anderi Mumbai-400059, India. | Not Sold | Brand New | India | 5 | - | 100,676 | 1 |

| | | | | | | | | | | | |
|-------------------------------|------|--|--|---|----------|-----------|------------|---|---|-----------|---|
| 29 | 2011 | Blister Packing Machine | Zhejiang Hoping Machinery Co., Ltd. | ZhongZhou Industrial Zone, Feiyun Town, Ruian City, Zhejiang, China. | Not Sold | Brand New | China | 5 | - | 1,490,788 | 1 |
| 30 | 2011 | Coating Machine | Changzhou Jiafa Granulating Drying Equipment Co., Ltd. | Sanhekou Industry Park District Jiaoxi Town, Changzhou, Jiangsu Province, China. | Not Sold | Brand New | China | 5 | - | 1,903,836 | 1 |
| 31 | 2011 | Air Shower | Best Power Engineering Co. | Pagar, Tongi, Gazipur | Not Sold | Brand New | Bangladesh | 5 | - | 2,190,000 | 1 |
| 32 | 2011 | Hot Air Oven | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 200,000 | 1 |
| 33 | 2011 | pH Meter | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 400,000 | 1 |
| 34 | 2011 | Moisture Analyzer | Denver Instrument GMBH | Weender Landstrabe 94-108, 37075 Gottingen, Germany. | Not Sold | Brand New | Germany | 5 | - | 794,977 | 1 |
| | | Electrochemistry Meters | | | | | | | | | |
| | | Electronic Balance | | | | | | | | | |
| 35 | 2011 | Control Panel | Best Power Engineering Co. | Pagar, Tongi, Gazipur | Not Sold | Brand New | Bangladesh | 5 | - | 5,685,275 | 1 |
| 36 | 2011 | HPLC System | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08, Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Singapore | 5 | - | 3,958,181 | 1 |
| 37 | 2012 | Spare Parts | Cosmotrade Associates | 89 motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 115,000 | 1 |
| 38 | 2012 | Injection Molding Machine with Standard Accessories; | Aman Machinery Co. Ltd. | 363-404 East Xihu Road, Chong, An Area Wuxi City Jiangsu China 214100. | Not Sold | Brand New | China | 5 | - | 9,338,756 | 1 |
| | | Auto-Feeder; | | | | | | | | | |
| | | Hopper Dryer; | | | | | | | | | |
| | | Water Chiller | | | | | | | | | |
| | | Crusher; | | | | | | | | | |
| | | Disposable syringe Assembling Machine with Standard Accessories; | | | | | | | | | |
| | | Printing Machine; | | | | | | | | | |
| | | Industrial Screw Air CompressorMachine | | | | | | | | | |
| Gas Steriliser; | | | | | | | | | | | |
| Wastage Gas Treatment Machine | | | | | | | | | | | |

| | | | | | | | | | | | |
|----|------|---|---|---|----------|-----------|------------|---|---|-----------|---|
| 39 | 2012 | Water Treatment & Multicolumn Distillation Plant | Best Power Engineering Co. | Pagar, Tongi, Gazipur | Not Sold | Brand New | Bangladesh | 5 | - | 5,824,688 | 1 |
| 40 | 2012 | Dry Heat Sterilizer (Tunnel) | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 6,674,221 | 1 |
| 41 | 2012 | Spare Parts | D.H Engineering Workshop | Pallabi, Mirpur, Dhaka-1216. | Not Sold | Brand New | Bangladesh | 5 | - | 45,000 | 1 |
| 42 | 2012 | Linear Vial Washing Machine | M/s Maruti P Mach Engineers | Plot No-1806, phaes-3, G.I.D.C Vatva, Ahmedabad-382 445, India. | Not Sold | Brand New | India | 5 | - | 1,744,401 | 1 |
| 43 | 2012 | Compressor | Classic Engineering | Century Arcade, Moghbazar, Dhaka-1217. | Not Sold | Brand New | Bangladesh | 5 | - | 48,500 | 1 |
| 44 | 2012 | Melting Point Apparatus | Best Power Engineering Co. | Pagar, Tongi, Gazipur | Not Sold | Brand New | Bangladesh | 5 | - | 65,000 | 1 |
| 45 | 2012 | Spare Parts-Vial Machine | Cosmotrade Associates | 89 Motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 120,000 | 1 |
| 46 | 2012 | Ultraviolet-Visible Spectroscopy | Cecil Instruments Ltd. | Milton Technical Centre Milton Cambridge CB 246, 6AZ. | Not Sold | Brand New | UK | 5 | - | 879,680 | 1 |
| 47 | 2012 | Spare Parts-Tunnel | Venus Scientific Store | Hatkhola Road, Dhaka-1203. | Not Sold | Brand New | Bangladesh | 5 | - | 89,000 | 1 |
| 48 | 2012 | Muoisture Analizar | Venus Scientific Store | Hatkhola Road, Dhaka-1203. | Not Sold | Brand New | Bangladesh | 5 | - | 105,000 | 1 |
| 49 | 2012 | Automatic Soft Gelatin Encapsulation Line | CMEC General Machinery Import & Export Co. Ltd. | No. 178 Guang An Men Wai, Street, Beijing China Post Code: 100055 | Not Sold | Brand New | China | 5 | - | 4,065,343 | 1 |
| 50 | 2012 | High Shear Homogenizer Brand New Single Layer Tank Storage Tank With Warm Keeping Insulation. Capacity -1000 Liters Storage Tank. Capacity-1000 Liters | Wuxi Yk Automation Technology Co. Ltd. | No-2855, Jiaoyang Road, Anzhen Town, Wuxi City, China. | Not Sold | Brand New | China | 5 | - | 1,295,838 | 1 |
| 51 | 2012 | Microprocessor | Cosmotrade Associates | 89 Motijheel C/A, Dhaka. | Not Sold | Brand New | Bangladesh | 5 | - | 170,000 | 1 |
| 52 | 2013 | Gas Chromatography System/GC | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 0201/08, Cintech IV, Singapore, Science Park 1, Singapore-118264. | Not Sold | Brand New | Singapore | 5 | - | 3,045,027 | 1 |

| | | | | | | | | | | | |
|----|------|---|--|--|----------|-----------|------------|---|---|------------|---|
| 53 | 2013 | Spare Parts-HVAC | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 5 | - | 442,473 | 1 |
| 54 | 2013 | Spare Parts-ETP | Poweredge Engineering | 92/1, Motijheel, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 5 | - | 100,000 | 1 |
| 55 | 2013 | Injection Molding Machine Spare Parts | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 5 | - | 144,420 | 1 |
| 56 | 2013 | Printing Machine Spare Parts | Sciencetech Corporation | 75 Science Laboratory Road, Dhanmondi, Dhaka-1205 | Not Sold | Brand New | Bangladesh | 5 | - | 220,000 | 1 |
| 57 | 2013 | Fluid Bed Dryer | Changzhou Jiafa Granulating Drying Equipment Co., Ltd. | Sanhekou Industry Park District Jiaoxi Town, Changzhou, Jiangsu Province, China. | Not Sold | Brand New | China | 5 | - | 1,258,470 | 1 |
| 58 | 2013 | Heat Exchanger | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 5 | - | 496,673 | 1 |
| 59 | 2013 | Complete Shanghai Mitsubishi Lifts | Allied Sky International (HK) Ltd. | 1/Floor, Block A Mau Lam Commercial Building, 16-18 Mau Lam Street Yau Ma Tei, Kowlon, Hongkong. | Not Sold | Brand New | China | 5 | - | 4,035,562 | 1 |
| 60 | 2013 | Tablet compression machine | Proton Engineers | B-72, Madhusam IND Estate, NR. S.P Ring Road, Odhav Cross Ahmedabad 382415, Gujrat, India. | Not Sold | Brand New | India | 6 | - | 1,078,338 | 1 |
| 61 | 2013 | Filling and Plugging Machine For Syringes | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 6 | - | 2,040,698 | 1 |
| 62 | 2013 | Pharmaceuticals Machinery | Shanghai Jianpu Import and Export Company Ltd. | 8F No: 100 jiujiang road, 200002 Shanghai, China. | Not Sold | Brand New | China | 6 | - | 10,971,829 | 1 |
| 63 | 2013 | Purified Water Treatment Plant | Rotech Pharmaceuticals Engineering CO., Ltd. | office 1502, Building 17, no 199, mincheng road, minhang District Shanghai, China 201100. | Not Sold | Brand New | China | 6 | - | 5,887,874 | 1 |
| | | Multicolumn Distillation Plant | | | | | | | | | |

| | | | | | | | | | | | |
|----|------|---|--|--|----------|-----------|------------|---|---|------------|---|
| 64 | 2013 | Water Filtering or Purifying Machine of Sterilisers | Shanghai Aitomu Machinery Co. Ltd. | No: 500, South Xiangyang Road Shanghai, China. | Not Sold | Brand New | China | 6 | - | 8,620,157 | 1 |
| 65 | 2014 | IKA Inline Homogenizer With Accessories | Bio-Xin (Pvt.) Ltd. | DOHS Saction-12, Mirpur, Dhaka-1216 | Not Sold | Brand New | Bangladesh | 7 | - | 2,153,457 | 1 |
| 66 | 2014 | Spare Parts | Mac Engineering | Hosnidalan Rd. Dhaka-1211. | Not Sold | Brand New | Bangladesh | 7 | - | 50,000 | 1 |
| 67 | 2014 | Pro-series Top Mount sand Filter | Wid Craft Enterprise | Sector #4,Road Uttara, Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 210,000 | 1 |
| | | Superior Universel Pump, sup300 series | | | | | | | | 65,000 | 1 |
| | | Surface Skimmer | | | | | | | | 40,000 | 1 |
| | | Wall Inlet & Main Inlet | | | | | | | | 15,000 | 1 |
| 68 | 2014 | Sandwich Panel System | Shanghai Jianpu Import and Export Company Ltd. | Add-15F No. 100 Jiujiang Road 200002 Shanghi, China. | Not Sold | Brand New | China | 7 | - | 14,727,637 | 1 |
| 69 | 2014 | Freeze Drying Microscope Lyostat 3 Basic System | Bio-Xin (Pvt.) Ltd. | DOHS Saction-12, Mirpur, Dhaka-1216 | Not Sold | Brand New | Bangladesh | | - | 4,655,000 | 1 |
| 70 | 2014 | Caplet shaped Die Punch Oval | Plus Pharma | 25/2 Narayangang, Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 86,400 | 1 |
| 71 | 2014 | Spare Parts | Kunshan Angel Precision Mould Co., Ltd | Building 3, Industrial Park Of Creative Business Center No: 2588, North Huangqing Road, Kunshan Jiangsu China. | Not Sold | Brand New | China | 7 | - | 1,769,344 | 1 |
| 72 | 2014 | Filling and Plugging Machine | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road, Shanghai 200040, China. | Not Sold | Brand New | China | 7 | - | 2,303,374 | 1 |
| 73 | 2014 | Sandwich Panel System | Shanghai Jianpu Import and Export Company Ltd. | Add-15F No. 100 Jiujiang Road 200002 Shanghi, China. | Not Sold | Brand New | China | 7 | - | 10,756,836 | 1 |
| 74 | 2014 | Jet Printer Machine | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 361,725 | 1 |
| 75 | 2014 | Sandwich Panel System | Shanghai Jianpu Import and Export Company Ltd. | Add-15F No. 100 Jiujiang Road 200002 Shanghi, China. | Not Sold | Brand New | China | 7 | - | 22,800,413 | 1 |
| 76 | 2014 | Sandwich Panel System | Shanghai Jianpu Import and Export Company Ltd. | Add-15F No. 100 Jiujiang Road 200002 Shanghi, China. | Not Sold | Brand New | China | 7 | - | 7,193,030 | 1 |

| | | | | | | | | | | | |
|----|------|---|--|---|----------|-----------|------------|---|---|------------|---|
| 77 | 2014 | Spare Parts | Chanmia Engineering Workshop | Nulapara, Vbanipur, Hazi Market, Mymmonsingh Road, Gazipur. | Not Sold | Brand New | Bangladesh | 7 | - | 190,000 | 1 |
| 78 | 2014 | Jucai Screw Air Compressor | New JES Machinery Corporation | 209, Nawabpur Road Dhaka | Not Sold | Brand New | China | 7 | - | 905,000 | 1 |
| | | Jucai Freezing Air Dryer | | | | | | | | | |
| | | Jucai Line Filter | | | | | | | | | |
| 79 | 2014 | Filling and Plugging Machine For Syringes | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 7 | - | 2,558,492 | 1 |
| 80 | 2015 | Equipment and Spare Parts | Shanghai Jianpu Import and Export Company Ltd. | 8F No. 100 Jiujiang Road 200002 Shanghai, China. | Not Sold | Brand New | China | 7 | - | 545,412 | 1 |
| 81 | 2015 | High Speed Rotary Tablet Press Machine | Shanghai Tianhe Pharmaceutical Machinery Co., Ltd. | Chenjia Town, Chongming Country, Shanghai 202162, China | Not Sold | Brand New | China | 7 | - | 3,121,090 | 1 |
| 82 | 2015 | Sterilizing & Dry Tunnel Machine | Shanghai China Sun Far-East Pharmaceutical Machinery Co. Ltd. | Add. No. 200 Jinshao RD. Baoshan Area, Shanghai China PC 200072 | Not Sold | Brand New | China | 7 | - | 20,788,773 | 1 |
| | | Vial Filling & Stoppering Machine | | | | | | | | | |
| | | Capping Machine | | | | | | | | | |
| | | Ultrasonic | | | | | | | | | |
| | | Washing Machine | | | | | | | | | |
| 83 | 2015 | Spare Parts | Cosmotrade Associates | 5/8 Block-c ,Lalmatia Dhaka | Not Sold | Brand New | Bangladesh | 7 | | 50,000 | 1 |
| 84 | 2015 | Drying Oven | Goodluck Scientific company | Hatkhola Road, Dhaka-1203. | Not Sold | Brand New | Bangladesh | 7 | - | 105,000 | 1 |
| | | Digital Incubator | | | Not Sold | Brand New | Bangladesh | 7 | - | 105,000 | 1 |
| 85 | 2015 | Heat-Shrink Wrapping Machine | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 7 | - | 3,677,314 | 1 |
| 86 | 2015 | De-Foiling Machine | Reza Engineering | Dilkusha C/A, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 7 | - | 200,000 | 1 |
| 87 | 2015 | Automatic Horizontal Cartoning Machine. Mode: JDZ-120 | Shanghai Marya Pharmceutical Engineering And Project Co., Ltd. | No 79th Rijing Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 7 | - | 2,951,214 | 1 |
| | | Automatic Cellophane Wrapping Machine | | | | | | | | | |

| | | | | | | | | | | | |
|-----|------|--|---|--|----------|-----------|------------|---|---|------------|---|
| 88 | 2015 | Automatic Capsule Filling Machine | Zhejiang Yuhong Import and Export Co., Ltd. | Room 4-44, No. 54 Dashani Street Haishu Ningbo, China. | Not Sold | Brand New | China | 7 | - | 1,128,563 | 1 |
| 89 | 2015 | Heat-Shrink Wrapping Machine | Shanghai Marya Pharmaceutical Engineering And Project Co., Ltd. | No 79th Rijing Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 7 | - | 1,647,292 | 1 |
| 90 | 2015 | Ducting Works | Upama Engineering | Kha-5712, South Badda, Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 353,000 | 1 |
| 91 | 2015 | De-Foiling Blister Machine | Reza Engineering | Dilkusha C/A, Dhaka-1000. | Not Sold | Brand New | Bangladesh | 7 | - | 200,000 | 1 |
| 92 | 2015 | Touch Sreen & Module for Coating Machine | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 7 | - | 553,175 | 1 |
| 93 | 2015 | Blister Packing Machine | Shanghai Marya Pharmaceutical Engineering And Project Co., Ltd. | No 79th Rijing Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 7 | - | 11,803,621 | 1 |
| 94 | 2015 | High Speed Blister Packing Machine | Shanghai Marya Pharmaceutical Engineering And Project Co., Ltd. | No 79th Rijing Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 7 | - | 11,369,913 | 1 |
| | | Automatic Horizontal Cartoning Machine | | | | | | | | | |
| | | Automatic Cellophane Wrapping Machine | | | | | | | | | |
| 95 | 2015 | Spare Parts | Cosmotrade Associates | 5/8 Block-c ,Lalmatia Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 238,950 | 1 |
| 96 | 2015 | Spare Parts | Chanmia Engineering Workshop | Hazi Market, Mymmonsingh Road, Gazipur. | Not Sold | Brand New | Bangladesh | 7 | - | 250,000 | 1 |
| 97 | 2015 | Leak Test Apparatus Digital | Cosmotrade Associates | 5/8 Block-c ,Lalmatia Dhaka | Not Sold | Brand New | Bangladesh | 7 | - | 120,000 | 1 |
| 98 | 2015 | Automatic Capsule Filling Machine | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 7 | - | 1,615,371 | 1 |
| 99 | 2015 | Evaporative Cooling Tower (old) | H.S. Electro - Machanics | CDA Market, Pahartali, Chattogram. | Not Sold | Brand New | Bangladesh | 7 | - | 270,000 | 1 |
| 100 | 2015 | Jucal Screw Air Compressor | New JES Machinery Corporation | 209, Nawabpur Road Dhaka | Not Sold | Brand New | China | 7 | - | 1,165,000 | 1 |
| | | Jucal Freezing Air Dryer | | | | | | | | | |
| | | Jucal Line Filter | | | | | | | | | |

| | | | | | | | | | | | |
|-----|------|---|-----------------------------------|---|----------|-----------|---------------|---|---|------------|-----------|
| 101 | 2015 | Bio Safety Cabinet | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 8 | - | 175,000 | 1 |
| 102 | 2015 | Conductivity Meter Bench type with Printer System | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 8 | - | 710,000 | 1 |
| | | Vocuum Pump & Vacuum Filtration | | | | | | | | | |
| | | Sartorius Analytical Balance | | | | | | | | | |
| | | Sartorius Moisture Analytical | | | | | | | | | |
| 103 | 2015 | High Pressure Homogenizer HPH | IKA Werke Gmbh & Co. KG | Janke & Kunkel Str, 10, D-79219 Staufen. | Not Sold | Brand New | Germany | 8 | - | 3,069,112 | 1 |
| 104 | 2015 | Electrophoresis Instrument | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08 Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Japan | 8 | - | 4,905,395 | 1 |
| 105 | 2015 | Spare Parts | Cosmotrade Associates | 5/8 Block-c ,Lalmatia Dhaka | Not Sold | Brand New | Bangladesh | 8 | - | 283,850 | 1 |
| 106 | 2016 | Mixture Machine | M/s Islam Tradeers | Narinda, Dhaka-1100. | Not Sold | Brand New | Bangladesh | 8 | - | 81,000 | 1 |
| 107 | 2016 | Spare Parts | M/s Zilani Enterprise | C.D.A Market, Pahartoli, Chattogram. | Not Sold | Brand New | Bangladesh | 8 | - | 117,200 | 1 |
| 108 | 2016 | Electric De-Humidifier | Shameem Refergeration Works Ltd. | Lake Circus, Kalabagan, Mirpur Road, Dhaka-1205. | Not Sold | Brand New | Bangladesh | 8 | - | 134,000 | 1 |
| 109 | 2016 | Cap Dispensing and Capping Machine | The United Engineering Company | 35 A, Hazra Road, Kolkaya 700029, India | Not Sold | Brand New | India | 8 | - | 450,066 | 1 |
| 110 | 2016 | Air Cooler Mini Chiller | Confidence Trade Limited | 45 Gulshan Avenue, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 8 | - | 700,000 | 1 |
| 111 | 2016 | Spare Parts | Cecil Instruments Ltd. | Milton Technical Centre Milton Cambridge CB 246, 6AZ. | Not Sold | Brand New | Great Britain | 9 | 2 | 760,779 | 152,156 |
| 112 | 2016 | Dry Granulation Machine | The Fitzpatrick Company | 832 Industrial Drive Elmhurst, IL 60126/USA. | Not Sold | Brand New | USA | 9 | 2 | 15,732,022 | 3,146,404 |
| 113 | 2016 | Tablet Hardness Tester | Copley Scientific Ltd. | Colwick Quays Business Park, Private, Road No. 2, Colwick, Nottingham NG42JY, United Kingdom. | Not Sold | Brand New | Great Britain | 9 | 2 | 900,767 | 180,153 |

| | | | | | | | | | | | |
|-----|------|---|--|---|----------|-----------|------------|---|---|------------|-----------|
| 114 | 2016 | Water Purifying Machine | Jilin Hongzhan Fluid Technology Co., Ltd. | Room 804-805, Aviation Int'l Build, A no 7655 Renmin STR.Changchun City, Jilin Province, China. | Not Sold | Brand New | China | 9 | 2 | 5,915,885 | 1,183,177 |
| 115 | 2016 | Cooling Tower, Square Type | Genius Premier SDN BHD | No-35-2, Jalan Puteri 4/1, Bandar Puteri, 4710 Puchong, Selangor Darul Ehsan, Malaysia. | Not Sold | Brand New | Malaysia | 9 | 2 | 2,653,172 | 530,634 |
| 116 | 2016 | Water Cooled Screw Chiller | Dunham-Brush Industries SDN BHD | LOT 5755-6, Kidamai Industrial Park, Bukit Angkat, 43000 Kajang Selangor Darul Ehsan, Malaysia. | Not Sold | Brand New | Malaysia | 9 | 2 | 15,747,100 | 1,574,710 |
| 117 | 2017 | Tablet Hardness Tester | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 9 | 2 | 410,000 | 82,000 |
| 118 | 2017 | Heat-exchanger with Compressor | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | China | 9 | 2 | 530,712 | 106,142 |
| 119 | 2017 | Hoping Blister Machine Spare Parts | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | China | 9 | 2 | 60,000 | 12,000 |
| 120 | 2017 | Tablet Compression Machine | Proton Engineers | Plot-357, Road-7, G.I.D.C, Kathwada, Ahmedabad-382415, Gujarat, India. | Not Sold | Brand New | India | 9 | 2 | 2,370,555 | 474,111 |
| 121 | 2017 | Change Parts, Blister | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 9 | 2 | 420,000 | 84,000 |
| 122 | 2017 | Purified Water Generation System | Zen Engineering | Plot-A-269, Road-33-A, MIDC, Near Esis Hospital Wagle Industrial Estate, Thane (W)-400 604, Maharashtra, India. | Not Sold | Brand New | India | 9 | 2 | 4,017,472 | 484,115 |
| 123 | 2017 | Cage Blender 500 Ltrs | Bectochem Loedige Process Technology Pvt. Ltd. | Everest Chamber, A-Wing 201, II FLR, Marol, Naka Andheri-Karul Road, Anderi East Mumbai-400059, India. | Not Sold | Brand New | India | 9 | 2 | 5,715,701 | 571,570 |
| | | Vibro Sifter Machine | | | | | | | | | |
| | | Material Handing Devices For Compression Machine and Roll Compactor | | | | | | | | | |

| | | | | | | | | | | | |
|-----|------|--|---|--|----------|-----------|------------|----|---|------------|-----------|
| 124 | 2017 | Sandwich Panel System with Cold Room Facility | CNBA Jianpu Resources Company Ltd. | 15 Floor, Financial Laza 333 Jiujiang Road, Huangpu District, Shanghai, China P.C 200001. | Not Sold | Brand New | China | 9 | 2 | 40,489,429 | 4,048,943 |
| | | | | | | | | 9 | 2 | 19,421,476 | 1,942,148 |
| 125 | 2017 | Sandwich Panel System with Cold Room Facility | Shanghai Marya Pharmaceutical Engineering and Project Co., Ltd. | No. 146th, Futedongyi Road, Pudong Area, Shanghai China, 200131. | Not Sold | Brand New | China | 9 | 2 | 2,113,037 | 422,607 |
| 126 | 2017 | Change Parts, Blister | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 9 | 2 | 420,000 | 84,000 |
| 127 | 2017 | Spare Parts of Hoping Blister Machine | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 9 | 2 | 200,000 | 40,000 |
| | 2017 | Bio Safety Cabinet | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 9 | 2 | 175,000 | 35,000 |
| 128 | 2017 | Boiler | Dehu Engineering (India) Private Ltd. | Gat No: 390, Dehu-Alandi Road, Talawade, Pune, Maharashtra State, India. | Not Sold | Brand New | India | 10 | 4 | 2,688,033 | 1,092,151 |
| 129 | 2017 | Passenger Lift | Allied Sky International (HK) Ltd. | 1/Floor, Block A Mau Lam Commercial Building, 16-18 Mau Lam Street Yau Ma Tei, Kowlon, Hongkong. | Not Sold | Brand New | China | 10 | 4 | 4,098,018 | 1,668,399 |
| 130 | 2017 | Air Compressor | Gardner Denver FZE | LB 180202, P.O Box: 61146, Jebel Ali Free Zone, Dubai, United Arab Emirates. | Not Sold | Brand New | Germany | 10 | 4 | 2,242,570 | 920,990 |
| 131 | 2017 | Sandwich Panel System with Cold Room Facility | Shanghai Marya Pharmaceutical Engineering and Project Co., Ltd. | No. 146th, Futedongyi Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 10 | 4 | 1,586,262 | 669,707 |
| 132 | 2017 | Sandwich Panel System with Cold Room Facility-HVAC | CNBA Jianpu Resources Company Ltd. | 25 Floor, Financial Plaza 333 Jiujiang Road, Huangpu District, Shanghai, China P.C 200001. | Not Sold | Brand New | China | 10 | 4 | 12,106,184 | 1,210,618 |
| | | | | | | | | | | 7,708,072 | 3,317,581 |
| | | | | | | | | | | 3,587,133 | 1,569,494 |
| | | | | | | | | | | 7,739,470 | 3,426,571 |
| 133 | 2017 | Passenger Elevator Lift | Matiz Elevator Co. Ltd. | Matiz Industrial Park, MCMP Nanlang, Zhongshan, Guangdong, China. | Not Sold | Brand New | China | 10 | 4 | 4,040,290 | 1,659,286 |

| | | | | | | | | | | | |
|-----|------|-----------------------------------|---|---|----------|-----------|-------|----|---|------------|-----------|
| 134 | 2017 | Incinerator | Nantong Yannuo Machinery Co. Ltd. | Build-1, NR. 88-1 East Outer Ring Road, Chongchuan, Nantong, Jiangsu, China. | Not Sold | Brand New | China | 10 | 4 | 2,604,343 | 1,085,262 |
| 135 | 2017 | Quality Control Equipment | Vishwakarma Industries | Jagat Khana, P.O.-Manjholi, Roper Road, Nalagarh, Dist. Solan Homachal Pradesh 174101, India. | Not Sold | Brand New | India | 10 | 4 | 1,079,055 | 456,159 |
| 136 | 2017 | Tablet Coating Machine | Shanghai Marya Pharmaceutical Engineering And Project Co., Ltd. | No. 146th, Futedongyi Road, Pudong Area, Shanghai China, 200131. | Not Sold | Brand New | China | 10 | 4 | 4,282,287 | 1,805,600 |
| 137 | 2017 | HPLC System Promince-1 | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08 Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Japan | 10 | 4 | 19,294,218 | 1,929,423 |
| | | Carbon Analyzer Model-TOC LCPH | | | | | | | | | |
| | | Spectrophotometer IRTRA CER-100 | | | | | | | | | |
| | | Spectrophotometer UV-1800 | | | | | | | | | |
| | | Analytical Balance AP135W | | | | | | | | | |
| 138 | 2017 | Blister Packing Machine | Shanghai Marya Pharmaceutical Engineering and Project Co., Ltd. | No. 146th, Futedongyi Road, Pudong Area Shanghai China, 200131. | Not Sold | Brand New | China | 10 | 4 | 2,073,458 | 912,322 |
| 139 | 2017 | Water purifying Machine | Zen Turnkey Solutions Pvt. Ltd. | Plot-15,16, 21/2, Midc Kalyan Badlapur Rd, Ambernath I/A, Ambernath (West), Maharashtra, India. | Not Sold | Brand New | India | 10 | 4 | 6,961,682 | 3,061,233 |
| | | | | | | | | | | 6,822,111 | 3,065,277 |
| 140 | 2017 | Blister Packing Machine | Shanghai Marya Pharmaceutical Engineering and Project Co., Ltd. | No. 146th, Futedongyi Road, Pudong Area, Shanghai China, 200131. | Not Sold | Brand New | China | 10 | 4 | 1,467,997 | 659,593 |
| | | Paper Plastic Packing Machine | | | | | | | | | |
| | | Rotary Tablet Press Machine | | | | | | | | | |
| | | Automatic Capsule Filling Machine | | | | | | | | | |

| | | | | | | | | | | | |
|-----|------|--|---|---|----------|-----------|---------------|----|---|------------|-----------|
| 141 | 2018 | Blister Packing Machine | Zhejiang Hoping Machinery Co. Ltd. | Zhongzhou Industrial Zone, Felyun Town, Ruian City, Zhejiang, China. | Not Sold | Brand New | China | 10 | 4 | 1,088,868 | 491,035 |
| 142 | 2018 | Fire Equipment for Machine | Asenware Ltd. | 701, BD 8, Dongfangmine Industry Zone, Dabao RD. Baoan Shenzhen, China-518101. | Not Sold | Brand New | China | 10 | 4 | 2,070,356 | 938,183 |
| | 2018 | Pressing Stamping Punching | Parle Elizabeth Tools Pvt. Ltd. | Rajvidesh Building, Prime Industrial Complex Sativili Road, Waliv, Vasai Road (East) 401208 Thane, India. | Not Sold | Brand New | India | 10 | 4 | 275,855 | 127,725 |
| 143 | 2018 | Fire Alarm Equipment Hydrant Box & Other | EMI Engineering Pte Ltd. | Meissa # 04-02, 100D Pasir Panjang Road, Singapore 118520. | Not Sold | Brand New | Singapore | 10 | 4 | 1,661,141 | 780,964 |
| | | Fire Alarm Equip. Pump | | | | | | | | 1,303,111 | 612,998 |
| 144 | 2018 | Blister Pack Inspection System with Accessories | Project Consultancy Services | Room-203, Jindal Towers, 21/IA/3, Darga Road, Kolkata-700017 India. | Not Sold | Brand New | India | 10 | 4 | 1,289,131 | 606,421 |
| 145 | 2018 | Sandwich Panel System with Cold Room Facility | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 4 | 13,615,998 | 1,361,600 |
| | | | | | | | | | | 46,420,217 | 9,173,071 |
| 146 | 2018 | Quality control equipment and Standard Accessories | Copley Scientific Ltd. | Colwick Quays Business Park Private Road No. 2, Colwick, Nottingham NG4 2JY, United Kingdom. | Not Sold | Brand New | Great Britain | 10 | 4 | 2,298,249 | 1,093,085 |
| 147 | 2018 | Analytical Balance | Sartorius Lab Instruments GMBH & Co. KG | OTTO-Brenner-Strabe 2027079 Goettingen, Germany. | Not Sold | Brand New | Germany | 10 | 4 | 2,116,137 | 1,026,761 |
| | | Printer YDP20-OCE | | | | | | | | | |
| | | Moisture Analyzer | | | | | | | | | |
| | | Water Purifying Machine | | | | | | | | | |
| | | Portable, Air Sampler Unit | | | | | | | | | |

| | | | | | | | | | | | |
|-----|------|--|------------------------------------|---|----------|-----------|------------|----|---|------------|------------|
| 148 | 2018 | Hand Pallet Brand | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 4 | 52,266 | 25,388 |
| 149 | 2018 | Sandwich Panel System with Cold Room Facility | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 4 | 30,527,017 | 14,979,147 |
| 150 | 2018 | Heat Exchanger | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 4 | 252,000 | 125,931 |
| 151 | 2018 | Diesel Generator 150KVA | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,000,000 | 500,822 |
| 152 | 2018 | HVAC-Sandwich Panel System with cold room Facility | Novelty International | North Kamalapur, Dhaka. | Not Sold | Brand New | Bangladesh | 10 | 5 | 44,102,825 | 22,111,827 |
| 153 | 2018 | Bottle Dryer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,000,000 | 501,918 |
| 154 | 2018 | Homogenizer | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 3,200,000 | 1,607,890 |
| 155 | 2018 | Double Door Autoclave | Jiangsu Shennong Autoclave Inc. | Jingang Town, Zhangjiagang City, Jiangsu Province, China. | Not Sold | Brand New | China | 10 | 5 | 2,795,436 | 1,405,377 |
| 156 | 2018 | Hand Pallet | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 28,000 | 14,092 |
| 157 | 2018 | Diesel Generator 930KVA | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 4,500,000 | 2,272,192 |
| 158 | 2018 | Diesel Generator 150KVA | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,000,000 | 504,932 |
| 159 | 2018 | Diesel Generator 650KVA | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 2,800,000 | 1,413,808 |
| 160 | 2018 | Gas Generator | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 4,500,000 | 2,273,425 |
| 161 | 2018 | Tray Dryer for Bottle Drying | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 265,000 | 135,041 |

| | | | | | | | | | | | |
|-----|------|-----------------------------------|--|---|----------|-----------|------------|----|---|------------|------------|
| 162 | 2018 | Blender Machine | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,345,000 | 687,240 |
| 163 | 2018 | Filling & Plugging Machine | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 10 | 5 | 2,632,168 | 1,346,372 |
| 164 | 2018 | Spare Parts-Blister Machine | S.A Engineering Service | Nayapur Bazar, Sonaggoan, Narayangong. | Not Sold | Brand New | Bangladesh | 10 | 5 | 30,000 | 15,386 |
| 165 | 2018 | Transformer | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,291,300 | 665,816 |
| 166 | 2018 | Magnehelic Pressure Gauge-HVAC | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,451,000 | 749,750 |
| 167 | 2018 | Air Cooler | Pervez Enginnering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 35,000 | 18,085 |
| 168 | 2018 | Dry Granulating Line | Changzhou Haijiang Drying Equipment Co. Ltd. | Henggou Village Zhenglu Town Wujin, District Changzhou China. | Not Sold | Brand New | China | 10 | 5 | 15,809,453 | 8,212,253 |
| 169 | 2018 | Powder Filling & Capping Machine | Shanghai Puxi Ltd. | 10A, No. 89, Fu Min Road Shanghai 200040, China. | Not Sold | Brand New | China | 10 | 5 | 4,215,966 | 2,195,767 |
| 170 | 2018 | Shell & Tube Evaporator | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,571,600 | 819,385 |
| 171 | 2018 | Effluent Treatment Plant | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209 | Not Sold | Brand New | Bangladesh | 10 | 5 | 40,677,000 | 21,285,773 |
| 172 | 2018 | Automatic Capsule Filling Machine | Zhejiang Yuhong Import and Export Co. Ltd. | 12-5 Building, 2456 Xinning Road, Ningbo, China. | Not Sold | Brand New | China | 10 | 5 | 1,647,198 | 863,764 |
| 173 | 2018 | Sampling Booth | Pervez Enginnering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,008,000 | 530,236 |
| 174 | 2018 | Sandwich Panel System with HVAC | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 5 | 1,432,017 | 756,419 |
| | | | | | | | | | | 35,691,909 | 17,845,954 |

| | | | | | | | | | | | |
|-----|------|-----------------------------------|------------------------------------|---|----------|-----------|---------------|----|---|------------|-----------|
| 175 | 2018 | Automatic Capsule Filling Machine | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,710,700 | 903,625 |
| 176 | 2018 | Filling Sealing Machine | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 408,000 | 216,072 |
| 177 | 2019 | Mini Chiller | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 5 | 1,375,000 | 730,445 |
| 178 | 2018 | Double Door Autoclave | Jiangsu Shennong Autoclave Inc. | Jingang Town, Zhangjiagang City, Jiangsu Province, China. | Not Sold | Brand New | China | 10 | 5 | 2,149,405 | 1,143,601 |
| 179 | 2018 | HVAC System | Novelty International | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 5 | 5,545,800 | 2,956,747 |
| 180 | 2018 | De-Foiling Machine | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 145,000 | 77,585 |
| 181 | 2018 | Gas Generator | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 4,450,000 | 2,388,370 |
| 182 | 2018 | Tray Dryer for Bottle Drying | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 530,000 | 284,748 |
| 183 | 2018 | Sugar Crushing Machine | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 200,000 | 107,836 |
| 184 | 2018 | Sampling Booth | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 202,500 | 109,295 |
| 185 | 2018 | Bio Safety Cabinet | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 175,000 | 94,644 |
| 186 | 2018 | Heat Exchanger | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 252,000 | 136,839 |
| 187 | 2018 | Cone Blender | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 225,000 | 122,240 |
| 188 | 2018 | Quality Control Instrument | Malvern Panalytical Ltd. | Groewood Road, Malvern, Worcestershire, WR14 1XZ UK. | Not Sold | Brand New | Great Britain | 10 | 5 | 13,639,172 | 7,424,941 |

| | | | | | | | | | | | |
|-----|------|--|----------------------------------|--|----------|-----------|------------|----|---|---------|---------|
| 189 | 2018 | Electronic Balance | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 164,000 | 89,324 |
| 190 | 2018 | Air Cooler | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 35,000 | 19,063 |
| 191 | 2018 | Dry Heat Sterilizer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 300,000 | 163,644 |
| 192 | 2018 | Air Curtain | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 176,000 | 96,245 |
| 193 | 2018 | Purified Water Treatment Plant Spare parts | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 140,000 | 76,559 |
| 194 | 2018 | Micropipette (1000 uL) | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 30,000 | 16,414 |
| 195 | 2018 | Spare Parts-HVAC | All in Technologies | Uttara, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 27,500 | 15,091 |
| 196 | 2018 | Blister Packing Machine Change Parts | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 150,000 | 82,562 |
| 197 | 2019 | Pass Box | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 200,000 | 110,466 |
| 198 | 2019 | Stability Chamber | Kesar Control Systems | 16-F, Simandhar Shopping Centre, NR. L.I.C. office, Highway, Nagalpur, Mehsana-384002, Guj. India. | Not Sold | Brand New | India | 10 | 5 | 545,184 | 303,660 |
| 199 | 2019 | Jet Printer Machine | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 324,000 | 180,730 |
| 200 | 2019 | Refrigerator | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 112,000 | 62,567 |
| 201 | 2019 | Freezer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 56,000 | 31,283 |

| | | | | | | | | | | | |
|-----|------|--|--|---|----------|-----------|------------|----|---|------------|-----------|
| 202 | 2019 | Passenger Elevator | Matiz Elevator Co., Ltd. | Jinsha Industrial Park, Kengzi, Pingshan, Shenzhen, Guangdong, China. | Not Sold | Brand New | China | 10 | 5 | 5,472,909 | 3,061,830 |
| 203 | 2019 | Injectable Powder Filling Producing Line with all Standard Accessories | L and P Pharma Pack LLP | Plot No. 806, G.I.D.C. Sectro-28 Gandhinagar-382028, Gujarat, India | Not Sold | Brand New | India | 10 | 5 | 12,964,161 | 7,259,930 |
| 204 | 2019 | Passenger Elevator | Matiz Elevator Co., Ltd. | Jinsha Industrial Park, Kengzi, Pingshan, Shenzhen, Guangdong, China. | Not Sold | Brand New | China | 10 | 5 | 1,426,299 | 798,727 |
| 205 | 2019 | Spare Parts for HVAC | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Germany | 10 | 5 | 29,000 | 16,304 |
| 206 | 2019 | Cone Blender | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 5 | 225,000 | 126,616 |
| 207 | 2019 | Bottle Visual Checking | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 45,000 | 25,323 |
| 208 | 2019 | Air & Steam Mixture Sterilizer | Zhangjiagang Ousirui Medical Technology Co. Ltd. | No.2 Xindong Road Daxin Village Daxin Town, Zhangjiagang City, Jiangsu Province, China. | Not Sold | Brand New | China | 10 | 5 | 4,257,815 | 2,399,541 |
| 209 | 2019 | Electronic Balance | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | China | 10 | 5 | 15,000 | 8,482 |
| 210 | 2019 | Dress Washing Machine | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 5 | 31,170 | 17,660 |
| 211 | 2019 | Batch Printer Machine | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 5 | 70,000 | 39,699 |

| | | | | | | | | | | | |
|-----|------|---|---|--|----------|-----------|------------|----|---|-------------|------------|
| 212 | 2019 | Packing Machine | Shanghai Digital Industry Imp. and Exp. Co., Ltd. | 433 XIE TU Road Shanghai 200023, China. | Not Sold | Brand New | China | 10 | 5 | 461,565 | 262,017 |
| 213 | 2019 | Rotary Bottle Washing Machine | Konark Machine Tools | 1, Anand Nagar, NR. Ramdevpir Mandir, Chandlodia, Ahmedabad, India. | Not Sold | Brand New | India | 10 | 5 | 1,366,591 | 778,395 |
| 214 | 2019 | Refrigerator | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 56,000 | 32,050 |
| 215 | 2019 | Digital Thermo-Hyrometer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 21,000 | 12,099 |
| 216 | 2019 | HPLC System | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08 Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Japan | 10 | 5 | 2,595,802 | 1,497,031 |
| 217 | 2019 | Water Flow Meter | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 5 | 21,010 | 12,220 |
| 218 | 2019 | Vial Washing, Sterilizing & Depyrogenic Machine | L and P Pharma Pack LLP | Plot No. 806, G.I.D.C. Sectro-28 Gandhinagar-382028, Gujarat, India. | Not Sold | Brand New | India | 10 | 5 | 6,754,444 | 3,930,531 |
| 219 | 2019 | Automatic Vial Filling & Stoppering & Capping Line | Irta Dosificacio I Tecnologia S.L | C/Diptacio, 75 Ent. 3A (08015) Barcelona-Spain. | Not Sold | Brand New | Spain | 10 | 5 | 38,000,468 | 22,133,971 |
| 220 | 2019 | Leaflet Folding Machine | Pratham Technologies Pvt. Ltd. | S. no. 14, Dhadge, Indl. Estate, Near Savli, Dhaba, Sinhagad Road, Nanded Phata, Pune-411041, India. | Not Sold | Brand New | India | 10 | 5 | 1,114,938 | 650,941 |
| 221 | 2019 | Sandwich Panel System with Cold Room Facility-HVAC System | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 5 | 101,451,423 | 60,731,880 |
| 222 | 2019 | Computerized System Pharmaceutical Industry Suspended Particles Machinery Monitoring System with Standard Accessories | Hiclean Tech Ltd. | Chase Business Center-Chd 39-41 Chase Side London England N14 5BP. | Not Sold | Brand New | China | 10 | 5 | 6,106,300 | 3,658,761 |

| | | | | | | | | | | | |
|-----|------|---|--|---|----------|-----------|------------|----|---|------------|------------|
| 223 | 2019 | Sampling Booth | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 6 | 203,380 | 122,529 |
| 224 | 2019 | Blender Machine | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 1,345,000 | 810,316 |
| 225 | 2019 | Isolator Machine | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 9,124,645 | 5,499,786 |
| 226 | 2019 | Weighing Balance | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 20,000 | 12,121 |
| 227 | 2019 | Mini-Chiller | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 6 | 1,400,000 | 850,740 |
| 228 | 2019 | Blow Molding Machine | Aman Machinery Co. Ltd. | No. 307-505, Guangnan Road, Wuxi City, Jiangsu Province, P.R. China. | Not Sold | Brand New | China | 10 | 6 | 4,696,325 | 2,856,395 |
| | | Bottle Blowing Mold | | | | | | | | | |
| 229 | 2019 | Sandwich Panel System with Cold Room Facility-HVAC System | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 6 | 2,425,912 | 1,475,486 |
| 230 | 2019 | Tray Dryer for Bottle Drying | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 276,250 | 168,323 |
| 231 | 2019 | Cooling Tower | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 6 | 1,420,000 | 865,227 |
| 232 | 2019 | Pressure Vessel | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 109,000 | 66,475 |
| 233 | 2019 | HVAC Local | Novelty International | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 39,283,450 | 24,097,437 |
| 234 | 2019 | Packing/Wrapping Machinery | Printemps International | Room No.-203, Jindal Towers, 21/1A/3, Darga Road, Kolkata-700017, India. | Not Sold | Brand New | India | 10 | 6 | 1,295,602 | 796,174 |
| 235 | 2019 | Mixture Machine | Beijing Tian Nuo Lang Trading Co. Ltd. | No. 62, Yunjing South Street, Tfongzhou District, Beijing, China | Not Sold | Brand New | China | 10 | 6 | 23,309,405 | 14,375,197 |

| | | | | | | | | | | | |
|-----|------|--------------------------------|---|--|----------|-----------|------------|----|---|-----------|-----------|
| 236 | 2019 | Shell & Tube Evaporator | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 866,000 | 536,445 |
| 237 | 2019 | Magnehelic Pressure Gauge-HVAC | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 740,000 | 459,814 |
| 238 | 2019 | Automatic Cartoning Machine | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 35,000 | 21,796 |
| 239 | 2019 | De-Foiling Machine | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 150,000 | 93,411 |
| 240 | 2019 | Washing Machine | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 30,000 | 18,789 |
| 241 | 2019 | De-Foiling Machine | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 190,000 | 119,049 |
| 242 | 2019 | Pressure Vessel | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 100,000 | 62,685 |
| 243 | 2019 | Sampling Booth | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 6 | 200,000 | 125,425 |
| 244 | 2019 | Air Curtain | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 6 | 45,000 | 28,221 |
| 245 | 2019 | SS 316 Check Valves Size 6" | Bectochem Consultants and Engineers Pvt. Ltd. | Plot No. 623/3-B Part-2, G.I.D.C. (Nr. Fire Station), Ankleshwar-393002, Gujarat, India. | Not Sold | Brand New | India | 10 | 6 | 3,064,781 | 1,924,515 |
| 246 | 2019 | Storage Vessel | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 30,000 | 18,838 |
| 247 | 2019 | Tray Dryer for Bottle Drying | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 300,000 | 188,384 |
| 248 | 2019 | Stability Chamber | Aralab Equipamentos | AV DE SANTA ISABEL, N07, ALBARRAQUE RIO DE MOURO 2635-047, PO | Not Sold | Brand New | Portugal | 10 | 6 | 1,265,017 | 796,094 |
| 249 | 2019 | Vacuum Cleaner | Royal Machinery Corporation Ltd. | South Salna, Gazipur | Not Sold | Brand New | Bangladesh | 10 | 6 | 30,000 | 18,945 |

| | | | | | | | | | | | |
|-----|------|---|-------------------------------------|---|----------|-----------|------------|----|---|------------|------------|
| 250 | 2019 | Cap Vac Vacuum Cleaner | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 30,000 | 18,945 |
| 251 | 2019 | Shell & Tube Evaporator | Novelty International | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 6 | 5,865,200 | 3,756,942 |
| 252 | 2019 | HVAC System (Local)-Cap Sealing | | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | | 10 | 6 | 780,000 | 498,132 |
| 253 | 2019 | Auto Tablet & Press Coating | | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | | 10 | 6 | 29,510,800 | 18,846,486 |
| 254 | 2019 | Roller Compactor Machine | | | Not Sold | Brand New | | 10 | 6 | 130,000 | 83,200 |
| 255 | 2019 | Filim Sealing Machine | Royal Machinery Corporation Ltd. | South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 410,000 | 261,052 |
| 256 | 2019 | Dry Heat Sterilizer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 301,811 | 195,640 |
| 257 | 2020 | Multi Mill | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 6 | 245,205 | 159,551 |
| 258 | 2020 | Dry Powder Filling-Stoppering Capping Machine | Pharmtech Machinery Co. Ltd. | Room 1008, Golden Wells Buliding No.-1, Gubei Road, Baoshan Dist., Shanghai, China. | Not Sold | Brand New | China | 10 | 6 | 2,996,019 | 1,963,418 |
| 259 | 2020 | Filim Sealing Machine | Royel Machinery Corporation Ltd. | Holding No-917/1, Block-C, South Salna, Gazipur, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 410,000 | 268,803 |
| 260 | 2019 | Automatic Blister Packing Machine | Zhejiang Hoping Machinery Co., Ltd. | Zhongzhou Industrial Zone, Felyun Town, Ruian City, Zhejiang, China. | Not Sold | Brand New | China | 10 | 6 | 8,687,537 | 5,717,114 |
| 261 | 2020 | Tablet Compressing Machine | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 6 | 720,000 | 478,948 |
| 262 | 2020 | De-Foiling Machine | RSK Engineering & Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | | Bangladesh | 10 | 6 | 198,765 | 133,254 |
| 263 | 2020 | Chiller Machine | Wattson Euro Panel Industries Ltd. | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 6 | 15,193,658 | 10,435,754 |

| | | | | | | | | | | | |
|-----|------|--|------------------------------------|--|----------|-----------|------------|----|---|------------|------------|
| 264 | 2020 | Sampling Booth | Pervez Engineering Workshop | Adharsha Bag, Paradoair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 6 | 224,780 | 157,038 |
| 265 | 2020 | Shell & Tube Evaporator | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 866,000 | 605,488 |
| 266 | 2020 | Dry Heat Sterilizer | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 6 | 243,435 | 170,204 |
| 267 | 2019 | Atomic Absorption Spectrophotometer | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08 Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Japan | 10 | 6 | 6,308,370 | 4,414,130 |
| 268 | 2020 | Fluid Bed Dryer-HVAC | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 7 | 4,447,451 | 3,122,964 |
| 269 | 2020 | Shell & Tube Evaporator Unit | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 7 | 1,200,000 | 851,507 |
| 270 | 2020 | Semi Filling Machine Semi Capping Machine | Shanghai Fuxi Ltd. | Shanghai Fuxi Ltd. 10A, No-89, FU MIN Road, Shanghai 200040, China. | Not Sold | Brand New | China | 10 | 7 | 1,147,350 | 818,548 |
| 271 | 2020 | Semi Automatic Rotary Bottle Washing Machine | HR Pharma Machinery | 31, Satellite Industrial Estate Kathwada- GIDC, Kathwada Ahmedabad-382415, India. | Not Sold | Brand New | India | 10 | 7 | 1,136,599 | 810,878 |
| 272 | 2020 | Auto Sealer | New Famous Hardware & Tools | Shop- 72-73, Nawabpur Tower, 198-202 Nawabpur Tower, Dhaka - 1100 | Not Sold | Brand New | Bangladesh | 10 | 7 | 44,000 | 31,403 |
| 273 | 2020 | Substation 5000 KVA | RS Power & Electric | Moonlit Regency 1st Floor (2/A), House # 2, Road # 03, Nikunja - 2, Khilkhet, Dhaka. | Not Sold | Brand New | Bangladesh | 10 | 7 | 19,000,000 | 13,664,384 |
| 274 | 2020 | Milling Machine & Surface Grinding Machine | Mujib Marine Collection | lalam Co. Market, B.M.A Gate, Bhatiyari, Chattogram | Not Sold | Brand New | Bangladesh | 10 | 7 | 1,200,000 | 869,589 |

| | | | | | | | | | | | |
|-----|------|----------------------------------|----------------------------------|---|-------------|--------------|------------|----|---|------------|------------|
| 275 | 2020 | Servo Drive | SP i-Dositecno | C/ Dels Renences , 44, 8304, Mataro, Spain. | Not Sold | Brand New | Spain | 10 | 7 | 576,680 | 417,896 |
| 276 | 2020 | Versaflo Powered Air Turbo | All in Technologies | Uttara, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 7 | 270,000 | 198,025 |
| 277 | 2020 | Change Parts, Blister Machine | SS Corporation | Dakkhinkhan, Dhaka-1230. | Not Sold | Brand New | Bangladesh | 10 | 7 | 171,000 | 125,416 |
| 278 | 2020 | Spare Parts | Precisa Techno Fabricators | Sector 7, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 7 | 246,000 | 186,084 |
| 279 | 2020 | HVAC-Air Handling Unit System | Novelty International | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 7 | 52,474,500 | 39,434,946 |
| 280 | 2020 | Sandwich Panel | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 7 | 29,571,746 | 22,223,370 |
| 281 | 2020 | Linear Vial Washing Machine | HR Pharma Machinery | 31, Satellite Industrial Estate Kathwada- GIDC, Kathwada Ahmedabad- 382415, India. | Not Sold | Brand New | India | 10 | 7 | 2,452,564 | 1,845,806 |
| 282 | 2020 | Spare Parts | D.H Engineering Workshop | Pallabi, Mirpur, Dhaka - 1216 | Not Sold | Brand New | Bangladesh | 10 | 7 | 123,500 | 92,405 |
| 283 | 2021 | Water Chiller | M/S H. S. Electro- Mechanics | CDA Market, Pahartali, Ctg | Not Sold | Brand New | Bangladesh | 10 | 7 | 2,800,000 | 2,107,288 |
| 284 | 2021 | Sandwich panel System | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District Shanghai, China. | Not Sold | Brand New | China | 10 | 7 | 3,994,295 | 3,018,155 |
| 285 | 2021 | Spectrophotometer | Cosmotrade Associates | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 7 | 135,000 | 103,007 |
| 286 | 2021 | Cold Room Equipment | Classic Engineering | Century Arcade, Moghbar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 7 | 400,000 | 310,466 |
| 287 | 2021 | Dispensing Booth | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 7 | 1,000,000 | 778,356 |
| 288 | 2021 | Oven | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka- 1204. | Not Sold | Brand New | Bangladesh | 10 | 7 | 200,000 | 155,397 |
| 289 | 2021 | Tablet Compreser Machine | M/s Nowab Engineering Works | 74/1, Lalmuhon Shah Street, Dulaikhal, Dhaka- 1100. | Not Sold | Brand New | Bangladesh | 10 | 7 | 49,500 | 38,488 |

| | | | | | | | | | | | |
|-----|------|--------------------------------------|------------------------------------|---|----------|-----------|------------|----|---|------------|------------|
| 290 | 2021 | Air Handling Unit | Classic Engineering | Century Arcade, Moghbazar, Dhaka - 1217. | Not Sold | Brand New | Bangladesh | 10 | 7 | 1,700,000 | 1,329,726 |
| 291 | 2021 | Muffle Furnace | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209 | Not Sold | Brand New | Bangladesh | 10 | 7 | 229,460 | 179,350 |
| 292 | 2021 | Automatic Polari Meter | A. Kruss Optronic Gmbh | Alsterdorfer Strasse 276-278, Alsterdorf, Hamburg, HH 22297 DE, Germany. | Not Sold | Brand New | Germany | 10 | 7 | 1,647,451 | 1,289,525 |
| | | Chars Normal Paper Printer | | | | | | | | | |
| | | Digital Refractometer | | | | | | | | | |
| 293 | 2021 | Oven | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 7 | 200,000 | 157,041 |
| 294 | 2021 | Ampoules Washing Machine | Krishna Calibration Centre | No:201, Shrinand City, New Maninagar, Ahmedabad, India. | Not Sold | Brand New | India | 10 | 7 | 720,212 | 575,380 |
| 295 | 2021 | Sandwich Panel with HVAC System | Pharma United Company Limited | RM 207, BLK-5, Lane 1500, Lian Hua Rd. (S), Minhang District, Shanghai 201100, China. | Not Sold | Brand New | China | 10 | 7 | 12,628,449 | 10,088,920 |
| 296 | 2021 | HVAC Local System | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 5,780,000 | 4,652,504 |
| 297 | 2021 | Chromatography Machine | Shimadazu (Asia Pacific) Pte Ltd. | 79 Science Park Drive No. 02-01/08, Cintech IV, Singapore Science Park 1, Singapore-118264. | Not Sold | Brand New | Singapore | 10 | 8 | 5,989,285 | 4,937,468 |
| 298 | 2021 | HPLC System | IKA Werke Gmbh & Co. KG | Janke & Kunkel Str, 10, D-79219 Staufen. | Not Sold | Brand New | Germany | 10 | 8 | 792,851 | 653,613 |
| 299 | 2021 | Pressure Vessel & SS Vessel with Lid | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 8 | 180,000 | 145,184 |
| 300 | 2021 | Sterilizing & Depyrogena Tunnel | M/S Venera Biotech System Pvt.Ltd | D-2/1, Rhodha Compound, AMP Gate Road, MIDC Industrial Area, Ambernath (W), Dist: Thane, Maharashtra-421501, India. | Not Sold | Brand New | India | 10 | 8 | 2,894,990 | 2,386,582 |

| | | | | | | | | | | | |
|-----|------|--|--------------------------------|--|----------|-----------|------------|----|---|------------|------------|
| 301 | 2021 | Automatic Eight Head Ampoule Filling & Sealing Machine | The United Engineering Company | 35A, Hazra Road Kolkata 700 029, India. | Not Sold | Brand New | India | 10 | 8 | 4,416,657 | 3,641,019 |
| 302 | 2021 | SS Vessel with Lid | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 8 | 150,000 | 122,507 |
| 303 | 2021 | Automatic Tube Filling Machine | Kankai Pharma Machinery | W 206 Shri Nand City 3 New Maninagar CRM Ahmedabad-382449, India | Not Sold | Brand New | India | 10 | 8 | 1,952,610 | 1,609,700 |
| 304 | 2021 | Dispensing Booth | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 8 | 750,000 | 618,288 |
| 305 | 2021 | Dissolution Tester DIS | Copley Scientific Ltd. | Colwick Quays Business Park Private Road No. 2, Colwick Nottingham, NG4 2JY, United Kingdom. | Not Sold | Brand New | Uk | 10 | 8 | 2,908,261 | 2,468,436 |
| | | Disintegration Tester | | | | | | | | | |
| | | Friability Tester | | | | | | | | | |
| | | Tablet Hardness Tester | | | | | | | | | |
| | | Tapped Density Tester | | | | | | | | | |
| 306 | 2021 | Air Filters | Hiclean Tech Ltd. | (China Branch Office) 18, Chuangtou Industrial Area, Yanghe Road, Suzhou, China. | Not Sold | Brand New | China | 10 | 8 | 2,309,695 | 1,960,393 |
| 307 | 2021 | Automatic Linear Vial Washing Machine | Kankai Pharma Machinery | W 206 Shri Nand City 3 New Maninagar CRM Ahmedabad-382449, India. | Not Sold | Brand New | India | 10 | 8 | 2,169,741 | 1,841,605 |
| 308 | 2021 | Oven | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 8 | 260,000 | 219,896 |
| 309 | 2021 | Pillo Packing Machine | Saehan Global Corp. | 802, 115 Na Dong, Deogyang Gu Goyang City, Gyunggi Do, Korea. | Not Sold | Brand New | Korea | 10 | 8 | 2,562,521 | 2,174,984 |
| 310 | 2021 | Sandwich Panel with HVAC Local System | Transtech Trading Ltd. | Sultan Building (Ground Floor), 147-Motijheel C/A, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 8 | 70,212,050 | 60,305,418 |

| | | | | | | | | | | | |
|-----|------|---|-------------------------------------|--|----------|-----------|------------|----|---|------------|------------|
| 311 | 2021 | Fire Hydrant Systems | Novelty International | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 10,087,230 | 8,663,963 |
| 312 | 2022 | HVAC System | Transtech Trading Ltd. | Sultan Building (Ground Floor), 147-Motijheel C/A, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 8 | 55,192,220 | 47,404,825 |
| 313 | 2022 | HVAC Chiller Machine | Novelty International | 5/8 Block-c ,Lalmatia, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 8 | 15,124,500 | 12,990,495 |
| 314 | 2022 | Powder Filling & Capping Machine | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 20,105,471 | 17,268,672 |
| 315 | 2022 | Cutter & Chopper Machine | Royal Machinery Corporation Limited | Block-C, South Salna, Gazipur, Bangladesh | Not Sold | Brand New | Bangladesh | 10 | 8 | 340,000 | 292,400 |
| 316 | 2022 | Effluent Treatment Plant (ETP) | Transtech Trading Ltd. | Sultan Building (Ground Floor), 147-Motijheel C/A, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 8 | 50,237,500 | 43,534,579 |
| 317 | 2022 | Dry & Close Granulating Line | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 40,192,600 | 34,829,916 |
| 318 | 2022 | Vial Washing, Sterilizing & Depyrogenic Machine | Novelty International | North Kamalapur, Dhaka. | Not Sold | Brand New | Bangladesh | 10 | 8 | 21,643,500 | 18,755,723 |
| 319 | 2022 | Automatic Blister Packing Machine | Trade Global Ltd. | North Kamalapur, Dhaka. | Not Sold | Brand New | Bangladesh | 10 | 8 | 18,608,456 | 16,125,629 |
| 320 | 2021 | Triple Jacketed Heating Vessel With Stirrer | Pervez Engineering Workshop | Adharsha Bag, Paradogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 8 | 225,000 | 194,979 |
| 321 | 2022 | SS Vessel | D.H Engineering Workshop | Pallabi, Mirpur, Dhaka - 1216 | Not Sold | Brand New | Bangladesh | 10 | 8 | 100,000 | 86,658 |
| 322 | 2022 | Servo Driver motor 750 watt | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 8 | 95,000 | 82,325 |
| 323 | 2022 | Drum Stacker | Royal Machinery Corporation Limited | Block-C, South Salna, Gazipur, Bangladesh | Not Sold | Brand New | Bangladesh | 10 | 8 | 155,000 | 135,466 |
| 324 | 2022 | Chaff Cutter & Chopper Machine | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 315,000 | 275,388 |
| 325 | 2022 | Spectrophotometer | Enrich Tech LLC | Janke Und Kunkel Strasse 10, 79219 Staufen, Germany. | Not Sold | Brand New | Germany | 10 | 8 | 2,156,949 | 1,919,980 |

| | | | | | | | | | | | |
|-----|------|--|-------------------------------------|---|----------|-----------|------------|----|---|------------|------------|
| 326 | 2022 | Sandwich Panel, Coving Curve, Angle | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 8 | 1,220,038 | 1,086,335 |
| 327 | 2022 | Fluid Bed Dryer-HVAC | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 9 | 7,643,207 | 6,895,639 |
| 328 | 2022 | PLC for Table Compression Machine & Servo Driver for Sachet Machine | RSK Engineering Services | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 9 | 113,000 | 104,424 |
| 329 | 2022 | Automatic Sticker Labeling Machine | Kankai Pharma Machinery | W 206 Shri Nand City 3 New Maningar CTM Ahmedabad-382449, India | Not Sold | Brand New | India | 10 | 9 | 305,801 | 282,594 |
| 330 | 2022 | Powder Packing, Multi-Type Grinding & Centrifugal oil Filter Machine | Esr International Ltd. | 65 Mymensingh Lean, Banglamotor, Dhaka-1000 | Not Sold | Brand New | Bangladesh | 10 | 9 | 750,000 | 693,082 |
| 331 | 2022 | Brand new FT-IR Spectromer Meter System | Bruker Optics GmbH & Co. | KG Rudoff-Plank-Strasse 27 Germany | Not Sold | Brand New | Germany | 10 | 9 | 4,321,080 | 3,993,151 |
| 332 | 2022 | Pressure Vessel | Classic Engineering | Century Arcade, Moghbazar, Dhaka-1217. | Not Sold | Brand New | Bangladesh | 10 | 9 | 110,500 | 102,114 |
| 333 | 2022 | Stability Chamber | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 9 | 5,220,000 | 4,886,778 |
| 334 | 2022 | Shell & Tube Evaporator | Classic Engineering | Century Arcade, Moghbazar, Dhaka-1217. | Not Sold | Brand New | Bangladesh | 10 | 9 | 869,500 | 813,995 |
| 335 | 2022 | Storage Vessel | Royal Machinery Corporation Limited | Block-C, South Salna, Gazipur, Bangladesh | Not Sold | Brand New | Bangladesh | 10 | 9 | 32,200 | 30,144 |
| 336 | 2022 | Vial Washing, Sterilizing & Depyrogenic Machine | Novelty International | Uttara Model Town, Dhaka-1230, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 9 | 21,855,500 | 20,460,341 |
| 337 | 2022 | Blender Machine | RSK ENGINEERIBG & SERVICES | Shahjandpur, Gulshan, Dhaka-1212. | Not Sold | Brand New | Bangladesh | 10 | 9 | 1,352,000 | 1,265,694 |
| 338 | 2022 | Filling Sealing Machine | Royal Machinery Corporation Limited | Block-C, South Salna, Gazipur, Bangladesh | Not Sold | Brand New | Bangladesh | 10 | 9 | 405,000 | 384,584 |
| 339 | 2022 | Magnehelic Pressure Gauge-HVAC | Transtech Trading Ltd. | Sultan Building (Ground Floor), 147-Motijheel C/A, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 9 | 1,455,000 | 1,381,652 |

| | | | | | | | | | | | |
|--------------|------|------------------------------|------------------------------------|--|----------|-----------|------------|----|---|----------------------|----------------------|
| 340 | 2022 | Air Curtain | Pervez Engineering Workshop | Adharsha Bag, Paragogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 9 | 46,000 | 43,681 |
| 341 | 2022 | Bottle Dryer | Classic Engineering | Century Arcade, Moghbazar, Dhaka-1217. | Not Sold | Brand New | Bangladesh | 10 | 9 | 102,000 | 96,858 |
| 342 | 2022 | Automatic Cartoning Machine | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 9 | 32,000 | 30,387 |
| 343 | 2022 | Roller Compactor Machine | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 9 | 6,025,500 | 5,721,749 |
| 344 | 2022 | Muffle Furnace | Wattson Euro Panel Industries Ltd. | Dhanmondi, Dhaka-1209 | Not Sold | Brand New | Bangladesh | 10 | 9 | 232,500 | 220,779 |
| 345 | 2023 | Dry & Close Granulating Line | Pharma Raw | Lake Circus, Kalabagan, Dhanmondi, Dhaka-1205 | Not Sold | Brand New | Bangladesh | 10 | 9 | 40,585,000 | 39,550,916 |
| 346 | 2023 | Linear Vial Washing Machine | Trade Global Ltd. | North Kamalapur, Dhaka, Bangladesh. | Not Sold | Brand New | Bangladesh | 10 | 9 | 2,520,000 | 2,455,792 |
| 347 | 2023 | Mini-Chiller Machine | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 9 | 2,752,500 | 2,682,368 |
| 348 | 2023 | Isolator Machine | Transtech Trading Ltd. | Sultan Building (Ground Floor), 147-Motijheel C/A, Dhaka | Not Sold | Brand New | Bangladesh | 10 | 9 | 9,560,500 | 9,316,904 |
| 349 | 2023 | Cooling Tower | Pervez Engineering Workshop | Adharsha Bag, Paragogair, Jatrabari, Dhaka-1204. | Not Sold | Brand New | Bangladesh | 10 | 9 | 1,456,500 | 1,419,389 |
| 350 | 2023 | HVAC System | Novelty International | Uttara Model Town, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 9 | 57,045,500 | 55,592,012 |
| 351 | 2023 | Stability Chamber | Airy Filtration Company Ltd. | Sector # 06, Uttara, Dhaka-1230 | Not Sold | Brand New | Bangladesh | 10 | 9 | 5,245,800 | 5,192,623 |
| 352 | 2023 | High Pressure Homogenizers | Bio-Xin (Pvt.) Ltd. | DOHS Saction-12, Mirpur, Dhaka-1216 | Not Sold | Brand New | Bangladesh | 10 | 9 | 33,738,000 | 33,395,998 |
| 353 | 2023 | Effluent Treatment Plant-ETP | Bismillah Boiler House | 138, Hazi Osman Goni Road, Alu-Bazar, Dhaka-1100 | Not Sold | Brand New | Bangladesh | 10 | 9 | 51,052,650 | 50,535,130 |
| 354 | 2023 | FT-IR Spectrophotometer | Pharma Raw | Lake Circus, Kalabagan, Dhanmondi, Dhaka-1205 | Not Sold | Brand New | Bangladesh | 10 | 9 | 3,383,419 | 3,361,172 |
| Total | | | | | | | | | | 1,904,045,508 | 1,040,829,998 |

- (ix) **Details of the machineries required to be bought by the issuer, cost of the machineries, name of the suppliers, date of placement of order and the date or expected date of supply, etc.**

The company has no plan to procure machinery except those to be bought by using IPO Proceeds.

- (x) **In case the machineries are yet to be delivered, the date of quotations relied upon for the cost estimates given shall also be mentioned;**

No machinery is required to be bought by the issuer except machinery to be bought from IPO proceeds.

- (xi) **If plant is purchased in brand new condition, then it should be mentioned;**

All plants and machineries of the Company were purchased in brand new condition.

AUDITOR'S CERTIFICATE REGARDING PURCHASED IN BRAND NEW CONDITION OF MACHINERIES

We do hereby declare that all the plants and machineries of Techno Drugs Ltd. were purchased in brand new condition. There are no re-conditioned or second-hand machineries installed in the Company.

Place: Dhaka;
Dated: 27th September 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

- (xii) **Details of the second hand or reconditioned machineries bought or proposed to be bought, if any, including the age of the machineries, balance estimated useful life, etc. as per PSI certificates of the said machineries as submitted to the Commission;**

The Company neither purchased any second hand or reconditioned machineries nor any plan to purchase in future.

- (xiii) **A physical verification report by the issue manager(s) regarding the properties as submitted to the Commission;**

**PHYSICAL VERIFICATION REPORT
of
TECHNO DRUGS LTD.**

This is to certify that we have visited the registered office and all factories of Techno Drugs Ltd. on August 19 and 20, 2023 and we have found the registered office and factory as details bellow:

Visited and accompanied by:

| Particulars | Name & Designation | Company |
|----------------|---|--------------------------|
| Visited by | : Md. Salauddin Sikder FCMA CEO & Managing Director | Imperial Capital Limited |
| | : Ahmed Arefin FCA Managing Director | EBL Investments Limited |
| Accompanied by | : Debasish Das Gupta Company Secretary | Techno Drugs Ltd. |
| | : Md. Ohidul Islam Plant Manager | |
| | : Parimal Chandra Sarkar Head of Project | |

Company Overview:

Techno Drugs Ltd. was incorporated in 2009 as a Private Limited Company of Bangladesh with the issuance of Certificate of incorporation bearing no. Reg. No. C-79890/09 dated on 30-Sep-2009 by the Registrar of Joint Stock Companies & Firms, Dhaka, Bangladesh. The Company Converted into public Limited Company and split of Share value from Tk. 1,000.00 to Tk. 10.00 dated on 18-Aug-2019.

Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human pharmaceuticals' drugs and animal health care drugs and selling them in local and international market.

The products of the company are sold in domestic and international markets.

Techno Drugs Ltd. has neither any subsidiary nor it is operated under a holding company.

The authorized and paid-up capital of the Company is as Follows:

Authorized Capital : Tk. 2,000,000,000.00

Paid Up Capital : Tk. 941,574,000.00

Proposed IPO Size : Tk. 1,000,000,000.00

Registered Office:

The registered & head office of the company is situated at J K Tower, 31 Segunbagicha, Dhaka-1000.

Location of the Factory:

There are signboards to indicate factory locations and in the factory premises we found well-displayed signboard.

The location of the factory is at Satirpara, Narsingdi-1600 and B.K. Bari Mirzapur, Gazipur-1703.

Location of the Depots:

The list of depots of Techno Drugs Ltd. along with their addresses is given below:

| Sl. | Depot Name | Depot Address |
|------------|-------------------|--|
| 1 | Barishal | House Name- Niloy, Holding No-872, Ward No-14, Barishal City Corporation, Barishal Sadar, C&B Road, Barishal |
| 2 | Sylhet | Holding No-16/A, Shoroshpur Charanir, Lama Bazar, Sylhet-3100, Sylhet Sadar, Sylhet |
| 3 | Rajshahi | House: 0233, Housing Estate, Sector-2, Post office: Rajshahi Shenanibash-6202, Boalia, Rajshahi. |
| 4 | Bogura | House-399/431, Opposite of Tajma Ceramic, Thonthonia, Bogura |
| 5 | Faridpur | Aloknondan- Holding No.-10/32/01, Alauddin Khan Road, South Alipur, Faridpur Sadar. |
| 6 | Rangpur | House No.-78/4, road no.-01, PTI road, Katkipara, kotoali Rangpur |
| 7 | Mymensingh | House No-6/1, Natokghor Lane, Kotoali, Mymensingh |
| 8 | Bhairab | Holding No-920, Kolompur, Bhairab, Kishorgonj |

| | | |
|----|------------|--|
| 9 | Jeshore | Holding No-1/B, Najnin Gopi Central Road, Jeshore Town, Police Station-Kotoali, Jeshore |
| 10 | Chattogram | 523, Shahid Nagar, Hathazari Road, (Near Oxygen) P.O Amin Jute Mills Ltd. Chattogram-4211 |
| 11 | Cumilla | Holding No-355/420, Munshi Bari, Rail Station Road, Adorssho Sadar, Cumilla |
| 12 | Khulna | Afroja Kanon, Holding No.-294, Road No.-17, Nirala Housing Area, Post Office: Khulna City-9100, Khulna Sadar, District: Khulna |
| 13 | Dinajpur | Shishuniketon Road, ShipahiPara, Block no.-10, Ward No.-09, Dinajpur |
| 14 | Kushtia | Road No.-48/1, Bicharpoti Mahbub Morshed Road, Kotapara (Peyaratala), Kushtia Sadar, Kushtia |
| 15 | Noakhali | House No.-08, Road No.-36, Housing Estate, Maijdi Court, Noakhali |
| 16 | Tangail | Plot No.-1030/1, Shabaliala, Suroj Road, Tangail |
| 17 | Dhaka | J K Tower, 31 Segunbagicha, Dhaka-1000 |

Principal products:

Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human pharmaceuticals' drugs and animal health care drugs.

The products of the company are sold in domestic and international markets.

List of Non-Biological Products:

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

| Sl. | Products Name | Generic Name & Composition | DAR No. | Expiry Date |
|-----|----------------------|---|-------------|-------------|
| 1 | MOTILEX 10 TABLET | Domperidone Maleate BP 12.73 mg (eq.to 10 mg Domperidone) | 353-102-118 | 22.05.2026 |
| 2 | MOTILEX (suspension) | Domperidone BP 100.0 mg | 353-103-018 | 22.05.2026 |
| 3 | Romilac 10 tablet | Ketorolac tromethamine USP10.0 mg | 353-104-064 | 22.05.2026 |
| 4 | LOTEM 10 TABLET | Montelukast Sodium USP 10.04 mg (eq. to 10.00 mg Montelukast) | 353-105-044 | 22.05.2026 |
| 5 | LOTEM ODT TABLET | Montelukast Sodium USP 4.15 mg (eq. to 4.00 mg Montelukast) | 353-106-044 | 22.05.2026 |
| 6 | LOTEM 5 ODT TABLET | Montelukast Sodium USP 5.188 mg (eq. to 5.00 mg Montelukast) | 353-107-044 | 22.05.2026 |
| 7 | PROLAN 30 CAPSULE | Dexlansoprazole Pellets 20% (as enteric coated) INN 150 mg (eq. to Dexlansoprazole 30 mg) | 353-108-067 | 22.05.2026 |
| 8 | PROLAN 60 CAPSULE | Dexlansoprazole Pellets 20% (as enteric coated) INN 300 mg (eq. to Dexlansoprazole 60 mg) | 353-109-067 | 22.05.2026 |
| 9 | Exonid 60 Tablet | Fexofenadine Hydrochloride USP 60.00 mg | 353-110-021 | 22.05.2026 |
| 10 | Exonid 120 Tablet | Fexofenadine Hydrochloride USP 120.00 mg | 353-111-021 | 22.05.2026 |

| | | | | |
|----|-------------------------|--|----------------|------------|
| 11 | Exonid 180 Tablet | Fexofenadine Hydrochloride USP 180.00 mg | 353-112-021 | 22.05.2026 |
| 12 | Exonid suspension | Fexofenadine Hydrochloride USP 0.600 gm | 353-113-021 | 22.05.2026 |
| 13 | Neo zinc B syrup | Zinc Sulfate USP 549gm (eqv. to 200 mg Elemental Zinc) + Thiamin HCl BP 100 mg+ Riboflavin 5-phosphate Sodium USP 50.8 mg (eqv. to Riboflavin 40mg)+ Pyridoxine HCl BP 40mg+ Nicotinamide BP 400 mg/100 ml | 353-114-078 | 07.07.2026 |
| 14 | Neo Zinc syrup | Zinc Sulfate Monohydrate USP 549 mg (epv. to 200 mg elemental Zinc)/100 ml | 353-115-062 | 07.07.2026 |
| 15 | Neo Zinc 20 Tab. | Zinc Sulphate Monohydrate USP 54.89 mg (eqv. to 20 mg elemental Zinc)/Tablet | 353-124-062 | 07.07.2026 |
| 16 | Algicar Plus Suspension | Sodium Alginate BP 5 gm, Sodium Bicarbonate BP 2.67 gm, Calcium Carbonate BP 1.6 gm/ 100 ml Suspension | 353-125-007 | 07.07.2026 |
| 17 | Neo Zinc B Tab. | Thiamine Mononitrate USP 5 mg, Riboflavin BP 2 mg, Pyridoxine Hydrochloride BP 2 mg, Nicotinamide BP 20 mg, Zinc Sulfate Monohydrate USP 27.45 mg (eqv. to 10 mg elemental Zinc)/Tablet | 353-126-078 | 07.07.2026 |
| 18 | Pyrovet bolus (vet) | Paracetamol BP 2 gm/Bolus | 353-131(v)-077 | 07.07.2026 |
| 19 | Metrovet bolus (vet) | Metronidazole BP 2 gm/Bolus | 353-132(v)-077 | 07.07.2026 |
| 20 | Coraltec-D | Calcium Carbonate USP 1250 mg (eqv. to 500 mg Elemental Calcium) Cholecalciferol (Vitamin D3) USP 2.30 mg (eqv. to 200 IU)/Tablet | 353-151-062 | 31.10.2026 |
| 21 | Coraltec-DX | Calcium Carbonate USP 1500 mg (eqv. to 600 mg Elemental Calcium) and Cholecalciferol (Vitamin D3) USP 4 mg (eqv. to 400 IU Vitamin D3)/Tablet | 353-152-062 | 31.10.2026 |
| 22 | Neovitan | Thiamine mononitrate (Vitamin B1) USP 100 mg, Pyridoxine Hydrochloride (Vitamin B6) BP 200 mg, Cyanocobalamin (Vitamin B12) 0.1% Premix 200 mg (eqv. to 200 mcg Cyanocobalamin)/Tablet | 353-153-078 | 31.10.2026 |
| 23 | Odiver 3 | Ivermectin BP 3 mg/Tablet | 353-162-008 | 31.10.2026 |
| 24 | Odiver 6 | Ivermectin BP 6 mg/Tablet | 353-163-008 | 31.10.2026 |
| 25 | Odiver 12 | Ivermectin BP 12 mg/Tablet | 353-164-008 | 31.10.2026 |
| 26 | Cozil .5 | Clonazepam USP 0.5 mg/Tablet | 353-167-046 | 31.10.2026 |
| 27 | Cozil 1 | Clonazepam USP 1 mg/Tablet | 353-168-046 | 31.10.2026 |
| 28 | Tesco GL | Guaifenesin BP 2 gm, Levomenthol BP 22 mg, Diphenhydramine Hydrochloride BP 280 mg/100 ml Syrup | 353-169-031 | 31.10.2026 |
| 29 | Esmosec 20 Tablet | Esomeprazole Magnesium Trihydrate USP 22.21 mg (eqv. to Esomeprazole 20 mg)/Tablet | 353-171-067 | 05.01.2027 |
| 30 | Esmosec 40 Tablet | Esomeprazole Magnesium Trihydrate USP 44.42 mg (eqv. to Esomeprazole 40 mg)/Tablet | 353-172-067 | 05.01.2027 |

| | | | | |
|----|------------------------|---|-------------|------------|
| 31 | Omsec 20 Capsule | Omeprazole Enteric Coated BP 285.71 mg (eqv. to Omeprazole 20 mg)/Capsule | 353-174-067 | 05.01.2027 |
| 32 | Tesco DL Oral Solution | Dextromethorphan Hydrobromide BP 130 mg, Levomenthol BP 40 mg, Diphenhydramine Hydrochloride BP 280 mg/ 100ml Oral Solution | 353-177-067 | 05.01.2027 |
| 33 | Omsec 40 Capsule | Omeprazole Enteric Coated BP 571.43 mg (eqv. to Omeprazole 40 mg)/Capsule | 353-178-067 | 15.03.2027 |
| 34 | Omten 5/20 Tablet | Amlodipine Besilate BP 6.935 mg (eqv. to 5 mg Amlodipine)/ Olmesartan Medoxomil USP 20 mg/ Tablet | 353-179-022 | 15.03.2027 |
| 35 | Omten 5/40 Tablet | Amlodipine Besilate BP 6.935 mg (eqv. to 5 mg Amlodipine)/ Olmesartan Medoxomil USP 40 mg/ Tablet | 353-180-022 | 15.03.2027 |
| 36 | Kilpro 400 Tablet | Metronidazole BP 400 mg/Tablet | 353-181-027 | 15.03.2027 |
| 37 | Ketodil Syrup | Ketotifen Fumarate BP 27.6 mg (eqv. to Ketotifen 20 mg)100 ml Syrup | 353-186-021 | 13.08.2027 |
| 38 | Apegestrol Suspension | Megestrol Acetate (Micronized) USP 4 gm/100ml Suspension | 353-187-010 | 13.08.2027 |
| 39 | Arodex Tablet | Anastrozole USP 1mg | 304-320-71 | 20.07.2025 |
| 40 | Captabine Tablet | Capecitabine USP 150mg | 304-321-71 | 20.07.2025 |
| 41 | Captabine Tablet | Capecitabine USP 500mg | 304-325-71 | 26.12.2025 |
| 42 | Zolomide 100 Capsule | Temozolomide Hydrochloride INN 100.00 mg | 304-343-71 | 30.01.2027 |
| 43 | Zolomide 250 Capsule | Temozolomide Hydrochloride INN 250.00 mg | 304-344-71 | 30.01.2027 |
| 44 | Tarcenib 100 Tablet | Erlotinib Hydrochloride INN 100.00 mg | 304-345-71 | 30.01.2027 |
| 45 | Tarcenib 150 Tablet | Erlotinib Hydrochloride INN 150.00 mg | 304-346-71 | 30.01.2027 |
| 46 | Imatin 400 Tablet | Imatinib Mesilate INN 477.874mg (eqv. To 400mg of Imatinib) | 304-386-010 | 17.02.2024 |
| 47 | Eposide 50 Capsule | Etoposide BP 50.0mg | 304-402-10 | 10.09.2024 |
| 48 | Apegestrol Tablet | Megestrol Acetate USP 160.0mg | 304-404-10 | 10.09.2024 |
| 49 | Imatin 100 Tablet | Imatinib Mesilate INN 119.50mg (eqv. To 100 mg of Imatinib) | 304-406-10 | 07.06.2025 |
| 50 | Reparib Cap. | Olaparib INN 100 mg/Capsule | 304-425-010 | 22.06.2027 |
| 51 | Fibronil Tab. | Ruxolitinib Phosphate INN 6.6 mg (eqv. to 5 mg)/Tablet | 304-426-011 | 22.06.2027 |
| 52 | Vinytek Tab. | Venetoclax INN 100 mg/Tablet | 304-428-012 | 22.06.2027 |

List of Biological Products:

[As approved by Directorate General of Drug Administration & Licensing Authority (Drugs), Government of the People's Republic of Bangladesh]

| Sl. | Products Name | Generic Name & Composition | DAR No. | Inclusion Date | Expiry Date |
|-----|---|--|------------|----------------|-------------|
| 1 | PREMICON TABLET | Conjugated Oestrogens USP 0.625mg/ Tablet | 353-09-56 | 07.09.2009 | 06.09.2024 |
| 2 | PROVERA INJECTION | Medroxyprogesterone Acetate USP 150.00mg/ml | 353-10-039 | 07.09.2009 | 06.09.2024 |
| 3 | CYNOCORT INJECTION | Triamcinolone Acetonide BP 40 mg/ml | 353-11-050 | 07.09.2009 | 06.09.2024 |
| 4 | NORGEST TABLET | Levonorgestrel BP 0.15mg + Ethinylestradiol BP 0.03mg/Tablet | 353-12-039 | 07.09.2009 | 06.09.2024 |
| 5 | TD Syringe 2ml Disposable & Reuse Prevention Feature PP Syringe | Polypropylene Ph. Gr. 2.2980gm + Polyethylene Ph. Gr. 1.0975gm | 353-17-41 | 18.02.2016 | 17.02.2026 |
| 6 | TD Syringe 5ml Disposable & Reuse Prevention Feature PP Syringe | Polypropylene Ph. Gr. 2.2980gm + Polyethylene Ph. Gr. 1.0975gm | 353-18-41 | 18.02.2016 | 17.02.2026 |
| 7 | MARVELOUS TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.02 mg/Tablet | 353-19-039 | 18.02.2019 | 17.02.2024 |
| 8 | MARVELOUS PLUS TABLET | Desogestrel BP (Micronized) 0.15 mg + Ethinylestradiol (Micronized) BP 0.03 mg /Tablet | 353-20-039 | 18.02.2019 | 17.02.2024 |
| 9 | ETHIDROS TABLET | Drospirenone BP (Micronized) 3 mg + Ethinylestradiol (Micronized) BP 0.02 mg/Tablet | 353-21-039 | 18.02.2019 | 17.02.2024 |
| 10 | ETHIDROS PLUS TABLET | Drospirenone BP (Micronized) 3 mg + Ethinylestradiol (Micronized) BP 0.03 mg/Tablet | 353-22-039 | 18.02.2019 | 17.02.2024 |
| 11 | ETHILA TABLET | Lynestrenol (Micronized) BP 0.75 mg + Ethinylestradiol (Micronized) BP 0.0375 mg /Tablet | 353-23-039 | 18.02.2019 | 17.02.2024 |
| 12 | ETHILA PLUS TABLET | Lynestrenol BP (Micronized) 2.5 mg + Ethinylestradiol (Micronized) BP 0.05 mg /Tablet | 353-24-039 | 18.02.2019 | 17.02.2024 |
| 13 | MISOCLEAN TABLET | Misoprostol (Misoprostol 1% Dispersion with Hypromellose) 20 mg /Tablet | 353-25-049 | 18.02.2019 | 17.02.2024 |
| 14 | MARVELOUS- FE TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.02 mg Ferrous Fumarate BP 75 mg /Tablet | 353-26-039 | 02.04.2019 | 01.04.2024 |
| 15 | MARVELOUS PLUS- FE TABLET | Desogestrel (Micronized) BP 0.15 mg + Ethinylestradiol (Micronized) BP 0.03 mg Ferrous Fumarate BP 75 mg /Tablet | 353-27-039 | 02.04.2019 | 01.04.2024 |

| | | | | | |
|----|----------------------------------|---|------------|------------|------------|
| 16 | ETHIDROS- FE TABLET | Drospirenone (Micronized) BP 3 mg + Ethinylestradiol (Micronized) BP 0.02 mg Ferrous Fumarate BP 75 mg /Tablet | 353-28-039 | 02.04.2019 | 01.04.2024 |
| 17 | ETHIDROS PLUS- FE TABLET | Drospirenone (Micronized) BP 3 mg + Ethinylestradiol (Micronized) BP 0.03 mg Ferrous Fumarate BP 75 mg /Tablet | 353-29-039 | 02.04.2019 | 01.04.2024 |
| 18 | ETHILA- FE TABLET | Lynestrenol (Micronized) BP 0.75 mg + Ethinylestradiol (Micronized) BP 0.0375 mg Ferrous Fumarate BP 75 mg /Tablet | 353-30-039 | 02.04.2019 | 01.04.2024 |
| 19 | ETHILA PLUS- FE TABLET | Lynestrenol (Micronized) BP 2.5 mg + Ethinylestradiol (Micronized) BP 0.05 mg Ferrous Fumarate BP 75 mg /Tablet | 353-31-039 | 02.04.2019 | 01.04.2024 |
| 20 | PENMOX PFS | Amoxicillin Trihydrate (Micronized) BP 2.875gm (eqv. to Amoxicillin 2.5 gm)/100ml | 353-32-023 | 03.10.2019 | 02.10.2024 |
| 21 | PENMOX 500 Powder for Injection | Amoxcillin Sodium (Sterile Powder) BP 530.000mg eqv. to Amoxicillin 500mg / Vial Powder for Injection | 353-33-023 | 03.10.2019 | 02.10.2024 |
| 22 | PENMOX 250 Powder for Injection | Amoxcillin Sodium (Sterile Powder) BP 265.000mg eqv. to Amoxicillin 250mg / Vial Powder for Injection | 353-34-023 | 03.10.2019 | 02.10.2024 |
| 23 | AMOCLAV PFS | Amoxicillin Trihydrate (Micronized) BP 2.875gm eqv. to Amoxicillin 2.5gm + Diluted Potassium Clavulanate [Diluted with Silica 1:1] BP 1.489gm (Contains Potassium Clavulanate 0.745 gm eqv. to Clavulanic Acid 0.625gm) / 100ml Powder for Suspension | 353-35-023 | 03.10.2019 | 02.10.2024 |
| 24 | AMOCLAV FORTE PFS | Amoxicillin Trihydrate (Micronized) BP 9.200gm (eqv. to Amoxicillin 8.0 gm) + Diluted Potassium Clavulanate [Diluted with Silica 1:1] BP 2.740gm (eqv. to Clavulanic Acid 1.15 gm) / 100ml Powder for Suspension | 353-36-023 | 03.10.2019 | 02.10.2024 |
| 25 | AMOCLAV 0.6 Powder for Injection | Amoxicillin Sodium BP 530.000mg eqv. to Amoxicillin 500.000mg + Potassium Clavulanate BP 119.120mg eqv. to Clavulanic Acid 100.000mg/Vial Powder for Injection | 353-37-023 | 03.10.2019 | 02.10.2024 |
| 26 | AMOCLAV 1.2 Powder for Injection | Amoxicillin Sodium BP 1060.000mg eqv. to Amoxicillin 1000.000mg + Potassium Clavulanate BP 238.240mg eqv. to Clavulanic Acid 200.000mg/Vial Powder for Injection | 353-38-023 | 03.10.2019 | 02.10.2024 |
| 27 | Femi plant (Sub-dermal Implant) | Levonorgestrel BP/USP 75.00mg/rod | 353-39-039 | 31.12.2019 | 30.12.2024 |
| 28 | Pronacillin Injection (Vet) | Procaine Benzylpenicillin (Penicillin G Procaine) (1000 Units/mg) BP 3.000 gm [equivalent to procaine Benzylpenicillin (Penicillin G Procaine) 30,00,000 Units] + Benzylpenicillin Sodium (Penicillin G Sodium) (1666.67 Units/mg) BP 0.600 gm [equivalent to Benzylpenicillin Sodium (Penicillin G Sodium) 10,00,000 Units]/vial | 353-40-077 | 18.02.2020 | 17.02.2025 |

| | | | | | |
|----|---------------------------------|--|------------|------------|------------|
| 29 | Amoxyvet-30 Powder (Vet) | Amoxicillin Trihydrate (Micronized) BP 34.500 gm (equivalent to Amoxicillin 30 gm)/100gm | 353-41-077 | 18.02.2020 | 17.02.2025 |
| 30 | Amoxyvet Injection (Vet) | Amoxicillin Sodium (Sterile Powder) BP 1.060 gm (equivalent to 1 gm)/Vial | 353-42-077 | 18.02.2020 | 17.02.2025 |
| 31 | Dolopen-500 Injection | Flucloxacillin Sodium (Sterile Powder) BP 544.060 mg (Equivalent to Flucloxacillin 500 mg)/Vial | 353-43-023 | 18.02.2020 | 17.02.2025 |
| 32 | Dolopen-250 Injection | Flucloxacillin Sodium (Sterile Powder) BP 272.030 mg (Equivalent to Flucloxacillin 250 mg)/Vial | 353-44-023 | 18.02.2020 | 17.02.2025 |
| 33 | Dolopen DS PFS | Flucloxacillin Sodium (Micronized) BP 2.7203 gm (Equivalent to Flucloxacillin 2.5 gm)/100ml | 353-45-023 | 18.02.2020 | 17.02.2025 |
| 34 | Dolopen-250 Capsule | Flucloxacillin Sodium (Compacted) BP 272.030 mg (Equivalent to Flucloxacillin 250 mg)/ Capsule | 353-46-023 | 18.02.2020 | 17.02.2025 |
| 35 | Dolopen-500 Capsule | Flucloxacillin Sodium (Compacted) BP 544.060 mg (Equivalent to Flucloxacillin 500 mg)/ Capsule | 353-47-023 | 18.02.2020 | 17.02.2025 |
| 36 | Penmox-500 Capsule | Amoxicillin Trihydrate (Compacted) BP 575.000 mg (Equivalent to Amoxicillin 500 mg) / Capsule | 353-48-023 | 18.02.2020 | 17.02.2025 |
| 37 | Amoclav 1gm Tablet | Amoxicillin Trihydrate (Compacted) BP 1006.250 mg (Equivalent to Amoxicillin 875 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-49-023 | 18.02.2020 | 17.02.2025 |
| 38 | Amoclav 375 Tablet | Amoxicillin Trihydrate (Compacted) BP 287.500 mg (equivalent to Amoxicillin 250 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-50-023 | 18.02.2020 | 17.02.2025 |
| 39 | Amoclav 625 Tablet | Amoxicillin Trihydrate (Compacted) BP 575.000 mg (Equivalent to Amoxicillin 500 mg) + Diluted Potassium Clavulanate (Diluted with Microcrystalline Cellulose 1:1) BP 297.800mg eqv. to Clavulanic Acid 125mg / Tablet | 353-51-023 | 18.02.2020 | 17.02.2025 |
| 40 | EC-Pill | Levonorgestrel (Micronized) BP 1.500 mg/ Tablet | 353-52-039 | 18.02.2020 | 17.02.2025 |
| 41 | TECHNOSOL Hand Rub | Chlorhexidine Gluconate Solution BP 2.5 ml | 353-53-071 | 06.04.2020 | 05.04.2025 |
| 42 | CITRUS-C Chewable Tablet | Ascorib Acid BP 112.5 mg Sodium Ascorbate BP 158.00 mg | 353-54-078 | 30.04.2020 | 29.04.2025 |
| 43 | PARASOL Antiseptic Disinfectant | Chlorhexidine Gluconate 20% Solution BP 1.500 gm (eq. to Chlorhexidine Gluconate 0.3gm), Cetrimide 40% Solution BP 7.500 gm (eq. to Cetrimide 3.0 gm) | 353-55-071 | 30.04.2020 | 29.04.2025 |
| 44 | QUENIL Tablet | Hydroxychloroquine Sulphate USP 200.00 mg | 353-56-024 | 30.04.2020 | 29.04.2025 |
| 45 | TD-QUINE Tablet | Chloroquine Phosphate BP 250.00 mg | 353-57-024 | 30.04.2020 | 29.04.2025 |

| | | | | | |
|----|---------------------------|---|----------------|------------|------------|
| 46 | TD-QUINE Syrup | Chloroquine Phosphate BP 0.960 gm | 353-58-024 | 30.04.2020 | 29.04.2025 |
| 47 | FAVILAVIR Tablet | Favipiravir INN 200.00 mg | 353-59-024 | 30.04.2020 | 29.04.2025 |
| 48 | PROSTENOL INJECTION (VET) | Cloprostenol Sodium BP 263 mcg (eqv. to Cloprostenol 250 mcg) /mL | 353-60(v)-077 | 13.08.2020 | 12.08.2025 |
| 49 | FERTILON INJECTION (VET) | Gonadorelin Acetate BP 0.105 mg eqv. to Gonadorelin 0.1 mg/mL | 353-61(v)-077 | 13.08.2020 | 12.08.2025 |
| 50 | Oxcin 10 INJECTION (VET) | Oxytocin BP 16.66 mcg (eqv. to 10 IU) /mL | 353-62(v)-077 | 13.08.2020 | 12.08.2025 |
| 51 | Dexavet INJECTION (VET) | Dexamethasone Sodium Phosphate BP 2.0 mg/mL | 353-63(v)-077 | 13.08.2020 | 12.08.2025 |
| 52 | Medrol 40 injection | Methylprednisolone Acetate BP 40.00 mg/mL | 353-64-072 | 01.09.2020 | 31.08.2025 |
| 53 | Medrol 80 injection | Methylprednisolone Acetate BP 80.00 mg/2mL | 353-65-072 | 01.09.2020 | 31.08.2025 |
| 54 | Decafos injection | Dexamethasone Sodium Phosphate BP 5 mg/mL | 353-66-072 | 01.09.2020 | 31.08.2025 |
| 55 | Syntocin injection | Oxytocin BP 8.33 mcg (eqv. to 5 IU) /mL | 353-67-049 | 01.09.2020 | 31.08.2025 |
| 56 | Tibone tablet | Tibolone BP 2.5 mg/Tablet | 353-68-056 | 01.09.2020 | 31.08.2025 |
| 57 | Anabolin injection | Nandrolone Phenylpropionate BP 25 mg/mL | 353-69-048 | 01.09.2020 | 31.08.2025 |
| 58 | Decabolon injection | Nandrolone Decanoate BP 50 mg/mL | 353-70-048 | 01.09.2020 | 31.08.2025 |
| 59 | Sustogen injection | Testosterone Propionate BP 30 mg+ Testosterone Phenyl propionate BP 60 mg+ Testosterone Isocaproate BP 60 mg+ Testosterone Decanoate BP 100 mg/mL | 353-071-056 | 01.09.2020 | 31.08.2025 |
| 60 | Amoclav BoLUS (VET) | Amoxicillin Trihydrate (Compacted) BP 460.000 mg (eqv. to Amoxicillin 400mg) /Bolus | 353-072(v)-023 | 30.11.2020 | 29.11.2025 |
| 61 | Amoclav BoLUS DS (VET) | Amoxicillin Trihydrate (Compacted) BP 920.000 mg (eqv. to Amoxicillin 800mg) + Diluted Potassium Clavulanate [Diluted with Microcrystalline Cellulose (1:1)] BP 476.480 mg (eqv. to Clavulanic Acid 200 mg)/Bolus | 353-073(v)-023 | 30.11.2020 | 29.11.2025 |
| 62 | Amoclav ORAL POWDER (VET) | Amoxicillin Trihydrate (Miconized) BP 10.00gm + Diluted Potassium Clavulanate [Diluted with Silica (1:1)] BP 5.00 gm (eqv. to Potassium Clavulanate 2.5 gm)/ 100 gm | 353-074(v)-023 | 30.11.2020 | 29.11.2025 |
| 63 | TDCef 200 Tablet | Cefixime Trihydrate (Compacted) BP 224.00 mg (eqv. to Cefixime 200mg) /Tablet | 353-075-023 | 02.02.2021 | 01.02.2026 |
| 64 | TDCef 400 Tablet | Cefixime Trihydrate (Compacted) BP 448.00 mg (eqv. to Cefixime 400mg) /Tablet | 353-076-023 | 02.02.2021 | 01.02.2026 |
| 65 | TDCef | Cefixime Trihydrate (Micronized) BP 2.240gm (eqv. to Cefixime 2gm) /100ml | 353-077-023 | 02.02.2021 | 01.02.2026 |
| 66 | TDCef DS | Cefixime Trihydrate (Micronized) BP 4.480gm (eqv. to Cefixime 4gm) /100ml | 353-078-023 | 02.02.2021 | 01.02.2026 |

| | | | | | |
|----|---------------------------------|---|---------------|------------|------------|
| 67 | Cefixon 500 IM | Ceftriaxone Sodium (Sterile Powder) USP 595.000 mg (eqv. to Ceftriaxone 500 mg) /Vial | 353-079-023 | 02.02.2021 | 01.02.2026 |
| 68 | Cefixon 500 IV | Ceftriaxone Sodium (Sterile Powder) USP 595.000 mg (eqv. to Ceftriaxone 500 mg) /Vial | 353-080-023 | 02.02.2021 | 01.02.2026 |
| 69 | Cefixon 1 gm IV | Ceftriaxone Sodium (Sterile Powder) USP 1.190 gm (eqv. to Ceftriaxone 1 gm) /Vial | 353-81-023 | 02.02.2021 | 01.02.2026 |
| 70 | Cefixon 2 gm IV | Ceftriaxone Sodium (Sterile Powder) USP 2.380gm (eqv. to Ceftriaxone 2 gm) /Vial | 353-82-023 | 02.02.2021 | 01.02.2026 |
| 71 | Rapiclav 250 Tablet | Cefuroxime Axetil (DC Granules) BP 300.7 mg (eqv. to Cefuroxime 250mg) + Diluted Potassium Clavulanate [Diluted with MCC (1:1)] BP 178.9 mg (eqv. to clavulanic Acid 62.5 mg)/Tablet | 353-83-023 | 02.02.2021 | 01.02.2026 |
| 72 | Rapiclav 500 Tablet | Cefuroxime Axetil (DC Granules) BP 601.400 mg (eqv. to Cefuroxime 500mg) + Diluted Potassium Clavulanate [Diluted with MCC (1:1)] BP 297.800 mg (eqv. to clavulanic Acid 125 mg)/Tablet | 353-84-023 | 02.02.2021 | 01.02.2026 |
| 73 | Rapiclav | Cefuroxime Axetil (Amorphous) BP 3.007 gm (eqv. to Cefuroxime 2.5 gm) + Diluted Potassium Clavulanate [Diluted with Silica (1:1)] BP 1.489 gm (eqv. to clavulanic Acid 0.625 gm)/Bottle | 353-85-023 | 02.02.2021 | 01.02.2026 |
| 74 | Dexavet injection (vet) | Dexamethasone Sodium Phosphate BP 2.0 mg/ml | 353-86(v)-077 | 07.03.2021 | 06.03.2026 |
| 75 | Cefixon 500 iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 595 mg (eqv. to Ceftriaxone 500 mg) | 353-87(v)-077 | 11.04.2021 | 10.04.2026 |
| 76 | Cefixon 1 gm iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 1.190 gm (eqv. to Ceftriaxone 1 gm) | 353-88(v)-077 | 11.04.2021 | 10.04.2026 |
| 77 | Cefixon 2 gm iv Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 2.380 gm (eqv. to Ceftriaxone 2 gm) | 353-89(v)-077 | 11.04.2021 | 10.04.2026 |
| 78 | Cefixon 500 IM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 595 mg (eqv. to Ceftriaxone 500 mg) | 353-90(v)-077 | 11.04.2021 | 10.04.2026 |
| 79 | Cefixon 1 gm iM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 1.190 gm (eqv. to Ceftriaxone 1 gm) | 353-91(v)-077 | 11.04.2021 | 10.04.2026 |
| 80 | Cefixon 2 gm iM Injection (vet) | Ceftriaxone Sodium (Sterile Powder) USP 2.380 gm (eqv. to Ceftriaxone 2 gm) | 353-92(v)-077 | 11.04.2021 | 10.04.2026 |
| 81 | Merom 1gm IV Injection | Sterile mixture of Meropenem Trihydrate and Sodium Carbonate Anhydrous USP 1.417 g (eqv. to 1.0 gm Meropenem)/Vial | 353-93-023 | 15.04.2021 | 14.04.2026 |

| | | | | | |
|-----|--------------------------------|---|----------------|------------|------------|
| 82 | Merom 500 IV Injection | Sterile mixture of Meropenem Trihydrate and Sodium Carbonate Anhydrous USP 708.70 mg (eqv. to 500.0 mg Meropenem) /Vial | 353-94-023 | 15.04.2021 | 14.04.2026 |
| 83 | Imipen 500 IV Injection | Imipenem Monohydrate USP 568.18 mg (eqv. to 500.0 mg Imipenem) Cilastatin Sodium USP 530.0 mg (eqv. to 500.0 mg Cilastatin) /Vial | 353-95-023 | 15.04.2021 | 14.04.2026 |
| 84 | Anacort | Hydrocortisone Sodium Succinate Sterile USP 134.00 mg (eqv. To 100.00 mg Hydrocortisone) /Vial | 353-96-071 | 15.04.2021 | 14.04.2026 |
| 85 | TDcef 200 | Cefixime Trihydrate (Compacted) BP 224.000 mg (eqv. to Cefixime 200 mg) | 353-97-023 | 15.04.2021 | 14.04.2026 |
| 86 | TDcef 400 | Cefixime Trihydrate (Compacted) BP 448.000 mg (eqv. to Cefixime 400 mg) | 353-98-023 | 15.04.2021 | 14.04.2026 |
| 87 | Water for Injection | Sterile Water for Injection BP 2ml/Ampoule | 353-99-079 | 15.04.2021 | 14.04.2026 |
| 88 | AVALON 500 TABLET | Azithromycin Dihydrate(compact) USP 524.059 mg (eq. to 500.0 mg Azithromycin) | 353-100-023 | 23.05.2021 | 22.05.2026 |
| 89 | AVALON (POWDER FOR SUSPENSION) | Azithromycin Dihydrate (Micronized) | 353-101-023 | 23.05.2021 | 22.05.2026 |
| 90 | SEVORAN INHALATION GAS | Sevoflurane USP 250 ml/ 250 ml Bottle | 353-116-004 | 08.07.2021 | 07.07.2026 |
| 91 | FLURANE INHALATION GAS | Isoflurane USP 100 ml/ 100 Bottle | 353-117-004 | 08.07.2021 | 07.07.2026 |
| 92 | Peron 5 | Prednisolone BP 5 mg/Tablet | 353-118-072 | 08.07.2021 | 07.07.2026 |
| 93 | Peron 10 | Prednisolone BP 10 mg/Tablet | 353-119-072 | 08.07.2021 | 07.07.2026 |
| 94 | Peron 20 | Prednisolone BP 20 mg/Tablet | 353-120-072 | 08.07.2021 | 07.07.2026 |
| 95 | Lidocaine1% Inj | Lidocaine Hydrochloride BP 10 mg/ml Injection | 353-121-005 | 03.08.2021 | 02.08.2026 |
| 96 | Lidocaine2% Inj | Lidocaine Hydrochloride BP 20 mg/ml Injection | 353-122-005 | 03.08.2021 | 02.08.2026 |
| 97 | Water for Injection | Sterile Water for Injection BP 1 ml/1ml ampoule | 353-123-079 | 08.07.2021 | 07.07.2026 |
| 98 | Amoclav injection (vet) | Amoxicillin Sodium (Sterile Powder) BP 1.060 gm (eqv. to Amoxicillin 1gm) / Vial Powder for | 353-127(v)-023 | 08.07.2021 | 07.07.2026 |
| 99 | Xfur injection (vet) | Ceftiofur Sodium Sterile USP 1.042 gm (eqv. to Ceftiofur 1.0 gm/vial | 353-128(v)-077 | 08.07.2021 | 07.07.2026 |
| 100 | Xfur injection (vet) | Ceftiofur Sodium Sterile USP 0.521 gm (eqv. to Ceftiofur 0.500 gm/vial | 353-129(v)-077 | 08.07.2021 | 07.07.2026 |
| 101 | Cefavet powder (vet) | Cefalexin Monohydrate (Micronized) BP 7.889 gm (eqv. to Cefalexin 7.5 gm)/100 gm Powder | 353-130(v)-077 | 08.07.2021 | 07.07.2026 |
| 102 | Thioton 500 | Thiopental Sodium, Sterile BP 500 mg/Vial Injection | 353-133-004 | 03.08.2021 | 02.08.2026 |
| 103 | Thioton 1 gm | Thiopental Sodium, Sterile BP 1 gm/Vial Injection | 353-134-004 | 03.08.2021 | 02.08.2026 |

| | | | | | |
|-----|------------------|---|-------------|------------|------------|
| 104 | Diapamiro-370 | Iopamidol USP 75.5 gm/100ml Injection | 353-135-041 | 03.08.2021 | 02.08.2026 |
| 105 | Diapac-350 | Iohexol USP 755 mg (eqv. to 350 mg Iodine)/ml Injection | 353-136-041 | 03.08.2021 | 02.08.2026 |
| 106 | Dixanol-320 | Iodixanol USP 651.5 mg (eqv. to 320 mg of organically bound iodine) /ml Injection | 353-137-041 | 03.08.2021 | 02.08.2026 |
| 107 | Relaxton | Atracurium Besylate USP 25 mg/2.5 ml Injection | 353-138-063 | 03.08.2021 | 02.08.2026 |
| 108 | Suxonium | Suxamethonium Chloride BP 100 mg/2 ml Injection | 353-139-063 | 03.08.2021 | 02.08.2026 |
| 109 | Propofol | Propofol USP 10 mg/ml Injection | 353-140-004 | 03.08.2021 | 02.08.2026 |
| 110 | Vencuron-10 | Vecuronium Bromide BP 10 mg/Vial Injection | 353-141-063 | 03.08.2021 | 02.08.2026 |
| 111 | Avalon IV | Azithromycin Dihydrate (Micronized) USP 524.059 mg (eqv. to Azithromycin 500 mg)/Vial Injection | 353-142-023 | 03.08.2021 | 02.08.2026 |
| 112 | Omsec IV | Omeprazole Sodium BP 44.63 mg (eqv. to Omeprazole 40 mg)/Vial Injection | 353-143-067 | 03.08.2021 | 02.08.2026 |
| 113 | Romilac 30 | Ketorolac Tromethamine USP Injection 30 mg/1ml Injection | 353-144-064 | 03.08.2021 | 02.08.2026 |
| 114 | Romilac 60 | Ketorolac Tromethamine USP Injection 30 mg/1ml Injection | 353-145-064 | 03.08.2021 | 02.08.2026 |
| 115 | Urilev IV | Levofloxacin Hemihydrate USP 512.5mg (eqv. to Levofloxacin 500mg)/100 ml IV Infusion | 353-146-023 | 03.08.2021 | 02.08.2026 |
| 116 | Panalon | Pancuronium Bromide BP 4mg/2ml Injection | 353-147-063 | 03.08.2021 | 02.08.2026 |
| 117 | Stigmin | Neostigmine Methylsulfate USP 0.5 mg/ml Injection | 353-148-037 | 03.08.2021 | 02.08.2026 |
| 118 | Duracain | Bupivacaine Hydrochloride Monohydrate USP 21.1 mg (eqv. to Anhydrous Bupivacaine Hydrochloride 20 mg)/4ml Injection | 353-149-005 | 03.08.2021 | 02.08.2026 |
| 119 | Maclar IV | Clarithromycin USP 500 mg/Vial Infusion | 353-150-023 | 03.08.2021 | 02.08.2026 |
| 120 | Neovitan IM Inj. | Thiamine hydrochloride (Vitamin B1) BP 100 mg, Pyridoxine Hydrochloride (Vitamin B6) BP 100 mg, Cyanocobalamin (Vitamin B12) BP 1/3ml Inj | 353-154-078 | 01.11.2021 | 31.10.2026 |
| 121 | Maclar | Clarithromycin taste masked granules USP 9.259 gm (eqv. to 2.5 gm Clarithromycin)/100 ml Powder for Suspension | 353-155-023 | 01.11.2021 | 31.10.2026 |
| 122 | Medrol 120 | Methylprednisolone Acetate BP 120 mg/3ml Injection | 353-156-072 | 01.11.2021 | 31.10.2026 |
| 123 | Pro-Medrol 125 | Methylprednisolone Sodium Succinate Sterile USP 165.8 mg (eqv. to 125 mg Methylprednisolone)/Vial Injection | 353-157-072 | 01.11.2021 | 31.10.2026 |
| 124 | Pro-Medrol 500 | Methylprednisolone Sodium Succinate Sterile USP 663 mg (eqv. to 500 mg Methylprednisolone)/Vial Injection | 353-158-072 | 01.11.2021 | 31.10.2026 |
| 125 | Pro-Medrol 1 g | Methylprednisolone Sodium Succinate Sterile USP 1326 mg (eqv. to 1000 mg Methylprednisolone)/Vial Injection | 353-159-072 | 01.11.2021 | 31.10.2026 |
| 126 | Syntocin 10 | Oxytocin BP 16.66 mcg (eqv. to 10 IU)/1ml Injecton | 353-160-049 | 01.11.2021 | 31.10.2026 |

| | | | | | |
|-----|-----------------------------|---|-------------|------------|------------|
| 127 | Lidocaine Plus | Lidocaine hydrochloride BP 20 mg Epinephrine Bitartrate BP 36 mcg (eqv. to 20 mcg Epinephrine)/ml Injection | 353-161-005 | 01.11.2021 | 31.10.2026 |
| 128 | Doxym 50 | Doxycycline Hyclate BP 57.70 mg (eqv. to 50mg Doxycycline)/Capsule | 353-165-023 | 01.11.2021 | 31.10.2026 |
| 129 | Doxym 100 | Doxycycline Hyclate BP 115.40 mg (eqv. to 100mg Doxycycline)/Capsule | 353-166-023 | 01.11.2021 | 31.10.2026 |
| 130 | Ciplon IV | Ciprofloxacin Lactate BP 254.32 mg (eqv. to Ciprofloxacin 200 mg)100ml IV Infusion | 353-170-023 | 01.11.2021 | 31.10.2026 |
| 131 | Esmosec 40 IV Inj. | Esomeprazole Sodium BP 42.55 mg (eqv. to Esomeprazole 40 mg)/Vial IV Injection | 353-173-067 | 06.01.2022 | 05.01.2027 |
| 132 | Pantosec IV Injection | Pantoprazole Sodium Sesquihydrate BP 45.12 mg (eqv. to Pantoprazole 40 mg) Vial IV Injection | 353-175-067 | 06.01.2022 | 05.01.2027 |
| 133 | Diascan Injection | Gadodiamide USP 287 mg (eqv. to 0.5 mg mmol) ml Injection | 353-176-041 | 06.01.2022 | 05.01.2027 |
| 134 | Kilpro IV Infusion | Metronidazole BP 500 mg/100ml Iv Infusion | 353-182-027 | 16.03.2022 | 15.03.2027 |
| 135 | Viscer Injection | Tiemonium methysulfate INN 5 mg/2ml Injection | 353-183-011 | 23.06.2022 | 22.06.2027 |
| 136 | Mifisol Tablet | Mifepristone USP 200 mg/ Tablet | 353-184-049 | 23.06.2022 | 22.06.2027 |
| 137 | Caprolex Injection | Aminocaproic Acid USP 2gm/10 ml Injection | 353-185-033 | 14.08.2022 | 13.08.2027 |
| 138 | SC-Drops (Sterile Solution) | Sodium Chloride BP 0.9 gm/100ml | 353-188-050 | 14.08.2022 | 13.08.2027 |
| 139 | Paclitex Injection | Paclitaxel USP 30 mg | 304-292-71 | 14.12.2009 | 13.12.2024 |
| 140 | Doxorub Injection 50 mg | Doxorubicin Hydrochloride USP 50 mg | 304-293-71 | 14.12.2009 | 13.12.2024 |
| 141 | Cesalin Injection 50 mg | Cisplatin BP 50 mg | 304-294-71 | 14.12.2009 | 13.12.2024 |
| 142 | 5-Fluril Injection | 5- Fluorouracil BP 500 mg | 304-295-71 | 14.12.2009 | 13.12.2024 |
| 143 | Cyclomide Injection 200 mg | Cuclophosphamide Monohydrate BP 214 mg (eq to Cuclophosphamide Anhydrous 200 mg) | 304-296-71 | 14.12.2009 | 13.12.2024 |
| 144 | Oxalotin Injection 50 mg | Oxaliplatin BP 50 mg | 304-297-71 | 14.12.2009 | 13.12.2024 |
| 145 | Carbotin Injection 450 mg | Carboplatin BP 450 mg | 304-298-71 | 14.12.2009 | 13.12.2024 |
| 146 | Gemcetin Injection 1 g | Gemcitabine Hydrochloride USP 1.1385 gm (eq to Anhydrous Gemcitabine 1 g) | 304-299-71 | 14.12.2009 | 13.12.2024 |
| 147 | Gemcetin Injection 200 m g | Gemcitabine Hydrochloride USP 228 mg (eq to Anhydrous Gemcitabine 200 mg) | 304-300-71 | 14.12.2009 | 13.12.2024 |
| 148 | Eposide Injection | Etoposide BP 100 mg | 304-301-71 | 14.12.2009 | 13.12.2024 |
| 149 | Cyclomide – 1g Injection | Cyclophosphamide Monohydrate BP 1070mg (eq. to Cyclophosphamide Anhydrous 1g) | 304-308-71 | 25.02.2010 | 24.02.2025 |
| 150 | Doxorub-10 Injection | Doxorubicin Hydrochloride USP 10mg | 304-309-71 | 25.02.2010 | 24.02.2025 |

| | | | | | |
|-----|--------------------------|--|-------------|------------|-------------|
| 151 | Carbotin 150 Injection | Carboplatin BP 150mg | 304-310-71 | 25.02.2010 | 24.02.2025 |
| 152 | Cesalin-10 Injection | Cisplatin BP 10mg | 304-311-71 | 25.02.2010 | 24.02.2025 |
| 153 | Vincrist Injection | Vincristine Sulphate USP 1mg | 304-317-71 | 20.04.2010 | 19.04. 2025 |
| 154 | Mtrex Injection | Methotrexate BP 50mg (as Methotrexate Sodium) | 304-318-71 | 20.04.2010 | 19.04.2025 |
| 155 | Docetax 80 Injection | Docetaxel INN 80 mg | 304-319-71 | 03.06.2010 | 02.06.2025 |
| 156 | Oxalotin 100 Injection | Oxaliplatin BP 100 mg | 304-331-71 | 20.10.2011 | 19.10.2026 |
| 157 | Mesna Injection | Mesna Disulfide USP 400mg | 304-335-71 | 22.11.2011 | 21.11.2026 |
| 158 | Ifamide 1 gm Injection | Ifosfamide USP 1.0 gm | 304-338-71 | 12.01.2012 | 11.01.2027 |
| 159 | Ifamide 2 gm Injection | Ifosfamide USP 2.0 gm | 304-339-71 | 12.01.2012 | 11.01.2027 |
| 160 | Paclitaxel 300 Injection | Paclitaxel USP 300.00 mg | 304-340-71 | 12.01.2012 | 11.01.2027 |
| 161 | Docetax 20 Injection | Docetaxel INN 20.00 mg | 304-342-71 | 31.01.2012 | 30.01.2027 |
| 162 | Ostometa Injection | Zoledronic Acid Monohydrate INN 4.264mg (eqv. To 4 mg of Zoledronic Acid Anhydrous) | 304-387-010 | 18.02.2014 | 17.02.2024 |
| 163 | Irotin 100 Injection | Irinotecan Hydrochloride Trihydrate USP 108.67mg (eqv. To 100.00mg Irinotecan Hydrochloride) | 304-393-10 | 29.05.2014 | 28.05.2024 |
| 164 | Irotin 40 Injection | Irinotecan Hydrochloride Trihydrate USP 43.47mg (eqv. To 40.00mg Irinotecan Hydrochloride) | 304-394-10 | 29.05.2014 | 28.05.2024 |
| 165 | Folicid 100 Injection | Folinic Acid (as Calcium folinate) BP 100.00mg | 304-395-10 | 29.05.2014 | 28.05.2024 |
| 166 | Folicid 50 Injection | Folinic Acid (as Calcium folinate) BP 50.00mg | 304-396-10 | 29.05.2014 | 28.05.2024 |
| 167 | Epicin 10 Injection | Epicubicin Hydrochloride BP 10.00mg | 304-397-10 | 29.05.2014 | 28.05.2024 |
| 168 | Epicin 50 Injection | Epicubicin Hydrochloride BP 50.00mg | 304-398-10 | 29.05.2014 | 28.05.2024 |
| 169 | Tagribo 80 Tablet | Osimertinib Mesylate INN 95.43 mg eqv. to Osimertinib 80 mg | 304-409-010 | 8/1/2020 | 7.01.2025 |
| 170 | Tagribo 40 Tablet | Osimertinib Mesylate INN 47.72 mg eqv. to Osimertinib 40 mg | 304-410-010 | 8/1/2020 | 7.01.2025 |

List of Products: Animal Health Division:

| Sl. | Products Name | Generic Name & Composition | DAR No. | Expiry Date |
|-----|----------------------------------|---|----------------|-------------|
| 1 | Flumil 10 (Vet) | Flumequine INN 10.00 gm | 304-3(V)-83 | 23.04.2026 |
| 2 | Peraclear Bolus (Vet) | Fenbendazole INN 0.250 gm | 304-5(V)-83 | 08.07.2026 |
| 3 | Tetranid Bolus (Vet) | TetramisoleHCl BP 2.00 gm | 304-8(V)-83 | 23.04.2026 |
| 4 | Aldazole Bolus (Vet) | Albendazole BP 600 mg | 304-10(V)-83 | 19.08.2026 |
| 5 | Sulfatrim Powder (Vet) | Sulfadiazine BP 4000 gm | 304-11(V)-83 | 19.08.2026 |
| 6 | Cositrim Powder (Vet) | Sulphachloropyridazine Sodium BP 10.00 gm | 304-12(V)-83 | 19.08.2026 |
| 7 | Technomysol Bolus (Vet) | LevamisoleHCl BP 600 mg | 304-15(V)-83 | 19.08.2026 |
| 8 | Flumil 20 (Vet) Oral Solution | Flumequine INN 20 gm | 304-16(V)-83 | 06.01.2027 |
| 9 | Sulphatrim Bolus (Vet) | Sulphadiazine BP 1.0 gm | 304-44(V)-77 | 10.11.2024 |
| 10 | Levex Bolus (Vet) | LevamisoleHCl BP 600 mg | 304-45(V)-77 | 10.11.2024 |
| 11 | Nemasole 46 Powder (Vet) | LevamisoleHCl BP 46.00 gm | 304-48(V)-83 | 21.11.2024 |
| 12 | Pirazin 100 (Vet) | Piperazine Citrate USP 100 gm | 304-55(V)-83 | 13.11.2026 |
| 13 | Nilamide Powder (Vet) | Sulphanilamide BP 100 gm | 304-56(V)-83 | 13.11.2026 |
| 14 | Tylosin Powder (Vet) | Tylosin Tartrate BP 100 gm | 304-64(V)-83 | 31.12.2026 |
| 15 | CypmetSollution (Vet) | Cypermethrin USP 20 gm | 304-235(V)-83 | 05.12.2026 |
| 16 | Furadon Powder (Vet) | Furaltadone Hydrochloride USP 556.28 mg (eqv. 500 mg) | 304-237(V)-83 | 05.12.2026 |
| 17 | Amprolin Powder (Vet) | Amprolium Hydrochloride USP 678.57 mg (Eqv. 600 mg) | 304-238(V)-83 | 05.12.2026 |
| 18 | Amprolin Plus Powder (Vet) | Amprolium USP 17.0 gm | 304-239(V)-83 | 05.12.2026 |
| 19 | Melovet Injection | Meloxicam BP 0.500 gm | 304-341(v)-83 | 11.01.2027 |
| 20 | TD Cough Oral Solution (vet) | Bromhexine Hydrochloride BP 10.00gm + Phenylbutazone BP 50.00gm | 304-384(v)-077 | 17.02.2024 |
| 21 | Gentacin Inj. 5% (Vet) | Gentamycin Sulphate BP 8.500 gm (eqv 5 gm) | 304-6(V)-83 | 23.04.2026 |
| 22 | Technomycin Bolus (Vet) | Oxytetracycline Hydrochloride BP 0.540 gm (eqv 5 gm) | 304-9(V)-83 | 08.07.2026 |
| 23 | Bional Forte Inj. (Vet) | Thiamine Hydrochloride BP 50 mg | 304-42(V)-77 | 10.11.2024 |
| 24 | Oxynil Inj. (Vet) | Nitroxynil BP 250 mg | 304-46(V)-77 | 10.11.2024 |
| 25 | Ciprosol 10 (Vet) Oral Solution | Ciprofloxacin Hydrochloride USP 200 mg | 304-49(V)-83 | 17.12.2025 |
| 26 | Vermic (Vet) Injectable Solution | Ivermectin BP 1.0 gm | 304-50(V)-83 | 17.12.2025 |
| 27 | Enrox 10 (Vet) Oral Solution | Enrofloxacin INN 10 gm | 304-51(V)-83 | 24.01.2026 |
| 28 | Technomycin-DS Bolus (Vet) | OxytetracyclineDihydrate BP 1.00 gm | 304-53(V)-83 | 24.01.2026 |
| 29 | Dimidin Inj. (Vet) | Sulphadimidin Sodium BP 33.33 gm | 304-54(V)-83 | 24.01.2026 |
| 30 | Adesol Forte Inj. (Vet) | Vitamin A BP 300,000 IU | 304-57(V)-83 | 13.11.2026 |

| | | | | |
|----|---|--|----------------|------------|
| 31 | Neovet 70 (Vet) | Neomycin Sulphate BP 700 mg (eqv. 476 mg) | 304-58(V)-77 | 13.11.2026 |
| 32 | Caldifos Inj. (Vet) | Calcium Gluconate BP 20 gm | 304-61(V)-83 | 13.11.2026 |
| 33 | Pyramin Oral Solution (Vet) | Pyrimethamine BP 15 gm | 304-241(V)-83 | 05.12.2026 |
| 34 | Ciprosol Inj. (Vet) | Ciprofloxacin Hydrochloride USP 5.822 gm (eqv. 5 gm) | 304-244(V)-83 | 05.12.2026 |
| 35 | Anthiomat Inj. | Lithium Antimony Thiomalate IP 60 mg (eqv. 12 mg) | 304-245(V)-83 | 05.12.2026 |
| 36 | XtravetInj (Vet). | Vitamin A BP 100000 IU | 304-248(V)-83 | 05.12.2026 |
| 37 | Oxylin Spray (Vet) | Oxytetracycline Hydrochloride USP 2.5 gm | 304-252(V)-83 | 05.12.2026 |
| 38 | Gentamax Powder (vet) | Gentamycin Sulfate BP 200.00mg | 304-381(v)-077 | 17.02.2024 |
| 39 | Roxyvet DS Bolus (vet) | Cobalt Sulfate BP 100.00mg + Dried Ferrous Sulfate BP 200.00mg + Thiamine Mononitrate BP 50.00mg + Vitamin B ₁₂ BP 40.00mcg + Choline Bitartrate BP 18.20mg | 304-385(v)-077 | 17.02.2024 |
| 40 | LEVOSOL 10% ORAL SOLUTION (VET) | Levofloxacin (as Levofloxacin Hemihydrate) USP 10.249 gm | 304-413-077 | 10.04.2026 |
| 41 | MELOVET Bolus (Vet) | Meloxicam BP 100 mg | 304-414v-077 | 10.04.2026 |
| 42 | MELOVET 2% Injection (Vet) (10 ml clear glass vial) | Meloxicam BP 20.0 mg | 304-415(V)-077 | 10.04.2026 |
| 43 | Marbosol Bolus (Vet) | Marbofloxacin BP 50 mg | 304-416(v)-077 | 7.07.2026 |
| 44 | Marbosol Injection (Vet) | Marbofloxacin BP 100 mg | 304-417(v)-077 | 7.07.2026 |
| 45 | Melovet 2% Injection (vet) (30 ml Amber Tubular Glass Vial) | Meloxicam BP 20 mg | 304-418(v)-077 | 7.07.2026 |
| 46 | Vermic Plus Injection (vet) | Ivermectin BP 10 mg | 304-419(v)-077 | 7.07.2026 |
| 47 | Vermic Pour-On Solution (vet) | Ivermectin BP 5.0 mg | 304-420(v)-077 | 10.31.2026 |
| 48 | Vermic 1% Oral Solution (vet) | Ivermectin BP 10.0 mg | 304-421(v)-077 | 10.31.2026 |
| 49 | ColistinSulphate Oral Solution (vet) | ColistinSulphate BP 120 mg | 304-422(v)-077 | 10.31.2026 |
| 50 | Ticor (vet) Oral Solution | Tilmicosin Phosphate USP 278.18 eq. to 250 mg | 304-423(v)-077 | 12.08.2026 |
| 51 | FM (vet) Inj. | FlunixinMeglumine USP 83 mg (eqv. to 50 mg of Flunixin)/ ml Injection (Vet) | 304-424(v)-077 | 1.10.2027 |

Description of Property:

We have identified the properties of Techno Drugs Ltd. are as follows:

- 1) **Land:** We have found 27.00 decimals of land at Narsingdi and 1290.50 decimals of land at Gazipur.

| Deed No. | R.S. Dag No. | Area of Land (Decimal) | Current use |
|--------------|--|------------------------|---|
| 6721 | 581//541/520/521/588/584/525/524/1084/1090/591/593/592 | 596.57 | Solid & Powder Production, Liquid Production, Change Room, FP Quarantine, IPQC, AHU ROOM, Cold Room, Office Room, R & D Department, Prayer Room, Washing Room, Injection Production Processing, Blister Room, Secondary Packing Hall, Batch Printing Area, Intermediate Storage, Finished Product Quarantine, QA & QC, Documentation Storage Room, Laundry Room, Distilled Water Plant Room, Retention Sample Room, Encapsulation Room, FG Quarantine Room, Bulk Room, RM Dispensing ROOM, Change Parts Room, Injection Filling Sealing Room, Secondary PM Room, Injectable Production, Water System, Production, Technical, Canteen, Admin & Accounts Office, Office & Security Room, Substation, Control panel & Office, Air Compressor, Chemicals Dosing System & Office, Workshop & Engineering store, Central Quality Control, Central Quality Assurance, Molding Section, Warehouse, Assembly & Printing, Packing & Micro Biology, Technical & Quality Control Laboratory, Raw Materials Warehouse & Packaging, Finished Goods & Packaging Materials store, Fire Pump Operation, Transformer Operation, Incinerator Operation, Boiler & HVAC Store, Label Printing, Different Solvent Dispensing, Residents |
| 10148 | 587/586/582/591/583 | 273.93 | |
| 10719 | 584 | 27.00 | |
| 11218 | 593/591/588 | 35.00 | |
| 8257 | 589 | 35.00 | |
| 7271 | 590 | 70.00 | |
| 10680 | 8438/8445 | 120.00 | |
| 9927 | 2671/2750/2566/2565 | 98.00 | |
| 11430 | 1243 | 35.00 | |
| 9507 | 48 | 27.00 | |
| Total | | 1,317.50 | |

2) Building & Civil Construction:

Location of factory: Satirpara, Narsingdi-1600:

| Sl. | Name of the Building | Total Floor | Total Area SFT | Used for | Construction Type |
|-----|---|---------------------------------------|----------------|--|--|
| 1. | General Production Building (Animal Health) | Ground Floor to 4 th Floor | 15,104 SFT | Solid & Powder Production, Liquid Production, Change Room, FP Quarantine, IPQC, AHU ROOM, Cold Room, Office Room, R & D Department, Office Room, Prayer Room, Washing Room, Injection Production Processing, Blister Room, Secondary Packing Hall, Batch Printing Area, Intermediate Storage, Finished Product Quarantine, QA & QC, Documentation Storage Room, Laundry Room, Distilled Water Plant Room, Retention Sample Room. | RCC- Grade Beam RCC- Floor Slab, RCC- Piller, RCC Slab with Beam, RCC Stair, RCC Lintel, Brick Wall, Paint wall inside & outside. Thai Aluminum Window with M.S Grill, Industrial Door & Sandwich Panel. |
| 2. | Oncology Production Building | Ground Floor to 4 th Floor | 15,800 SFT | Change Room, Materials Entrance, RM Store, FG Store, Officers Room, Solid Production, Encapsulation Room, FG Quarantine Room, Bulk Room, IPQC, RM Dispensing ROOM, Change Parts Room, QA & QC Area, Injection Filling Sealing Room, Secondary PM Room, Injectable Production, Water System, AHU. | |
| 3. | Admin and Raw Materials Store Building | Ground Floor to 4 th Floor | 28,620 SFT | Administration, Raw Materials Store & Packing Materials Store. | |
| 4. | Finished Goods and Warehouse Building | Ground Floor to 2 nd Floor | 11,157 SFT | Finished Goods | |

Location of factory: B.K. Bari Mirzapur, Gazipur-1703:

| Sl. | Name of the Building | Total Floor | Total Area SFT | Used for | Construction Type | Remarks |
|-----|----------------------|---------------------------------------|----------------|---|---|---------|
| 1. | Hormone Building | Ground Floor to 3 rd Floor | 1,32,290 SFT | Production, Quality Control, Technical, Canteen & Office. | RCC- Grade Beam RCC- Floor Slab, RCC- Piller, RCC Slab with Beam, | |

| | | | | | | |
|-----|-----------------------------------|---------------------------------------|--------------|---|---|--|
| 2. | Penicillin Building | Ground Floor to 3 rd Floor | 66,552 SFT | Production, Quality Control, Technical & Packing store. | RCC Stair, RCC Lintel, Steel Structure Lintel, Brick Wall, Paint wall inside & outside. Thai Aluminum Window with M.S Grill, Industrial Door, Sandwich Panel & HVAC System. | |
| 3. | Cephalosporin Building | Ground Floor to 3 rd Floor | 66,552 SFT | Production, Technical, Quality Control, Workshop & Engineering store. | | |
| 4. | General Production Building | Ground Floor to 3 rd Floor | 1,42,000 SFT | Production & Ware House & Technical. | | |
| 5. | Medical Device & Biotech Building | Ground Floor to 2 nd Floor | 55,440 SFT | Production, Central Quality Control, Central Quality Assurance, Molding Section, Warehouse, Assembly & Printing, Packing & Micro Biology. | | 2 nd Floor Construction in Progress |
| 6. | Anti-Tuberculosis (TB) Building | Ground Floor to 4 th Floor | 28,152 SFT | Production, Technical & Quality Control Laboratory. | | 2 nd & 3 rd Floor Construction in Progress |
| 7. | Warehouse-I Building | Ground Floor to 2 nd Floor | 8,400 SFT | Raw Materials Warehouse & Packaging. | | |
| 8. | Warehouse-II Building | Prefabricated building | 24,360 SFT | Finished Goods & Packaging Materials store. | | |
| 9. | Admin Building | Ground Floor to 2 nd Floor | 7,830 SFT | Admin & Accounts Office. | | |
| 10. | Gate House | Ground Floor to 1 st Floor | 3,800 SFT | Office & Security Room. | | |
| 11. | Utility Building | Ground Floor to 2 nd Floor | 4,899 SFT | Substation, Control panel & Office. | | |

| | | | | | |
|-----|--------------------------|---------------------------------------|------------|---|--|
| 12. | ETP Building | Ground Floor to 2 nd Floor | 1,425 SFT | Air Compressor, Chemicals Dosing System & Office. | |
| 13. | R&D and Canteen Building | Ground Floor to 4 th Floor | 18,605 SFT | Canteen Office | 2 nd , 3 rd & 4 th Floor Construction in Progress |
| 14. | Pump House Building | Ground Floor | 400 SFT | Fire Pump Operation | |
| 15. | Transformer Room | Ground Floor | 460 SFT | Transformer Operation | |
| 16. | Incinerator | Ground Floor | 1,764 SFT | Incinerator Operation | |
| 17. | Boiler Room | Ground Floor to 1 st Floor | 2,072 SFT | Boiler & HVAC Store | |
| 18. | Printing Unit | Ground Floor to 1 st Floor | 4,800 SFT | Label Printing & Office | |
| 19. | Solvent Store Building | Ground Floor | 960 SFT | Different Solvent Dispensing | |
| 20. | Banglow | Ground Floor to 1 st Floor | 3,200 SFT | Residents | |

3) Plant & Machinery, Office Equipment and Other Assets:

After visiting the factory site, we are absolutely convinced with their reports. The machineries list are as follows:

| Sl. | Name of Machinery | Quantity |
|-----|--|----------|
| 1 | Air Handling Unit | 1 Set |
| 2 | Air & Steam Mixture Sterilizer | 1 Set |
| 3 | Air Compressor | 4 Sets |
| 4 | Air Cooler | 3 Sets |
| 5 | Air Curtain | 3 Sets |
| 6 | Air Filters | 1 Set |
| 7 | Air Shower | 2 Sets |
| 8 | Ampoules Washing Machine | 1 Set |
| 9 | Analytical Balance | 2 Sets |
| 10 | Atomic Absorption Spectrophotometer | 1 Set |
| 11 | Auto Sealer | 1 Set |
| 12 | Autoclave | 1 Set |
| 13 | Auto-Feeder | 1 Set |
| 14 | Automatic Capsule Filling Machine | 5 Sets |
| 15 | Automatic Cartoning Machine | 2 Sets |
| 16 | Automatic Horizontal Cartoning Machine | 2 Set |
| 17 | Automatic Eight Head Ampoule Filling & Sealing Machine | 1 Set |
| 18 | Automatic Tube Filling Machine | 1 Set |
| 19 | Automatic Soft Gelatin Encapsulation Line | 1 Set |
| 20 | Automatic Polari Meter | 1 Set |
| 21 | Automatic Sticker Labeling Machine | 1 Set |
| 22 | Batch Printer Machine | 1 Set |

| | | |
|----|---|--------|
| 23 | Blister Packing Machine | 1 Set |
| 24 | Bio Safety Cabinet | 3 Sets |
| 25 | Blender Machine | 5 Sets |
| 26 | Boiler | 1 Set |
| 27 | Bottle Dryer | 1 Set |
| 28 | Bottle Visual Checking | 1 Set |
| 29 | Blow Molding Machine | 1 Set |
| 30 | Bottle Blowing Mold | 1 Set |
| 31 | Bottle Dryer | 1 Set |
| 32 | Brand New Single Layer Tank | 1 Set |
| 33 | Brand new FT-IR Spectrome Meter System | 1 Set |
| 34 | Cap Dispensing and Capping Machine | 1 Set |
| 35 | Cap Sealing | 1 Set |
| 36 | Caplet shaped Die Punch Oval | 1 Set |
| 37 | Capping Machine | 1 Set |
| 38 | Carbon Analyzer Model-TOC LCPH | 1 Set |
| 39 | Cutter & Chopper Machine | 2 Sets |
| 40 | Chiller Machine | 5 Sets |
| 41 | Coating Machine | 1 Set |
| 42 | Cold Room Equipment | 1 Set |
| 43 | Chars Normal Paper Printer | 1 Set |
| 44 | Chars Normal Paper Printer | 1 Set |
| 45 | Chromatography Machine | 1 Set |
| 46 | Compressor | 1 Set |
| 47 | Complete Shanghai Mitsubishi Lifts | 1 Set |
| 48 | Conductively Meter Bench type with Printer System | 1 Set |
| 49 | Computerized System Suspended Particles Machinery Monitoring System with Standard Accessories | 1 Set |
| 50 | Cooling Tower | 4 Sets |
| 51 | Control Panel | 1 Set |
| 52 | Crusher; | 1 Set |
| 53 | De-Foiling Machine | 6 Sets |
| 54 | Die Punch | 2 Sets |
| 55 | Desktop Liquid Filling Line | 1 Set |
| 56 | Dihumidifier | 1 Set |
| 57 | Digital Incubator | 1 Set |
| 58 | Digital Thermo-Hygrometer | 1 Set |
| 59 | Digital Refractometer | 1 Set |
| 60 | Disintegration Tester | 1 Set |
| 61 | Dispensing Booth | 2 Sets |
| 62 | Double Door Autoclave | 2 Sets |
| 63 | Disposable syringe Assembling Machine with Standard Accessories; | 1 Set |
| 64 | Dissolution Tester DIS | 1 Set |
| 65 | Dry Granulating Line | 4 Sets |
| 66 | Dry Heat Sterilizer (Tunnel) | 1 Set |
| 67 | Drum Stacker | 1 Set |
| 68 | Ducting Works | 1 Set |
| 69 | Dry Powder Filling-Stoppering Capping Machine | 1 Set |
| 70 | Effluent Treatment Plant-ETP | 3 Sets |
| 71 | Electronic Balance | 5 Sets |
| 72 | Electrochemistry Meters | 1 Set |
| 73 | Equipment and Spare Parts | 1 Set |
| 74 | Electrophoresis Instrument | 1 Set |

| | | |
|-----|--|--------|
| 75 | Electric De-Humidifier | 1 Set |
| 76 | Filling and Plugging Machine for Syringes | 4 Sets |
| 77 | Fire Alarm Equipment | 3 Sets |
| 78 | Fire Hydrant Systems | 1 Set |
| 79 | Filling Sealing Machine | 4 Sets |
| 80 | Fluid Bed Dryer | 3 Sets |
| 81 | Freezer/Refrigerator | 5 Sets |
| 82 | Friability Tester | 1 Set |
| 83 | Generator | 6 Sets |
| 84 | Gas Steriliser; | 1 Set |
| 85 | Gas Chromatography System/GC | 1 Set |
| 86 | Hand Pallet | 2 Sets |
| 87 | Heat Exchanger | 4 Sets |
| 88 | High Pressure Homogenizers | 5 Sets |
| 89 | Heat-Shrink Wrapping Machine | 2 Sets |
| 90 | Hooping Blister Machine | 2 Sets |
| 91 | HPLC System | 5 Sets |
| 92 | HVAC System | 6 Sets |
| 93 | Horizontal Sachet Packing Machine | 1 Set |
| 94 | Hopper Dryer | 1 Set |
| 95 | IKA Inline Homogenizer with Accessories | 2 Sets |
| 96 | Isolator Machine | 4 Sets |
| 97 | Incinerator | 1 Set |
| 98 | Injection Molding Molding Machine with Standard Accessories | 1 Set |
| 99 | Injectable Powder Filling Producing Line with all Standard Accessories | 1 Set |
| 100 | Jucaí Screw Air Compressor | 2 Sets |
| 101 | Jucaí Freezing Air Dryer | 2 Sets |
| 102 | Jucaí Line Filter | 2 Sets |
| 103 | Line Filter | 1 Set |
| 104 | Linear Vial Washing Machine | 4 Sets |
| 105 | Leak Test Apparatus Digital | 1 Set |
| 106 | Leaflet Folding Machine | 1 Set |
| 107 | Magnehelic Pressure Gauge | 3 Sets |
| 108 | Mean Droplet Size Analyzer | 1 Set |
| 109 | Magnetic Stirrer | 1 Set |
| 110 | Melting Point Apparatus | 1 Set |
| 111 | Material Handling Devices For Compression Machine and Roll Compactor | 1 Set |
| 112 | Mixture Machine | 2 Sets |
| 113 | Microprocessor | 1 Set |
| 114 | Micropipette (1 Set000 uL) | 1 Set |
| 115 | Milling Machine & Surface Grinding Machine | 1 Set |
| 116 | Moisture Analyzer | 5 Sets |
| 117 | Multicolumn Distillation Plant | 1 Set |
| 118 | Multi Mill | 1 Set |
| 119 | Oven | 5 Sets |
| 120 | Passenger Elevator | 4 Sets |
| 121 | Pass Box | 1 Set |
| 122 | Packing/Wrapping Machinery | 6 Sets |
| 123 | pH Meter | 1 Set |
| 124 | Pharmaceuticals Machinery | 2 Sets |
| 125 | Powder Filling & Capping Machine | 2 Sets |

| | | |
|-----|--|---------|
| 126 | Pressure Vessel | 4 Sets |
| 127 | Pressing Stamping Punching | 1 Set |
| 128 | Printing Machine | 4 Sets |
| 129 | Portable, Air Sampler Unit | 1 Set |
| 130 | PLC for Table Compression Machine & Servo Driver for Sachet Machine | 1 Set |
| 131 | Powder Packing, Multi-Type Grinding & Centrifugal oil Filter Machine | 1 Set |
| 132 | Pro-series Top Mount sand Filter | 1 Set |
| 133 | Quality Control Equipment | 5 Sets |
| 134 | Roller Compactor Machine | 2 Sets |
| 135 | Rotary Bottle Washing Machine | 2 Sets |
| 136 | Rotary Tablet Press Machine | 3 Sets |
| 137 | Sampling Booth | 5 Sets |
| 138 | Sandwich panel System-HVAC System | 20 Sets |
| 139 | Sartorius Analytical Balance | 1 Set |
| 140 | Servo Drive | 2 Sets |
| 141 | Semi Filling Machine Semi Capping Machine | 1 Set |
| 142 | Shell & Tube Evaporator | 6 Sets |
| 143 | SS Vessel with Lid | 2 Sets |
| 144 | SS 31 Set6 Check Valves Size 6" | 1 Set |
| 145 | Spare Parts | 24 Sets |
| 146 | Spectrophotometer | 7 Sets |
| 147 | Stability Chamber | 4 Sets |
| 148 | Storage Tank | 2 Sets |
| 149 | Storage Vessel | 2 Sets |
| 150 | Superior Universel Pump, sup300 series | 1 Set |
| 151 | Surface Skimmer | 1 Set |
| 152 | Sugar Crushing Machine | 1 Set |
| 153 | Substation 5000 KVA | 1 Set |
| 154 | Tablet compression machine | 4 Sets |
| 155 | Tablet Press Machine | 2 Sets |
| 156 | Tablet Hardness Tester | 3 Sets |
| 157 | Touch Sreen & Module for Coating Machine | 1 Set |
| 158 | Tablet Coating Machine | 1 Set |
| 159 | Transformer | 1 Set |
| 160 | Triple Jacketed Heating Vessel with Stirrer | 1 Set |
| 161 | Tapped Density Tester | 1 Set |
| 162 | Tray Dryer for Bottle Drying | 4 Sets |
| 163 | Ultraviolet-Visible Spectroscopy | 1 Set |
| 164 | Ultrasonic | 1 Set |
| 165 | Vacuum Cleaner | 2 Sets |
| 166 | Versaflo Powered Air Turbo | 1 Set |
| 167 | Vial Washing, Sterilizing & Depyrogenic Machine/Dry Heat Sterilizer | 8 Sets |
| 168 | Vortex Mixer | 1 Set |
| 169 | Vocuum Pump & Vacuum Filtration | 1 Set |
| 170 | Vibro Sifter Machine | 1 Set |
| 171 | Vial Filling Stoppering & Capping Line | 2 Sets |
| 172 | Water Chiller | 2 Sets |
| 173 | Water Purifying Machine | 6 Sets |
| 174 | Wastage Gas Treatment Machine | 1 Set |
| 175 | Water Treatment & Multicolumn Distillation Plant | 1 Set |
| 176 | Water Filtering or Purifying Machine of Sterilisers | 1 Set |

| | | |
|-----|----------------------------|--------|
| 177 | Wall Inlet & Main Inlet | 1 Set |
| 178 | Water Cooled Screw Chiller | 1 Set |
| 179 | Water Flow Meter | 1 Set |
| 180 | Washing Machine | 3 Sets |
| 181 | Weighing Balance | 1 Set |

Besides, these assets, we have also found other assets like furniture & fixture, office equipment, laboratory equipment, motor vehicle, electric equipments are available in project area.

It is also mentionable here that during our visit, we also checked inventory register and roster (workers' duty register) and found total 1,490 numbers of employees and workers. we also noticed that all machineries of Techno Drugs Ltd. are in good condition and running well.

Signboard:

The signboards of the company are displayed at the registered office and factory premises and there is no other office/factory within the said factory premises.

Sd/-

Ahmed Arefin FCA
Managing Director
EBL Investments Limited

Sd/-

Md. Salauddin Sikder FCMA
CEO & Managing Director
Imperial Capital Limited

(xiv) If the issuer is entitled to any intellectual property right or intangible asset, full description of the property, whether the same are legally held by the issuer and whether all formalities in this regard have been complied with;

The Company has no intellectual property right.

(xv) Full description of other properties of the issuer;

Fixed assets:

| Sl. | Particulars | Written Down Value |
|-----|----------------------|--------------------|
| 1 | Furniture & Fixture | 22,026,432 |
| 2 | Office Equipment | 3,664,922 |
| 3 | Laboratory Equipment | 5,367,390 |
| 4 | Motor vehicle | 1,859,828 |
| 5 | Electric Equipments | 63,498,350 |

Intangible assets:

| Sl. | Particulars | Written Down Value |
|--------------|--------------|--------------------|
| 1 | ERP Software | 7,222,755 |
| Total | | 7,222,755 |

(f) Plan of Operation and discussion of Financial Condition:

The issuer's revenue and results from operation, financial position and changes in financial position and cash flows for the last five years:

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|--|----------------------|----------------------|----------------------|----------------------|----------------------|
| RESULTS FROM OPERATION | | | | | |
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Cost of Goods Sold | (1,573,642,291) | (3,213,382,241) | (2,380,115,347) | (1,183,126,627) | (1,275,677,113) |
| Gross Profit | 1,159,834,813 | 1,815,159,593 | 1,461,264,210 | 830,772,839 | 889,124,664 |
| Operating Expenses | (620,877,889) | (883,212,585) | (614,677,429) | (333,125,586) | (366,112,860) |
| Profit from Operation | 538,956,924 | 931,947,008 | 846,586,781 | 497,647,253 | 523,011,804 |
| Finance Expenses | (269,811,323) | (261,303,536) | (242,398,585) | (195,084,678) | (152,458,437) |
| Other Income | 2,859,050 | 12,929,115 | 18,349,561 | 27,964,502 | 17,763,058 |
| Profit before WPPF and Tax | 272,004,652 | 683,572,587 | 622,537,756 | 330,527,077 | 388,316,425 |
| Contribution to WPPF | (12,952,602) | (32,551,076) | (29,644,655) | (15,739,385) | (18,491,258) |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Income Tax Expenses | (63,545,690) | (171,243,084) | (231,950,271) | (151,178,609) | (143,543,201) |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |
| Earnings Per Share (Basic) | 2.08 | 5.10 | 3.91 | 2.32 | 3.36 |
| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
| CHANGES IN FINANCIAL POSITION | | | | | |
| Non-Current Assets: | 3,825,522,959 | 3,495,222,379 | 2,627,133,139 | 2,334,517,554 | 1,858,747,915 |
| Current Assets | 2,215,732,793 | 1,868,788,859 | 1,756,544,720 | 1,448,978,606 | 1,117,626,314 |
| Total Assets | 6,041,255,752 | 5,364,011,238 | 4,383,677,859 | 3,783,496,160 | 2,976,374,229 |
| Shareholders' Equity | 2,612,349,279 | 2,432,399,449 | 1,449,626,603 | 1,019,923,774 | 781,198,589 |
| Share Capital | 941,574,000 | 941,574,000 | 818,760,000 | 687,600,000 | 99,600,000 |
| Revaluation Surplus | 487,437,890 | 502,994,419 | - | - | - |
| Retained Earnings | 1,183,337,389 | 987,831,030 | 630,866,603 | 269,923,774 | 681,598,589 |
| Non-Current Liabilities | 1,304,960,954 | 1,197,406,594 | 1,215,988,087 | 1,195,601,870 | 1,089,024,650 |
| Current Liabilities | 2,123,945,519 | 1,734,205,195 | 1,718,063,169 | 1,567,970,516 | 1,106,150,990 |
| Total Equity and Liabilities | 6,041,255,752 | 5,364,011,238 | 4,383,677,859 | 3,783,496,160 | 2,976,374,229 |
| Net Asset Value (NAV) per share | 27.74 | 25.83 | 17.71 | 14.83 | 78.43 |
| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
| CHANGES IN CASH FLOWS | | | | | |
| Net Cash from Operating Activities | 210,097,920 | 593,052,719 | 277,793,974 | 151,868,870 | 119,274,770 |
| Net Cash Used in Investing Activities | (654,041,154) | (400,570,608) | (440,784,102) | (626,122,468) | (786,359,468) |
| Net Cash Flows from Financing Activities | 338,476,742 | (90,090,599) | (24,198,413) | 521,976,625 | 711,391,828 |

(a) Internal and external sources of cash;

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|---|----------------------|----------------------|----------------------|----------------------|----------------------|
| Internal Sources of Cash | | | | | |
| Share Capital | 941,574,000 | 941,574,000 | 818,760,000 | 687,600,000 | 99,600,000 |
| Share Money Deposit | - | - | - | 62,400,000 | - |
| Retained Earnings | 1,183,337,389 | 987,831,030 | 630,866,603 | 269,923,774 | 681,598,589 |
| Sub-Total | 2,124,911,389 | 1,929,405,030 | 1,449,626,603 | 1,019,923,774 | 781,198,589 |
| External Sources of Cash | | | | | |
| Long Term Loan Net of Current Maturity | 1,055,549,905 | 973,761,159 | 1,024,205,653 | 1,043,887,568 | 1,014,532,784 |
| Lease Liabilities Net of Current Maturity | 32,920,433 | 32,193,314 | 27,347,857 | 29,557,002 | - |
| Current Maturity of Lease Liabilities | 27,757,903 | 21,268,354 | 18,063,586 | 13,679,741 | - |
| Current Maturity of Long Term Loan | 414,024,638 | 474,435,457 | 367,396,794 | 326,326,115 | 132,001,931 |
| Short Term Loan | 1,187,853,989 | 854,577,233 | 975,586,918 | 1,070,939,386 | 831,927,129 |
| Sub-Total | 2,718,106,868 | 2,356,235,516 | 2,412,600,806 | 2,484,389,812 | 1,978,461,844 |
| Grand Total | 4,843,018,257 | 4,285,640,546 | 3,862,227,409 | 3,504,313,585 | 2,759,660,433 |

(b) **Any material commitments for capital expenditure and expected sources of funds for such expenditure;**

The Company has not yet made any material commitment for capital expenditure except for those that are mentioned in Chapter (XXII) under the head 'Use of Proceeds' from IPO fund.

(c) **Causes for any material changes from period to period in revenues, cost of goods sold, other operating expenses and net income;**

The company's revenue as well as direct costs and net income have continued to change due to increasement of providing services.

| Particular | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|----------------------|------------------|------------------|------------------|------------------|------------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Cost of Goods Sold | 1,573,642,291 | 3,213,382,241 | 2,380,115,347 | 1,183,126,627 | 1,275,677,113 |
| Operating Expenses | 620,877,889 | 883,212,585 | 614,677,429 | 333,125,586 | 366,112,860 |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |

Causes for changes:

Revenues:

30-Jun-2019: Revenue was increased by 43.45% in 2019 from 2018. This is normal business growth.

30-Jun-2020: Revenue was decreased by 6.97% in 2020 from 2019. Due to Covid-19 and international crisis.

30-Jun-2021: Revenue was increased by 90.74% in 2021 from 2020. This is normal business growth due to increase in tender sales to Govt. and starts commercial production from new plant.

30-Jun-2022: Revenue was increased by 30.90% in 2022 from 2021. This is normal business growth.

30-Jun-2023: Revenue was decreased by 45.64% in 2023 from 2022. The Company's major sales come from the Govt. tender but this financial year Govt. did not call any tender, on the other hand from November 2022 the fall of opening of LC due to Dollar reserve matter.

Cost of Goods Sold:

30-Jun-2019: Direct cost of the company has been increased 43.23% in 2019 from 2018 due to increase of sales.

30-Jun-2020: Direct cost of the company has been decreased 7.26% in 2020 from 2019 due to decrease of sales.

30-Jun-2021: Direct cost of the company has been increased 101.17% in 2021 from 2020 due to increase of sales.

30-Jun-2022: Direct cost of the company has been increased 35.01% in 2022 from 2021 due to increase of sales.

30-Jun-2023: Direct cost of the company has been decreased 51.03% in 2023 from 2022 due to decrease of sales.

Other operating expenses:

The company has incurred business administrative expense during the last five years which is regular and relevant with sales.

Net income:

The growth of net profit after Tax is consistent with the growth of revenue. No unusual change has been occurred during the last five years on the above matters except in the year 2020 and 2023.

Earnings per share are properly calculated through using weighted average number of ordinary shares for each year.

(d) Any seasonal aspects of the issuer's business;

As the products of pharmaceuticals industry are of basic in nature and mainly antidiabetic, cardiovascular and nervous system modulators, Bangladesh Pharma market is consistent with population and economic growth

(e) Any known trends, events or uncertainties that may have material effect on the issuer's future business;

The Pharmaceutical industry has a 5 years' CAGR of 15.6%, the sector is predicted to grow to \$5.11 billion by 2023. The key growth drivers are - growing GNI per Capita, population growth, changing disease profile, lifestyle change and rapid urbanization.

Besides local market, contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition, pandemic etc. can affect the business as well.

(f) Any assets of the company used to pay off any liabilities;

None of the assets of the company has been disposed to pay off any liabilities of the Company.

(g) Any loan taken from or given to any related party or connected person of the issuer with details of the same;

The Company did not take or give any loan from or to any related party or connected person of the issuer from its inception.

(h) Any future contractual liabilities the issuer may enter into within next one year, and the impact, if any, on the financial fundamentals of the issuer;

The Company has no plan to enter into any contract creating future liabilities for the Company except for those that are created in the normal course of business activities.

(i) The estimated amount, where applicable, of future capital expenditure;

The company has a plan to incur capital expenditure by using IPO Proceeds, which have been stated in section 'Use of IPO proceeds and projects implementation schedule'.

- (j) **Any VAT, income tax, customs duty or other tax liability which is yet to be paid, including any contingent liabilities stating why the same was not paid prior to the issuance of the prospectus. Updated income tax status for the last 5 years or from commercial operation, which is shorter;**

VAT: There is no VAT liability of the Company as on 30 June, 2023 except the contingent liabilities mentioned below:

| Sl. | Details of Litigation | VAT Demand (Tk.) | Status |
|-----|---|------------------|---|
| 1. | Mismatch of Vat able & non VAT able items | 378,540,702.69 | Under process for appeal to the High Court. |

Customs Duty or other tax liabilities: There is no customs duty and Excise Duty Liability of the Company as on 30 June, 2023.

Income Tax: The TIN number of the company is 353088771582/Circle-157, Taxes Zone-8, Dhaka. Following are the details of income tax related information of the Company:

| Accounting year | Assessment Year | Assessment Status |
|-----------------|-----------------|--|
| 2018-2019 | 2019-2020 | As per certificate given by DCT dated 04.03.2020 of Taxes Circle-157, Taxes Zone-8, Dhaka, the Company's income tax assessment has been completed for the assessment year 2019-2020 under section 82C/83(2). |
| 2019-2020 | 2020-2021 | As per certificate given by DCT dated 22.03.2021 of Taxes Circle-157, Taxes Zone-8, Dhaka, the Company's income tax assessment has been completed for the assessment year 2020-2021 under section 82C/83(2). |
| 2020-2021 | 2021-2022 | As per certificate given by DCT dated 10.01.2022 of Taxes Circle-157, Taxes Zone-8, Dhaka, the Company's income tax assessment has been completed for the assessment year 2021-2022 under section 82C/83(2). |
| 2021-2022 | 2022-2023 | Return submitted on 20-03-2023 and assessment is under process. |
| 2022-2023 | 2023-2024 | Return will be submitted on due time. |

- (k) Any financial commitment, including lease commitment, the company had entered into during the past five years or from commercial operation, which is shorter, giving details as to how the liquidation was or is to be affected;

Financial and Lease commitments during last five years

For the period ended 30 June, 2023

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2023 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,159,059,574 | 9.00% | 131,939,451 | 1,448,824 |
| AB Bank Ltd. | | | - | | 15,616 | - |
| IPDC Finance Ltd. | | | 40,201,612 | | 3,721,970 | - |
| Community Bank Ltd. | | | 205,642,095 | | 18,598,975 | 3,203,792 |
| IDLC Finance Ltd. | | | 64,671,262 | | 464,300 | 464,300 |
| Sub-Total | | | 1,469,574,542 | | 153,811,711 | 4,652,616 |
| One Bank Ltd. | Lender | Short Term | 591,127,427 | 9.00% | 32,620,001 | 30,805,539 |
| AB Bank Ltd. | | | 434,851,184 | 9.00% | 38,846,472 | - |
| LANKAN Alliance Finance Ltd. | | | 100,000,000 | 11.00% | 9,083,152 | 916,667 |
| Lanka Bangla Finance Ltd. | | | 40,310,107 | 9.50% | 3,437,193 | 679,051 |
| Meridian Finance Ltd. | | | 21,565,271 | 9.50% | 2,254,504 | 336,637 |
| Sub-Total | | | 1,187,853,989 | | 86,241,322 | 32,737,894 |
| Bank Charge & Other Fee | | | | | 5,936,791 | |
| Sub-Total | | | 2,657,428,532 | | 245,989,824 | |
| IPDC Finance Ltd. | Lender | Lease | 35,006,325 | | 6,113,943 | - |
| Grand Total | | | 2,692,434,856 | | 252,103,767 | 37,854,809 |

For the period ended 30 June, 2022

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2022 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|---------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,118,509,095 | 9.00% | 109,616,894 | 20,147,254 |
| AB Bank Ltd. | | | 2,343,657 | | 3,065,737 | - |
| IPDC Finance Ltd. | | | 45,333,069 | | 2,598,495 | - |
| Community Bank Ltd. | | | 282,010,796 | | 13,661,418 | - |
| Sub-Total | | | 1,448,196,617 | | 128,942,544 | 20,147,254 |
| One Bank Ltd. | Lender | Short Term | 472,233,344 | 9.00% | 39,657,122 | - |
| AB Bank Ltd. | | | 282,343,889 | 9.00% | 58,730,770 | - |

| | | | | | | |
|------------------------------------|--------|-------|----------------------|--------|--------------------|-------------------|
| LANKAN Alliance Finance Ltd. | | | 100,000,000 | 10.50% | 3,500,000 | - |
| Sub-Total | | | 854,577,233 | | 101,887,892 | - |
| Bank Charge & Other Fee | | | | | 4,696,717 | |
| Sub-Total | | | 2,302,773,849 | | 235,527,153 | |
| IPDC Finance Ltd. | Lender | Lease | 35,141,199 | | 5,629,130 | - |
| Grand Total | | | 2,337,915,048 | | 241,156,283 | 20,147,254 |

For the period ended 30 June, 2021

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2021 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,324,203,243 | 9.00% | 130,183,356 | - |
| AB Bank Ltd. | | | 67,399,204 | 9.00% | 10,523,564 | - |
| Sub-Total | | | 1,391,602,447 | | 140,706,920 | - |
| One Bank Ltd. | Lender | Short Term | 502,899,507 | 9.00% | 41,637,753 | - |
| AB Bank Ltd. | | | 472,687,411 | 9.00% | 54,912,320 | - |
| Sub-Total | | | 975,586,918 | | 96,550,073 | - |
| Bank Charge & Other Fee | | | | | 329,695 | |
| Sub-Total | | | 2,367,189,364 | | 237,586,688 | |
| IPDC Finance Ltd. | Lender | Lease | 15,836,070 | 10.75% | 4,811,897 | - |
| Grand Total | | | 2,383,025,434 | | 242,398,585 | - |

For the period ended 30 June, 2020

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2020 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,217,922,644 | 13.00% | 37,168,695 | - |
| AB Bank Ltd. | | | 152,291,039 | 11.00% | 26,632,553 | - |
| Sub-Total | | | 1,370,213,683 | | 63,801,248 | - |
| One Bank Ltd. | Lender | Short Term | 527,910,835 | 13.00% | 43,408,385 | - |
| AB Bank Ltd. | | | 507,282,569 | 14.00% | 83,442,997 | - |
| Reliance Finance Ltd | | | 35,745,982 | 0.00% | 4,196,588 | - |
| Sub-Total | | | 1,070,939,386 | | 131,047,970 | - |
| Bank Charge & Other Fee | | | | | 235,460 | |
| Grand Total | | | 2,441,153,069 | | 195,084,678 | - |

For the period ended 30 June, 2019

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2019 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 915,731,244 | 13.00% | - | - |
| AB Bank Ltd. | | | 230,803,471 | 11.00% | 38,713,653 | - |
| Sub-Total | | | 1,146,534,715 | | 38,713,653 | - |
| One Bank Ltd. | Lender | Short Term | 361,856,730 | 13.00% | 20,592,074 | - |
| AB Bank Ltd. | | | 470,070,399 | 14.50% | 93,052,560 | - |
| Sub-Total | | | 831,927,129 | | 113,644,634 | - |
| Bank Charge & Other Fee | | | | | 100,150 | |
| Grand Total | | | 1,978,461,844 | | 152,458,437 | - |

(I) **Details of all personnel related schemes for which the company has to make provision for in future years;**

The company maintains Short Term Employee Benefits as per IAS 19 Employee Benefits. The cost of employee benefit is charged of as revenue expenditure in the period to which the contributions relate.

Short Term Employee Benefits:

Short-term employee benefits include wages, salaries, festival bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

Workers Profit Participation Fund (WPPF)

The company has created a fund for workers "Workers Profit Participation Fund (WPPF)" as per Bangladesh Labor Act, 2006 (Amended up to 2018) by 5% of profit after charging such expenses.

(m) Break down of all expenses related to the public issue;

The following amount to be paid to the Issue Managers, Underwriters and other costs are as follows:

| Sl. | Particulars | Basis | Amount in BDT (approx.) | |
|-----------|---|---|-------------------------|-----------|
| A. | MANAGERS TO THE ISSUE FEES | | | 3,450,000 |
| 1 | Managers to the Issue fee | Zero point Three percent of the public offer amount | 3,000,000 | |
| 2 | VAT against Issue Management Fees | 15% of issue management fees | 450,000 | |
| B. | FEES RELATED TO LISTING WITH THE STOCK EXCHANGES | | | 6,732,121 |
| 3 | Draft prospectus scrutiny fee for DSE & CSE | Fixed | 100,000 | |
| 4 | DSE and CSE Annual Fee | @ 0.05% on Tk. 100 Crore of paid-up capital and 0.02% on the rest amount of paid-up capital; (minimum Tk. 50 thousand and Maximum Tk. 6 lacs for each exchanges | 1,121,426 | |
| 5 | Fees related to Listing with the stock exchanges | @ 0.25% on Tk. 10 Crore and 0.15% on the rest amount of paid up capital range; (minimum 50 thousand and maximum Tk. 1 crore for each exchanges) | 4,110,695 | |
| 6 | Data Transmission Fee for DSE & CSE | Fixed | 400,000 | |
| 7 | Electronic Bidding Fee | Estimated (To be paid at actual) | 1,000,000 | |
| C. | BSEC FEES | | | 4,050,000 |
| 8 | Application fee | Fixed | 50,000 | |
| 9 | Consent fee | fee @ 0.40% on entire offer | 4,000,000 | |
| D. | IPO RELATED FEES | | | 1,464,615 |
| 10 | Underwriting Commission (0.50%) | Commission @ 0.50% on Underwritten Amount | 969,231 | |
| 11 | VAT against Underwriting Commission | 15% of Underwriting Commission | 145,385 | |
| 12 | Auditors Certification fees | At Actual | 250,000 | |
| 13 | Credit Rating Fees | At Actual | 100,000 | |
| E. | CDBL FEES AND EXPENSES | | | 899,736 |
| 14 | Security Deposit | At Actual | 500,000 | |
| 15 | Documentation fee | At Actual | 2,500 | |
| 16 | Annual fee | At Actual | 100,000 | |
| 17 | Connection Fee (TK. 500 per month* 12) | At Actual | 6,000 | |
| 18 | Initial Public Offering fee | @.015% of issue size+.015% of Pre-IPO paid up capital | 291,236 | |

| F. | PRINTING AND POST PUBLIC OFFER EXPENSES | | | 13,403,528 |
|--------------------|--|------------------------------------|-----------|-------------------|
| 19 | Registrar to the Issue Fees | At Actual | 800,000 | |
| 20 | VAT against Registrar to the Issue Fees | 15% on Registrar to the Issue Fees | 120,000 | |
| 21 | Publication of prospectus | Estimated (to be paid at actual) | 1,500,000 | |
| 22 | Abride Version of Prospectus and Notice in 4 daily news paper | Estimated (to be paid at actual) | 800,000 | |
| 23 | Notice for prospectus, Lottery, Refund etc. in 4 daily news paper | Estimated (to be paid at actual) | 500,000 | |
| 24 | Share Software charge & Data Processing, Allotment and Refund etc. | Estimated (to be paid at actual) | 5,000,000 | |
| 25 | Road Show related expenses | Estimated (to be paid at actual) | 2,500,000 | |
| 26 | Stationary & Other Expenses | Estimated (to be paid at actual) | 2,183,528 | |
| Grand Total | | | | 30,000,000 |

Note: The estimated IPO expenses will be paid at actual and any excess adjustment will be paid from own source.

- (n) **If the issuer has revalued any of its assets, the name, qualification and experiences of the valuer and the reason for the revaluation, showing the value of the assets prior to the revaluation separately for each asset revalued in a manner which shall facilitate comparison between the historical value and the amount after revaluation and giving a summary of the valuation report along with basis of pricing and certificates required under the revaluation guideline of the Commission;**

Revaluation of Land and Land Developments

As per IAS16: Property, Plant and Equipment paragraph 34, "the frequency of revaluations depends upon the changes in fair values of the items of property, plant and equipment being revalued. When the fair value of a revalued asset differs materially from its carrying amount, a further revaluation is required. Some items of property, plant and equipment experience significant and volatile changes in fair value, thus necessitating annual revaluation. Such frequent revaluations are unnecessary for items of property, plant and equipment with only insignificant changes in fair value. Instead, it may be necessary to revalue the item only every thereof five years." To comply with the above paragraph, The Company made its first valuation of Land and Land Development, on 31 December 2021 by an independent valuer to reflect fair value (Market Approach) thereof following 'Current Cost Method' as per IFRS-13 'Fair Value Measurement'

| Particulars of Assets | Name of Valuer | Qualification of the Valuer | Date of Revaluation | Carrying amount of Assets | Value of the assets after revaluation | Revaluation Surplus in 30.06.2023 |
|------------------------------|-----------------------|------------------------------------|----------------------------|----------------------------------|--|--|
| Land and Land Development | G.KIBRIA & CO. | Chartered Accountants | 31-Dec-21 | 170,244,053 | 688,795,000 | 518,550,947 |

The increase in the carrying amount of revalued assets is recognized in the separate component of equity as Revaluation Surplus. However, the increase recognized in the Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2022. Other Non-Current Assets were kept outside the scope of the revaluation works. These are expected to be realizable at written down value (WDV) as mentioned in the statement of Financial Position of the company. The Company revalued its Land and Land Development as per valuation guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC) dated on 18th August 2013 clause 09 Part A.

AUDITOR'S ADDITIONAL DISCLOSURE ON REVALUATION OF LAND & LAND DEVELOPMENT OF TECHNO DRUGS LTD.

This is to certify that revaluation of Land & Land Development of Techno Drugs Limited incorporate it in the statements of financial position as at 30 June 2022 carried out by independent valuer G. KIBRIA & CO., Chartered Accountants have been made and report has been prepared in accordance with Bangladesh Accounting Standards (BAS) and Bangladesh Financial Reporting Standards (BFRS) and other applicable laws, rules, regulations and guidelines. We also certify that proper accounting treatments, including provisions, tax and other liabilities have been made; revaluation reserve has been created in the financial statements to consider the valuation as per applicable rules and standards.

Place: Dhaka
Date: September 27, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

- (o) Where the issuer is a holding or subsidiary company, full disclosure about the transactions, including its nature and amount, between the issuer and its subsidiary or holding company, including transactions which had taken place within the last five years of the issuance of the prospectus or since the date of incorporation of the issuer, whichever is later, clearly indicating whether the issuer is a debtor or a creditor;

The Company has no holding or subsidiary company.

- (p) Financial Information of Group Companies and Companies under common ownership by more than 50%: following information for the last three years based on the audited financial statements, in respect of all the group companies of the issuer, wherever applicable, along with significant notes of auditors:

The Company has no subsidiary nor it is operated under a holding company and it does not have any associated company.

- (q) Where the issuer is a banking company, insurance company, non-banking financial institution or any other company which is regulated and licensed by another primary regulator, a declaration by the board of directors shall be included in the prospectus stating that all requirements of the relevant laws and regulatory requirements of its primary regulator have been adhered to by the issuer;

Not applicable.

- (r) A report from the auditors regarding any allotment of shares to any person for any consideration otherwise than cash along with relationship of that person with the issuer and rationale of issue price of the shares;

AUDITOR'S CERTIFICATE REGARDING ANY ALLOTMENT OF SHARES TO PROMOTERS OR SPONSOR SHAREHOLDERS FOR ANY CONSIDERATION OTHER THAN IN CASH

The Company issued the following ordinary shares for consideration in other than cash:

Net Assets:

| Date of issue | Person to whom those are issued | No. of shares allotted | Relationship with the issuer | Issue price | Consideration & Valuation | Reasons for the issue | Benefit from the issue |
|---------------|---------------------------------|------------------------|------------------------------|-------------|---------------------------|-----------------------|--|
| 8-Sep-12 | Shahjalal Uddin Ahmed | 8,000,000 | Managing Director | Tk. 10.00 | Other than Cash | To acquire net assets | Acquisition of net assets as well as operational and products licenses |

Bonus:

| Date of issue | Persons to whom those are issued | No. of shares allotted | Relationship with the issuer | Issue price | Consideration & Valuation | Reasons for the issue | Benefit from the issue |
|---------------|----------------------------------|------------------------|------------------------------|-------------|---------------------------|------------------------------------|---------------------------------|
| 7-Jan-20 | All existing shareholders | 57,300,000 | Shareholder | Tk. 10.00 | Bonus | Distribution of accumulated profit | Enhancements of working capital |
| 30-Dec-21 | | 12,281,400 | | | | | |

Place: Dhaka
Date: September 27, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

- (s) **Any material information, which is likely to have an impact on the offering or change the terms and conditions under which the offer has been made to the public;**

There is no material information, which is likely to have an impact on the offering or change the terms and conditions under which the offer has been made to the public.

- (t) **Business strategies and future plans - projected financial statements shall be required only for companies not started commercial operation yet and authenticated by Chairman, two Directors, Managing Director, CFO, and Company Secretary;**

Strategies:

Business strategy refers to a framework wherein a company develops action and tactical plans depending on the company's goals and objectives. Business strategies help in decision making processes which in turn support different departmental needs all working together to achieve the overall objectives of a company.

Techno Drugs Ltd. considers the following as its business strategies:

Improvement of Local Market Share

Techno Drugs Ltd. since its inception has been giving importance to ensuring the availability of locally manufactured and quality pharmaceutical products in Bangladesh. As a result, Techno Drugs always focuses on improving the local market share of its pharmaceutical products.

Expand in the International Market Scene

Techno Drugs Ltd. emphasizes on manufacturing quality and innovative pharmaceutical products and increase exports to expand into the international market.

Innovate and Develop Quality Pharmaceutical Products

Techno Drugs Ltd. since inception has been inclined towards developing and manufacturing innovative and high-quality pharmaceutical products. Techno Drugs started production of Anti-Cancer medicines for the first time in the country when the country depended on imported Oncology medicines at that time.

Revolutionize and Leverage Hormonal Medicine

Techno Drugs Ltd. is a major manufacturer of Hormonal medicine. In addition to that the company is the fifth Contraceptive Implant manufacturer in the world and the first of its kind in Bangladesh. Techno Drugs Ltd. is also the largest injectable hormonal medicine manufacturer and supplier to the Government of Bangladesh. Techno Drugs Ltd. has a separate hormonal division and modern production process which it intends to leverage to cater the orders of the Government of Bangladesh.

Future Plans

Techno Drugs Ltd. will utilize the IPO proceeds for acquisition and installation of machineries & equipment, BMRE at Satirpara, Narsingdi-1600, building and other construction at B.K. Bari Mirzapur, Gazipur-1703 and partial loan repayment.

(u) **Discussion on the results of operations shall inter-alia contain the following:**

(1) **A summary of the past financial results after adjustments as given in the auditor's report containing significant items of income and expenditure;**

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|-------------------------|------------------|------------------|------------------|------------------|------------------|
| Non-Current Assets | 3,825,522,959 | 3,495,222,379 | 2,627,133,139 | 2,334,517,554 | 1,858,747,915 |
| Current Assets | 2,215,732,793 | 1,868,788,859 | 1,756,544,720 | 1,448,978,606 | 1,117,626,314 |
| Shareholders' Equity | 2,612,349,279 | 2,432,399,449 | 1,449,626,603 | 1,019,923,774 | 781,198,589 |
| Non-Current Liabilities | 1,304,960,954 | 1,197,406,594 | 1,215,988,087 | 1,195,601,870 | 1,089,024,650 |
| Current Liabilities | 2,123,945,519 | 1,734,205,195 | 1,718,063,169 | 1,567,970,516 | 1,106,150,990 |
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Cost of Goods Sold | 1,573,642,291 | 3,213,382,241 | 2,380,115,347 | 1,183,126,627 | 1,275,677,113 |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |

(2) **A summary of major items of income and expenditure;**

Major items of income:

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|-----------------------|------------------|------------------|------------------|------------------|------------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Profit from Operation | 1,159,834,813 | 1,815,159,593 | 1,461,264,210 | 830,772,839 | 889,124,664 |

Major items of Expenditure:

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|--------------------|------------------|------------------|------------------|------------------|------------------|
| Cost of Goods Sold | 1,573,642,291 | 3,213,382,241 | 2,380,115,347 | 1,183,126,627 | 1,275,677,113 |
| Operating Expenses | 620,877,889 | 883,212,585 | 614,677,429 | 333,125,586 | 366,112,860 |
| Finance Expenses | 269,811,323 | 261,303,536 | 242,398,585 | 195,084,678 | 152,458,437 |

(3) The income and sales on account of major products or services;

The income and sales (local sales) on account of major products or services are as follows:

| Sl. | Name of Products | For the year ended Jun 30, 2023 | |
|-----|------------------------|---------------------------------|--------|
| | | Revenue (Tk.) | % |
| 1 | Anti-Cancer Products | 138,438,667 | 5.06% |
| 2 | Health Care Products | 733,945,982 | 26.85% |
| 3 | Animal Health Products | 1,861,092,456 | 68.09% |

(4) In case, other income constitutes more than 10% of the total income, the breakup of the same along with the nature of the income, i.e., recurring or non-recurring;

The other income of the Company does not constitute more than 10% of the total income.

(5) If a material part of the income is dependent upon a single customer or a few major customers, disclosure of this fact along with relevant data. Similarly, if any foreign customer constitutes a significant portion of the issuer's business, disclosure of the fact along with its impact on the business considering exchange rate fluctuations;

The Company's material part of the income is not dependent upon a single customer or a few major customers. The company has export sales hence deals with foreign customer but it does not constitute a significant portion of the issuer's business.

(6) In case the issuer has followed any unorthodox procedure for recording sales and revenues, its impact shall be analyzed and disclosed.

The Company has not followed any unorthodox procedure for recording of sales and revenues.

(v) Comparison of recent financial year with the previous financial years on the major heads of the profit and loss statement, including an analysis of reasons for the changes in significant items of income and expenditure, inter-alia, containing the following:

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|----------------------|---------------|---------------|---------------|---------------|---------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Operating Expenses | 620,877,889 | 883,212,585 | 614,677,429 | 333,125,586 | 366,112,860 |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |

Analysis of reasons for the changes in significant items of income and expenditure:

Revenues:

30-Jun-2019: Revenue was increased by 43.45% in 2019 from 2018. This is normal business growth.

30-Jun-2020: Revenue was decreased by 6.97% in 2020 from 2019. Due to Covid-19 and international crisis.

30-Jun-2021: Revenue was increased by 90.74% in 2021 from 2020. This is normal business growth due to increase in tender sales to Govt. and starts commercial production from new plant.

30-Jun-2022: Revenue was increased by 30.90% in 2022 from 2021. This is normal business growth.

30-Jun-2023: Revenue was decreased by 45.64% in 2023 from 2022. The Company's major sales come from the Govt. tender but this financial year Govt. did not call any tender, on the other hand from November 2022 the fall of opening of LC due to Dollar reserve matter.

Direct Costs:

30-Jun-2019: Direct cost of the company has been increased 43.23% in 2019 from 2018 due to increase of sales.

30-Jun-2020: Direct cost of the company has been decreased 7.26% in 2020 from 2019 due to decrease of sales.

30-Jun-2021: Direct cost of the company has been increased 101.17% in 2021 from 2020 due to increase of sales.

30-Jun-2022: Direct cost of the company has been increased 35.01% in 2022 from 2021 due to increase of sales.

30-Jun-2023: Direct cost of the company has been decreased 51.03% in 2023 from 2022 due to decrease of sales.

Other operating expenses:

The company has incurred business administrative expense during the last five years which is regulars and relevant with sales.

Net income:

The growth of net profit after Tax is consistent with the growth of revenue. No unusual change has been occurred during the last five years on the above matters except in the year 2023.

- (1) **Unusual or infrequent events or transactions including unusual trends on account of business activity, unusual items of income, change of accounting policies and discretionary reduction of expenses etc.**

There is no an unusual or infrequent event or transactions including unusual trends on account of business activity, unusual items of income, change of accounting policies and discretionary reduction of expenses etc.

- (2) **Significant economic changes that materially affect or are likely to affect income from continuing operations;**

There are no significant economic changes that materially affect or are likely to affect income from continuing operations.

- (3) **Known trends or uncertainties that have had or are expected to have a material adverse impact on sales, revenue or income from continuing operations;**

Products of pharmaceuticals industry are related to healthcare needs of the population. There is a lot of scope to increase the market significantly, which depends on factors like increase of per capital income, increase health consciousness among mass people. Besides local market, contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc. can affect the business as well.

(4) Future changes in relationship between costs and revenues, in case of events such as future increase in labor or material costs or prices that will cause a material change are known;

Any event such as increase in labor or material costs or prices will not affect the operational result of the company significantly as the end price of the products are adjusted in line with changes in raw material and associated costs, keeping operating margin the same. We also expect the revenue to grow with the introduction new products.

(5) The extent to which material increases in net sales or revenue are due to increased sales volume, introduction of new products or services or increased sales prices;

During the last five years i.e., 2018 to 2023, the net profit after tax is increased by Tk. 56,430,035 with a growth rate of 24.94% due to introduction of new products in every year.

There is no record of discontinuance of any line of business, loss of agencies or markets and similar factors.

(6) Total turnover of each major industry segment in which the Issuer operated

Pharmaceuticals products are of the basic needs for all living being. It is one of the fastest growing industries in the world. According to Light Castle Partners, with a historical 5 years' CAGR of 15.6%, the sector is predicted to grow to \$5.11 billion by 2023. Currently, 98% of pharmaceutical demand is met locally, while only 2% are served via imports. Out of these, 80% are Generic drugs and 20% are patented drugs.

Pharmaceutical shipments from Bangladesh grew 25% year-on-year to \$169 million in the last fiscal thanks to the addition of anti-coronavirus drugs to the export basket, continuous improvement of quality and policy support. Drugs worth \$136 million were exported in fiscal 2019-20, according to data of the Export Promotion Bureau.

(7) Status of any publicly announced new products or business segment;

The Company did not announce new products or business segment.

(8) The extent to which the business is seasonal.

As the products of pharmaceuticals industry are one of the basic needs and primarily chronic care related, Bangladesh Pharma market is consistent. As such, company's business is not seasonal.

(w) Defaults or rescheduling of borrowings with financial institutions or banks, conversion of loans into equity along with reasons thereof, lock out, strikes and reasons for the same etc. during the history of operation of the company;

Rescheduling of borrowings with banks:

The Company has not rescheduled its borrowing with any lending institutions except One Bank Limited due to effect of nCovid-19.

Conversion of loans into equity along with reasons thereof, lock out, strikes and reasons for the same etc. during the history of operation of the company

There is no history of conversion of loan into equity, lock out and strikes.

(x) **Details regarding the changes in the activities of the issuer during the last five years which may have had a material effect on the profits or loss, including discontinuance of lines of business, loss of agencies or markets and similar factors;**

During the last five years i.e., 2018 to 2023, the net profit after tax is increased by Tk. 56,430,035 with a growth rate of 24.94% due to introduction of new products in every year.

There is no record of discontinuance of any line of business, loss of agencies or markets and similar factors

(y) **Injunction or restraining order, if any, with possible implications;**

The Company did not receive any injunction or restraining from any competent authority or any regulatory bodies

(z) **Technology, market, managerial competence and capacity built-up;**

Technology

Techno Drugs Ltd. is vertically integrated generic pharmaceuticals formulation products manufacturer, marketer, promoter and distributor.

Its manufacturing process is heavily technology driven, dynamic in nature and using highly sophisticated state-of-the-art cutting edge technology.

The plant adheres to GMP standard, hygiene and safety. The facilities are unique for Integrated Building Management System (IBMS), World-class Structural Design, Dust-free Environment, well-designed HVAC System, Zero Cross- contamination, Vacuum Transfer Close System, Different Storage Conditions, High-tech Chemical & Microbiological Laboratories, Modern R&D facility, Most up-to-date Purified Water Generation plant, Fire Management System and Eco-friendly Effluent Treatment Plant.

TDL maintains total Quality System, which includes Strict Monitoring, End-to-end Regulation. State-of-the-art Equipment, True Measurements, Equipment Calibration, Trained professionals.

Local market, demand and supply forecasts for the sector:

The pharmaceutical market of Bangladesh is expected to surpass \$6 billion by 2025 with an absolute growth of 114% from its 2019 levels, according to a report from a Dublin-based market insight and analysis firm, Research and Markets.

"The pharmaceutical market has been witnessing excellent growth in recent years, and it is expected to have a compound annual growth rate of more than 12 per cent during the 2019-2025 period," said the report titled "Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025".

In 1981, there were only 166 licensed pharmaceutical manufacturers in the country. The local market and production, however, was largely dominated by eight multinational companies, which used to cover almost 75% of the local demand. Medium size local companies used to meet about 15% of the demand and the remaining 10% was met by small companies. The Drug Regulatory Committee enforced some new regulations on multinationals to constrain their domination and also to encourage the local companies.

Following the 1982 ordinance, the value of locally produced medicine rose from Tk 1.1 million in 1981 to Tk 19.23 billion in 2000. Nearly 95% of total domestic demand for medicines was met by local production.

At present, there are 257 licensed pharmaceutical companies in Bangladesh, with about 150 of them functional. Bangladeshi medicines are now being exported to 145 countries.

Managerial competence

All the members of the management team of the company are highly qualified, trained and skilled professionals, well experienced and extremely devoted. The management team is led by Shah Jalal Uddin Ahmed, Managing Director who acts for maximizing the best interest of the company.

The expert team of TDL, which consists of Pharmacists and Engineers and a good number of professionals from various disciplines, are seasoned and experienced enough to use the facilities for production to fulfill the demand of target customers. Successive strong financial performance is the result of unwavering commitment of the promoters, managements' efficiency, employees' sincerity, use of appropriate technology, among others.

Capacity built-up

To keep pace with the contemporary technology and customer demand the Company continuously is investing and deploying enough resources including human resources.

(aa) Changes in accounting policies in the last three years;

There is no change in the accounting policies of the Company during last three years except rights-of-use-assets under IFRS-16

- (bb) **Significant developments subsequent to the last financial year: A statement by the directors whether in their opinion there have arisen any circumstances since the date of the last financial statements as disclosed in the prospectus and which materially and adversely affect or is likely to affect the trading or profitability of the issuer, or the value of its assets, or its ability to pay its liabilities within the next twelve months;**

A statement by the directors

In our opinion, there have no such circumstances arisen since the date of the last financial statements as disclosed in the prospectus which materially and adversely affect or is likely to affect the trading or profitability of the Techno Drugs Ltd. or the value of its assets, or its ability to pay its liabilities within the next twelve months.

Sd/-
Shah Jalal Uddin Ahmed
Managing Director

Sd/-
Khaleda Akhter Khan
Chairman

Sd/-
Mehreen Ahmed
Director

Sd/-
Arefeen Raafi Ahmed
Director

Sd/-
Md. Mamunur Rashid
Director

Sd/-
SK. Motiur Rahman
Independent Director

Sd/-
Uttam Kumar Saha, FCA
Independent Director

Date: September 27, 2023

(cc) If any quarter of the financial year of the issuer ends after the period ended in the audited financial statements as disclosed in the prospectus, unaudited financial statements for each of the said quarters duly authenticated by the CEO and CFO of the issuer;

Un-audited financial statements for the period ended March 31, 2024 are as follows:

Techno Drugs Limited
Statement of Financial Position (Un-Audited)
As at 31st March, 2024

| Particulars | Amount | |
|---|----------------------|----------------------|
| | 31-Mar-24 | 30-Jun-23 |
| ASSETS: | | |
| Non-Current Assets: | 3,818,694,028 | 3,825,522,959 |
| Property, Plant and Equipments at Carrying Value | 3,558,807,133 | 3,586,136,067 |
| Intangible Assets | 6,622,483 | 7,222,755 |
| Investment In Share | 270,000 | 270,000 |
| Capital Work In Progress | 164,775,087 | 179,878,620 |
| Right-of-Use Assets | 88,219,324 | 52,015,516 |
| Current Assets: | 2,513,500,175 | 2,215,732,793 |
| Inventories | 998,159,730 | 700,599,952 |
| Finished Goods For Govt. Tender | - | 238,536,250 |
| Advances, Deposits and Prepayments | 478,994,501 | 399,192,394 |
| Accounts Receivable | 981,125,092 | 789,714,772 |
| Investment in FDR | 49,896,535 | 53,218,850 |
| Cash and Cash Equivalents | 5,324,316 | 34,470,574 |
| TOTAL ASSETS | 6,332,194,203 | 6,041,255,752 |
| SHARE HOLDERS' EQUITY & LIABILITIES: | | |
| Shareholders' Equity: | 2,855,279,874 | 2,612,349,279 |
| Share Capital | 941,574,000 | 941,574,000 |
| Revaluation Surplus | 487,437,890 | 487,437,890 |
| Retained Earnings | 1,426,267,984 | 1,183,337,389 |
| Non-Current Liabilities: | 1,230,637,190 | 1,304,960,954 |
| Deferred Tax Liability | 217,243,736 | 216,490,616 |
| Long Term Loan Net of Current Maturity | 950,131,437 | 1,055,549,905 |
| Lease Liabilities Net of Current Maturity | 63,262,017 | 32,920,433 |
| Current Liabilities: | 2,246,277,139 | 2,123,945,519 |
| Current Maturity of Lease Liabilities | 38,395,093 | 27,757,903 |
| Current Maturity of Long Term Loan | 419,141,554 | 414,024,638 |
| Short Term Loan | 1,175,405,714 | 1,187,853,989 |
| Provision for Current Tax | 307,480,241 | 215,272,129 |
| Accounts & Others Payable | 222,382,796 | 212,359,709 |
| Liabilities for WPPF | 83,471,741 | 66,677,150 |
| TOTAL SHARE HOLDERS' EQUITY AND LIABILITIES | 6,332,194,203 | 6,041,255,752 |
| No. of Ordinary Share use to compute NAVPS | 94,157,400 | 94,157,400 |
| Net Assets Value (NAV) per share with Revaluation | 30.32 | 27.74 |
| Net Assets Value (NAV) per share without Revaluation | 25.15 | 22.57 |

| | | | |
|-------------------------|----------------------------------|----------------------------------|--|
| Sd/- Chairman | Sd/- Managing Director | Sd/- Company Secretary | Sd/- Chief Financial Officer |
|-------------------------|----------------------------------|----------------------------------|--|

Dhaka, Bangladesh
Dated: 25 April, 2024

Techno Drugs Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-Audited)
For the period ended 31st March, 2024

| Particulars | Amount (In Taka) | |
|-----------------------------------|----------------------|----------------------|
| | 01-Jul-23 | 01-Jul-22 |
| | To | To |
| | 31-Mar-24 | 31-Mar-23 |
| Revenue | 3,080,421,271 | 2,235,605,345 |
| Cost of Goods Sold | (1,786,239,369) | (1,318,834,798) |
| Gross Profit | 1,294,181,903 | 916,770,547 |
| Operating Expenses | (719,620,589) | (478,387,805) |
| Administrative Expenses | (178,275,680) | (131,013,461) |
| Selling & Distribution Expenses | (541,344,909) | (347,374,345) |
| Profit from Operation | 574,561,314 | 438,382,741 |
| Finance Expenses | (222,888,036) | (189,217,464) |
| Other Income | 1,013,140 | 372,080 |
| Profit before WPPF and Tax | 352,686,417 | 249,537,357 |
| Contribution to WPPF | (16,794,591) | (11,882,731) |
| Profit Before Tax | 335,891,826 | 237,654,626 |
| Income Tax Expenses | (92,961,231) | (59,123,278) |
| Current Tax | (92,208,112) | (59,146,631) |
| Deferred Tax | (753,120) | 23,354 |
| Net Profit After Tax | 242,930,595 | 178,531,348 |
| Total Comprehensive Income | 242,930,595 | 178,531,348 |

Earnings per Share (EPS) - Basic

2.58

1.90

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Dhaka, Bangladesh
Dated: 25 April, 2024

Techno Drugs Limited
Statement of Changes in Equity (Un-Audited)
As at 31st March, 2024

| Particulars | Share Capital | Retained Earnings | Revaluation Surplus | Total Taka |
|---------------------------------|--------------------|----------------------|---------------------|----------------------|
| Balance 1st July 2023 | 941,574,000 | 1,183,337,389 | 487,437,890 | 2,612,349,279 |
| Net Profit after Tax | - | 242,930,595 | - | 242,930,595 |
| Balance 31st March, 2024 | 941,574,000 | 1,426,267,983 | 487,437,890 | 2,855,279,874 |

As at 31st March, 2023

| Particulars | Share Capital | Retained Earnings | Revaluation Surplus | Total Taka |
|---------------------------------|--------------------|----------------------|---------------------|----------------------|
| Balance 1st July 2022 | 941,574,000 | 987,831,030 | 502,994,419 | 2,432,399,448 |
| Net Profit after Tax | - | 178,531,348 | - | 178,531,348 |
| Balance 31st March, 2023 | 941,574,000 | 1,166,362,378 | 502,994,419 | 2,610,930,797 |

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Company Secretary

Sd/-
Chief Financial Officer

Dhaka, Bangladesh

Dated: 25 April, 2024

Techno Drugs Limited
Statement of Cash Flows (Un-Audited)
For the period ended 31st March, 2024

| Particulars | Amount (In Taka) | |
|--|-----------------------------|------------------------------|
| | 1-Jul-23 To 31-Mar-24 | 01-Jul-22 To 31-Mar-23 |
| A. Cash Flows from Operating Activities: | | |
| Received from Customers | 2,889,010,951 | 1,929,106,820 |
| Received from Others | 1,013,140 | 372,080 |
| Paid to Suppliers | (1,468,253,022) | (1,102,635,672) |
| Paid to Employees | (652,092,441) | (432,218,821) |
| Paid to Others | (175,151,455) | (135,264,338) |
| Paid for Finance Cost | (225,782,055) | (178,897,986) |
| Cash generated from operation | 368,745,118 | 80,462,082 |
| Income Tax Paid | (92,208,112) | (9,665,183) |
| Net Cash generated from Operating Activities | 276,537,007 | 70,796,899 |
| B. Cash Flows from Investing Activities: | | |
| Cash Paid for Acquisition of Property Plant and Equipme | (14,223,715) | (35,960,101) |
| Intangible Assets | (92,000) | (5,045,775) |
| Received/(Paid) against Investment in FDR | 3,322,315 | (20,504,739) |
| Cash Paid for Capital Work-In-Progress | (158,267,302) | (460,878,178) |
| Net Cash used in Investing Activities | (169,260,702) | (522,388,794) |
| C. Cash Flows from Financing Activities: | | |
| Received/(Paid) against Long Term Borrowings | (100,301,552) | (4,412,722) |
| Received/(Paid) against Short Term Borrowings | (12,448,275) | 363,738,660 |
| Payment against Lease Liability | (15,664,575) | (7,547,998) |
| Interest expenses on lease liability | (8,008,161) | (2,903,482) |
| Net Cash Generated/(Used) from Financing Activities | (136,422,563) | 348,874,458 |
| Net Cash Inflow/(Outflow) from Total Activities (A+B+C) | (29,146,258) | (102,717,437) |
| Opening Cash & Cash Equivalents | 34,470,574 | 139,937,066 |
| Cash and Cash Equivalents at the End | 5,324,316 | 37,219,630 |
| Net Operating Cash Flows Per Share (NOCFPS) | 2.94 | 0.75 |

Sd/- Chairman Sd/- Managing Director Sd/- Company Secretary Sd/- Chief Financial Officer

Dhaka, Bangladesh
Dated: 25 April, 2024

(dd) **Factors that may affect the results of operations.**

Factors like increase of per capita income, increase in health consciousness among mass people, local market, contract, manufacturing and emerging overseas market can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc. can affect the business as well.

CHAPTER (VII)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

(a) **Overview of business and strategies:**

Overview of business:

Techno Drugs Ltd. was incorporated in 2009 as a Private Limited Company of Bangladesh with the issuance of Certificate of incorporation bearing no. Reg. No. C-79890/09 dated on 30-Sep-2009 by the Registrar of Joint Stock Companies & Firms, Dhaka, Bangladesh. The Company Converted into public Limited Company and split of Share value from Tk. 1,000.00 to Tk. 10.00 dated on 18-Aug-2019.

Techno Drugs Ltd. (TDL) has been established with the target to manufacture of both Human pharmaceuticals' drugs and animal health care drugs and selling them in local and international market.

The products of the company are sold in domestic and international markets.

Techno Drugs Ltd. has neither any subsidiary nor it is operated under a holding company.

Strategies:

Business strategy refers to a framework wherein a company develops action and tactical plans depending on the company's goals and objectives. Business strategies help in decision making processes which in turn support different departmental needs all working together to achieve the overall objectives of a company.

Techno Drugs Ltd. considers the following as its business strategies:

Improvement of Local Market Share

Techno Drugs Ltd. since its inception has been giving importance to ensuring the availability of locally manufactured and quality pharmaceutical products in Bangladesh. As a result, Techno Drugs always focuses on improving the local market share of its pharmaceutical products.

Expand in the International Market Scene

Techno Drugs Ltd. emphasizes on manufacturing quality and innovative pharmaceutical products and increase exports to expand into the international market.

Innovate and Develop Quality Pharmaceutical Products

Techno Drugs Ltd. since inception has been inclined towards developing and manufacturing innovative and high-quality pharmaceutical products. Techno Drugs started production of Anti-Cancer medicines for the first time in the country when the country depended on imported Oncology medicines at that time.

Revolutionize and Leverage Hormonal Medicine


Techno Drugs Ltd. is a major manufacturer of Hormonal medicine. In addition to that the company is the fifth Contraceptive Implant manufacturer in the world and the first of its kind in Bangladesh. Techno Drugs Ltd. is also the largest injectable hormonal medicine manufacturer and supplier to the Government of Bangladesh. Techno Drugs Ltd. has a separate hormonal division and modern production process which it intends to leverage to cater the orders of the Government of Bangladesh.

Future Plans

Techno Drugs Ltd. will utilize the IPO proceeds for acquisition and installation of machineries & equipment, BMRE at Satirpara, Narsingdi-1600, building and other construction at B.K. Bari Mirzapur, Gazipur-1703 and partial loan repayment.

(b) **SWOT ANALYSIS:**

SWOT analysis is a structured planning method that helps to evaluate the strengths, weaknesses, opportunities and threats involved in a business venture. It identifies the internal and external factors that affect a business venture. Strength and Weakness are evaluated with internal factors whereas Opportunity and Threat are evaluated by external factors. A brief SWOT analysis of the company has been furnished here.



- (c) **Analysis of the financial statements of last five years with reason(s) of fluctuating revenue or sales, other income, total income, cost of material, finance cost, depreciation and amortization expense, other expense; changes of inventories, net profit before & after tax, EPS etc.**

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Other Income | 2,859,050 | 12,929,115 | 18,349,561 | 27,964,502 | 17,763,058 |
| Total Income | 2,736,336,155 | 5,041,470,949 | 3,859,729,117 | 2,041,863,968 | 2,182,564,835 |
| Cost of Materials | 1,573,642,291 | 3,213,382,241 | 2,380,115,347 | 1,183,126,627 | 1,275,677,113 |
| Finance Expenses | 269,811,323 | 261,303,536 | 242,398,585 | 195,084,678 | 152,458,437 |
| Depreciation Expense | 290,433,614 | 251,126,931 | 212,421,686 | 164,025,348 | 134,148,463 |
| Amortization Expense | 917,125 | 412,547 | 412,547 | 206,274 | - |
| Others Expense | 620,877,889 | 883,212,585 | 614,677,429 | 333,125,586 | 366,112,860 |
| Changes of Inventories | 53,958,977 | 184,715,341 | 121,279,464 | 79,826,072 | 81,856,052 |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |
| Earnings Per Share (Diluted) | 2.08 | 5.10 | 3.83 | 1.74 | 2.40 |

Reason of Fluctuation

Revenues:

30-Jun-2019: Revenue was increased by 43.45% in 2019 from 2018. This is normal business growth.

30-Jun-2020: Revenue was decreased by 6.97% in 2020 from 2019. Due to Covid-19 and international crisis.

30-Jun-2021: Revenue was increased by 90.74% in 2021 from 2020. This is normal business growth due to increase in tender sales to Govt. and starts commercial production from new plant.

30-Jun-2022: Revenue was increased by 30.90% in 2022 from 2021. This is normal business growth.

30-Jun-2023: Revenue was decreased by 45.64% in 2023 from 2022. The Company's major sales come from the Govt. tender but this financial year Govt. did not call any tender, on the other hand from November 2022 the fall of opening of LC due to Dollar reserve matter.

Total Income:

Since revenue was increased so naturally total income was increased.

Cost of Materials:

30-Jun-2019: Direct cost of the company has been increased 43.23% in 2019 from 2018 due to increase of sales.

30-Jun-2020: Direct cost of the company has been decreased 7.26% in 2020 from 2019 due to decrease of sales.

30-Jun-2021: Direct cost of the company has been increased 101.17% in 2021 from 2020 due to increase of sales.

30-Jun-2022: Direct cost of the company has been increased 35.01% in 2022 from 2021 due to increase of sales.

30-Jun-2023: Direct cost of the company has been decreased 51.03% in 2023 from 2022 due to decrease of sales.

Finance Cost and Bank charge:

The Company has taken term loan and short term loan from bank to support business working capital.

Depreciation and Amortization:

The depreciation and amortization on property, plant, equipment and software have increased steadily on the basis of addition.

Other Expenses:

The company has incurred business administrative expense during the last five years which is regulars and relevant with sales.

Net profit before and after Tax and earning per share:

The growth of net profit after Tax is consistent with the growth of revenue. No unusual change has been occurred during the last five years on the above matters except in the year 2023.

Earnings per share are properly calculated through using weighted average number of ordinary shares for each year.

(d) Known trends demands, commitments, events or uncertainties that are likely to have an effect on the company's business:

Products of pharmaceuticals industry are related to healthcare needs of the population. There is a lot of scope to increase the market significantly, which depends on factors like increase of per capital income, increase health consciousness among mass people. Besides local market, contract manufacturing and emerging overseas market also can play a greater role. On the contrary, factors like natural disaster, entrance of new technology, increase in competition etc. can affect the business as well.

(e) Trends or expected fluctuations in liquidity:

There are no trends or expected fluctuations in liquidity.

(f) Off-balance sheet arrangements those have or likely to have a current or future effect on financial condition:

There are no off-balance sheet arrangements those have or likely to have a current or future effect on financial condition.

CHAPTER (VIII)

DIRECTORS AND OFFICERS

(a) Name, Father's name, age, residential address, educational qualification, experience and position of each of the directors of the company and any person nominated or represented to be a director, showing the period for which, the nomination has been made and the name of the organization which has nominated him:

| SL | Name of Director, Father's Name, Age & Experience | | Residential Address | Educational Qualification | Name of the Institutions and Duration for Nominated Director |
|----|--|--|--|--|--|
| 1 | Name: Shah Jalal Uddin Ahmed Position: Managing Director Father's Name: Late Mainuddin Ahmed Age: 70 Years Experience: 47 Years | | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | B. Pharma, M. Pharma | - |
| 2 | Name: Khaleda Akhter Khan Position: Chairman Father's Name: Late Mohammad Masum Khan Age: 69 Years Experience: 43 Years | | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | BSS | - |
| 3 | Name: Mehreen Ahmed Position: Director Father's Name: Shah Jalal Uddin Ahmed Age: 36 Years Experience: 13 Years | | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | B. Pharma, PhD in Pre-Clinical Oncology from University of Nottingham, UK and her MSC in Pharmacology from University of Hertfordshire, UK | - |

| | | | | | |
|---|-----------------------|------------------------------|--|--|---|
| 4 | Name: | Arefeen Raafi Ahmed | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | B. Sc from University of Western Sydney, Australia in ICT | - |
| | Position: | Director | | | |
| | Father's Name: | Shah Jalal Uddin Ahmed | | | |
| | Age: | 32 Years | | | |
| | Experience: | 13 Years | | | |
| 5 | Name: | Md. Mamunur Rashid | Vill: Barikhola, PO: Laur Fatehpur, PS: Nabinagar, Dist: B. Baria | Masters of Kamil under Bangladesh Madrasha Education Board | - |
| | Position: | Director | | | |
| | Father's Name: | Md. Shafiqul Islam | | | |
| | Age: | 44 Years | | | |
| | Experience: | 19 Years | | | |
| 6 | Name: | SK. Motiur Rahman | 10/B Concord, 5 Segunbagicha, Ramna, Dhaka | Barrister-At-Law, LL.M; LL.B (Hons), Diploma in Law | 3 Yrs. (From 31-Aug-2023 to 30-Aug-2026) |
| | Position: | Independent Director | | | |
| | Father's Name: | Shaikh Golam Rasul | | | |
| | Age: | 35 Years | | | |
| | Experience: | 11 Years | | | |
| 7 | Name: | Uttam Kumar Saha, FCA | Level-5, Green Zone Tower, 1 No Hatkhola Road, Wari Dhaka-1203 | B.Com (Hons), M.Com, FCA | 3 Yrs. (From 31-Aug-2023 to 30-Aug-2026) |
| | Position: | Independent Director | | | |
| | Father's Name: | Lal Mohon Saha | | | |
| | Age: | 40 Years | | | |
| | Experience: | 14 Years | | | |

(b) **The date on which he first became a director and the date on which his current term of office shall expire:**

| SL. | Name of the Director | Position | Date of first Directorship | Date of Expiration of Current term |
|-----|------------------------|----------------------|----------------------------|------------------------------------|
| 1 | Shah Jalal Uddin Ahmed | Managing Director | 30 Sep, 2009 | 15th AGM in 2024 |
| 2 | Khaleda Akhter Khan | Chairman | 30 Sep, 2009 | 14th AGM in 2023 |
| 3 | Mehreen Ahmed | Director | 30 Sep, 2009 | 15th AGM in 2024 |
| 4 | Arefeen Raafi Ahmed | Director | 30 Sep, 2009 | 14th AGM in 2023 |
| 5 | Md. Mamunur Rashid | Director | 31 Aug, 2023 | 16th AGM in 2025 |
| 6 | SK. Motiur Rahman | Independent Director | 31 Aug, 2023 | 17th AGM in 2027 |
| 7 | Uttam Kumar Saha, FCA | | 31 Aug, 2023 | 17th AGM in 2027 |

(c) **If any director has any type of interest in other businesses, names and types of business of such organizations. If any director is also a director of another company or owner or partner of any other concern, the names of such organizations:**

| Sl. | Name of Director | Designation in TDL | Directorship/Ownership with Other Companies | |
|-----|------------------------|----------------------|---|----------|
| | | | Companies | Position |
| 1 | Shah Jalal Uddin Ahmed | Managing Director | G C Box Ltd. | MD |
| | | | Techno Cosmeceuticals Ltd. | MD |
| | | | Techno Agrovet & Fisheries Ltd. | Director |
| 2 | Khaleda Akhter Khan | Chairman | G C Box Ltd. | Chairman |
| | | | Techno Cosmeceuticals Ltd. | Chairman |
| | | | Techno Agrovet & Fisheries Ltd. | Director |
| 3 | Mehreen Ahmed | Director | G C Box Ltd. | Director |
| | | | Techno Cosmeceuticals Ltd. | Director |
| | | | Greentech Holidays Limited. | Chairman |
| | | | Techno Agrovet & Fisheries Ltd. | Chairman |
| 4 | Arefeen Raafi Ahmed | Director | G C Box Limited. | Director |
| | | | Pulse Tech Limited | MD |
| | | | Techno Cosmeceuticals Ltd. | Director |
| | | | Greentech Holidays Ltd. | MD |
| | | | MedBox Solution Ltd. | Director |
| | | | Techno Agrovet & Fisheries Ltd. | Director |
| 5 | Md. Mamunur Rashid | Director | Not involved in other organization | - |
| 6 | SK. Motiur Rahman | Independent Director | Not involved in other organization | - |
| 7 | Uttam Kumar Saha, FCA | Independent Director | Not involved in other organization | - |

(d) **Statement of if any of the directors of the issuer are associated with the securities market in any manner. If any director of the Issuer Company is also a director of any issuer of other listed securities during last three years, then dividend payment history and market performance of that issuer:**

None of the Directors is involved in securities market and not involved with other listed securities during last three years.

- (e) **Any family relationship (father, mother, spouse, brother, sister, son, daughter, spouse's father, spouse's mother, spouse's brother, spouse's sister) among the directors and top five officers:**

| Name | Position | Relationship with other directors |
|------------------------|----------------------|---|
| Shah Jalal Uddin Ahmed | Managing Director | Husband of Khaleda Akhter Khan and father of Mehreen Ahmed & Arefeen Raafi Ahmed. |
| Khaleda Akhter Khan | Chairman | Wife of Shah Jalal Uddin Ahmed and mother of Mehreen Ahmed & Arefeen Raafi Ahmed. |
| Mehreen Ahmed | Director | Daughter of Shah Jalal Uddin Ahmed & Khaleda Akhter Khan and sister of Arefeen Raafi Ahmed. |
| Arefeen Raafi Ahmed | Director | Son of Shah Jalal Uddin Ahmed & Khaleda Akhter Khan and brother of Mehreen Ahmed. |
| Md. Mamunur Rashid | Director | No family relation |
| Kazi Ashikur Rasul | Independent Director | No family relation |
| Uttam Kumar Saha, FCA | Independent Director | No family relation |

(f) A very brief description of other businesses of the directors:

Shah Jalal Uddin Ahmed

Managing Director

| Sl. No. | Name of Companies | Date of Incorporation | Nature of Business | Legal Status | Equity capital (Total) in Taka |
|---------|---------------------------------|-----------------------|------------------------|-------------------------|--------------------------------|
| 1 | G C Box Ltd. | 10-Oct-94 | Paper & Packaging | Private Limited Company | 1,500,000 |
| 2 | Techno Cosmeceuticals Ltd. | 9-Mar-22 | Herbal & Cosmetics | Private Limited Company | 5,000,000 |
| 3 | Techno Agrovet & Fisheries Ltd. | 13-Apr-23 | Agro,Dairy & Fisheries | Private Limited Company | 3,000,000 |

Khaleda Akhter Khan

Chairman

| Sl. No. | Name of Companies | Date of Incorporation | Nature of Business | Legal Status | Equity capital (Total) in Taka |
|---------|---------------------------------|-----------------------|------------------------|-------------------------|--------------------------------|
| 1 | G C Box Ltd. | 10-Oct-94 | Paper & Packaging | Private Limited Company | 1,500,000 |
| 2 | Techno Cosmeceuticals Ltd. | 9-Mar-22 | Herbal & Cosmetics | Private Limited Company | 5,000,000 |
| 3 | Techno Agrovet & Fisheries Ltd. | 13-Apr-23 | Agro,Dairy & Fisheries | Private Limited Company | 3,000,000 |

Mehreen Ahmed

Director

| Sl. No. | Name of Companies | Date of Incorporation | Nature of Business | Legal Status | Equity capital (Total) in Taka |
|---------|---------------------------------|-----------------------|------------------------|-------------------------|--------------------------------|
| 1 | G C Box Ltd. | 10-Oct-94 | Paper & Packaging | Private Limited Company | 1,500,000 |
| 2 | Techno Cosmeceuticals Ltd. | 9-Mar-22 | Herbal & Cosmetics | Private Limited Company | 5,000,000 |
| 3 | Greentech Holidays Limited. | 4-Apr-21 | Travel & Tourism | Private Limited Company | 3,000,000 |
| 4 | Techno Agrovet & Fisheries Ltd. | 13-Apr-23 | Agro,Dairy & Fisheries | Private Limited Company | 3,000,000 |

Arefeen Raafi Ahmed*Director*

| Sl. No. | Name of Companies | Date of Incorporation | Nature of Business | Legal Status | Equity capital (Total) in Taka |
|---------|----------------------------------|-----------------------|---------------------------------|-------------------------|--------------------------------|
| 1 | G C Box Limited. | 10-Oct-94 | Paper & Packaging | Private Limited Company | 1,500,000 |
| 2 | Pulse Tech Limited | 4-Apr-21 | Software Development & Services | Private Limited Company | 1,000,000 |
| 3 | Techno Cosmeceuticals Ltd. | 9-Mar-22 | Herbal & Cosmetics | Private Limited Company | 5,000,000 |
| 4 | Greentech Holidays Ltd. | 4-Apr-21 | Travel & Tourism | Private Limited Company | 3,000,000 |
| 5 | MedBox Solution Ltd. | 20-Apr-22 | Medicin Distrebutor Online | Private Limited Company | 5,000,000 |
| 6 | Techno Agrovvet & Fisheries Ltd. | 13-Apr-23 | Agro,Dairy & Fisheries | Private Limited Company | 3,000,000 |

Md. Mamunur Rashid*Director*

Not involved in other business.

SK. Motiur Rahman*Independent Director*

Not involved in other business.

Uttam Kumar Saha, FCA*Independent Director*

Not involved in other business.

(g) **Short bio-data of each director:**

Shah Jalal Uddin Ahmed

Managing Director

Shah Jalal Uddin Ahmed was born in Brahmanbaria, Bangladesh in the year 1953. He has completed his B.Sc. (Hon's) Bachelors in Pharmacy and M.Sc. Masters in Pharmacy from The University of Dhaka. He is a renowned pharmacist of the country and beyond. He started his career back in the late 70's in a leading pharmaceutical industry of Bangladesh, where he earned enormous fame for his excellence in manufacturing innovative products. After working 19 years in the same industry, he thought it's time for a change and with the experiences he has gained over the years in pharmaceutical formulation, inspired him to establish a new pharmaceutical industry on his own. And that this how Techno Drugs Ltd emerged. Since its inception, Techno Drugs Ltd has always been giving priority to the availability of locally manufactured medicines and a high quality of product that ultimately leads to maintaining a steady growth in the market. Mr. Shah Jalal Uddin Ahmed is a registered pharmacist of the Bangladesh Pharmacy Council. He also has an Executive Membership of Bangladesh Association of Pharmaceutical Industries. He is a senior member of Bangladesh Pharmaceutical Society, and one of the top pharmacists of the country. He is a member of Dhaka Chamber of Commerce and Industry and Narsingdi Chamber of Commerce and Industry. He is the innovator of many new pharmaceutical products in Bangladesh. He has a portfolio of introducing over 77 generics formulations for the first time in the country.

Khaleda Akhter Khan

Chairman

Mrs. Khaleda Akhter Khan is the Chairman and one of the sponsor directors of Techno Drugs Ltd. She was born in Gazipur, Bangladesh in the year 1954. She has completed her B.Sc. in Zoology (Hon's) and finished her M.Sc. in Fisheries, from The University of Dhaka. She started her carrier as a banker at Agrani Bank Ltd in the year 1983. With over 25 years of banking experience, she started at Techno Drugs Ltd as the Finance Director of the company since the company's incorporation in 2009. She single handedly monitored the accounts department until she was assigned to be the Chairman of the company by the board. Now she oversees the overall business of the company as Chairman. Her interpersonal skills, leadership behavior, high analytical ability in business and very hard working nature made her worth being the Chairman of Techno Drugs Ltd.

Mehreen Ahmed

Director

Dr. Mehreen Ahmed is the only daughter and the elder of two children of Khaleda Akhter Khan and Shah Jalal Uddin Ahmed. She was born in Barishal, Bangladesh in the year 1987. She is an Executive Director and one of the sponsor directors of the company. She has completed her B.Sc. Bachelors in Pharmacy from The University of Asia Pacific and obtained the registration of Bangladesh Pharmacy Council before moving to The United Kingdom for her Master's degree. She has completed her M.Sc. Pharmacology Masters in Pharmacy from The University of Hertfordshire, UK. She has also achieved her PhD in Pre-Clinical Oncology from The University of Nottingham, UK. She then moved to Sweden to pursue her postdoctoral fellowship at The Lund University, Sweden. Her leadership skills, knowledge about the industry gathered from the top institutions of the world, highly analytical and research oriented abilities in pharmaceutical formulation, and her hard working nature made her worthy of being a director of Techno Drugs Ltd.

Arefeen Raafi Ahmed

Director

Arefeen Raafi Ahmed is the only son and the younger of two children of Khaleda Akhter Khan and Shah Jalal Uddin Ahmed. He was born in Barishal, Bangladesh in the year 1991. He is an Executive Director and one of the sponsor directors of the company. He has graduated in B.Sc. ICT, Information and Communication Technology, from The University of Western Sydney, Australia. He has more than 11 years of experience in managing and leading teams across multiple sectors. He is also The Managing Director of Pulse Tech Ltd., a leading healthcare technology company of Bangladesh, and Managing Director of Greentech Holidays Ltd., a travel and tourism based industry. Mr. Arefeen Raafi Ahmed is the Executive Director of Greentech Resort and Convention Center, a leading resort of the country situated at Gazipur. He is also the Director of G.C. Box Ltd., a corrugated carton manufacturing industry, Medbox Solution Ltd., a medicine supply chain solution by Pulse Tech Ltd. Besides this, he is the 2023 National Vice President of JCI Bangladesh and a Senator of Junior Chamber International. He is also an active member of Bangladesh Association of Pharmaceuticals Industries, and Dhaka Chamber of Commerce and Industry. He is also the Director of the 2023-2025 executive committee of Bangladesh China Chamber of Commerce and industry. Being a member of Dubai Chamber of Commerce and Industry is just one of the many associations he is associated with. He is performing his duty at Techno Drugs Ltd., by looking after the entire sales and marketing team nationwide and internationally. His regular works, CSR activities, international presence and creative and innovative ideas to the board adds value to the overall company.

Md. Mamunur Rashid

Director

Md. Mamunur Rashid, a successful entrepreneur, is involved with many businesses where he is driving his profession with enthusiasm and sincerity. He has completed his Masters of Kamil under Bangladesh Madrasa Education Board. Besides being a Director of Techno Drugs Limited, Mr. Md. Mamunur Rashid is the proprietor of Gawsia Export Zone, Xtrenza Model Pharma, Standard Publication and many more business entities. His interpersonal skills and leadership behavior in business and hardworking nature made him worthy as director of Techno Drugs Ltd.

SK. Motiur Rahman

Independent Director

Sk. Motiur Rahman is an enthusiastic professional with drive, determination and excellent team working skills, having more than 11 years of experience as a legal professional. He is currently working in various areas of law including preparation of legal arguments for court, drafting documents and negotiating settlement both for individual clients and commercial companies and at the same time has specialization in conducting banking cases, security documentation, loan syndication, commercial litigation, and intellectual property suits. He is actively engaged as a member of Lincoln's Inn (UK), member of Dhaka Club, Padma Club, Local President JCI of Jashore, Development officer of Asia Pacific Development Council.

He has impressive educational background i.e., Bachelor of Laws (LLB) from the University of Wolverhampton, Master of Law (LLM) from the Queen Mary University of London and Bar Professional Training Course (Barrister-At-Law) from City University of London. He is currently serving as a partner of Sk. G. Rasul & Associates a well reputed Law firm in Bangladesh.

Uttam Kumar Saha, FCA

Independent Director

Uttam Kumar Saha, FCA currently serves as an independent director of Techno Drugs Limited. He is a Fellow Member of the Institute of Chartered Accountants of Bangladesh (ICAB) having more than 14 years of experience and managing key roles of various leading company in Bangladesh. He has experienced as financial lead, like Merchant Bank, Healthcare, Energy, Textile, Garments, Manufacturing and others sector. He obtained his B.com (H), M.com (Accounting) from National University. He is currently serving as a Senior Partner of Dewan Nazrul Islam & Co. Chartered Accountants.

(h) Loan status of the issuer, its directors and shareholders who hold 10% or more shares in the paid-up capital of the issuer in terms of the CIB Report of Bangladesh Bank:

Neither the Company nor any of its directors or shareholders who hold 10% or more shares in the paid-up capital of the Issuer is loan defaulter in terms of the CIB Report of Bangladesh Bank.

- (i) Name with position, educational qualification, age, date of joining in the company, overall experience (in year), previous employment, salary paid for the financial year of the Chief Executive Officer, Managing Director, Chief Financial Officer, Company Secretary, Advisers, Consultants and all Departmental Heads. If the Chairman, any director or any shareholder received any monthly salary than this information should also be included:

| Name | Position | Department | Educational Qualification | Age | Date of Joining | Overall Experience (Years) | Previous employment | Salary for the Year ended 30 June, 2023 |
|--------------------------|----------------------------------|----------------------|---------------------------|-----|-----------------|----------------------------|----------------------------------|---|
| Shah Jalal Uddin Ahmed | Managing Director | Administration | M. Pharm | 70 | 30-Sep-09 | 47 | Opsonin Pharmaceuticals Ltd. | 12,000,000 |
| Mehreen Ahmed | Director (Factory Operation) | Factory | PhD | 36 | 30-Sep-09 | 13 | N/A | 6,000,000 |
| Arefeen Raafi Ahmed | Director (Admin, Marketing & IT) | Head Office | BSc ICT | 32 | 30-Sep-09 | 13 | N/A | 6,000,000 |
| Shah Rakib Uddin Ahmed | RD | Head Office | BCom | 61 | 01-Oct-09 | 25 | Opsonin Pharmaceuticals Ltd. | 2,160,000 |
| Shah Sohel Ahmed | RD | BK Bari Factory | BSc | 50 | 01-Oct-09 | 28 | N/A | 1,680,000 |
| Shah Ripon Ahmed | RD | Narshingdi Factory | BCom | 47 | 01-Oct-09 | 28 | N/A | 1,620,000 |
| Shoab Ahmed | Chief Sales & Marketing Officer | Sales & Marketing | MSc | 50 | 01-Jan-19 | 18 | ACI Pharmaceuticals Ltd. | 1,800,000 |
| Pijush Kumar Chakroborty | Chief Financial Officer | Accounts and Finance | FCA | 41 | 01-Feb-14 | 11 | Paramount Textile Ltd. | 2,160,000 |
| Parimal Chandra Sarkar | Head of Project | B.K Bari Factory | BSc in Mechanical | 57 | 06-Apr-16 | 26 | Opsonin Pharmaceuticals Ltd | 1,986,000 |
| Debasish Das Gupta | Company Secretary | Company Secretarial | MBA | 39 | 01-Apr-19 | 13 | Haque, Hasan, Ahmed & Associates | 1,440,000 |

| | | | | | | | | |
|-----------------------------|-----------------|------------------------|---------------------|----|-----------|----|-------------------------------------|-----------|
| Mr. Majedul Karim | AGM | Commercial & Admin | Diploma in Hardware | 45 | 15-May-02 | 21 | N/A | 1,578,000 |
| Md. Shafiqul Islam Talukder | Plant Manager | BK Bari Factory | M Pharm | 54 | 01-Dec-23 | 28 | Concord Pharmaceuticals Ltd | - |
| Md. Shafiqul Islam | Plant In Charge | Narshingdi Factory | M Pharm | 45 | 15-Oct-22 | 18 | IBN Sina Pharma Pharmaceuticals Ltd | 1,020,000 |
| Md. Aktaruzzaman | Deputy Manager | Information Technology | BSc in CSE | 33 | 15-Mar-18 | 11 | Opsonin Pharmaceuticals Ltd. | 1,140,000 |
| Ishrat Jabeen | Manager | HR | MBA | 48 | 27-Jun-19 | 17 | PRAN-RFL Group | 1,020,000 |
| Md. Liakat Ali Khan | General Manager | Sales & Marketing | MSc | 65 | 17-Mar-22 | 34 | Ziska Pharmaceuticals Ltd. | 1,800,000 |
| Md. Zakir Hossain | General Manager | Sales & Marketing | MSc | 52 | 01-Oct-09 | 22 | Ms. Techno Drugs | 2,880,000 |
| Md. Anisur Rahman | Manager | Distribution | MSc | 40 | 22-Jul-10 | 13 | N/A | 960,000 |

The Company has no permanent advisor and consultant.

- (j) **Changes in the key management persons during the last three years. Any change otherwise than by way of retirement in the normal course in the senior key management personnel particularly in charge of production, planning, finance and marketing during the last three years prior to the date of filing the information memorandum. If the turnover of key management personnel is high compared to the industry, reasons should be discussed:**

The following changes have been made in the senior key management personnel during the last three years:

| Name of the employee | Position/Designation | Date of Joining | Remarks |
|----------------------|----------------------|-----------------|-----------------|
| Md. Shafiqul Islam | Plant In Charge | 15-Oct-22 | Newly appointed |
| Md. Liakat Ali Khan | General Manager | 17-Mar-22 | Newly appointed |

(k) A profile of the sponsors including their names, father's names, age, personal addresses, educational qualifications, and experiences in the business, positions or posts held in the past, directorship held, other ventures of each sponsor and present position:

| Name, Father's Name, Age & Personal Address | | Educational Qualification | Experience (Years) | Position/Post | | Holding in other Venture |
|---|--|---------------------------|--------------------|-----------------------------|-----------------------------|--|
| | | | | Past | Present | |
| Name: | Shah Jalal Uddin Ahmed | B. Pharma, M. Pharma | 47 Years | Sponsor & Managing Director | Sponsor & Managing Director | G C Box Ltd. Techno Cosmeceuticals Ltd. Techno Agrovvet & Fisheries Ltd. |
| Father's Name: | Late Mainuddin Ahmed | | | | | |
| Age: | 70 Years | | | | | |
| Personal Address: | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | | | | | |
| Name: | Khaleda Akhter Khan | BSS | 43 Years | Sponsor & Chairman | Sponsor & Chairman | G C Box Ltd. Techno Cosmeceuticals Ltd. Techno Agrovvet & Fisheries Ltd. |
| Father's Name: | Late Mohammad Masum Khan | | | | | |
| Age: | 69 Years | | | | | |
| Personal Address: | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | | | | | |

| | | | | | | |
|--------------------------|--|--|----------|--------------------|--------------------|--|
| Name: | Mehreen Ahmed | | | | | |
| Father's Name: | Director | B. Pharma, PhD in Pre-Clinical Oncology from University of Nottingham, UK and her MSC in Pharmacology from University of Hertfordshire, UK | 13 Years | Sponsor & Director | Sponsor & Director | G C Box Ltd. Techno Cosmeceuticals Ltd. Greentech Holidays Limited. Techno Agrovet & Fisheries Ltd. |
| Age: | 36 Years | | | | | |
| Personal Address: | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | | | | | |
| Name: | Arefeen Raafi Ahmed | | | | | |
| Father's Name: | Shah Jalal Uddin Ahmed | B. Sc from University of Western Sydney, Australia in ICT | 13 Years | Sponsor & Director | Sponsor & Director | G C Box Limited. Pulse Tech Limited Techno Cosmeceuticals Ltd. Greentech Holidays Ltd. MedBox Solution Ltd. Techno Agrovet & Fisheries Ltd. |
| Age: | 32 Years | | | | | |
| Personal Address: | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | | | | | |

- (l) **If the present directors are not the sponsors and control of the issuer was acquired within five years immediately preceding the date of filing prospectus details regarding the acquisition of control, date of acquisition, terms of acquisition, consideration paid for such acquisition etc.**

The following directors are not the sponsors of the Company and control of the issuer was acquired in following manner:

| Name | Acquisition of Control | Date of Acquisition | Terms of Acquisition | Consideration paid for such Acquisition |
|-----------------------|------------------------|---------------------|----------------------|---|
| Md. Mamunur Rashid | 31 Aug, 2023 | 11-Apr-21 | - | Cash |
| SK. Motiur Rahman | 31 Aug, 2023 | N/A | - | Appoint as |
| Uttam Kumar Saha, FCA | 31 Aug, 2023 | N/A | - | Independent Director |

- (m) **If the sponsors or directors do not have experience in the proposed line of business, the fact explaining how the proposed activities would be carried out or managed:**

The sponsors and directors are highly experienced to carry out this line of business.

- (n) **Interest of the key management persons:**

There is no other interest with the key management persons except remuneration/salary, office rent received by them.

- (o) **All interests and facilities enjoyed by a director, whether pecuniary or non-pecuniary:**

Facilities whether pecuniary or non-pecuniary enjoyed by the Directors will remain unchanged during the publication period of the Prospectus.

- (p) **Number of shares held and percentage of shareholding (pre issue):**

| Sl. | Name of Director | Position | Number of Shares Held | % | |
|--------------|------------------------|----------------------|-----------------------|---------------|---------------|
| | | | | Pre-IPO | Post-IPO |
| 1 | Shah Jalal Uddin Ahmed | Managing Director | 59,455,000 | 63.14% | 45.61% |
| 2 | Khaleda Akhter Khan | Chairman | 7,475,000 | 7.94% | 5.73% |
| 3 | Mehreen Ahmed | Director | 4,485,000 | 4.76% | 3.44% |
| 4 | Arefeen Raafi Ahmed | Director | 4,485,000 | 4.76% | 3.44% |
| 5 | Md. Mamunur Rashid | Director | 6,876,200 | 7.30% | 5.27% |
| 6 | SK. Motiur Rahman | Independent Director | - | 0.00% | 0.00% |
| 7 | Uttam Kumar Saha, FCA | | - | 0.00% | 0.00% |
| Total | | | 82,776,200 | 87.91% | 63.50% |

- (q) **Change in board of directors during last three years:**

| Sl. | Name of the Director | Date of first Directorship | Date of retirement | Present Status |
|-----|-----------------------|----------------------------|--------------------|----------------------|
| 1 | Md. Mamunur Rashid | 31 Aug, 2023 | 16th AGM in 2025 | Director |
| 2 | SK. Motiur Rahman | 31 Aug, 2023 | 17th AGM in 2027 | Independent Director |
| 3 | Uttam Kumar Saha, FCA | 31 Aug, 2023 | 17th AGM in 2027 | Independent Director |

- (r) **Director's engagement with similar business:**

There is no engagement of any director with similar business.

CHAPTER (IX)

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

- (a) **The prospectus shall contain a description of any transaction during the last five years, or any proposed transactions certified by the auditors, between the issuer and any of the following persons, giving the name of BO the persons involved in the transaction, their relationship with the issuer, the nature of their interest in the transaction and the amount of such interest, namely: -**

This is to certify that the Financial Statements of Techno Drugs Ltd. furnished for our audit does not have any transaction during the last five years, or any proposed transaction, between the issuer and any of the following persons:

- (i) Any director or sponsor or executive officer of the issuer;
- (ii) Any person holding 5% or more of the outstanding shares of the issuer;
- (iii) Any related party or connected person of any of the above persons;

Except the transactions described in the following table:

A. Remuneration:

| Name | Nature of Transaction | Amount in (BDT) | | | | | | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|
| | | June 30, 2023 | | June 30, 2022 | | June 30, 2021 | | June 30, 2020 | | June 30, 2019 | |
| | | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued |
| Khaleda Akther Khan | Remuneration | - | - | - | - | 9,600,000 | 800,000 | 9,600,000 | 800,000 | 9,600,000 | 800,000 |
| Shah Jalal Uddin Ahmed | | 12,000,000 | 12,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 |
| Mehreen Ahmed | | 6,000,000 | 6,000,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 |
| Arefeen Raafi Ahmed | | 6,000,000 | 6,000,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 |
| Total | | 24,000,000 | 24,000,000 | 24,000,000 | 2,000,000 | 33,600,000 | 2,800,000 | 33,600,000 | 2,800,000 | 33,600,000 | 2,800,000 |

B. Office Rent:

| Name | Nature of Transaction | Amount in (BDT) | | | | | | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|----------|-------------------|----------|-------------------|----------|-------------------|----------|
| | | June 30, 2023 | | June 30, 2022 | | June 30, 2021 | | June 30, 2020 | | June 30, 2019 | |
| | | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued |
| Khaleda Akther Khan | Office Rent | 7,560,000 | 7,560,000 | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - |
| Shah Jalal Uddin Ahmed | | 7,560,000 | 7,560,000 | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - |
| Total | | 15,120,000 | 15,120,000 | 15,120,000 | - | 15,120,000 | - | 15,120,000 | - | 15,120,000 | - |

Place: Dhaka
Date: September 27, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

- (b) **Any transaction or arrangement entered into by the issuer or its subsidiary or associate or entity owned or significantly influenced by a person who is currently a director or in any way connected with a director of either the issuer company or any of its subsidiaries or holding company or associate concerns, or who was a director or connected in any way with a director at any time during the last three years prior to the issuance of the prospectus;**

There is no transaction or arrangement entered into by the issuer or its subsidiary or associate or entity owned or significantly influenced by a person who is currently a director or in any way connected with a director of either the issuer company or any of its subsidiaries or holding company or associate concerns, or who was a director or connected in any way with a director at any time during the last three years prior to the issuance of the prospectus except the transaction mentioned in CHAPTER (IX) (a).

- (c) **Any loans either taken or given from or to any director or any person connected with the director, clearly specifying details of such loan in the prospectus, and if any loan has been taken from any such person who did not have any stake in the issuer, its holding company or its associate concerns prior to such loan, rate of interest applicable, date of loan taken, date of maturity of loan. and present outstanding of such loan.**

No such loan was taken or given from or to Directors or any person connected with the Directors of Techno Drugs Ltd.

CHAPTER (X)

EXECUTIVE COMPENSATION

- (a) The total amount of remuneration or salary or perquisites paid to the top five salaried officers of the issuer in the last accounting year and the name and designation of each such officer:

| SL | Name | Designation | Remuneration/salaries (Tk.) For the year ended 30.06.2023 |
|----|--------------------------|--|---|
| 1 | Shah Jalal Uddin Ahmed | Managing Director | 12,000,000 |
| 2 | Mehreen Ahmed | Director (Factory Operation) | 6,000,000 |
| 3 | Arefeen Raafi Ahmed | Director (Admin, Marketing & IT) | 6,000,000 |
| 4 | Md. Zakir Hossain | General Manager (Sales & Marketing) | 2,880,000 |
| 5 | Pijush Kumar Chakroborty | Chief Financial Officer | 2,160,000 |

- (b) Aggregate amount of remuneration paid to all directors and officers as a group during the last accounting year:

| SL. | Particular | Nature of Transaction | Amount (in Taka) |
|-----|---------------------|-----------------------|-------------------------------|
| | | | For the year ended 30.06.2023 |
| 1 | Directors | Remuneration | 12,000,000 |
| 2 | Managing Director | Remuneration | 12,000,000 |
| 3 | Directors | Board Meeting Fee | - |
| 4 | Officers and staffs | Salary and Allowances | 506,404,230 |

- (c) If any shareholder director received any monthly salary or perquisite or benefit it must be mentioned along with date of approval in AGM or EGM, terms thereof and payments made during the last accounting year:

Shah Jalal Uddin Ahmed, Managing Director; Mehreen Ahmed, Director and Arefeen Raafi Ahmed have received Tk. 12,000,000.00, Tk. 6,000,000.00 and Tk. 6,000,000.00 per year. This remuneration was approved in the Annual General Meeting (AGM) dated December 31, 2017.

- (d) The board meeting attendance fees received by the director including the managing director along with date of approval in AGM or EGM:

None of directors has received board meeting attendance fees including the managing director.

- (e) Any contract with any director or officer providing for the payment of future compensation:

There is no contract between the Company and any of directors or officers regarding any future compensation to be paid to them.

- (f) If the issuer intends to substantially increase the remuneration paid to its directors and officers in the current year, appropriate information regarding thereto:

The company has no intention to substantially increase the remuneration paid to its directors and officers in the current year. But the company would provide annual increment to the employees considering the business growth, rate of inflation and performance of the individual.

- (g) Any other benefit or facility provided to the above persons during the last accounting year:

The company has not paid any other benefit/facility to its directors except as stated above.

CHAPTER (XI)

OPTIONS GRANTED TO DIRECTORS, OFFICERS AND EMPLOYEES

The Company did not grant any stock option to any Officer, Director or any other employee of the Company or to any other person involved with the Company. But Techno Drugs Ltd. intends to offer shares to its employees and others as part of the private offer of the IPO, and shares will be allocated and issued subject to approval of the BSEC at the time of allotment to the public (IPO).

CHAPTER (XII)

TRANSACTION WITH THE DIRECTORS AND SUBSCRIBERS TO THE MEMORANDUM

(a) The names of the directors and subscribers to the memorandum, the nature and amount of anything of value received or to be received by the issuer from the above persons, or by the said persons, directly or indirectly, from the issuer during the last five years along with the description of assets, services or other consideration received or to be received;

The Directors and subscribers to the memorandum of association have received the following benefits directly or indirectly from the issuer during the last five years:

i. Remuneration:

| Name | Nature of Transaction | Amount in (BDT) | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Khaleda Akther Khan | Remuneration | - | - | 9,600,000 | 9,600,000 | 9,600,000 |
| Shah Jalal Uddin Ahmed | Remuneration | 12,000,000 | 12,000,000 | 12,000,000 | 12,000,000 | 12,000,000 |
| Mehreen Ahmed | Remuneration | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 |
| Arefeen Raafi Ahmed | Remuneration | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 | 6,000,000 |
| Total | | 24,000,000 | 24,000,000 | 33,600,000 | 33,600,000 | 33,600,000 |

ii. Office Rent:

| Name | Nature of Transaction | Amount in (BDT) | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| | | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Khaleda Akther Khan | Office Rent | 7,560,000 | 7,560,000 | 7,560,000 | 7,560,000 | 7,560,000 |
| Shah Jalal Uddin Ahmed | Office Rent | 7,560,000 | 7,560,000 | 7,560,000 | 7,560,000 | 7,560,000 |
| Total | | 15,120,000 | 15,120,000 | 15,120,000 | 15,120,000 | 15,120,000 |

iii. Allotment of shares against fund:

The Directors and subscribers to the memorandum of association have received allotment of shares against share money deposit during the last five years.

(b) If any assets were acquired or to be acquired within next two financial years from the aforesaid persons, the amount paid for such assets and the method used to determine the price shall be mentioned in the prospectus, and if the assets were acquired by the said persons within five years prior to transfer those to the issuer, the acquisition cost thereof paid by them.

Techno Drugs Ltd. has received the following fund or assets from its Directors and subscribers to the memorandum during the last five years:

i. Fund against allotment of shares:

Techno Drugs Ltd. has received share money deposit against allotment of shares from the Directors and subscribers to the memorandum of association during the last five years.

ii. Assets (net assets as well as operational and products licenses): Techno Drugs Ltd. has acquired net assets from Shahjalal Uddin Ahmed against other than cash.

| Transferor | Transferee | Relations | Deed Value (Tk.) | Selling Price (Tk.) | Method used to determine the price |
|-----------------------|-------------------|-------------------|-------------------------|----------------------------|---|
| Shahjalal Uddin Ahmed | Techno Drugs Ltd. | Managing Director | 8,000,000 | 8,000,000 | At competitive market price |

CHAPTER (XIII)

OWNERSHIP OF THE COMPANY'S SECURITIES

a) The names, addresses, BO ID Number of all shareholders of the company before IPO, indicating the amount of securities owned and the percentage of the securities represented by such ownership, in tabular form:

| Sl. | Name of the Shareholders | Position | Address | BO IDs | Number of Shares Held | Pre IPO % |
|--------------|-------------------------------|-----------------------------|---|------------------|-----------------------|----------------|
| 1 | Shah Jalal Uddin Ahmed | Sponsor & Managing Director | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | 1202750076139668 | 59,455,000 | 63.14% |
| 2 | Khaleda Akhter Khan | Sponsor & Chairman | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | 1202750076139767 | 7,475,000 | 7.94% |
| 3 | Arefeen Raafi Ahmed | Sponsor & Director | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | 1602770068934171 | 4,485,000 | 4.76% |
| 4 | Mehreen Ahmed | Sponsor & Director | 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217 | 1202750076139791 | 4,485,000 | 4.76% |
| 5 | Md. Mamunur Rashid | Director | Vill: Barikhola, PO: Laur Fatehpur, PS: Nabinagar, Dist: B. Baria | 1204570024992933 | 6,876,200 | 7.30% |
| 6 | Md. Shah Rakib Uddin Ahmed | Shareholder | Flat No.-504, Eastern Villa,6 Segun Bagicha Dhaka | 1203390042873060 | 27,000 | 0.03% |
| 7 | Shah Ripan Ahmed | Shareholder | 162/2, Uttar Satir Para, Narsindi Sader, Narsindi | 1202750076139577 | 27,000 | 0.03% |
| 8 | Shah Sohel Ahmed | Shareholder | 162/2, Uttar Satir Para, Narsindi Sader, Narsindi | 1202750076139550 | 27,000 | 0.03% |
| 9 | Md. Reazul Hoque | Shareholder | 277/2, Nur E Monjil, Elephant Road, Katabon, Newmarket, Dhaka | 1204030074681788 | 1,500,000 | 1.59% |
| 10 | Greentech Holidays Ltd. | Shareholder | JK Tower, 31, Segunbagicha, Dhaka | 1602770075662000 | 1,500,200 | 1.59% |
| 11 | S. M. Al Jubayer Ahmed | Shareholder | 22, Doctor Goli, Malibagh, Dhaka | 1203040062626201 | 1,500,000 | 1.59% |
| 12 | TMC Pvt. Ltd. | Shareholder | Rupsa Tower, Flat14, Plot-17, Banani C/A, Dhaka | 1201960076155185 | 1,400,000 | 1.49% |
| 13 | Picked Agrotec Ltd. | Shareholder | Paramount Heights (4th floor), 4-D-2, 65/1, Box Culvert Road, Purana Paltan, Dhaka | 1205150075651025 | 600,000 | 0.64% |
| 14 | Excel Farmganic Limited | Shareholder | Charabagh, Savar, Ashulia, Dhaka | 1202930074520221 | 500,000 | 0.53% |
| 15 | Md. Salim Sarker | Shareholder | Sarker Bari, Nagor Par, Muradnagar, Comilla | 1201950000604573 | 2,300,000 | 2.44% |
| 16 | Colour N Life Limited | Shareholder | Bishal Center, 12/A, 216, Shahid Sangbadik Selina Parvin Road, Boro Mogbazar, Dhaka | 1202530074766514 | 500,000 | 0.53% |
| 17 | CMC Enterprise | Shareholder | Ga-185, Mohakhali, Dhaka | 1205700076154397 | 800,000 | 0.85% |
| 18 | Conducive Corp. Services Ltd. | Shareholder | Motaleb Tower (5th floor), 8/2, Paribagh, Shahbagh, Dhaka | 1201960076155209 | 700,000 | 0.74% |
| Total | | | | | 94,157,400 | 100.00% |

b) There shall also be a table showing the name and address, age, experience, BO ID Number, TIN number, numbers of shares held including Percentage, position held in other companies of all the directors before the public issue:

| Sl. | Name of Director, Address, Age & Experience | No. of Share | % Pre-IPO | Position held in Other Organization | |
|-----|--|--------------|-----------|--|---|
| | | | | Other Organization | Position |
| 1 | <p>Name: Shah Jalal Uddin Ahmed <i>Managing Director</i> 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Age: 70 Years</p> <p>Experience: 47 Years</p> <p>BO ID No.: 1202750076139668</p> <p>TIN No.: 649304260655</p> | 59,455,000 | 63.14% | <p>G C Box Ltd.</p> <p>Techno Cosmeceuticals Ltd.</p> <p>Techno Agrovet & Fisheries Ltd.</p> | <p>Managing Director</p> <p>Managing Director</p> <p>Director</p> |
| 2 | <p>Name: Khaleda Akhter Khan <i>Chairman</i> 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Age: 69 Years</p> <p>Experience: 43 Years</p> <p>BO ID No.: 1202750076139767</p> <p>TIN No.: 196559794944</p> | 7,475,000 | 7.94% | <p>G C Box Ltd.</p> <p>Techno Cosmeceuticals Ltd.</p> <p>Techno Agrovet & Fisheries Ltd.</p> | <p>Chairman</p> <p>Chairman</p> <p>Director</p> |

| | | | | | |
|---|--|-----------|-------|--|--|
| 3 | <p>Name: Mehreen Ahmed <i>Director</i> 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Age: 36 Years</p> <p>Experience: 13 Years</p> <p>BO ID No.: 1605640068934171</p> <p>TIN No.: 477808262714</p> | 4,485,000 | 4.76% | G C Box Ltd. Techno Cosmeceuticals Ltd. Greentech Holidays Limited. Techno Agrovet & Fisheries Ltd. | Director Director Chairman Chairman |
| 4 | <p>Name: Arefeen Raafi Ahmed <i>Director</i> 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Address: 5/G, Aminabad Co-Operative Housing Society, 56-57, Siddeswari Road, Dhaka-1217</p> <p>Age: 32 Years</p> <p>Experience: 13 Years</p> <p>BO ID No.: 1602770068934171</p> <p>TIN No.: 792817971260</p> | 4,485,000 | 4.76% | G C Box Limited. Pulse Tech Limited Techno Cosmeceuticals Ltd. Greentech Holidays Ltd. MedBox Solution Ltd. Techno Agrovet & Fisheries Ltd. | Director Managing Director Director Managing Director Director Director |
| 5 | <p>Name: Md. Mamunur Rashid <i>Director</i> Vill: Barikhola, PO: Laur Fatehpur, PS: Nabinagar, Dist: B. Baria</p> <p>Address: Vill: Barikhola, PO: Laur Fatehpur, PS: Nabinagar, Dist: B. Baria</p> <p>Age: 44 Years</p> <p>Experience: 19 Years</p> | 6,876,200 | 7.30% | Not involved in other organization | - |

| | | | | | |
|---|--|---|---|------------------------------------|---|
| | BO ID No.: 1204570024992933 | | | | |
| | TIN No.: 835818109106 | | | | |
| 6 | Name: SK. Motiur Rahman <i>Independent Director</i> Address: 10/B Concord, 5 Segunbagicha, Ramna, Dhaka Age: 35 Years Experience: 11 Years BO ID No.: - TIN No.: 151412941517 | - | - | Not involved in other organization | - |
| 7 | Name: Uttam Kumar Saha, FCA <i>Independent Director</i> Address: Level-5, Green Zone Tower, 1 No Hatkhola Road, Wari Dhaka-1203 Age: 40 Years Experience: 14 Years BO ID No.: - TIN No.: 737659796282 | - | - | Not involved in other organization | - |

c) The average cost of acquisition of equity shares by the directors certified by the auditors:

Techno Drugs Ltd. has been allotted shares in face value through in cash; other than cash & bonus and the average cost of acquisition of equity by the directors is Tk. 10.00 each. Necessary particulars of shareholdings, allotment date and consideration are given below:

| Date | Allotment/ Transfer | Shah Jalal Uddin Ahmed | Khaleda Akhter Khan | Mehreen Ahmed | Arefeen Raafi Ahmed | Md. Mamunur Rashid | SK. Motiur Rahman | Uttam Kumar Saha, FCA | Consideration | Face value of Share (Tk.) |
|--------------|------------------------|------------------------------|---------------------------|------------------|------------------------|-----------------------|-------------------------|--------------------------|--------------------|---------------------------------------|
| | | Managing Director | Chairman | Director | Director | Director | Independent Director | Independent Director | | |
| 30-Sep-09 | Allotment | 10,000 | 10,000 | 10,000 | 10,000 | - | - | - | Cash | 10.00 |
| 8-Sep-12 | Allotment | 8,000,000 | - | - | - | - | - | - | Other than cash | 10.00 |
| 16-Oct-17 | Allotment | 1,920,000 | - | - | - | - | - | - | Cash | 10.00 |
| 29-Jun-19 | Transfer | (1,485,000) | 495,000 | 495,000 | 495,000 | - | - | - | Cash | 10.00 |
| 7-Jan-20 | Allotment | 42,225,000 | 2,525,000 | 2,525,000 | 2,525,000 | - | - | - | Bonus | 10.00 |
| 25-Oct-20 | Allotment | 1,030,000 | 3,470,000 | 870,000 | 870,000 | - | - | - | Cash | 10.00 |
| 11-Apr-21 | Allotment | - | - | - | - | 6,876,000 | - | - | Cash | 10.00 |
| 30-Dec-21 | Allotment | 7,755,000 | 975,000 | 585,000 | 585,000 | 1,031,400 | - | - | Bonus | 10.00 |
| 16-May-22 | Transfer | - | - | - | - | (1,031,200) | - | - | Cash | 10.00 |
| Total | | 59,455,000 | 7,475,000 | 4,485,000 | 4,485,000 | 6,876,200 | - | - | | |

The Company has changed the face value of its ordinary share from Tk. 1000.00 to Tk. 10.00 by passing a special resolution in its extraordinary general meeting held on August 18, 2019 and necessary amendments in capital clause of the Memorandum and Articles of Association were made accordingly.

Place: Dhaka
Date: September 27, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

d) A detail description of capital built up in respect of shareholding (name-wise) of the issuer's sponsors or directors. In this connection, a statement to be included: -

Shah Jalal Uddin Ahmed

Managing Director

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|-----------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| 30-Sep-09 | Cash | Ordinary Share | 10,000 | 10.00 | 10.00 | 10,000 | 63.14% | 45.61% | Own Source |
| 8-Sep-12 | Other than cash | | 8,000,000 | 10.00 | 10.00 | 8,010,000 | | | |
| 16-Oct-17 | Cash | | 1,920,000 | 10.00 | 10.00 | 9,930,000 | | | |
| 29-Jun-19 | Cash | | (1,485,000) | 10.00 | 10.00 | 8,445,000 | | | |
| 7-Jan-20 | Bonus | | 42,225,000 | 10.00 | 10.00 | 50,670,000 | | | |
| 25-Oct-20 | Cash | | 1,030,000 | 10.00 | 10.00 | 51,700,000 | | | |
| 30-Dec-21 | Bonus | | 7,755,000 | 10.00 | 10.00 | 59,455,000 | | | |

Khaleda Akhter Khan

Chairman

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| 30-Sep-09 | Cash | Ordinary Share | 10,000 | 10.00 | 10.00 | 10,000 | 7.94% | 5.73% | Own Source |
| 29-Jun-19 | Cash | | 495,000 | 10.00 | 10.00 | 505,000 | | | |
| 7-Jan-20 | Bonus | | 2,525,000 | 10.00 | 10.00 | 3,030,000 | | | |
| 25-Oct-20 | Cash | | 3,470,000 | 10.00 | 10.00 | 6,500,000 | | | |
| 30-Dec-21 | Bonus | | 975,000 | 10.00 | 10.00 | 7,475,000 | | | |

Mehreen Ahmed

Director

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| 30-Sep-09 | Cash | Ordinary Share | 10,000 | 10.00 | 10.00 | 10,000 | 4.76% | 3.44% | Own Source |
| 29-Jun-19 | Cash | | 495,000 | 10.00 | 10.00 | 505,000 | | | |
| 7-Jan-20 | Bonus | | 2,525,000 | 10.00 | 10.00 | 3,030,000 | | | |
| 25-Oct-20 | Cash | | 870,000 | 10.00 | 10.00 | 3,900,000 | | | |
| 30-Dec-21 | Bonus | | 585,000 | 10.00 | 10.00 | 4,485,000 | | | |

Arefeen Raafi Ahmed

Director

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| 30-Sep-09 | Cash | Ordinary Share | 10,000 | 10.00 | 10.00 | 10,000 | 4.76% | 3.44% | Own Source |
| 29-Jun-19 | Cash | | 495,000 | 10.00 | 10.00 | 505,000 | | | |
| 7-Jan-20 | Bonus | | 2,525,000 | 10.00 | 10.00 | 3,030,000 | | | |
| 25-Oct-20 | Cash | | 870,000 | 10.00 | 10.00 | 3,900,000 | | | |
| 30-Dec-21 | Bonus | | 585,000 | 10.00 | 10.00 | 4,485,000 | | | |

Md. Mamunur Rashid

Director

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| 11-Apr-21 | Cash | Ordinary Share | 6,876,000 | 10.00 | 10.00 | 6,876,000 | 7.30% | 5.27% | Own Source |
| 30-Dec-21 | Bonus | | 1,031,400 | 10.00 | 10.00 | 7,907,400 | | | |
| 16-May-22 | Cash | | (1,031,200) | 10.00 | 10.00 | 6,876,200 | | | |

SK. Motiur Rahman*Independent Director*

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

Uttam Kumar Saha, FCA*Independent Director*

| Date of Allotment/ Transfer of fully paid- up shares | Consideration | Nature of issue | No. of Equity shares | Face value | Issue Price/Acquisition Price/Transfer Prices | Cumulative no. of Equity shares | % Pre-issue paid up capital | % Post issue paid up capital | Sources of fund |
|--|---------------|-----------------|----------------------|------------|---|---------------------------------|-----------------------------|------------------------------|-----------------|
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

The Company has changed the face value of its ordinary share from Tk. 1000.00 to Tk. 10.00 by passing a special resolution in its extraordinary general meeting held on August 18, 2019 and necessary amendments in capital clause of the Memorandum and Articles of Association were made accordingly.

e) Detail of shares issued by the company at a price lower than the issue price:

All the shares are issued by the Company at face value of Tk. 10.00 before this issue.

f) History of significant (5% or more) changes in ownership of securities from inception:

| Date | Allotment/Transfer | Shah Jalal Uddin Ahmed | Khaleda Akhter Khan | Md. Mamunur Rashid |
|--------------|--------------------|---------------------------|------------------------|-----------------------|
| | | No. of Share | | |
| 30-Sep-09 | Allotment | 10,000 | 10,000 | - |
| 8-Sep-12 | Allotment | 8,000,000 | - | - |
| 16-Oct-17 | Allotment | 1,920,000 | - | - |
| 29-Jun-19 | Transfer | (1,485,000) | 495,000 | - |
| 7-Jan-20 | Allotment | 42,225,000 | 2,525,000 | - |
| 25-Oct-20 | Allotment | 1,030,000 | 3,470,000 | - |
| 11-Apr-21 | Allotment | - | - | 6,876,000 |
| 30-Dec-21 | Allotment | 7,755,000 | 975,000 | 1,031,400 |
| 16-May-22 | Transfer | - | - | (1,031,200) |
| Total | | 59,455,000 | 7,475,000 | 6,876,200 |

The Company has changed the face value of its ordinary share from Tk. 1000.00 to Tk. 10.00 by passing a special resolution in its extraordinary general meeting held on August 18, 2019.

CHAPTER (XIV)

CORPORATE GOVERNANCE

(a) A disclosure to the effect that the issuer has complied with the requirements of Corporate Governance Guidelines of the Commission:

MANAGEMENT DISCLOSURE REGARDING COMPLIANCE WITH THE REQUIREMENTS OF CORPORATE GOVERNANCE CODE OF BANGLADESH SECURITIES AND EXCHANGE COMMISSION

We would like to declare that we have complied with all the requirements of the applicable regulations of Corporate Governance Code of Bangladesh Securities and Exchange Commission (BSEC) in respect of corporate governance including the constitution of the Board and committees thereof. The corporate governance framework is based on an effective independent Board, separation of the Boards supervisory role from the executive management team and constitution of the Board Committees, as required under applicable law.

Sd/-

Shah Jalal Uddin Ahmed

Managing Director

Techno Drugs Ltd.

(b) A compliance report of Corporate Governance requirements certified by competent authority:

Report to the Shareholders of Techno Drugs Ltd. on compliance on the Corporate Governance Code.

We have examined the compliance status to the Corporate Governance Code by **Techno Drugs Ltd.** for the period ended 30th June 2023. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, Dated: 3 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

- (a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission Except under conditions number 1(2)(c), 1(7)(b), 5(3)(c), 5(4)(a), 6(3)(c) 6(5)(c) 8 & 9(2).
- (b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;
- (c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the securities laws and other relevant laws ; and
- (d) The governance of the company is satisfactory.

For Podder & Associates

Sd/-

Jayanta Kumer Podder

Cost & Management Accountants

Place: Dhaka

Dated: 27 September 2023

(c) Details relating to the issuer's audit committee and remuneration committee, including the names of committee members and a summary of the terms of reference under which the committees operate:

Techno Drugs Ltd

Status of Compliance with the Corporate Governance Code (CGC)

For the year ended 30th June 2023

Status of compliance with the conditions imposed by the Commission's Notification No. SEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

(Report under Condition No. 9)

| Condition No. | Title | Complied | Not Complied | Remarks (IF ANY) |
|---------------|--|----------|--------------|---|
| 1 | Board of Directors | | | |
| 1(1) | Size of the Board of Directors | | | |
| | The total number of the board members of the company shall not be less than 5 (five) and more than 20 (twenty) | √ | | |
| 1(2) | Independent Directors | | | |
| 1(2)(a) | At least one fifth (1/5) of the total number of directors in the company's board shall be independent directors. | √ | | The boards of Directors are comprised of 07 Directors including Two (02) Independent Director |
| 1(2)(b) | For the purpose of this clause 'independent director' means a director- | | | |
| 1(2)(b)(i) | Who either does not hold any share in the company or holds less than one percent (1%) shares of the total paid-up shares of the company; | √ | | |
| 1(2)(b)(ii) | who is not a sponsor of the company and is not connected with the company's any sponsor or director or nominated director or shareholder of the company or any of its associates, sister concerns, subsidiaries and parents or holding entities who holds one percent (1%) or more shares of the total paid up shares of the company on the basis of family relationship and his or her family members shall not hold above mentioned shares in the company; | √ | | |
| 1(2)(b)(iii) | who has not been an executive of the company in immediately preceding 2 (two) financial years; | √ | | |
| 1(2)(b)(iv) | who does not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary or associated companies; | √ | | |
| 1(2)(b)(v) | who is not a member or TREC (Trading Right Entitlement Certificate) holder, director or officer of any stock exchange; | √ | | |

| | | | | |
|---------------|--|---|---|---|
| 1(2)(b)(vi) | who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market; | √ | | |
| 1(2)(b)(vii) | who is not a partner or an executive or was not a partner or an executive during the preceding 3 (three) years of the concerned company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this Code; | √ | | |
| 1(2)(b)(viii) | who is not independent director in more than 5 (five) listed companies; | √ | | |
| 1(2)(b)(ix) | who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or any advance to a bank or a Non-Bank Financial Institution (NBFI); | √ | | |
| 1(2)(b)(x) | who has not been convicted for a criminal offence involving moral turpitude; | √ | | |
| 1(2)(c) | The independent director(s) shall be appointed by the Board and approved by the shareholders in the Annual General Meeting (AGM); | - | √ | Independent director has been appointed by the board of directors and to be placed before the shareholders for approval in the next AGM |
| 1(2)(d) | The post of independent director(s) cannot remain vacant for more than 90 (ninety) days; | √ | | |
| 1(2)(e) | The tenure of office of an independent director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only. | √ | | |
| 1(3) | Qualification of Independent Director | | | |
| 1(3)(a) | Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws, regulatory requirements and corporate laws and can make meaningful contribution to business; | √ | | |
| 1(3)(b) | Independent Director shall have following qualifications | | | |
| 1(3)(b)(i) | Business leader who is or was a promoter or director of an unlisted company having minimum paid up capital of Tk. 100.00 million or any listed company or a member of any national or international chamber of commerce or business association; | - | - | |

| | | | | |
|--------------|---|---|---|---------------------|
| 1(3)(b)(ii) | Corporate leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Deputy Managing Director or Chief Financial Officer or Head of Finance or Accounts or Company Secretary or Head of Internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted company having minimum paid up capital of Tk. 100.00 million or of a listed company; | - | - | |
| 1(3)(b)(iii) | Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or law; | - | - | |
| 1(3)(b)(iv) | University Teacher who has educational background in Economics or Commerce or Business Studies or Law; | - | - | |
| 1(3)(b)(v) | Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification; | √ | | |
| 1(3)(c) | The independent director shall have at least 10 (ten) years of experiences in any field mentioned in clause (b); | √ | | |
| 1(3)(d) | In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the Commission; | - | - | No such issue arose |
| 1(4) | Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer | | | |
| 1(4)(a) | The positions of the Chairperson of the Board and the Managing Director and/ or Chief Executive Officer (CEO) of the company shall be filled by different individuals; | √ | | |
| 1(4)(b) | The Managing Director (MD) and/ or Chief Executive Officer (CEO) of a listed company shall not hold the | √ | | |

| | | | | |
|-------------|--|---|---|---------------------|
| | same position in another listed company; | | | |
| 1(4)(c) | The Chairperson of the Board shall be elected from among the non-executive directors of the company; | √ | | |
| 1(4)(d) | The Board shall clearly define respective roles and responsibilities of the chairperson and the Managing Director and/ or Chief Executive Officer; | √ | | |
| 1(4)(e) | In the absence of the chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Board's meeting; the reason of absence of the regular Chairperson shall be duly recorded in the minutes. | √ | | |
| 1(5) | The Directors' Report to Shareholders: | | | |
| | The Board of the company shall include the following additional statements or disclosures in the Directors' Report prepared under section 184 of the companies Act, 1994 (Act No. XVIII of 1994):- | | | |
| 1(5)(i) | An industry outlook and possible future developments in the industry; | √ | | |
| 1(5)(ii) | The Segment-wise or product-wise performance; | √ | | |
| 1(5)(iii) | Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any; | √ | | |
| 1(5)(iv) | A discussion on Cost of Goods sold, Gross Profit Margin and Net Profit Margin, where applicable; | √ | | |
| 1(5)(v) | A discussion on continuity of any Extra-Ordinary activities and their implications (gain or loss); | √ | | |
| 1(5)(vi) | A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions; | √ | | |
| 1(5)(vii) | A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments; | - | - | No such issue arose |
| 1(5)(viii) | An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing, etc; | - | - | No such issue arose |

| | | | | |
|-------------|--|---|--|--|
| 1(5)(ix) | An explanation on any significant variance that occurs between Quarterly Financial performance and Annual Financial statements; | √ | | No such issue arose |
| 1(5)(x) | A statement of remuneration paid to the directors including independent directors | √ | | Independent Directors have not received any remuneration |
| 1(5)(xi) | The financial statements prepared by the management of the issuer company present fairly its state of affairs, the result of its operations, cash flows and changes in equity; | √ | | |
| 1(5)(xii) | Proper books of account of the issuer company have been maintained; | √ | | |
| 1(5)(xiii) | Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment; | √ | | |
| 1(5)(xiv) | International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there from has been adequately disclosed; | √ | | |
| 1(5)(xv) | The system of internal control is sound in design and has been effectively implemented and monitored; | √ | | |
| 1(5)(xvi) | Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress; | √ | | |
| 1(5)(xvii) | There is no significant doubt upon the issuer company's ability to continue as a going concern, if the issuer company is not considered to be a going concern, the fact along with reasons there of shall be disclosed; | √ | | |
| 1(5)(xviii) | An explanation that significant deviations from the last year's operating results of the issuer company shall be highlighted and the reasons thereof shall be explained; | √ | | |
| 1(5)(xix) | Key operating and financial data of at least preceding 5 (five) years shall be summarized; | √ | | |

| | | | | |
|----------------|---|---|---|------------------------------------|
| 1(5)(xx) | An explanation on the reasons if the issuer company has not declared dividend (cash or stock) for the year; | - | - | Business Expansion & Re-investment |
| 1(5)(xxi) | Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend; | √ | | |
| 1(5)(xxii) | The total number of Board meetings held during the year and attendance by each director; | √ | | |
| 1(5)(xxiii) | A report on the pattern of shareholding disclosing the aggregate number of shares (along with name-wise details where stated below) held by:- | | | |
| 1(5)(xxiii)(a) | Parent or Subsidiary or Associated Companies and other related parties (name-wise details); | √ | | |
| 1(5)(xxiii)(b) | Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children (name-wise details); | √ | | |
| 1(5)(xxiii)(c) | Executives; and | √ | | |
| 1(5)(xxiii)(d) | Shareholders holding ten percent (10%) or more voting interest in the company (name-wise details); | √ | | |
| 1(5)(xxiv) | In case of the appointment or reappointment of a director, a disclosure on the following information to the shareholders:- | | | |
| 1(5)(xxiv)(a) | a brief resume of the director | √ | | |
| 1(5)(xxiv)(b) | nature of his or her expertise in specific functional areas; | √ | | |
| 1(5)(xxiv)(c) | names of companies in which the person also holds the directorship and the membership of committees of the Board; | √ | | |
| 1(5)(xxv) | Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on: | √ | | |
| 1(5)(xxv)(a) | accounting policies and estimation for preparation of financial statements; | √ | | |
| 1(5)(xxv)(b) | changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes; | √ | | |

| | | | | |
|--------------|--|---|--|--|
| 1(5)(xxv)(c) | comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof; | √ | | |
| 1(5)(xxv)(d) | compare such financial performance or results and financial position as well as cash flows with the peer industry scenario; | √ | | |
| 1(5)(xxv)(e) | briefly explain the financial and economic scenario of the country and the globe; | √ | | |
| 1(5)(xxv)(f) | risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; | √ | | |
| 1(5)(xxv)(g) | future plan or projection or forecast for company's operation, performance and financial position, with justification thereof, i.e., actual position shall be explained to the shareholders in the next AGM; | √ | | |
| 1(5)(xxvi) | Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A; | √ | | |
| 1(5)(xxvii) | The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C . | √ | | |
| 1(6) | Meetings of the Board of Directors: | | | |
| | The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code. | √ | | |
| 1(7) | Code of Conduct for the Chairperson, other Board members and Chief Executive Officer | | | |
| 1(7)(a) | The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the company; | √ | | |

| | | | | |
|-------------|--|---|---|--------------------------------|
| 1(7)(b) | The code of conduct as determined by the NRC shall be posted on the website of the company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency. | | √ | Will be complied while listing |
| 2 | Governance of Board of Directors of Subsidiary Company | Techno Drugs Ltd. does not have any Subsidiary Company | | |
| 2(a) | Provisions relating to the composition of the Board of the holding company shall be made applicable to the composition of the Board of the subsidiary company; | - | - | N/A |
| 2(b) | At least 1 (one) independent director on the Board of the holding company shall be a director on the Board of the subsidiary company; | - | - | N/A |
| 2(c) | The minutes of the Board meeting of the subsidiary company shall be placed for review at the following Board meeting of the holding company; | - | - | N/A |
| 2(d) | The minutes of the respective Board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also; | - | - | N/A |
| 2(e) | The Audit Committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company. | - | - | N/A |
| 3 | Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS) | | | |
| 3(1) | Appointment | | | |
| 3(1)(a) | The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC); | √ | | |
| 3(1)(b) | The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals; | √ | | |

| | | | | |
|-------------|---|---|--|--|
| 3(1)(c) | The MD or CEO, CS, CFO and HIAC of a listed company shall not hold any executive position in any other company at the same time; | √ | | |
| 3(1)(d) | The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS; | √ | | |
| 3(1)(e) | The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s). | √ | | |
| 3(2) | Requirement to attend Board of Directors' Meetings: | | | |
| | The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board provided that CS, CFO and HIAC shall not attend such part of a meetings of the Board relating to their personal matter. | √ | | |
| 3(3) | Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO) | | | |
| 3(3)(a) | The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief: | √ | | |
| 3(3)(a)(i) | these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and | √ | | |
| 3(3)(a)(ii) | these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws; | √ | | |
| 3(3)(b) | The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board or its members | √ | | |
| 3(3)(c) | The certification of the MD or CEO and CFO shall be disclosed in the Annual Report. | √ | | |
| 4 | Board of Directors' Committee:- For ensuring good governance in the company, the Board shall have at least following subcommittees: | | | |
| 4(i) | Audit Committee | √ | | |
| 4(ii) | Nomination and Remuneration Committee | √ | | |

| | | | |
|-------------|---|---|--|
| 5 | Audit Committee | | |
| 5(1) | Responsibility to the Board of Directors | | |
| 5(1)(a) | The company shall have an Audit Committee as a sub-committee of the Board; | √ | |
| 5(1)(b) | The Audit Committee shall assist the Board in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business; | √ | |
| 5(1)(c) | The Audit Committee shall be responsible to the Board; the duties of the Audit Committee shall be clearly set forth in writing. | √ | |
| 5(2) | Constitution of the Audit Committee | | |
| 5(2)(a) | The Audit Committee shall be composed of at least 3 (three) members; | √ | |
| 5(2)(b) | The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director; | √ | |
| 5(2)(c) | All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience; | √ | |
| 5(2)(d) | When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee; | √ | |
| 5(2)(e) | The company secretary shall act as the secretary of the Committee; | √ | |
| 5(2)(f) | The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director. | √ | |

| | | | | |
|-------------|---|---|---|---|
| 5(3) | Chairperson of the Audit Committee | | | |
| 5(3)(a) | The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director; | √ | | |
| 5(3)(b) | In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes. | | | No such Incidence arose |
| 5(3)(c) | Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM); | - | √ | After appointed as chairman no AGM held yet |
| 5(4) | Meeting of the Audit Committee | | | |
| 5(4)(a) | The Audit Committee shall conduct at least its four meetings in a financial year | - | √ | After constituted this committee one financial year is not pass yet |
| 5(4)(b) | The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must. | - | - | |
| 5(5) | Role of Audit Committee: The Audit Committee shall:- | | | |
| 5(5)(a) | Oversee the financial reporting process; | √ | | |
| 5(5)(b) | monitor choice of accounting policies and principles; | √ | | |
| 5(5)(c) | monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report; | √ | | |
| 5(5)(d) | oversee hiring and performance of external auditors; | √ | | |
| 5(5)(e) | hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption; | √ | | |
| 5(5)(f) | review along with the management, the annual financial statements before submission to the Board for approval; | √ | | |

| | | | | |
|----------------|--|---|---|------------------------------------|
| 5(5)(g) | review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval; | √ | | |
| 5(5)(h) | review the adequacy of internal audit function; | √ | | |
| 5(5)(i) | review the Management's Discussion and Analysis before disclosing in the Annual Report; | √ | | |
| 5(5)(j) | review statement of all related party transactions submitted by the management; | √ | | |
| 5(5)(k) | review Management Letters or Letter of Internal Control weakness issued by statutory auditors; | √ | | |
| 5(5)(l) | oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors; | √ | | |
| 5(5)(m) | oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission: | - | - | No such Incidence arose |
| 5(6) | Reporting of the Audit Committee | | | |
| 5(6)(a) | Reporting to the Board of Directors | | | |
| 5(6)(a)(i) | The Audit Committee shall report on its activities to the Board. | √ | | |
| 5(6)(a)(ii) | The Audit Committee shall immediately report to the Board on the following findings, if any:- | | | |
| 5(6)(a)(ii)(a) | report on conflicts of interests; | | | No such Incidence arose |
| 5(6)(a)(ii)(b) | suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements; | | | No such Incidence arose |
| 5(6)(a)(ii)(c) | suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations; | | | No such Incidence arose |
| 5(6)(a)(ii)(d) | any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately; | | | No such Incidence arose |
| 5(6)(b) | Reporting to the Authorities: | | | |
| | If the Audit Committee has reported to the Board about anything which has material impact on the financial | | | No such reportable incidence arose |

| | | | | |
|-------------|--|---|---|--|
| | condition and results of operation and has discussed with the Board and the management that any rectification is necessary and if the Audit Committee finds that such rectification has been unreasonably ignored, the Audit Committee shall report such finding to the Commission, upon reporting of such matters to the Board for three times or completion of a period of 6 (six) months from the date of first reporting to the Board, whichever is earlier. | | | |
| 5(7) | Reporting to the Shareholders and General Investors: | | | |
| | Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company. | √ | | |
| 6 | Nomination and Remuneration Committee (NRC) | | | Formed in the 148th Board of Directors meeting held on 31st August, 2023 |
| 6(1) | Responsibility to the Board of Directors | | | |
| 6(1)(a) | The company shall have a Nomination and Remuneration Committee (NRC) as a subcommittee of the Board; | √ | | |
| 6(1)(b) | The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive; | - | - | No such case in arise after formation of NRC |
| 6(1)(c) | The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b). | √ | - | |
| 6(2) | Constitution of the NRC | | | |
| 6(2)(a) | The Committee shall comprise of at least three members including an independent director; | √ | | |
| 6(2)(b) | All members of the Committee shall be non-executive directors; | √ | | |
| 6(2)(c) | Members of the Committee shall be nominated and appointed by the Board; | √ | | |

| | | | | |
|-------------|--|---|---|---|
| 6(2)(d) | The Board shall have authority to remove and appoint any member of the Committee; | √ | | |
| 6(2)(e) | In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee; | - | - | No such Incidence arose |
| 6(2)(f) | The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee; | - | - | No such Incidence arose |
| 6(2)(g) | The company secretary shall act as the secretary of the Committee; | √ | | |
| 6(2)(h) | The quorum of the NRC meeting shall not constitute without attendance of at least an independent director; | √ | | |
| 6(2)(i) | No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the company. | √ | | |
| 6(3) | Chairperson of the NRC | | | |
| 6(3)(a) | The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director; | √ | | |
| 6(3)(b) | In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes; | | | No such Incidence arose |
| 6(3)(c) | The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders. | | √ | Will attend in upcoming AGM |
| 6(4) | Meeting of the NRC | | | |
| 6(4)(a) | The NRC shall conduct at least one meeting in a financial year; | - | - | After constituted this committee one financial year is not pass yet |
| 6(4)(b) | The Chairperson of the NRC may convene any emergency meeting | - | - | No such case in arise after formation of NRC |

| | | | | |
|---------------|---|---|---|---|
| | upon request by any member of the NRC; | | | |
| 6(4)(c) | The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h); | - | - | After constituted this committee one financial year is not pass yet |
| 6(4)(d) | The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC. | - | - | |
| 6(5) | Role of the NRC | | | |
| 6(5)(a) | NRC shall be independent and responsible or accountable to the Board and to the shareholders; | √ | | |
| 6(5)(b) | NRC shall oversee, among others, the following matters and make report with recommendation to the Board; | √ | | |
| 6(5)(b)(i) | formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following: | √ | | |
| 6(5)(b)(i)(a) | the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully; | √ | | |
| 6(5)(b)(i)(b) | the relationship of remuneration to performance is clear and meets appropriate performance benchmarks; | √ | | |
| 6(5)(b)(i)(c) | remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the company and its goals; | √ | | |
| 6(5)(b)(ii) | devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality; | √ | | |
| 6(5)(b)(iii) | identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the | √ | | |

| | | | | |
|-------------|--|---|---|--------------------------------|
| | criteria laid down, and recommend their appointment and removal to the Board; | | | |
| 6(5)(b)(iv) | formulating the criteria for evaluation of performance of independent directors and the Board; | √ | | |
| 6(5)(b)(v) | identifying the company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria; | √ | | |
| 6(5)(b)(vi) | developing, recommending and reviewing annually the company's human resources and training policies; | √ | | |
| 6(5)(c) | The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual Report. | | √ | Will be complied while listing |
| 7 | External or Statutory Auditors | | | |
| 7(1) | The issuer company shall not engage its external or statutory auditors to perform the following services of the company, namely:- | | | |
| 7(1)(i) | appraisal or valuation services or fairness opinions; | √ | | |
| 7(1)(ii) | financial information systems design and implementation; | √ | | |
| 7(1)(iii) | book-keeping or other services related to the accounting records or financial statements; | √ | | |
| 7(1)(iv) | broker-dealer services; | √ | | |
| 7(1)(v) | actuarial services; | √ | | |
| 7(1)(vi) | internal audit services or special audit services; | √ | | |
| 7(1)(vii) | any service that the Audit Committee determines; | √ | | |
| 7(1)(viii) | audit or certification services on compliance of corporate governance as required under condition No. 9(1); | √ | | |
| 7(1)(ix) | any other service that creates conflict of interest. | √ | | No such incident arose |
| 7(2) | No partner or employees of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company; his or her family members also shall not hold any shares in the said company | √ | | |
| 7(3) | Representative of external or statutory auditors shall remain present in the Shareholders' Meeting | √ | | |

| | | | | |
|----------|---|---|---|--|
| | (AGM or EGM) to answer the queries of the shareholders. | | | |
| 8 | Maintaining a website by the Company | | | |
| 8(1) | The company shall have an official website linked with the website of the stock exchange. | - | √ | Will be complied while listing |
| 8(2) | The company shall keep the website functional from the date of listing. | - | √ | Will be complied while listing |
| 8(3) | The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s). | - | √ | Will be complied while listing |
| 9 | Reporting and Compliance of Corporate Governance | | | |
| 9(1) | The company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report. | √ | | |
| 9(2) | The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting. | - | √ | Board recommended the Professional for due appointment by the Shareholders in Upcoming AGM |
| 9(3) | The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions or not. | √ | | |

Sd/-

Shah Jalal Uddin Ahmed

Managing Director

Audit committee:

| | |
|------------------------------|---------------------------------------|
| Uttam Kumar Saha, FCA | Chairman, Independent Director |
| Md. Mamunur Rashid | Member |
| SK. Motiur Rahman | Member, Independent Director |
| Debasish Das Gupta | Secretary |

Nomination and Remuneration Committee (NRC):

| | |
|--------------------------|---------------------------------------|
| SK. Motiur Rahman | Chairman, Independent Director |
| Md. Mamunur Rashid | Member |
| Uttam Kumar Saha, FCA | Member, Independent Director |
| Debasish Das Gupta | Secretary |

CHAPTER (XV)

VALUATION REPORT OF SECURITIES PREPARED BY THE ISSUE MANAGER

The valuation report of securities offered is prepared and justified by the issue managers, EBL Investments Limited and Imperial Capital Limited on the basis of the financial and all other information pertinent to the Issue.

Quantitative factors for valuation:

1. Research & Development (R&D):

R&D is imperative for any pharmaceutical company. Our focus is to continue investing in R&D to develop differentiated generics and innovative specialty products. At TDL, we have a development centre and a strong R&D team to cater to these requirements. We continue to be disciplined in identifying future R&D projects for the local generics and export market and the focus is on developing differentiated generics. Investments for developing the long-term specialty pipeline are expected to continue.

2. Focus on improving productivity:

TDL continues with efforts to reduce expenses to achieve an optimum cost structure relevant to today's business and market realities. These efforts are being implemented in multiple areas of the business with greater involvement of people in order to make the Company more efficient. Further enhancement of manufacturing efficiencies, optimizing manufacturing footprint, rationalizing generics R&D investments, reducing fixed costs and interest cost are some of the areas targeted for efficiency improvement.

3. Business Model

The business model involves critical growth strategies to drive sustainable growth and achieve higher efficiencies. TDL is strategically poised to capitalize on the emerging opportunities in the local pharmaceutical sector, to deliver consistent long-term stakeholder value by following the model:

- Enhance share of specialty product;
- Focus on key markets – achieve market share of critical mass;
- Ensure sustained compliance with global cGMP regulatory standards;
- Optimize operational costs;
- Focus on access to products, technology, market presence;
- Future investments directed towards differentiated products as well as enhancing presence in key markets.

4. Focus on specialty and consumer healthcare Product

Consumer health products do not require prescription from healthcare professionals and can be purchased Over the Counter (OTC) from a pharmacy store. Today's informed patients believe in taking better healthcare decisions and are engaging in effective health management through digital tools. Leveraging uninterrupted access to information, the consumer is wielding growing power, leading to creation of new market segments and new models of healthcare.

The issue manager(s) shall, among others, consider the following methods for valuation of the securities:

The valuation report of the securities shall be prepared on the basis of the financial and all other information pertinent to the issue. The fair value is determined under different valuation methods referred in clause no. Annexure-E (B)(14) of Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015.

We have considered the following methods to determine the share price:

| Particulars | | Amount (in Tk.) |
|-------------|--|-----------------|
| Method 1: | a) Share price on Net Asset Value (NAV)/Equity based valuation with revaluation reserve | 27.74 |
| | b) Share price on Net Asset Value (NAV)/Equity based valuation without revaluation reserve | 22.57 |
| Method 2: | a) Earnings based Value per share based on Overall Market P/E | 46.61 |
| | b) Earnings based Value per share based on Pharmaceuticals Sector P/E | 57.16 |
| Method 3: | Average market price of similar stock based valuation | 384.92 |
| Method 4: | P/BV multiple of similar stock based valuation | 67.31 |
| Method 5: | P/E multiple of similar stock based valuation | 58.31 |

Method 1: a) Share price on Net Asset Value (NAV)/Equity based valuation with revaluation reserve

| Sl. No. | Particulars | Amount (in Tk.) |
|---|---------------------|----------------------|
| a) | Share Capital | 941,574,000 |
| b) | Revaluation Surplus | 487,437,890 |
| c) | Retained Earnings | 1,183,337,389 |
| Total Shareholders' Equity (A) | | 2,612,349,279 |
| Number of Share Outstanding as on June 30, 2023 (B) | | 94,157,400 |
| Net Asset Value per share (with revaluation reserve) as per Audit Report as on June 30, 2023 (A/B) | | 27.74 |

Method 1: b) Share price on Net Asset Value (NAV)/Equity based valuation without revaluation reserve

| Sl. No. | Particulars | Amount (in Tk.) |
|--|-------------------|----------------------|
| a) | Share Capital | 941,574,000 |
| b) | Retained Earnings | 1,183,337,389 |
| Total Shareholders' Equity (A) | | 2,124,911,389 |
| Number of Share Outstanding as on June 30, 2023 (B) | | 94,157,400 |
| Net Asset Value per share (without revaluation reserve) as per Audit Report as on June 30, 2023 (A/B) | | 22.57 |

Method 2: Historical Earnings based value per share:

a) Earnings based Value per share based on Overall Market P/E

| Year | No. of Share | Profit after Tax | Weight (%) | Weighted Average Net Profit after Tax |
|--|--------------------|----------------------|---------------|---------------------------------------|
| 30-Jun-19 | 9,960,000 | 226,281,965 | 0.0285 | 6,459,440 |
| 30-Jun-20 | 68,760,000 | 163,609,083 | 0.1971 | 32,242,512 |
| 30-Jun-21 | 81,876,000 | 360,942,830 | 0.2347 | 84,699,456 |
| 30-Jun-22 | 94,157,400 | 479,778,427 | 0.2699 | 129,473,462 |
| 30-Jun-23 | 94,157,400 | 195,506,359 | 0.2699 | 52,759,532 |
| Total | 348,910,800 | 1,426,118,664 | 1.0000 | 305,634,402 |
| Weighted Average Profit after Tax | | | | 305,634,402 |
| No. of shares outstanding before IPO | | | | 94,157,400 |
| Diluted EPS based on weighted Average of Net Profit after Tax | | | | 3.25 |
| Overall Market P/E | | | | 14.36 |
| Earnings based Value per share | | | | 46.61 |

Calculation of Average Price Earnings of Market:

| Particulars | Mar-23 | Apr-23 | May-23 | Average |
|--------------------|--------|--------|--------|--------------|
| Overall Market P/E | 14.24 | 14.35 | 14.50 | 14.36 |

Source: DSE Monthly Review.

b) Earnings based Value per share based on Pharmaceuticals Sector P/E

| Year | No. of Share | Profit after Tax | Weight (%) | Weighted Average Net Profit after Tax |
|--|--------------------|----------------------|---------------|---------------------------------------|
| 30-Jun-19 | 9,960,000 | 226,281,965 | 0.0285 | 6,459,440 |
| 30-Jun-20 | 68,760,000 | 163,609,083 | 0.1971 | 32,242,512 |
| 30-Jun-21 | 81,876,000 | 360,942,830 | 0.2347 | 84,699,456 |
| 30-Jun-22 | 94,157,400 | 479,778,427 | 0.2699 | 129,473,462 |
| 30-Jun-23 | 94,157,400 | 195,506,359 | 0.2699 | 52,759,532 |
| Total | 348,910,800 | 1,426,118,664 | 1.0000 | 305,634,402 |
| Weighted Average Profit after Tax | | | | 305,634,402 |
| No. of shares outstanding before IPO | | | | 94,157,400 |
| Diluted EPS based on weighted Average of Net Profit after Tax | | | | 3.25 |
| Pharmaceuticals Sector P/E | | | | 17.61 |
| Earnings based Value per share | | | | 57.16 |

Calculation of average Price Earnings of Pharmaceuticals Sector:

| Particulars | Mar-23 | Apr-23 | May-23 | Average |
|----------------------------|--------|--------|--------|--------------|
| Pharmaceuticals Sector P/E | 17.54 | 17.59 | 17.70 | 17.61 |

Source: DSE Monthly Review.

Method 3: Average market price of similar stock based valuation:

| Month end close price | | | | | | |
|---|-----------|---------------|------------------------------|-------------------|-----------------|-----------------------------|
| Sl. | Date | ACI Limited | Beximco Pharmaceuticals Ltd. | Orion Pharma Ltd. | Renata Ltd. | Square Pharmaceuticals Ltd. |
| 1 | 31-Oct-22 | 273.20 | 149.20 | 111.50 | 1,303.20 | 209.80 |
| 2 | 30-Nov-22 | 260.20 | 155.10 | 85.80 | 1,217.90 | 209.80 |
| 3 | 29-Dec-22 | 260.20 | 146.20 | 82.70 | 1,217.90 | 209.80 |
| 4 | 31-Jan-23 | 260.20 | 146.20 | 85.10 | 1,217.90 | 209.80 |
| 5 | 28-Feb-23 | 260.20 | 146.20 | 83.00 | 1,217.90 | 209.80 |
| 6 | 30-Mar-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 209.80 |
| 7 | 30-Apr-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 209.80 |
| 8 | 31-May-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 209.80 |
| 9 | 26-Jun-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 209.80 |
| 10 | 31-Jul-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 209.80 |
| 11 | 31-Aug-23 | 260.20 | 146.20 | 79.60 | 1,217.90 | 211.10 |
| 12 | 27-Sep-23 | 260.20 | 115.60 | 79.60 | 1,217.90 | 209.80 |
| Average Price | | 261.28 | 144.64 | 83.78 | 1,225.01 | 209.91 |
| Average Price of these 5 (Five) Stocks | | | | | | 384.92 |

Source: DSE Monthly Review.

Average market price of similar stock based valuation (Assumption)

1. The average month end close price of the peer Company from October 2022 to September 2023 is considered.

Method 4: P/BV multiple of similar stock based valuation:

| Sl. | Name of the Company | Average Price of last One Year | NAV | P/BV |
|----------------|------------------------------|--------------------------------|--------|-------------|
| 1 | ACI Limited | 261.28 | 141.98 | 1.84 |
| 2 | Beximco Pharmaceuticals Ltd. | 144.64 | 100.06 | 1.45 |
| 3 | Orion Pharma Ltd. | 83.78 | 82.53 | 1.02 |
| 4 | Renata Ltd. | 1,225.01 | 274.39 | 4.46 |
| 5 | Square Pharmaceuticals Ltd. | 209.91 | 116.70 | 1.80 |
| Average | | | | 2.43 |

| Price/ Book Value (P/BV) multiple of similar stock based valuation | Amount in Tk. |
|--|---------------|
| Net Asset Value (NAV) per Share of Techno Drugs Limited (A) | 27.74 |
| Average P/BV of peer Companies (B) | 2.43 |
| Fair Price (A X B) | 67.31 |

P/BV multiple of similar stock based valuation (Assumption)

- The average month end close price of the peer Company from October 2022 to September 2023 is considered and NAVs has been considered based on Annual Report of 2022 for ACI Limited, Beximco Pharmaceuticals Limited, Orion Pharma Ltd., Renata Ltd. and Square Pharmaceuticals Limited;
- The NAV of Techno Drugs Ltd. is as of FY 2022-2023.

Method 5: P/E multiple of similar stock based valuation:

| Sl. | Name of the Company | Average Price of last One Year | EPS | P/E |
|----------------|------------------------------|--------------------------------|-------|--------------|
| 1 | ACI Limited | 261.28 | 5.23 | 49.96 |
| 2 | Beximco Pharmaceuticals Ltd. | 144.64 | 11.48 | 12.60 |
| 3 | Orion Pharma Ltd. | 83.78 | 3.62 | 23.14 |
| 4 | Renata Ltd. | 1,225.01 | 47.68 | 25.69 |
| 5 | Square Pharmaceuticals Ltd. | 209.91 | 20.51 | 10.23 |
| Average | | | | 17.96 |

| P/E multiple of similar stock based valuation | Amount in Tk. |
|--|---------------|
| Weighted Average EPS of Techno Drugs Limited (A) | 3.25 |
| P/E of peer Companies (B) | 17.96 |
| Fair Price (A X B) | 58.31 |

P/BV multiple of similar stock based valuation (Assumption)

- 1 The average month end close price of the peer Company from October 2022 to September 2023 is considered and EPS has been considered based on Annual Report of 2022 for ACI Limited, Beximco Pharmaceuticals Limited, Orion Pharma Ltd., Renata Ltd. and Square Pharmaceuticals Limited;
- 2 The EPS of Techno Drugs Ltd. is as of FY 2022-2023.

Rationale:

There are 34 listed Pharmaceutical companies in the capital market. Among the listed companies we have taken into consideration 5 Pharmaceutical companies because of the similarity in the nature of business.

Sd/-

Ahmed Arefin FCA
 Managing Director
EBL Investments Limited

Sd/-

Md. Salauddin Sikder FCMA
 CEO & Managing Director
Imperial Capital Limited

CHAPTER (XVI)

DEBT SECURITIES

The Company has not issued or is planning to issue any debt security within six months.

CHAPTER (XVII)

PARTIES INVOLVED AND THEIR RESPONSIBILITIES

| Major Parties Involved | | Responsibilities of the Parties |
|-------------------------------|---|--|
| (a) Issue Manager(s) | <ul style="list-style-type: none"> ▪ EBL Investments Limited ▪ Imperial Capital Limited | The Issue Manager(s) is responsible to comply with all the requirements as per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015 including preparation and disclosures made in the prospectus and other responsibilities as mentioned in the due diligence certificate. |
| (b) Registrar to the Issue | <ul style="list-style-type: none"> ▪ BMSL Investment Limited | The Registrar to the Issue will act as the registrar to the issue for the public issue as described in the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015. |
| (c) Underwriters | <ul style="list-style-type: none"> ▪ EBL Investments Limited ▪ BMSL Investment Limited | The Underwriter(s) is responsible to underwrite the public offering on a firm- commitment basis as per requirement of Bangladesh Securities and Exchange Commission (Public Issue) Rules 2015. |
| (d) Statutory Auditors | <ul style="list-style-type: none"> ▪ Islam Quazi Shafique & Co. | Auditor's objective is to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing (ISAs) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually, or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
| (e) Cost Auditors | N/A | N/A |
| (f) Valuer | <ul style="list-style-type: none"> ▪ G. KIBRIA & CO. | To discover the fair value of the asset of the Company. |
| (g) Credit Rating Company | <ul style="list-style-type: none"> ▪ Emerging Credit Rating Ltd. | Credit rating agency is responsible for conducting the long term and short term rating of the Company based on its financial statements and other relevant qualitative and quantitative information in line with Credit Rating Companies Rules, 2022. |

CHAPTER (XVIII)

MATERIAL CONTRACTS

(a) Agreements entered into by the Issuer:

The following are material agreements have been entered into by the Company:

1. Registrar to the Issue Agreements between the Company and Registrar to the Issue;
 - i. BMSL Investment Limited.
2. Underwriting Agreements between the Company and the Underwriter(s);
 - i. EBL Investments Limited;
 - ii. BMSL Investment Limited.
3. Issue Management Agreement between the Company and Issue Manager(s);
 - i. Imperial Capital Limited;
 - ii. EBL Investments Limited.

(b) Material parts of the agreements:

| Contract | Material parts of the agreements | |
|--|---|---|
| Registrar to the Issue Agreements with; I. BMSL Investment Limited | Signing Date: | With BMSL Investment Limited on 27 September, 2023 |
| | Tenure: | This Agreement shall be valid until completion of subscription of shares and unless this Agreement is extended or earlier terminated in accordance with the terms of this Agreement |
| | Principal Terms and Condition: | <ol style="list-style-type: none">1. As per Article 1.1, Subject to the terms and conditions hereunder, the Company shall engage the Registrar to the Issue for rendering services in relation to registrar to the issue.2. The Scope of service of 'The Registrar to the Issue shall perform as per Article 2.3. As per Article 6, The Registrar to the Issue hereby undertake to keep in strict compliance to all information (whether written or oral) proprietary documents and data secured in connection with or as a result of this Agreement and shall limit the availability of such information to employees, who have a need to see and use it for the express and limited purpose stated in this Agreement.4. As per Article 3.1, without prejudice the Company hereby declares that it agrees to comply with Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, Listing Regulations of the Stock Exchanges, Companies Act, 1994, Securities and Exchange Ordinance, 1969 and other relevant rules, regulations, practices, |

| | | |
|--|--|--|
| | | <p>directives, guidelines, etc. issued by Bangladesh Securities and Exchange Commission and other relevant laws.</p> <p>5. As per Article 3.3, The Company shall extend all facilities and help the Registrar to the Issue to ascertain for themselves the true state of affairs of the Company.</p> <p>6. As per Article 4, without prejudice to other stipulations relative to the responsibility of the Registrar to the Issue, it is responsible towards the Company for strict compliance of this Agreement and to comply with all terms therein.</p> |
|--|--|--|

| Contract | Material parts of the agreements | |
|--|---|--|
| <p>Underwriting agreements with</p> <p>1. EBL Investments Limited;</p> <p>2. BMSL Investment Limited.</p> | Signing Date: | With EBL Investments Limited, BMSL Investment Limited on 27 September, 2023 and revised on 30 April, 2024 |
| | Tenure: | This Agreement shall be valid until completion of subscription of shares and unless this Agreement is extended or earlier terminated in accordance with the terms of this Agreement. |
| | Principal Terms and Condition: | <p>1. As per Article 1.03, in case of under subscription up to 35% of quota allotted for the GP category, the unsubscribed portion of securities shall be taken up by the underwriter.</p> <p>2. As per Article 1.04, the underwriting agreement and the underwritten amount and allocation of underwriting portion shall be revised after completion of the bidding period, where the cut-off price will be determined at nearest integer of the lowest bid price at which the total securities offered to eligible investors would be exhausted. The public offering price will be determined at 10% discount (at nearest integer) from the cut-off price.</p> <p>3. As per Article 4.06, Notwithstanding anything contained in this Agreement, in case of any inconsistency between the provision of this Agreement and the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, shall prevail</p> <p>4. As per Article 2.03, prior to the publication of the Prospectus, the Company shall obtain a consent from the Bangladesh Securities and Exchange Commission permitting the issue as described in Article 2.01 and provide for payment of initial underwriting commission not exceeding 0.50% on the amount underwritten.</p> |

| | | |
|--|--|---|
| | | <p>5. As per Article 2.06, If and to the extent that the shares offered to the public by a prospectus authorized hereunder shall not have been subscribed and paid for in cash in full by the Closing Date of subscription, the Company shall within 10 (Ten) days of the closure of subscription call upon the underwriter in writing with a copy of the said writing to the Bangladesh Securities and Exchange Commission, to subscribe the shares not subscribed by the closing date and to pay for in cash in full, inclusive of any premium if applicable, for such unsubscribed shares within 15 (Fifteen) days after being called upon to do so. If payment is made by Cheque/Bank Draft by the underwriter it will be deemed that the underwriter has not fulfilled his obligation towards his underwriting commitment under this Agreement, until such time as the Cheque/Bank Draft has been encashed and the Company's account credited. In any case within 7 (seven) days after the expiry of the aforesaid 15 (fifteen) days, the Company shall send proof of subscription and payment by the underwriter to the Commission.</p> <p>In the case of failure by the underwriter to pay for the shares under the terms mentioned above, the said underwriter will not be eligible to underwrite any issue, until such time as he fulfils his underwriting commitment under this Agreement and also other penalties as may be determined by the Commission may be imposed.</p> <p>In the case of failure by the underwriter to pay for the shares within the stipulated time, the Company/issuer will be under no obligation to pay any underwriting commission under this Agreement.</p> <p>In the case of failure by the Company to call upon the underwriter for the aforementioned purpose within the stipulated time, the Company and its Directors shall individually and collectively be held responsible for the consequences and/or penalties as determined by the Bangladesh Securities and Exchange Commission under the law.</p> <p>6. As per Article 2.08, the liability of the underwriter under this clause shall be in proportion to but not exceeding the shares agreed to be underwritten by it; provided that the aforementioned request of the Company</p> |
|--|--|---|

| | | |
|--|--|--|
| | | <p>shall be supported by official certificates and other documents of subscription obtained from the Banker to the Issue and a declaration of the Company as to the final result of the Public subscription.</p> <p>7. As per Article 2.09, the Company shall pay to the underwriter an underwriting commission at the rate of 0.50% of the amount underwritten hereby agreed to be underwritten by it.</p> <p>8. As per Article 4.03, this Agreement shall be valid until completion of subscription of shares in accordance with section 2.05.</p> <p>9. As per Article 4.05, the rights and responsibilities of either party shall terminate in the event of full subscription of the public offering of shares.</p> <p>10. As per Article 4.07, the underwriter warrants and represents that it has certificate of registration from the Bangladesh Securities and Exchange Commission to fully underwrite or place primary securities in a firm commitment basis.</p> |
|--|--|--|

| Contract | Material parts of the agreements | |
|---|---|--|
| <p>Issue Management Agreements with;</p> <p>I. EBL Investments Limited;</p> <p>II. Imperial Capital Limited.</p> | Signing Date: | With EBL Investments Limited and Imperial Capital Limited on August 14, 2023 |
| | Tenure: | This Agreement shall be valid until completion of subscription of shares and unless this Agreement is extended or earlier terminated in accordance with the terms of this Agreement |
| | Principal Terms and Condition: | <ol style="list-style-type: none"> 1. As per Article 2.1, the scope of the services to be rendered by the ISSUE MANAGER to the ISSUER under this agreement shall cover Regulatory Compliance, Underwriting Co-operation and after consent tasks. 2. As per Article 2.2, the ISSUER undertakes to bear all the PUBLIC ISSUE related expenses including road show, share application processing, lottery conduction, allotment and dispatch of letters of allotment and refund warrant. The ISSUER shall also bear all expenses related to printing and issuance of share certificate and connected government stamps and hologram expenses. 3. As per Article 2.3, notwithstanding the above, if any other services required but not listed herein above for the effective PUBLIC ISSUE shall perform the same. |

| | | |
|--|--|---|
| | | <p>4. As per Article 3.1, without prejudice ISSUER hereby declares that it agrees to comply with all statutory formalities under Companies Act, 1994, Guidelines issued by Bangladesh Securities and Exchange Commission and other relevant status to enable it to make the issue.</p> <p>5. As per Article 6.1, The ISSUE MANAGER(S) hereby undertake to keep in strict compliance all information (whether written or oral) proprietary documents and data secured in connection with or as a result of this Agreement (Confidential Information) and shall limit the availability of such information to employees, who have a need to see and use it for the express and limited purpose stated in this Agreement.</p> <p>6. As per Article 8.1, The Issue Manager shall ensure compliance of the Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015, Dhaka Stock Exchange (Listing) Regulations, 2015, Chittagong Stock Exchange (Listing) Regulations, 2015, Companies Act, 1994, The Securities and Exchange Ordinance, 1969, The Securities Act, 1920 and other relevant rules, regulations, practices, directives, guidelines, etc.</p> <p>7. As per Article 8.2, The Issue Manager shall issue a Due Diligence Certificate to execute the PUBLIC ISSUE as per Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015.</p> |
|--|--|---|

(c) Fees payable to different parties:

| SL. | Name of the Parties | Role | Fees in Tk. | Fees Payable |
|--------------|--------------------------|---------------|------------------|--|
| 1 | BMSL Investment Limited | Registrar | 800,000 | At Actual |
| Total | | | 800,000 | |
| 1 | EBL Investments Limited | Underwriter | 434,389 | Underwriting commission at the rate of 0.50% on 35% of the GP category (i.e., Tk. 969,231) |
| 2 | BMSL Investment Limited | | 534,842 | |
| Total | | | 969,231 | |
| 1 | EBL Investments Limited | Issue Manager | 1,500,000 | 0.3% of the public offer amount (i.e., Tk. 3,000,000) |
| 2 | Imperial Capital Limited | | 1,500,000 | |
| Total | | | 3,000,000 | |

CHAPTER (XIX)

OUTSTANDING LITIGATIONS, FINE OR PENALTY

(a) **The following litigations including outstanding litigations against the issuer or any of its directors and fine or penalty imposed by any authority:**

The issuer or any of its directors was not involved in any of the following type of legal proceedings mentioned below;

- (i) **Litigation involving Civil Laws:** No cases filed against the company or any of its directors.
- (ii) **Litigation involving Criminal Laws:** No cases filed against the company or any of its directors.
- (iii) **Litigation involving Securities, Finance and Economic Laws:** No cases filed against the company or any of its directors.
- (iv) **Litigation involving Labor Laws:** No cases filed against the company or any of its directors.
- (v) **Litigation involving Taxation (Income tax, VAT, Customs Duty and any other taxes or duties):** No cases filed against the company or any of its directors.
- (vi) **Litigation involving any other Laws:** No cases filed against the company or any of its directors.

(b) **Cases including outstanding litigations filed by the Company or any of its directors:**

There are no cases including outstanding case filed by the issuer or any of its directors to any of the following types of legal proceedings mentioned below;

- (i) **Litigation involving Civil Laws:** No cases filed by the company or any of its directors.
- (ii) **Litigation involving Criminal Laws:** No cases filed by the company or any of its directors.
- (iii) **Litigation involving Securities, Finance and Economic Laws:** No cases filed by the company or any of its directors.
- (iv) **Litigation involving Labor Laws:** No cases filed by the company or any of its directors.
- (v) **Litigation involving Taxation (Income tax, VAT, Customs Duty and any other taxes or duties):** No cases filed by the company or any of its directors except the contingent liabilities mentioned below:

| Sl. | Details of Litigation | VAT Demand (Tk.) | Status |
|-----|---|------------------|---|
| 1 | Mismatch of Vat able & non VAT able items | 378,540,702.69 | Under process for appeal to the High Court. |

- (vi) **Litigation involving any other Laws:** No cases filed by the company or any of its directors.

CHAPTER (XX)

RISK FACTORS AND MANAGEMENT'S PERCEPTIONS ABOUT THE RISKS

(i) Internal risk factors may include, among others:

Risk Factors and Management's Perception about The Risks:

In the business world return and risks has reciprocal relationship. Thus, TDL would be subject to risk of a typical nature for similar pharmaceutical companies. The majority of these risks are commercial and business risks that can be mitigated effectively. Before making any investment decision, Investors should take the risk factors into consideration. Such major risk factors are described in brief as under:

- a) **Credit Risk:** This is the risk of default on a debt that may arise because of default by the borrower to pay the loan. In operating any business there is always credit risk lies in the business. As there is always lending and borrowing between parties in the form of money and goods.

Management Perception: *Techno Drugs Ltd. is involved in manufacturing, distributing and selling pharmaceutical products. We gave credit sales for 60 days to 90 days period for our local sales. We also sell to government as well. As for credit sales, company tries to ensure credit policy so that operating cycle can be efficient.*

- b) **Liquidity Risk:** The risk that a company may be unable to meet short term financial demands. This usually occurs due to the inability to convert its current assets to cash without a loss of capital or income. Liquidity is a common phenomenon of the business.

Management Perception: *Finance is an arts and science of managing fund so that it can manage working capital in efficient way. Techno Drugs Ltd. is also doing its level best to manage working capital management in efficient way to maintain liquidity risk. Management is dealing with accounts payable, inventory and accounts receivable efficiently.*

- c) **Risk associated with the issuer's interest in subsidiaries, joint ventures and associates:** If the subsidiaries make loss, it affects parent company's balance sheet. In case of associate, there is chance of decline value of investment in associate company. As for joint venture, a joint venture (JV) is a business arrangement in which two or more parties agree to pool their resources for the purpose of accomplishing a specific task. This task can be a new project or any other business activity. In a joint venture (JV), each of the participants is responsible for profits, losses and costs associated with it.

Management Perception: *Techno Drugs Ltd. has no subsidiary, joint ventures and associates.*

- d) **Significant revenue generated from limited number of customers, losing any one or more of which would have a material adverse effect on the issuer:** There is risk involved in having limited number of customer and losing of that particular customer has negative impact on company's sales and cash flow as well.

Management Perception: *The Company is always keen to find out new buyers which boost up the sales. We are not dependent on any particular or limited number of customers to operate our business. However, we have government as our client for significant portion of our sales. In this regard, we could face adverse in future that could be resolved for the local demand of our product since our products are very basic product for human lives.*

- e) **Dependency on a single or few suppliers of raw materials, failure of which may affect production adversely:** There is also risk involved in having limited number of suppliers as well. Single or few suppliers may exploit the company by price hike, untimely delivery and low quality of product.

Management Perception: *Like our wide range of customers, we have more suppliers home and abroad. As a result, we are not dependent on a single or few suppliers of raw materials, failure of which may affect production adversely.*

- f) **More than 20% revenue of the issuer comes from sister concern or associate or subsidiary:** Having 20% revenue generation from sister concern or associate or subsidiary makes issuer dependent on others companies. Hence, there is dependency risk.

Management Perception: *We do not have sister concern, associate or subsidiary.*

- g) **Negative earnings, negative cash flows from operating activities, declining turnover or profitability, during last five years, if any:** Negative earning and negative operating cash flow is risk the going concern risk for the entity.

Management Perception: *We have been operating our business efficiently. The company doesn't have any negative earnings, negative cash flows from operating activities over the last five years.*

- h) **Loss making associate/subsidiary/group companies of the issuer:** When associate/subsidiary/group companies of the issuer are loss making, it affects the issuer and there is negative impact on cash flow of issuer and Balance Sheet as well.

Management Perception: *We do not have associate, subsidiary or any group of companies.*

- i) **Financial weakness and poor performance of the issuer or any of its subsidiary or associates:** Financial weakness and poor performance of the issuer have negative impact on the company. As a result, it will be tough to pay loan interest, debt service and dividend. Future growth will be hampered.

Management Perception: *Sales is one of the key indicators of success of a business if there is good margin of profit. Techno Drugs Ltd. has been generating stable sales growth.*

- j) **Decline in value of any investment:** If investment value decline, it will reduce the profit and assets as well.

Management Perception: *Techno Drugs Ltd. does not have any investment.*

- k) **Risk associated with useful economic life of plant and machinery, if purchased in second hand or reconditioned:** There is obsolescence risk relating to plant and machinery. If the machinery is purchased in second hand or reconditioned, there high risk of repair and maintenance which has impact on profitability of the company.

Management Perception: *The machineries that are used for Techno Drugs Ltd. are branded machineries for overall operation.*

- l) **Adverse effect on future cash flow if interest free loan given to related party or such loans taken from directors may recall:** It is loan given and taken from related party and directors as well. If company gives such loan without interest to related party, there is interest burden for the company if the money was taken as loan. On the other hand, if such loans are taken from directors, it will have an impact on the cash flow to pay off the loan to the Directors.

Management Perception: *We do not provide any interest free loan to related party. We also did not take any loan from Directors.*

- m) **Potential conflict of interest, if the sponsors or directors of the issuer are involved with one or more ventures which are in the same line of activity or business as that of the issuer and if any supplier of raw materials or major customer is related to the same sponsors or directors:** In these cases there is high chance of compromise among the related companies because of conflict of Interest.

Management Perception: *There is no potential conflict of interest as no sponsors or directors are involved in same line activity.*

- n) **Related party transactions entered into by the company those may adversely affect competitive edge:** Related party transaction of the issuer creates conflict of interest which reduces the competitive advantage of the issuer.

Management Perception: *There is no related party transaction other than office rent, remuneration and Investment in G C Box Ltd.*

- o) **Any restrictive covenants in any shareholders' agreement, sponsors' agreement or any agreement for debt or preference shares or any restrictive covenants of banks in respect of the loan/ credit limit and other banking facilities:** All information must be known to the potential investor so that investor's interest may not be hampered in future. So, any restrictive covenants, if it goes against potential investors, will make investors in jeopardy.

Management Perception: *There are no restrictive covenants in any shareholders' agreement, sponsors' agreement or any agreement relating to debt or preference shares or any restrictive covenants of Banks in respect of loan or credit limit and other banking facilities.*

- p) **Business operations may be adversely affected by strikes, work stoppages or increase in wage demands by employees:** In such case, company's business operation will be hampered.

Management Perception: *In our operating history, our business operation has been running smoothly. Our employees are pleased with the different incentive packages for our employees. Because we believe that employees are very important part of the business.*

- q) **Seasonality of the business of the issuer:** It is the risk involving that company is not doing business round the year.

Management Perception: *We sell pharmaceutical products which are life-saving products and basics pharmaceutical products as well. Hence, it is not seasonal business rather business operation runs round the year.*

- r) **Expiry of any revenue generating contract that may adversely affect the business:** This is the risk of losing customers affecting future sales.

Management Perception: *We do not have revenue generating contract. However, we have regular local customers. In addition, we sell our products to government as per their requirements.*

- s) **Excessive dependence on debt financing which may adversely affect the cash flow:** Excessive dependence on debt causes huge interest burden of the company and high risk of insolvency that may result in bankruptcy.

Management Perception: *We have debt financing as it is capital intensive business. However, it is manageable under the prudent leadership of our management.*

- t) **Excessive dependence on any key management personnel absence of whom may have adverse effect on the issuer's business performance:** Excessive dependence on key management affects the business if the management is changed in future, which will create vacuum. Besides, if the key management personnel are of bad intention, excessive dependence will also affect the business.

Management Perception: *The organizational structure is well organized in such a way that if any key management person leaves the company, there will not have impact on Company's overall performance as other team members of his nearest position capable of taking the responsibility.*

- u) **Enforcement of contingent liabilities which may adversely affect financial condition:** It is the future burden of liabilities that the investors will take on their shoulders. Contingent liabilities reduced the assets or create obligation to pay the liabilities.

Management Perception: *We do not have any contingent liabilities which may adversely affect financial condition.*

- v) **Insurance coverage not adequately protect against certain risks of damages:** Insurance ensures and protects to deal with uncertainty of future material loss/damage. So, insurance coverage is important for the business.

Management Perception: *The Company has fire insurance coverage for its valuable assets to provide adequate protection.*

- w) **Absence of assurance that directors will continue its engagement with Company after expiry of lock in period:** Directors run the company with the accumulated finance from public and other financing source. If directors discontinue running the business, there will be negative impact on business and share price as well.

Management Perception: *Our directors are involved in the business for long time and they will continue the business after expiry of lock in period.*

- x) **Ability to pay any dividends in future will depend upon future earnings, financial condition, cash flows, working capital requirements and capital expenditure:** Dividend payment is highly dependent on company's ability to generate profit. If company cannot earn good amount of profit from operation, it is unlikely to pay dividend.

Management Perception: *The Company has been earning profit and a profitable entity. We are in belief that we will be able to pay dividend from our profit.*

- y) **History of non-operation, if any and short operational history of the issuer and lack of adequate background and experience of the sponsors:** If there is any non-operation of the company, it creates negative impression. Apart from this, short operation history indicates company is gathering knowledge and expertise to be competitive in the market.

Management Perception: *There was no non-operation history of the company. The company has employed experienced people to run the business under good leadership in the board.*

- z) **Risks related to engagement in new type of business, if any:** If it is new business, there is risk of viability of the new business.

Management Perception: *There is no such risk as we are not engaged in any new type of business.*

- aa) **Risk in investing the securities being offered with comparison to other available investment options:** If the issue price goes down after floating, there is investment risk for the potential investors.

Management Perception: *Techno Drugs Ltd. is a profitable entity and business growth will continue in the long run. There is presence of certain degree of risk associated with investing in the securities in the capital market. The potential investors are requested to carefully read the prospectus and understand the business potential of the company before making investment decision.*

- bb) **Any penalty or action taken by any regulatory authorities for non-compliance with provisions of any law:** *It creates a negative impression on the issuer.*

Management Perception: *There were no such penalties or action taken by any regulatory authorities for non-compliance with provisions of any law.*

- cc) **Litigations against the issuer for Tax and VAT related matters and other government claims, along with the disclosures of amount, period for which such demands or claims are outstanding, financial implications and the status of the case:** *It creates a negative impression on the issuer.*

Management Perception: *We did not have any litigation relating to Tax. With regard to VAT, there is a litigation in the court.*

- dd) **Registered office or factory building or place of operation is not owned by the issuer:** Factory building should be owned by the company. Otherwise, there is risk of hike in factory rent in the years to come and threat of shifting the factory as well.

Management Perception: *Our factory building is owned and registered office is rented.*

- ee) **Lack of renewal of existing regulatory permissions/ licenses:** In this case company is not following the law to renew its all licenses.

Management Perception: *There is no such issue relating to lack of existing regulatory permissions/ licenses.*

- ff) **Failure in holding AGM or declaring dividend or payment of interest by any listed securities of the issuer or any of its subsidiaries or associates:** Failure in holding AGM or declaring dividend indicates the lack of compliance to the regulatory rules. Failure of payment of interest indicate the poor cash generation to the company to pay interest and debt service. The overall impression will be negative for the company.

Management Perception: *There is no incident of failure in holding AGM or declaring dividend or payment of interest by the issuers.*

- gg) **Issuances of securities at lower than the IPO offer price within one year:** The management ultimate goal is to maximize the wealth of the company. If share price goes up, it maximizes wealth of the company. On the other hand, if share price goes down, it minimizes the wealth of the company.

Management Perception: *Techno Drugs Ltd. has not issued securities at lower than IPO offer price within one year.*

hh) **Refusal of application for public issue of any securities of the issuer or any of its subsidiaries or associates at any time by the Commission:** If any refusal happened in the above cases, it will create negative impression to the issuer.

Management Perception: Such cases did not happen for our company.

(ii) External risk factors may include among others:

a) **Interest Rate Risks:** When interest rate fluctuates, it causes interest risk. Companies who have debt financing are exposed to this risk highly.

Management Perception: The Management of the Company is always aware of the interest rate. If the interest rate increases the cost of the credit fund will increase. At present, interest rate has been set by 6 month weighted average treasury rate plus 3% premium. Hence, interest rate slightly increased to around 10% from earlier single digit 9%. This increased cost will be adjusted in selling price.

b) **Exchange Rate Risks:** Foreign exchange risk or currency risk is a financial risk that exists when a financial transaction is denominated in a currency other than that of the base currency of the company. This risk arises when investment's value changed due to the changes in currency exchange rates.

Management Perception: Our foreign currency reserve has been hovering around 23 billion as per IMF guideline as of July 2023. In order to make stable foreign currency rate, Bangladesh Bank were always in effort to cool the foreign exchange rate. However, IMF suggest to allow market-based exchange rate. As a result, exchange rate risk has been increased for business industries than earlier. All have to deal with new floating rate regime. Since, we do import for our raw materials, we are exposed to exchange rate risk. As a result, production cost will be increased, which will be adjusted in selling price.

c) **Industry Risks:** Industry risk is related with the factors affecting the company such as Raw Material, labor, demand of the product, government policy to the sector, competitor's rivalry.

Management Perception: Techno Drugs Ltd. is aware of the above fact. Industry risk is inherent in any kind of business. At the moment, our industry is in favoring position for operating business. Pharmaceutical Industry in Bangladesh has huge potential because of highly dense country and over populated country. Industry is growing at 10% plus. Hence, we expect better future.

d) **Economic and Political risks:** This risk can be described as the likelihood that an investment will be affected by macroeconomic conditions such as government regulation, exchange rates, or political stability. In other words, while financing a project, the risk that the output of the project will not produce adequate revenues for covering operating costs and repaying the debt obligations. In a nutshell, economic risk refers to the risk that a venture will be economically unsustainable due to various reasons.

Management Perception: Bangladesh economy is enjoying 6% plus economic growth though it was hampered in fiscal year 2019-20 due to covid-19. Earlier, our expected economic growth by the government is over 8%. As a result, huge development work is underway by the government. Hence, huge expensive infrastructure has been under construction that will create employment and per capita income is also going up as well. As economy is expanding, so is our business viability and profitability.

Political risks: Bangladesh experienced with political unrest for over the years. Political instability hampers the smooth operation of business.

Management Perception: *Our political situation is a bit murky because of coming election that will be held in December 2023. Government has been in effort to maintain business friendly situation for over a decade. We expect that after election, political situation will be calm.*

e) **Market and Technology-related Risks;**

Market risks: *Techno Drugs Ltd. is operating in a free-market economy regime. The company might have to face stiff competition from its competitors.*

Management perception: *Market risk is dealt with efficiently by the experienced management.*

Technology-related risks: *Technology always plays a vital role for each and every type of business. Innovation of new and cost-effective technology can increase productivity and reduce costs of production. On the other hand, obsolete technology may have a negative impact on the business.*

Management perception: *As a pharmaceutical company, we have to keep pace with the latest research and technological advancement as well. It's a continuous process to adapt with better solution for human lives.*

f) **Potential or existing government regulations:** *Potential or existing Govt. regulations may hamper the smooth operation of the industry.*

Management perception: *We are enjoying good atmosphere in operating our business. Government regulations are favorable to promote business and employment. Unless any policy change that may negatively and materially affect the industry as a whole, the business of the Company is expected not to be affected significantly.*

g) **Potential or existing changes in global or national policies:** *Policies from government has a positive or negative impact on any company along with existing changes in globally.*

Management perception: *Nowadays global and national policies do not change without prior notice. For potential changes in policies, local and global leaders consider different issues including industry's opinion. We are optimistic that if any policies change unpredictably, we can improvise with new policies without hampering our smooth operation. Moreover, the management is always concerned about the prevailing and unforeseen future changes in the global or national policy and equipped them to respond appropriately and timely to safeguard its interest.*

h) **Statutory clearances and approvals those are yet to be received by the issuer:** *Statutory clearance and approval is imperative for any business to start off. There are many statutory clearances and approvals needed from the regulatory authority in order to be monitored, controlled and guided.*

Management Perception: *Techno Drugs Ltd. has been running its business for long time. The company has collected all the statutory clearance to operate the business. Hence, there are no such risks for the Company.*

- i) **Competitive condition of the business:** *Techno Drugs Ltd.* is operating in a free market economy. The company has to face stiff competition from its competitors.

Management Perception: *Bangladesh is a densely populated country and labor force are abundant that is conducive for business. As a result, all the companies get benefited with cheap labor cost. There are many companies at the moment doing business. Hence, there is rivalry among the competitors to serve the customers with low price and best quality. Over the last few years, our company has built a trustworthy relationship with customers, which helps the company to have competitive advantage.*

- j) **Complementary and supplementary products/services which may have an impact on business of the issuer:** Complementary goods or services that are used in conjunction with another goods or services. Usually, the complementary goods have no value when consumed alone, but when combined with another good or service, it adds to the overall value of the offering. Complementary goods are used together. For example, if we have a car, we also need petrol to run the car.

Management Perception: *The Company has not faced any challenges relating to complementary and supplementary products. Management are concerned with the issue. In future, if necessary, management may diversify the product to be competitive over the competitors.*

CHAPTER (XXI)

DESCRIPTION OF THE ISSUE

(a) **Issue Size:** Taka 1,000,000,000.00

(b) **Number of securities to be issued:**

Public issue of 36,199,095 Ordinary shares.

(c) **Authorized capital and paid-up capital;**

| Particular | Type of Securities | Number of securities | Nominal Price | Amount in BDT |
|---|--------------------|----------------------|---------------|----------------------|
| Authorized Capital | Ordinary Shares | 200,000,000 | 10 | 2,000,000,000 |
| Total Paid-up capital before IPO (i) | | 94,157,400 | 10 | 941,574,000 |
| Initial Public Offering (IPO) (ii) | | 36,199,095 | 10 | 361,990,950 |
| Total Paid-up Capital after IPO [i + ii] | | 130,356,495 | 10 | 1,303,564,950 |

(d) **Face value, premium and offer price per unit of securities;**

| | |
|-----------------------|---|
| Face value per Share | Tk. 10.00 each |
| Premium | Tk. 14.00 for General Public (GP) and Tk. 24.00 for Eligible Investors (EI) & Employees and others |
| Offer Price per Share | Tk. 24.00 for General Public (GP) and Tk. 34.00 for Eligible Investors (EI) & Employees and others each |

(e) **Number of securities to be entitled for each category of applicants;**

| Category | Percentage (%) | No. of shares | Amount (BDT) |
|--|--|-------------------|----------------------|
| Private Offer- TDL's Employees and others | 15% of the total securities | 5,429,865 | 184,615,410 |
| Distribution of Securities excluding the portion under private offer: | | | |
| Eligible Investors (EI) | 25% of IPO shall be reserved for EI including Mutual Funds and CIs | 7,692,307 | 261,538,438 |
| General Public (GP) | 5% of IPO shall be reserved for NRB | 1,538,461 | 36,923,064 |
| | 70% of IPO shall be reserved for GP excluding NRB | 21,538,462 | 516,923,088 |
| Total | | 36,199,095 | 1,000,000,000 |

(f) **Holding structure of different classes of securities before and after the issue;**

| Sl. | Category of Shareholders | No. of Ordinary Shares Hold | | Percentage of Holding | |
|--------------|----------------------------------|-----------------------------|--------------------|-----------------------|----------------|
| | | Pre-IPO | Post-IPO | Pre-IPO | Post-IPO |
| 1 | Director & Sponsor | 82,776,200 | 82,776,200 | 87.91% | 63.50% |
| 2 | Institutional | - | 4,492,307 | 0.00% | 3.45% |
| 3 | Mutual Funds and CIS | - | 3,200,000 | 0.00% | 2.45% |
| 4 | Individual | 11,381,200 | 38,349,527 | 12.09% | 29.42% |
| 5 | Non Resident Bangladeshis (NRBs) | - | 1,538,461 | 0.00% | 1.18% |
| Total | | 94,157,400 | 130,356,495 | 100.00% | 100.00% |

(g) Objective of the issue including financing requirements and feasibility in respect of enhanced paid-up capital.

- Objective of the issue including financing requirements and feasibility in respect of enhanced paid-up capital are available in the Section- XXII under the head of "Use of Proceeds" of this red-herring prospectus.
- Net proceeds from Initial Public Offering (IPO) will be used for acquisition and installation of machineries & equipment, BMRE at Satirpara, Narsingdi-1600, building and other construction at B.K. Bari Mirzapur, Gazipur-1703, Partial loan repayment and IPO expenses.

| Sl. | Particulars | Amount in Tk. |
|-----|---|----------------------|
| 1 | Acquisition and installation of machineries & equipment | 270,000,000 |
| 2 | BMRE at Satirpara, Narsingdi-1600 | 250,000,000 |
| 3 | Building and other construction at B.K. Bari Mirzapur, Gazipur-1703 | 150,000,000 |
| 4 | Partial loan repayment | 300,000,000 |
| 5 | IPO Expenses | 30,000,000 |
| | Total | 1,000,000,000 |

Note: The estimated IPO expenses will be paid at actual and any excess adjustment will be paid from own source.

Feasibility:

Feasibility report is not required since the Company will not start new line of business with the money raised from the Initial Public Offering (IPO).

Status of Bidding of Shares of Techno Drugs Ltd.:

The electronic bidding of **Techno Drugs Ltd.** through electronic subscription system (ESS) by the Eligible Investors has been successfully completed on April 24, 2024. Based on the Bidding of Eligible Investors, the Cut-off price of ordinary shares of **Techno Drugs Ltd.** was determined at Tk. 34.00 (Taka Thirty-Four) only. The details of the bidding are as follows:

| | | |
|------------------------------|---|----------------------------------|
| Issue Name | : | TECHNODRUG |
| Issue Type | : | Large Cap – BBM |
| El Issue Size | : | 7,692,307 no. of ordinary shares |
| Cut-off Price | : | Tk. 34.00 |
| Total Bid Volume | : | 22,229,211 |
| Total Bids | : | 188 no. of Els |
| Total Successful Bids | : | 64 no. of Els |

Aggregate Bidding Result

| BOID | Investor Name | Bid Price | Bid Volume | Allotted Vol. | Allotted Value |
|------------------|---|-----------|------------|---------------|----------------|
| 1201890074667178 | ADOT CURVE VENTURES LIMITED | 34 | 125,000 | 125,000 | 4,250,000 |
| 1601670032656781 | AIBL 1st Islamic Mutual Fund | 34 | 90,000 | 90,000 | 3,060,000 |
| 1605550068820427 | ALPHA CAPITAL MANAGEMENT LIMITED Employees' Gratuity Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1605550049519826 | Alpha Capital Management Limited. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1605570061564795 | BANCO FINANCE AND INVESTMENT LIMITED | 34 | 125,000 | 125,000 | 4,250,000 |
| 1605420043478871 | BANGLADESH FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620064112891 | BCB ICL GROWTH FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202180045048887 | BDBL Securities Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201820068652934 | Bashundhara Multi Food Products Ltd.-Staff Provident Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580073395731 | CAPITEC-IBBL SHARIAH UNIT FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580062240983 | CAPM BDBL MUTUAL FUND 01 | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580064275550 | CAPM IBBL Islamic Mutual Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620049839524 | CAPM UNIT FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1606570075807869 | CBC CAPITAL & EQUITY MANAGEMENT LTD. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620068180805 | CWT Emerging Bangladesh First Growth Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1205590070412843 | CWT Private Equity Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620076067046 | CWT-COMMUNITY BANK SHARIAH FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580076138513 | Capitec Grameen Bank Growth Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580066440664 | Capitec Padma P.F. Shariah Unit Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1204500028949639 | City Brokerage Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202980067355662 | Crown Global Tex Limited Employee's Provident Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620075077431 | EKUSH GROWTH FUND | 34 | 117,000 | 117,000 | 3,978,000 |
| 1604620068167620 | Esquire ICL Apparel Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1601670032193259 | Green Delta Mutual Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620074839081 | HFAML Shariah Unit Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580064096932 | HFAML UNIT FUND | 34 | 59,000 | 59,000 | 2,006,000 |
| 1604620066681657 | HFAML-ACME Employees Unit Fund | 34 | 59,000 | 59,000 | 2,006,000 |

| | | | | | |
|------------------|---|----|---------|---------|-----------|
| 1604580038429901 | ICB AMCL FIRST AGRANI BANK MUTUAL FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201530000001725 | ICB Capital Management Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201530000003518 | ICB UNIT Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604790028773041 | IIDFC Capital Limited | 34 | 117,000 | 117,000 | 3,978,000 |
| 1201530000003501 | INVESTMENT CORPORATION OF BANGLADESH | 34 | 125,000 | 125,000 | 4,250,000 |
| 1603700045112394 | ISLAMI BANK CAPITAL MANAGEMENT LIMITED | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201850000007904 | International Securities Co Ltd | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202010061719713 | Investment Promotion Services Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202610029280542 | JAHAN SECURITIES LTD. | 34 | 125,000 | 21,307 | 724,438 |
| 1201730029204716 | KAZI EQUITIES LTD. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202210025379170 | KHWAJA EQUITY SERVICES LTD. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620073858922 | LB GRATUITY WEALTH BUILDER FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580071936324 | LB Gratuity Opportunities Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1606570075991670 | LIZ FASHION INDUSTRY LTD. EMPLOYEES CONTRIBUTORY PROVIDENT FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620062083293 | LankaBangla 1st Balanced Unit Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604580064681637 | LankaBangla Al-Arafah Shariah Unit Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1204030045890257 | LankaBangla Asset Management Company Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201830000007813 | LankaBangla Securities Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201830060975261 | LankaBangla Securities Limited Employees Provident Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201540030520453 | MAM Securities Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201470000000763 | Mona Financial Consultancy & Securities Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1601670040102015 | NCCBL Mutual Fund-1 | 34 | 125,000 | 125,000 | 4,250,000 |
| 1206050066863343 | New Era Securities Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201520020432993 | Parkway Securities Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1206220074863781 | Rahman Equity Management Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1604620075593723 | SANDHANI AML SLIC FIXED INCOME FUND | 34 | 125,000 | 125,000 | 4,250,000 |
| 1201470073706337 | SANDHANI ASSET MANAGEMENT LTD. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202300037954236 | SHAHED SECURITIES LTD. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1205670000803592 | SUNLIFE INSURANCE COMPANY LIMITED | 34 | 124,000 | 124,000 | 4,216,000 |
| 1604580067859198 | Shanta Amanah Shariah Fund | 34 | 125,000 | 125,000 | 4,250,000 |
| 1203490060953009 | Shanta Asset Management Ltd. | 34 | 105,000 | 105,000 | 3,570,000 |
| 1604620064617121 | Shanta First Income Unit Fund | 34 | 125,000 | 125,000 | 4,250,000 |

| | | | | | |
|--------------------|-------------------------------|----|------------------|------------------|--------------------|
| 1203490029025239 | Shanta Securities Ltd. | 34 | 125,000 | 125,000 | 4,250,000 |
| 1202550050945829 | Sheltech Brokerage Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1205590053704098 | UCB Stock Brokerage Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1204780065237057 | United Securities Limited | 34 | 125,000 | 125,000 | 4,250,000 |
| 1204280029275995 | VISION CAPITAL MANAGEMENT LTD | 34 | 125,000 | 125,000 | 4,250,000 |
| Records: 64 | | | 7,796,000 | 7,692,307 | 261,538,438 |

List of Employees and others for 15% shares allocation as part of IPO in line with 4 (1) (I) of Bangladesh Securities and Exchange Commission (Public Issue) Rules, 2015:

List of Employees:

| Sl. | Name (as per BO ID) | BO ID | Total Quantity | Total Amount | Category of Applicant | Employee ID | Service Start Date | Designation | Lock in Period |
|------------------|-------------------------------------|------------------|------------------|-------------------|-----------------------|-------------|--------------------|-------------------------|----------------|
| 1 | Ashoke Kumer Adhikary | 1201980020283614 | 15,000 | 510,000 | Employee | 11175 | 1-Jan-19 | Sr. Executive | 2 Yrs. |
| 2 | Asis Kumar Kar | 1201960069389998 | 30,000 | 1,020,000 | | 11192 | 1-Sep-19 | Asst. Manager | 2 Yrs. |
| 3 | Biswajit Kumar Saha | 1201590040022455 | 72,100 | 2,451,400 | | 11270 | 1-Jun-21 | Sales Manager | 2 Yrs. |
| 4 | Debasish Das Gupta | 1205700076564399 | 110,000 | 3,740,000 | | 11181 | 1-Apr-19 | Company Secretary | 2 Yrs. |
| 5 | Ibrahim Khalil | 1605650076580210 | 200,000 | 6,800,000 | | 11341 | 15-Oct-23 | Manager | 2 Yrs. |
| 6 | Majedul Karim | 1205700076569490 | 66,450 | 2,259,300 | | 18804 | 1-Apr-10 | AGM | 2 Yrs. |
| 7 | Md Asaduzzaman | 1203600076578228 | 1,000 | 34,000 | | 11236 | 1-Feb-21 | Sales Manager | 2 Yrs. |
| 8 | Md Kamal Hossain | 1203600076578145 | 251,500 | 8,551,000 | | 11332 | 1-Jul-23 | Asst. Manager | 2 Yrs. |
| 9 | Md Navid Arefin Khan | 1203600076578011 | 265,000 | 9,010,000 | | 11268 | 1-Jun-21 | Sr. Executive | 2 Yrs. |
| 10 | Md Rejaul Karim | 1203600076578097 | 5,000 | 170,000 | | 42063 | 23-Jun-18 | Head of Ins. Business | 2 Yrs. |
| 11 | Md. Anisur Rahman | 1203600076578509 | 8,800 | 299,200 | | 36001 | 25-Jul-10 | Manager- Distribution | 2 Yrs. |
| 12 | Md. Jamal Hossain Akond | 1203600076578541 | 12,500 | 425,000 | | 41758 | 6-Mar-16 | Sales Manager | 2 Yrs. |
| 13 | Md. Sharif Hossain | 1203410076565773 | 64,000 | 2,176,000 | | 11207 | 2-Feb-20 | Manager- commercial | 2 Yrs. |
| 14 | MM. Ahsanul Kabir | 1201820076575829 | 30,000 | 1,020,000 | | 11216 | 3-Aug-20 | Manager | 2 Yrs. |
| 15 | Nure Alam Siddiqui & Gulrana Fatema | 1203600076580451 | 22,000 | 748,000 | | 11046 | 1-Oct-11 | Officer | 2 Yrs. |
| 16 | Parimal Chandra Sarker | 1201820076578442 | 26,050 | 885,700 | | 60000 | 4-Jun-16 | Head of Plant | 2 Yrs. |
| 17 | Pijush Kumar Chakroborty | 1205700056840823 | 120,000 | 4,080,000 | | 11052 | 1-Feb-14 | Chief Financial Officer | 2 Yrs. |
| 18 | Shoab Ahmed | 1605650074777631 | 32,400 | 1,101,600 | | 11176 | 1-Jan-19 | CEO- sales & Mkt. | 2 Yrs. |
| 19 | Subrata Kumar Chanda | 1203600076578196 | 116,000 | 3,944,000 | | 14004 | 1-May-16 | Manager | 2 Yrs. |
| Total (A) | | | 1,447,800 | 49,225,200 | | | | | |

List of others:

| Sl. | Name (as per BO ID) | BO ID | Total Quantity | Total Amount | Category of Applicant | Employee ID | Service Start Date | Designation | Lock in Period |
|-----|------------------------|------------------|----------------|--------------|-----------------------|-------------|--------------------|-------------|----------------|
| 1 | Ashan Ullah Chowdhury | 1203600061474384 | 306,850 | 10,432,900 | Others | N/A | N/A | N/A | 2 Yrs. |
| 2 | Md. Nafiz imtiaz khan | 1203680064004665 | 7,000 | 238,000 | | N/A | N/A | N/A | 2 Yrs. |
| 3 | Md.Khalilur Rahman | 1206000076576012 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 4 | Mohammad Nazmul | 1205700076578485 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 5 | Moral Khairuzzaman | 1201950064083031 | 5,000 | 170,000 | | N/A | N/A | N/A | 2 Yrs. |
| 6 | Avijit Kumer Bhoumik | 1205080076465621 | 70,000 | 2,380,000 | | N/A | N/A | N/A | 2 Yrs. |
| 7 | Mr. Golam abbas | 1201580000165530 | 10,000 | 340,000 | | N/A | N/A | N/A | 2 Yrs. |
| 8 | Shahin Alam Jia | 1201950074187570 | 5,000 | 170,000 | | N/A | N/A | N/A | 2 Yrs. |
| 9 | Shaikh Hasibur Rahman | 1204030026755158 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 10 | Shakhawat Hossain | 1201530064381454 | 10,000 | 340,000 | | N/A | N/A | N/A | 2 Yrs. |
| 11 | Sharif Mohammad Kibria | 1203490062583521 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 12 | SK. Golam Rosul | 1205080075696051 | 29,500 | 1,003,000 | | N/A | N/A | N/A | 2 Yrs. |
| 13 | Tanjin Ara Siddiqua | 1202540069161914 | 29,500 | 1,003,000 | | N/A | N/A | N/A | 2 Yrs. |
| 14 | Mosammat Momena Begum | 1203570040183580 | 75,000 | 2,550,000 | | N/A | N/A | N/A | 2 Yrs. |
| 15 | Md. Shamsul Alam | 1605120062625788 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 16 | Mohammad Iqbal Hossain | 1203040068815698 | 350,000 | 11,900,000 | | N/A | N/A | N/A | 2 Yrs. |
| 17 | Mst. Ummey Kulsum | 1205950075587419 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 18 | Aswat Aksir Mujib Wasi | 1206210066332994 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 19 | Md. Majibur Rahman | 1206210075297466 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 20 | M M Fazlul Haque | 1201950076569591 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 21 | Bishwajit Das | 1203520026120606 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 22 | Md. Sarwar Alam | 1201950058581308 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 23 | M. Imran Hamid | 1606060021517606 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 24 | Md. Towhid Bin Shafi | 1206350075977384 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 25 | Mohammad Al- Amin | 1203590065262262 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 26 | Tahid Ahmed Chowdhury | 1202550068218293 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 27 | Md. Mahbulul Alam | 1203040004499405 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 28 | Salma Rahman | 1202680001468058 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 29 | Ashis Kumar Saha | 1203390076572338 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 30 | Mizanur Rahman Mridha | 1201510068904997 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 31 | Kazi Md. Rafiqul Islam | 1203490069545029 | 40,000 | 1,360,000 | | N/A | N/A | N/A | 2 Yrs. |
| 32 | Syedda Yeasmeen Meer | 1204030075375648 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 33 | Md. Sarwar Hossain | 1201970076567898 | 175,000 | 5,950,000 | | N/A | N/A | N/A | 2 Yrs. |
| 34 | Colour N Life Limited | 1202530074766514 | 175,000 | 5,950,000 | | N/A | N/A | N/A | 2 Yrs. |
| 35 | Md. Mahbulur Rahman | 1201950053882751 | 150,000 | 5,100,000 | | N/A | N/A | N/A | 2 Yrs. |

| | | | | | | | | | |
|--------------------|-------------------------|------------------|------------------|--------------------|--|-----|-----|-----|--------|
| 36 | Shajeda Begum | 1202300054217381 | 100,000 | 3,400,000 | | N/A | N/A | N/A | 2 Yrs. |
| 37 | S.M. Mafijul Islam | 1203680018795911 | 25,000 | 850,000 | | N/A | N/A | N/A | 2 Yrs. |
| 38 | Nasir Uddin Ahmed | 1201510022535068 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 39 | Most. Jannatul Ferdous | 1205030052466759 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 40 | Sakir Akter | 1201830076581603 | 75,000 | 2,550,000 | | N/A | N/A | N/A | 2 Yrs. |
| 41 | Md. Nuruzzaman Khan | 1206000075664457 | 25,000 | 850,000 | | N/A | N/A | N/A | 2 Yrs. |
| 42 | Noor Jahan | 1606060048408481 | 150,000 | 5,100,000 | | N/A | N/A | N/A | 2 Yrs. |
| 43 | Md. Saroar Hossain | 1201950075354079 | 75,000 | 2,550,000 | | N/A | N/A | N/A | 2 Yrs. |
| 44 | Md. Tarequl Islam | 1202750003769587 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 45 | Prodip Kumar Roy | 1201910003589624 | 144,215 | 4,903,310 | | N/A | N/A | N/A | 2 Yrs. |
| 46 | Mohammad Towfiqul Islam | 1204090053883178 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| 47 | Md. Sadrul Huda | 1204500076257434 | 25,000 | 850,000 | | N/A | N/A | N/A | 2 Yrs. |
| 48 | Md. Shibbir Hossain | 1205150073854204 | 25,000 | 850,000 | | N/A | N/A | N/A | 2 Yrs. |
| 49 | Anupam Kumar Chowdhury | 1205150068801253 | 50,000 | 1,700,000 | | N/A | N/A | N/A | 2 Yrs. |
| Total (B) | | | 3,982,065 | 135,390,210 | | | | | |
| Total (A+B) | | | 5,429,865 | 184,615,410 | | | | | |

CHAPTER (XXII)

USE OF PROCEED

(a) Use of net proceeds of the offer indicating the amount to be used for each purpose with head-wise break-up;

Sources of Fund:

| Particulars | Amount in BDT |
|---|---------------|
| Total fund raised through Initial Public Offering (IPO) | 1,000,000,000 |

Proceeds from Initial Public Offering (IPO) will be used for acquisition and installation of machineries & equipment, BMRE at Satirpara, Narsingdi-1600, building and other construction at B.K. Bari Mirzapur, Gazipur-1703, Partial loan repayment and IPO expenses.

| Sl. | Particulars | Amount in Tk. |
|-----|---|----------------------|
| 1 | Acquisition and installation of machineries & equipment | 270,000,000 |
| 2 | BMRE at Satirpara, Narsingdi-1600 | 250,000,000 |
| 3 | Building and other construction at B.K. Bari Mirzapur, Gazipur-1703 | 150,000,000 |
| 4 | Partial loan repayment | 300,000,000 |
| 5 | IPO Expenses [Details at page number 152-153] | 30,000,000 |
| | Total | 1,000,000,000 |

Note: The estimated IPO expenses will be paid at actual and any excess adjustment will be paid from own source.

Details of acquisition and installation of machineries & equipment:

| Sl. | Machinery Name | Qty | Unit | Rate in (USD) | Conv. Rate | Amount (BDT) |
|-----|--|-----|------|---------------|------------|--------------|
| 1 | Paste preparation vessel GMP Model capacity 100 Mtr. | 1 | Pcs | 7,000 | 110 | 770,000 |
| 2 | Rapid mixture granulator (RMG) GMP Model capacity 120 Kg. | 1 | Pcs | 50,000 | 110 | 5,500,000 |
| 3 | Fluid bed dryer GMP Model capacity 120 Kg. with complete accessories | 1 | Pcs | 60,000 | 110 | 6,600,000 |
| 4 | Multimill GMP Model capacity 120 Kg. per hour | 1 | Pcs | 8,000 | 110 | 880,000 |
| 5 | Vibro shifter GMP Model capacity 120 Kg. per hour with 2 no. sieves | 1 | Pcs | 12,000 | 110 | 1,320,000 |
| 6 | V-Blender GMP Model capacity 500 Ltr. with safety device. | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 7 | High-speed tablet compression machine D-type double rotary GMP Model | 1 | Pcs | 105,000 | 110 | 11,550,000 |
| 8 | Tablet film coating machine with solution preparation tank and air inlet and outlet system GMP Model | 1 | Pcs | 115,000 | 110 | 12,650,000 |
| 9 | High speed blister packing machine with different change parts GMP Model | 1 | Pcs | 125,000 | 110 | 13,750,000 |
| 10 | Packing conveyer belt GMP Model | 1 | Pcs | 4,000 | 110 | 440,000 |
| 11 | Encapsulation machine with polishing and checking complete set GMP Model 24,000 capsule per hour | 1 | Pcs | 40,000 | 110 | 4,400,000 |
| 12 | Medium speed blister machine with different change part | 1 | Pcs | 80,000 | 110 | 8,800,000 |
| 13 | Roll compactor for dry granulation capacity 120Kg. per hour | 1 | Pcs | 130,000 | 110 | 14,300,000 |

| | | | | | | |
|----|---|----|-----|---------|-----|------------|
| 14 | Soft gel encapsulation machine GMP Model 60 stroke per minute. | 1 | Pcs | 110,000 | 110 | 12,100,000 |
| 15 | Soft gel preparation vessel & Soft gel storage tank and drying unit. | 1 | Pcs | 95,000 | 110 | 10,450,000 |
| 16 | Automatic linear washing machine GMP Model | 1 | Pcs | 30,000 | 110 | 3,300,000 |
| 17 | Sterilization & Depyrogenating tunnel GMP Model | 1 | Pcs | 72,000 | 110 | 7,920,000 |
| 18 | Automatic ampoules filling sealing Machine with LAF GMP Model | 1 | Pcs | 85,000 | 110 | 9,350,000 |
| 19 | Bottle washing machine GMP Model | 1 | Pcs | 10,000 | 110 | 1,100,000 |
| 20 | Tray dryer for bottle drying GMP Model | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 21 | Liquid manufacturing vessel & Transfer pump GMP Model | 1 | Pcs | 20,000 | 110 | 2,200,000 |
| 22 | Liquid storage tank & filtration GMP Model | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 23 | Liquid filling & sealing machine GMP Model | 1 | Pcs | 25,000 | 110 | 2,750,000 |
| 24 | Automatic self adhesive sticker labelling machine GMP Model | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 25 | Turn table GMP Model | 1 | Pcs | 4,000 | 110 | 440,000 |
| 26 | Packing conveyor GMP Model | 1 | Pcs | 4,000 | 110 | 440,000 |
| 27 | Automatic linear vial washing machine GMP Model | 1 | Pcs | 35,000 | 110 | 3,850,000 |
| 28 | Automatic vial filling and rubber stoppering machine GMP Model | 1 | Pcs | 50,000 | 110 | 5,500,000 |
| 29 | Automatic vial capping machine GMP Model | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 30 | Air shower | 2 | Pcs | 21,000 | 110 | 2,310,000 |
| 31 | Jet printer | 2 | Pcs | 10,000 | 110 | 1,100,000 |
| 32 | Sampling booth | 2 | Pcs | 12,000 | 110 | 1,320,000 |
| 33 | Dispensing booth | 2 | Pcs | 14,000 | 110 | 1,540,000 |
| 34 | Pass box (dynamic) | 2 | Pcs | 10,000 | 110 | 1,100,000 |
| 35 | Pass box (static) | 6 | Pcs | 12,000 | 110 | 1,320,000 |
| 36 | Stability Chamber - 600L | 1 | Pcs | 8,000 | 110 | 880,000 |
| 37 | Stability Chamber - 1000L | 1 | Pcs | 10,000 | 110 | 1,100,000 |
| 38 | Stability Chamber - 2000L | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 39 | Chiller compressor, Model- MSC2246NHL6V5KOMB4C | 2 | Pcs | 51,000 | 110 | 5,610,000 |
| 40 | Calibration Equipment GMP Model | | | | | |
| | 12 Chanel data logger | 1 | | | | |
| | Temperature sensor | 10 | | | | |
| | Portable data logger | 12 | | | | |
| | Temperature + Relative humidity data logger | 1 | Pcs | 12,000 | 110 | 1,320,000 |
| | Temperature + Relative humidity indicator/monitor | 1 | | | | |
| | Smart log Pro Software. Version 1.0.16 (Optional) | 1 | | | | |
| 41 | BMS System GMP Model | 1 | Pcs | 45,000 | 110 | 4,950,000 |
| 42 | Purified Water Generation & Distribution system and Water for injection generation & distribution system GMP Model : | 1 | lot | 65,000 | 110 | 7,150,000 |
| | UV Lamp | | | | | |

| | | | | | | |
|--|---|---|------|---------|-----|--------------------|
| | UV Ballast | | | | | |
| | UV Intensity | | | | | |
| | RO 1 pH And Conductivity Meter Emerson 1056 & Conductivity sensor | | | | | |
| | HMI of WFI Distribution System | | | | | |
| | Level sensor PR 23 RY | | | | | |
| | Air pressure switch | | | | | |
| | Level controller | | | | | |
| | Online programming charges for PLC & HMI | | | | | |
| | ¼" Sample Valve | | | | | |
| | Online programming charges for PW generation system | | | | | |
| | Online programming charges for multi column | | | | | |
| | 5" Vent filter with cartridge & 1.5" elbow | | | | | |
| | PH sensor emerson make | | | | | |
| | Single channel conductivity meter emerson make | | | | | |
| | UPVC piping set | | | | | |
| 43 | Water cool Chiller 100 TR with cooling tower and piping and insulation GMP Model | 4 | Pcs | 155,000 | 110 | 17,050,000 |
| 44 | Chilled water pipe, insulation for chiller GMP Model | 1 | lot | 20,000 | 110 | 2,200,000 |
| 45 | Sheet metal ducting work for AHU (Air Handling Unit) supply diffuser and return grill GMP Model | 1 | lot | 30,000 | 110 | 3,300,000 |
| 46 | Air Handling Unit & Dehumidifier for HVAC System GMP Model | 4 | Pcs | 80,000 | 110 | 8,800,000 |
| 47 | Ointment cream manufacturing GMP Model | 1 | Pcs | 30,000 | 110 | 3,300,000 |
| 48 | Ointment filling and sealing machine GMP Model | 1 | Pcs | 40,000 | 110 | 4,400,000 |
| 49 | Change Parts & Spare Parts for I-Dosi (Spain) of Vial filling & Rubber stoppering machine of Servo drive & Vibrator controller GMP Model | 1 | Llot | 30,000 | 110 | 3,300,000 |
| 50 | Granulation Suite with auto loading and unloading and containment system GMP Model | 1 | lot | 105,000 | 110 | 11,550,000 |
| 51 | Filter integrity machine with filtration unit GMP Model | 1 | Pcs | 25,000 | 110 | 2,750,000 |
| 52 | Autoclave 100 ltr. Capacity GMP Model | 1 | Pcs | 15,000 | 110 | 1,650,000 |
| 53 | Autoclave 500 ltr. Capacity GMP Model | 1 | Pcs | 25,000 | 110 | 2,750,000 |
| 54 | Autoclave 2000 ltr. Capacity GMP Model | 1 | Pcs | 40,000 | 110 | 4,400,000 |
| 55 | Electronic balance 0 to 500 gram with printer GMP Model | 5 | Pcs | 7,000 | 110 | 770,000 |
| 56 | Electronic balance 10 mg to 5 kg. with printer GMP Model | 5 | Pcs | 6,500 | 110 | 715,000 |
| 57 | Electronic balance 1 gram to 150 kg. with printer GMP Model | 5 | Pcs | 5,000 | 110 | 550,000 |
| Total value in Taka | | | | | | 247,445,000 |
| Installation & Others | | | | | | 22,555,000 |
| Total cost of machineries & equipment | | | | | | 270,000,000 |

Details of BMRE at Satirpara, Narsingdi-1600:

| Sl. | Project | Cost Breakdown | Amount in (BDT) |
|-----|--|--|-----------------------|
| 1 | General Production Building: Ground floor 1st floor 2nd Floor 3rd Floor | Civil Construction: Partition wall, Brick wall plaster & Floor epoxy. | 27,000,000.00 |
| | | Clean Room Wall panel, Ceiling panel with coving with GMP Concept | 22,000,000.00 |
| | | Utility | 10,000,000.00 |
| | | HVAC System | 55,000,000.00 |
| | | Product Development Machinery | 15,000,000.00 |
| | | Water System-Purify & WFI with Generation & Distribution | 25,000,000.00 |
| | | Injectable Machine-Washing, Drying, Vial Filling, Rubber Stoppering, Capping & Levelling | 25,000,000.00 |
| | | Electrical Service | 10,000,000.00 |
| | | Fire Detection & Fighting System | 10,000,000.00 |
| | | Sanitary & Plumbing | 2,500,000.00 |
| | | Consultancy & Engineering | 2,500,000.00 |
| | | Contingencies | 2,500,000.00 |
| | Sub-total | 206,500,000.00 | |
| 2 | Oncology Production Building | Building maintenance inside & outside of the building. | 2,500,000.00 |
| | | Dedicated R & D Machine | 12,500,000.00 |
| | | Utility Machinery | 5,000,000.00 |
| | | Electrical Service | 2,500,000.00 |
| | | Fire Detection & Fighting System | 5,000,000.00 |
| | | Sanitary & Plumbing | 1,500,000.00 |
| | | Contingencies | 2,000,000.00 |
| | Sub-total | 31,000,000.00 | |
| 3 | Admin & Warehouse Building | Building maintenance inside & outside of the building. | 2,000,000.00 |
| | | Electrical Service | 1,000,000.00 |
| | | Fire Detection & Fighting System | 2,000,000.00 |
| | | Sanitary & Plumbing | 1,000,000.00 |
| | | Mapping System for Temperature Monitoring of Warehouse. | 5,000,000.00 |
| | | Contingencies | 1,500,000.00 |
| | Sub-total | 12,500,000.00 | |
| | | Grand Total | 250,000,000.00 |

Details of building and other construction at B.K. Bari Mirzapur, Gazipur-1703:

| Sl. | Description | Amount in (BDT) |
|-----|--|-----------------------|
| 1 | Anti-Tuberculosis (TB) Building-2 nd & 3 rd Floor | 42,000,000.00 |
| 2 | ETP Internal & External Drain Line | 5,000,000.00 |
| 3 | Fire Hydrant & Detection system | 15,000,000.00 |
| 4 | Sanitary & Plumbing | 5,000,000.00 |
| 5 | Scarp Yard-Wastage Material store | 5,000,000.00 |
| 6 | Internal Road Construction around the factory | 8,000,000.00 |
| 7 | Medical Device Building, Biotech Building & General Building Internal Partition & Technical Floor. | 10,000,000.00 |
| 8 | Self-Levelling, Epoxy Flooring for different building. | 15,000,000.00 |
| 9 | R & D Unit, Office Area & Canteen Building-2 nd , 3 rd & 4 th Floor | 45,000,000.00 |
| | Total | 150,000,000.00 |

(b) Utilization of the total amount of paid-up capital and share premium, if any, including the sponsors' contribution and capital raised of the issuer at the time of submission of prospectus, in details with indication of use of such funds in the financial statements;

Tk. 400,000.00 (Taka Four Lac), Tk. 80,000,000.00 (Taka Eight Crore), Tk. 19,200,000.00 (Taka One Crore Ninety-Two Lac), Tk. 15,000,000.00 (Taka One Crore Fifty Lac), Tk. 573,000,000.00 (Taka Fifty-Three Crore Thirty Lac), Tk. 62,400,000.00 (Taka Six Crore Twenty-Four Lac), Tk. 68,760,000.00 (Taka Six Crore Eighty-Seven Lac Sixty Thousand) and Tk. 122,814,000.00 (Taka Twelve Crore Twenty-Eight Lac Fourteen Thousand totaling Tk. 941,574,000.00 (Taka Ninety-Four Crore Fifteen Lac Seventy-Four Thousand have been raised prior to the public issue on dated 30-Sep-09, 8-Sep-12, 16-Oct-17, 11-Jul-19, 7-Jan-20, 25-Oct-20, 11-Apr-21 and 30-Dec-21 respectively. The 2nd, 5th and 8th (last) allotments were raised through other than in cash, bonus and bonus respectively of Tk. 80,000,000.00, Tk. 573,000,000.00 and Tk. 122,814,000.00 totaling Tk. 775,814,000.00 and rest of Tk. 165,760,000.00 was used for the Company and their indication of use in the financial statements are as follows:

| Accounting Year | Items | Amount in BDT | Reflected in Cash Flows |
|-----------------|----------------------|--------------------|---|
| 30-Jun-2010 | Preliminary Expenses | 60,000 | In the statement of Cash Flows, this amount is included as cash paid to Preliminary Expenses purpose. |
| 30-Jun-2011 | Working Capital | 340,000 | In the statement of Cash Flows, this amount is included as cash paid to supplier in the head of Operating Activities. |
| 30-Jun-2018 | Working Capital | 19,200,000 | In the statement of Cash Flows, this amount is included as cash paid to suppliers in the head of Operating Activities. |
| 30-Jun-2020 | Working Capital | 15,000,000 | In the statement of Cash Flows, this amount is included as cash paid to suppliers in the head of Operating Activities. |
| 30-Jun-2021 | Working Capital | 62,400,000 | In the statement of Cash Flows, this amount is included as cash paid to suppliers, employees and others in the head of Operating Activities. |
| | Working Capital | 68,760,000 | In the statement of Cash Flows, this amount is included as cash paid to suppliers, employees and others in the head of Operating Activities. Cash paid for FDR in the head of Investing Activities. |
| Total | | 165,760,000 | |

(c) If one of the objects is an investment in a joint venture, a subsidiary, an associate or any acquisition, details of the form of investment, nature of benefit expected to accrue to the issuer as a result of the investment, brief description of business and financials of such venture;

The Company has no plan to invest the IPO proceeds in any subsidiary, associate, joint venture companies or any acquisition.

(d) If IPO proceeds are not sufficient to complete the project, then source of additional fund must be mentioned. In this connection, copies of contract to meet the additional funds are required to be submitted to the Commission. The means and source of financing, including details of bridge loan or other financial arrangement, which may be repaid from the proceeds of the issue along with utilization of such funds;

Not applicable in this case.

- (e) A schedule mentioning the stages of implementation and utilization of funds received through public offer in a tabular form, progress made so far, giving details of land acquisition, civil works, installation of plant and machinery, the approximate date of completion of the project and the projected date of full commercial operation etc. The schedule shall be signed by the Chief Executive Officer or Managing Director, Chief Financial Officer and Chairman on behalf of Board of Directors of the issuer;

| Sl. No. | Projects | Progress made so Far | Approximate date of Completion of the projects | Projected date of full commercial operation |
|---------|---|---|--|--|
| 1 | Land Acquisition | No land is required to be acquired | - | - |
| 2 | Acquisition and Installation of Machineries & Equipment | Acquisition and Installation of Machineries & Equipment will be started after receiving of IPO fund | Within 21 months after receiving IPO fund | Within 3 months of the completion of the project |
| 3 | Building and Other Construction | Building & Other Construction works will be started after receiving of IPO fund | | |
| 4 | Partial loan repayment | Loan repayment will be incurred after receiving of IPO fund | Within 2 months after receiving IPO fund | - |

Sd/-

Shah Jalal Uddin Ahmed
Managing Director

Sd/-

Pijush Kumar Chakroborty FCA
Chief Financial Officer

Sd/-

Khaleda Akhter Khan
Chairman

On behalf of Board

- (f) If there are contracts covering any of the activities of the issuer for which the proceeds of sale of securities are to be used, such as contracts for the purchase of land or contracts for the construction of buildings, the issuer shall disclose the terms of such contracts, and copies of the contracts shall be enclosed as annexure to the prospectus;

There is no such contract yet to be engaged by the Company.

- (g) If one of the objects of the issue is utilization of the issue proceeds for working capital, basis of estimation of working capital requirement along with the relevant assumptions, reasons for raising additional working capital substantiating the same with relevant facts and figures and also the reasons for financing short with long term investments and an item-wise break-up of last three years working capital and next two years projection;

No objects of the issue are utilization of the issue proceeds for working capital.

- (h) Where the issuer proposes to undertake one or more activities like diversification, modernization, expansion, etc., the total project cost activity-wise or project-wise, as the case may be;

The company has a plan to construct building which have been mentioned in use of IPO Proceeds and project implementation schedule.

- (i) Where the issuer is implementing the project in a phased manner, the cost of each phase, including the phases, if any, which have already been implemented;**

The company has a plan to expand and upgrade upon receiving the funds, which have been mentioned in use of IPO Proceeds and project implementation schedule.

- (j) The details of all existing or anticipated material transactions in relation to utilization of the issue proceeds or project cost with sponsors, directors, key management personnel, associates and group companies;**

There is no existing or anticipated material transaction in relation to utilization of the issue proceeds or project cost with sponsors, directors, key management personnel, associates and group companies.

- (k) Summary of the project appraisal or feasibility report by the relevant professionals not connected with the issuer, issue manager and registrar to the issue with cost of the project and means of finance, weaknesses and threats, if any, as given in the appraisal or feasibility report.**

Not applicable here.

CHAPTER (XXIII)

LOCK-IN

(a) Ordinary shares of the issuer, at the time of according consent to the public issue, shall be subject to lock-in, from the first trading day at the exchange in the following manner:

- (a) Shares held by sponsors, directors and shareholders holding 10% (ten percent) or more, for 03 (three) years;
- (b) In case, any existing sponsor or director of the issuer transfers any share to any person, those transferred shares, for 03 (three) years;
- (c) Shares allotted to any person, before 4 (four) years or more of according consent to the public issue, other than the persons mentioned in clause (a) and (b), for 01 (one) year;
- (d) Shares held by alternative investment funds, for 01 (one) year;
- (e) Shares held by any person, other than the shares mentioned in clause (a), (b), (c) and (d) above, for 02 (two) years:

Provided that ordinary shares converted from any other type of securities shall also be subject to lock-in as mentioned above."

(b) The following table indicates the Lock-In status of the shareholders of Techno Drugs Ltd.:

| Sl. | Name of the Shareholders | Position | BO IDs | Number of Shares | | | Total Number of Shares | Pre IPO % | Post IPO % |
|-----|----------------------------|-----------------------------|------------------|------------------|-----------|-------|------------------------|-----------|------------|
| | | | | Lock-in period | | | | | |
| | | | | 3 Yrs. | 2 Yrs. | 1 Yr. | | | |
| 1 | Shah Jalal Uddin Ahmed | Sponsor & Managing Director | 1202750076139668 | 59,455,000 | - | - | 59,455,000 | 63.14% | 45.61% |
| 2 | Khaleda Akhter Khan | Sponsor & Chairman | 1202750076139767 | 7,475,000 | - | - | 7,475,000 | 7.94% | 5.73% |
| 3 | Arefeen Raafi Ahmed | Sponsor & Director | 1602770068934171 | 4,485,000 | - | - | 4,485,000 | 4.76% | 3.44% |
| 4 | Mehreen Ahmed | Sponsor & Director | 1202750076139791 | 4,485,000 | - | - | 4,485,000 | 4.76% | 3.44% |
| 5 | Md. Mamunur Rashid | Director | 1204570024992933 | 6,876,200 | - | - | 6,876,200 | 7.30% | 5.27% |
| 6 | Md. Shah Rakib Uddin Ahmed | Shareholder | 1203390042873060 | - | 27,000 | - | 27,000 | 0.03% | 0.02% |
| 7 | Shah Ripan Ahmed | Shareholder | 1202750076139577 | - | 27,000 | - | 27,000 | 0.03% | 0.02% |
| 8 | Shah Sohail Ahmed | Shareholder | 1202750076139550 | - | 27,000 | - | 27,000 | 0.03% | 0.02% |
| 9 | Md. Reazul Hoque | Shareholder | 1204030074681788 | - | 1,500,000 | - | 1,500,000 | 1.59% | 1.15% |
| 10 | Greentech Holidays Ltd. | Shareholder | 1602770075662000 | - | 1,500,200 | - | 1,500,200 | 1.59% | 1.15% |
| 11 | S. M. Al Jubayer Ahmed | Shareholder | 1203040062626201 | - | 1,500,000 | - | 1,500,000 | 1.59% | 1.15% |
| 12 | TMC Pvt. Ltd. | Shareholder | 1201960076155185 | - | 1,400,000 | - | 1,400,000 | 1.49% | 1.07% |
| 13 | Picked Agrotec Ltd. | Shareholder | 1205150075651025 | - | 600,000 | - | 600,000 | 0.64% | 0.46% |

| | | | | | | | | | | |
|--------------|-------------------------------|-------------|------------------|---|-------------------|-------------------|-----------|-------------------|----------------|---------------|
| 14 | Excel Farmganic Limited | Shareholder | 1202930074520221 | - | 500,000 | - | 500,000 | 0.53% | 0.38% | |
| 15 | Md. Salim Sarker | Shareholder | 1201950000604573 | - | 2,300,000 | - | 2,300,000 | 2.44% | 1.76% | |
| 16 | Colour N Life Limited | Shareholder | 1202530074766514 | - | 500,000 | - | 500,000 | 0.53% | 0.38% | |
| 17 | CMC Enterprise | Shareholder | 1205700076154397 | - | 800,000 | - | 800,000 | 0.85% | 0.61% | |
| 18 | Conducive Corp. Services Ltd. | Shareholder | 1201960076155209 | - | 700,000 | - | 700,000 | 0.74% | 0.54% | |
| Total | | | | | 82,776,200 | 11,381,200 | - | 94,157,400 | 100.00% | 72.23% |

**Starts from the first trading day in the stock exchange.*

CHAPTER (XXIV)

MARKETS FOR THE SECURITIES BEING OFFERED

Stock Exchanges:

The issuer shall apply to all the relevant exchanges in Bangladesh within seven working days from the date of consent for public offer accorded by the Commission.



Dhaka Stock Exchange PLC (DSE)

DSE Tower, Plot # 46, Road # 21, Nikunja-2, Dhaka-1229; and



Chittagong Stock Exchange PLC (CSE)

CSE Building, 1080 Sheikh Mujib Road, Chittagong.

Declaration about Listing of Shares with Stock Exchanges:

None of the Stock Exchanges, if for any reason, grant listing within 75 days from the closure of subscription, any allotment in terms of this prospectus shall be void and the Company shall refund the subscription money within fifteen days from the date of refusal for listing by the stock exchange, or from the date of expiry of the said 75 (seventy-five) days, as the case may be.

In case of non-refund of the subscription money within the aforesaid fifteen days, the Company directors, in addition to the issuer company, shall be collectively and severally liable for refund of the subscription money, with interest at the rate of 2% (two %) per month above the insurance rate, to the subscribers concerned.

The issue managers, in addition to the issuer Company, shall ensure due compliance of the above-mentioned conditions and shall submit compliance report thereon to the Commission within seven days of expiry of the aforesaid fifteen days' time period allowed for refund of the subscription money.

Trading and Settlement;

Trading and Settlement Regulation of the stock exchanges will apply in respect of trading and settlement of the shares of the Company.

THE ISSUE SHALL BE PLACED IN "N" CATEGORY

CHAPTER (XXV)

DESCRIPTION OF SECURITIES OUTSTANDING OR BEING OFFERED

All types of securities outstanding or being offered with date or proposed date of such issue and to whom those are offered, number of securities and issue or offer price along with the following information:

a) Dividend, Voting, Pre-emption Rights:

The share capital of the company is divided into Ordinary Shares, carrying equal rights to vote and receive dividend in terms of the relevant provisions of the Companies Act 1994 and the Articles of Association of the company. All Shareholders shall have the usual voting right in person or by proxy in connection with, among others, election of Directors & Auditors and other usual agenda of General Meeting – Ordinary or Extra Ordinary. On a show of hand, every shareholder presents in person and every duly authorized representative of a shareholder present at a General Meeting shall have one vote and on a poll every shareholder present in person or by proxy shall have one vote for every share held by him or her. In case of any additional issue of shares for raising further capital, the existing shareholders shall be entitled to Issue of Right shares in terms of the guidelines issued by the Bangladesh Securities and Exchange Commission from time to time.

b) Conversion and Liquidation Rights:

In terms of the provisions of the Companies Act 1994, Articles of Association of the Company and other relevant rules in force, the shares of the Company are freely transferable. The Company shall not charge any fee for registering transfer of shares. No transfer shall be made to a firm, an infant or person of unsound mind.

c) Dividend Policy:

- i. The profit of the company, subject to any special right relating thereto created or authorized to be created by the Memorandum of Association and subject to the provisions of the Articles of Association, shall be divisible among the members in proportion to the capital paid-up on the shares held by them respectively.
- ii. No larger dividend shall be declared than is recommended by the Directors, but the Company in its General Meeting may declare a smaller dividend. The declaration of Directors as to the amount of Net Profit of the Company shall be conclusive.
- iii. No dividend shall be payable except out of profits of the Company or any other undistributed profits. Dividend shall not carry interest as against the Company.
- iv. The Directors may from time to time pay the members such interim dividend as in their judgment the financial position of the Company may justify.
- v. A transfer of shares shall not pass the right to any dividend declared thereon before the registration of transfer.
- vi. There is no limitation on the payment of dividends to the common stockholders of the Company.

d) Other Rights of the securities holders:

In terms of provisions of the Companies Act 1994, Articles of Association of the Company and other relevant rules in force, the shares of the Company are transferable. The Company shall not charge any fee, other than Government duties for registering transfer of shares. No transfer shall be made to a minor or person of unsound mind.

CHAPTER (XXVI)

FINANCIAL STATEMENTS

- (a) **The latest financial statements prepared and audited by the Commission's panel auditors in adherence to the provisions of the Securities and Exchange Rules, 1987, the কোম্পানি আইন, ১৯৯৪, International financial Reporting and Auditing Standards as adopted in Bangladesh from time to time and any other law as applicable;**

**AUDITORS' REPORT
TO THE SHAREHOLDERS OF TECHNO DRUGS LIMITED**

Audit Opinion:

We have audited the accompanying financial statements of **Techno Drugs Limited**, which comprise the statement of Financial position as at 30 June 2023 and the Statement of profit or loss and other comprehensive income, Statement of changes in equity and Statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

In our opinion, the financial statements present fairly, in all material respects, the financial position of **Techno Drugs Limited** as at 30 June 2023, its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRS) and other applicable laws and regulations.

Basis for the Audit Opinion:

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters for the audit of financial statements are as below-

| Key Audit Matters/Description | Our responses to Key Matters |
|---|---|
| <p>Carrying Value of Property, Plant and equipment (PPE) (Refer to the Note No. 3 and annexure-A(i))</p> <p>PPE includes the Company's long – term assets, which flow economic benefits to the entities more than one year. PPE is measured at historical cost of land and land development, building and premises and plant, Laboratory Equipment, Motor Vehicle and Electric Equipment's.</p> <p>Apparently, the carrying value of PPE represents significant portion of the company's assets which is a function of depreciation charges and involved estimation. Therefore, it has been considered as a significant area of auditor's judgement and requires</p> | <p>We have tested the design and operating effectiveness of key controls over PPE. Our audit procedures included, among others, considering the impairment risk of the assets.</p> <p>Followings are our audit procedures on the carrying value and impairment risk of PPE:</p> <ul style="list-style-type: none"> - Reviewing basis of recognition, measurement and valuation of asset. - Observing procedures of assets acquisition, depreciation and disposal. - Checking ownership of the major assets. - Checking the Capital-Work-in Progress (CWIP) and its transfer to PPE as well as Capital Expenditure Commitment. |

| | |
|---|---|
| <p>special attention. There is also a risk that the impairment charges may not have been recognized.</p> | <ul style="list-style-type: none"> - Performing due physical asset verification at the year end. - Finally assessed the appropriateness and presentation of disclosures against relevant accounting standards. <p>Our testing did not identify any issues with regard to CV of PPE and any indicators that would trigger impairment.</p> |
| <p>Inventories (Refer to the Note No. 08) and Finished Goods for Govt. Tender (Refer to the Note No. 09)</p> | |
| <p>The company had inventory of BDT 700,599,952/- in note-08 and Finished Goods for Govt. Tender of BDT Tk. 238,536,250/- separately in Note-09 of financial statement as at June 30, 2023. This material item is subject to considerable inherent risk due to the complexity of the system necessary for proper recognition, measurement, and recording considering the application of The International Accounting Standards 2 "Inventories".</p> <p>Therefore, there is a risk that Inventories are valued by the disclosed basis of note 08 and 09.</p> <p>Inventories can be over or undervalued or might need provision for obsolescence.</p> | <p>We checked the appropriateness of calculation and presentation of the value of inventory by means of the following:</p> <ul style="list-style-type: none"> - Evaluating the design and implementation of key inventory controls operating across the company. - we physically verified inventory (test basis) during our audit work (other than the date of financial statements) and checked the necessary controls implemented by the company. Obtained physical inventory count report as of balance date as a part of control procedures and checked the cost of raw materials purchased and authenticity of valuation method applied. |
| <p>Accounts Receivable (Refer to the Note No. 11)</p> | |
| <p>At the reporting date, Accounts receivable BDT 789,714,772 being about 13.10565% of the total assets of the Company is a material item to the financial statements.</p> <p>There is a significant risk regarding recoverability of the amounts and misstatement of the items.</p> <p>As such, management is required to make judgments in determining whether accounts receivable is being appropriately valued and also need to make provision for aged accounts receivable, if required.</p> | <p>Our audit procedures to Key audit matters;</p> <ul style="list-style-type: none"> - Tested the operating effectiveness of key controls over accounts receivable. - Being a part of auditor's responsibility as regarding external confirmation. - We requested for external confirmation. Tested on a sample basis the value disclosed according to the reply obtained. Assessed whether appropriate provisions have been recognized for aged accounts receivable, if required and evaluating management's basis for determining the recoverability |
| <p>Deferred Tax Liability (Refer to the Note No. 17)</p> | |
| <p>The company reported net deferred tax liabilities to Taka 216,490,616/- as at 30th June 2023. Significant judgement is required in relation to deferred tax liabilities as their settlement is</p> | <p>We obtained an understanding, evaluated the design and tested the operational effectiveness of the company key controls over the recognition and measurement of deferred tax and the assumptions used in estimating the company</p> |

| | |
|---|---|
| <p>dependent on forecasts of future profitability over a number of years.</p> | <p>future taxable income. We also assessed the completeness and accuracy of the data used for the estimation of future taxable income. Finally, we assessed the appropriateness and presentation of disclosures against IAS 12 (Income Tax).</p> |
| <p>Long Term Loan Net of Current Maturity (Refer to the Note No. 18) and Current Maturity of Long-Term Loan` (Note:20)</p> | |
| <p>At the reporting date, the position of long-term loans remains amounting to Tk. 1,055,549,905/- which represents 30.90373% of total liabilities and Current Maturity of Long-Term Loan 414,024,638 which represents 12.12155% combinedly 43.02528% for the company. Evidently, the company are dependent on long term liability to run the business. Therefore, long term loan has been considered as key audit matter.</p> | <p>We obtained an understanding, evaluated the design and tested the operational effectiveness over the long-term loans. Our audit procedures included, among others, the following;</p> <ul style="list-style-type: none"> - Understood and reviewed the nature or types of loans. - Obtained the repayment schedules, loan statement and facility offer letters to review terms, debt covenants, interest rates and other conditions associated with the loans. - Recalculated the interest related to loans. - Checked the adjustments or repayments of loans through bank statements as per repayment schedule. - Reviewed the segregation between current and non-current portion of loans. - Observed whether there is any overdue payment relevant to loans and - Finally assessed the appropriateness and presentation of disclosures against relevant accounting standards. <p>The procedures above did not identify any issues with regard to the long-term loans.</p> |
| <p>Short Term Loan (Refer to the Note No. 21)</p> | |
| <p>At the reporting date, the position of Short-term loans remains amounting to Tk. 1,187,853,989/- which represents 34.64235% of total liabilities and increased by 28.057%. Though Short-term loans are financial instruments designed to provide quick access to capital for urgent needs. But Increasing loan dependency by consistently relying on short-term loans can have significant consequences for businesses. Therefore, Short term loan has been considered as key audit matter.</p> | <p>Management is responsible for the proper classification and disclosure of short-term loans in the financial statements. Our audit procedures included:</p> <ul style="list-style-type: none"> - Confirming the existence of the short-term loans with the respective lenders. - Checked the adjustments or repayments of loans through bank statements as per repayment schedule. - Reviewed the segregation between current and non-current portion of loans. - Observed whether there is any overdue payment relevant to loans. - Confirming the accuracy of any accrued interest and related costs. - Verifying the accuracy and completeness of the loan note disclosures in the financial statement footnotes. |

| | |
|---|---|
| | <p>We considered any subsequent events or developments related to the short-term loans that may require disclosure or adjustment in the financial statements. However, the procedures above did not identify any issues with regard to the short-term loans.</p> |
| <p>Non-Payment of Related Party (Refer to the Note No. 35) and Liabilities for WPPF (Refer to the Note No.24)</p> | |
| <p>Materiality depends on various factors including the financial significance of the amounts involved and their impact on the overall financial statements. Nonpayment of remuneration Tk.24,000,000/-, office rent Tk. 15,120,000/- and liabilities of WPPF Tk.66,677,150/- must have a significant financial impact on the audited entity. It can lead to financial losses, penalties and even insolvency in extreme cases. At the reporting date, the position of unpaid remuneration and office rent Tk. 2,40,00,000/- and 15,120,000/- respectively from out of total related party unpaid transaction remains amounting to Tk. 40,391,984/- which represents 18.42157% of total liabilities in the heads of Accounts & Others Payable Tk. 212,359,709/-. This financial impact can materially affect the financial statements and the overall financial health of the company. For instance, non-payment of director's remuneration may affect the company's profitability, while non-payment of WPPF may have legal and employee relations consequences. Therefore, these amounts have been considered as key audit matter.</p> | <p>We obtained an understanding, evaluated the design and tested the operational effectiveness over Related party disclosure and WPPF. Out audit procedures included, among others, the following;</p> <ul style="list-style-type: none"> - Confirming the existence of Related Party and WPPF. - Ensuring that any material related party transactions or commitments are appropriately disclosed. <p>The procedures above did not identify any issues with regard to the related party and Liabilities of WPPF.</p> |
| <p>Revenue (Refer to the Note No. 23)</p> | |
| <p>At reporting period, the revenue of the company was 2,733,477,105/- which has decreased by 45.64076%. Company's major sales come from the Govt. tender but this financial year Govt. not call any tender, on the other hand from November 2022 the fall of opening of LC due to Dollar reserve matter. This is main reason for fall down of sales.</p> <p>The sales of the company are derived from 17 depots owned by the company which are located over the country and accounted for on the basis of monthly statements sent by the depots. As a result, to obtain</p> | <p>Revenue is measured net of discounts, incentives and discounts provided by the customers on the Company's sales. The estimation of discounts, incentives and discounts recognized based on sales made during the year is material and considered to be complex and judgmental.</p> <p>We have tested the design and operating effectiveness of key controls focusing on the followings;</p> <ul style="list-style-type: none"> - Performing analytical procedures to find the reason of decreasing revenue. - Understanding the generating process of revenue. |

sufficient audit evidence, magnitude audit work and evidence is required. The revenue consists of local sales and export earnings during the year though in previous year there was revenue earning of BDT- **5,028,541,834/-**.

We identified the revenue recognition in key audit matter because sales revenue is the only key performance indicator of the company and there remains an inherent risk for recognition by the management to meet specific targets or expectations because of increasing reliance on loans as disclosed in the financial statements.

- Assessing the risks involved in revenue generation process.
- Checking the reasonableness of the calculation of revenue.
- Verifying the timing of revenue recognition.
- Critically verifying the recording process of revenue and
- In overall, assessed the appropriateness and presentation of disclosures against relevant accounting standards.

The procedures above did not identify any issues with regard to revenue.

Other Information

Management is responsible for the preparation and fair presentation of these Financial Statements in accordance with International Financial Reporting Standards (IFRS). This responsibility includes: designing, implementing, and maintaining internal control relevant to the preparation and fair presentation of Financial Statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these financial statements

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- A) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- B) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.

- C) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- D) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.
- E) Evaluate the overall presentation, structure and content of the Company' financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Report on other Legal and Regulatory Requirement:

In accordance with the Section 213 of Companies Act 1994 and the Securities and Exchange Rules,1987 and relevant notification issued by Bangladesh Securities and Exchange Commission, we also report the following:

- a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our Audit and made due verification thereof;
- b. In our opinion, the Company as required by law has been kept proper books of accounts, so far as it appeared from our examination of those books;
- c. The Financial Statements dealt with by the report are in agreement with the books of account.
- d. the expenditure incurred was for the purpose of the Company's business

Dated: 26th September 2023
Dhaka.

Sd/-
Biplab Hossain FCA(ICAB), ACA(ICAEW)
Partner
Enrollment Number: 1368
Islam Quazi Shafique & Co
Chartered Accountants
DVC:2309261368AS258594

Techno Drugs Limited
Statement of Financial Position
As at 30th June, 2023

| Particulars | Notes | Amount | |
|---|-------|----------------------|----------------------|
| | | 30th June, 2023 | 30th June 2022 |
| ASSETS: | | | |
| Non-Current Assets: | | 3,825,522,959 | 3,495,222,379 |
| Property, Plant and Equipments at Carrying Value | 3 | 3,586,136,067 | 3,382,394,234 |
| Intangible Assets | 4 | 7,222,755 | 3,094,105 |
| Investment In Share | 5 | 270,000 | 270,000 |
| Capital Work In Progress | 6 | 179,878,620 | 49,640,983 |
| Right-of-Use Assets | 7 | 52,015,516 | 59,823,057 |
| Current Assets: | | 2,215,732,793 | 1,868,788,859 |
| Inventories | 8 | 700,599,952 | 646,640,975 |
| Finished Goods For Govt. Tender | 9 | 238,536,250 | - |
| Advances, Deposits and Prepayments | 10 | 399,192,394 | 344,431,150 |
| Accounts Receivable | 11 | 789,714,772 | 707,183,113 |
| Investment in FDR | 12 | 53,218,850 | 30,596,556 |
| Cash and Cash Equivalents | 13 | 34,470,574 | 139,937,066 |
| TOTAL ASSETS | | 6,041,255,752 | 5,364,011,238 |
| SHARE HOLDERS' EQUITY & LIABILITIES: | | | |
| Shareholders' Equity: | | 2,612,349,279 | 2,432,399,449 |
| Share Capital | 14 | 941,574,000 | 941,574,000 |
| Revaluation Surplus | 15 | 487,437,890 | 502,994,419 |
| Retained Earnings | 16 | 1,183,337,389 | 987,831,030 |
| Non-Current Liabilities: | | 1,304,960,954 | 1,197,406,595 |
| Deferred Tax Liability | 17 | 216,490,616 | 191,452,122 |
| Long Term Loan Net of Current Maturity | 18 | 1,055,549,905 | 973,761,159 |
| Lease Liabilities Net of Current Maturity | 19.01 | 32,920,433 | 32,193,314 |
| Current Liabilities: | | 2,123,945,519 | 1,734,205,195 |
| Current Maturity of Lease Liabilities | 19.02 | 27,757,903 | 21,268,354 |
| Current Maturity of Long Term Loan | 20 | 414,024,638 | 474,435,457 |
| Short Term Loan | 21 | 1,187,853,989 | 854,577,233 |
| Provision for Current Tax | 22 | 215,272,129 | 162,208,405 |
| Accounts & Others Payable | 23 | 212,359,709 | 167,991,199 |
| Liabilities for WPPF | 24 | 66,677,150 | 53,724,548 |
| TOTAL SHARE HOLDERS' EQUITY AND LIABILITIES | | 6,041,255,752 | 5,364,011,238 |
| No. of Ordinary Share use to compute NAVPS | | 94,157,400 | 94,157,400 |
| Net Assets Value (NAV) per share with Revaluation | 32 | 27.74 | 25.83 |
| Net Assets Value (NAV) per share without Revaluation | 32 | 22.57 | 20.49 |

The accompanying notes form an integral part of these financial statements.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Dhaka, Bangladesh

Dated: 26th September, 2023

Sd/-

ISLAM QUAZI SHAFIQUE & CO.

Chartered Accountants

Signed by: Biplab Hossain FCA(ICAB), ACA(England & Wales)

Designation : Partner

Enrolment Number : 1368

DVC: 2309261368AS258594

Statement of Financial Position

Techno Drugs Limited
Statement of Changes in Equity
As at 30th June, 2023

| Particulars | Share Capital | Retained Earnings | Revaluation Surplus | Total Taka |
|---|--------------------|----------------------|---------------------|----------------------|
| Balance 1st July 2022 | 941,574,000 | 987,831,030 | 502,994,419 | 2,432,399,448 |
| Deferred Tax (Expenses)/Income on Revaluation Surplus | - | - | (15,556,528) | (15,556,528) |
| Net Profit after Tax | - | 195,506,359 | - | 195,506,359 |
| Balance 30th June 2023 | 941,574,000 | 1,183,337,389 | 487,437,890 | 2,612,349,279 |

Statement of Changes in Equity
As at 30th June 2022

| Particulars | Share Capital | Retained Earnings | Revaluation Surplus | Total Taka |
|---|--------------------|--------------------|---------------------|----------------------|
| Balance 1st July 2021 | 818,760,000 | 630,866,603 | - | 1,449,626,603 |
| Stock Dividend Issued (2020-21) | 122,814,000 | (122,814,000) | - | - |
| Addition of Revaluation Surplus | | | 518,550,947 | 518,550,947 |
| Deferred Tax (Expenses)/Income on Revaluation Surplus | | - | (15,556,528) | (15,556,528) |
| Net Profit after Tax | - | 479,778,427 | | 479,778,427 |
| Balance 30th June 2022 | 941,574,000 | 987,831,031 | 502,994,419 | 2,432,399,449 |

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Dhaka, Bangladesh

Dated: 26th September, 2023

Sd/-

ISLAM QUAZI SHAFIQUE & CO.

Chartered Accountants

Signed by: Biplab Hossain FCA(ICAB), ACA(England & Wales)

Designation : Partner

Enrolment Number :1368

DVC: 2309261368AS258594

Statement of Changes in Equity

Techno Drugs Limited
Statement of Cash Flows
For the year ended 30th June, 2023

| Particulars | Notes | Amount (In Taka) | |
|--|-----------|------------------------------------|------------------------------------|
| | | 01 July 2022 To 30 June 2023 | 01 July 2021 To 30 June 2022 |
| A. Cash Flows from Operating Activities: | | | |
| Received from Customers | | 2,650,945,446 | 4,803,820,117 |
| Received from Others | | 2,859,050 | 12,929,115 |
| Paid to Suppliers | | (1,472,638,076) | (2,827,200,149) |
| Paid to Employees | | (534,638,135) | (729,426,902) |
| Paid to Others | | (174,585,940) | (233,596,474) |
| Paid Finance Cost | | (245,989,824) | (235,527,153) |
| Cash generated from operation | | 225,952,520 | 790,998,554 |
| Income Tax Paid | | (15,854,601) | (155,244,009) |
| Payment of WPPF | | - | (42,701,826) |
| Net Cash generated from Operating Activities | | 210,097,920 | 593,052,719 |
| B. Cash Flows from Investing Activities: | | | |
| Cash Paid for Acquisition of Property Plant and Equipment | | (47,678,971) | (38,047,692) |
| Intangible Assets | | (5,045,775) | - |
| Received/(Paid) against Investment in FDR | | (22,622,295) | 194,003,407 |
| Cash Paid for Capital Work-In-Progress | | (578,694,113) | (556,526,323) |
| Net Cash used in Investing Activities | | (654,041,154) | (400,570,608) |
| C. Cash Flows from Financing Activities: | | | |
| Received/(Paid) against Long Term Borrowings | | 21,377,926 | 56,594,169 |
| Received/(Paid) against Short Term Borrowings | | 333,276,756 | (121,009,684) |
| Payment against Lease Liability | | (10,063,997) | (20,045,954) |
| Interest expenses on lease liability | | (6,113,943) | (5,629,130) |
| Net Cash Generated/(Used) from Financing Activities | | 338,476,742 | (90,090,599) |
| Net Cash Inflow/(Outflow) from Total Activities (A+B+C) | | (105,466,492) | 102,391,511 |
| Opening Cash & Cash Equivalents | | 139,937,066 | 37,545,555 |
| Cash and Cash Equivalents at the End | | 34,470,574 | 139,937,066 |
| Net Operating Cash Flows Per Share (NOCFPS) | 33 | 2.23 | 6.30 |

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Dhaka, Bangladesh
Dated: 26th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants
Signed by: Biplob Hossain FCA(ICAB), ACA(England & Wales)
Designation : Partner
Enrolment Number : 1368
DVC: 2309261368AS258594

Statement of Cash Flows

TECHNO DRUGS LIMITED

Notes, Comprising of Significant Accounting Policy and Other Explanatory Information
For the year ended 30th June, 2023

1.00 **About the Company:**

1.01 **Legal form of the Company:**

The company namely Techno Drugs Limited was incorporated on 30th September, 2009 vide registration no.C-79890/09 as a private limited company in Bangladesh under the Companies Act, 1994. Subsequently the company was converted into Public Limited Company and its face value of shares to Tk.10.00 from Tk.1000.00 on 18th August, 2019. The Company started its commercial operation from July, 2010.

1.02 **Address of Registered Office & Factory:**

The company's registered office is situated at J.K. Tower, 31 Segun Bagicha, Dhaka, Bangladesh. The Company its factory is located at Narsingdi and Gazipur and several depots around the country.

1.03 **Nature of Business Activities:**

The principal activities of the company are manufacturing, distribution and marketing of both Human and Animal health care drugs and selling them in local and international market. The company is also major hormonal products manufacturer and supplier for ministry of family planning of Bangladesh Government.

2.00 **Basis of Preparation and Presentation of Financial Statements:**

2.01 **Preparation and Presentation of Financial Statements of the company**

The Board of Directors is responsible for the preparation of financial statements under section 183 of the Companies Act, 1994 and in accordance with an applicable financial reporting framework.

2.02 **Statement of Compliance:**

The Financial Statements have been prepared in compliance with the requirements of the Companies Act, 1994 and other relevant local laws as applicable and in accordance with the applicable International Accounting Standards (IASs), The Securities and Exchange Rules, 2020 and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), The requirement of Financial Reporting Act-2015 and others laws and regulations applicable for the company.

2.03 **Regulatory Compliances:**

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- a) The Income Tax Act 2023;
- b) The Income Tax Rules 1984;
- c) The Value Added Tax and Supplementary Duty Act 2012;
- d) The Value Added Tax and Supplementary Duty Rules 2016;
- e) The Customs Act, 1969;
- f) Bangladesh Labor Act, 2006 (Amended 2018);
- g) Negotiable Instrument Act, 1881; and
- h) The Securities and Exchange Rules, 2020.

2.04 **Basis of Measurement:**

Measurement is the process of determining the monetary amounts at which the elements of the financial Statements are to be recognized and carried in the statement

of financial position and profit or loss and other comprehensive income. The measurement basis adopted by the Company is historical cost of inventories are at the lower of cost and net realizable value and marketable securities (if any) are at market value. Under the historical cost, assets are recorded at the amount of cash or cash equivalents paid or the fair value of the consideration given to acquire them at the time of their acquisition. Liabilities are recorded at the amount of proceeds received in exchange for the obligation, or in some circumstances (for example, income taxes), at the amounts of cash or cash equivalents expected to be paid to satisfy the liability in the normal course of business. The Financial Statements have been prepared on a going concern basis under the historical cost convention applying accrual basis of accounting in accordance with the International Financial Reporting Standards (IFRS).

2.05 Components of Financial Statements:

According to IAS-1 Presentation of Financial Statements the complete set of financial statements includes the following components:

- a) Statement of Financial Position as at 30th June, 2023.
- b) Statement of Profit or Loss and Other Comprehensive Income for the year ended 30th June, 2023.
- c) Statement of Changes in Equity for the year ended 30th June, 2023.
- d) Statement of Cash Flows for the year ended 30th June, 2023 and
- e) Notes, Comprising Significant Accounting Policies and Other Explanatory Information.

2.06 Reporting Year and Comparative Information:

The year of financial statements of the company covers one year from 01st July, 2022 to 30th June, 2023. Comparative information has been disclosed in respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

2.07 Functional and Presentational Currency and Level of Precision:

These financial statements are prepared in Bangladeshi Taka (BDT.), which is the company's functional and presentational currency. All financial information is presented in BDT currency and has been rounded off to the nearest taka.

2.08 Authorization Date for Issuance of Financial Statements:

The financial statements have been authorized by the Board of Directors on **24.09.2023**

2.09 Compliance with the IASs and IFRSs

| Sl. No. | Name of the IAS | IAS's No. |
|---------|---|-----------|
| 1 | Presentation of Financial Statements | 1 |
| 2 | Inventories | 2 |
| 3 | Statement of Cash Flows | 7 |
| 4 | Accounting Policies, Changes in Accounting Estimates and Errors | 8 |
| 5 | Events after the Reporting Period | 10 |
| 6 | Income Taxes | 12 |
| 7 | Property, Plant and Equipment | 16 |
| 8 | Employee Benefits | 19 |
| 9 | The Effects of Changes in Foreign Exchange Rates | 21 |
| 10 | Borrowing Costs | 23 |
| 11 | Related Party Disclosures | 24 |
| 12 | Financial Instruments: Presentation | 32 |

| | | |
|----------------|--|-----------------|
| 13 | Earnings per Share | 33 |
| 14 | Impairment of Assets | 36 |
| 15 | Provisions, Contingent Liabilities and Contingent Assets | 37 |
| 16 | Intangible Assets | 38 |
| Sl. No. | Name of the IFRS | IFRS No. |
| 1 | First-time Adoption of International Financial Reporting Standards | 1 |
| 2 | Financial Instruments: Disclosures | 7 |
| 3 | Financial Instruments | 9 |
| 4 | Fair Value Measurement | 13 |
| 5 | Revenue from Contracts with Customers | 15 |
| 6 | Leases | 16 |

2.10 Use of Estimates and Judgments:

The preparation of these financial statements is in conformity with IASs/IFRSs which require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Estimates and underlying assumptions are reviewed on an ongoing basis and used for accounting of certain terms such as provision for expenses and depreciation

2.11 Accrual Basis:

The financial statements have been prepared on accrual basis of accounting except cash flows information.

2.12 Going Concern:

Management have assessed the going concern assumptions during the preparation of the financial statements of the company, Management believe that no events or conditions give rise to doubt about the ability of the company to continue in operation in the foreseeable future. This conclusion is drawn based on knowledge of the company, the estimated economic outlook and related identified risks and uncertainties. It has been concluded that it is reasonable to apply the going concern concept as the underlying assumption for the financial statements.

The company has adequate resources to continue its operation for the foreseeable future. The current credit facilities and resources of the company provides sufficient fund to meet the present requirements of its existing business.

2.13 Significant Accounting Policies:

The accounting policies set out below has been applied in presenting these financial statements.

Changes in significant accounting policies

Except the changes following, the Company has consistently applied the accounting policies to all periods presented in these financial statements. The Company has initially adopted IFRS 16 'Leases' from 1 July 2019. There is no material impact on financial statements on initial application of the standards. **As a Lessee** On 1st July 2019, IFRS 16 'Lease' has been adopted and all leasing arrangements except those having less than 12 months of useful life and underlying asset values of less than BDT 425,000 (\geq \$ 5000 as per IFRS 16) when new, have been capitalized as "right to use" assets with a corresponding financial liability on the balance sheet. Leased assets are capitalized from the start date of the lease agreement at the present value of the future leased payments, based on the rate of interest entered in the asset master data. Low value (less than BDT 425,000) and short term leases (less than 12 months) have been excluded from the recognition requirements and expensed in operating profit as rental costs. Lease reassessment and lease modification to increase/decrease the value of an asset depending on a change in scope of lease agreement can be made if necessary.

2.14 Property, Plant and Equipment:

Recognition and Measurement

The cost of an item of property, plant and equipment is recognized as an asset if, and only if: it is probable that future economic benefits will flow to the entity; and the cost of the item can be measured reliably. Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any.

All Property, Plant and Equipment (PPE) are stated at cost less accumulated depreciation as per IAS 16 Property, Plant and Equipment. The cost of acquisition of an asset comprises of its purchase price and any directly attributable cost of bringing the asset to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

Subsequent cost

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its costs can be measured reliably. The day to day maintaining cost on PPE is recognized in the Statements of Profit or Loss and Other Comprehensive Income as incurred.

Retirement and Disposals

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of the asset under other income in the Statement of Profit or Loss and Other Comprehensive Income. Depreciation has been charged on disposal assets up to the date of disposal. There is no such retirement on disposals of assets during the year.

Depreciation

Depreciation is charged on the cost of fixed assets in order to write off such amounts over the estimated useful lives, using the straight-line method in accordance with IAS - 16. Depreciation is charged on additions made during the year from the date in which those assets are available for use according to IAS 16 Para 55.

No depreciation is charged on land and land development. The rates of depreciation used to write off the amount of assets are as follows:

| Particulars | 30th June, 2023 | 30th June, 2022 |
|---------------------------|-----------------------------------|-----------------------------------|
| Land and Land Development | 0% | 0% |
| Building and Civil works | 3% | 3% |
| Plant and Machinery | 10% | 10% |
| Office Equipment | 20% | 20% |
| Laboratory Equipment | 20% | 20% |
| Furniture and Fixture | 10% | 10% |
| Motor Vehicles | 20% | 20% |
| Electric Equipment | 10% | 10% |

Revaluation of Land and Land Developments

As per IAS16: Property, Plant and Equipment paragraph 34, "the frequency of revaluations depends upon the changes in fair values of the items of property, plant and equipment being revalued. When the fair value of a revalued asset differs materially from its carrying amount, a further revaluation is required. Some items of property, plant and equipment experience significant and volatile changes in fair

value, thus necessitating annual revaluation. Such frequent revaluations are unnecessary for items of property, plant and equipment with only insignificant changes in fair value. Instead, it may be necessary to revalue the item only every thereof five years." To comply with the above paragraph, The Company made its first valuation of Land and Land Development, on 31 December 2021 by an independent valuer to reflect fair value (Market Approach) thereof following 'Current Cost Method' as per IFRS-13 'Fair Value Measurement'

| Particulars of Assets | Name of Valuer | Qualification of the Valuer | Date of Revaluation | Carrying amount of Assets | Value of the assets after revaluation | Revaluation Surplus in 30.06.2023 |
|---------------------------|----------------|-----------------------------|---------------------|---------------------------|---------------------------------------|-----------------------------------|
| Land and Land Development | G.KIBRIA & CO. | Chartered Accountants | 31-Dec-21 | 170,244,053 | 688,795,000 | 518,550,947 |

The increase in the carrying amount of revalued assets is recognized in the separate component of equity as Revaluation Surplus. However, the increase recognized in the Statement of Profit or Loss and Other Comprehensive Income for the year ended June 30, 2022. Other Non-Current Assets were kept outside the scope of the revaluation works. These are expected to be realizable at written down value (WDV) as mentioned in the statement of Financial Position of the company. The Company revalued its Land and Land Development as per valuation guidelines issued by the Bangladesh Securities and Exchange Commission (BSEC) dated on 18th August 2013 clause 09 Part A.

Impairment of Assets

The carrying values of all Property, Plant and Equipment are reviewed for impairment on annual basis to assess whether there is any indication that the assets might be impaired. It is confirmed that no such fixed assets have been impaired during the year and for this reason no provision has been made for impairment of assets as per IAS 36 Impairment of Assets.

2.15 Right-of-use Assets:

IFRS 16: Leases has introduced a single on-balance sheet lease accounting model for leases and replaces the previously adopted IAS 17: Leases. The standard requires that an asset acquired under a lease be recognized as Right of use Asset and the corresponding liability as lease liability. The Lease shall measure the lease liability at the present value of the future lease payment discounted using the interest rate implicit in the lease. The asset shall be depreciated over the lease period and the interest on the lease shall be charged as finance expense.

The Company has been consistently recording its underlying assets acquired under lease as right-of-use assets and the corresponding obligation as Lease Liabilities in the financial statements. The company has reclassified the assets acquired under the lease into "Right-of-use Assets" and presented them in the Statement of Financial Position following IFRS 16. Interest costs on lease liabilities and depreciation of Right-of Use Assets are charged to the profit or loss account.

Depreciation on Right of Use Assets

Depreciation on Right of use Assets (Finance Lease) is computed using the straight line method so as to write off the assets over their expected useful life. After considering the useful life of assets as per IAS 16 Property, Plant & Equipment the annual depreciation rates applied under which is considered reasonable by the management. Depreciation of an asset begins when it is available for use i.e., when it is in the location and condition necessary for it to be capable of operating in the manner intended by the management.

2.16 **Intangible Assets**

Recognition and measurement

Intangible assets that are acquired by the Company and have finite useful life are measured at cost less accumulated amortization and accumulated impairment loss, if any. Intangible assets are recognized as an asset if, and only if: it is probable that expected future economic benefits that are attributable to the asset will flow to the Company; and the cost of the item can be measured reliably. The cost of an intangible asset comprises its purchase price, import duties and non-refundable taxes and any directly attributable cost of preparing the asset for its intended use.

Subsequent cost

Subsequent expenditure on intangible assets is capitalized only if it is probable that it will increase the future economic benefits associated with the specific asset.

De-recognition

Intangible assets are derecognized from the statement of financial position on disposal or when no future economic benefits are expected from their use or disposal. The gain or loss arising from the de recognition of an intangible asset is recognized in the statement of profit or loss and other comprehensive income at the time of de-recognition.

Amortization

Intangible assets are amortized on straight line method from the date when asset is available for use over its estimated useful life. The amount of amortization has been presented under the Statement of Profit or Loss and Other Comprehensive Income.

Rate of amortization on software is as under

| Particulars | 30 June, 2023 |
|--------------------|----------------------|
| Software | 10% |

2.17 **Capital work-in-progress:**

Property, plant and equipment under construction/acquisition are accounted for as capital work-in progress until construction/ acquisition is complete and measured at cost. As the capital work in process has not yet been finished and is not contributing to the production process to generate revenue, depreciation is not applied for capital work in process.

2.18 **Inventories:**

In compliance with the requirements of IAS 2 Inventories, the inventories have been valued at cost or net realizable value whichever is lower, which is consistent with the previous year's practice. Net realizable value is based on estimated selling price in the ordinary course of business less any further cost expected to be incurred to make the sale cost of inventories has been determined following weighted average method.

2.19 **Advances, Deposits and Prepayments:**

Advances are initially measured at cost. After initial recognition, advances are carried at cost less deductions, adjustments or transfer to other account heads such as PPE or inventory or expenses. Deposits are measured at payment value without any adjustment for time value. Prepayments are initially measured at cost. After initial recognition, prepayments are carried at cost less charges to Statement of Profit or Loss and Other Comprehensive Income on accrual basis.

2.20 **Cash and Cash Equivalents:**

Cash and cash equivalents comprises cash in hand, cash at bank and other short term deposits which are available for use by the company without any restriction. There is insignificant risk of change in value of the same.

2.21 Accounts Receivable:

These are carried forward at their original invoiced value. Amount and represents net realizable value. Management considered the entire bills receivable as good and is collectable. Expected credit loss/Bad Debt Provision has been calculated on accounts receivable as per management discretion.

2.22 Income Taxes:

Income tax expense comprises of current and deferred tax. Income tax expense is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted in accordance with the requirements of IAS 12 Income Taxes.

Current Tax

Current tax is the expected tax payable on the taxable income for the financial year, using tax rates enacted or subsequently enacted as of reporting date and any adjustment to tax payable in respect of previous year's as per Income Tax Act 2023 and Finance Act 2023.

Deferred Tax

Deferred tax is recognized in compliance with IAS 12 Income Taxes, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purpose and amounts used for taxation purpose.

VAT

The Company have both VAT able and Non-VAT able product. The company paid VAT only on VAT able items and enjoying exemption for Non-VAT able items as per related S R O of National Board of Revenue.

2.23 Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IFRS 9 Financial Instruments

Financial Assets

Financial assets of the company include cash and cash equivalents and accounts receivables. The company initially recognizes receivable on the date they are originated. All other financial assets are recognized initially in the date at which the company becomes a party to the contractual provisions of the transaction. The company derecognizes a financial asset when, and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and reward of ownership of the financial assets are transferred. Expected credit loss has been calculated on accounts receivable as per management discretion.

Financial Liabilities

Financial liabilities are recognized initially on the transaction date at which the Company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligation is discharged or cancelled or expires.

Financial liabilities include liabilities for expenses, liabilities for capital expenditure, bank loans and other current liabilities.

2.24 Statement of Cash Flows:

Statement of Cash Flows has been prepared in accordance with IAS 7 Statement of Cash Flows and the cash flows from the operating activities have been presented under direct method considering the provisions of Paragraph 19 of IAS 7 which provides

that "Entities are encouraged to report cash flows from operating activities using the direct method" and as per requirement of the Securities and Exchange Rules, 2020.

As per Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006/158/208/Admin/81 dated 08 August 2018, Cash Flows from operating activities has been reconciled with net income using the indirect method.

2.25 Related Party Disclosures:

The company carried out a number of transactions with related parties. The information as required by IAS 24 Related Party Disclosures has been disclosed in a separate note to the financial statements.

2.26 Impairment:

Financial assets

The company considers evidence of impairment for financial assets at both a specific asset and collective asset level at each reporting date. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor will enter bankruptcy, etc. accordingly, 100% provision will be made over the amount such outstanding.

Non-financial assets

The carrying amounts of the company's non-financial assets (tangible and intangible) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any).

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

2.27 Revenue from Contracts with Customers:

With Compliance of IFRS 15, revenue has been recognized by applying the following five steps:

1. Identify the contract with the customer
2. Identify the performance obligations in the contract
3. Determine the transaction price
4. Allocate the transaction price
5. Recognize revenue when (or as) a performance obligation is satisfied.

We have recognized revenue when all the recognition criteria are met. Summary of item wise impact of IFRS 15 is not required as the company has recognized revenue on goods upon satisfying the above criteria as per previous practice.

2.28 Borrowing Costs:

Interest and other cost incurred in the company in connection with the borrowing of fund are recognized as expenses in the year in which they are incurred and the borrowings cost related to Building construction are capitalized (if any) as per IAS 23 Borrowing Costs.

2.29 Earnings per Share (EPS):

The company calculates its Earnings per Share (EPS) in accordance with IAS 33 Earnings per Share and (2) Financial Reporting Council (FRC) gazette notification, which has been shown on the face of the Statement of Profit or Loss and Other Comprehensive Income.

Basic Earnings:

This represents earnings for the year attributable to the ordinary shareholders. As there are no preference dividends, minority interest or extraordinary items, the net profit after tax for the period has been considered as fully attributable to ordinary shareholders.

Basic Earnings per Share:

This has been calculated by dividing profit or loss attributable to ordinary shareholders of the company by the weighted average number of ordinary shares outstanding during the year.

Diluted Earnings per Share:

No diluted earnings per share are required to be calculated for the period under audit, as there was no scope for dilution during the year.

2.30 Provisions, accruals and contingencies

Provisions

A provision is recognized in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the date of statement of financial position.

Accruals

Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amount due to employees.

Contingencies

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or a present obligation that arises from past events but is not recognized because it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company.

2.31 Employee Benefit:

The company maintains Short Term Employee Benefits as per IAS 19 Employee Benefits. The cost of employee benefit is charged of as revenue expenditure in the period to which the contributions relate.

Short Term Employee Benefits:

Short-term employee benefits include wages, salaries, festival bonuses etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

Workers Profit Participation Fund (WPPF)

The company has created a fund for workers "Workers profit participation fund (WPPF)" as per Bangladesh Labor Act, 2006 (Amended up to 2018) by 5% of profit after charging such expenses.

2.32 Other Income

Other income derived from sales of wastage/scrap and interest received from bank.

2.33 Measurement of Fair Values:

When measuring the fair value of an asset or a liability, the company uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included in level 1 that are observable for asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

If the inputs used to measure the fair value of an asset or a liability might be categorized in different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2.34 Operating Segments:

No Segmental reporting is applicable for the company as required by "IFRS 8: Operating Segments" as the company operates in a single industry segment and within as a geographical segment

2.35 Risk Exposure:

Financial risk management

Techno Drugs Ltd.'s activities expose it to a variety of financial risk and those activities involve the analysis, evaluation, acceptance and management of some degree of risk or combination of risk. Taking risk is core to the financial business, and operational risks are an inevitable consequence of being in business. Techno Drugs Ltd.'s aim is therefore to achieve an appropriate balance between risk and return and minimize potential adverse effects on Techno Drugs Ltd.'s financial performance.

Techno Drugs Ltd.'s risk management policies are designed to identify and analyze these risks, to set appropriate risk limits and controls, and to monitor the risk and adherence to limits by means of reliable and up- to- date information systems. Techno Drugs Ltd regularly reviews its risk management policies and systems to reflect changes in markets, products and emerging best practices.

Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations which arises principally from the Company's receivable from customers and balances with banks including short-term deposit.

Customer credit risk, where appropriate, is assessed by using qualitative and quantitative criteria. Outstanding accounts receivable is regularly monitored and appropriate impairment charge, if applicable, is considered as per Company's policy.

Credit risk relating to balances with banks is managed by treasury department in accordance with the Company's policy.

Liquidity Risk

Liquidity risk is the risk that the Company may encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or other financial assets or liabilities. The Company's approach to managing liquidity risk is to ensure, as far as possible, that it will always have sufficient liquidity and arrangements in place to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to Company's reputation.

Market Risk

Market risk is the risk that includes changes in market prices, such as foreign exchange rates, interest rates and equity prices that may affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a Financial Instrument will fluctuate because of changes in market interest rates.

External risk factors may include among others:

Industry Risk

i) Environmental Issue: Environmentalists are likely to create pressure on government to protect or banning those factories, which are not follow proper ETP, waste management solution, Air pollution etc. which are negative effects on living being and environment thereby causing closure of business of the company. We have a good setup for ETP and incinerator for waste management, a very good and sophisticated fire alarm system with integrated fire hydrant and firehouse arrangement with carbon dioxide fire extinguisher, dry powder and sand bucket. The company also strictly follows the laid down regulations for marketing the products and therefore does not foresee any problems in doing the business.

2.36 Leases

The entity has adopted IFRS 16 from 01 July, 2019 and have been reviewed office rent agreement in light of the new rules in IFRS 16. On adoption of IFRS 16 the entity recognizes a right-of-use asset and a lease liability. The lease liability is measured at the present value of the lease payments that are not paid at date of 01 July, 2019 discounted using the incremental borrowing rate. Subsequently, right-of-use asset is adjusted for depreciation and lease liability is adjusted for interest and lease payments. Depreciation has been charged on right-of use assets on a straight line basis during the lease period

2.37 Events after the Reporting Period:

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date when the financial statements are authorized for issue. Two types of events can be identified:

Adjusting Events: - those that provide evidence of conditions that existed at the end of the reporting period.

Non adjusting Events: - those that are indicative of conditions that arose after the reporting period.

Management of the company has taken close look whether any events after the reporting period exist that need to take into account during the preparation of financial statements. No event after the reporting period exists and management has prepared the financial statements in accordance.

Techno Drugs Limited
Notes to the Financial Statements
For the year ended 30th June, 2023

| | | Amount in Taka | |
|-------------|--|----------------------|----------------------|
| | | 30th June, 2023 | 30th June 2022 |
| 3.00 | Property, Plant & Equipment: | | |
| | This is made-up as follows: | | |
| | Cost | | |
| | Opening balance | 3,987,878,360 | 3,433,338,792 |
| | Add: Addition during the period | 494,175,447 | 554,539,568 |
| | Closing Balance | 4,482,053,807 | 3,987,878,360 |
| | Revaluation | | |
| | Opening balance | 518,550,947 | - |
| | Add: Revaluation Surplus during the period | - | 518,550,947 |
| | Closing Balance | 518,550,947 | 518,550,947 |
| | Accumulated Depreciation: | | |
| | Opening balance | 1,124,035,073 | 872,908,142 |
| | Add: Charged during the period | 290,433,614 | 251,126,931 |
| | Closing Balance | 1,414,468,687 | 1,124,035,073 |
| | Written Down Value-Annexure-A (i) | 3,586,136,067 | 3,382,394,234 |
| 3.01 | Land (At Revaluation): | | |
| | This is made-up as follows: | | |
| | At Revaluation | | |
| | Opening Balance | 518,550,947 | - |
| | Add: Revaluation surplus during the period | - | 518,550,947 |
| | Total: | 518,550,947 | 518,550,947 |
| | The Details of above have been shown in Annexure-'A (i)' G Kibria & Co. Chartered Accountants, Dhaka, Bangladesh, the valuer revalued the Land at 'Current Cost Accounting Method (CCA)'. Due to this revaluation, a net revaluation surplus amounting to Tk. 518,550,947 had arisen. | | |
| 4.00 | Intangible Assets: | | |
| | This is made-up as follows: | | |
| | Cost | | |
| | Opening Balance | 4,125,473 | 4,125,473 |
| | Add. Addition during the period | 5,045,775 | - |
| | | 9,171,248 | 4,125,473 |
| | Accumulated Amortization | | |
| | Opening Balance | 1,031,368 | 618,821 |
| | Add. Charged during the period | 917,125 | 412,547 |
| | Total Charged | 1,948,493 | 1,031,368 |
| | Written Down Value as at 30th June, 2023 | 7,222,755 | 3,094,105 |
| | Details have been shown in-Annexure-A (ii) | | |
| 5.00 | Investment: | | |
| | This is made up as follows: | | |
| | G C Box Limited (2,700 Shares @ Tk.100 each) | 270,000 | 270,000 |
| | Total: | 270,000 | 270,000 |
| 6.00 | Capital Work-In-Progress: | | |
| | This is made-up as follows: | | |
| | Building and Civil Works | | |
| | Opening Balance | 41,997,776 | 9,918,535 |
| | Add: Addition during the period | 328,126,663 | 215,535,991 |
| | | 370,124,439 | 225,454,526 |
| | Less: Transferred to Building | 190,245,819 | 183,456,750 |
| | | 179,878,620 | 41,997,776 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| | Amount in Taka | |
|--|---------------------------|--------------------------|
| | 30th June, 2023 | 30th June 2022 |
| Plant and Machinery | | |
| Opening Balance | 7,643,207 | 5,780,000 |
| Add: Addition during the period | 250,567,450 | 340,990,332 |
| | 258,210,657 | 346,770,332 |
| Less: Transferred to Plant and Machinery | 258,210,657 | 339,127,125 |
| | <u>-</u> | <u>7,643,207</u> |
| Balance as at 30th June, 2023 | <u>179,878,620</u> | <u>49,640,983</u> |

This represents mainly construction of building, installation of plant and machinery with their necessary components and other fixed assets procured from foreign and local vendors for B.K. Bari factory premises located in BK Bari Gazipur to increase the overall production capacity of the company which are not ready for commercially use.

7.00 Right-of-Use Assets:

This is made-up as follows:

A) Cost

Opening Balance

| | | |
|-------------------|------------|------------|
| On Rental Assets | 57,879,930 | 53,151,752 |
| On Lease Vehicles | 52,331,125 | 22,871,125 |

Addition during the period

| | | |
|-------------------|-----------|------------|
| On Rental Assets | 9,440,666 | 4,728,178 |
| On Lease Vehicles | 9,800,000 | 29,460,000 |

Closing Balance

| | |
|--------------------|--------------------|
| 129,451,721 | 110,211,055 |
|--------------------|--------------------|

B) Depreciation

Opening Balance

| | | |
|-------------------|------------|------------|
| On Rental Assets | 42,486,149 | 27,840,620 |
| On Lease Vehicles | 7,901,849 | 954,955 |

Charge during the period

| | | |
|-------------------|------------|------------|
| On Rental Assets | 14,888,646 | 14,645,530 |
| On Lease Vehicles | 12,159,560 | 6,946,894 |

Closing Balance

| | |
|-------------------|-------------------|
| 77,436,205 | 50,387,998 |
|-------------------|-------------------|

Written Dwon Value (A-B)

| | |
|-------------------|-------------------|
| 52,015,516 | 59,823,057 |
|-------------------|-------------------|

8.00 Inventories:

This is made-up as follows:

| | | |
|-----------------------|---------------------------|---------------------------|
| Raw Materials | 411,252,163 | 329,178,572 |
| Packing Materials | 97,660,512 | 75,363,527 |
| Store and Spare Parts | 4,751,454 | 4,332,713 |
| Work in Process | 41,257,481 | 38,944,550 |
| Finished Goods | 145,678,342 | 198,821,613 |
| Total | <u>700,599,952</u> | <u>646,640,975</u> |

i) The inventory quantity can not be disclosed/inserted here as some of material contain in litre some are in pieces some are in box and some are in kg, gram, milli-gram, ton, litre and pcs.

ii) There is no damage goods item in the inventory list.

iii) Inventories are pledged as security for loan finance.

9.00 Finished Goods For Govt. Tender :

This is made-up as follows:

| | | |
|--|---------------------------|-----------------|
| 3rd Generation Birth Control Oral Pill (Sukhi) | 238,536,250 | - |
| | <u>238,536,250</u> | <u>-</u> |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

10.00 Advances, Deposits & Prepayments:

This is made-up as follows:

| | | | |
|--|-------------|--------------------|--------------------|
| Advance Income Tax | Note: 10.01 | 163,240,019 | 148,385,418 |
| VAT Current Account | | 41,041,090 | 41,041,090 |
| Advances to Staff | | 6,467,823 | 7,660,096 |
| Advance for Rent | | 285,000 | 285,000 |
| Advance to C & F Agents | | 2,356,781 | 2,554,672 |
| Security Money | | 27,960,322 | 12,391,066 |
| Advance to Suppliers & Others | | 97,376,427 | 70,457,802 |
| L.C Margin for Raw Materials | | 40,711,954 | 26,680,653 |
| Bank Guarantee Margin for Tender Sales | | 14,198,554 | 30,703,873 |
| Prepaid Insurance | | 5,554,424 | 4,271,480 |
| Total | | 399,192,394 | 344,431,150 |

10.01 Advance Income Tax :

This is made-up as follows:

| | | | |
|--|--|--------------------|--------------------|
| Opening balance | | 148,385,418 | 185,373,084 |
| Add: Paid during the period | | 14,854,601 | 148,385,418 |
| | | 163,240,019 | 333,758,502 |
| Less: Adjustment for Assessment year 2021-2022 | | - | 185,373,084 |
| Total | | 163,240,019 | 148,385,418 |

10.02 Disclosure as per Schedule XI, Part I, Para 6 of the Companies Act, 1994

| Particulars | 30th June, 2023 | 30th June, 2022 |
|--|--------------------|--------------------|
| Advances, deposits & prepayments considered good and in respect of which the company is fully secured. | 392,724,571 | 336,771,054 |
| Advances, deposits & prepayments considered good for which the company holds no security other than the debtor's personal security. | - | - |
| Advances, deposits & prepayments considered doubtful or bad. | - | - |
| Advances, deposits & prepayments due by directors or other officers of the company or any of them either severally or jointly with any other person or Advance, deposits & prepayment due by firms or private companies respectively in which any director is a partner or a director or a member. | - | - |
| Advances, deposits & prepayments due by companies under the same | - | - |
| The maximum amount due by directors or other officers of the company at any time during the period. | 6,467,823 | 7,660,096 |
| Total | 399,192,394 | 344,431,150 |

11.00 Accounts Receivable:

This is made-up as follows:

| | | | |
|----------------------------------|--|----------------------|----------------------|
| Opening Balance | | 707,183,113 | 482,461,395 |
| Add: Addition during the period | | 2,733,477,105 | 5,028,541,834 |
| | | 3,440,660,218 | 5,511,003,230 |
| Less: Received during the period | | 2,650,945,446 | 4,803,820,117 |
| Total | | 789,714,772 | 707,183,113 |

Ageing and classification of trade receivable as per Schedule XI, Part I, Para 4 of the Companies Act, 1994

| Ageing of Accounts Receivable | 30-Jun-23 | 30-Jun-22 |
|-------------------------------|--------------------|--------------------|
| More than six months | - | - |
| Less than six months | 789,714,772 | 707,183,113 |
| Total | 789,714,772 | 707,183,113 |

| Particulars | 30-Jun-23 | 30-Jun-22 |
|--|-------------|-------------|
| Receivables considered good and in respect of which the company is fully | - | - |
| Receivables considered good for which the company holds no security | 789,714,772 | 707,183,113 |
| Receivables considered doubtful or bad. | - | - |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| | Amount in Taka | |
|---|--------------------|--------------------|
| | 30th June, 2023 | 30th June 2022 |
| Receivable due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member. | - | - |
| Receivables due by companies under the same management. | - | - |
| The maximum amount due by directors or other officers of the company at any time during the period. | - | - |
| Total | 789,714,772 | 707,183,113 |

12.00 Investment in FDR:

This is made-up as follows:

| | | |
|------------------------------|-------------------|-------------------|
| AB Bank Ltd. | - | 15,000,000 |
| One Bank Ltd. | 258,249 | 247,827 |
| IPDC Finance Ltd. | 10,485,193 | 5,110,099 |
| LANKAN Alliance Finance Ltd. | 10,696,504 | 10,238,630 |
| Lanka Bangla Finance Ltd. | 5,701,918 | - |
| Meridian Finance Ltd. | 5,197,260 | - |
| IDLC Finance Ltd. | 20,879,726 | - |
| Total | 53,218,850 | 30,596,556 |

13.00 Cash & Cash Equivalents:

| | | |
|------------------------|-------------------|--------------------|
| Cash in Hand | 6,933,300 | 10,549,346 |
| Cash at Bank: | 27,537,275 | 129,387,720 |
| AB Bank Ltd. | 18,767,197 | 91,774,339 |
| Agrani Bank Ltd. | 499,540 | 500,960 |
| Dhaka Bank Ltd. | 112,090 | 111,803 |
| Dutch Bangla Bank Ltd. | 1,466,945 | 15,116,152 |
| Trust Bank Ltd. | 2,411 | 653,283 |
| Sonali Bank Ltd. | 176,814 | 1,178,252 |
| Simanto Bank Ltd. | 10,285 | 6,090 |
| IFC Bank Ltd. | 543,083 | 7,602,297 |
| One Bank Ltd. | 5,543,300 | 1,868,116 |
| Community Bank Ltd. | 1,616 | 10,368,615 |
| NRB Bank Ltd. | 178,908 | 180,173 |
| Midland Bank Ltd. | 7,873 | 9,023 |
| Mercantile Bank Ltd. | 216,910 | 18,620 |
| Meghna Bank Ltd. | 1,195 | - |
| NCC Bank Ltd. | 9,109 | - |
| Total | 34,470,574 | 139,937,066 |

14.00 Share Capital:

This is made-up as follows:

| | | |
|---|--------------------|--------------------|
| Authorized: | | |
| 20,00,00,000 Ordinary Shares of Tk. 10 each | 2,000,000,000 | 2,000,000,000 |
| Issued,Subscribed and Paid-up Capital: | | |
| Opening balance | 941,574,000 | 818,760,000 |
| Add: 1,22,81,400 Bonus Shares issued of Tk. 10 each | - | 122,814,000 |
| Total | 941,574,000 | 941,574,000 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

14.01 Share Holding Position:

| Name of Shareholders | Designation | Percentage | Number | Amount | Amount |
|------------------------|-------------------|---------------|-------------------|--------------------|--------------------|
| Khaleda Akther Khan | Chairman | 7.94 | 7,475,000 | 74,750,000 | 74,750,000 |
| Shah Jalal Uddin Ahmed | Managing Director | 63.14 | 59,455,000 | 594,550,000 | 594,550,000 |
| Mehreen Ahmed | Director | 4.76 | 4,485,000 | 44,850,000 | 44,850,000 |
| Arefeen Raafi Ahmed | Director | 4.76 | 4,485,000 | 44,850,000 | 44,850,000 |
| Others Shareholders | Share Holder | 19.40 | 18,257,400 | 182,574,000 | 182,574,000 |
| Total | | 100.00 | 94,157,400 | 941,574,000 | 941,574,000 |

15.00 Revaluation Surplus:

This is made-up as follows:

| | | |
|---|--------------------|--------------------|
| Opening Balance | 502,994,419 | - |
| Add: Surplus during the period | - | 518,550,947 |
| Less: Deferred Tax (Expenses)/Income on Revaluation Surplus | (15,556,528) | (15,556,528) |
| Total: | 487,437,890 | 502,994,419 |

16.00 Retained Earnings:

This is made-up as follows:

| | | |
|---|----------------------|--------------------|
| Opening Balance | 987,831,030 | 630,866,603 |
| Less: Stocked Dividend issued during the period | - | 122,814,000 |
| | 987,831,030 | 508,052,603 |
| Add: Profit for the period | 195,506,359 | 479,778,427 |
| Total | 1,183,337,389 | 987,831,030 |

17.00 Deferred Tax Expenses

This is made-up as follows:

| | | |
|---|--------------------|--------------------|
| Opening Balance | 191,452,122 | 164,434,577 |
| Add: Provision made during the period | 9,481,966 | 11,461,016 |
| Deferred Tax Liability excluding Revaluation Surplus | 200,934,088 | 175,895,593 |
| Deferred Tax Liability on Revaluation Surplus | 15,556,528 | 15,556,528 |
| Less: Adjustment during the period | - | - |
| Total | 216,490,616 | 191,452,122 |

17.01 Deferred Tax Expenses during the period

Asset (Other Than Land) Written Down Value as (Accounting Base)

| | | |
|---|---------------|---------------|
| Asset (Other Than Land) Written Down Value as (Accounting Base) | 2,822,834,064 | 2,615,920,323 |
| Adjustment of WPPF | 66,677,150 | 53,724,548 |
| Asset (Other Than Land) Written Down Value as (Tax Base) | 2,073,393,880 | 1,928,936,828 |
| Deductible Temporary Difference on Asset | 682,763,033 | 633,258,948 |

Deductible Temporary Difference on Asset

| | Accounting Base | Tax Base | | |
|--|--------------------|----------|--------------------|--------------------|
| ROU Assets Written Down Value | 52,015,516 | - | | |
| Lease Liability Written Down Value | (60,678,336) | - | | |
| Deductible Temporary Difference for Lease | (8,662,820) | - | (8,662,820) | 6,361,390 |
| Total Deductible Temporary Difference | | | 674,100,213 | 639,620,338 |

| | | |
|------------------------------|------------------|-------------------|
| Effective Tax Rate | 27.50% | 27.50% |
| Deferred Tax Liability | 185,377,559 | 175,895,593 |
| Less: Opening Deferred Tax | 175,895,593 | 164,434,577 |
| Deferred Tax Expenses | 9,481,966 | 11,461,016 |

17.02 Deferred Tax on revaluation surplus

| Asset name | WDV | Rate | Deferred Tax Liability as on 30th June, 2023 | Deferred Tax Liability as on 30th June, 2022 |
|---------------------------------------|-------------|------|--|--|
| Land & Land Development | 518,550,947 | 6% | 15,556,528 | 15,556,528 |
| Total | 518,550,947 | | 15,556,528 | 15,556,528 |
| Opening Balance | | | - | - |
| Deferred Tax (Expenses)/Income | | | (15,556,528) | (15,556,528) |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

18.00 Long Term Loan Net of Current Maturity:

This is made-up as follows:

Loan from Bank & Finance:

| | | |
|---------------------|----------------------|--------------------|
| One Bank Ltd. | 907,430,344 | 785,474,803 |
| IPDC Finance Ltd. | 27,746,596 | 32,878,053 |
| Community Bank Ltd. | 82,243,403 | 155,408,304 |
| IDLC Finance Ltd. | 38,129,562 | - |
| Total | 1,055,549,905 | 973,761,159 |

Terms & Conditions:

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|---------------------|------------------|---------------|---|
| One Bank Limited | Term Loan | 9% | Facility Limit: Tk. 116.90 Crore |
| | | | Purpose: Civil Construction & Capital Machineries |
| | | | Validity/ Expiry: 6 years. |
| | | | Security: 967.50 decimal land & others. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|----------------------|------------------|---------------|--|
| IPDC Finance Limited | Term Loan | 9% | Facility Limit: Tk. 5.00 Crore |
| | | | Purpose: Business Expsnsion |
| | | | Validity/ Expiry: 5 years from disbursment date. |
| | | | Security: 10% FDR on loan amount & others. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|------------------------|------------------|---------------|--|
| Community Bank Limited | Term Loan | 9% | Facility Limit: Tk. 30.00 Crore |
| | | | Purpose: To set up Machineries for Gazipur Factory. |
| | | | Validity/ Expiry: 3 years from disbursment date. |
| | | | Security: 2034.09 decimal land (third party) & others. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|----------------------|------------------|---------------|--|
| IDLC Finance Limited | Term Loan | 9.75% | Facility Limit: Tk. 7.00 Crore |
| | | | Purpose: For Construction of Factory Building |
| | | | Validity/ Expiry: 3 years from disbursment date. |
| | | | Security: Lien on FDR 2 Crore & Others |

19.00 Lease Liabilities:

| | | |
|--|-------------------|-------------------|
| Opening Balance | 53,461,667 | 45,411,442 |
| Rental Lease | 18,320,468 | 29,575,373 |
| Vehicles Lease | 35,141,199 | 15,836,070 |
| Add: Addition during the period | 17,280,666 | 28,096,179 |
| Rental Lease | 9,440,666 | 4,728,178 |
| Vehicles Lease | 7,840,000 | 23,368,001 |
| Add: Interest Expenses | 6,113,943 | 5,629,130 |
| Rental Lease | 2,305,577 | 3,108,518 |
| Vehicles Lease | 3,808,366 | 2,520,612 |
| Less: Payment during the period | 16,177,940 | 25,675,084 |
| Rental Lease | 4,394,700 | 19,091,600 |
| Vehicles Lease | 11,783,240 | 6,583,484 |
| Closing Balance | 60,678,336 | 53,461,667 |

19.01 Principal Payment due within two to five period

32,920,433

32,193,314

19.02 Principal Payment due within one period

27,757,903

21,268,354

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

20.00 Current Maturity of Long Term Loan:

This is made-up as follows:

Loan from Bank & Finance:

| | | |
|---------------------|--------------------|--------------------|
| AB Bank Ltd. | - | 2,343,657 |
| One Bank Ltd. | 251,629,230 | 333,034,292 |
| IPDC Finance Ltd. | 12,455,016 | 12,455,016 |
| Community Bank Ltd. | 123,398,692 | 126,602,492 |
| IDLC Finance Ltd. | 26,541,700 | - |
| Total | 414,024,638 | 474,435,457 |

The Amount represent current maturity of long term loan obtained from above bank/finance which are repayable within next 12 (Twelve) months from the date of Balance Sheet.

21.00 Short Term Loans:

This is made-up as follows:

21.01 Loan from AB Bank Ltd:

| | 434,851,184 | 282,343,889 |
|----------------------|-------------|-------------|
| Cash Credit | 152,456,230 | 112,391,714 |
| LATR | 56,483,063 | - |
| Time Loan | 225,911,891 | 80,100,000 |
| Acceptance Liability | - | 89,852,175 |

21.02 Loan from ONE Bank Ltd:

| | 591,127,427 | 472,233,344 |
|----------------------|-------------|-------------|
| Cash Credit | 204,737,758 | 77,022,621 |
| LATR | 87,814,926 | 114,163,370 |
| Time Loan | 287,190,298 | 163,524,633 |
| Acceptance Liability | 11,384,445 | 117,522,720 |

21.03 Loan from Finance Ltd:

| | | |
|------------------------------|-------------|-------------|
| LANKAN Alliance Finance Ltd. | 100,000,000 | 100,000,000 |
| Lanka Bangla Finance Ltd. | 40,310,107 | - |
| Meridian Finance Ltd. | 21,565,272 | - |

| | | |
|--------------|----------------------|--------------------|
| Total | 1,187,853,989 | 854,577,233 |
|--------------|----------------------|--------------------|

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|--|--|---------------|--|
| AB Bank Limited | Cash Credit | 9% | Facility Limit: Tk. 15.00 Crore |
| | | | Purpose: To meet up workings capital requirements |
| | Validity/ Expiry: 15.09.2023 | | |
| | Revolving LTR | | Facility Limit: Tk. 20.00 Crore |
| | | | Purpose: LC Retirement. |
| | Validity/ Expiry: 15.09.2023 | | |
| Revolving Time Loan | Facility Limit: Tk. 23.00 Crore | | |
| | Purpose: Local Materias Purchases,Duty Vat Payments | | |
| | | | Validity/ Expiry: 120 days for each Time Loan |
| Security | | | |
| i). First Charge over all present and future inventories and trade receivable of Techno Drugs Limited under pari-passu security sharing agreement. | | | |
| ii). First Charge over all present and future Fixed Assets of Techno Drugs Limited under pari-passu security sharing agreement. | | | |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|----------------------------|---|---------------|--|
| One Bank Limited | Cash Credit | 9% | Facility Limit: Tk. 20.00 Crore |
| | | | Purpose: To meet up workings capital requirements |
| | Validity/ Expiry: 1 year from the date of disbursement | | |
| | Revolving LTR | | Facility Limit: Tk. 50.00 Crore |
| | | | Purpose: LC Retirement. |
| | Validity/ Expiry: 180 days for each LTR | | |
| Revolving Time Loan | Facility Limit: Tk. 25.00 Crore | | |
| | Purpose: Local Materias Purchases,Duty Vat Payments | | |
| | | | Validity/ Expiry: 180 days for each Time Loan |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

| <u>Security</u> |
|--|
| i). First Charge over all present and future inventories and trade receivable of Techno Drugs Limited under pari-passu security sharing agreement. |
| ii). First Charge over all present and future Fixed Assets of Techno Drugs Limited under pari-passu security sharing agreement. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|--|----------------------------------|---------------|---|
| LANKAN Alliance Finance Limited | Revolving Short Term Loan | 11.00% | Facility Limit: Tk. 10.00 Crore |
| | | | Purpose: To meet Working Capital |
| | | | Validity/ Expiry: 1 Year from the date of disbursement |
| | | | Security: 10% FDR on Principal Loan Amount. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|----------------------------------|------------------------|---------------|---|
| Lanka Bangla Finance Ltd. | Short Term Loan | 9.50% | Facility Limit: Tk. 5.50 Crore |
| | | | Purpose: To meet Regular Business Capital for purchasing raw materials |
| | | | Validity/ Expiry: 24 Months from the date of |
| | | | Security: 10% FDR on Principal Loan Amount. |

| Name of Institution | Type of Facility | Interest Rate | Particulars |
|------------------------------|------------------------|---------------|---|
| Meridian Finance Ltd. | Short Term Loan | 9.50% | Facility Limit: Tk. 5.00 Crore |
| | | | Purpose: To meet Working Capital |
| | | | Validity/ Expiry: 1 year from the date of disbursement |
| | | | Security: 10% FDR on Principal Loan Amount. |

22.00 Provision for Current Tax:

The break-up is as follows:

| | | | |
|----------------------------|-------------|--------------------|--------------------|
| Opening balance | | 162,208,405 | 194,658,012 |
| Add. Current charged | Note: 22.01 | 54,063,724 | 159,782,068 |
| Past years Short Provision | | - | 1,873,573 |
| Charged during the period | | 54,063,724 | 157,908,495 |
| | | 216,272,129 | 354,440,080 |
| Less. Adjustments | | | |
| For the year 2016-2017 | | - | (2,462,936) |
| For the year 2018-2019 | | - | (2,522,082) |
| For the year 2019-2020 | | (1,000,000) | - |
| For the year 2020-2021 | | - | (185,373,084) |
| For the year 2020-2021 | | - | (1,873,573) |
| Total | | 215,272,129 | 162,208,405 |

Current Tax has arrived as follows:

| | | | |
|--|-------------|---------------|---------------|
| Profit Before Tax | | 259,052,049 | 651,021,511 |
| Add: Depreciation as per Accounting Base | | 291,350,739 | 251,539,478 |
| Depreciation as per Tax Base | | (353,807,426) | (328,348,281) |
| Taxable Business Profit / (Loss) | | 196,595,361 | 574,212,709 |
| Tax rate | | 27.50% | 27.50% |
| Income Tax as per Regular Tax Rate (i) | | 54,063,724 | 157,908,495 |
| Advance Tax Paid during the | Note: 10.01 | 14,854,601 | 148,385,418 |
| Tax as per 163 U/S (iii) | | 16,691,912 | 32,378,427 |

Tax as per 163 U/S

| | | | |
|--|--|-------------------|--------------------|
| Collection from Sales | | 2,650,945,446 | 4,803,820,117 |
| Tax Rate | | 0.60% | 0.60% |
| | | 15,905,673 | 28,822,921 |
| Other Income | | 2,859,050 | 12,929,115 |
| Tax Rate | | 27.50% | 27.50% |
| | | 786,239 | 3,555,507 |
| Total | | 16,691,912 | 32,378,427 |
| Current tax need to be charged for the year (higher of i, ii, iii) | | 54,063,724 | 157,908,495 |
| Add. Short Provision | | - | 1,873,573 |
| For the year 2020-2021 | | - | 1,873,573 |
| Total current tax | | 54,063,724 | 159,782,068 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| | | Amount in Taka | |
|--------------|--------------------------------------|--------------------|--------------------|
| | | 30th June, 2023 | 30th June 2022 |
| 23.00 | Accounts & Others Payable | | |
| | The break-up is as follows: | | |
| | Trade & Others Payables | 78,063,172 | 65,918,322 |
| | Payable for Salary & Remuneration | 68,787,078 | 58,067,578 |
| | Payable for Utility Bill | 3,799,006 | 4,813,092 |
| | Payable for Audit Fees | 345,000 | 345,000 |
| | Vat Payable | 8,796,186 | 11,155,932 |
| | Provision for Bad Debts | 11,492,595 | 7,544,021 |
| | Interest Payable on Loan | 37,854,810 | 20,147,254 |
| | Advance against Export | 3,221,862 | - |
| | Total | 212,359,709 | 167,991,199 |

23.01 Provision for Bad Debts:

This is made-up as follows:

| | | |
|---------------------------------------|-------------------|------------------|
| Opening Balance | 7,544,021 | 4,008,105 |
| Add: Provision Made during the period | 3,948,574 | 3,535,916 |
| | <u>11,492,595</u> | <u>7,544,021</u> |
| Less: Adjustment | - | - |
| Closing Balance | 11,492,595 | 7,544,021 |

During the period, management of the company made a provision @ 0.5% of outstanding accounts receivable considering the expected lifetime credit loss in accordance with para 5.5.2 of IFRS 9.

24.00 Liabilities for WPPF:

This is made-up as follows:

| | | |
|----------------------|-------------------|-------------------|
| Contribution to WPPF | 66,677,150 | 53,724,548 |
| Total | 66,677,150 | 53,724,548 |

24.01 Contribution to WPPF:

The break-up is as follows:

| | | |
|---------------------------------|-------------------|-------------------|
| Opening balance | 53,724,548 | 63,875,298 |
| Add: Addition during the period | 12,952,602 | 32,551,076 |
| | <u>66,677,150</u> | <u>96,426,373</u> |
| Less: Paid during the period | - | 42,701,826 |
| Total | 66,677,150 | 53,724,548 |

As per Bangladesh Labor Act, 2006 (Amended 2018) the amount is computed @ 5% of net profit before Income Tax.

Techno Drugs Limited
Notes to the Financial Statements
For the year ended 30th June, 2023

| | | Amount in Taka | |
|--|--|---------------------------|----------------------|
| | | 30th June, 2023 | 30th June 2022 |
| 25.00 Revenue: | | | |
| | This is made-up as follows: | | |
| | Sales VAT able Items | 1,609,034,217 | 1,619,159,755 |
| | Less: VAT 15% | 209,874,028 | 211,194,751 |
| | Net VAT able Items | 1,399,160,189 | 1,407,965,004 |
| | Add. Non Vat able Items | 1,330,923,933 | 3,620,576,830 |
| | Local Sales | 2,730,084,122 | 5,028,541,834 |
| | Export | 3,392,983 | - |
| | Total | 2,733,477,105 | 5,028,541,834 |
| 26.00 Cost of Goods Sold: | | | |
| | This is arrived as follows: | | |
| | Raw Materials consumed | Note: 26.01 1,184,107,230 | 2,499,251,876 |
| | Packing Materials consumed | Note: 26.02 143,811,916 | 280,990,403 |
| | Store and Spare consumed | Note: 26.03 11,124,537 | 21,481,965 |
| | Add: Factory Overhead | Note: 26.04 426,018,387 | 481,120,150 |
| | Total Manufacturing Cost | 1,765,062,069 | 3,282,844,394 |
| | Opening Stock Work-In-Process | 38,944,550 | 30,243,780 |
| | Closing Stock Work-In-Process | (41,257,481) | (38,944,550) |
| | Cost of Goods Manufactured | 1,762,749,138 | 3,274,143,624 |
| | Opening Stock Finished Goods | 198,821,613 | 145,487,965 |
| | Finished Goods available for sale | 1,961,570,751 | 3,419,631,589 |
| | Cost of Sample Transferred to Selling Expenses | (3,713,868) | (7,427,735) |
| | Closing Stock Finished Goods for General Sales | (145,678,342) | (198,821,613) |
| | Closing Stock Finished Goods for Tender Sales | (238,536,250) | - |
| | Cost of Goods Sold | 1,573,642,291 | 3,213,382,241 |
| 26.01 Raw Materials Consumed: | | | |
| | The break-up is as follows: | | |
| | Opening Raw Materials | 329,178,572 | 242,468,409 |
| | Add: Purchase Raw Materials | 1,266,180,821 | 2,585,962,039 |
| | Less: Closing Raw Materials | 411,252,163 | 329,178,572 |
| | Total | 1,184,107,230 | 2,499,251,876 |
| 26.02 Packing Materials Consumed: | | | |
| | The break-up is as follows: | | |
| | Opening Packing Materials | 75,363,527 | 41,579,658 |
| | Add: Purchase Packing Materials | 166,108,901 | 314,774,272 |
| | Less: Closing Packing Materials | 97,660,512 | 75,363,527 |
| | Total | 143,811,916 | 280,990,403 |
| 26.03 Store and Spare Consumed: | | | |
| | The break-up is as follows: | | |
| | Opening Spares & Tools | 4,332,713 | 2,145,822 |
| | Add: Purchase during the period | 11,543,278 | 23,668,856 |
| | Less: Closing Spares & Tools | 4,751,454 | 4,332,713 |
| | Total | 11,124,537 | 21,481,965 |
| 26.04 Factory Overhead: | | | |
| | This consists of as follows: | | |
| | Car Maintenance Expenses | 1,156,432 | 1,862,430 |
| | Carrying & Handling Expenses | 7,153,817 | 12,792,338 |
| | Cleaning, Washing & Security Service | 2,098,765 | 3,931,565 |
| | Depreciation | 246,868,572 | 213,457,891 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| | Amount in Taka | |
|--|--------------------|--------------------|
| | 30th June, 2023 | 30th June 2022 |
| Donation & Subscription | 156,750 | 306,900 |
| Entertainment Expenses | 987,654 | 1,907,386 |
| Fuel, Patrol & Lubricant | 5,435,412 | 9,635,631 |
| Insurance Premium | 7,540,801 | 5,716,971 |
| Lab Materials | 5,345,890 | 9,957,350 |
| Medical Expenses | 612,443 | 457,624 |
| Renewals Fee & Local Tax | 725,931 | 2,586,502 |
| Other Expenses | 450,908 | 1,489,411 |
| Printing & Stationery Expenses | 1,345,782 | 2,754,682 |
| Repair & Maintenance Expenses | 2,567,832 | 6,497,607 |
| Research & Development Expenses | 1,545,322 | 4,651,297 |
| Salary, wages & other benefits | 95,890,575 | 137,713,794 |
| Training & Meeting Expenses | 2,078,614 | 4,192,440 |
| Telephone, Postage & Internet Expenses | 2,256,323 | 4,312,382 |
| Traveling & Conveyance Expenses | 2,567,890 | 4,572,206 |
| Uniform for workers | 286,750 | 567,202 |
| Utility Bill | 38,945,924 | 51,756,541 |
| Total | 426,018,387 | 481,120,150 |
| | | |
| 27.00 Administrative Expenses: | | |
| This consists of as follows: | | |
| Audit Fees | 345,000 | 345,000 |
| Books, Newspaper & Periodicals | 56,277 | 102,073 |
| Car Maintenance | 1,478,345 | 2,567,543 |
| Depreciation | 43,565,042 | 37,669,040 |
| Depreciation Charges for the Right-of-Use As: Note: 7.00 | 23,550,383 | 18,337,716 |
| Amortization Note: 4.00 | 917,125 | 412,547 |
| Director Remuneration | 24,000,000 | 24,000,000 |
| Entertainment Expenses | 989,674 | 2,345,678 |
| Fuel, Patrol & Lubricant | 1,789,645 | 3,649,323 |
| Legal & Consultancy Fees | 87,240 | 177,000 |
| Other Expenses | 245,671 | 892,837 |
| Printing & Stationery Expenses | 1,189,764 | 2,316,105 |
| Repair & Maintenance Expenses | 1,589,324 | 3,245,632 |
| Registration & Renewal | 693,558 | 1,714,143 |
| Salary, Allowance & Others Benefits | 58,578,980 | 76,315,957 |
| Telephone & Postage Expenses | 1,246,790 | 2,489,939 |
| Travelling & Conveyance Expenses | 1,457,809 | 2,841,141 |
| Training, Meeting & Conference Expenses | 1,053,421 | 3,703,377 |
| Utility Bill | 4,668,633 | 4,813,487 |
| Provision for Bad Debts Note: 23.01 | 3,948,574 | 3,535,916 |
| Total | 171,451,255 | 191,474,453 |
| | | |
| 28.00 Selling & Distribution Expenses: | | |
| This is made-up as follows: | | |
| Advertisement Expenses | 262,479 | 588,886 |
| Car Maintenance | 2,235,789 | 3,919,060 |
| Carrying & Handling Expenses | 11,098,456 | 38,642,525 |
| Entertainment Expenses | 1,899,655 | 3,840,294 |
| Fuel, Patrol & Lubricant | 4,634,789 | 8,302,490 |
| Marketing & Promotional Expenses | 15,177,274 | 29,778,946 |
| Other Expenses | 206,783 | 499,883 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| | | Amount in Taka | |
|--|-------------|----------------------|----------------------|
| | | 30th June, 2023 | 30th June 2022 |
| Depreciation Charge for the Right-of-Use Ass | Note: 7.00 | 3,497,824 | 3,254,707 |
| Printing & Stationery Expenses | | 1,745,349 | 3,566,492 |
| Repair & Maintenance Expenses | | 488,764 | 937,898 |
| Salary, Allowance & Others Benefits | | 351,934,675 | 476,781,183 |
| Sample cost | Note: 26.00 | 3,713,868 | 7,427,735 |
| Sales Commission | | 15,287,545 | 29,700,649 |
| Telephone & Postage Expenses | | 1,678,456 | 3,244,826 |
| Training, Meeting & Conference Expenses | | 5,989,345 | 9,603,383 |
| Travelling & Conveyance Expenses | | 446,520 | 1,092,356 |
| Incentive | | 16,145,678 | 29,833,034 |
| TA/ DA Expenses | | 11,567,345 | 39,536,707 |
| Utility Bill | | 1,416,041 | 1,187,077 |
| Total | | 449,426,634 | 691,738,131 |
| 29.00 Finance Expenses: | | | |
| This is made-up as follows: | | | |
| Interest Charged on Long Term Loan | | 138,781,372 | 149,089,798 |
| Interest Charged on Short Term Loan | | 118,979,217 | 101,887,891 |
| Bank Charges & Others Fee | | 5,936,791 | 4,696,717 |
| Interest Expenses on Lease Liability | Note: 19.00 | 6,113,943 | 5,629,130 |
| Total | | 269,811,323 | 261,303,536 |
| 30.00 Other Income/(Loss): | | | |
| This is made-up as follows: | | | |
| Sale of Scrap | | 245,679 | 955,230 |
| Gain/(Loss) on Exchange rate | | (5,659) | - |
| Bank Interest Income | | 2,619,031 | 11,973,885 |
| Total | | 2,859,050 | 12,929,115 |
| 31.00 Earnings per Share - Basic | | | |
| Net Profit After Tax | | 195,506,359 | 479,616,606 |
| Weightd average number of ordinary shares | | 94,157,400 | 94,157,400 |
| Basic Earning per share (EPS) | | 2.08 | 5.10 |
| 32.00 Net Assets Value Per Share (NAV): | | | |
| i) Net Assets Value (NAV) Per Share with revaluation: | | | |
| Total Assets | | 6,041,255,752 | 5,364,011,238 |
| Less: Total outside Liability | | 3,428,906,472 | 2,931,611,789 |
| Net Assets Value | | 2,612,349,279 | 2,432,399,449 |
| Number of ordinary shares | | 94,157,400 | 94,157,400 |
| Net Assets Value Per Share | | 27.74 | 25.83 |
| ii) Net Assets Value (NAV) Per Share without revaluation: | | | |
| Total Assets | | 5,553,817,861 | 4,861,016,819 |
| Less: Total outside Liability | | 3,428,906,472 | 2,931,611,789 |
| Net Assets Value | | 2,124,911,389 | 1,929,405,030 |
| Number of share outstanding | | 94,157,400 | 94,157,400 |
| Net Assets Value Per Share | | 22.57 | 20.49 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

33.00 Net Operating Cash Flows (NOCFPS) per share-Basic:

| | | |
|--|-------------|-------------|
| Net cash generated from operating activities | 210,097,920 | 593,052,719 |
| Weighted Average No. of Shares Outstanding | 94,157,400 | 94,157,400 |
| Net Operating Cash Flows Per Share | 2.23 | 6.30 |

34.00 Reconciliation of Net Profit with Cash Flow from Operating Activities:

| Particulars | July 2022 To June 2023 | July 2021 To June 2022 |
|---|------------------------------|------------------------------|
| Net Profit Before tax | 259,052,049 | 651,021,511 |
| Adjustment for: | | |
| Depreciation on Property, Plant and Equipment | 290,433,614 | 251,126,931 |
| Depreciation Charge for the Right-of-Use Asset | 27,048,207 | 21,592,423 |
| Amortization on Intangible Asset | 917,125 | 412,547 |
| Interest Expense on the Lease Liability | 6,113,943 | 5,629,130 |
| | 583,564,938 | 929,782,543 |
| Increase/ Decrease Inventories | (292,495,227) | (184,715,341) |
| Increase/ Decrease Advance Deposit & Prepayments | (39,906,643) | 168,593,357 |
| Increase/ Decrease Trade and other receivables | (82,531,659) | (224,721,718) |
| Increase/ Decrease liabilities for expense & Services | 44,368,510 | 69,508,636 |
| Increase/ Decrease contribution to WPPF | 12,952,602 | (10,150,750) |
| | 225,952,520 | 748,296,726 |
| Income Tax Paid | (15,854,601) | (155,244,009) |
| Net Cash Generated from operating Activities | 210,097,920 | 593,052,719 |

Techno Drugs Limited
Notes to the Financial Statements
For the year ended 30th June, 2023

35.00 Related party Disclosure:

The name of related parties nature of transaction and their respective period end balance have been set out in accordance with the provisions of para 18 disclosure of transaction between related parties of IAS 24 "Related Party Disclosure";s. The company in normal course of business carried out transactions at fair value with following related parties:

| Name of the Related Party | Relationship | Nature of Transaction | Balance as on 1st July 2022 | Transaction July 2022 To June 2023 | Balance as on 30th June 2023 |
|---------------------------|---------------------|--------------------------------|-----------------------------|------------------------------------|------------------------------|
| Khaleda Akhter Khan | Chairman | Office Rent | - | - | 7,560,000 |
| Shah Jalal Uddin Ahme | Managing Director | Office Rent | - | - | 7,560,000 |
| | | Remuneration | 1,000,000 | - | 12,000,000 |
| Mehreen Ahmed | Director | Remuneration | 500,000 | - | 6,000,000 |
| Arefeen Raafi Ahmed | Director | Remuneration | 500,000 | - | 6,000,000 |
| G C Box Limited | Common Board Member | Purchases of Packing Materials | 1,795,661 | 16,566,068 | 1,271,984 |

Para 18 (b) (c) (d) Disclosure requirements of IAS 24:

| | |
|---|---|
| (b) Commitments for outstanding | Refundable on due course. |
| (b)(i) Security of the transaction: | There is no security as outstanding balance is for remuneration. No security for outstanding balance for transaction with G C Box, as parties are within common management. |
| (b)(i) Nature of the settlement: | Through Bank. |
| (b)(ii) Details of the guarantee: | There is no guarantee as outstanding balance is for remuneration. Outstanding for business transaction with G C Box as parties are within common management. |
| (c) Provisions for doubtful debts related to the amount of outstanding balances. | There is no provision for doubtful debts because there is no possibility of non-payment. |
| (d) The expenses recognized during the period in respect of bad or doubtful debts due from related party | No expenses for bad or doubtful debts were recognized during the period for related party. |

| Amount in Taka | |
|-----------------|----------------|
| 30th June, 2023 | 30th June 2022 |

Para 17 Disclosure of key management personnel compensation.

- a) Short-term employee benefits;
b) Not Paid any post employment benefits;
c) Not Paid any other long term benefits;
d) Not Paid any termination benefits; and
e) Not paid any share-based payment

| | |
|------------|------------|
| 24,000,000 | 24,000,000 |
| Nil | Nil |
| Nil | Nil |
| Nil | Nil |
| Nil | Nil |

36.00 Disclosure as per Companies Act, 1994:

36.01 Disclosure as per requirement of Schedule XI, part-II, Para 3 (a)

Turnover:

| Particulars | 30th June, 2023 | 30th June, 2022 |
|----------------------------|-----------------|-----------------|
| Turnover in BDT. | 2,733,477,105 | 5,028,541,834 |
| Turnover in Quantity (Pcs) | 189,721,800 | 334,069,044 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

36.02 Disclosure as per requirement of Schedule XI, part-II, Para 3(d)

(i) Raw Materials consumed

| Particulars | 30th June, 2023 | 30th June, 2022 |
|------------------------------------|-----------------|-----------------|
| Raw Materials (Value in BDT.) | 1,184,107,230 | 2,499,251,876 |
| Raw Materials Quantities (Kg/Lit.) | 1,218,772 | 2,518,530 |

(ii) Finished Goods

| Particulars | 30th June, 2023 | 30th June, 2022 |
|--|-----------------|-----------------|
| Opening Quantity (Pcs/Tube/Bottle) | 15,399,500 | 27,456,170 |
| Production Quantity during the period (Pcs/Tube/Bottle) | 197,115,260 | 322,012,374 |
| Closing Quantity (Pcs/Tube/Bottle) | 22,792,960 | 15,399,500 |

36.03 Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3

| Particulars | 30th June, 2023 | 30th June, 2022 |
|---|-----------------|-----------------|
| Salary/Wages per month, Below Tk. 8,000 | Nil | Nil |
| Salary/Wages per month, Above 8,000 | 1,518 | 1,713 |
| Total No. of Employees | 1,518 | 1,713 |

36.04 Aggregated amount of Remuneration, Fees, Salary & Wages of employees are given below:

| Particulars | 30th June, 2023 | 30th June, 2022 |
|---|--------------------|--------------------|
| Director Remuneration | 24,000,000 | 24,000,000 |
| Salary, wages & other benefits (Factory) | 95,890,575 | 137,713,794 |
| Salary, Allowance & Others Benefit (Admin, Marketing & Selling) | 410,513,655 | 553,097,141 |
| Total | 530,404,230 | 714,810,935 |

36.05 Disclosure as per requirement of para 4, part II, schedule XI

| Particulars | 30th June, 2023 | 30th June, 2022 |
|---|-------------------|-------------------|
| (a) Managerial Remuneration paid or payable during the financial year to the directors, including managing director, a managing agent or manager. | 24,000,000 | 24,000,000 |
| (b) Expenses reimbursed to the managing agent; | - | - |
| (c) Commission or other remuneration payable separately to a managing agent or his associate; | - | - |
| (d) Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.; | - | - |
| (e) The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year. | - | - |
| (f) Any other perquisites or benefits in cash or in kind stating, approximate money value where practicable; | - | - |
| (g) Other allowances and commission including guarantee commission. | - | - |
| Pensions etc. | - | - |
| (i) Pensions | - | - |
| (ii) Gratuities | - | - |
| (iii) Payments from a provident funds, in excess of own subscription and interest thereon | - | - |
| (iv) Compensation for loss of office | - | - |
| (v) Consideration in connection with retirement from office. | - | - |
| Total | 24,000,000 | 24,000,000 |

Techno Drugs Limited
Notes to The Financial Statements
For the year ended 30th June, 2023

36.06 Disclosure as per requirement of Schedule XI, Part II, Para 7

| Particulars | Unit | Installed Capacity FY 22-23 | Actual Production FY 22-23 | Capacity Utilization FY 22-23 |
|----------------|--------|--------------------------------|----------------------------------|-------------------------------------|
| Tablet | Pcs | 350,510,425 | 140,204,170 | 40% |
| Capsule | Pcs | 93,630,700 | 35,179,670 | 38% |
| Injection | Pcs | 34,547,500 | 16,529,260 | 48% |
| Powder | Bottle | 3,544,534 | 1,488,690 | 42% |
| Liquid & Syrup | Bottle | 6,987,679 | 3,713,470 | 53% |
| Total | | 489,220,838 | 197,115,260 | |

36.07 Disclosure as per requirements of Schedule XI, Part II, Para 8

(a) Value of imports calculated on CIF/FOB basis by the company during the financial year ended 30th June, 2023 in respect of raw materials, components and spare parts and capital goods were as follows:

| Particulars | Import |
|-----------------------|---------------|
| | Amount in BDT |
| i) Raw Materials | 191,475,566 |
| ii) Packing Materials | 27,663,069 |
| iii) Capital Goods | 4,683,896 |

(b) The Company did not have any expenditure in foreign currency during the financial year on account of royalty, know-how, professional consultation fees, interest and other matters.

(c) Value of all imported raw materials, spare parts and components consumed during the financial year and the value of all indigenous raw materials, spare parts and components similarly consumed and the percentage of each to the total consumption:

| Particulars | Total Consumption | Imported Taka. | (%) | Local Taka. | (%) |
|-------------------|----------------------|--------------------|--------|----------------------|---------|
| Raw Materials | 1,184,107,230 | 191,475,566 | 16.17% | 992,631,664 | 83.83% |
| Packing Materials | 143,811,916 | 27,663,069 | 19.24% | 116,148,847 | 80.76% |
| Store Items | 11,124,537 | - | 0.00% | 11,124,537 | 100.00% |
| Total | 1,339,043,682 | 219,138,635 | | 1,119,905,047 | |

(d) No amount has been remitted during the period in foreign currencies on account of dividends for non-residents shareholders,

(e) Earnings in foreign exchange classified under the following heads, namely

- i) Export made during the period Tk. 3,392,983.00
- ii) No royalty, Know-how, Professional and consultation fees were received
- iii) No Interest and Dividend received except Note no. 30
- iv) No other income received except Note no. 30

37.00 Claim not acknowledged as Debt:

There was no claim against the company acknowledged as debt as on 30th June 2023.

38.00 Contingent liability:

The company has a contingent liability on account of unresolved disputed on VAT claims by the authority aggregating to Tk. 37,85,40,702.69. The company has filed VAT reference cases with the High Court Division of the Supreme court against this claims. Considering the merits of the cases, it has not been deemed necessary to make provisions for such disputed claims. If any liability arise on disposal of the cases, the company shall provide for such liability in the year of final disposal.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Techno Drugs Limited
Schedule of Property, Plant & Equipment
As at 30th June, 2023

Annexure-A (i)

| Sl. No. | Particulars | C O S T | | | Rate | D E P R E C I A T I O N | | | Written Down Value |
|---------|-------------------------|----------------------|--------------------------|----------------------|------|-------------------------|--------------------------|----------------------|----------------------|
| | | Opening Balance | Addition during the year | Total | | Opening Balance | Addition during the year | Total | |
| 1 | Land & Land Development | 251,017,069 | 956,743 | 251,973,812 | 0% | - | - | - | 251,973,812 |
| 2 | Building | 1,686,432,666 | 190,245,819 | 1,876,678,485 | 3% | 146,042,398 | 52,271,700 | 198,314,097 | 1,678,364,388 |
| 3 | Plant & Machinery | 1,645,834,851 | 258,210,657 | 1,904,045,508 | 10% | 691,331,343 | 171,884,168 | 863,215,511 | 1,040,829,998 |
| 4 | Furniture & Fixture | 37,966,805 | 9,638,274 | 47,605,079 | 10% | 21,300,053 | 4,278,594 | 25,578,647 | 22,026,432 |
| 5 | Office Equipment | 19,881,732 | 5,490,796 | 25,372,528 | 20% | 17,182,180 | 4,525,426 | 21,707,606 | 3,664,922 |
| 6 | Laboratory Equipment | 91,478,579 | 15,231,800 | 106,710,379 | 20% | 82,033,393 | 19,309,596 | 101,342,989 | 5,367,390 |
| 7 | Motor vehicle | 104,103,743 | 11,426,567 | 115,530,310 | 20% | 90,809,264 | 22,861,218 | 113,670,482 | 1,859,828 |
| 8 | Electric Equipments | 151,162,915 | 2,974,791 | 154,137,706 | 10% | 75,336,444 | 15,302,912 | 90,639,356 | 63,498,350 |
| | Sub-Total-A | 3,987,878,360 | 494,175,447 | 4,482,053,807 | | 1,124,035,073 | 290,433,614 | 1,414,468,687 | 3,067,585,120 |

Revaluation:

| Sl. No. | Particulars | C O S T | | | Rate | D E P R E C I A T I O N | | | Written Down Value |
|---------|-------------------------|--------------------|--------------------------|--------------------|------|-------------------------|-------------------------|----------|--------------------|
| | | Opening Balance | Addition during the year | Total | | Opening Balance | Charged during the year | Total | |
| 1 | Land & Land Development | 518,550,947 | - | 518,550,947 | 0% | - | - | - | 518,550,947 |
| | Sub-Total-B | 518,550,947 | - | 518,550,947 | | - | - | - | 518,550,947 |

| | | | | | | | | |
|--|----------------------|--------------------|----------------------|--|----------------------|--------------------|----------------------|----------------------|
| Balance as on June 30, 2023 (A+B) | 4,506,429,307 | 494,175,447 | 5,000,604,754 | | 1,124,035,073 | 290,433,614 | 1,414,468,687 | 3,586,136,067 |
|--|----------------------|--------------------|----------------------|--|----------------------|--------------------|----------------------|----------------------|

Note:

Allocation of depreciation charged during the year:

| Head of Accounts | Proportion | Amount |
|-------------------------|-------------|--------------------|
| Manufacturing Expenses | 85% | 246,868,572 |
| Administrative Expenses | 15% | 43,565,042 |
| | 100% | 290,433,614 |

Techno Drugs Limited
Schedule of Property, Plant & Equipment
As at 30th June, 2022

| Sl. No. | Particulars | C O S T | | | Rate | D E P R E C I A T I O N | | | Written Down Value |
|---------|-------------------------|----------------------|--------------------------|----------------------|------|-------------------------|--------------------------|----------------------|----------------------|
| | | Opening Balance | Addition during the year | Total | | Opening Balance | Addition during the year | Total | |
| 1 | Land & Land Development | 250,162,229 | 854,840 | 251,017,069 | 0% | - | - | - | 251,017,069 |
| 2 | Building | 1,502,975,916 | 183,456,750 | 1,686,432,666 | 3% | 98,582,934 | 47,459,464 | 146,042,398 | 1,540,390,268 |
| 3 | Plant & Machinery | 1,306,707,726 | 339,127,125 | 1,645,834,851 | 10% | 546,831,087 | 144,500,256 | 691,331,343 | 954,503,509 |
| 4 | Furniture & Fixture | 35,739,253 | 2,227,552 | 37,966,805 | 10% | 17,632,111 | 3,667,941 | 21,300,053 | 16,666,752 |
| 5 | Office Equipment | 16,321,656 | 3,560,076 | 19,881,732 | 20% | 13,564,855 | 3,617,325 | 17,182,180 | 2,699,552 |
| 6 | Laboratory Equipment | 80,779,734 | 10,698,845 | 91,478,579 | 20% | 64,787,991 | 17,245,401 | 82,033,393 | 9,445,186 |
| 7 | Motor vehicle | 96,833,743 | 7,270,000 | 104,103,743 | 20% | 71,023,469 | 19,785,795 | 90,809,264 | 13,294,479 |
| 8 | Electrict Equipments | 143,818,535 | 7,344,380 | 151,162,915 | 10% | 60,485,695 | 14,850,749 | 75,336,444 | 75,826,471 |
| | Sub-Total-A | 3,433,338,792 | 554,539,568 | 3,987,878,360 | | 872,908,142 | 251,126,931 | 1,124,035,073 | 2,863,843,287 |

Revaluation:

| Sl. No. | Particulars | C O S T | | | Rate | D E P R E C I A T I O N | | | Written Down Value |
|---------|-------------------------|-----------------|--------------------------|--------------------|------|-------------------------|-------------------------|----------|--------------------|
| | | Opening Balance | Addition during the year | Total | | Opening Balance | Charged during the year | Total | |
| 1 | Land & Land Development | - | 518,550,947 | 518,550,947 | 0% | - | - | - | 518,550,947 |
| | Sub-Total-B | - | 518,550,947 | 518,550,947 | | - | - | - | 518,550,947 |

| | | | | | | | | |
|--|----------------------|----------------------|----------------------|--|--------------------|--------------------|----------------------|----------------------|
| Balance as on June 30, 2022 (A+B) | 3,433,338,792 | 1,073,090,515 | 4,506,429,307 | | 872,908,142 | 251,126,931 | 1,124,035,073 | 3,382,394,234 |
|--|----------------------|----------------------|----------------------|--|--------------------|--------------------|----------------------|----------------------|

Note:

Allocation of depreciation charged during the year:

| Head of Accounts | Proporation | Amount |
|-------------------------|-------------|--------------------|
| Manufacturing Expenses | 85% | 213,457,891 |
| Administrative Expenses | 15% | 37,669,040 |
| | 100% | 251,126,931 |

Techno Drugs Limited
Schedule of Intangible assets
As at 30th June, 2023

Annexure-A (ii)

| Particulars | COST | | | Rate | ACCUMULATED AMORTIZATION | | | Written down value as at 30.06.2023 |
|--------------|--------------------------|--------------------------|--------------------------|------|--------------------------|-------------------------|--------------------------|-------------------------------------|
| | Balance as at 01.07.2022 | Addition during the year | Balance as at 30.06.2023 | | Balance as at 01.07.2022 | Charged during the year | Balance as at 30.06.2023 | |
| ERP Software | 4,125,473 | 5,045,775 | 9,171,248 | 10% | 1,031,368 | 917,125 | 1,948,493 | 7,222,755 |
| Total | 4,125,473 | 5,045,775 | 9,171,248 | | 1,031,368 | 917,125 | 1,948,493 | 7,222,755 |

As at 30th June, 2022

| Particulars | COST | | | Rate | ACCUMULATED AMORTIZATION | | | Written down value as at 30.06.2022 |
|--------------|--------------------------|--------------------------|--------------------------|------|--------------------------|-------------------------|--------------------------|-------------------------------------|
| | Balance as at 01.07.2021 | Addition during the year | Balance as at 30.06.2022 | | Balance as at 01.07.2021 | Charged during the year | Balance as at 30.06.2022 | |
| ERP Software | 4,125,473 | - | 4,125,473 | 10% | 618,821 | 412,547 | 1,031,368 | 3,094,105 |
| Total | 4,125,473 | - | 4,125,473 | | 618,821 | 412,547 | 1,031,368 | 3,094,105 |

(b) **Information as is required under section 186 of the কোম্পানি আইন, ১৯৯৪ relating to holding company;**

This information is not applicable for Techno Drugs Ltd.

(c) **Selected ratios as specified in Annexure-D;**

Auditor's certificate regarding calculation of EPS and Ratios

This is to certify that Techno Drugs Ltd. has maintained the following ratios as computed on the basis of the audited financial statements for the year ended June 30, 2023, 2022, 2021, 2020 and 2019.

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|--|-----------|-----------|-----------|-----------|-----------|
| | Ratio | | | | |
| I. Liquidity Ratios: | | | | | |
| (i) Current Ratio | 1.04 | 1.08 | 1.02 | 0.92 | 1.01 |
| (ii) Quick Ratio | 0.53 | 0.51 | 0.43 | 0.53 | 0.56 |
| II. Operating Efficiency Ratios: | | | | | |
| (i) Accounts Receivable Turnover Ratio | 3.65 | 8.45 | 9.58 | 8.15 | 16.09 |
| (ii) Inventory Turnover Ratio | 2.34 | 5.80 | 5.93 | 3.93 | 5.80 |
| (iii) Asset Turnover Ratio | 0.48 | 1.03 | 0.94 | 0.60 | 0.87 |
| III. Profitability Ratios: | | | | | |
| (i) Gross Margin Ratio | 42.43% | 36.10% | 38.04% | 41.25% | 41.07% |
| (ii) Operating Profit Ratio | 19.72% | 18.53% | 22.04% | 24.71% | 24.16% |
| (iii) Net Profit Ratio | 7.15% | 9.54% | 9.40% | 8.12% | 10.45% |
| (iv) Return on Assets Ratio | 3.43% | 9.84% | 8.84% | 4.84% | 9.06% |
| (v) Return on Equity Ratio | 7.75% | 24.72% | 29.23% | 18.17% | 33.87% |
| (vi) Earnings Per Share (EPS) | 2.08 | 5.10 | 3.91 | 2.32 | 3.36 |
| (vii) Earnings before interest, taxes, depreciation and amortization (EBITDA) margin | 30.34% | 23.53% | 27.57% | 32.86% | 30.36% |
| IV. Solvency Ratios: | | | | | |
| (i) Debt to Total Assets Ratio | 0.45 | 0.44 | 0.55 | 0.66 | 0.66 |
| (ii) Debt to Equity Ratio | 1.04 | 0.97 | 1.66 | 2.44 | 2.53 |
| (iii) Times Interest Earned Ratio | 2.00 | 3.57 | 3.49 | 2.55 | 3.43 |
| (iv) Debt Service Coverage Ratio | 0.40 | 0.30 | 0.52 | 0.27 | 0.36 |
| V. Cash Flow Ratios: | | | | | |
| (i) Net Operating Cash Flow per Share (NOCFPS) | 2.23 | 6.30 | 3.01 | 2.16 | 1.77 |
| (ii) NOCFPS to EPS Ratio | 1.07 | 1.24 | 0.77 | 0.93 | 0.53 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

Ratio Calculation

| Particulars | Formula | 30-Jun-23 | | 30-Jun-22 | | 30-Jun-21 | | 30-Jun-20 | | 30-Jun-19 | |
|--|---|--------------------------------|--------|--------------------------------|--------|--------------------------------|--------|--------------------------------|--------|--------------------------------|--------|
| | | Calculation | Ratio | Calculation | Ratio | Calculation | Ratio | Calculation | Ratio | Calculation | Ratio |
| I. Liquidity Ratios: | | | | | | | | | | | |
| (i) Current Ratio | Current Assets/Current Liabilities | 2,215,732,793 2,123,945,519 | 1.04 | 1,868,788,859 1,734,205,195 | 1.08 | 1,756,544,720 1,718,063,169 | 1.02 | 1,448,978,606 1,567,970,516 | 0.92 | 1,117,626,314 1,106,150,990 | 1.01 |
| (ii) Quick Ratio | (Current Assets-Inventories-Advance, Deposit & Prepayments)/Current Liabilities | 1,115,940,447 2,123,945,519 | 0.53 | 877,716,735 1,734,205,195 | 0.51 | 744,606,913 1,718,063,169 | 0.43 | 831,677,222 1,567,970,516 | 0.53 | 614,193,825 1,106,150,990 | 0.56 |
| II. Operating Efficiency Ratios: | | | | | | | | | | | |
| (i) Accounts Receivable Turnover Ratio | Net Sales/Average Accounts Receivables | 2,733,477,105 748,448,943 | 3.65 | 5,028,541,834 594,822,254 | 8.45 | 3,841,379,557 400,810,544 | 9.58 | 2,013,899,466 246,955,832 | 8.15 | 2,164,801,777 134,505,692 | 16.09 |
| (ii) Inventory Turnover Ratio | Cost of Goods Sold /Average Inventory | 1,573,642,291 673,620,464 | 2.34 | 3,213,382,241 554,283,305 | 5.80 | 2,380,115,347 401,285,902 | 5.93 | 1,183,126,627 300,733,134 | 3.93 | 1,275,677,113 219,892,072 | 5.80 |
| (iii) Asset Turnover Ratio | Net Sales/Average Total Assets | 2,733,477,105 5,702,633,495 | 0.48 | 5,028,541,834 4,873,844,548 | 1.03 | 3,841,379,557 4,083,587,009 | 0.94 | 2,013,899,466 3,379,935,195 | 0.60 | 2,164,801,777 2,497,672,143 | 0.87 |
| III. Profitability Ratios: | | | | | | | | | | | |
| (i) Gross Margin Ratio | Gross Profit/Net Sales | 1,159,834,813 2,733,477,105 | 42.43% | 1,815,159,593 5,028,541,834 | 36.10% | 1,461,264,210 3,841,379,557 | 38.04% | 830,772,839 2,013,899,466 | 41.25% | 889,124,664 2,164,801,777 | 41.07% |
| (ii) Operating Profit Ratio | Operating Profit/Net Sales | 538,956,924 2,733,477,105 | 19.72% | 931,947,008 5,028,541,834 | 18.53% | 846,586,781 3,841,379,557 | 22.04% | 497,647,253 2,013,899,466 | 24.71% | 523,011,804 2,164,801,777 | 24.16% |
| (iii) Net Profit Ratio | Net Profit after Tax/Net Sales | 195,506,359 2,733,477,105 | 7.15% | 479,778,427 5,028,541,834 | 9.54% | 360,942,830 3,841,379,557 | 9.40% | 163,609,083 2,013,899,466 | 8.12% | 226,281,965 2,164,801,777 | 10.45% |
| (iv) Return on Assets Ratio | Net Profit after Tax/Average Total Assets | 195,506,359 5,702,633,495 | 3.43% | 479,778,427 4,873,844,548 | 9.84% | 360,942,830 4,083,587,009 | 8.84% | 163,609,083 3,379,935,195 | 4.84% | 226,281,965 2,497,672,143 | 9.06% |
| (v) Return on Equity Ratio | Net Profit after Tax/Average Total Shareholders' Equity | 195,506,359 2,522,374,364 | 7.75% | 479,778,427 1,941,013,026 | 24.72% | 360,942,830 1,234,775,188 | 29.23% | 163,609,083 900,561,181 | 18.17% | 226,281,965 668,057,607 | 33.87% |
| (vi) Earnings Per Share (EPS) | Net Profit after Tax/Weighted Average Number of Ordinary Shares Outstanding | 195,506,359 94,157,400 | 2.08 | 479,778,427 94,157,400 | 5.10 | 360,942,830 92,312,918 | 3.91 | 163,609,083 70,384,712 | 2.32 | 226,281,965 67,260,000 | 3.36 |
| (vii) Earnings before interest, taxes, depreciation and amortization (EBITDA) margin | EBITDA/Net Sales | 829,390,538 2,733,477,105 | 30.34% | 1,183,073,939 5,028,541,834 | 23.53% | 1,059,008,467 3,841,379,557 | 27.57% | 661,672,602 2,013,899,466 | 32.86% | 657,160,267 2,164,801,777 | 30.36% |
| IV. Solvency Ratios: | | | | | | | | | | | |
| (i) Debt to Total Assets Ratio | Total Debt/Total Assets | 2,718,106,868 6,041,255,752 | 0.45 | 2,356,235,516 5,364,011,238 | 0.44 | 2,412,600,806 4,383,677,859 | 0.55 | 2,484,389,812 3,783,496,160 | 0.66 | 1,978,461,844 2,976,374,229 | 0.66 |
| (ii) Debt to Equity Ratio | Total Debt/Total Equity | 2,718,106,868 2,612,349,279 | 1.04 | 2,356,235,516 2,432,399,449 | 0.97 | 2,412,600,806 1,449,626,603 | 1.66 | 2,484,389,812 1,019,923,774 | 2.44 | 1,978,461,844 781,198,589 | 2.53 |
| (iii) Times Interest Earned Ratio | EBIT/Financial Expenses | 538,956,924 269,811,323 | 2.00 | 931,947,008 261,303,536 | 3.57 | 846,586,781 242,398,585 | 3.49 | 497,647,253 195,084,678 | 2.55 | 523,011,804 152,458,437 | 3.43 |
| (iv) Debt Service Coverage Ratio | Net Operating Profit / Total Debt Service | 538,956,924 1,359,083,264 | 0.40 | 1,183,073,939 3,903,355,674 | 0.30 | 1,059,008,467 2,055,400,765 | 0.52 | 661,672,602 2,444,292,425 | 0.27 | 657,160,267 1,820,789,105 | 0.36 |
| V. Cash Flow Ratios: | | | | | | | | | | | |
| (i) Net Operating Cash Flow per Share (NOCFPS) | Net Operating Cash Flow/ Number of Ordinary Shares Outstanding | 210,097,920 94,157,400 | 2.23 | 593,052,719 94,157,400 | 6.30 | 277,793,974 92,312,918 | 3.01 | 151,868,870 70,384,712 | 2.16 | 119,274,770 67,260,000 | 1.77 |
| (ii) NOCFPS to EPS Ratio | Net Operating Cash Flow per Share/EPS | 2.23 2.08 | 1.07 | 6.30 5.10 | 1.24 | 3.01 3.91 | 0.77 | 2.16 2.32 | 0.93 | 1.77 3.36 | 0.53 |

Industry average ratios compare with Techno Drugs Ltd.:

| Name of the Ratio | 30-Jun-22 | | 30-Jun-21 | | 30-Jun-20 | | 30-Jun-19 | |
|--|-----------|---------------|-----------|---------------|-----------|---------------|-----------|---------------|
| | TDL | Industry Avg. | TDL | Industry Avg. | TDL | Industry Avg. | TDL | Industry Avg. |
| I. Liquidity Ratios: | | | | | | | | |
| (i) Current Ratio | 1.08 | 4.52 | 1.02 | 4.90 | 0.92 | 4.58 | 1.01 | 4.06 |
| (ii) Quick Ratio | 0.51 | 3.43 | 0.43 | 3.69 | 0.53 | 3.43 | 0.56 | 3.09 |
| II. Operating Efficiency Ratios: | | | | | | | | |
| (i) Accounts Receivable Turnover Ratio | 8.45 | 10.78 | 9.58 | 11.70 | 8.15 | 10.46 | 16.09 | 9.79 |
| (ii) Inventory Turnover Ratio | 5.80 | 2.52 | 5.93 | 2.77 | 3.93 | 2.84 | 5.80 | 2.87 |
| (iii) Asset Turnover Ratio | 1.03 | 0.70 | 0.94 | 0.71 | 0.60 | 0.68 | 0.87 | 0.70 |
| III. Profitability Ratios: | | | | | | | | |
| (i) Gross Margin Ratio | 36.10% | 51.04% | 38.04% | 52.37% | 41.25% | 51.83% | 41.07% | 52.73% |
| (ii) Operating Profit Ratio | 18.53% | 17.40% | 22.04% | 19.70% | 24.71% | 20.95% | 24.16% | 20.28% |
| (iii) Net Profit Ratio | 9.54% | 14.51% | 9.40% | 15.36% | 8.12% | 13.39% | 10.45% | 13.52% |
| (iv) Return on Assets Ratio | 9.84% | 8.53% | 8.84% | 9.47% | 4.84% | 7.87% | 9.06% | 8.54% |
| (v) Return on Equity Ratio | 24.72% | 12.29% | 29.23% | 13.10% | 18.17% | 7.49% | 33.87% | 9.00% |
| (vi) Earnings Per Share (EPS) | 5.10 | 19.10 | 3.91 | 18.65 | 2.32 | 9.28 | 3.36 | 9.20 |
| (vii) Earnings before interest, taxes, depreciation and amortization (EBITDA) margin | 23.53% | 21.11% | 27.57% | 24.15% | 32.86% | 26.35% | 30.36% | 25.04% |
| IV. Solvency Ratios: | | | | | | | | |
| (i) Debt to Total Assets Ratio | 0.44 | 0.29 | 0.55 | 0.27 | 0.66 | 0.27 | 0.66 | 0.26 |
| (ii) Debt to Equity Ratio | 0.97 | 1.10 | 1.66 | 1.10 | 2.44 | 1.38 | 2.53 | 1.11 |
| (iii) Times Interest Earned Ratio | 3.57 | 6.55 | 3.49 | 13.62 | 2.55 | 8.55 | 3.43 | 10.74 |
| (iv) Debt Service Coverage Ratio | 0.30 | 8.20 | 0.52 | 16.30 | 0.27 | 10.26 | 0.36 | 12.79 |
| V. Cash Flow Ratios: | | | | | | | | |
| (i) Net Operating Cash Flow per Share (NOCFPS) | 6.30 | 12.70 | 3.01 | 10.11 | 2.16 | 23.51 | 1.77 | 9.88 |
| (ii) NOCFPS to EPS Ratio | 1.24 | 0.80 | 0.77 | 0.14 | 0.93 | 0.31 | 0.53 | 1.13 |

Note: The stand-alone ratio of Techno Drugs Ltd. has been calculated based on audited financial statements and Industry average ratios are calculated on the basis of financial data collected from annual report of following 5 (Five) publicly traded companies corresponding accounting years.

| Sl. No. | Name of the Company | Considered Accounting Year |
|---------|------------------------------|--|
| 1 | ACI Limited | For the year ended 30 June 2019, 2020, 2021 and 2022 |
| 2 | Beximco Pharmaceuticals Ltd. | |
| 3 | Orion Pharma Ltd. | |
| 4 | Renata Ltd. | |
| 5 | Square Pharmaceuticals Ltd. | |

Analysis:

The industry average ratios have been calculated considering five listed companies of the pharmaceutical sector. The chosen listed companies are some of the leading pharmaceutical companies of Bangladesh and some of them have top market capitalization in the bourses.

Liquidity Ratios:

In terms of liquidity, TDL has maintained a good current ratio level throughout the four years. However, their quick ratio levels are below optimal levels. Comparing with the industry average, TDL has lower liquidity levels compared to its listed peers.

Operating Efficiency Ratios:

In terms of operating efficiency, TDL has maintained good operating efficiency level throughout the four years. Comparing with industry peers, TDL has higher inventory turnover and asset turnover levels which means that it has been properly using inventory and assets to generate sales. However, TDL has lower accounts receivable turnover compared to its peers which was higher in the pre-pandemic period.

Profitability Ratios:

In terms of profitability, TDL has comparatively good performance on stand-alone basis. However, comparing with industry peers, TDL has lower gross profit margin and lower net profit margin throughout the four years. On the flipside, comparing with industry peers, TDL has higher operating profit margin, higher return on equity and higher EBITDA margin throughout four years. Although, net profit ratio and earnings per share of TDL is lower compared to industry average, they are both on an increasing trend since June 2020.

Solvency Ratios:

In terms of solvency, comparing with industry peers, TDL has high debt levels compared to both total assets and equity. However, both the debt to total assets ratio and debt to equity ratio of TDL is on a decreasing trend since June 2019. Despite high debt levels, TDL has good position in times interest earned ratio but less optimal position in debt service coverage ratio.

Cash Flow Ratios:

In terms of cash flows, compared to industry average, TDL has lower net operating cash flow per share. However, net operating cash flow per share of the company has been increasing since June 2019. In addition, TDL has higher NOCFPS to EPS ratio compared to industry average.

- (d) **Auditors report under Section 135(1), Paragraph 24(1) of Part II of Schedule III of the কোম্পানি আইন, ১৯৯৪. The report shall include comparative income statements and balance sheet and aforementioned ratios for immediate preceding five accounting years of the issuer. If the issuer has been in commercial operation for less than five years, the above mentioned inclusion and submission will have to be made for the period since commercial operation;**

Auditors' report Under Section-135 (1) and Para-24(1) of Part-II of Schedule-III of the Companies Act, 1994

We have examined the financial statements of Techno Drugs Ltd. for the year ended June 30, 2023, 2022, 2021, 2020 and 2019. Financial Statement for the year ended June 30, 2023, 2022, 2021, 2020 and 2019 were audited by us. In pursuance of Section-135 (1) and Para-24 (1) of Part-II of Schedule-III of the Companies Act, 1994, our report is as under:

A) Statements of Assets and Liabilities of the Company are as under:

| Particulars | Amount in Taka | | | | |
|--|----------------------|----------------------|----------------------|----------------------|----------------------|
| | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
| ASSETS: | | | | | |
| Non-Current Assets: | 3,825,522,959 | 3,495,222,379 | 2,627,133,139 | 2,334,517,554 | 1,858,747,915 |
| Property, Plant and Equipments at Carrying Value | 3,586,136,067 | 3,382,394,234 | 2,560,430,650 | 2,097,470,412 | 1,724,222,526 |
| Intangible Assets | 7,222,755 | 3,094,105 | 3,506,652 | 3,919,199 | - |
| Investment In Share | 270,000 | 270,000 | 270,000 | 270,000 | - |
| Capital Work In Progress | 179,878,620 | 49,640,983 | 15,698,535 | 193,626,501 | 134,525,389 |
| Right-of-Use Assets | 52,015,516 | 59,823,057 | 47,227,302 | 39,231,442 | - |
| Current Assets | 2,215,732,793 | 1,868,788,859 | 1,756,544,720 | 1,448,978,606 | 1,117,626,314 |
| Inventories | 700,599,952 | 646,640,975 | 461,925,634 | 340,646,170 | 260,820,098 |
| Finished Goods For Govt. Tender | 238,536,250 | - | - | - | - |
| Advances, Deposits and Prepayments | 399,192,394 | 344,431,150 | 550,012,173 | 276,655,214 | 242,612,391 |
| Accounts Receivable | 789,714,772 | 707,183,113 | 482,461,395 | 319,159,692 | 174,751,972 |
| Investment in FDR | 53,218,850 | 30,596,556 | 224,599,963 | 287,783,433 | 262,430,784 |
| Cash and Cash Equivalents | 34,470,574 | 139,937,066 | 37,545,555 | 224,734,097 | 177,011,069 |
| Total Assets | 6,041,255,752 | 5,364,011,238 | 4,383,677,859 | 3,783,496,160 | 2,976,374,229 |
| SHARE HOLDERS' EQUITY & LIABILITIES: | | | | | |
| Shareholders' Equity | 2,612,349,279 | 2,432,399,449 | 1,449,626,603 | 1,019,923,774 | 781,198,589 |
| Share Capital | 941,574,000 | 941,574,000 | 818,760,000 | 687,600,000 | 99,600,000 |
| Revaluation Surplus | 487,437,890 | 502,994,419 | - | - | - |
| Share Money Deposit | - | - | - | 62,400,000 | - |
| Retained Earnings | 1,183,337,389 | 987,831,030 | 630,866,603 | 269,923,774 | 681,598,589 |
| Non-Current Liabilities | 1,304,960,954 | 1,197,406,594 | 1,215,988,087 | 1,195,601,870 | 1,089,024,650 |
| Deferred Tax Liability | 216,490,616 | 191,452,122 | 164,434,577 | 122,157,299 | 74,491,866 |
| Long Term Loan Net of Current Maturity | 1,055,549,905 | 973,761,159 | 1,024,205,653 | 1,043,887,568 | 1,014,532,784 |
| Lease Liabilities Net of Current Maturity | 32,920,433 | 32,193,314 | 27,347,857 | 29,557,002 | - |
| Current Liabilities | 2,123,945,519 | 1,734,205,195 | 1,718,063,169 | 1,567,970,516 | 1,106,150,990 |
| Current Maturity of Lease Liabilities | 27,757,903 | 21,268,354 | 18,063,586 | 13,679,741 | - |
| Current Maturity of Long Term Loan | 414,024,638 | 474,435,457 | 367,396,794 | 326,326,115 | 132,001,931 |
| Short Term Loan | 1,187,853,989 | 854,577,233 | 975,586,918 | 1,070,939,386 | 831,927,129 |
| Provision for Current Tax | 215,272,129 | 162,208,405 | 194,658,012 | 82,205,066 | 78,345,531 |
| Accounts & Others Payable | 212,359,709 | 167,991,199 | 98,482,563 | 40,589,566 | 45,385,141 |
| Liabilities for WPPF | 66,677,150 | 53,724,548 | 63,875,298 | 34,230,643 | 18,491,258 |
| Total Equity and Liabilities | 6,041,255,752 | 5,364,011,238 | 4,383,677,859 | 3,783,496,160 | 2,976,374,229 |
| Net Asset Value (NAV) per share | 27.74 | 25.83 | 17.71 | 14.83 | 78.43 |

B) The statements of operating results of the Company is as follow:

Amount in Taka

| Particulars | 01 Jul 2022 to 30 Jun 2023 | 01 Jul 2021 to 30 Jun 2022 | 01 Jul 2020 to 30 Jun 2021 | 01 Jul 2019 to 30 Jun 2020 | 01 Jul 2018 to 30 Jun 2019 |
|-----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Revenue | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Cost of Goods Sold | (1,573,642,291) | (3,213,382,241) | (2,380,115,347) | (1,183,126,627) | (1,275,677,113) |
| Gross Profit | 1,159,834,813 | 1,815,159,593 | 1,461,264,210 | 830,772,839 | 889,124,664 |
| Operating Expenses | (620,877,889) | (883,212,585) | (614,677,429) | (333,125,586) | (366,112,860) |
| Administrative Expenses | (171,451,255) | (191,474,453) | (152,813,771) | (113,600,215) | (110,264,431) |
| Selling & Distribution Expenses | (449,426,634) | (691,738,131) | (461,863,658) | (219,525,370) | (255,848,429) |
| Profit from Operation | 538,956,924 | 931,947,008 | 846,586,781 | 497,647,253 | 523,011,804 |
| Finance Expenses | (269,811,323) | (261,303,536) | (242,398,585) | (195,084,678) | (152,458,437) |
| Other Income | 2,859,050 | 12,929,115 | 18,349,561 | 27,964,502 | 17,763,058 |
| Profit before WPPF and Tax | 272,004,652 | 683,572,587 | 622,537,756 | 330,527,077 | 388,316,425 |
| Contribution to WPPF | (12,952,602) | (32,551,076) | (29,644,655) | (15,739,385) | (18,491,258) |
| Profit Before Tax | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Income Tax Expenses | (63,545,690) | (171,243,084) | (231,950,271) | (151,178,609) | (143,543,201) |
| Current Tax | (54,063,724) | (159,782,068) | (189,672,994) | (103,513,176) | (92,481,421) |
| Deferred Tax | (9,481,966) | (11,461,016) | (42,277,277) | (47,665,433) | (51,061,780) |
| Net Profit after Tax | 195,506,359 | 479,778,427 | 360,942,830 | 163,609,083 | 226,281,965 |
| Earnings Per Share (Basic) | 2.08 | 5.10 | 3.91 | 2.32 | 3.36 |
| Earnings Per Share (Diluted) | 2.08 | 5.10 | 3.83 | 1.74 | 2.40 |

*Considering the latest number of shares i.e. 94,157,400 for all years in calculating Diluted Earnings Per Share (EPS)

C) **Dividend declared:**

| Particulars | 30-Jun-23 | 30-Jun-22 | 30-Jun-21 | 30-Jun-20 | 30-Jun-19 |
|------------------------------|------------------|------------------|------------------|------------------|------------------|
| Cash Dividend | Nil | Nil | Nil | Nil | Nil |
| Stock Dividend (Bonus Share) | Nil | Nil | 15% | Nil | 500% |

- D) Techno Drugs Ltd. was incorporated in Bangladesh as a Private Limited Company with the issuance of Certificate of incorporation bearing no. Reg. No. C-79890/09 dated on 30-Sep-2009 by the Registrar of Joint Stock Companies & Firms, Dhaka, Bangladesh. The Company Converted into public Limited Company and split of Share value from Tk. 1,000.00 to Tk. 10.00 dated on 18-Aug-2019.
- E) The Company started its commercial operation in July 01, 2010.
- F) The Company has no subsidiary as on the balance sheet date.
- G) No proceeds or part of the proceeds of the issue of shares would be applied directly by the company in the purchase of any business.
- H) The Company did not prepare any statement of accounts for the period subsequent to June 30, 2023.
- I) Figures related to previous years have been re-arranged whenever considered necessary.

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(e) Financial spread sheet analysis for the latest audited financial statements;

Techno Drugs Ltd.
Statement of Financial Position
As at June 30, 2023

| Particulars | Amount | Percentage on Total Asset | Grand Total |
|---|----------------------|---------------------------------|----------------|
| ASSETS | | | |
| NON-CURRENT ASSETS | 3,825,522,959 | | 63.32% |
| Property, Plant and Equipments at Carrying Value | 3,586,136,067 | 59.36% | |
| Land & Land Development | 770,524,759 | 12.75% | |
| Building | 1,678,364,388 | 27.78% | |
| Plant & Machinery | 1,040,829,998 | 17.23% | |
| Furniture & Fixture | 22,026,432 | 0.36% | |
| Office Equipment | 3,664,922 | 0.06% | |
| Laboratory Equipment | 5,367,390 | 0.09% | |
| Motor vehicle | 1,859,828 | 0.03% | |
| Electric Equipments | 63,498,350 | 1.05% | |
| Intangible Assets | 7,222,755 | 0.12% | |
| ERP Software | 7,222,755 | 0.12% | |
| Investment In Share | 270,000 | 0.00% | |
| Capital Work In Progress | 179,878,620 | 2.98% | |
| Right-of-Use Assets | 52,015,516 | 0.86% | |
| CURRENT ASSETS | 2,215,732,793 | 36.68% | 36.68% |
| Inventories | 700,599,952 | 11.60% | |
| Raw Materials | 411,252,163 | 6.81% | |
| Packing Materials | 97,660,512 | 1.62% | |
| Store and Spare Parts | 4,751,454 | 0.08% | |
| Work in Process | 41,257,481 | 0.68% | |
| Finished Goods | 145,678,342 | | |
| Finished Goods for Govt. Tender | 238,536,250 | | |
| Advances, Deposits and Prepayments | 399,192,394 | 6.61% | |
| Advance Income Tax | 163,240,019 | 2.70% | |
| VAT Current Account | 41,041,090 | 0.68% | |
| Advances to Staff | 6,467,823 | 0.11% | |
| Advance for Rent | 285,000 | 0.00% | |
| Advance to C & F Agents | 2,356,781 | 0.04% | |
| Security Money | 27,960,322 | 0.46% | |
| Advance to Suppliers & Others | 97,376,427 | 1.61% | |
| L.C Margin for Raw Materials | 40,711,954 | 0.67% | |
| Bank Guarantee Margin for Tender Sales | 14,198,554 | 0.24% | |
| Prepaid Insurance | 5,554,424 | 0.09% | |
| Accounts Receivable | 789,714,772 | 13.07% | |
| Investment in FDR | 53,218,850 | 0.88% | |
| Cash and Cash Equivalents | 34,470,574 | 0.57% | |
| Total Assets | 6,041,255,752 | | 100.00% |
| EQUITY AND LIABILITIES | | | |
| SHAREHOLDER'S EQUITY | 2,612,349,280 | | 43.24% |
| Share Capital | 941,574,000 | 15.59% | |
| Revaluation Surplus | 487,437,890 | 8.07% | |
| Retained Earnings | 1,183,337,389 | 19.59% | |

| | | | |
|---|----------------------|--------------|----------------|
| NON-CURRENT LIABILITIES | 1,304,960,954 | | 21.60% |
| Deferred Tax Liability | 216,490,616 | 3.58% | |
| Long Term Loan Net of Current Maturity | 1,055,549,905 | 17.47% | |
| Lease Liabilities Net of Current Maturity | 32,920,433 | 0.54% | |
| CURRENT LIABILITIES | 2,123,945,519 | | 35.16% |
| Current Maturity of Lease Liabilities | 27,757,903 | 0.46% | |
| Current Maturity of Long Term Loan | 414,024,638 | 6.85% | |
| Short Term Loan | 1,187,853,989 | 19.66% | |
| Provision for Current Tax | 215,272,129 | 3.56% | |
| Accounts & Others Payable | 212,359,709 | 3.52% | |
| Trade & Others Payables | 78,063,172 | 1.29% | |
| Payable for Salary & Remuneration | 68,787,078 | 1.14% | |
| Payable for Utility Bill | 3,799,006 | 0.06% | |
| Payable for Audit Fees | 345,000 | 0.01% | |
| Vat Payable | 8,796,186 | 0.15% | |
| Provision for Bad Debts | 11,492,595 | 0.19% | |
| Interest Payable on Loan | 37,854,810 | 0.63% | |
| Advance against Export | 3,221,862 | 0.05% | |
| Liabilities for WPPF | 66,677,150 | 1.10% | |
| Total Equity and Liabilities | 6,041,255,752 | | 100.00% |

Techno Drugs Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended June 30, 2023

| Particulars | For the year ended Jun 30, 2023 | Percentage on Total Turnover | Grand Percentage |
|--|---------------------------------|------------------------------|------------------|
| Revenue | 2,733,477,105 | | 100% |
| Revenue | 2,733,477,105 | | |
| Less: Cost of Goods Sold | 1,573,642,291 | | 57.57% |
| Raw Materials consumed | 1,184,107,230 | 43.32% | |
| Packing Materials consumed | 143,811,916 | 5.26% | |
| Store and Spare consumed | 11,124,537 | 0.41% | |
| Factory Overhead | 426,018,387 | 15.59% | |
| Total Manufacturing Cost | 1,765,062,069 | 64.57% | |
| Opening Stock Work-In-Process | 38,944,550 | 1.42% | |
| Closing Stock Work-In-Process | 41,257,481 | 1.51% | |
| Cost of Goods Manufactured | 1,762,749,138 | 64.49% | |
| Opening Stock Finished Goods | 198,821,613 | 7.27% | |
| Finished Goods available for sale | 1,961,570,751 | 71.76% | |
| Cost of Sample Transferred to Selling Expenses | 3,713,868 | 0.14% | |
| Closing Stock Finished Goods for General Sales | 145,678,342 | 5.33% | |
| Closing Stock Finished Goods for Tender Sales | 238,536,250 | 8.73% | |
| Cost of Goods Sold | 1,573,642,291 | 57.57% | |
| Gross Profit | 1,159,834,813 | | 42.43% |
| Less: Operating Expenses | 620,877,889 | | 22.71% |
| Administrative Expenses | 171,451,255 | 6.27% | |
| Selling & Distribution Expenses | 449,426,634 | 16.44% | |
| Profit from Operation | 538,956,924 | | 19.72% |
| Less: Finance Expenses | 269,811,323 | 9.87% | |
| Add: Other Income | 2,859,050 | 0.10% | |
| Profit before WPPF and Tax | 272,004,652 | | 9.95% |
| Contribution to WPPF | 12,952,602 | 0.47% | |
| Profit before Tax | 259,052,049 | | 9.48% |
| Income Tax Expenses | 63,545,690 | | 2.32% |
| Current Tax | 54,063,724 | 1.98% | |
| Deferred Tax | 9,481,966 | 0.35% | |
| Net Profit After Tax | 195,506,359 | | 7.15% |

- (f) **Earnings Per Share (EPS) on fully diluted basis (with the total existing number of shares) in addition to the weighted average number of shares basis. Future projected Net Income should not be considered while calculating the weighted average EPS;**

As per audited financial statement for the year ended June 30, 2023

| Particulars | Amount in Taka |
|---|----------------|
| Net Profit after Tax | 195,506,359 |
| Total existing number of Share | 94,157,400 |
| Weighted average number of Share | 94,157,400 |
| Earnings per Share (EPS)-Fully Diluted Basis | 2.08 |
| Earnings per Share (EPS)-Weighted average no. of Share basis | 2.08 |

- (g) All extra-ordinary income or non-recurring income coming from other than core operations should be shown separately while showing the Net Profit as well as the Earnings Per Share;

As per audited financial statement for the year ended June 30, 2023

| Particulars | Amount in Taka |
|---|--------------------|
| Profit Before Tax | 259,052,049 |
| Less: Other Income | 2,859,050 |
| Profit before Income Tax except Other Income | 256,192,999 |
| Less: Income Tax Expense | 63,545,690 |
| Net Profit after Tax | 192,647,309 |
| No. of shares | 94,157,400 |
| Earnings per Share (EPS) | 2.05 |

- (h) **Quarterly or half-yearly EPS should not be annualized while calculating the EPS;**
This information is not applicable for TDL.
- (i) **Net asset value (with and without considering revaluation surplus or reserve) per unit of the securities being offered at the date of the latest audited statement of financial position.**
The Company has revalued its Land & Land Development.

As per audited financial statement for the year ended June 30, 2023

| Particulars | Amount in Taka |
|---|----------------------|
| Share Capital | 941,574,000 |
| Revaluation Surplus | 487,437,890 |
| Retained Earnings | 1,183,337,389 |
| Total Shareholders' Equity (with revaluation reserve) | 2,612,349,280 |
| Total Number of Ordinary Share | 94,157,400 |
| Net Assets Value (NAV) (with revaluation reserve) at BDT 10.00 per share | 27.74 |

As per audited financial statement for the year ended June 30, 2023

| Particulars | Amount in Taka |
|--|----------------------|
| Share Capital | 941,574,000 |
| Retained Earnings | 1,183,337,389 |
| Total Shareholders' Equity (without revaluation reserve) | 2,124,911,389 |
| Total Number of Ordinary Share | 94,157,400 |
| Net Assets Value (NAV) (without revaluation reserve) at BDT 10.00 per share | 22.57 |

- (j) **The Commission may require the issuer to re-audit the audited financial statements, if any deficiency or anomaly is found in the financial statements. In such a case, cost of audit should be borne by the concerned issuer.**
If require, TDL will bear the cost of audit.

(k) Following statements for the last five years or any shorter period of commercial operation certified by the auditors:-

(i) Statement of long term and short term borrowings including borrowing from related party or connected persons with rate of interest and interest paid or accrued;

Certification on statement of long term and short term borrowings including borrowing from related party or connected persons with rate of interest and interest paid or accrued of Techno Drugs Ltd.

After due verification, we certify that the long term and short term borrowings including borrowing from related party or connected persons with rate of interest and interest paid or accrued of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 made up as follows:

For the period ended 30 June, 2023

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2023 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,159,059,574 | 9.00% | 131,939,451 | 1,448,824 |
| AB Bank Ltd. | | | - | | 15,616 | - |
| IPDC Finance Ltd. | | | 40,201,612 | | 3,721,970 | - |
| Community Bank Ltd. | | | 205,642,095 | | 18,598,975 | 3,203,792 |
| IDLC Finance Ltd. | | | 64,671,262 | | 464,300 | 464,300 |
| Sub-Total | | | 1,469,574,542 | | 153,811,711 | 4,652,616 |
| One Bank Ltd. | Lender | Short Term | 591,127,427 | 9.00% | 32,620,001 | 30,805,539 |
| AB Bank Ltd. | | | 434,851,184 | 9.00% | 38,846,472 | - |
| LANKAN Alliance Finance Ltd. | | | 100,000,000 | 11.00% | 9,083,152 | 916,667 |
| Lanka Bangla Finance Ltd. | | | 40,310,107 | 9.50% | 3,437,193 | 679,051 |
| Meridian Finance Ltd. | | | 21,565,271 | 9.50% | 2,254,504 | 336,637 |
| Sub-Total | | | 1,187,853,989 | | 86,241,322 | 32,737,894 |
| Bank Charge & Other Fee | | | | | 5,936,791 | |
| Sub-Total | | | 2,657,428,532 | | 245,989,824 | |
| IPDC Finance Ltd. | Lender | Lease | 35,006,325 | | 6,113,943 | - |
| Grand Total | | | 2,692,434,856 | | 252,103,767 | 37,854,809 |

For the period ended 30 June, 2022

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2022 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,118,509,095 | 9.00% | 109,616,894 | 20,147,254 |
| AB Bank Ltd. | | | 2,343,657 | | 3,065,737 | - |
| IPDC Finance Ltd. | | | 45,333,069 | | 2,598,495 | - |
| Community Bank Ltd. | | | 282,010,796 | | 13,661,418 | - |
| Sub-Total | | | 1,448,196,617 | | 128,942,544 | 20,147,254 |
| One Bank Ltd. | Lender | Short Term | 472,233,344 | 9.00% | 39,657,122 | - |
| AB Bank Ltd. | | | 282,343,889 | 9.00% | 58,730,770 | - |
| LANKAN Alliance Finance Ltd. | | | 100,000,000 | 10.50% | 3,500,000 | - |
| Sub-Total | | | 854,577,233 | | 101,887,892 | - |
| Bank Charge & Other Fee | | | | | 4,696,717 | |
| Sub-Total | | | 2,302,773,849 | | 235,527,153 | |
| IPDC Finance Ltd. | Lender | Lease | 35,141,199 | | 5,629,130 | - |
| Grand Total | | | 2,337,915,048 | | 241,156,283 | 20,147,254 |

For the period ended 30 June, 2021

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2021 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 1,324,203,243 | 9.00% | 130,183,356 | - |
| AB Bank Ltd. | | | 67,399,204 | 9.00% | 10,523,564 | - |
| Sub-Total | | | 1,391,602,447 | | 140,706,920 | - |
| One Bank Ltd. | Lender | Short Term | 502,899,507 | 9.00% | 41,637,753 | - |
| AB Bank Ltd. | | | 472,687,411 | 9.00% | 54,912,320 | - |
| Sub-Total | | | 975,586,918 | | 96,550,073 | - |
| Bank Charge & Other Fee | | | | | 329,695 | |
| Sub-Total | | | 2,367,189,364 | | 237,586,688 | |
| IPDC Finance Ltd. | Lender | Lease | 15,836,070 | 10.75% | 4,811,897 | - |
| Grand Total | | | 2,383,025,434 | | 242,398,585 | - |

| For the period ended 30 June, 2020 | | | | | | |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2020 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
| One Bank Ltd. | Lender | Long Term | 1,217,922,644 | 13.00% | 37,168,695 | - |
| AB Bank Ltd. | | | 152,291,039 | 11.00% | 26,632,553 | - |
| Sub-Total | | | 1,370,213,683 | | 63,801,248 | - |
| One Bank Ltd. | Lender | Short Term | 527,910,835 | 13.00% | 43,408,385 | - |
| AB Bank Ltd. | | | 507,282,569 | 14.00% | 83,442,997 | - |
| Reliance Finance Ltd | | | 35,745,982 | 0.00% | 4,196,588 | - |
| Sub-Total | | | 1,070,939,386 | | 131,047,970 | - |
| Bank Charge & Other Fee | | | | | 235,460 | |
| Grand Total | | | 2,441,153,069 | | 195,084,678 | - |

For the period ended 30 June, 2019

| Name of Party | Nature of Relationship | Nature of Borrowing | Balance as 30 June, 2019 (BDT) | Interest Rate | Interest Paid (BDT) | Interest Accrued (BDT) |
|------------------------------------|------------------------|---------------------|--------------------------------|---------------|---------------------|------------------------|
| One Bank Ltd. | Lender | Long Term | 915,731,244 | 13.00% | - | - |
| AB Bank Ltd. | | | 230,803,471 | 11.00% | 38,713,653 | - |
| Sub-Total | | | 1,146,534,715 | | 38,713,653 | - |
| One Bank Ltd. | Lender | Short Term | 361,856,730 | 13.00% | 20,592,074 | - |
| AB Bank Ltd. | | | 470,070,399 | 14.50% | 93,052,560 | - |
| Sub-Total | | | 831,927,129 | | 113,644,634 | - |
| Bank Charge & Other Fee | | | | | 100,150 | |
| Grand Total | | | 1,978,461,844 | | 152,458,437 | - |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(ii) **Statement of principal terms of secured loans and assets on which charge have been created against those loans with names of lenders, purpose, sanctioned amount, rate of interest, primary security, collateral or other security, re-payment schedule and status;**

Certification on statement of principal terms of secured loans and assets on which charge have been created against those loans with names of lenders, purpose, sanctioned amount, rate of interest, primary security, collateral or other security, re-payment schedule and status of Techno Drugs Ltd.

After due verification, we certify that the principal terms of secured loans and assets on which charge have been created against those loans with names of lenders, purpose, sanctioned amount, rate of interest, primary security, collateral or other security, re-payment schedule and status of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|---|--------------------------------|----------------------|----------------------|--------------------|
| Names of lenders | ONE Bank Ltd. | | | | |
| Purpose | To purchase capital machinery and construction of building. | | | | |
| Sanctioned Amount | 116.90 Crore | 167.00 Crore | 167.00 Crore | 189.00 Crore | 189.00 Crore |
| Rate of Interest | 9.00% | 9.00% | 9.00% | 13.00% | 13.00% |
| Primary security, Collateral or other security | 967.50 decimal land, Factory Building and Machinery. | | | | |
| Re-payment schedule | 24 Quarterly Equal Installment | 20 Quarterly Equal Installment | | | |
| Status (Outstanding Balance Tk.) | 1,159,059,574 | 1,118,509,095 | 1,324,203,243 | 1,217,922,644 | 915,731,244 |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|--|--------------------|--------------------|--------------------|--------------------|
| Names of lenders | ONE Bank Ltd. | | | | |
| Purpose | Working Capital | | | | |
| Sanctioned Amount | 95.00 Crore | 81.00 Crore | 81.00 Crore | 60.00 Crore | 60.00 Crore |
| Rate of Interest | 9.00% | 9.00% | 9.00% | 13.00% | 13.00% |
| Primary security, Collateral or other security | Hypothecation all Fixed & Floating Assets, Mortgage of Land & Personal Guarantee of Directors. | | | | |
| Re-payment schedule | To be adjustment within one year. | | | | |
| Status (Outstanding Balance Tk.) | 591,127,427 | 472,233,344 | 502,899,507 | 527,910,835 | 361,856,730 |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|--|------------------|-------------------|--------------------|--------------------|
| Names of lenders | AB Bank Ltd. | | | | |
| Purpose | To purchase capital machinery. | | | | |
| Sanctioned Amount | 30.00 Crore | 30.00 Crore | 30.00 Crore | 30.00 Crore | 30.00 Crore |
| Rate of Interest | 9.00% | 9.00% | 9.00% | 11.00% | 11.00% |
| Primary security, Collateral or other security | 27 Decimal Land in the name of Techno Drugs Limited 402.40 Decimal Land, third party (Director) | | | | |
| Re-payment schedule | | | | | |
| Status (Outstanding Balance Tk.) | - | 2,343,657 | 67,399,204 | 152,291,039 | 230,803,471 |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|--|--------------------|--------------------|--------------------|--------------------|
| Names of lenders | AB Bank Ltd. | | | | |
| Purpose | Working Capital | | | | |
| Sanctioned Amount | 58.00 Crore | 78.80 Crore | 78.80 Crore | 78.80 Crore | 78.80 Crore |
| Rate of Interest | 9.00% | 9.00% | 9.00% | 14.00% | 14.50% |
| Primary security, Collateral or other security | Hypothecation all Fixed & Floating Assets, Mortgage of Land & Personal Guarantee of Directors. | | | | |
| Re-payment schedule | To be adjustment within one year. | | | | |
| Status (Outstanding Balance Tk.) | 434,851,184 | 282,343,889 | 472,687,411 | 507,282,569 | 470,070,399 |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|--|--------------------|---------------|---------------|---------------|
| Names of lenders | Community Bank Ltd. | | | | |
| Purpose | To purchase capital machinery. | | | | |
| Sanctioned Amount | 30.00 Crore | 30.00 Crore | | | |
| Rate of Interest | 9.00% | 9.00% | | | |
| Primary security, Collateral or other security | 133 Decimal Land in the name of Techno Drugs Limited 1901.09 Decimal Land in the name of Mr. Shah Jalal Uddin Ahmed | | | | |
| Re-payment schedule | By 33 Equal Monthly Installments | | | | |
| Status (Outstanding Balance Tk.) | 205,642,095 | 282,010,796 | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|----------------------------------|-------------------|---------------|---------------|---------------|
| Names of lenders | IPDC Finance Ltd. | | | | |
| Purpose | For Business Expansion | | | | |
| Sanctioned Amount | 5.00 Crore | 5.00 Crore | | | |
| Rate of Interest | 9.00% | 9.00% | | | |
| Primary security, Collateral or other security | 10% FDR on loan amount & others. | | | | |
| Re-payment schedule | By 60 Equal Monthly Installments | | | | |
| Status (Outstanding Balance Tk.) | 40,201,612 | 45,333,069 | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|---|---------------|---------------|---------------|---------------|
| Names of lenders | IDLC Finance Ltd. | | | | |
| Purpose | For Construction of Factory Building | | | | |
| Sanctioned Amount | 7.00 Crore | | | | |
| Rate of Interest | 9.75% | | | | |
| Primary security, Collateral or other security | Lien on FDR/Cash Security 2 Crore & Personal Guarantee. | | | | |
| Re-payment schedule | By 36 Equal Monthly Installments | | | | |
| Status (Outstanding Balance Tk.) | 64,671,262 | | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|---|--------------------|---------------|---------------|---------------|
| Names of lenders | LANKAN Alliance Finance Ltd. | | | | |
| Purpose | Working Capital | | | | |
| Sanctioned Amount | 10.00 Crore | 10.00 Crore | | | |
| Rate of Interest | 11.00% | 10.50% | | | |
| Primary security, Collateral or other security | 10% FDR on loan amount & others. | | | | |
| Re-payment schedule | Interest amount will be paid monthly & Principal amount equally on quarterly basis. | | | | |
| Status (Outstanding Balance Tk.) | 100,000,000 | 100,000,000 | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|---|---------------|---------------|---------------|---------------|
| Names of lenders | Lanka Bangla Finance Ltd. | | | | |
| Purpose | To meet Regular Business Capital for purchasing raw materials | | | | |
| Sanctioned Amount | 5.50 Crore | | | | |
| Rate of Interest | 9.50% | | | | |
| Primary security, Collateral or other security | 10% FDR on Principal Loan Amount. | | | | |
| Re-payment schedule | By 24 Equal Monthly Installments | | | | |
| Status (Outstanding Balance Tk.) | 40,310,107 | | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|-----------------------------------|---------------|---------------|---------------|---------------|
| Names of lenders | Meridian Finance Ltd. | | | | |
| Purpose | To meet Working Capital | | | | |
| Sanctioned Amount | 5.00 Crore | | | | |
| Rate of Interest | 9.50% | | | | |
| Primary security, Collateral or other security | 10% FDR on Principal Loan Amount. | | | | |
| Re-payment schedule | By 12 Equal Monthly Installments. | | | | |
| Status (Outstanding Balance Tk.) | 21,565,271 | | | | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|-----------------------------------|---------------|---------------|-------------------|---------------|
| Names of lenders | Reliance Finance Ltd | | | | |
| Purpose | To meet Working Capital | | | | |
| Sanctioned Amount | | | | 3.75 Crore | |
| Rate of Interest | | | | 11.00% | |
| Primary security, Collateral or other security | FDR on Principal Loan Amount. | | | | |
| Re-payment schedule | To be adjustment within one year. | | | | |
| Status (Outstanding Balance Tk.) | | | | 35,745,982 | |

| Particulars | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
|---|--|-------------------|-------------------|---------------|---------------|
| Names of lenders | IPDC Finance Ltd. (Lease) | | | | |
| Purpose | Purchase of Vehicles | | | | |
| Sanctioned Amount (Taka in lac) | 5.00 Crore | 5.00 Crore | 2.00 Crore | | |
| Rate of Interest | 9.00% | 9.00% | 10.75% | | |
| Primary security, Collateral or other security | Personal Guarantee of all Directors of Techno Drugs Ltd. | | | | |
| Re-payment schedule | By 60 Equal Monthly Installment | | | | |
| Status (Outstanding balance Tk.) | 35,006,325 | 35,141,199 | 15,836,070 | - | |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(iii) Statement of unsecured loans with terms and conditions;

Certification on statement of unsecured loans with terms and conditions of Techno Drugs Ltd.

This is to certify that Techno Drugs Ltd. did not take any unsecured loan from 1st July, 2018 to 30th June, 2023.

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(iv) Statement of inventories showing amount of raw material, packing material, stock-in-process and finished goods, consumable items, store and spares parts, inventory of trading goods etc.;

Certification on statement of inventories showing amount of raw materials, packing materials, stock-in process and finished goods, consumable items, store and spares parts, inventory of trading goods etc. of Techno Drugs Ltd.

After due verification, we certify that the statement of inventories showing amount of raw materials, packing material, stock-in process and finished goods, consumable Items, store and spare parts, inventory of trading goods etc. of Techno Drugs Limited from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Raw Materials | 411,252,163 | 329,178,572 | 242,468,409 | 172,468,409 | 134,789,450 |
| Packing Materials | 97,660,512 | 75,363,527 | 41,579,658 | 35,098,765 | 34,567,321 |
| Stock-In-Process | 41,257,481 | 38,944,550 | 30,243,780 | 21,143,780 | 21,567,892 |
| Finished Goods | 145,678,342 | 198,821,613 | 145,487,965 | 110,145,673 | 69,895,435 |
| Store and Spares Parts | 4,751,454 | 4,332,713 | 2,145,822 | 1,789,543 | - |
| Total | 700,599,952 | 646,640,975 | 461,925,634 | 340,646,170 | 260,820,098 |

| Particulars | Amount in Taka | | | | |
|--------------------------------------|----------------|---------------|---------------|---------------|---------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Finished Goods For Government Tender | 238,536,250 | - | - | - | - |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(v) Statement of trade receivables showing receivable from related party and connected persons;

Certification on statement of trade receivables showing receivable from related party and connected persons of Techno Drugs Ltd.

After due verification, we certify that the statement of trade receivables showing receivable from related party and connected persons of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| General | 789,714,772 | 707,183,113 | 482,461,395 | 319,159,692 | 174,751,972 |
| From related party | - | - | - | - | - |
| From connected persons | - | - | - | - | - |
| Total | 789,714,772 | 707,183,113 | 482,461,395 | 319,159,692 | 174,751,972 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(vi) Statement of any loan given by the issuer including loans to related party or connected persons with rate of interest and interest realized or accrued;

Certification on statement of any loan given by Techno Drugs Ltd. including loans to related party or connected persons with rate of interest and interest realized or accrued.

This is to certify that Techno Drugs Ltd. did not give any loan to related party or connected persons with rate of interest and interest realized or accrued from 1st July, 2018 to 30th June, 2023.

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(vii) Statement of other income showing interest income, dividend income, discount received, other non operating income;

Certification on statement of other income showing interest income, dividend income, discount received, other non operating income of Techno Drugs Ltd.

After due verification, we certify that the statement of other income showing interest income, dividend income, discount received, other non-operating income of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|----------------------------|------------------|-------------------|-------------------|-------------------|-------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Interest Income | 2,619,031 | 11,973,885 | 17,784,736 | 26,729,942 | 17,763,058 |
| Dividend Income | - | - | - | - | - |
| Discount Received | - | - | - | - | - |
| Other Non-operating Income | 245,679 | 955,230 | 564,825 | 1,234,560 | - |
| Total | 2,864,710 | 12,929,115 | 18,349,561 | 27,964,502 | 17,763,058 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(viii) Statement of turnover showing separately in cash and through banking channel;

Certification on statement of turnover showing separately in cash and through banking channel of Techno Drugs Ltd.

After due verification, we certify that the turnover showing separately in cash and through banking channel of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|-------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| In Cash | | - | - | - | - |
| Through Banking Channel | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |
| Total Turnover | 2,733,477,105 | 5,028,541,834 | 3,841,379,557 | 2,013,899,466 | 2,164,801,777 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(ix) Statement of related party transaction;

Certification on statement of related party transaction of Techno Drugs Ltd.

After due verification, we certify that the statement of related party transaction of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

A. Remuneration:

| Name | Nature of Transaction | Amount in (BDT) | | | | | | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|
| | | June 30, 2023 | | June 30, 2022 | | June 30, 2021 | | June 30, 2020 | | June 30, 2019 | |
| | | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued |
| Khaleda Akther Khan | Remuneration | - | - | - | - | 9,600,000 | 800,000 | 9,600,000 | 800,000 | 9,600,000 | 800,000 |
| Shah Jalal Uddin Ahmed | Remuneration | 12,000,000 | 12,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 | 12,000,000 | 1,000,000 |
| Mehreen Ahmed | Remuneration | 6,000,000 | 6,000,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 |
| Arefeen Raafi Ahmed | Remuneration | 6,000,000 | 6,000,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 | 6,000,000 | 500,000 |
| Total | | 24,000,000 | 24,000,000 | 24,000,000 | 2,000,000 | 33,600,000 | 2,800,000 | 33,600,000 | 2,800,000 | 33,600,000 | 2,800,000 |

B. Office Rent:

| Name | Nature of Transaction | Amount in (BDT) | | | | | | | | | |
|------------------------|-----------------------|-------------------|-------------------|-------------------|----------|-------------------|----------|-------------------|----------|-------------------|----------|
| | | June 30, 2023 | | June 30, 2022 | | June 30, 2021 | | June 30, 2020 | | June 30, 2019 | |
| | | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued | Total Amount | Accrued |
| Khaleda Akther Khan | Office Rent | 7,560,000 | 7,560,000 | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - |
| Shah Jalal Uddin Ahmed | Office Rent | 7,560,000 | 7,560,000 | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - | 7,560,000 | - |
| Total | | 15,120,000 | 15,120,000 | 15,120,000 | - | 15,120,000 | - | 15,120,000 | - | 15,120,000 | - |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(x) Reconciliation of business income shown in tax return with net income shown in audited financial statements;

Certification regarding reconciliation of business income shown in tax return with net income shown in audited financial statements of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023.

After due verification, we certify that the reconciliation of business income shown in tax return with net income before tax shown in audited financial statements of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|---|---------------------------|--------------------|--------------------|--------------------|--------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Net income before tax as per Audited Financial Statements | 259,052,049 | 651,021,511 | 592,893,101 | 314,787,693 | 369,825,166 |
| Add: Accounting Depreciation | 291,350,739 | 251,539,478 | 212,834,233 | 164,231,622 | 134,148,463 |
| Sub Total | 550,402,788 | 902,560,989 | 805,727,334 | 479,019,315 | 503,973,629 |
| Less: Tax Depreciation | 353,807,426 | 328,348,281 | 408,904,369 | 347,011,018 | 298,530,522 |
| Business Income/(Loss) | 196,595,362 | 574,212,708 | 396,822,965 | 132,008,297 | 205,443,107 |
| Business Income shown in Tax Return | Not due till date. | 574,212,708 | 396,822,965 | 132,008,297 | 205,443,107 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(xi) Confirmation that all receipts and payments of the issuer above Tk.5,00,000/- (five lac) were made through banking channel;

Certification on confirmation that all receipts and payments of Techno Drugs Ltd. above Tk. 500,000/- (Five Lac) were made through Banking Channel.

This is to certify that all receipts and payments of Techno Drugs Ltd. above Tk. 500,000 (Five Lac) were made through banking channel except few cases and circumstances from 1st July, 2018 to 30th June, 2023.

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(xii) Confirmation that Bank Statements of the issuer are in conformity with its books of accounts;

Certification on confirmation that Bank Statements of Techno Drugs Ltd. are in conformity with its books of accounts.

This is to certify that the bank statements of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 are in conformity with its books of accounts.

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

(xiii) Statement of payment status of TAX, VAT and other taxes or duties;

Certification on statement of payment status of TAX, VAT and other taxes or duties of Techno Drugs Ltd.

After due verification, we certify that the status of Tax, VAT and other taxes or duties of Techno Drugs Ltd. from 1st July, 2018 to 30th June, 2023 were as follows:

| Particulars | Amount in Taka | | | | |
|------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 | June 30, 2019 |
| Tax | 15,854,601 | 155,244,009 | 190,373,084 | 72,220,048 | 99,653,641 |
| VAT | 212,233,774 | 228,401,796 | 138,936,849 | 117,213,018 | 117,971,810 |
| Others Taxes or Duties | - | - | - | - | - |
| Total | 228,088,375 | 383,645,805 | 329,309,933 | 189,433,066 | 217,625,451 |

Place: Dhaka
Date: 27th September, 2023

Sd/-
ISLAM QUAZI SHAFIQUE & CO.
Chartered Accountants

CHAPTER (XXVII)

CREDIT RATING REPORT

Techno Drugs Limited**Credit Rating Report** (Agreement-2023-05-28-73176)

| Valid From | Valid Till | Rating Action | Long Term Rating | Short Term Rating | Outlook |
|----------------|----------------|----------------|------------------|-------------------|---------|
| April 07, 2023 | April 06, 2024 | Surveillance-5 | A | ST-2 | Stable |
| April 07, 2022 | April 06, 2023 | Surveillance-4 | A | ST-2 | Stable |
| April 07, 2021 | April 06, 2022 | Surveillance-3 | A- | ST-2 | Stable |

Date of Incorporation : September 09, 2009

Managing Director : Mr. Shah Jalal Uddin Ahmed

Authorized Capital : BDT 2,000.00 Million

Paid up Capital : BDT 941.57 Million

Bank Loan Limit : Short and Long Term **BDT 4,634.06 million**

Contact Analysts : Prosenjit Datta Kanongo prosenjit@emergingrating.com
Md. Harun Chowdhury harun@emergingrating.com

2023 Surveillance Review

Techno Drugs Limited

Major Rating Factors

Strengths

- Commercial production of new expansion facilities aiding in revenue growth
- Increasing product lines including human, veterinary and oncology drugs
- Experienced management team
- Decreasing leverage position

Challenge/ Risks

- On time completion of rest of the expansion plan
- Highly competitive market and counterfeit or look alike products
- Rising cost of raw materials

Rationale

Emerging Credit Rating Limited (hereafter referred to as 'ECRL') has affirmed **A** long term credit rating (Pronounced as Single A) and **ST-2** short term credit rating to Techno Drugs Limited (hereinafter referred to as 'TDL'). The outlook of the rating is **Stable**. The company is manufacturing variety of human and animal drug. The ratings are consistent with ECRL's methodology for this type of company. The rating is based on the audited financial of FY 2019-2022, bank information and other relevant information till the date of rating.

Techno Drug Limited was incorporated as a private limited pharmaceuticals company on September 09, 2009. Subsequently, the company converted into Public Limited Company vide EGM dated 18th August, 2019. Initially, the company was engaged in manufacturing of Animal Drug. Presently, the company is manufacturing variety of human and animal drug. Moreover, TDL has taken a master plan to set up additional unit under BMRE program at BK Bari, Gazipur over 1,300 decimal lands. The rest of the facilities are on construction and will go on to commercial production on stages. The final stage will be completed by December 2024, and commercial production will start by January 2025 as per the project schedule.

TDL's revenue climbed by 30.90% in FY2022, reaching BDT 5,028.54 million, owing to utilization of the increased production capacity facilitated by the partial completion of the expansion project. As per management correspondence, the new expansion unit has enabled the company to increase its production capacity by approximately 30.00%, which is reflected in the rising revenue trend. The cost of items sold followed this trend, growing as a result of increased expenses associated with raw materials and production. Operating costs increased by 43.69%, primarily due to increased employee-related expenses. Despite rising finance costs, the company achieved a significant net profit of BDT 479.78 million, a 32.92% rise year on year, largely compensating higher expenses.

Liquidity remained moderate over four years, with a current ratio of 1.08 times suggesting reasonable coverage of current liabilities. Total current assets climbed by 6.39% as inventories, receivables, and cash balance increased while current liabilities increased by 0.94 percent. On the other hand, the quick asset ratio fell slightly from 0.75 to 0.70. Moreover, In FY2022, the company's cash position improved significantly with a surplus cash flow of BDT 593.05 million.

In addition, the company's sustained performance increased cumulative retained earnings, boosting equity. Long-term debt gradually declined, resulting in a debt-to-equity ratio of 0.95 times in FY2022, down from 1.63 times in FY2021. Furthermore, OPBIT interest coverage ratio exhibited a comfortable coverage of the interest obligations by generated operating profit in 2022.

Techno Drugs Limited has been banking with multiple banks and financial institutions. As per sanction letters the company's total bank facility limit stood at BDT 4,634.06 million. The short-term loan facilities consisted by LC, BG, OD and time loan for the purpose of import raw materials and machineries, meet working capital requirements and the term loan for expansion of existing business. The company also received stimulus packages from both bank due to the pandemic. TDL's total loan outstanding liabilities were BDT 2,786.79 million as on the above mentioned dates. There is an overdue of BDT 7.95 million against the loan from IDLC Finance Limited. Against the availed facilities, the company has kept registered mortgage, personal guarantee of the directors, lien of FDR, registered irrevocable power of attorney etc. as securities.

The concern's **Stable** outlook represents current business set up, additional new facilities, distribution and management's experience. The future direction of the rating will depend on the ability to generate incremental revenue and profit margin, on time completion of expansion plans and proper utilization of new facilities.

Exhibit 1: Financial Highlights: Techno Drugs Limited

| FYE: June | 2022 | 2021 | 2020 | 2019 |
|------------------------------|-------------|-------------|-------------|-------------|
| Revenue (BDT in millions) | 5,028.54 | 3,841.38 | 2,013.90 | 2,164.80 |
| Revenue Growth (%) | 30.90 | 90.74 | (6.97) | 43.45 |
| COGS (BDT in millions) | 3,213.38 | 2,380.12 | 1,183.13 | 1,275.68 |
| Gross Profit Margin (%) | 35.01 | 101.17 | (7.26) | 43.23 |
| Operating Profit Margin (%) | 36.10 | 38.04 | 41.25 | 41.07 |
| Net Profit Margin (%) | 18.53 | 21.91 | 24.71 | 24.16 |
| Current Ratio (x) | 1.08 | 1.02 | 0.92 | 1.01 |
| Cash Conversion Cycle (Days) | 106 | 100 | 138 | 86 |
| Debt-to-Equity (x) | 0.95 | 1.63 | 2.39 | 2.53 |
| Interest coverage Ratio (x) | 3.78 | 3.68 | 2.68 | 3.56 |
| ROA (%) | 8.94 | 8.23 | 4.32 | 7.60 |
| ROE (%) | 19.72 | 24.90 | 16.04 | 28.97 |
| CFO (BDT in millions) | 2.27 | 0.12 | 0.06 | 0.06 |

FY2019-FY2022 data obtained from audited report

A. BUSINESS DESCRIPTION

A.1. Company Background

Techno Drug Limited was incorporated as a private limited pharmaceuticals company on September 09, 2009. Subsequently, the company converted into Public Limited Company vide EGM dated 18th August, 2019. As proprietorship concern Mr. Shah Jalal Uddin Ahmed established the manufacturing unit named as Techno Drug as a fast growing veterinary (Animal Health Division) pharmaceutical company in Bangladesh. Head office and Manufacturing unit located at 31, Segunbagicha, Dhaka, Bangladesh and its factory is located at Narsingdi and Gazipur. Commercial production started on July 01, 2010. Initially, the company was engaged in manufacturing of Animal Drug. Presently, the company is manufacturing variety of human and animal drug. Main activities of the company are Producer, Distributor, Service provider and Pharmaceutical preparations NES.

The company is on a mission as a pioneer of Veterinary and Oncology medicine manufacturing company in Bangladesh, it wants to uphold company goodwill and introduce new innovative Human and Veterinary medicines for the local and global market. TDL's vision is to become the global market leader in pharmaceutical formulation by developing and manufacturing quality medicines at affordable prices.

It has total 17 sales depots in Dhaka, Barishal, Bhairab, Bogura, Chattogram, Cumilla, Dinajpur, Faridpur, Jashore, Khulna, Kushtia, Mymensingh, Noakhali, Rajshahi, Rangpur and Sylhet. It has own vehicle support for medicine delivery and sales promotion.

Techno Drugs Ltd., an innovative pharmaceutical, providing chemotherapeutic agents mostly first ever produced in Bangladesh for the management of cancer. This company is backed by a group of well experienced pharmacists involved in formulation, R&D, QA, QC & overall management. The company is aimed at health professionals involved in anticancer management in Bangladesh. It will provide an access of essential information to the prescribers for selecting effective drugs necessary for chemotherapy. It will also provide proper dosing along with the adverse effects for single & multiple drug therapy. Techno Drugs Ltd. is developing leading positions in major therapeutic areas like oncology, cardiovascular, diabetes, immune suppressor, anesthetics, lifesaving antibiotics & contrast media in Bangladesh.

A.2. Product, Infrastructure and Process

This is a WHO affiliated and ISO 9001:2008 certified company. Main product variety includes animal and human as follows in the Dosage Forms a) Tablets, b) Capsules, c) Suspension, and d) Inject able,

1. Veterinary (112): Local sales only through distributors.
2. Human (72): Sales through distributors and local sales contribution 30%. It also provides drugs to government hospital and various health organizations as per requirement. **Export unit:** 100% export of the contraceptive product to India, Germany, Nepal and Philippine. Main buyers of the product are Helm AG (Germany) and Menufth Pharmaceuticals Ltd (India).
 - a. Anti-cancer (21); Entire product sold to locally through distributor. Rajshahi Medical College, Chittagong Medical College and NICR are the major clients of this segment of product.
 - b. Other authorized medicines

Top rated products of the company are Levonic Inj (cancer), MTREX and Epicin. Featured products are Tolfavet-Inj, Td Pyrin, Oxynil, Metafos, Caldimax and Biomix-DB.

1. **Veterinary:** The Company has already grown up globally through realization of exporting veterinary pharmaceuticals around the world. The company became a one of the leading veterinary pharmaceutical products manufactures in Bangladesh and abroad. It exported after completed the national demand also trying to save foreign currency to make a healthy and prosperous Bangladesh.

- Human:** The Company started manufacturing human medicines and got a satisfactory result in producing a number of Health Care Medicines like Antibiotics, NSAIDS, Antiulcerants, Gastro Intestinal Drugs, Antidiabetic Drugs, Cardiovascular Drugs, Respiratory Drugs, etc. The company has started manufacturing Anti-Cancer Drugs from the year 2010 and by this time which is accepted with satisfaction to the Doctors as well as Hospitals and Markets. It may be stated that this company is pioneer in manufacturing Oncology and contraceptive hormone (oral and injectable) Products with a remarkable goodwill. The company is exporting some medicines and in the field of Anti-Cancer Drugs a huge amount of money is saved by way of not importing those products which is directly beneficial to our countries economy.


A.3. Production capacity, Infrastructure and Process

The company utilizes machineries such as Hormone, Dispersing & Blending Isolator, Bin to Bin Transfer Arrangement, Case Blender, Roll Compactor, Sampling Canopy, Case Bleander, Material Handling Device, Rotary Tablet Compressor, Series Rotary, Utility Machinery, Quality control, Micro Biology, Product Development, Warehouse, Penicillin, Cephalosporin, Medical Device, General Production, Implant etc.

Current production capacities of human and animal medicine are 2.80 – 3.00 million tablet for Hormone Solid, 80,000 Hormone Injection, Cephalosporin Solid 500,000 pcs tablet, 300,000 pcs capsule, 30000 pcs dry syrup, Cephalosporin injection 30,000 pcs, Panicanil sold table 500000 pcs, capsule 300000 [cs, dry syrup 30000 pcs, Panicanil Injection 30,000 pcs per shift of operation. TDL has two separate units (Animal Drug and Human Drug) having two factories in Narsingdi located at Satir Para for Human Drug (Unit 1 Manufacturing of Human Drug: 75,000 sq ft) and another is at BSCIC for Animal Drug (Unit 2 Manufacturing of Veterinary Drug: 4,000 sft each of six storied building). Both factory buildings are equipped with modern machineries and modern facilities.

The plant and machines of TDL has been designed, procured and installed by reputed partners from Germany, Switzerland and UK and other reputed suppliers. Both the unit has its own utility infrastructure to adequately support manufacturing operations. For Unit-1 (Veterinary and Human Drug Unit), presently it has available Gas connection, own 3 Gas generators for 650, 930 and 150 KVA, purified water plant for pure water, own transformer facility of 5,000, 2,000, 1,500 KVA, For Unit-2 (Export oriented Drug production Unit), presently it has available Gas connection, own Gas generator for 300 KVA, purified water plant for pure water.

The manufacturing unit consists of 8 manufacturing sections for manufacturing 8 different dosage forms of 28 therapeutic classes with total number of 300+ products. Manufacturing process passes through following process



Storage: It has raw material warehouse for different types of items. Total storage area is about 2200 square feet which consists 1 room for under test raw material, 1 room for sampling booth, 1 room for quality control, 1 room for sensitive raw material, 1 room for dispensing booth and 1 room for general raw materials storage. It has heavy duty hydraulic trolley and drum lifting trolley for handle bulk material.

The supply chain is managed by raw material & packaging material with checking warehouse. If there is shortage, requisition is delivered to supply chain which is then approved by Head Office. The raw materials are imported from European Countries, China through L/C. After the raw materials are imported, it is checked by QC and QA departments. After passing the approved quality, the raw materials are dispersed for production. The production plan is being supplied from marketing department. For quality control, the company uses various machineries such as Laser Particle Size Analyzer, Ultrapure Water System, Electric Muffle Furnace, Universal Oven, Conductivity Meter, Tapped Density Tester, Fume Hood, Dissolution Tester, Analytical Balance, Bench top pH and mV meter etc.

A.4. Expansion of Existing Production Facilities

The physical facilities of existing plant located at Satir Para, Narsingdi is not sufficient to meet up the increasing demand of local and international demand. So, TDL has taken a master plan to set up additional unit under BMRE program at BK Bari, Gazipur over 1,300 decimal lands. The expansion projects will be equipped with modern facilities and state of the art machineries and technology to manufacture more sophisticated human and veterinary medicines. In order to support the additional products, TDL will also expand the existing 17 rental depots located in different area of Bangladesh.

Current scenario of expansion unit: The project land was invested as equity by the directors of the company. Land development work has been done. Majority of the civil construction has been completed and the remaining will be completed after installation of all the machineries. The construction of effluent treatment plant is under progress. TDL has already imported machineries and other machineries from Asia and Europe, as per project profile. And other supportive machineries will have procured very soon. The site has got all infrastructural facilities like water, power, gas, telephone, road communication etc, as per project profile. The company has completed construction and started commercial production of Hormone, Penicillin, Cephalosporin and Implant divisions as depicted in the table below. The rest of the facilities are on construction and will go on to commercial production on stages. The final stage will be completed by December 2024, and commercial production will start by January 2025 as per the project schedule.

Exhibit 4: Project Implementation Schedule as on July 2023

| Particulars | Hormone | Penicillin | Cephalosporin | Implant | General | Bio-tech | Medical Device | Tuberculosis |
|------------------------|-----------|------------|---------------|-----------|---------------|-----------------------------|-------------------|-----------------------------|
| Land & Development | Completed | | | | | | | |
| Civil Works | Complete | Complete | Complete | Completed | Completed | Completed | Completed | Completed |
| Foreign Procurement | Complete | Complete | Complete | Completed | Completed | Completed | Completed | 30% done [May ~ Sept/24] |
| Local Procurement | Complete | Complete | Complete | Completed | Completed | Completed | Completed | 30% done [May ~ Oct /24] |
| Fabrication & Erection | Complete | Complete | Complete | Completed | Completed | 50% done [May ~ Sept/24] | Completed | 30% done [May ~ Oct/24] |
| Installation | Complete | Complete | Complete | Completed | Completed | 30% done [May ~ Oct/24] | Completed | 20% done [May ~ Oct/24] |
| Trial Production | Complete | Complete | Complete | Completed | Dec/23 50% | Oct ~ Nov/ 24 | Jul ~ Sept/ 23 | Nov ~ Dec/ 24 |
| Commercial Production | Running | Running | Running | Running | Jan/24 50% | Dec/24 | Dec/23 | Jan/25 |


B. INDUSTRY ANALYSIS

Introduction

The pharmaceutical industry is one of the leading industries in Bangladesh. According to the Bangladesh Association of Pharmaceutical Industries, 257 licensed companies are operating their business across the country. Since the industry's inception, this industry has been contributing to the economy by meeting the local demand for medicine and generating skilled employment in this sector. At present, 98% of the local market is fulfilled by local companies. According to Bangladesh's drug and manufacturing association, about 150 manufacturers operate actively in the market these firms produce the generic, vaccine, anti-cancer, and hormone drugs. Though Bangladesh's domestic industry is proliferating, the export growth is not satisfactory compared to other export items. According to the Export Promotion Bureau, the total medicine export of Bangladesh for the financial year 2021-2022 was BDT 1,601 crore against the import of BDT 1,272 crore. The worldwide pharmaceutical market is predicted to develop at a 3-6% CAGR until 2025, reaching USD1.6 trillion in total value. This does not include COVID-19 vaccine spending, which is expected to make a total of USD157 billion through 2025.

Import and Export

Figure 1 represents Bangladesh's last ten years' import and export scenario. In recent years, the rise in pharmaceutical product export growth has been outstanding as the rising demand for COVID medicine, an anti-cancer drug, and covid-19 medicine.



Source: Export Promotion Bureau of Bangladesh (2021), and (Bangladesh Bank Publication, 2022)

Pharmaceutical goods' export increased from BDT 1,433 crore to BDT 1,601 in 2020-21 financial year crore due to rising demand for low-cost and covid-19 medicine. According to the Bangladesh Bank and export promotion bureau, the pharmaceutical industry export is growing by 17% annually. In FY2022, the growth rate has been 11.73%. In contrast, the industry's average import increased by 6%. Though medicine exports have increased over the years, import of raw materials have increased parallelly, which is the industry's major disadvantage. Despite its significant export potential, our pharmaceutical sector largely relies on imports for raw, and almost 90% of the raw materials are import-dependent.


Opportunities and Challenges of Export

The pharmaceutical business in Bangladesh has seen tremendous expansion in recent years, with practically all local demands being met by the local manufacturers. They contribute to the economy and play an essential part in achieving medical sufficiency. The following are the primary core strengths of the pharmaceutical industry.

Opportunities


The pharmaceutical industry of Bangladesh has vast opportunities, and some economic and social indicators fuel the opportunities of those industries; for instance, while having lower labor costs, increasing the per capita income will be a game changer for this industry. Moreover, some firms received FDA clearance, and exporting to developed countries along with the TRIPS agreement extension is an excellent opportunity for this sector. However, government policy support will be a vital issue for the pharmaceutical industry.

According to the Bangladesh Bureau of Statistics, per capita income increases by 9% yearly. Per capita income in 2021 was USD 2,503.04, and recent data from the Bangladesh Bureau of Statistics show that per capita income is USD 2,824. The growth in per capita income will encourage individuals to spend more on healthcare, which will positively influence the development of the pharmaceutical industry.



Source: (World Bank, 2021)

Exporting to developed countries is a significant possibility for Bangladesh, as just a few firms have received FDA clearance, which is a remarkable success for any local company. Square, Beximco, and Sk-F just acquired FDA clearance and approval from the EU and Australian health authorities. Following the Covid-19 outbreak, exports to developed countries have ramped up. The graph represents exports to developed countries based on statistics from Bangladesh's export promotion bureau.



Source: Export Promotion Bureau of Bangladesh (2021) and (The Daily Star, 2022)

The graph above shows that export to developed countries is not substantial since most pharmaceutical producers did not obtain clearance from the respective countries' authorities. Few businesses have acquired FDA and EU permission. Export to developed countries is a potential market for Bangladeshi pharmaceutical manufacturers. The World Trade Organization has extended the TRIPS agreement until 2033, allowing Bangladeshi manufacturers to create generic medicines without paying the expense of drug patents. Compared to competing countries, this will maintain industry competitiveness after graduation from LDC status. Furthermore, because of the beneficial TRIPS agreement, the Bangladesh government provides policy assistance to this business. Recently, the government announced

plans to create an API park in Munshiganj to attract investment and lessen reliance on imported raw materials. Bangladesh has the competitive advantage of manufacturing pharmaceutical products at a lower cost due to the lower labor cost. According to the Bangladesh Investment Development Authority, the manufacturing cost of medicines is 10 to 15% less than India and China, the two most significant contributors to pharmaceutical export sectors. At the same time, Bangladesh has the opportunity to export pharmaceutical products more than India and China.

Challenges of the Pharmaceutical Industry

The spread of counterfeit medicines in the domestic market represents a significant challenge for our pharmaceutical industry, and it has a detrimental effect on the company's reputation. The adjacent country, India, has emerged as a rival, but inferior medicine from some manufacturers is a significant threat to the market's ongoing growth. Production of counterfeit medicine has a long-term impact on health, resulting in many diseases of the human body. Presently, Bangladesh imports 99.5% of the overall pharmaceutical raw materials, mainly from China and India. API can also be purchased from a European source. Nevertheless, procuring API from a European country is costlier. Because of supplier concentration and high switching costs, the supplier has strong bargaining power. Due to the concentration of suppliers, the price negotiation benefit is very low for local manufacturers, and the recent devaluation of the taka causes a rise in the import cost of raw materials.

One of the primary disadvantages of this market is the unhealthy rivalry among local pharmaceutical companies. Pharmaceutical businesses spend a considerable amount of money on product marketing, yet most of the time, it involves harmful marketing rivalry. High marketing costs were invested in purchasing gifts for doctors and providing excessive commissions to various stakeholders. Unhealthy marketing competition raises the cost of medicine; which consumers eventually carry. The pharmaceutical sector can potentially be the second most successful contributor to exports in the foreseeable future. This industry has competitive advantages over other exporting countries, such as cheap manufacturing costs and a trained labor base, allowing it to compete in the export industry.

Furthermore, the Bangladesh government promotes this industry by adopting favorable actions to attract investment. To minimize the reliance on imports, the government has built an API park to generate medicinal raw materials, putting the pharmaceutical sector in a competitive position. However, there are several difficulties in this market that might obstruct the enormous growth of the pharmaceutical industry.

C. BUSINESS RISK ANALYSIS

C.1. Compliance Risk

The Company operates under the Drugs Ordinance, Companies Act, 1994, Directorate of Drug Administration (DDA) Regulations, Income Tax Ordinance 1984, Income Tax Rules 1984, Customs Act, 1969, Value Added Tax (VAT) Act 1991 and Value Added Tax (VAT) Rules 1991. Any abrupt changes of the policies made by the regulatory authorities may adversely affect the business of the Company. The company operates in a highly regulated market with registration of products, operational reviews and inspections required by Directorate of Drug Administration (DDA) periodically. The company received Certificate of Good Manufacturing Practice (GMP) for Pharmaceutical Products from the Directorate General of Drug Administration Ministry of Health & Family Welfare dated April 21, 2021.

C.2. Industry Risk

Pharmaceutical industry is a competitive industry in Bangladesh. The industry faces a number of aggressive competitors within the country and abroad as well. There are over 257 other manufacturers of pharmaceutical products in Bangladesh which the company has to compete with. The industry rivalry of this kind of business is moderate to high. The exit barrier is moderate to high with backward & forward linkages for many of the industry participants in Bangladesh. But the Bangladeshi industries have certain advantage in this industry over other

countries of the world, one of them are competitive labor price and availability. Due to low bargaining power the industry has to depend on international policy. Influence of medical practitioner, wholesalers and retail outlet also dominate the product of certain companies.

Bangladesh's pharmaceutical sector largely relies on imports for raw, and almost 90% of the raw materials are import-dependent which leads to higher costs, risk due to change in international policy, import regulation, exchange rate risks etc. However, an API Industrial Park is being set up by the Government at Munshiganj, 37 Km from the capital city Dhaka. The project is being implemented on 200 acres of land. There will be 42 plots in which Pharmaceutical Ingredient Manufacturing Industrial units will be set up. Producing the API locally will decrease the cost of locally manufactured drugs and it will add to the cost advantage for exports.

C.3. Technology Risk

Technology always plays a vital role for each and every type of business. Better technology can increase productivity and reduce costs of production. Firms are exposed to technology risks when there are better technologies available in the market than the one used by the company which may cause operational inefficiency. TDL has adopted latest technology according to its needs committed in maintaining quality and brand image. In connection with this, TDL has imported machinery from European countries such as Spain, Korea, China and also Asian countries such as Indonesia, Malaysia etc. to maintain manufacturing quality and standard. For quality maintaining, the entity follows the GMP guideline. The inventory is handled by QA and QC where temperature, quality, IPQC is checked before producing the medicines.

C.4. Operating Risk

The major requirements for smooth operations of pharmaceuticals industry are continuous power support; smooth functioning of the machineries and efficient & quality performance of the workers. The profitability of the company can be adversely affected from unavailability or increase in price of raw materials of pharmaceutical products, natural calamities like flood, cyclone, and earthquake. These events are likely to hamper the normal business operation of the entity and can adversely impact the profitability of TDL. TDL has arranged back up power support for its plants. The company has installed high-tech and latest machineries at its plants. In order to ensure efficient and quality performance of tasks, it has a good number of SOPs and well-trained staff.

C.5. Changes in National and International Policy

Bangladesh and other LDCs are exempted from patent protection by WTO for an extended period until 2033 (from original 2016). Bangladesh is allowed to produce any patented medicines without taking prior permission from innovator. However, since Bangladesh is looking forward to graduating from LDC by 2026, Bangladesh is likely to lose the patent exemption facility 7 years before the expiration date. Which may stop the development of the pharmaceutical industry in Bangladesh because if Bangladesh loses the benefits of the TRIPS agreement, pharmaceutical companies will have to enact new patent laws. As a result, manufacturing of many types of generic medicine is likely to cease. If domestic manufacturers want to maintain production of these medicines, they may have to pay royalties on patents. As a result, the overall price of medicine in Bangladesh may increase. Otherwise companies will face patent violations and exports will be severely hampered.

In addition, the pharmaceuticals industry in Bangladesh is highly regulated as compared to other industries due to its impact on the citizens. As Per the Drugs (Control) Ordinance, 1982, The Government may, by notification in the official Gazette, fix the maximum price at which any medicine may be sold, and can also fix the maximum price at which any pharmaceutical raw material may be imported or sold. This could limit the profitability of the pharmaceutical manufactures since they cannot increase the price if costs increase.

C.6. Interest Rate Risk

As TDL uses credit facilities from various financial institutions, it is exposed to interest rate risks. The Bangladesh Bank (BB) has removed the previously imposed interest rate cap of 6%-9% and introduced a reference rate driven by market forces, which will be regulated based on the average treasury bills rate effective from July 1, 2023. This could have an adverse impact on the finance cost of the company in the coming years.

C.7. Exchange Rate Risk

Since TDL procures some of its raw materials from international market, and also exports in the international markets, it does have exposure in exchange rates such as the USD/Euro/Pound. Recent appreciation of USD against BDT has had an adverse impact on the raw material costs of the company. Although, the export proceeds would have been positively impacted by this, the company did not generate any export revenue during the year.

D. FINANCIAL RISK ANALYSIS

The rating process was based on qualitative aspects which are based on the company's policies in relation with the operating strategies, financial leverage and ultimate financial goals of the companies. For this purpose of the overall financial risk assessment of the company, ECRL divided the financial portion into five different criteria which are Profitability Analysis, Liquidity Analysis, Cash flow Analysis, Asset Management, Capital Structure, and overall Financial Flexibility. Detailed analysis is presented below:


D.1. Profitability

Exhibit 2: Selected Indicators: Techno Drugs Limited

| FYE: June | 2022 | 2021 | 2020 | 2019 |
|-------------------------------------|-------------|-------------|-------------|-------------|
| Revenue (BDT in Millions) | 5,028.54 | 3,841.38 | 2,013.90 | 2,164.80 |
| Revenue Growth (%) | 30.90 | 90.74 | (6.97) | 43.45 |
| COGS (BDT in Millions) | 3,213.38 | 2,380.12 | 1,183.13 | 1,275.68 |
| COGS Growth (%) | 35.01 | 101.17 | (7.26) | 43.23 |
| Gross Profit Margin (%) | 36.10 | 38.04 | 41.25 | 41.07 |
| Operating Profit Margin (%) | 18.53 | 21.91 | 24.71 | 24.16 |
| Net Profit Margin (%) | 9.54 | 9.40 | 8.12 | 10.45 |
| Net Profit After Tax (BDT Millions) | 479.78 | 360.94 | 163.61 | 226.28 |
| ROA (%) | 8.94 | 8.23 | 4.32 | 7.60 |
| ROE (%) | 19.72 | 24.90 | 16.04 | 28.97 |

FY2019-FY2022 data obtained from audited report

The revenue of TDL has been experiencing a remarkable growth trajectory for the last two years consecutively. In FY2022, the revenue of company surged by 30.90% and stood at BDT 5,028.54 million from BDT 3,841.38 million in the previous year. Such a significant growth was achieved due to utilization of the increased production capacity facilitated by the partial completion of the expansion project. As per management correspondence, the new expansion unit has enabled the company to increase its production capacity by approximately 30.00%. However, although the company is involved in exporting its products, 100% of the revenue was generated from local sales during the period. The cost of goods sold has followed a similar trajectory to the revenue figures. As a manufacturing company, expenses related to raw materials, factory overhead, and other costs have increased significantly in tandem with the revenue growth. Due to the nature of the industry, majority of the raw materials of the company are imported. Hence, global inflation and appreciation of BDT against USD has adversely affected the raw material cost of the company. As a consequence, the growth of the cost of goods sold outpaced the revenue growth, leading to a slightly lower gross profit margin compared to the previous year.



Meanwhile, TDL exhibited a 43.69% increase in its total operating costs including administrative costs, and selling and distribution costs. The major driver of operating cost of the company are employee related cost since 39.86% of the total administrative costs, and 68.93% of the total selling and distribution costs relates to Salary, allowance & other benefits to employees. With the increase in production capacity and expansion of the overall operation, administrative salary expenses demonstrated a substantial increase of 50.01%, whereas selling and distribution-related salary costs experienced a growth of 43.10%. Notably, all the cost items of the company exhibited considerable increase in FY2022. This led to a moderate fall in operating profit margin from 21.91% in FY2021 to 18.53% in FY2022. The profitability of TDL further shrunk by higher finance costs due to higher utilization of debt finance during the year and lower non-operating income. The augmented revenue stream effectively offset the rising direct and indirect expenses, culminating in a notable net profit of BDT 479.78 million in FY2022, representing a substantial increase of 32.92% from BDT 360.94 million recorded in the preceding year. As a consequence, the net profit margin has experienced a marginal increase in the latest year under review. Meanwhile, the return on assets (ROA) and return on equity (ROE) shows adequate utilization of its assets and equity.

Exhibit 3: Selected Indicators: Techno Drugs Limited

| FYE 31 December | Year-1 | | | Year-2 | | | Year-3 | | |
|-------------------------------------|----------|----------|----------|----------|----------|----------|-----------|----------|----------|
| | *50% | *75% | 100% | *50% | *75% | 100% | *50% | *75% | 100% |
| Capacity Utilization | | | | | | | | | |
| Revenue (BDT in millions) | 2,493.13 | 3,739.69 | 4,986.25 | 2,825.55 | 4,238.32 | 5,651.09 | 30,853.56 | 4,628.03 | 6,170.71 |
| COGS (BDT in Millions) | 1,296.36 | 1,944.53 | 2,592.71 | 1,453.24 | 2,179.85 | 2,906.47 | 1,572.03 | 2,358.05 | 3,144.06 |
| Operating Income (BDT in millions) | 233.61 | 831.99 | 1,430.38 | 373.44 | 1,059.59 | 1,745.75 | 478.75 | 1,235.41 | 1,992.08 |
| Net Profit After Tax (BDT millions) | (12.61) | 376.34 | 765.29 | (28.89) | 417.11 | 863.11 | 70.53 | 562.36 | 1,054.19 |
| Gross Profit Margin (%) | 48.00 | 48.00 | 48.00 | 48.57 | 48.57 | 48.57 | 49.05 | 49.05 | 49.05 |
| Operating Profit Margin (%) | 9.37 | 22.25 | 28.69 | 13.22 | 25.00 | 30.89 | 15.52 | 26.69 | 32.28 |
| Net Profit Margin (%) | (0.51) | 10.06 | 15.35 | (1.02) | 9.84 | 15.27 | 2.29 | 12.15 | 17.08 |
| Return On Assets (%) | - | - | 27.43 | - | - | 25.83 | - | - | 27.43 |
| Return On Equity (%) | - | - | 10.96 | - | - | 11.90 | - | - | 10.96 |

Year-1 to Year-3 projected data of expansion unit obtained from project profile

*ECRL Projections

In addition of existing production facilities of Techno Drugs Limited, the company had taken a master plan to set up additional unit under BMRE program at BK Bari, Gazipur over 935 decimal lands. The expansion unit will be utilized to produce anthelmintics, antibiotic, antidepressant, antidepressant, antifibrinolytic, and steroid products. According to the projection done by the management of TDL, there will be a continuous growth in terms of revenue from the Year-1 to Year-3. In the Year-1, TDL's projected revenue will be BDT 4,986.25 million through 100% capacity. The projected revenue is in addition of existing projects. As per project data, the

projected gross profit will range from 48% to 49.05% for the first 3 financial years. However, the projected operating profit and net profit will fluctuate due to utilization of production capacity. The company has completed construction and started commercial production of Hormone, Penicillin, Cephalosporin and Implant divisions. The rest of the facilities are on construction and will go on to commercial production on stages. The final stage will be completed by December 2024, and commercial production will start by January 2025 as per the project schedule.


D.3. Liquidity & Cash Flow Coverage

Exhibit 4: Selected Indicators: Techno Drugs Limited

| FYE: June | 2022 | 2021 | 2020 | 2019 |
|------------------------------|--------|--------|--------|--------|
| Cash Ratio (x) | 0.08 | 0.02 | 0.14 | 0.16 |
| Current Ratio (x) | 1.08 | 1.02 | 0.92 | 1.01 |
| Quick Assets Ratio (x) | 0.70 | 0.75 | 0.71 | 0.77 |
| Cash Conversion Cycle (Days) | 106 | 100 | 138 | 86 |
| CFO (BDT in Millions) | 593.05 | 277.79 | 151.87 | 119.27 |
| CFO Debt Coverage (x) | 0.27 | 0.12 | 0.06 | 0.06 |

FY2019-FY2022 data obtained from audited report

Over the past four years, the company's liquidity position has remained at a moderate level, with a current ratio of 1.08 times, in comparison to its current liabilities at the end of FY2022. The current assets demonstrate a moderate coverage of the current liabilities, indicating a stringent working capital condition. With the increase of closing stock of inventories, receivables and cash balance, and the decrease of investment in FDR and advance, deposit and prepayments, total current assets of the company showed an overall increase of 6.39% in FY2022. On the other hand, with the increase in current maturity of lease liabilities and long term loan, accounts and other payable and, decrease of short term loan, provisions and WPPF liabilities, the current liabilities displayed a marginal incline of 0.94% in FY2022. As a consequence, there was a marginal improvement in the current ratio in FY2022. In the meantime, the due to the increase in closing stock of inventories, the quick asset ratio declined marginally from 0.75 in FY2021 to 0.70 times in FY2022. The cash conversion cycle of the company slightly increased from 100 days in FY2021 to 106 days in FY2022 mainly influenced by the increase in inventory and receivables at the year end.



The cash position of the company noticeably improved in FY2022 as the company generated surplus cash flow of BDT 593.05 million from operating activities facilitated by higher payments received from customers as compared to payments made to suppliers and others. However, the cash flow showed 27% coverage of the total debt of the company.


D.4. Leverage & Capital Structure

Exhibit 5: Selected Indicators: Techno Drugs Limited

| FYE: June | 2022 | 2021 | 2020 | 2019 |
|---------------------------------------|------|------|------|------|
| Debt-to-Equity (x) | 0.95 | 1.63 | 2.39 | 2.53 |
| OPBIT Interest Coverage ratio (x) | 3.78 | 3.54 | 2.55 | 3.43 |
| Total Liabilities to Total Assets (x) | 0.55 | 0.67 | 0.73 | 0.74 |
| Long Term Debt Ratio (x) | 0.40 | 0.71 | 1.02 | 1.30 |
| Short Term Debt Ratio(x) | 0.55 | 0.93 | 1.37 | 1.23 |

FY2019-FY2022 data obtained from audited report

The consistent profitability of the company has enlarged the cumulative retained earnings of the company which ultimately strengthened the company's equity base over the years. On the other hand, while the short term debt remained stable, with regular repayment, long term debt of the company is gradually decreasing. Consequently, the leverage risk of the company has consistently decreased over the years and in FY2022 the debt to equity ratio stood at 0.95 times down from 1.63 times in the previous year. Furthermore, the company finished construction on various ongoing projects that added to the asset base growing it higher in FY2022. OPBIT interest coverage ratio exhibited a comfortable coverage of the interest obligations by generated operating profit in 2022.



D.5. Bank Facilities & Credit History

Exhibit 6: Bank Facilities: Techno Drugs Limited

| Bank | Mode | Limit (BDT in Million) | Outstanding (BDT in Million) |
|---|------------------|------------------------|------------------------------|
| AB Bank Limited (As on June 30, 2023) | OD | 150.00 | 152.45 |
| | L/C | 250.00 | - |
| | Rev. TR | 200.00 | 5.65 |
| | Rev. TL | 230.00 | 225.91 |
| | Rev. BG | 100.00 | 17.00 |
| | Sub-Total | 930.00 | 434.85 |
| One Bank Limited (As on June 27, 2023) | Term Loan-1 | 268.38 | 268.71 |
| | Term Loan-2 | 599.88 | 600.63 |
| | Term Loan-3 | 198.28 | 198.53 |
| | Term Loan-4 | 92.52 | 92.64 |

| | | | |
|---|---------------------------|-----------------|-----------------|
| | SLC/ULC | 500.00 | 80.80 |
| | PAD | (500.00) | - |
| | Acceptance | (500.00) | 11.40 |
| | LTR | (475.00) | 96.20 |
| | Forced Loan | (71.60) | 75.60 |
| | Time Loan-1 | (50.00) | - |
| | Time Loan-2 | 200.00 | 203.70 |
| | Time Loan-3 | 50.00 | 30.40 |
| | Overdraft | 200.00 | 204.74 |
| | Bank Guarantee | 300.00 | 48.00 |
| | SLC | 475.00 | - |
| | ULC | (475.00) | - |
| | Acceptance | (475.00) | - |
| | Time Loan-4 | 95.00 | - |
| | Time Loan-5 | 100.00 | - |
| | Sub-Total | 3,079.06 | 1,911.35 |
| Community Bank Limited (As on June 30, 2023) | Term Loan (Green Finance) | 300.00 | 208.80 |
| | Sub-Total | 300.00 | 208.80 |
| Meridian Finance & Investment Limited (As on June 30, 2023) | Term Finance | 50.00 | 21.90 |
| | Sub-Total | 50.00 | 21.90 |
| LankaBangla Finance Limited (As On June 30, 2023) | Term Finance | 55.00 | 41.49 |
| | Sub-Total | 55.00 | 41.49 |
| Lankan Alliance Finance Limited (As on June 30, 2023) | Short Term Loan | 100.00 | 100.00 |
| | Sub-Total | 100.00 | 100.00 |
| IPDC Finance Limited (As On June 30, 2023) | Term Loan | 50.00 | 4.27 |
| | Sub-Total | 50.00 | 4.27 |
| IDLC Finance Limited (As on July 05, 2023) | Term Loan | 70.00 | 64.13 |
| | Sub-Total | 70.00 | 64.13 |
| | Grand Total | 4,634.06 | 2,786.79 |

Techno Drugs Limited has been banking with multiple banks and financial institutions. As per sanction letters the company's total bank facility limit stood at BDT 4,634.06 million. The short-term loan facilities consisted by LC, BG, OD and time loan for the purpose of import raw materials and machineries, meet working capital requirements and the term loan for expansion of existing business. The company also received stimulus packages from both bank due to the pandemic. TDL's total loan outstanding liabilities were BDT 2,786.79 million as on the above mentioned dates. There is an overdue of BDT 7.95 million against the loan from IDLC Finance Limited.

D.6. Collateral and Security

D.6.1. AB Bank Limited

The Company kept its fixed assets (Land and building) & other as collateral against bank loan from AB Bank Ltd, Kakrail Branch, Dhaka.

Exhibit 7: Registered List of Collateral

(Amount BDT in Millions)

| Particulars | MV |
|--|---------------|
| 8.02 katha land along with three-storied office building with warehouse; 31, Segunbagicha, Dhaka | 223.15 |
| 20.625 decimal land with 5000 square feet tin shed structure, plot 27, 28, BSCIC | 11.34 |
| 20.625 decimal land plot along two separate building (2 storied & 4 storied); Plot 17, 18, BSCIC | 45.11 |
| 15 decimals land along with factory building at Khatian no: Sabek-1423, Plot no: Sabek-1371, Narsingdi. | 29.89 |
| 8.50 decimals land with warehouse at Khatian no: sabek-1036, R.S.-1755, Bujarat-8156, Plot no: sabek-1367, R.S.-8248, Narsingdi. | 40.67 |
| 12 decimal land, Narsingdi | 19.20 |
| 365.50 decimal land along with 3 storied buildings and other constructions | 130.34 |
| 15 decimal land along with 3 storied factory building, Narsingdi | 21.00 |
| Total BDT in Millions | 520.70 |

Security and conditions:

- Personal guarantee of all directors of the company
- Registered 1st ranking Pari-Passu Charge with with RJSC&F by way of hypothecation of all fixed and floating assets of the company (both present and future) covering bank's full exposure.
- Post-dated cheques

D.6.2. One Bank Limited

- Demand Promissory Note and Letter of Continuity each for BDT 3,450.00 million
- Letter of Trust Receipt
- Counter Guarantee against BG facility
- Lien of OBL FDR BDT 0.20 million with letter of lien and encashment
- Registered mortgage of 967.50 decimal lands with all structured situated on Gazipur.
- Registered irrevocable general power of attorney of 967.50 decimal lands.
- Personal guarantee of the directors of the company.

D.6.3. Community Bank Bangladesh Limited

- Registered mortgage with RIGPA of total 2,034.09 decimal land
- Charge with RJSC&F covering the entire limit on all Fixed and Floating Assets
- Personal Guarantee of all Directors of the Company
- MICR Cheque covering the entire facility amount by Community Bank Bangladesh Limited to Techno Drugs Limited
- Duly signed Standard Security & Charge Documents as applicable

D.6.4. Meridian Finance & Investment Limited

- Cash security of BDT 5.00 million
- Personal guarantee of the directors
- 12 post-dated cheques each covering monthly installments amount

D.6.5. LankaBangla Finance Limited

- Demand promissory note with all usual charge documents
- TDR of 10% of the loan amount
- Hypothecation on all present and future fixed and floating assets
- Personal guarantee of the directors
- 100% insurance coverage of the total finance amount

D.6.6. Lankan Alliance Finance Limited

- 10% lien on FDR
- Insurance policy over stocks
- Personal guarantee of the directors

D.6.7. IPDC Finance Limited

- 10% lien on FDR
- Hypothecation on all present and future fixed and floating assets
- Personal guarantee of the directors

D.6.8. IDLC Finance Limited

- Personal guarantee of the directors
- Lien on FDR

E. MANAGEMENT AND OTHER QUALITATIVE FACTORS

The overall policy and strategic management function is being performed by Managing Director of the company. All other decisions of the company and daily operations are also taken by the Managing Director, Chairman and qualified work team. Overall business operation, policy management and strategic function are followed by company's policy.

Mr. Shah Jalal Uddin Ahmed, is the key person of the company who obtained his M. Pharm degree from Dhaka University in 1977. Initially he started his career as a Lecturer at Barisal Medical College, Barisal in 1979. Afterward he joined in Oponin Pharma Limited and worked there for 16 years. Then he started his own venture, i.e., Techno Drug (TD) in 1995. Mr. Ahmed has been engaged in creation of new drug in the medical arena of the country.

Mrs. Khaleda Akhter Khan, Chairperson of the company is engaged in this line of business for a considerable time of period. Mrs. Khan is a Biological Science graduate and started her career with Agrani Bank Ltd. Later she joined in Techno Drug as Finance Director. Ms. Mehreen Ahmed has obtained her B. Pharma Degree from Asia Pacific University of Bangladesh Limited. Currently Ms. Ahmed is pursuing her higher education in Pharmacy in United Kingdom. Mr. Arefeen Raafi Ahmed is devoted himself to successfully run their business operation smoothly. This company is backed by a group of well experienced pharmacists involved in formulation, R&D, QA, QC & overall management.

E.1. Human Resources

At present total 1,586 numbers of employees working in this company in different segment of work as per company hierarchy. Out of total employees, 142 people are working in head office, 565 working in factory and rest 879 are in field. The company provides free food subsidy for the factory people from own canteen arrangement, yearly festival bonus along with monthly salary. After completion of expansion projects additional employees will be employed.

F. COMPANY INFORMATION

Shareholding Positions

| Name of Shareholders | Designation | Number of Shares | Shareholding Percentage |
|------------------------|-------------------|-------------------|-------------------------|
| Khaleda Akhter Khan | Chairman | 7,475,000 | 7.94 |
| Shah Jalal Uddin Ahmed | Managing Director | 59,455,000 | 63.14 |
| Mehreen Ahmed | Director | 4,485,000 | 4.76 |
| Arefeen Raafi Ahmed | Director | 4,485,000 | 4.76 |
| Others Shareholders | Share Holder | 18,257,400 | 19.40 |
| Total | | 94,157,400 | 100.00 |

Office Address

Corporate Office : 31, Segunbagicha Dhaka-1000,
Factory : Satir Para, Narsingdi and BK Bari, Gazipur
Phone : PABX: 8356037. 8356038; Factory: 062862842, 062862843
Fax : 880-2-8355821
E-mail : techno-drugs@hotmail.com; Web site: www.technodrugsLtd.com

List of Abbreviation

| | | | |
|------|--------------------------------|-----|--------------------------|
| ECRL | Emerging Credit Rating Limited | TDL | Techno Drugs Limited |
| MT | Metric Ton | ROA | Return on Asset |
| ROE | Return on Equity | CFO | Cash Flow from Operation |



EMERGING
Credit Rating Ltd
an independent house of risk assessment

April 28, 2024

To
Mr. Shah Jalal Uddin Ahmed
Managing Director
Techno Drugs Limited
31, Segunbagicha Dhaka-1000,

Subject: Credit Rating Extension of "Techno Drugs Limited"

Dear Sir,

We are pleased to inform you that Emerging Credit Rating Limited (ECRL) has extended the following rating to **"Techno Drugs Limited"**.

| Valid From | Valid Till | Rating Action | Long Term | Short Term | Outlook |
|----------------|--------------|----------------|-----------|------------|---------|
| April 07, 2024 | May 20, 2024 | Surveillance-5 | A | ST-2 | Stable |

The Long Term and Short Term ratings are valid up to limit expiry date or **May 20, 2024**, whichever is earlier. The rating may be changed or revised prior to expiry, if warranted by extraordinary circumstances in the management, operations and/or performance of the entity rated.

We hope the rating will serve the intended purpose of your organization.

Yours Sincerely,

Arifur Rahman, FCCA, FCA, CSAA
Chief Executive Officer



SHAMS Rangs, House-104, Park Road, Level A1, A2 & A5, Baridhara, Dhaka -1212
Phone : 880 2 986 0911, +880 2 986 0897, Fax: +880 2 986 0828, Web: www.emergingrating.com

CHAPTER (XXVIII)

PUBLIC ISSUE APPLICATION PROCEDURE

Step-1 (Applicant)

1. An applicant for public issue of securities shall submit an application/buy instruction to the Stockbroker/ Merchant Banker where the applicant maintains customer account, within the cut-off date (i.e. the subscription closing date), which shall be **commenced after 20 (twenty) working days and remain open up to 25th (twenty fifth) working days** from the date of publication of an abridged version of the prospectus.
2. The application/buy instruction may be submitted in prescribed paper or electronic form, which shall contain the Customer ID, Name, BO Account Number, Total Amount and Category of the Applicant. At the same time:
 - a) Non-Resident Bangladeshi (NRB) applicants shall:
 - Apply to Stockbroker/ Merchant Banker through BDT/NITA and provide bank certificate evidencing remit of foreign currency in the ESS;
 - Provide relevant documents in ESS in supporting of NRB.
 - b) Eligible investors shall submit an application through the electronic subscription system of the exchange(s) and deposit the full amount intended to subscribe by the method as determined by exchange(s).
 - c) The General Public and Non-resident Bangladeshi (NRB) applicants shall submit the application in the electronic subscription system of the exchange(s) through the Stockbrokers/Merchant Bankers where the applicant maintains customer account.

Step-2 (Intermediary)

3. The registered Stock broker/Merchant Banker in the ESS shall:
 - a) Post the amount separately in the customer account equivalent to the application money;
 - b) Accumulate all the applications/buy instructions received up to the cut-off date and transfer the amount to their respective Consolidated Customer Account;
4. The registered Stockbroker/Merchant Banker in the ESS shall prepare category wise lists of the applicants containing Customer ID, Name, BO Account Number and within **3 (three) working days** from the cut-off date, upload to the ESS, the lists of applicants in electronic (text format with tilde '~' separator) format, deposit the full amount received from the General Public and Non-Resident Bangladeshi (NRB) applicants by the method as determined by exchange(s).
5. The application/buy instructions shall be preserved by the Stock broker/Merchant Bankers up to **6 (six) months** from listing of the securities with the exchange.
6. The Exchanges shall prepare a consolidated list of the applications and send the applicants' BOIDs in electronic (text) format in a CDROM to CDBL for verification **on the next working day**. Simultaneously, the Issuer shall post the consolidated list of applicants on its website and websites of the Exchanges. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not, verify more than two applications by an individual, verify more than two applications using same bank account and investment criteria.
7. **On the next working day**, CDBL shall provide the Exchanges with an updated database of the applicants containing BO Account Number, Name, Addresses, Parent s' Name and Joint Account information along with the verification report.

8. After receiving verification report and information from CDBL, the Exchanges shall scrutinize the applications, prepare category wise consolidated lists of valid and invalid applications **within 5 (five) working days**.
9. **On the next working day**, the Exchanges shall provide the Commission, Issuer and Issue Manager with the soft copy of subscription result.

Step-3 (Issuer)

10. The Issuer and issue manager shall post the final status of subscription on their **websites within 6 (six) hours** and on the websites of the Commission and Exchanges **within 12 (twelve) hours** of receiving information by the Commission and the Exchanges.
11. **Within 3 (three) working days** of receipt of the subscription result, the Issuer and Exchanges shall:
 - a) Process pro-rata allotment of securities to the General Public and Non-Resident Bangladeshi (NRB) applicants;
 - b) Prepare category wise lists of invalid applicants who are subject to penal provisions as per conditions of the consent letter issued by the Commission in electronic (text format with tilde '~' separator) format mentioning the penalty amount against each applicant;
 - c) Issuer shall issue allotment letters in the names of allottees in electronic format, and
 - d) Issuer shall credit the allotted shares to the respective BO accounts on the basis of allotment data (BOID and number of securities) via their CDBL VeDAS Terminal.
12. **15% Private Offer to employees or others of the Issuer:**

According to the compliance with the provisions of the Commission's Notification No. BSEC/CMRRCD/2009-193/27/Admin/127 dated 19 July 2021, application process of the 'employees & others' category of the issuer in the initial public offering (IPO) through ESS of the Exchanges shall be conducted as follows:

- a. Employees or others will get 15% of total IPO size subject to payment of 20% premium over fair value for each share. Unsubscribed portion of employees or others will be entitled for General Public (GP) excluding NRB.
- b. The issuer shall upload the list of the existing employees or others in the electronic subscription system of the exchange(s) in electronic (text format with tilde separator) format containing Customer ID, Name (as per BO ID), BO ID, Total Quantity, Total Amount, Category of the Applicant, NID, Employee ID, Service Start Date and Designation.
- c. The existing employees of the issuer or others shall submit application in the electronic subscription system of the exchange(s) through the Stockbrokers/Merchant Bankers where the applicant maintains customer account.
- d. The registered Stockbroker/Merchant Banker in the ESS shall upload the lists of existing employees of the issuer in electronic (text format with tilde '~' separator) format.
- e. The Exchanges shall verify (name, BO ID, amount, duplicate, etc.) the applications of existing employees and send the valid BOIDs in electronic (text) format to CDBL for verification. CDBL shall verify the BOIDs as to whether the BO accounts of the applicants are active or not.
- f. CDBL shall provide the Exchanges with an updated database of the applicants containing BO Account Number, Name, Addresses, Parent s' Name and Joint Account information along with the verification report.

The Existing employees of the issuer whose applications are valid and active will be allotted securities as per their applied quantities, **subject to a lock-in period of 2 (two) years from the first trading day at the exchanges**

Step-4 (Intermediary)

13. **On the next working day**, Exchanges shall:
- remit the number of allotted applicants to the Issuer's respective Escrow Account opened for subscription purpose.
 - send the penalty amount who are subject to penal provisions to the Issuer's respective Escrow Accounts along with a list.
 - distribute the information and allotment letters to the stock broker/Merchant Bankers concerned in electronic format with a request to refund the balance application money.
14. **On the next working day** of receiving the documents from the Exchanges, the Stockbrokers/Merchant Banker shall refund the excess application money in the customer accounts and inform the applicants about allotment of securities.

Miscellaneous:

15. The Issuer, Issue Manager(s), Stockbrokers and Merchant Bankers shall ensure compliance of the above.
16. The Issuer shall pay the costs related to process the Eligible Investors allotment if claimed by the Exchange concerned up to an amount of Tk. 2,00,000/- (Taka Two Lac) only and Tk. 8,00,000/- (Taka Eight Lac) only for processing the applications of General Public and Non-Resident Bangladeshi (NRB) applicants.
17. The Stockbroker/Merchant Bankers shall be entitled to a service charge of Tk. 5/- (Taka five) only per application irrespective of the amount or category for the service provided till withdrawal of the money. The service charge shall be paid by the applicant at the time of submitting an application.
18. The Exchanges shall provide the Issuer with a statement of the remittance.
19. The exchange shall send the penalty amount to the Commission through a bank draft/payment order issued in favor of the Bangladesh Securities and Exchange Commission.
20. The concerned Exchange is authorized to settle any complaints and take necessary actions against any Stockbroker/ Merchant Banker in case of violation of any provision of the public issue application process with intimation to the Commission.

"All eligible Stock Brokers and Merchant Bankers shall receive the IPO Subscription"

The IPO subscription money collected from successful applicants (other than NRB applicants) by the Stockbrokers/Merchant Bankers will be remitted to the Company's Account No: - 0131020007835 with One Bank Limited, Dhanmondi Branch, Dhaka for this purpose.

The IPO subscription money collected from successful applicants shall be deposited to the following account opened by the Company for IPO purpose is as follows:

| Sl. | Name of the A/C | Account No. | Type of A/C | Currency | Bank & Branch |
|-----|-------------------|---------------|-----------------|----------|---|
| 1 | Techno Drugs Ltd. | 0131020007835 | Current Account | BDT | One Bank Limited, Dhanmondi Branch, Dhaka |

CHAPTER (XXIX)

OTHERS

DECLARATION REGARDING COST AUDIT

This is to inform you that Ministry of Commerce in its Gazette dated 12 January, 2003 ordered 5 listed companies in the stock exchanges from power sector and 6 listed companies in the stock exchanges from jute sector would be under Cost Audit Compliance. Later on, 3 December, 2009 Ministry of Commerce issued Gazette by which 42 listed companies in the stock exchanges from Garments and Textiles sector, 12 listed companies in the stock exchanges from Pharmaceutical sector and all state-owned companies involved in manufacturing of Chemical Fertilizer would be under Cost Audit Compliance.

Since Techno Drugs Ltd. is not bracketed in above mentioned companies, Cost Audit by Professional Accountant is not applicable for "Techno Drugs Ltd.".

Sd/-

Shah Jalal Uddin Ahmed
Managing Director
Techno Drugs Ltd.

Sd/-

Pijush Kumar Chakroborty FCA
Chief Financial Officer
Techno Drugs Ltd.

Sd/-

Ahmed Arefin FCA
Managing Director
EBL Investments Limited

Sd/-

Md. Salauddin Sikder FCMA
CEO & Managing Director
Imperial Capital Limited

Date: September 27, 2023